Pubmed,miR_Name,miRBase_name,miR_ID,Drug,CID,Material_1,Material_2,Material_3,Material_4,Condition,Experiment,Level,Effect,Target,Regulation,Year,Reference,Support
16762633,miR-200b ,hsa-mir-200b,MI0000342,Gemcitabine,60750,"KMCH-1, Mz-ChA-1, TFK and H69",-,-,-,cholangiocarcinoma,in vitro,Low,Resistant,PTPN12,-,2006,Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines.,"Inhibition of miR-21 and miR-200b increased sensitivity to gemcitabine, whereas inhibition of miR-141 decreased cell growth."
16762633,miR-21,hsa-mir-21,MI0000077,Gemcitabine,60750,"KMCH-1, Mz-ChA-1, TFK and H69",-,-,-,cholangiocarcinoma,in vitro,Low,Resistant,PTEN,-,2006,Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines.,"Inhibition of miR-21 and miR-200b increased sensitivity to gemcitabine, whereas inhibition of miR-141 decreased cell growth."
17686970,miR-24,hsa-mir-24-1,MI0000080,Methotrexate,126941,HT1080,-,-,-,fibrosarcoma,in vitro,Low,association,DHFR,-,2007,A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance.,"SNP-829C3T near the miR-24 binding site in the 3 UTR of DHFR stabilizes the DHFR message and leads to high mRNA levels, high DHFR protein levels, and increased MTX resistance"
18199536,miR-214,hsa-mir-214,MI0000290,Cisplatin,2767,HIOSE,-,-,-,ovarian cancer,in vitro,Low,Resistant,PTEN,Akt pathway,2008,MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN.,"Significantly, miR-214 induces cell survival and cisplatin resistance through targeting the 3'-untranslated region (UTR) of the PTEN, which leads to down-regulation of PTEN protein and activation of Akt pathway. "
18246122,miR-100,hsa-mir-100,MI0000102,TRAIL therapy,-,"CALU-1, A459, A549,H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,p27Kip1,-,2008,MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.,"Three of these miRs, miR-222, -221 and -100, showed dramatic overexpression with 5- to 8-fold higher levels in resistant NSCLC cells compared to the sensitive NSCLC cells.Downregulation occurred for only two miRs, miR-9 and -96"
18246122,miR-125b,hsa-mir-125b-1,MI0000446,TRAIL therapy,-,"CALU-1, A459, A549,H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,p27Kip1,-,2008,MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.,"Three of these miRs, miR-222, -221 and -100, showed dramatic overexpression with 5- to 8-fold higher levels in resistant NSCLC cells compared to the sensitive NSCLC cells.Downregulation occurred for only two miRs, miR-9 and -96"
18246122,miR-15b,hsa-mir-15b,MI0000438,TRAIL therapy,-,"CALU-1, A459, A549,H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2008,MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.,"Three of these miRs, miR-222, -221 and -100, showed dramatic overexpression with 5- to 8-fold higher levels in resistant NSCLC cells compared to the sensitive NSCLC cells.Downregulation occurred for only two miRs, miR-9 and -96"
18246122,miR-221,hsa-mir-221,MI0000298,TRAIL therapy,-,"CALU-1, A459, A549,H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2008,MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.,"Three of these miRs, miR-222, -221 and -100, showed dramatic overexpression with 5- to 8-fold higher levels in resistant NSCLC cells compared to the sensitive NSCLC cells.Downregulation occurred for only two miRs, miR-9 and -96"
18246122,miR-222,hsa-mir-222,MI0000299,TRAIL therapy,-,"CALU-1, A459, A549,H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2008,MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.,"Three of these miRs, miR-222, -221 and -100, showed dramatic overexpression with 5- to 8-fold higher levels in resistant NSCLC cells compared to the sensitive NSCLC cells.Downregulation occurred for only two miRs, miR-9 and -96"
18246122,miR-9,hsa-mir-9-1,MI0000466,TRAIL therapy,-,"CALU-1, A459, A549,H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Sensitive,-,-,2008,MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.,"Three of these miRs, miR-222, -221 and -100, showed dramatic overexpression with 5- to 8-fold higher levels in resistant NSCLC cells compared to the sensitive NSCLC cells.Downregulation occurred for only two miRs, miR-9 and -96"
18246122,miR-96,hsa-mir-96,MI0000098,TRAIL therapy,-,"CALU-1, A459, A549,H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Sensitive,-,-,2008,MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.,"Three of these miRs, miR-222, -221 and -100, showed dramatic overexpression with 5- to 8-fold higher levels in resistant NSCLC cells compared to the sensitive NSCLC cells.Downregulation occurred for only two miRs, miR-9 and -96"
18449891,miR-15b,hsa-mir-15b,MI0000438,Vincristine,241903,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Sensitive,BCL-2,-,2008,miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.,"A marked increase in apoptosis, as assessed by flow cytometry, was observed in miR-15b or miR-16 precursor-transfected SGC7901/VCR cells after VCR treatment compared to precursor control-transfected cells."
18449891,miR-16,hsa-mir-16-1,MI0000070,Vincristine,241903,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Sensitive,BCL-2,-,2008,miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.,"A marked increase in apoptosis, as assessed by flow cytometry, was observed in miR-15b or miR-16 precursor-transfected SGC7901/VCR cells after VCR treatment compared to precursor control-transfected cells."
18493594,miR-17,hsa-mir-17,MI0000071,Chemotherapy,-,"SH-EP, SK-N-AS, SH-SY-5Y, LAN-5 and IMR32",-,-,-,neuroblastoma ,in vitro,Low,Resistant,P21,-,2008,Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM.,In vitro or in vivo treatment with antagomir-17-5p abolishes the growth of MYCN-amplified and therapy-resistant neuroblastoma through p21 and BIM upmodulation.
18619946,miR-27a,hsa-mir-27a,MI0000085,Hydroxyurea,3657,-,KB-3-1 vs KB-V1 ,-,-,cervix carcinoma,in vitro,Low,Resistant,MDR1,-,2008,Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells.,The sensitivity to and intracellular accumulation of cytotoxic drugs that are transported by P-glycoprotein were enhanced by the treatment with the antagomirs of miR-27a or miR-451.
18619946,miR-27a,hsa-mir-27a,MI0000085,Hydroxyurea,3657,-,A2780 vs A2780DX5,-,-,ovarian cancer,in vitro,Low,Resistant,MDR1,-,2008,Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells.,The sensitivity to and intracellular accumulation of cytotoxic drugs that are transported by P-glycoprotein were enhanced by the treatment with the antagomirs of miR-27a or miR-451.
18619946,miR-27a,hsa-mir-27a,MI0000085,Vinblastine,241903,KB-3-1 and KB-V1 ,-,-,-,cervix carcinoma,in vitro,Low,Resistant,MDR1,-,2008,Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells.,The sensitivity to and intracellular accumulation of cytotoxic drugs that are transported by P-glycoprotein were enhanced by the treatment with the antagomirs of miR-27a or miR-451.
18619946,miR-27a,hsa-mir-27a,MI0000085,Vinblastine,241903,-,A2780 vs A2780DX5,-,-,ovarian cancer,in vitro,Low,Resistant,MDR1,-,2008,Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells.,The sensitivity to and intracellular accumulation of cytotoxic drugs that are transported by P-glycoprotein were enhanced by the treatment with the antagomirs of miR-27a or miR-451.
18619946,miR-451,hsa-mir-451a,MI0001729,Hydroxyurea,3657,-,KB-3-1 vs KB-V1 ,-,-,cervix carcinoma,in vitro,Low,Resistant,MDR1,-,2008,Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells.,The sensitivity to and intracellular accumulation of cytotoxic drugs that are transported by P-glycoprotein were enhanced by the treatment with the antagomirs of miR-27a or miR-451.
18619946,miR-451,hsa-mir-451a,MI0001729,Hydroxyurea,3657,-,A2780 vs A2780DX5,-,-,ovarian cancer,in vitro,Low,Resistant,MDR1,-,2008,Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells.,The sensitivity to and intracellular accumulation of cytotoxic drugs that are transported by P-glycoprotein were enhanced by the treatment with the antagomirs of miR-27a or miR-451.
18619946,miR-451,hsa-mir-451a,MI0001729,Vinblastine,241903,KB-3-1 and KB-V1 ,-,-,-,cervix carcinoma,in vitro,Low,Resistant,MDR1,-,2008,Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells.,The sensitivity to and intracellular accumulation of cytotoxic drugs that are transported by P-glycoprotein were enhanced by the treatment with the antagomirs of miR-27a or miR-451.
18619946,miR-451,hsa-mir-451a,MI0001729,Vinblastine,241903,-,A2780 vs A2780DX5,-,-,ovarian cancer,in vitro,Low,Resistant,MDR1,-,2008,Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells.,The sensitivity to and intracellular accumulation of cytotoxic drugs that are transported by P-glycoprotein were enhanced by the treatment with the antagomirs of miR-27a or miR-451.
18645025,let-7a,hsa-let-7a-1,MI0000060,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,let-7b,hsa-let-7b,MI0000063,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,let-7d,hsa-let-7d,MI0000065,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,let-7f,hsa-let-7f-1,MI0000067,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,let-7g,hsa-let-7g,MI0000433,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,let-7i,hsa-let-7i,MI0000434,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-100,hsa-mir-100,MI0000102,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-103,hsa-mir-103a-1,MI0000109,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-106a,hsa-mir-106a,MI0000113,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-106b,hsa-mir-106b,MI0000734,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-107,hsa-mir-107,MI0000114,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-10a,hsa-mir-10a,MI0000266,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-125a,hsa-mir-125a,MI0000469,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-125b,hsa-mir-125b-1,MI0000446,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-127,hsa-mir-127,MI0000472,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-128b,hsa-mir-128-2,MI0000727,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-130a,hsa-mir-130a,MI0000448,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-132,hsa-mir-132,MI0000449,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-133a,hsa-mir-133a-1,MI0000450,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-133b,hsa-mir-133b,MI0000822,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-140,hsa-mir-140,MI0000456,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-141,hsa-mir-141,MI0000457,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-145 ,hsa-mir-145,MI0000461,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-146b,hsa-mir-146b,MI0003129,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-148a,hsa-mir-148a,MI0000253,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-149,hsa-mir-149,MI0000478,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-152,hsa-mir-152,MI0000462,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-155,hsa-mir-155,MI0000681,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-15a,hsa-mir-15a,MI0000069,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-15b,hsa-mir-15b,MI0000438,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-16,hsa-mir-16-1,MI0000070,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-17,hsa-mir-17,MI0000071,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-181b,hsa-mir-181b-1,MI0000270,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-181d,hsa-mir-181d,MI0003139,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-182,hsa-mir-182,MI0000272,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-185,hsa-mir-185,MI0000482,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-186,hsa-mir-186,MI0000483,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-187,hsa-mir-187,MI0000274,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-18a,hsa-mir-18a,MI0000072,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-18b,hsa-mir-18b,MI0001518,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-191,hsa-mir-191,MI0000465,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-192,hsa-mir-192,MI0000234,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-193b,hsa-mir-193b,MI0003137,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-194,hsa-mir-194-1,MI0000488,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-195,hsa-mir-195,MI0000489,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-196b,hsa-mir-196b,MI0001150,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-199a,hsa-mir-199a-1,MI0000242,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-199a*,hsa-mir-199a-1,MI0000242,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-200a,hsa-mir-200a,MI0000737,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-200a*,hsa-mir-200a,MI0000737,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-200b,hsa-mir-200b,MI0000342,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-200c,hsa-mir-200c,MI0000650,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-203,hsa-mir-203a,MI0000283,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-205,hsa-mir-205,MI0000285,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-206,hsa-mir-206,MI0000490,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-20a,hsa-mir-20a,MI0000076,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-20b,hsa-mir-20b,MI0001519,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-210,hsa-mir-210,MI0000286,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-212,hsa-mir-212,MI0000288,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-214,hsa-mir-214,MI0000290,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-215,hsa-mir-215,MI0000291,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-22,hsa-mir-22,MI0000078,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-221,hsa-mir-221,MI0000298,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-222,hsa-mir-222,MI0000299,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-224,hsa-mir-224,MI0000301,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-23a,hsa-mir-23a,MI0000079,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-23b,hsa-mir-23b,MI0000439,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-25 ,hsa-mir-25,MI0000082,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-26a,hsa-mir-26a-1,MI0000083,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-27a,hsa-mir-27a,MI0000085,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-27b,hsa-mir-27b,MI0000440,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-28,hsa-mir-28,MI0000086,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-29a,hsa-mir-29a,MI0000087,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-29b,hsa-mir-29b-1,MI0000105,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-301,hsa-mir-301a,MI0000745,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-30a,hsa-mir-30a,MI0000088,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-30e,hsa-mir-30e,MI0000749,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-31,hsa-mir-31,MI0000089,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-320,hsa-mir-320a,MI0000542,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-323,hsa-mir-323a,MI0000807,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-324,hsa-mir-324,MI0000813,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-328,hsa-mir-328,MI0000804,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-331,hsa-mir-331,MI0000812,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-339,hsa-mir-339,MI0000815,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-342,hsa-mir-342,MI0000805,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-345,hsa-mir-345,MI0000825,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-34a,hsa-mir-34a,MI0000268,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-34c,hsa-mir-34c,MI0000743,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-362,hsa-mir-362,MI0000762,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-368,-,-,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-373*,hsa-mir-373,MI0000781,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-374,hsa-mir-374a,MI0000782,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-375,hsa-mir-375,MI0000783,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-376a,hsa-mir-376a-1,MI0000784,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-378,hsa-mir-378a,MI0000786,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-409,hsa-mir-409,MI0001735,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-410,hsa-mir-410,MI0002465,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-411,hsa-mir-411,MI0003675,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-421,hsa-mir-421,MI0003685,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-422a,hsa-mir-422a,MI0001444,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-424,hsa-mir-424,MI0001446,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-429,hsa-mir-429,MI0001641,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-431,hsa-mir-431,MI0001721,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-432,hsa-mir-432,MI0003133,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-433,hsa-mir-433,MI0001723,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-450,hsa-mir-450a-1,MI0001652,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-451,hsa-mir-451a,MI0001729,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Sensitive,MDR1,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,"More importantly, transfection of the MCF-7/DOX-resistant cells with microRNA-451 resulted in the increased sensitivity of cells to DOX, indicating that correction of altered expression of miRNA may have significant implications for therapeutic strategies aiming to overcome cancer cell resistance."
18645025,miR-455,hsa-mir-455,MI0003513,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-484,hsa-mir-484,MI0002468,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-485,hsa-mir-485,MI0002469,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-486,hsa-mir-486-1,MI0002470,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-487a,hsa-mir-487a,MI0002471,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-487b,hsa-mir-487b,MI0003530,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-489,hsa-mir-489,MI0003124,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-493,hsa-mir-493,MI0003132,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-495,hsa-mir-495,MI0003135,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-503,hsa-mir-503,MI0003188,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-532,hsa-mir-532,MI0003205,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-542,hsa-mir-542,MI0003686,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-550,hsa-mir-550a-1,MI0003600,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-557,hsa-mir-557,MI0003563,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-565,hsa-mir-565,MI0003571,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-574,hsa-mir-574,MI0003581,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-584,hsa-mir-584,MI0003591,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-590,hsa-mir-590,MI0003602,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-594,hsa-mir-594,MI0003606,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-615,hsa-mir-615,MI0003628,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-637,hsa-mir-637,MI0003652,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-654,hsa-mir-654,MI0003676,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-660,hsa-mir-660,MI0003684,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-7,hsa-mir-7-1,MI0000263,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-9,hsa-mir-9-1,MI0000466,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-93,hsa-mir-93,MI0000095,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-96,hsa-mir-96,MI0000098,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18645025,miR-99b,hsa-mir-99b,MI0000746,Doxorubicin (Adriamycin),31703,-,MCF7 vs MCF-7/DOX,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.,We identified 137 miRNA genes (63 up-regulated and 75 down-regulated) that were differentially expressed (P < 0.05) in the MCF-7/DOX cells compared with the parental MCF-7 cells
18695884,let-7a,hsa-let-7a-1,MI0000060,Capecitabine,60953,-,-,-,Patientss,rectal adenocarcinoma,in vivo,High,Resistant,,-,2008,Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer.,"We evaluated small nuclear RNAs U6B, U19, U43 and microRNAs Let-7a, miR33 and miR198."
18695884,miR198,hsa-mir-198,MI0000240,Capecitabine,60953,-,-,-,Patientss,rectal adenocarcinoma,in vivo,High,Resistant,,-,2008,Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer.,"We evaluated small nuclear RNAs U6B, U19, U43 and microRNAs Let-7a, miR33 and miR198."
18695884,miR-33,hsa-mir-33a,MI0000091,Capecitabine,60953,-,-,-,Patientss,rectal adenocarcinoma,in vivo,High,Resistant,,-,2008,Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer.,"We evaluated small nuclear RNAs U6B, U19, U43 and microRNAs Let-7a, miR33 and miR198."
18708351,miR-171,-,-,Tamoxifen,2733526,-,OHT-R vs MCF-7,-,-,breast cancer,in vitro,High,Resistant,p27Kip1,-,2008,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.,"Eight miRNA genes, miR-221, miR-222, miR-181, miR-375, miR-32, miR-171, miR-213, and miR-203, were significantly overexpressed ( 1.5-fold) in OHTR cells compared with MCF-7 cells"
18708351,miR-181,-,-,Tamoxifen,2733526,-,OHT-R vs MCF-7,-,-,breast cancer,in vitro,High,Resistant,p27Kip1,-,2008,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.,"Eight miRNA genes, miR-221, miR-222, miR-181, miR-375, miR-32, miR-171, miR-213, and miR-203, were significantly overexpressed ( 1.5-fold) in OHTR cells compared with MCF-7 cells"
18708351,miR-200,-,-,Tamoxifen,2733526,-,OHT-R vs MCF-7,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.,"Eight miRNA genes, miR-221, miR-222, miR-181, miR-375, miR-32, miR-171, miR-213, and miR-203, were significantly overexpressed ( 1.5-fold) in OHTR cells compared with MCF-7 cells"
18708351,miR-203,hsa-mir-203a,MI0000283,Tamoxifen,2733526,-,OHT-R vs MCF-7,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.,"Eight miRNA genes, miR-221, miR-222, miR-181, miR-375, miR-32, miR-171, miR-213, and miR-203, were significantly overexpressed ( 1.5-fold) in OHTR cells compared with MCF-7 cells"
18708351,miR-21,hsa-mir-21,MI0000077,Tamoxifen,2733526,-,OHT-R vs MCF-7,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.,"Eight miRNA genes, miR-221, miR-222, miR-181, miR-375, miR-32, miR-171, miR-213, and miR-203, were significantly overexpressed ( 1.5-fold) in OHTR cells compared with MCF-7 cells"
18708351,miR-213,hsa-mir-181a-1,MI0000289,Tamoxifen,2733526,-,OHT-R vs MCF-7,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.,"Eight miRNA genes, miR-221, miR-222, miR-181, miR-375, miR-32, miR-171, miR-213, and miR-203, were significantly overexpressed ( 1.5-fold) in OHTR cells compared with MCF-7 cells"
18708351,miR-221,hsa-mir-221,MI0000298,Tamoxifen,2733526,MCF-7,-,-,-,breast cancer,in vitro,Low,Resistant,p27Kip1,-,2008,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.,Ectopic expression of miR-221/222 rendered the parental MCF-7 cells resistant to tamoxifen.
18708351,miR-222,hsa-mir-222,MI0000299,Tamoxifen,2733526,MCF-7,-,-,-,breast cancer,in vitro,Low,Resistant,p27Kip1,-,2008,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.,Ectopic expression of miR-221/222 rendered the parental MCF-7 cells resistant to tamoxifen.
18708351,miR-23,hsa-mir-23a,MI0000079,Tamoxifen,2733526,-,OHT-R vs MCF-7,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.,"seven miRNAs, miR-342, miR-489, miR-21, miR-24, miR-27, miR-23, and miR-200, were underexpressed ( 50%) in OHTR cells"
18708351,miR-24,hsa-mir-24-1,MI0000080,Tamoxifen,2733526,-,OHT-R vs MCF-7,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.,"seven miRNAs, miR-342, miR-489, miR-21, miR-24, miR-27, miR-23, and miR-200, were underexpressed ( 50%) in OHTR cells"
18708351,miR-27,hsa-mir-27a,MI0000085,Tamoxifen,2733526,-,OHT-R vs MCF-7,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.,"seven miRNAs, miR-342, miR-489, miR-21, miR-24, miR-27, miR-23, and miR-200, were underexpressed ( 50%) in OHTR cells"
18708351,miR-32,hsa-mir-32,MI0000090,Tamoxifen,2733526,-,OHT-R vs MCF-7,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.,"seven miRNAs, miR-342, miR-489, miR-21, miR-24, miR-27, miR-23, and miR-200, were underexpressed ( 50%) in OHTR cells"
18708351,miR-342,hsa-mir-342,MI0000805,Tamoxifen,2733526,-,OHT-R vs MCF-7,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.,"seven miRNAs, miR-342, miR-489, miR-21, miR-24, miR-27, miR-23, and miR-200, were underexpressed ( 50%) in OHTR cells"
18708351,miR-375,hsa-mir-375,MI0000783,Tamoxifen,2733526,-,OHT-R vs MCF-7,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.,"seven miRNAs, miR-342, miR-489, miR-21, miR-24, miR-27, miR-23, and miR-200, were underexpressed ( 50%) in OHTR cells"
18708351,miR-489,hsa-mir-489,MI0003124,Tamoxifen,2733526,-,OHT-R vs MCF-7,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.,"seven miRNAs, miR-342, miR-489, miR-21, miR-24, miR-27, miR-23, and miR-200, were underexpressed ( 50%) in OHTR cells"
18758960,let-7a,hsa-let-7a-1,MI0000060,Doxorubicin (Adriamycin),31703,HepG2,-,-,-,hepatocellular carcinoma,in vitro,Low,Resistant,caspase-3,-,2008,Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3.,"Enforced let-7a expression increased the resistance in A431 cells and HepG2 cells to apoptosis induced by therapeutic drugs such as interferon-gamma, doxorubicin and paclitaxel."
18758960,let-7a,hsa-let-7a-1,MI0000060,Doxorubicin (Adriamycin),31703,A431,-,-,-,squamous carcinoma,in vitro,Low,Resistant,caspase-3,-,2008,Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3.,"Enforced let-7a expression increased the resistance in A431 cells and HepG2 cells to apoptosis induced by therapeutic drugs such as interferon-gamma, doxorubicin and paclitaxel."
18758960,let-7a,hsa-let-7a-1,MI0000060,Interferon-gamma,-,HepG2,-,-,-,hepatocellular carcinoma,in vitro,Low,Resistant,caspase-3,-,2008,Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3.,"Enforced let-7a expression increased the resistance in A431 cells and HepG2 cells to apoptosis induced by therapeutic drugs such as interferon-gamma, doxorubicin and paclitaxel."
18758960,let-7a,hsa-let-7a-1,MI0000060,Interferon-gamma,-,A431,-,-,-,squamous carcinoma,in vitro,Low,Resistant,caspase-3,-,2008,Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3.,"Enforced let-7a expression increased the resistance in A431 cells and HepG2 cells to apoptosis induced by therapeutic drugs such as interferon-gamma, doxorubicin and paclitaxel."
18758960,let-7a,hsa-let-7a-1,MI0000060,Paclitaxel,36314,HepG2,-,-,-,hepatocellular carcinoma,in vitro,Low,Resistant,caspase-3,-,2008,Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3.,"Enforced let-7a expression increased the resistance in A431 cells and HepG2 cells to apoptosis induced by therapeutic drugs such as interferon-gamma, doxorubicin and paclitaxel."
18758960,let-7a,hsa-let-7a-1,MI0000060,Paclitaxel,36314,A431,-,-,-,squamous carcinoma,in vitro,Low,Resistant,caspase-3,-,2008,Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3.,"Enforced let-7a expression increased the resistance in A431 cells and HepG2 cells to apoptosis induced by therapeutic drugs such as interferon-gamma, doxorubicin and paclitaxel."
18790736,miR-221,hsa-mir-221,MI0000298,Tamoxifen,2733526,"T47D, BT474, MDA-MB-361, MCF-7, MDA-MB-453, MDA-MB-157, SKBr3, MDA-MB-468, Hs578T, MDA-MB-231, MDA-MB-435s and MCF-10A",-,-,-,breast cancer,in vitro,Low,Resistant,Eralpha,-,2008,MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer.,"Notably, miR-221- and/or miR-222-transfected MCF-7 and T47D cells became resistant to tamoxifen compared with vector-treated cells."
18790736,miR-222,hsa-mir-222,MI0000299,Tamoxifen,2733526,"T47D, BT474, MDA-MB-361, MCF-7, MDA-MB-453, MDA-MB-157, SKBr3, MDA-MB-468, Hs578T, MDA-MB-231, MDA-MB-435s and MCF-10A",-,-,-,breast cancer,in vitro,Low,Resistant,Eralpha,-,2008,MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer.,"Notably, miR-221- and/or miR-222-transfected MCF-7 and T47D cells became resistant to tamoxifen compared with vector-treated cells."
18803879,miR-34,hsa-mir-34a,MI0000268,Cisplatin,2767,Kato III ,-,-,-,gastric cancer,in vitro,Low,Sensitive,Bcl-2,-,2008,Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres.,"miR-34 restoration in Kato III cells rendered the cells 2-3-fold more sensitive to the four chemotherapeutic agents, as compared with the cells transfected with the control mimic, based on IC50 data."
18803879,miR-34,hsa-mir-34a,MI0000268,Docetaxel,148124,Kato III ,-,-,-,gastric cancer,in vitro,Low,Sensitive,Bcl-2,-,2008,Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres.,"miR-34 restoration in Kato III cells rendered the cells 2-3-fold more sensitive to the four chemotherapeutic agents, as compared with the cells transfected with the control mimic, based on IC50 data."
18803879,miR-34,hsa-mir-34a,MI0000268,Doxorubicin (Adriamycin),31703,Kato III ,-,-,-,gastric cancer,in vitro,Low,Sensitive,Bcl-2,-,2008,Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres.,"miR-34 restoration in Kato III cells rendered the cells 2-3-fold more sensitive to the four chemotherapeutic agents, as compared with the cells transfected with the control mimic, based on IC50 data."
18803879,miR-34,hsa-mir-34a,MI0000268,Gemcitabine,60750,Kato III ,-,-,-,gastric cancer,in vitro,Low,Sensitive,Bcl-2,-,2008,Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres.,"miR-34 restoration in Kato III cells rendered the cells 2-3-fold more sensitive to the four chemotherapeutic agents, as compared with the cells transfected with the control mimic, based on IC50 data."
18818206,miR-1,hsa-mir-1-1,MI0000651,Doxorubicin (Adriamycin),31703,"A549, H1299, N417 and BEAS-2B",-,-,-,lung cancer,in vitro,Low,Sensitive,MET,-,2008,Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.,"Further, ectopic miR-1 induced apoptosis in A549 cells in response to the potent anticancer drug doxorubicin."
18823650,let-7e,hsa-let-7e,MI0000066,Cisplatin,2767,-,A2780 vs A2780/DDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-010a,hsa-mir-10a,MI0000266,Cisplatin,2767,-,A2780 vs A2780/DDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-016b,-,-,Cisplatin,2767,-,A2780 vs A2780/DDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-019b,hsa-mir-19b-1,MI0000074,Cisplatin,2767,-,A2780 vs A2780/DDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-020,hsa-mir-20a,MI0000076,Cisplatin,2767,-,A2780 vs A2780/DDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-023a,hsa-mir-23a,MI0000079,Cisplatin,2767,-,A2780 vs A2780/DDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-023b,hsa-mir-23b,MI0000439,Cisplatin,2767,-,A2780 vs A2780/DDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-026a,hsa-mir-26a-1,MI0000083,Cisplatin,2767,-,A2780 vs A2780/DDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-029c,hsa-mir-29c,MI0000735,Cisplatin,2767,-,A2780 vs A2780/DDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-092,hsa-mir-92a-1,MI0000093,Cisplatin,2767,-,A2780 vs A2780/DDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-093,hsa-mir-93,MI0000095,Cisplatin,2767,-,A2780 vs A2780/DDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-099,hsa-mir-99a,MI0000101,Cisplatin,2767,-,A2780 vs A2780/DDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-100,hsa-mir-100,MI0000102,Cisplatin,2767,-,A2780 vs A2780/DDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-106,hsa-mir-106a,MI0000113,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,M-CSF,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-106,hsa-mir-106a,MI0000113,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-106a,hsa-mir-106a,MI0000113,Cisplatin,2767,-,A2780 vs A2780/DDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-106a,hsa-mir-106a,MI0000113,Cisplatin,2767,-,A2780 vs A2780/DDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-107,hsa-mir-107,MI0000114,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-125a,hsa-mir-125a,MI0000469,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-125b,hsa-mir-125b-1,MI0000446,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-126,hsa-mir-126,MI0000471,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-128a,hsa-mir-128-1,MI0000447,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-130a,hsa-mir-130a,MI0000448,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-130b,hsa-mir-130b,MI0000748,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-137,hsa-mir-137,MI0000454,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-182,hsa-mir-182,MI0000272,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-197,hsa-mir-197,MI0000239,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-199a,hsa-mir-199a-1,MI0000242,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-204,hsa-mir-204,MI0000284,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-20b,hsa-mir-20b,MI0001519,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-21,hsa-mir-21,MI0000077,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-218,hsa-mir-218-1,MI0000294,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-30c,hsa-mir-30c-2,MI0000254,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-321,hsa-mir-321,MI0000543,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18823650,miR-335,hsa-mir-335,MI0000816,Paclitaxel,36314,-,"A2780 vs A2780TAX, A2780 vs A2780TC1, and A2780 vs A2780TC3",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,Role of microRNAs in drug-resistant ovarian cancer cells,The microRNAand the relative p and FDR values are shown in Table 1.
18834855,miR-34a,hsa-mir-34a,MI0000268,Camptothecin,24360,PC3,-,-,-,prostate cancer,in vitro,Low,Sensitive,SIRT1,-,2008,Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells.,Ectopic miR-34a expression resulted in cell cycle arrest and growth inhibition and attenuated chemoresistance to anticancer drug camptothecin by inducing apoptosis.
18971180,miR-100,hsa-mir-100,MI0000102,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-106a,hsa-mir-106a,MI0000113,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-106b,hsa-mir-106b,MI0000734,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-108a,-,-,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-125a,hsa-mir-125a,MI0000469,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-125b,hsa-mir-125b-1,MI0000446,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-130a,hsa-mir-130a,MI0000448,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-141,hsa-mir-141,MI0000457,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-155,hsa-mir-155,MI0000681,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-183,hsa-mir-183,MI0000273,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-193a,hsa-mir-193a,MI0000487,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-200a,hsa-mir-200a,MI0000737,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-200b,hsa-mir-200b,MI0000342,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-200c,hsa-mir-200c,MI0000650,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-203,hsa-mir-203a,MI0000283,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-20b,hsa-mir-20b,MI0001519,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-210,hsa-mir-210,MI0000286,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-22,hsa-mir-22,MI0000078,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-221,hsa-mir-221,MI0000298,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-222,hsa-mir-222,MI0000299,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-23a,hsa-mir-23a,MI0000079,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-25,hsa-mir-25,MI0000082,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-301,hsa-mir-301a,MI0000745,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-31,hsa-mir-31,MI0000089,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-339,hsa-mir-339,MI0000815,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-34a,hsa-mir-34a,MI0000268,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-421,hsa-mir-421,MI0003685,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-455,hsa-mir-455,MI0003513,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-590,hsa-mir-590,MI0003602,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-680,-,-,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-92,hsa-mir-92a-1,MI0000093,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,miR-93,hsa-mir-93,MI0000095,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,mmu-miR-20b,mmu-mir-20b,MI0003536,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,mmu-miR-703,mmu-mir-703,MI0004687,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,rno-mir-301a,rno-mir-301a,MI0000593,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
18971180,rno-mir-93,rno-mir-93,MI0000880,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2008,Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR,"Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR4 cells."
19074899,let-7i,hsa-let-7i,MI0000434,Cisplatin,2767,SKOV3 and 2008,-,-,Patients,ovarian and breast cancer,in vitro and in vivo,Low,Sensitive,-,-,2008,MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.,Both loss-of-function (by synthetic let-7i inhibitor) and gain-of-function (by retroviral overexpression of let-7i) studies showed that reduced let-7i expression significantly increased the resistance of ovarian and breast cancer cells to the chemotherapy drug
19074899,miR-126,hsa-mir-126,MI0000471,Cisplatin,2767,"SKOV3, 2008, OVCAR10, OVCAR3, HeLa, MCF7, MDA-MB-468",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.,"Importantly, nine miRNAs exhibited even greater statistical significance (P < 0.015) and of those, six were higher in the noncomplete response group and three were higher in the complete response group (Fig. 1A and B)."
19074899,miR-152,hsa-mir-152,MI0000462,Cisplatin,2767,"SKOV3, 2008, OVCAR10, OVCAR3, HeLa, MCF7, MDA-MB-468",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2008,MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.,"Importantly, nine miRNAs exhibited even greater statistical significance (P < 0.015) and of those, six were higher in the noncomplete response group and three were higher in the complete response group (Fig. 1A and B)."
19074899,miR-196a,hsa-mir-196a-1,MI0000238,Cisplatin,2767,"SKOV3, 2008, OVCAR10, OVCAR3, HeLa, MCF7, MDA-MB-468",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2008,MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.,"Importantly, nine miRNAs exhibited even greater statistical significance (P < 0.015) and of those, six were higher in the noncomplete response group and three were higher in the complete response group (Fig. 1A and B)."
19074899,miR-198,hsa-mir-198,MI0000240,Cisplatin,2767,"SKOV3, 2008, OVCAR10, OVCAR3, HeLa, MCF7, MDA-MB-468",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2008,MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.,"Importantly, nine miRNAs exhibited even greater statistical significance (P < 0.015) and of those, six were higher in the noncomplete response group and three were higher in the complete response group (Fig. 1A and B)."
19074899,miR-1b-1,hsa-mir-1b-1,MI0000435,Cisplatin,2767,"SKOV3, 2008, OVCAR10, OVCAR3, HeLa, MCF7, MDA-MB-468",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2008,MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.,"Importantly, nine miRNAs exhibited even greater statistical significance (P < 0.015) and of those, six were higher in the noncomplete response group and three were higher in the complete response group (Fig. 1A and B)."
19074899,miR-214,hsa-mir-214,MI0000290,Cisplatin,2767,"SKOV3, 2008, OVCAR10, OVCAR3, HeLa, MCF7, MDA-MB-468",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2008,MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.,"Importantly, nine miRNAs exhibited even greater statistical significance (P < 0.015) and of those, six were higher in the noncomplete response group and three were higher in the complete response group (Fig. 1A and B)."
19074899,miR-216,hsa-mir-216a,MI0000292,Cisplatin,2767,"SKOV3, 2008, OVCAR10, OVCAR3, HeLa, MCF7, MDA-MB-468",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2008,MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.,"Importantly, nine miRNAs exhibited even greater statistical significance (P < 0.015) and of those, six were higher in the noncomplete response group and three were higher in the complete response group (Fig. 1A and B)."
19074899,miR-22,hsa-mir-22,MI0000078,Cisplatin,2767,"SKOV3, 2008, OVCAR10, OVCAR3, HeLa, MCF7, MDA-MB-468",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2008,MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.,"Importantly, nine miRNAs exhibited even greater statistical significance (P < 0.015) and of those, six were higher in the noncomplete response group and three were higher in the complete response group (Fig. 1A and B)."
19074899,miR-223,hsa-mir-223,MI0000300,Cisplatin,2767,"SKOV3, 2008, OVCAR10, OVCAR3, HeLa, MCF7, MDA-MB-468",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2008,MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.,"Importantly, nine miRNAs exhibited even greater statistical significance (P < 0.015) and of those, six were higher in the noncomplete response group and three were higher in the complete response group (Fig. 1A and B)."
19074899,miR-321*,hsa-mir-321,MI0000543,Cisplatin,2767,"SKOV3, 2008, OVCAR10, OVCAR3, HeLa, MCF7, MDA-MB-468",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2008,MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.,"Importantly, nine miRNAs exhibited even greater statistical significance (P < 0.015) and of those, six were higher in the noncomplete response group and three were higher in the complete response group (Fig. 1A and B)."
19074899,miR-370,hsa-mir-370,MI0000778,Cisplatin,2767,"SKOV3, 2008, OVCAR10, OVCAR3, HeLa, MCF7, MDA-MB-468",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2008,MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.,"Importantly, nine miRNAs exhibited even greater statistical significance (P < 0.015) and of those, six were higher in the noncomplete response group and three were higher in the complete response group (Fig. 1A and B)."
19074899,miR-509,hsa-mir-509-1,MI0003196,Cisplatin,2767,"SKOV3, 2008, OVCAR10, OVCAR3, HeLa, MCF7, MDA-MB-468",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2008,MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.,"Importantly, nine miRNAs exhibited even greater statistical significance (P < 0.015) and of those, six were higher in the noncomplete response group and three were higher in the complete response group (Fig. 1A and B)."
19074899,miR-520e,hsa-mir-520e,MI0003143,Cisplatin,2767,"SKOV3, 2008, OVCAR10, OVCAR3, HeLa, MCF7, MDA-MB-468",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2008,MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.,"Importantly, nine miRNAs exhibited even greater statistical significance (P < 0.015) and of those, six were higher in the noncomplete response group and three were higher in the complete response group (Fig. 1A and B)."
19074899,miR-521,hsa-mir-521-1,MI0003176,Cisplatin,2767,"SKOV3, 2008, OVCAR10, OVCAR3, HeLa, MCF7, MDA-MB-468",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2008,MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.,"Importantly, nine miRNAs exhibited even greater statistical significance (P < 0.015) and of those, six were higher in the noncomplete response group and three were higher in the complete response group (Fig. 1A and B)."
19082437,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,MCF-7,-,-,-,breast cancer,in vitro,Low,Resistant,-,p21 and p27,2009,Knockdown of Dicer in MCF-7 human breast carcinoma cells results in G1 arrest and increased sensitivity to cisplatin.,"In this study, we found that knockdown of Dicer by siRNA led to significant G1 arrest and increased sensitivity to the DNA damaging agent, cisplatin, in breast cancer cell line MCF-7."
19158092,miR-21,hsa-mir-21,MI0000077,Hydrogen Peroxide (H2O2),784,Vascular Smooth Muscle Cell,-,-,-,vascular smooth muscle cell,in vitro,Low,Resistant,PDCD4,-,2009,Involvement of MicroRNAs in hydrogen peroxide-mediated gene regulation and cellular injury response in vascular smooth muscle cells.,H(2)O(2)-induced VSMC apoptosis and death were increased by miR-21 inhibitor and decreased by pre-miR-21.
19237188,let-7e,hsa-let-7e,MI0000066,Doxorubicin (Adriamycin),31703,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-106a,hsa-mir-106a,MI0000113,Doxorubicin (Adriamycin),31703,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-126,hsa-mir-126,MI0000471,Doxorubicin (Adriamycin),31703,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-132,hsa-mir-132,MI0000449,Doxorubicin (Adriamycin),31703,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-142,hsa-mir-142,MI0000458,Doxorubicin (Adriamycin),31703,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-181a,hsa-mir-181a-2,MI0000269,Doxorubicin (Adriamycin),31703,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-181a,hsa-mir-181a-2,MI0000269,Doxorubicin (Adriamycin),31703,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-181b,hsa-mir-181b-1,MI0000270,Gemcitabine,60750,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-185,hsa-mir-185,MI0000482,Gemcitabine,60750,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-19c,miR-19c,-,Gemcitabine,60750,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-21,hsa-mir-21,MI0000077,Gemcitabine,60750,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-213,hsa-mir-181a-1,MI0000289,Paclitaxel,36314,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-23b,hsa-mir-23b,MI0000439,Paclitaxel,36314,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-330,hsa-mir-330,MI0000803,Paclitaxel,36314,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-331,hsa-mir-331,MI0000812,Paclitaxel,36314,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-339,hsa-mir-339,MI0000815,Docetaxel,148124,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-340,hsa-mir-340,MI0000802,Docetaxel,148124,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-34b,hsa-mir-34b,MI0000742,Docetaxel,148124,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-371,hsa-mir-371a,MI0000779,Docetaxel,148124,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-381,hsa-mir-381,MI0000789,Docetaxel,148124,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-431,hsa-mir-431,MI0001721,Docetaxel,148124,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-502,hsa-mir-502,MI0003186,Topotecan,60700,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-514,hsa-mir-514a-1,MI0003198,Topotecan,60700,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-515,hsa-mir-515-1,MI0003144,Topotecan,60700,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-518,hsa-mir-518a-1,MI0003170,Cisplatin,2767,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-518c-AS,-,-,Cisplatin,2767,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-520f,hsa-mir-520f,MI0003146,Cisplatin,2767,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-520f,hsa-mir-520f,MI0003146,Cisplatin,2767,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19237188,miR-99b,hsa-mir-99b,MI0000746,Cisplatin,2767,"OV19, TOV21G, TOV112D, FUOV1, C13, OV2008, A2780CP, A2780S, IGROV1, T8, OVCAR5, IMCC3, A2008, OVCAR3,  SKOV3, IOSER",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2009,MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy,"Overall, linear regression analysis identified a total of 27 miRNAs (Table 1) that were significantly associated with OVCA cell responsiveness to one or more chemotherapeutic agents in the 16 cell lines."
19270061,miR-328,hsa-mir-328,MI0000804,Mitoxantrone,4212,-,MCF-7 vs MCF-7/MIX,-,-,breast cancer,in vitro,Low,Sensitive,ABCG2,-,2009,MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells.,"Finally, miR-328-directed down-regulation of ABCG2 expression in MCF-7/MX100 cells resulted in an increased mitoxantrone sensitivity, as manifested by a significantly lower IC(50) value (2.46 +/- 1.64 microM) compared with the control (151 +/- 32 microM)."
19276373,miR-205,hsa-mir-205,MI0000285,Gefitinib,123631,"SKBr3, MCF7 and HEK293",-,-,-,breast cancer,in vitro,Low,Sensitive,HER3 receptor,-,2009,microRNA-205 regulates HER3 in human breast cancer.,"The reintroduction of miR-205 in SKBr3 cells inhibits their clonogenic potential and increases the responsiveness to tyrosine-kinase inhibitors Gefitinib and Lapatinib, abrogating the HER3-mediated resistance and restoring a potent proapoptotic activity."
19276373,miR-205,hsa-mir-205,MI0000285,Lapatinib,25183872,"SKBr3, MCF-7 and HEK293",-,-,-,breast cancer,in vitro,Low,Sensitive,HER3 receptor,-,2009,microRNA-205 regulates HER3 in human breast cancer.,"The reintroduction of miR-205 in SKBr3 cells inhibits their clonogenic potential and increases the responsiveness to tyrosine-kinase inhibitors Gefitinib and Lapatinib, abrogating the HER3-mediated resistance and restoring a potent proapoptotic activity."
19351832,miR-221,hsa-mir-221,MI0000298,Dihydrotestosterone,10635,"LNCaP, LNCaP-Abl and LAPC-4",-,-,-,prostate cancer,in vitro,Low,Resistant,P27,-,2009,The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.,Knocking down the expression level of miR-221 and miR-222 with antagonist miRs in the LNCaP-Abl cell line restored the response to the DHT induction of PSA transcription and also increased the growth response of the LNCaP-Abl cells to the androgen treatment.
19351832,miR-222,hsa-mir-222,MI0000299,Dihydrotestosterone,10635,"LNCaP, LNCaP-Abl and LAPC-4",-,-,-,prostate cancer,in vitro,Low,Resistant,P27,-,2009,The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.,Knocking down the expression level of miR-221 and miR-222 with antagonist miRs in the LNCaP-Abl cell line restored the response to the DHT induction of PSA transcription and also increased the growth response of the LNCaP-Abl cells to the androgen treatment.
19412672,let-7e,hsa-let-7e,MI0000066,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,let-7e,hsa-let-7e,MI0000066,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,let-7e*,hsa-let-7e,MI0000066,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,let-7e*,hsa-let-7e,MI0000066,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,let-7f,hsa-let-7f-1,MI0000067,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,let-7f,hsa-let-7f-1,MI0000067,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,let-7g,hsa-let-7g,MI0000433,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,"E2F3, and PXR",-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,let-7g,hsa-let-7g,MI0000433,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,"E2F3, and PXR",-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,let-7i,hsa-let-7i,MI0000434,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,let-7i,hsa-let-7i,MI0000434,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-1,hsa-mir-1-1,MI0000651,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-1,hsa-mir-1-1,MI0000651,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-100,hsa-mir-100,MI0000102,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-100,hsa-mir-100,MI0000102,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-101*,hsa-mir-101-1,MI0000103,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-101*,hsa-mir-101-1,MI0000103,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-10a,hsa-mir-10a,MI0000266,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-10a,hsa-mir-10a,MI0000266,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-10b,hsa-mir-10b,MI0000267,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-10b,hsa-mir-10b,MI0000267,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-125b-1*,hsa-mir-125b-1,MI0000446,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-125b-1*,hsa-mir-125b-1,MI0000446,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-128a,hsa-mir-128-1,MI0000447,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,"E2F3, and PXR",-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-128a,hsa-mir-128-1,MI0000447,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,"E2F3, and PXR",-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-128b,miR-128b,MI0000727,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,"E2F3, and PXR",-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-128b,miR-128b,MI0000727,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,"E2F3, and PXR",-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-130b*,hsa-mir-130b,MI0000748,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-130b*,hsa-mir-130b,MI0000748,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-132,hsa-mir-132,MI0000449,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-132,hsa-mir-132,MI0000449,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-135a,hsa-mir-135a-1,MI0000452,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-135a,hsa-mir-135a-1,MI0000452,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-135b,hsa-mir-135b,MI0000810,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-135b,hsa-mir-135b,MI0000810,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-140,hsa-mir-140,MI0000456,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-140,hsa-mir-140,MI0000456,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-141,hsa-mir-141,MI0000457,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-141,hsa-mir-141,MI0000457,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-141*,hsa-mir-141,MI0000457,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-141*,hsa-mir-141,MI0000457,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-142,hsa-mir-142,MI0000458,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-142,hsa-mir-142,MI0000458,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-143*,hsa-mir-143,MI0000459,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-143*,hsa-mir-143,MI0000459,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-145,hsa-mir-145,MI0000461,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-145,hsa-mir-145,MI0000461,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-146a,hsa-mir-146a,MI0000477,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-146a,hsa-mir-146a,MI0000477,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-146b,hsa-mir-146b,MI0003129,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-146b,hsa-mir-146b,MI0003129,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-148a,hsa-mir-148a,MI0000253,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-148a,hsa-mir-148a,MI0000253,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-151,hsa-mir-151a,MI0000809,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-151,hsa-mir-151a,MI0000809,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-153,hsa-mir-153-1,MI0000463,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-153,hsa-mir-153-1,MI0000463,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-154*,hsa-mir-154,MI0000480,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-154*,hsa-mir-154,MI0000480,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-155,hsa-mir-155,MI0000681,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-155,hsa-mir-155,MI0000681,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-15a*,hsa-mir-15a,MI0000069,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-15a*,hsa-mir-15a,MI0000069,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-15b*,hsa-mir-15b,MI0000438,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-15b*,hsa-mir-15b,MI0000438,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-16,hsa-mir-16-1,MI0000070,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-16,hsa-mir-16-1,MI0000070,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-181a,hsa-mir-181a-2,MI0000269,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-181a,hsa-mir-181a-2,MI0000269,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-181a*,hsa-mir-181a-2,MI0000269,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-181a*,hsa-mir-181a-2,MI0000269,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-181c,hsa-mir-181c,MI0000271,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-181c,hsa-mir-181c,MI0000271,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-181d,hsa-mir-181d,MI0003139,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-181d,hsa-mir-181d,MI0003139,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-182*,hsa-mir-182,MI0000272,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-182*,hsa-mir-182,MI0000272,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-186,hsa-mir-186,MI0000483,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-186,hsa-mir-186,MI0000483,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-18a,hsa-mir-18a,MI0000072,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-18a,hsa-mir-18a,MI0000072,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-190,hsa-mir-190a,MI0000486,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-190,hsa-mir-190a,MI0000486,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-192*,hsa-mir-192,MI0000234,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-192*,hsa-mir-192,MI0000234,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-193a,hsa-mir-193a,MI0000487,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-193a,hsa-mir-193a,MI0000487,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-196a,hsa-mir-196a-1,MI0000238,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-196a,hsa-mir-196a-1,MI0000238,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-196b,hsa-mir-196b,MI0001150,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-196b,hsa-mir-196b,MI0001150,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-199a,hsa-mir-199a-1,MI0000242,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-199a,hsa-mir-199a-1,MI0000242,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-199b,hsa-mir-199b,MI0000282,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-199b,hsa-mir-199b,MI0000282,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-19a,hsa-mir-19a,MI0000073,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-19a,hsa-mir-19a,MI0000073,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-19b,hsa-mir-19b-1,MI0000074,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-19b,hsa-mir-19b-1,MI0000074,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-19b-1*,hsa-mir-19b-1,MI0000074,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-19b-1*,hsa-mir-19b-1,MI0000074,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-200a,hsa-mir-200a,MI0000737,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-200a,hsa-mir-200a,MI0000737,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-200c,hsa-mir-200c,MI0000650,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-200c,hsa-mir-200c,MI0000650,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-205,hsa-mir-205,MI0000285,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-205,hsa-mir-205,MI0000285,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-206,hsa-mir-206,MI0000490,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-206,hsa-mir-206,MI0000490,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-21,hsa-mir-21,MI0000077,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-21,hsa-mir-21,MI0000077,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-214*,hsa-mir-214,MI0000290,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-214*,hsa-mir-214,MI0000290,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-216a,hsa-mir-216a,MI0000292,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-216a,hsa-mir-216a,MI0000292,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-216b,hsa-mir-216b,MI0005569,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-216b,hsa-mir-216b,MI0005569,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-219,hsa-mir-219a-1,MI0000296,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,"K-RAS, and PTEN",-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-219,hsa-mir-219a-1,MI0000296,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,"K-RAS, and PTEN",-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-220,-,-,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-220,-,-,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-221,hsa-mir-221,MI0000298,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-221,hsa-mir-221,MI0000298,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-25,hsa-mir-25,MI0000082,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-25,hsa-mir-25,MI0000082,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-26a,hsa-mir-26a-1,MI0000083,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-26a,hsa-mir-26a-1,MI0000083,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-26a-MM1,-,-,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-26a-MM1,-,-,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-28,hsa-mir-28,MI0000086,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-28,hsa-mir-28,MI0000086,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-299,hsa-mir-299,MI0000744,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-299,hsa-mir-299,MI0000744,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-29a*,hsa-mir-29a,MI0000087,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-29a*,hsa-mir-29a,MI0000087,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-29c,hsa-mir-29c,MI0000735,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,"K-RAS, and PTEN",-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-29c,hsa-mir-29c,MI0000735,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,"K-RAS, and PTEN",-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-301b,hsa-mir-301b,MI0005568,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-301b,hsa-mir-301b,MI0005568,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-302a,hsa-mir-302a,MI0000738,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-302a,hsa-mir-302a,MI0000738,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-302c,hsa-mir-302c,MI0000773,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-302c,hsa-mir-302c,MI0000773,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-302c*,hsa-mir-302c,MI0000773,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-302c*,hsa-mir-302c,MI0000773,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-30a*,hsa-mir-30a,MI0000088,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-30a*,hsa-mir-30a,MI0000088,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-30b*,hsa-mir-30b,MI0000441,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-30b*,hsa-mir-30b,MI0000441,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-30d*,hsa-mir-30d,MI0000255,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-30d*,hsa-mir-30d,MI0000255,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-30e,hsa-mir-30e,MI0000749,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-30e,hsa-mir-30e,MI0000749,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-30e*,hsa-mir-30e,MI0000749,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-30e*,hsa-mir-30e,MI0000749,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-31,hsa-mir-31,MI0000089,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-31,hsa-mir-31,MI0000089,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-31*,hsa-mir-31,MI0000089,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-31*,hsa-mir-31,MI0000089,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-32,hsa-mir-32,MI0000090,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-32,hsa-mir-32,MI0000090,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-320,hsa-mir-320a,MI0000542,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-320,hsa-mir-320a,MI0000542,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-330,hsa-mir-330,MI0000803,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-330,hsa-mir-330,MI0000803,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-331,hsa-mir-331,MI0000812,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-331,hsa-mir-331,MI0000812,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-339,hsa-mir-339,MI0000815,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-339,hsa-mir-339,MI0000815,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-33a,hsa-mir-33a,MI0000091,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-33a,hsa-mir-33a,MI0000091,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-33a*,hsa-mir-33a,MI0000091,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-33a*,hsa-mir-33a,MI0000091,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-33b,hsa-mir-33b,MI0003646,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-33b,hsa-mir-33b,MI0003646,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-345,hsa-mir-345,MI0000825,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-345,hsa-mir-345,MI0000825,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-34a,hsa-mir-34a,MI0000268,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-34a,hsa-mir-34a,MI0000268,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-34b,hsa-mir-34b,MI0000742,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-34b,hsa-mir-34b,MI0000742,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-361,hsa-mir-361,MI0000760,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-361,hsa-mir-361,MI0000760,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-367,hsa-mir-367,MI0000775,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-367,hsa-mir-367,MI0000775,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-369,hsa-mir-369,MI0000777,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-369,hsa-mir-369,MI0000777,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-370,hsa-mir-370,MI0000778,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-370,hsa-mir-370,MI0000778,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-373,hsa-mir-373,MI0000781,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-373,hsa-mir-373,MI0000781,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-373*,hsa-mir-373,MI0000781,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-373*,hsa-mir-373,MI0000781,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-374a*,hsa-mir-374a,MI0000782,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-374a*,hsa-mir-374a,MI0000782,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-376c,hsa-mir-376c,MI0000776,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-376c,hsa-mir-376c,MI0000776,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-410,hsa-mir-410,MI0002465,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-410,hsa-mir-410,MI0002465,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-412,hsa-mir-412,MI0002464,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-412,hsa-mir-412,MI0002464,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-425,hsa-mir-425,MI0001448,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-425,hsa-mir-425,MI0001448,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-429,hsa-mir-429,MI0001641,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-429,hsa-mir-429,MI0001641,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-431,hsa-mir-431,MI0001721,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-431,hsa-mir-431,MI0001721,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-448,hsa-mir-448,MI0001637,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-448,hsa-mir-448,MI0001637,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-450a,hsa-mir-450a-1,MI0001652,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-450a,hsa-mir-450a-1,MI0001652,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-451,hsa-mir-451a,MI0001729,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-451,hsa-mir-451a,MI0001729,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-453,hsa-mir-453,MI0001728,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-453,hsa-mir-453,MI0001728,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-454,hsa-mir-454,MI0003820,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-454,hsa-mir-454,MI0003820,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-455,hsa-mir-455,MI0003513,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-455,hsa-mir-455,MI0003513,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-485,hsa-mir-485,MI0002469,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-485,hsa-mir-485,MI0002469,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-491,hsa-mir-491,MI0003126,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-491,hsa-mir-491,MI0003126,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-496,hsa-mir-496,MI0003136,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-496,hsa-mir-496,MI0003136,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-497,hsa-mir-497,MI0003138,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-497,hsa-mir-497,MI0003138,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-499,hsa-mir-499a,MI0003183,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-499,hsa-mir-499a,MI0003183,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-502,hsa-mir-502,MI0003186,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-502,hsa-mir-502,MI0003186,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-505,hsa-mir-505,MI0003190,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-505,hsa-mir-505,MI0003190,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-509,hsa-mir-509-1,MI0003196,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-509,hsa-mir-509-1,MI0003196,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-514,hsa-mir-514a-1,MI0003198,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-514,hsa-mir-514a-1,MI0003198,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-517a,hsa-miR-517a,MI0003161,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-517a,hsa-miR-517a,MI0003161,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-517b,hsa-miR-517b,MI0003165,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-517b,hsa-miR-517b,MI0003165,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-517c,hsa-mir-517c,MI0003174,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-517c,hsa-mir-517c,MI0003174,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-519b,hsa-mir-519b,MI0003151,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-519b,hsa-mir-519b,MI0003151,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-520a,hsa-mir-520a,MI0003149,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-520a,hsa-mir-520a,MI0003149,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-520b,hsa-miR-520b,MI0003155,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-520b,hsa-miR-520b,MI0003155,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-520c,hsa-miR-520c-3p,MI0003158,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-520c,hsa-miR-520c-3p,MI0003158,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-520d,hsa-mir-520d,MI0003164,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-520d,hsa-mir-520d,MI0003164,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-520g,hsa-miR-520g,MI0003166,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-520g,hsa-miR-520g,MI0003166,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-520h,hsa-miR-520h,MI0003175,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-520h,hsa-miR-520h,MI0003175,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-526b*,hsa-mir-526b,MI0003150,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-526b*,hsa-mir-526b,MI0003150,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-532,hsa-mir-532,MI0003205,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-532,hsa-mir-532,MI0003205,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-539,hsa-mir-539,MI0003514,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-539,hsa-mir-539,MI0003514,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-541*,hsa-mir-541,MI0005539,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-541*,hsa-mir-541,MI0005539,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-542,hsa-mir-542,MI0003686,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-542,hsa-mir-542,MI0003686,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-545,hsa-mir-545,MI0003516,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-545,hsa-mir-545,MI0003516,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-548a,hsa-mir-548a-1,MI0003593,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-548a,hsa-mir-548a-1,MI0003593,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-555,hsa-mir-555,MI0003561,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-555,hsa-mir-555,MI0003561,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-560,hsa-mir-560,MI0003566,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-560,hsa-mir-560,MI0003566,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-563,hsa-mir-563,MI0003569,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-563,hsa-mir-563,MI0003569,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-568,hsa-mir-568,MI0003574,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-568,hsa-mir-568,MI0003574,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-569,hsa-mir-569,MI0003576,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-569,hsa-mir-569,MI0003576,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-571,hsa-mir-571,MI0003578,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-571,hsa-mir-571,MI0003578,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-576,hsa-mir-576,MI0003583,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-576,hsa-mir-576,MI0003583,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-578,hsa-mir-578,MI0003585,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-578,hsa-mir-578,MI0003585,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-582,hsa-mir-582,MI0003589,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-582,hsa-mir-582,MI0003589,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-586,hsa-mir-586,MI0003594,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-586,hsa-mir-586,MI0003594,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-587,hsa-mir-587,MI0003595,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-587,hsa-mir-587,MI0003595,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-588,hsa-mir-588,MI0003597,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-588,hsa-mir-588,MI0003597,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-589*,hsa-mir-589,MI0003599,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-589*,hsa-mir-589,MI0003599,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-590,hsa-mir-590,MI0003602,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-590,hsa-mir-590,MI0003602,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-591,hsa-mir-591,MI0003603,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-591,hsa-mir-591,MI0003603,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-592,hsa-mir-592,MI0003604,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-592,hsa-mir-592,MI0003604,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-593*,hsa-mir-593,MI0003605,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-593*,hsa-mir-593,MI0003605,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-601,hsa-mir-601,MI0003614,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-601,hsa-mir-601,MI0003614,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-605,hsa-mir-605,MI0003618,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-605,hsa-mir-605,MI0003618,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-606,hsa-mir-606,MI0003619,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-606,hsa-mir-606,MI0003619,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-613,hsa-mir-613,MI0003626,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-613,hsa-mir-613,MI0003626,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-629,hsa-mir-629,MI0003643,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-629,hsa-mir-629,MI0003643,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-633,hsa-mir-633,MI0003648,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-633,hsa-mir-633,MI0003648,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-639,hsa-mir-639,MI0003654,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-639,hsa-mir-639,MI0003654,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-643,hsa-mir-643,MI0003658,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-643,hsa-mir-643,MI0003658,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-649,hsa-mir-649,MI0003664,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-649,hsa-mir-649,MI0003664,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-651,hsa-mir-651,MI0003666,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-651,hsa-mir-651,MI0003666,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-652,hsa-mir-652,MI0003667,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-652,hsa-mir-652,MI0003667,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-655,hsa-mir-655,MI0003677,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-655,hsa-mir-655,MI0003677,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-660,hsa-mir-660,MI0003684,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-660,hsa-mir-660,MI0003684,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-662,hsa-mir-662,MI0003670,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-662,hsa-mir-662,MI0003670,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-7-1*,hsa-mir-7-1,MI0000263,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-7-1*,hsa-mir-7-1,MI0000263,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-758,hsa-mir-758,MI0003757,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-758,hsa-mir-758,MI0003757,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-760,hsa-mir-760,MI0005567,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-760,hsa-mir-760,MI0005567,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-765,hsa-mir-765,MI0005116,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-765,hsa-mir-765,MI0005116,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-767,hsa-mir-767,MI0003763,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-767,hsa-mir-767,MI0003763,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-769,hsa-mir-769,MI0003834,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-769,hsa-mir-769,MI0003834,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-876,hsa-mir-876,MI0005542,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-876,hsa-mir-876,MI0005542,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-886,hsa-mir-886,MI0005527,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-886,hsa-mir-886,MI0005527,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-888,hsa-mir-888,MI0005537,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-888,hsa-mir-888,MI0005537,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-92a,hsa-mir-92a-1,MI0000093,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-92a,hsa-mir-92a-1,MI0000093,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-93,hsa-mir-93,MI0000095,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-93,hsa-mir-93,MI0000095,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-96,hsa-mir-96,MI0000098,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-96,hsa-mir-96,MI0000098,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-99a,hsa-mir-99a,MI0000101,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19412672,miR-99a,hsa-mir-99a,MI0000101,Verapamil,2520,-,MCF-7 vs MCF-7/AdrVp,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin,"Following array processing and normalization of raw array data, 181 human microRNAs were detected differentially expressed between the two cell lines, in which 16 microRNAs down-regulated and 165 microRNAs up-regulated in MCF7/AdrVp"
19435867,miR-21,hsa-mir-21,MI0000077,Gemcitabine,60750,"AsPC-1, KP-1N, KP-2, KP-3, PANC-1, SUIT-2, MIA PaCa-2, CAPAN-1, CAPAN-2, CFPAC-1, H48N, HS766T, SW1990 and NOR-P1",-,-,-,pancreatic cancer,in vitro,Low,Resistant,-,-,2009,"MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance.","The cancer cells transfected with the miR-21 precursor showed significantly increased proliferation, Matrigel invasion, and chemoresistance for gemcitabine compared with the control cells."
19435871,miR-200c,hsa-mir-200c,MI0000650,Epothilone B,448013,Hec50,-,-,-,endometrial cancer,in vitro,Low,Sensitive,TUBB3,ZEB1 and ZEB2,2009,MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents.,"As observed with paclitaxel, pre-200c treatment causes substantial and statistically significant increase in chemosensitivity to these two additional microtubule poisons."
19435871,miR-200c,hsa-mir-200c,MI0000650,Paclitaxel,36314,Hec50,-,-,-,endometrial cancer,in vitro,Low,Sensitive,TUBB3,ZEB1 and ZEB2,2009,MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents.,"A significant increase in chemosensitivity to paclitaxel, but not cisplatin, was detected in Hec50 cells transfected with miR-200c."
19435871,miR-200c,hsa-mir-200c,MI0000650,Vincristine,241903,Hec50,-,-,-,endometrial cancer,in vitro,Low,Sensitive,TUBB3,ZEB1 and ZEB2,2009,MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents.,"As observed with paclitaxel, pre-200c treatment causes substantial and statistically significant increase in chemosensitivity to these two additional microtubule poisons."
19458054,miR-155,hsa-mir-155,MI0000681,Doxorubicin (Adriamycin),31703,"HCT-116, DLD-1 and SW480",-,Mice,-,colorectal cancer,in vitro and in vivo,Low,Sensitive,P21,-,2009,A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.,Ad-p53/miR-p21 also significantly increased the chemosensitivity of cancer cells to adriamycin (doxorubicin).
19559015,miR-21,hsa-mir-21,MI0000077,Teniposide,452548,U373MG,-,-,-,glioblastoma,in vitro,Low,Resistant,LRRFIP1,NF-kappaB signaling,2009,MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme.,Suppression of miR-21 by specific antisense oligonucleotides in glioblastoma cell U373 MG led to enhanced cytotoxicities of VM-26 against U373 MG cells.
19581388,miR-27b,hsa-mir-27b,MI0000440,Cyclophosphamide,2907,PANC1,-,-,-,pancreas cancer,in vitro,Low,Resistant,CYP3A4,-,2009,MicroRNAs regulate CYP3A4 expression via direct and indirect targeting.,"Furthermore, overexpression of miR-27b or mmu-miR-298 in PANC1 cells led to a lower sensitivity to cyclophosphamide."
19584283,miR-122,hsa-mir-122,MI0000442,Doxorubicin (Adriamycin),31703,HepG2,-,-,-,hepatocarcinoma,in vitro,Low,Sensitive,cyclin G1,-,2009,MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.,"We assayed the effects of a restored miR-122 expression in triggering doxorubicin-induced apoptosis and we proved that miR-122, as well as cyclin G1 silencing, increases sensitivity to doxorubicin challenge."
19633292,miR-21,hsa-mir-21,MI0000077,Doxorubicin (Adriamycin),31703,MCF-7,-,-,-,breast cancer,in vitro,Low,Sensitive,PDCD4,-,2009,"Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells.","To further evaluate the role of miR-21 in oncogenesis and chemoresistance, MCF-7 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and inhibit its target functions."
19633292,miR-21,hsa-mir-21,MI0000077,Paclitaxel,36314,MCF-7,-,-,-,breast cancer,in vitro,Low,Sensitive,PDCD4,-,2009,"Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells.","To further evaluate the role of miR-21 in oncogenesis and chemoresistance, MCF-7 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and inhibit its target functions."
19654291,let-7a,hsa-let-7a-1,MI0000060,Gemcitabine,60750,"MiaPaCa-2, Panc-1, Aspc-1, L3.6pl, Colo357, BxPC-3, and HPAC",-,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2009,Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-mesenchymal transition in gemcitabineresistantpancreatic cancer cells,"We found that the expression of miR-200b, miR-200c, let-7b, let-7c, let-7d, and let-7e was significantly down-regulated in gemcitabine-resistant cells that showed EMT characteristics such as elongated fibroblastoid morphology"
19654291,let-7b,hsa-let-7b,MI0000063,Gemcitabine,60750,"MiaPaCa-2, Panc-1, Aspc-1, L3.6pl, Colo357, BxPC-3, and HPAC",-,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2009,Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-mesenchymal transition in gemcitabineresistantpancreatic cancer cells,"We found that the expression of miR-200b, miR-200c, let-7b, let-7c, let-7d, and let-7e was significantly down-regulated in gemcitabine-resistant cells that showed EMT characteristics such as elongated fibroblastoid morphology"
19654291,let-7c,hsa-let-7c,MI0000064,Gemcitabine,60750,"MiaPaCa-2, Panc-1, Aspc-1, L3.6pl, Colo357, BxPC-3, and HPAC",-,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2009,Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-mesenchymal transition in gemcitabineresistantpancreatic cancer cells,"We found that the expression of miR-200b, miR-200c, let-7b, let-7c, let-7d, and let-7e was significantly down-regulated in gemcitabine-resistant cells that showed EMT characteristics such as elongated fibroblastoid morphology"
19654291,let-7d,hsa-let-7d,MI0000065,Gemcitabine,60750,"MiaPaCa-2, Panc-1, Aspc-1, L3.6pl, Colo357, BxPC-3, and HPAC",-,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2009,Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-mesenchymal transition in gemcitabineresistantpancreatic cancer cells,"We found that the expression of miR-200b, miR-200c, let-7b, let-7c, let-7d, and let-7e was significantly down-regulated in gemcitabine-resistant cells that showed EMT characteristics such as elongated fibroblastoid morphology"
19654291,let-7f,hsa-let-7f-1,MI0000067,Gemcitabine,60750,"MiaPaCa-2, Panc-1, Aspc-1, L3.6pl, Colo357, BxPC-3, and HPAC",-,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2009,Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-mesenchymal transition in gemcitabineresistantpancreatic cancer cells,"We found that the expression of miR-200b, miR-200c, let-7b, let-7c, let-7d, and let-7e was significantly down-regulated in gemcitabine-resistant cells that showed EMT characteristics such as elongated fibroblastoid morphology"
19654291,miR-200b,hsa-mir-200b,MI0000342,Gemcitabine,60750,"MiaPaCa-2, Panc-1, Aspc-1, L3.6pl, Colo357, BxPC-3, and HPAC",-,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2009,Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-mesenchymal transition in gemcitabineresistantpancreatic cancer cells,"We found that the expression of miR-200b, miR-200c, let-7b, let-7c, let-7d, and let-7e was significantly down-regulated in gemcitabine-resistant cells that showed EMT characteristics such as elongated fibroblastoid morphology"
19654291,miR-200c,hsa-mir-200c,MI0000650,Gemcitabine,60750,"MiaPaCa-2, Panc-1, Aspc-1, L3.6pl, Colo357, BxPC-3, and HPAC",-,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2009,Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-mesenchymal transition in gemcitabineresistantpancreatic cancer cells,"We found that the expression of miR-200b, miR-200c, let-7b, let-7c, let-7d, and let-7e was significantly down-regulated in gemcitabine-resistant cells that showed EMT characteristics such as elongated fibroblastoid morphology"
19671845,miR-200,-,-,Cetuximab,91820602,"253J BV, UMUC3, UMUC5, KU7 and T24",-,-,-,bladder cancer,in vitro,Low,Sensitive,-,-,2009,miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.,"Stable expression of miR-200 in mesenchymal UMUC3 cells increased E-cadherin levels, decreased expression of ZEB1, ZEB2, ERRFI-1, and cell migration, and increased sensitivity to EGFR-blocking agents."
19723889,miR-16,hsa-mir-16-1,MI0000070,Genistein,5280961,New Zealand Black B-cell ,-,-,-,chronic lymphocytic leukemia,in vitro,Low,Sensitive,cyclin D1,-,2009,Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity.,miR-16 Enhances the Ability of Nutlin and Genistein to Promote Apoptosis of Malignant B-1 Cells.
19723889,miR-16,hsa-mir-16-1,MI0000070,Nutlin,216345,New Zealand Black B-cell ,-,-,-,chronic lymphocytic leukemia,in vitro,Low,Sensitive,cyclin D1,-,2009,Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity.,miR-16 Enhances the Ability of Nutlin and Genistein to Promote Apoptosis of Malignant B-1 Cells.
19726678,miR-122,hsa-mir-122,MI0000442,Sorafenib,216239,"HepG2, Hep3B and SK-Hep-1",-,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,"ADAM10, SRF and Igf1R",-,2009,MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.,"Taken together, these results reveal that miR-122 expression promotes growth inhibitory property of sorafenib toward HCC cells."
19734943,miR-140,hsa-mir-140,MI0000456,5-Fluorouracil,3385,HCT-116 ,-,-,-,colon cancer,in vitro,Low,Resistant,HDAC4,-,2009,Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells.,Blocking endogenous miR-140 by locked nucleic acid-modified anti-miR partially sensitized resistant colon cancer stem-like cells to 5-FU treatment.
19734943,miR-140,hsa-mir-140,MI0000456,Methotrexate,126941,HCT116 ,-,-,-,colon cancer,in vitro,Low,Resistant,HDAC4,-,2009,Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells.,Blocking endogenous miR-140 by locked nucleic acid-modified anti-miR partially sensitized resistant colon cancer stem-like cells to 5-FU treatment.
19812400,miR-26,-,-,Interferon-alpha,-,-,-,-,Patients,liver cancer,in vivo,Low,Resistant,-,-,2009,"MicroRNA expression, survival, and response to interferon in liver cancer.",Patient whose tumors had low miR-26 expression had shorter overall survival but a better response to interferon therapy than did Patient whose tumors had high expression of the microRNA.
19839049,miR-200b,hsa-mir-200b,MI0000342,Doxorubicin (Adriamycin),31703,MCF-7 and  MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Sensitive,"BTG2, CRADD, GADD45A and TNF ",-,2010,E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.,"Additionally, disruption of ZEB1-histone deacetylase repressor complexes and down-regulation of SIRT1 histone deacetylase up-regulate proapoptotic genes in the p53 apoptotic pathway resulting in the increased sensitivity of cancer cells to the chemotherapeutic agent doxorubicin."
19839049,miR-200c,hsa-mir-200c,MI0000650,Doxorubicin (Adriamycin),31703,MCF-7 and  MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Sensitive,"BTG2, CRADD, GADD45A and TNF ",-,2010,E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.,"Additionally, disruption of ZEB1-histone deacetylase repressor complexes and down-regulation of SIRT1 histone deacetylase up-regulate proapoptotic genes in the p53 apoptotic pathway resulting in the increased sensitivity of cancer cells to the chemotherapeutic agent doxorubicin."
19843160,miR-143 ,hsa-mir-143,MI0000459,5-Fluorouracil,3385,"HCT-116, SW480, LoVo and SW620",-,-,-,colorectal cancer,in vitro,Low,Sensitive,ERK5,-,2009,MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells.,"In addition, miR-143 increases the sensitivity of colon cancer cells to 5-fluorouracil, probably acting through extracellular-regulated protein kinase 5/nuclear factor-kappaB regulated pathways. "
19883630,miR-17,hsa-mir-17,MI0000071,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19883630,miR-187,hsa-mir-187,MI0000274,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19883630,miR-197,hsa-mir-197,MI0000239,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19883630,miR-19b,hsa-mir-19b-1,MI0000074,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19883630,miR-23b,hsa-mir-23b,MI0000439,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19883630,miR-26b,hsa-mir-26b,MI0000084,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19883630,miR-29a,hsa-mir-29a,MI0000087,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19883630,miR-29b,hsa-mir-29b-1,MI0000105,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19883630,miR-29c,hsa-mir-29c,MI0000735,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19883630,miR-30d,hsa-mir-30d,MI0000255,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19883630,miR-320,hsa-mir-320a,MI0000542,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19883630,miR-326,hsa-mir-326,MI0000808,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,Low,Sensitive,MRP-1,-,2010,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1.,Repression of MRP-1 expression by miR-326 increased sensitivity of MCF-7/VP MDR cells to VP-16 and doxorubicin.
19883630,miR-326,hsa-mir-326,MI0000808,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,Low,Sensitive,MRP-1,-,2010,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1.,Repression of MRP-1 expression by miR-326 increased sensitivity of MCF-7/VP MDR cells to VP-16 and doxorubicin.
19883630,miR-429,hsa-mir-429,MI0001641,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19883630,miR-7,hsa-mir-7-1,MI0000263,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19883630,miR-9,hsa-mir-9-1,MI0000466,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19883630,miR-91,hsa-mir-91,MI0000092,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19883630,miR-92-2,hsa-mir-92a-2,MI0000094,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2009,Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1,Seventeen of miRNAs were differentially expressed in MCF-7/VP cells and their parent cells.
19896708,miR-138,hsa-miR-138-5p,MI0000455,Vincristine,241903,-,HL-60 vs HL-60/VCR,-,-,leukemia,in vitro,Low,Sensitive,-,-,2010,miR-138 might reverse multidrug resistance of leukemia cells.,"Fig. 1 shows that the expression of miR-138 was less in HL-60/VCR than in HL-60 cells, indicating that miR-138 might be related to drugresistant phenotype of leukemia cells."
19900214,miR-192a,-,-,Docetaxel,148124,-,SPC-A1 vs SPC-A1/DOC,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2010,Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1),"In the fold-change analysis  ( Table 1 ),  6 of the 52 flagged miRNAs in SPC-A1/docetaxel cell line showed at least a 2-fold change in expression level compared to the control SPC-A1 cell line"
19900214,miR-194a,-,-,Docetaxel,148124,-,SPC-A1 vs SPC-A1/DOC,-,-,Non-small Cell Lung Cancer,in vitro,High,Sensitive,-,-,2010,Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1),"In the fold-change analysis  ( Table 1 ),  6 of the 52 flagged miRNAs in SPC-A1/docetaxel cell line showed at least a 2-fold change in expression level compared to the control SPC-A1 cell line"
19900214,miR-200b,hsa-mir-200b,MI0000342,Docetaxel,148124,-,SPC-A1 vs SPC-A1/DOC,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2010,Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1),"In the fold-change analysis  ( Table 1 ),  6 of the 52 flagged miRNAs in SPC-A1/docetaxel cell line showed at least a 2-fold change in expression level compared to the control SPC-A1 cell line"
19900214,miR-212a,-,-,Docetaxel,148124,-,SPC-A1 vs SPC-A1/DOC,-,-,Non-small Cell Lung Cancer,in vitro,High,Sensitive,-,-,2010,Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1),"In the fold-change analysis  ( Table 1 ),  6 of the 52 flagged miRNAs in SPC-A1/docetaxel cell line showed at least a 2-fold change in expression level compared to the control SPC-A1 cell line"
19900214,miR-424a,-,-,Docetaxel,148124,-,SPC-A1 vs SPC-A1/DOC,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2010,Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1),"In the fold-change analysis  ( Table 1 ),  6 of the 52 flagged miRNAs in SPC-A1/docetaxel cell line showed at least a 2-fold change in expression level compared to the control SPC-A1 cell line"
19900214,miR-98a,-,-,Docetaxel,148124,-,SPC-A1 vs SPC-A1/DOC,-,-,Non-small Cell Lung Cancer,in vitro,High,Sensitive,-,-,2010,Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1),"In the fold-change analysis  ( Table 1 ),  6 of the 52 flagged miRNAs in SPC-A1/docetaxel cell line showed at least a 2-fold change in expression level compared to the control SPC-A1 cell line"
19960259,miR-27a,hsa-mir-27a,MI0000085,5-Fluorouracil,3385,ECA109 and TE-13,-,-,-,esophageal squamous cell carcinoma,in vitro,Low,Resistant,MDR1,-,2010,Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma.,"Down-regulation of miR-27a could confer sensitivity of both P-glycoprotein-related and P-glycoprotein-non-related drugs on esophageal cancer cells, and might promote ADR-induced apoptosis, accompanied by increased accumulation and decreased releasing amount of ADR."
19960259,miR-27a,hsa-mir-27a,MI0000085,Cisplatin,2767,ECA109 and TE-13,-,-,-,esophageal squamous cell carcinoma,in vitro,Low,Resistant,MDR1,-,2010,Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma.,"Down-regulation of miR-27a could confer sensitivity of both P-glycoprotein-related and P-glycoprotein-non-related drugs on esophageal cancer cells, and might promote ADR-induced apoptosis, accompanied by increased accumulation and decreased releasing amount of ADR."
19960259,miR-27a,hsa-mir-27a,MI0000085,Doxorubicin (Adriamycin),31703,ECA109 and TE-13,-,-,-,esophageal squamous cell carcinoma,in vitro,Low,Resistant,MDR1,-,2010,Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma.,"Down-regulation of miR-27a could confer sensitivity of both P-glycoprotein-related and P-glycoprotein-non-related drugs on esophageal cancer cells, and might promote ADR-induced apoptosis, accompanied by increased accumulation and decreased releasing amount of ADR."
19960259,miR-27a,hsa-mir-27a,MI0000085,Vincristine,241903,ECA109 and TE-13,-,-,-,esophageal squamous cell carcinoma,in vitro,Low,Resistant,MDR1,-,2010,Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma.,"Down-regulation of miR-27a could confer sensitivity of both P-glycoprotein-related and P-glycoprotein-non-related drugs on esophageal cancer cells, and might promote ADR-induced apoptosis, accompanied by increased accumulation and decreased releasing amount of ADR."
20023698,miR-181b,hsa-mir-181b-1,MI0000270,Doxorubicin (Adriamycin),31703,"HepG2, Hep3B, SK-Hep1 and SNU-182",-,-,-,hepatocellular carcinoma,in vitro,Low,Resistant,TIMP3,-,2010,TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3.,miR-181b also enhanced resistance of HCC cells to the anticancer drug doxorubicin.
20054641,miR-128a,hsa-mir-128-1,MI0000447,Anastrozole,2187,-,"MCF-7 vs MCF-7/ARO and T-only vs (T + LET R, T +ANA R, T+EXE R and T+TAM R)",-,-,breast cancer,in vitro,High,Resistant,TGFbR1,-,2010,The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.,Inhibition of endogenous miR-128a resulted in resensitization of the letrozole-resistant lines to TGFBeta growth inhibitory effects.
20054641,miR-128a,hsa-mir-128-1,MI0000447,Exemestane,60198,-,"MCF-7 vs MCF-7/ARO and T-only vs (T + LET R, T +ANA R, T+EXE R and T+TAM R)",-,-,breast cancer,in vitro,High,Resistant,TGFbR1,-,2010,The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.,Inhibition of endogenous miR-128a resulted in resensitization of the letrozole-resistant lines to TGFBeta growth inhibitory effects.
20054641,miR-128a,hsa-mir-128-1,MI0000447,Letrozole,3902,-,"MCF-7 vs MCF-7/ARO and T-only vs (T + LET R, T +ANA R, T+EXE R and T+TAM R)",-,-,breast cancer,in vitro,High,Resistant,TGFbR1,-,2010,The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.,Inhibition of endogenous miR-128a resulted in resensitization of the letrozole-resistant lines to TGFBeta growth inhibitory effects.
20054641,miR-128a,hsa-mir-128-1,MI0000447,Tamoxifen,2733526,-,"MCF-7 vs MCF-7/ARO and T-only vs (T + LET R, T +ANA R, T+EXE R and T+TAM R)",-,-,breast cancer,in vitro,High,Resistant,TGFbR1,-,2010,The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.,Inhibition of endogenous miR-128a resulted in resensitization of the letrozole-resistant lines to TGFBeta growth inhibitory effects.
20082533,miR-21,hsa-mir-21,MI0000077,Paclitaxel,36314,MCF-7,-,-,-,breast carcinoma,in vitro,Low,Resistant,BCL-2,PI3K/AKT pathway,2010,Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells.,These results indicated that the miR-21 plays an important role in the resistance of breast carcinoma cells to chemotherapeutic drugs.
20099276,miR-10a,hsa-mir-10a,MI0000266,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-10b,hsa-mir-10b,MI0000267,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-126,hsa-mir-126,MI0000471,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-127,hsa-mir-127,MI0000472,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-132,hsa-mir-132,MI0000449,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-141,hsa-mir-141,MI0000457,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-146a,hsa-mir-146a,MI0000477,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-194,hsa-mir-194-1,MI0000488,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-196,hsa-mir-196a-1,MI0000238,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-200b,hsa-mir-200b,MI0000342,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-200c,hsa-mir-200c,MI0000650,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-205,hsa-mir-205,MI0000285,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,MRP1,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-206,hsa-mir-206,MI0000490,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-214,hsa-mir-214,MI0000290,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-221,hsa-mir-221,MI0000298,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-222,hsa-mir-222,MI0000299,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-29a,hsa-mir-29a,MI0000087,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-29b,hsa-mir-29b-1,MI0000105,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-342,hsa-mir-342,MI0000805,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-345,hsa-mir-345,MI0000825,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-429,hsa-mir-429,MI0001641,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-489,hsa-mir-489,MI0003124,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,"MRP2, ITGB8",-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20099276,miR-7,hsa-mir-7-1,MI0000263,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,MRP1,-,2010,Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin,Table 1 lists a number of miRNAs that exhibited pronounced changes in expression in the MCF-7/CDDP cells when compared with the parental MCF-7 breast cancer cells.
20103677,miR-100,hsa-mir-100,MI0000102,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-106b,hsa-mir-106b,MI0000734,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-126*,hsa-mir-126,MI0000471,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-130a,hsa-mir-130a,MI0000448,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-130b,hsa-mir-130b,MI0000748,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-135a,hsa-mir-135a-1,MI0000452,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-136,hsa-mir-136,MI0000475,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-146a,hsa-mir-146a,MI0000477,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,Mcl-1,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-146b,hsa-mir-146b,MI0003129,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-148b,hsa-mir-148b,MI0000811,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-181a,hsa-mir-181a-2,MI0000269,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-181b,hsa-mir-181b-1,MI0000270,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-192,hsa-mir-192,MI0000234,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-193b,hsa-mir-193b,MI0003137,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-196a,hsa-mir-196a-1,MI0000238,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-206,hsa-mir-206,MI0000490,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-224,hsa-mir-224,MI0000301,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-345,hsa-mir-345,MI0000825,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-425*,hsa-mir-425,MI0001448,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-483,hsa-mir-483,MI0002467,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-548a,hsa-mir-548a-1,MI0003593,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-548c,hsa-mir-548c,MI0003630,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-551b,hsa-mir-551b,MI0003575,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-565,hsa-mir-565,MI0003571,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-570,hsa-mir-570,MI0003577,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-585,hsa-mir-585,MI0003592,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-627,hsa-mir-627,MI0003641,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-657,hsa-mir-657,MI0003681,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-660,hsa-mir-660,MI0003684,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-663,hsa-mir-663a,MI0003672,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-668,hsa-mir-668,MI0003761,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-768,hsa-mir-768,MI0005117,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20103677,miR-99b,hsa-mir-99b,MI0000746,Sorafenib,216239,"HepG2, Hep-394, Hep-SWX, Huh-7",-,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2010,Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.,We postulated that the differential sensitivity to sorafenib in Hep-394 cells arose as a result of alterations in miRNA expression induced by HCV proteins.
20113523,miR-21,hsa-mir-21,MI0000077,Paclitaxel,36314,U251 and LN229,-,-,-,glioblastoma,in vitro,Low,Resistant,-,-,2010,MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.,"Interestingly, the above data suggested that in both the PTEN mutant and the wild-type GBM cells, miR-21 blockage increased the chemosensitivity to taxol."
20143188,miR-21,hsa-mir-21,MI0000077,Arsenic Trioxide,57347814,HL60 and K562,-,-,-,myelogenous leukemia,in vitro,Low,Resistant,PDCD4,-,2011,miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines.,"Meanwhile, enforced pre-miR-21 expression increased resistance to ATO, nevertheless not affecting cell growth alone."
20148895,miR-21,hsa-mir-21,MI0000077,Arsenic Trioxide,57347814,K562,-,-,-,chronic myelogenous leukemia,in vitro,Low,Resistant,PDCD4,-,2010,Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis.,"Therefore, AMO-miR-21 sensitized leukemic K562 cells to ATO by inducing apoptosis partially due to its up-regulation of PDCD4 protein level."
20162574,miR-181b,hsa-mir-181b-1,MI0000270,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung cancer,in vitro,Low,Sensitive,BCL2,-,2010,miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines.,"Enforced miR-181b expression reduced BCL2 protein level and sensitized SGC7901/VCR and A549/CDDP cells to VCR-induced and CDDP-induced apoptosis, respectively."
20162574,miR-181b,hsa-mir-181b-1,MI0000270,Vincristine,241903,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Sensitive,BCL2,-,2010,miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines.,"Enforced miR-181b expression reduced BCL2 protein level and sensitized SGC7901/VCR and A549/CDDP cells to VCR-induced and CDDP-induced apoptosis, respectively."
20219416,let-7c,hsa-let-7c,MI0000064,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,let-7d,hsa-let-7d,MI0000065,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,let-7e,hsa-let-7e,MI0000066,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,let-7g,hsa-let-7g,MI0000433,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,miR-181d,hsa-mir-181d,MI0003139,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,miR-188,hsa-mir-188,MI0000484,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Sensitive,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,miR-20b,hsa-mir-20b,MI0001519,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,TOP2B,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,miR-214,hsa-mir-214,MI0000290,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,miR-23a,hsa-mir-23a,MI0000079,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,miR-30d,hsa-mir-30d,MI0000255,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,miR-342,hsa-mir-342,MI0000805,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Sensitive,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,miR-373*,hsa-mir-373,MI0000781,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,miR-432,hsa-mir-432,MI0003133,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,miR-498,hsa-mir-498,MI0003142,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,miR-518c*,hsa-mir-518c,MI0003159,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,miR-584,hsa-mir-584,MI0003591,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,miR-608,hsa-mir-608,MI0003621,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20219416,miR-628 ,hsa-mir-628,MI0003642,Cisplatin,2767,-,Tca8113 vs Tca/CDDP,-,-,tongue squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines,Nineteen out of the 480 miRNAs were found differentially expressed between the Tca8113 and Tca/cisplatin cells (P < 0.05).
20371173,miR-125a,hsa-mir-125a,MI0000469,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,MRP1/ABCC1,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-127,hsa-mir-127,MI0000472,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-134,hsa-mir-134,MI0000474,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-143,hsa-mir-143,MI0000459,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-145,hsa-mir-145,MI0000461,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-195,hsa-mir-195,MI0000489,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-216a,hsa-mir-216a,MI0000292,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-217,hsa-mir-217,MI0000293,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-299,hsa-mir-299,MI0000744,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-324,hsa-mir-324,MI0000813,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-329,hsa-mir-329-1,MI0001725,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-376a,hsa-mir-376a-1,MI0000784,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-376c,hsa-mir-376c,MI0000776,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-379,hsa-mir-379,MI0000787,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Resistant,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-382,hsa-mir-382,MI0000790,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Resistant,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-409,hsa-mir-409,MI0001735,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-432,hsa-mir-432,MI0003133,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-485,hsa-mir-485,MI0002469,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Resistant,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-487b,hsa-mir-487b,MI0003530,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Resistant,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-494,hsa-mir-494,MI0003134,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-495,hsa-mir-495,MI0003135,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-654,hsa-mir-654,MI0003676,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Resistant,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371173,miR-99b,hsa-mir-99b,MI0000746,Doxorubicin (Adriamycin),31703,-,NCI-H69 vs NCI-H69/ADR,-,-,small cell lung cancer,in vitro,High,Resistant,-,-,2010,Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis,The expression profiles of 61 miRNAs changed significantly (3.0-256-fold) including 24 up-regulated miRNAs and 37 down-regulated miRNAs in H69AR cells as compared to H69 cells.
20371610,miR-155,hsa-mir-155,MI0000681,Doxorubicin (Adriamycin),31703,"MCF-10A, MCF-7, MDA-MB-157, MDA-MB-231, MDA-MB-361, MDA-MB-435, MDA-MB-453, MDA-MB-468, HS578T, SKBR3 and T47D",-,-,Patients,breast cancer,in vitro and in vivo,Low,Resistant,FOXO3a,-,2010,"MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer.","Ectopic expression of miR-155 induces cell survival and chemoresistance to multiple agents, whereas knockdown of miR-155 renders cells to apoptosis and enhances chemosensitivity."
20371610,miR-155,hsa-mir-155,MI0000681,Etoposide,36462,"MCF-10A, MCF-7,MDA-MB-157, MDA-MB-231, MDA-MB-361, MDA-MB-435, MDA-MB-453, MDA-MB-468, HS578T, SKBR3 and T47D",-,-,Patients,breast cancer,in vitro and in vivo,Low,Resistant,FOXO3a,-,2010,"MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer.","Ectopic expression of miR-155 induces cell survival and chemoresistance to multiple agents, whereas knockdown of miR-155 renders cells to apoptosis and enhances chemosensitivity."
20371610,miR-155,hsa-mir-155,MI0000681,Paclitaxel,36314,"MCF-10A, MCF-7,MDA-MB-157, MDA-MB-231, MDA-MB-361, MDA-MB-435, MDA-MB-453, MDA-MB-468, HS578T, SKBR3, T47D",-,-,Patients,breast cancer,in vitro and in vivo,Low,Resistant,FOXO3a,-,2010,"MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer.","Ectopic expression of miR-155 induces cell survival and chemoresistance to multiple agents, whereas knockdown of miR-155 renders cells to apoptosis and enhances chemosensitivity."
20388782,miR-200,-,-,Gemcitabine,60750,"BxPC-3, MIAPaCa-E and MIAPaCa-M",-,-,-,pancreatic cancer,in vitro,Low,Sensitive,PTEN,-,2010,Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.,We have also documented attenuated expression of miR-200 and increased expression of miR-21 (a signature of tumor aggressiveness) in gemcitabine-resistant cells relative to gemcitabine-sensitive cells. 
20388782,miR-21,hsa-mir-21,MI0000077,Gemcitabine,60750,"BxPC-3, MIAPaCa-E and MIAPaCa-M",-,-,-,pancreatic cancer,in vitro,Low,Sensitive,PTEN,-,2010,Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.,We have also documented attenuated expression of miR-200 and increased expression of miR-21 (a signature of tumor aggressiveness) in gemcitabine-resistant cells relative to gemcitabine-sensitive cells. 
20388802,miR-212,hsa-mir-212,MI0000288,TRAIL therapy,-,Calu-1 and  H460,-,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,PED,-,2010,miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED.,"In this work, we identify miR-212 as a negative regulator of PED expression. We also show that ectopic expression of this miR increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death in NSCLC cells."
20390345,miR-200b,hsa-mir-200b,MI0000342,Doxorubicin (Adriamycin),31703,MDA-MB-231 ,-,-,-,breast cancer,in vitro,Low,Sensitive,FTH1,-,2011,Role of ferritin alterations in human breast cancer cells.,"More importantly, miR-200b-induced down-regulation of ferritin was associated with an increased sensitivity of the MDA-MB-231 cells to the chemotherapeutic agent doxorubicin."
20406806,miR-148a,hsa-mir-148a,MI0000253,Paclitaxel,36314,-,PC-3 vs PC-3/Taxol,-,-,prostate cancer,in vitro,Low,Sensitive,MSK1,-,2010,"MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression.","Transfection with miR-148a precursor inhibited cell growth, and cell migration and invasion, and increased the sensitivity to anti-cancer drug paclitaxel in PC3 cells."
20433742,miR-215,hsa-mir-215,MI0000291,Methotrexate,126941,HCT116 and U2OS,-,-,-,osteosarcoma and colon cancer,in vitro,Low,Resistant,DHFR and TS,-,2010,Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells.,"However, the cells transfected with miR-215 were considerably less sensitive to both chemotherapeutic agents than were control cells. "
20433742,miR-215,hsa-mir-215,MI0000291,Raltitrexed,-,HCT116 and U2OS,-,-,-,osteosarcoma and colon cancer,in vitro,Low,Resistant,DHFR and TS,-,2010,Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells.,"However, the cells transfected with miR-215 were considerably less sensitive to both chemotherapeutic agents than were control cells. "
20444541,hcmv-miR-US25-2,hcmv-mir-US25-2,MI0001685,Temozolomide,5394,"U251MG vs U251R, U251MG,U87MG, M059K and M059J",-,-,-,glioblastoma,in vitro,High,Resistant,-,-,2010,"miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.",Thirteen miRNAs were overexpressed (>2.0-fold) and two were underexpressed (<0.5-fold) in U251R cells compared to U251Wt cells. Fold changes of representative miRNAs expression are listed in Table 1.
20444541,miR-106b*,hsa-mir-106b,MI0000734,Temozolomide,5394,"U251MG vs U251R, U251MG,U87MG, M059K and M059J",-,-,-,glioblastoma,in vitro,High,Resistant,-,-,2010,"miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.",Thirteen miRNAs were overexpressed (>2.0-fold) and two were underexpressed (<0.5-fold) in U251R cells compared to U251Wt cells. Fold changes of representative miRNAs expression are listed in Table 1.
20444541,miR-10a*,hsa-miR-10a-3p,MI0000266,Temozolomide,5394,-,U251MG vs U251/TEM,-,-,glioblastoma,in vitro,Low,Sensitive,-,-,2010,"miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.","Suppression of miR-455-3p or miR-10a(*) had no effect on cell growth, but showed modest cell killing effect in the presence of TMZ. On the other hand, knockdown of miR-195 alone displayed moderate cell killing effect, and combination with TMZ strongly enhanced the effect."
20444541,miR-132,hsa-mir-132,MI0000449,Temozolomide,5394,"U251MG vs U251R, U251MG,U87MG, M059K and M059J",-,-,-,glioblastoma,in vitro,High,Resistant,-,-,2010,"miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.",Thirteen miRNAs were overexpressed (>2.0-fold) and two were underexpressed (<0.5-fold) in U251R cells compared to U251Wt cells. Fold changes of representative miRNAs expression are listed in Table 1.
20444541,miR-193a,hsa-mir-193a,MI0000487,Temozolomide,5394,"U251MG vs U251R, U251MG,U87MG, M059K and M059J",-,-,-,glioblastoma,in vitro,High,Resistant,-,-,2010,"miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.",Thirteen miRNAs were overexpressed (>2.0-fold) and two were underexpressed (<0.5-fold) in U251R cells compared to U251Wt cells. Fold changes of representative miRNAs expression are listed in Table 1.
20444541,miR-193b*,hsa-mir-193b,MI0003137,Temozolomide,5394,"U251MG vs U251R, U251MG,U87MG, M059K and M059J",-,-,-,glioblastoma,in vitro,High,Resistant,-,-,2010,"miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.",Thirteen miRNAs were overexpressed (>2.0-fold) and two were underexpressed (<0.5-fold) in U251R cells compared to U251Wt cells. Fold changes of representative miRNAs expression are listed in Table 1.
20444541,miR-195,hsa-mir-195,MI0000489,Temozolomide,5394,-,U251MG vs U251/TEM,-,-,glioblastoma,in vitro,Low,Sensitive,-,-,2010,"miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.","Suppression of miR-455-3p or miR-10a( *) had no effect on cell growth, but showed modest cell killing effect in the presence of TMZ. On the other hand, knockdown of miR-195 alone displayed moderate cell killing effect, and combination with TMZ strongly enhanced the effect."
20444541,miR-210,hsa-mir-210,MI0000286,Temozolomide,5394,"U251MG vs U251R, U251MG,U87MG, M059K and M059J",-,-,-,glioblastoma,in vitro,High,Resistant,-,-,2010,"miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.",Thirteen miRNAs were overexpressed (>2.0-fold) and two were underexpressed (<0.5-fold) in U251R cells compared to U251Wt cells. Fold changes of representative miRNAs expression are listed in Table 1.
20444541,miR-452,hsa-mir-452,MI0001733,Temozolomide,5394,"U251MG vs U251R, U251MG,U87MG, M059K and M059J",-,-,-,glioblastoma,in vitro,High,Resistant,-,-,2010,"miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.",Thirteen miRNAs were overexpressed (>2.0-fold) and two were underexpressed (<0.5-fold) in U251R cells compared to U251Wt cells. Fold changes of representative miRNAs expression are listed in Table 1.
20444541,miR-455,hsa-mir-455,MI0003513,Temozolomide,5394,-,U251MG vs U251/TEM,-,-,glioblastoma,in vitro,Low,Sensitive,-,-,2010,"miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.","Suppression of miR-455-3p or miR-10a( *) had no effect on cell growth, but showed modest cell killing effect in the presence of TMZ. On the other hand, knockdown of miR-195 alone displayed moderate cell killing effect, and combination with TMZ strongly enhanced the effect."
20444541,miR-500*,hsa-mir-500a,MI0003184,Temozolomide,5394,"U251MG vs U251R, U251MG,U87MG, M059K and M059J",-,-,-,glioblastoma,in vitro,High,Resistant,-,-,2010,"miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.",Thirteen miRNAs were overexpressed (>2.0-fold) and two were underexpressed (<0.5-fold) in U251R cells compared to U251Wt cells. Fold changes of representative miRNAs expression are listed in Table 1.
20444541,miR-502,hsa-mir-502,MI0003186,Temozolomide,5394,"U251MG vs U251R, U251MG,U87MG, M059K and M059J",-,-,-,glioblastoma,in vitro,High,Resistant,-,-,2010,"miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.",Thirteen miRNAs were overexpressed (>2.0-fold) and two were underexpressed (<0.5-fold) in U251R cells compared to U251Wt cells. Fold changes of representative miRNAs expression are listed in Table 1.
20444541,miR-503,hsa-mir-503,MI0003188,Temozolomide,5394,"U251MG vs U251R, U251MG,U87MG, M059K and M059J",-,-,-,glioblastoma,in vitro,High,Sensitive,-,-,2010,"miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.",Thirteen miRNAs were overexpressed (>2.0-fold) and two were underexpressed (<0.5-fold) in U251R cells compared to U251Wt cells. Fold changes of representative miRNAs expression are listed in Table 1.
20444541,miR-584,hsa-mir-584,MI0003591,Temozolomide,5394,"U251MG vs U251R, U251MG,U87MG, M059K and M059J",-,-,-,glioblastoma,in vitro,High,Sensitive,-,-,2010,"miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.",Thirteen miRNAs were overexpressed (>2.0-fold) and two were underexpressed (<0.5-fold) in U251R cells compared to U251Wt cells. Fold changes of representative miRNAs expression are listed in Table 1.
20460378,miR-100,hsa-mir-100,MI0000102,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-100,hsa-mir-100,MI0000102,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-106b,hsa-mir-106b,MI0000734,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-106b,hsa-mir-106b,MI0000734,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-125b,hsa-mir-125b-1,MI0000446,Paclitaxel,36314,"435TR1, 435TRP, MDA-435 and BT474",-,-,-,breast cancer,in vitro,Low,Resistant,Bak1,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,Overexpression of miR-125b markedly inhibited Taxol-induced cytotoxicity in all of the cell lines tested.
20460378,miR-140,hsa-mir-140,MI0000456,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-140,hsa-mir-140,MI0000456,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-146a,hsa-mir-146a,MI0000477,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-146a,hsa-mir-146a,MI0000477,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-146b,hsa-mir-146b,MI0003129,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-146b,hsa-mir-146b,MI0003129,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-15b,hsa-mir-15b,MI0000438,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-15b,hsa-mir-15b,MI0000438,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-16,hsa-mir-16-1,MI0000070,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-16,hsa-mir-16-1,MI0000070,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-17,hsa-mir-17,MI0000071,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-17,hsa-mir-17,MI0000071,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-20b,hsa-mir-20b,MI0001519,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-20b,hsa-mir-20b,MI0001519,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-221,hsa-mir-221,MI0000298,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-221,hsa-mir-221,MI0000298,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-222,hsa-mir-222,MI0000299,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-222,hsa-mir-222,MI0000299,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-27a,hsa-mir-27a,MI0000085,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-27a,hsa-mir-27a,MI0000085,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-29a,hsa-mir-29a,MI0000087,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-29a,hsa-mir-29a,MI0000087,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-29b,hsa-mir-29b-1,MI0000105,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-29b,hsa-mir-29b-1,MI0000105,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-30a,hsa-mir-30a,MI0000088,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-30a,hsa-mir-30a,MI0000088,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-30b,hsa-mir-30b,MI0000441,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-30b,hsa-mir-30b,MI0000441,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-363,hsa-mir-363,MI0000764,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-363,hsa-mir-363,MI0000764,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-620,hsa-mir-620,MI0003634,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-620,hsa-mir-620,MI0003634,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-801,hsa-mir-801,MI0005202,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-801,hsa-mir-801,MI0005202,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Resistant,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460378,miR-923,hsa-mir-923,MI0005715,Paclitaxel,36314,"MDA-MB-435,435TR1, 435TRP, MDA-MB-436. 436TRP, SKBr3, SKRr3-TRP, BT474 ,MDA-MB-231, MCF7",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* S,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxolresistant cells by more than 1.5-fold (Fig. 1A and supplemental Table S1)."
20460378,miR-923,hsa-mir-923,MI0005715,Paclitaxel,36314,-,MDA-435 vs MDA-435/Taxol,-,-,breast cancer,in vitro,High,Sensitive,-,-,2010,MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.,"Eight miRNAs were up-regulated in Taxol-resistant cells by more than 1.5-fold, and 13 miRNAs were down-regulated in Taxol-resistant cells by more than 1.5-fold"
20460539,miR-21,hsa-mir-21,MI0000077,Gemcitabine,60750,"LPc028, LPc067, LPc111 and LPc006",-,-,Patients,pancreatic cancer,in vitro and in vivo,Low,Resistant,PTEN and Akt,-,2010,MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.,"Pre-miR-21 transfection significantly decreased antiproliferative effects and apoptosis induction by gemcitabine, whereas matrix metalloproteinase (MMP)-2/MMP-9 and vascular endothelial growth factor expression were upregulated."
20462046,miR-21,hsa-mir-21,MI0000077,Arsenic Trioxide,57347814,K562,-,-,-,leukemic,in vitro,Low,Resistant,PDCD,-,2010,Study on the sensitivity of leukemic cells to arsenic trioxide enhanced by targeted suppression of mIRNA-21,"Combined use of AMO-miR-21 and As2O3 could increase the sensitivity of K562 cells to As2O3, which provides a novel potential approach for treatment of leukemia."
20485139,miR-296,hsa-mir-296,MI0000747,5-Fluorouracil,3385,ECA109,-,-,-,esophageal squamous cell carcinoma,in vitro,Low,Resistant,MDR1,"Bcl-2, Bax, Bcl-xL, and Bak",2010,The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma.,"Taken together, miR-296 affected not only the sensitivity of cells to P-gp-related drugs VCR and ADR, but also to P-gp-nonrelated drugs 5-flu and CDDP."
20485139,miR-296,hsa-mir-296,MI0000747,Cisplatin,2767,ECA109,-,-,-,esophageal squamous cell carcinoma,in vitro,Low,Resistant,MDR1,"Bcl-2, Bax, Bcl-xL, and Bak",2010,The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma.,"Taken together, miR-296 affected not only the sensitivity of cells to P-gp-related drugs VCR and ADR, but also to P-gp-nonrelated drugs 5-flu and CDDP."
20485139,miR-296,hsa-mir-296,MI0000747,Doxorubicin (Adriamycin),31703,ECA109,-,-,-,esophageal squamous cell carcinoma,in vitro,Low,Resistant,MDR1,"Bcl-2, Bax, Bcl-xL, and Bak",2010,The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma.,"Taken together, miR-296 affected not only the sensitivity of cells to P-gp-related drugs VCR and ADR, but also to P-gp-nonrelated drugs 5-flu and CDDP."
20485139,miR-296,hsa-mir-296,MI0000747,Vincristine,241903,ECA109,-,-,-,esophageal squamous cell carcinoma,in vitro,Low,Resistant,MDR1,"Bcl-2, Bax, Bcl-xL, and Bak",2010,The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma.,"Taken together, miR-296 affected not only the sensitivity of cells to P-gp-related drugs VCR and ADR, but also to P-gp-nonrelated drugs 5-flu and CDDP."
20487546,miR-181a,hsa-mir-181a-2,MI0000269,Fludarabine,657237,-,-,-,Patients,chronic lymphocytic leukemia,in vivo,Low,Resistant,-,-,2010,Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.,"We found that miR-181a and miR-221 were strongly over-represented in cells of resistant Patient, and that miR-29a was significantly down-regulated in Patient resistant in vitro."
20487546,miR-221,hsa-mir-221,MI0000298,Fludarabine,657237,-,-,-,Patients,chronic lymphocytic leukemia,in vivo,Low,Resistant,-,-,2010,Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.,"We found that miR-181a and miR-221 were strongly over-represented in cells of resistant Patient, and that miR-29a was significantly down-regulated in Patient resistant in vitro."
20487546,miR-29a,hsa-mir-29a,MI0000087,Fludarabine,657237,-,-,-,Patients,chronic lymphocytic leukemia,in vivo,Low,Sensitive,-,-,2010,Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.,"We found that miR-181a and miR-221 were strongly over-represented in cells of resistant Patient, and that miR-29a was significantly down-regulated in Patient resistant in vitro."
20498843,miR-21,hsa-mir-21,MI0000077,5-Fluorouracil,3385,PL45 and BxPC-3,-,-,Patients,pancreatic cancer,in vitro and in vivo,Low,Resistant,-,-,2010,Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.,"Low miR-21 expression was associated with benefit from adjuvant treatment in two independent cohorts of PDAC cases, and anti-miR-21 increased anticancer drug activity in vitro."
20498843,miR-21,hsa-mir-21,MI0000077,Gemcitabine,60750,PL45 and BxPC-3,-,-,Patients,pancreatic cancer,in vitro and in vivo,Low,Resistant,-,-,2010,Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.,"Low miR-21 expression was associated with benefit from adjuvant treatment in two independent cohorts of PDAC cases, and anti-miR-21 increased anticancer drug activity in vitro."
20501828,miR-199a,hsa-mir-199a-1,MI0000242,Doxorubicin (Adriamycin),31703,"Huh-7, HepG2 and SNU475",-,-,-,hepatocarcinoma,in vitro,Low,Sensitive,mTOR and c-Met,mTOR and c-Met,2010,MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.,"Restoring attenuated levels of miR-199a-3p in HCC cells led to G(1)-phase cell cycle arrest, reduced invasive capability, enhanced susceptibility to hypoxia, and increased sensitivity to doxorubicin-induced apoptosis."
20548249,miR-92a-2*,hsa-mir-92a-2,MI0000094,Carboplatin,38904,-,-,-,Patients,small cell lung cancer,in vivo,Low,Resistant,-,-,2010,MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in Patient with small cell lung cancer.,Our results demonstrate that higher tumor miR-92a-2* levels are associated with chemoresistance and with decreased survival in Patient with SCLC.
20548249,miR-92a-2*,hsa-mir-92a-2,MI0000094,Cisplatin,2767,-,-,-,Patients,small cell lung cancer,in vivo,Low,Resistant,-,-,2010,MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in Patient with small cell lung cancer.,Our results demonstrate that higher tumor miR-92a-2* levels are associated with chemoresistance and with decreased survival in Patient with SCLC.
20581857,miR-21,hsa-mir-21,MI0000077,Docetaxel,148124,-,PC3 vs PC3R,-,-,prostate cancer,in vitro,Low,Resistant,PDCD4,-,2010,Involvement of microRNA-21 in mediating chemoresistance to docetaxel in androgen-independent prostate cancer PC3 cells,"Ectopic expression of miR-21 increased the resistance to docetaxel in PC3 wild type cells. In contrast, silencing of miR-21 in PC3R cells sensitized the cells to docetaxel."
20624637,miR-27a,hsa-mir-27a,MI0000085,Paclitaxel,36314,-,A2780 vs A2780/Taxol,-,-,ovarian cancer,in vitro,Low,Resistant,HIPK2,-,2010,MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.,"Transfection of A2780/Taxol cells with the inhibitors of miR-27a decreased the expression of MDR1 mRNA and P-gp protein, increased HIPK2 protein expression, enhanced the sensitivity of A2780/taxol cells to paclitaxel."
20627087,miR-186*,hsa-mir-186,MI0000483,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,Low,Resistant,-,-,2010,Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway.,"In addition, transfection of cells with a miR-186 * inhibitor promoted A549/DDP apoptosis, and overexpression of miR-186 * significantly inhibited curcumin-induced apoptosis in A549/DDP cells."
20633539,miR-21,hsa-mir-21,MI0000077,Temozolomide,5394,U87MG,-,-,-,glioblastoma,in vitro,Low,Resistant,-,"Bax, Bcl-2, Caspase-3",2010,MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.,"However, over-express miR-21 in U87MG cells could significantly reduce TMZ-induced apoptosis (P<0.05)."
20646448,miR-27a,hsa-mir-27a,MI0000085,Paclitaxel,36314,-,A2780 vs A2780/Taxol,-,-,ovarian cancer,in vitro,Low,Resistant,HIPK2,-,2010,Expression of microRNA 27a and its correlation with drug resistance in human ovarian cancer A2780/Taxol cells,"The expression of miR-27a is up regulated in A2780/Taxol cells, which may regulate MDRl and P-gp expression by targeting HIPK2."
20670480,miR-21,hsa-mir-21,MI0000077,Cytarabine,6253,HL60,-,-,-,leukemia,in vitro,Low,Sensitive,PDCD4,-,2010,Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis.,Our study suggests that AMO-miR-21 significantly sensitizes HL60 cells to Ara-C by inducing apoptosis and these effects of AMO-miR-21 may be partially due to its up-regulation of PDCD4.
20677554,miR-186*,hsa-mir-186,MI0000483,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung carcinoma,in vitro,Low,Resistant,-,-,2010,Curcumin promoted the apoptosis of cisplain-resistant human lung carcinoma cells A549/DDP through down-regulating miR-186*,"Down-regulation of miR-186* expression by curcumin elevated the apoptosis, and the survival rate of A549/DDP cells decreased; but up-regulation of miR-186* expression by transfection its mimics restrained the apoptosis, the survival rate of A549/DDP cells increased."
20687223,miR-34a,hsa-mir-34a,MI0000268,Paclitaxel,36314,-,PC-3 vs PC-3/Taxol,-,-,prostate cancer,in vitro,Low,Sensitive,Bcl2 and SIRT1,HuR,2010,MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.,MiR-34a over-expression and SIRT1 knockdown attenuated paclitaxel resistance of PC3PR cells.
20693279,let-7a,hsa-let-7a-1,MI0000060,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Sensitive,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,let-7b,hsa-let-7b,MI0000063,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Sensitive,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,let-7d,hsa-let-7d,MI0000065,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Resistant,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,let-7i,hsa-let-7i,MI0000434,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Resistant,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-1,hsa-mir-1-1,MI0000651,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Sensitive,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-10a,hsa-mir-10a,MI0000266,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Resistant,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-128a,hsa-mir-128-1,MI0000447,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Resistant,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-132,hsa-mir-132,MI0000449,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Resistant,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-135b,hsa-mir-135b,MI0000810,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Resistant,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-140,hsa-mir-140,MI0000456,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Resistant,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-148a,hsa-mir-148a,MI0000253,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Sensitive,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-148b,hsa-mir-148b,MI0000811,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Sensitive,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-150,hsa-mir-150,MI0000479,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Sensitive,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-155,hsa-mir-155,MI0000681,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Sensitive,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-15a,hsa-mir-15a,MI0000069,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Resistant,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-181a,hsa-mir-181a-2,MI0000269,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Sensitive,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-181b,hsa-mir-181b-1,MI0000270,Imatinib,5291,-,MYL vs MYL/IMA and K562 vs K562/IMA,-,-,myelogenous leukemia,in vitro,Low,Sensitive,Mcl-1,-,2010,Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.,"In particular, the expression of the miR181 family (a-d) was significantly reduced (-11- to 25-fold) in MYL-R cells."
20693279,miR-181c,hsa-mir-181c,MI0000271,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Sensitive,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-181d,hsa-mir-181d,MI0003139,Imatinib,5291,-,MYL vs MYL/IMA and K562 vs K562/IMA,-,-,myelogenous leukemia,in vitro,Low,Sensitive,Mcl-1,-,2010,Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.,"In particular, the expression of the miR181 family (a-d) was significantly reduced (-11- to 25-fold) in MYL-R cells."
20693279,miR-183,hsa-mir-183,MI0000273,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Sensitive,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-18b,hsa-mir-18b,MI0001518,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Resistant,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-196a,hsa-mir-196a-1,MI0000238,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Resistant,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-21,hsa-mir-21,MI0000077,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Sensitive,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-210,hsa-mir-210,MI0000286,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Resistant,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-212,hsa-mir-212,MI0000288,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Resistant,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-27b,hsa-mir-27b,MI0000440,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Resistant,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-29b,hsa-mir-29b-1,MI0000105,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Resistant,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-34c,hsa-mir-34c,MI0000743,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Resistant,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-9,hsa-mir-9-1,MI0000466,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Sensitive,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20693279,miR-96,hsa-mir-96,MI0000098,Imatinib,5291,-,MYL and MYL/IMA,-,-,myelogenous leukemia,in vitro,High,Sensitive,-,-,2010,Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia,Duplicate experiments demonstrated that 15 miRNAs had a  >2-fold increase in expression in MYL-R cells relative to MYL cells (Fig. 2A) and that 15 miRNAs showed a  >2-fold decrease in relative expression (Fig. 2B). 
20696752,miR-200c,hsa-mir-200c,MI0000650,Cetuximab,91820602,"Calu-1, NCI-H520, and SKMES-1; H596; Calu-3, NCI-H522, and NCI-H1395; NCI-H1299 and NCI-H460; ",-,-,Patients,non-small cell lung cancer,in vitro and in vivo,Low,Sensitive,-,-,2010,"Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer.","Moreover, miR-200c overexpression restored the sensitivity of NCI-H1299 cells to cisplatin and cetuximab."
20696752,miR-200c,hsa-mir-200c,MI0000650,Cisplatin,2767,"Calu-1, NCI H520, SKMES-1, H596, Calu-3, NCI-H522, NCI-H1395, NCI-H1299 and NCI-H460",-,-,Patients,non-small cell lung cancer,in vitro and in vivo,Low,Sensitive,-,-,2010,"Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer.","Moreover, miR-200c overexpression restored the sensitivity of NCI-H1299 cells to cisplatin and cetuximab."
20811155,miR-106b,hsa-mir-106b,MI0000734,Cisplatin,2767,"Tera, Tera-CP, 2102EP, Scha and 833KE",-,-,Patients,testicular cancer,in vitro and in vivo,Low,Associated,P21,-,2010,Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.,We also demonstrated in EC cell lines and human tumor tissue that high cytoplasmic p21 expression and cisplatin resistance of EC were inversely associated with the expression of Oct4 and miR-106b seed family members.
20829195,miR-101,hsa-mir-101-1,MI0000103,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-105,hsa-mir-105-1,MI0000111,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-1233,hsa-mir-1233-1,MI0006323,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-148b*,hsa-mir-148b,MI0000811,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-153,hsa-mir-153-1,MI0000463,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-193a,hsa-mir-193a,MI0000487,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-218-1*,hsa-mir-218-1,MI0000294,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-29b-1,hsa-mir-29b-1,MI0000105,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-29b-2*,hsa-mir-29b-2,MI0000107,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-380,hsa-mir-380,MI0000788,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-518a,hsa-mir-518a-1,MI0003170,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-582,hsa-mir-582,MI0003589,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-605,hsa-mir-605,MI0003618,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-661,hsa-mir-661,MI0003669,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-744*,hsa-mir-744,MI0005559,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-876,hsa-mir-876,MI0005542,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-886,hsa-mir-886,MI0005527,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-892b,hsa-mir-892b,MI0005538,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20829195,miR-935,hsa-mir-935,MI0005757,ABT-263 (navitoclax),24978538,"HCT-116, and CHL1",-,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2010,A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax),"Using a cutoff of 25 % sensitization to ABT-263 treatment, 19 miRNAs were confirmed to sensitize HCT-116 cells to ABT-263 without significantly reducing the viability of the cells in the absence of the drug (Table 1; Supplementary Fig. S2A)."
20856931,miR-212,hsa-mir-212,MI0000288,Cetuximab,91820602,SCC1 and 1Cc8 ,-,-,-,head and neck squamous cell carcinoma,in vitro,Low,Sensitive,HB-EGF,-,2010,Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.,Increased expression of HB-EGF due to down-regulation of miR-212 is a possible mechanism of cetuximab resistance.
20876285,miR-15a,hsa-mir-15a,MI0000069,Tamoxifen,2733526,MCF-7,-,Mice,-,breast cancer,in vitro and in vivo,Low,Sensitive,BCL2,-,2010,Oncogenic HER2 Delta 16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.,Reintroduction of miR-15a/16 reduced tamoxifen-induced BCL-2 expression and sensitized MCF-7/HER2delta16 to tamoxifen.
20876285,miR-16,hsa-mir-16-1,MI0000070,Tamoxifen,2733526,MCF-7,-,Mice,-,breast cancer,in vitro and in vivo,Low,Sensitive,BCL2,-,2010,Oncogenic HER2 Delta 16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.,Reintroduction of miR-15a/16 reduced tamoxifen-induced BCL-2 expression and sensitized MCF-7/HER2delta16 to tamoxifen.
20969775,miR-143,hsa-mir-143,MI0000459,pegIFN/RBV therapy,-,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Resistant,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20969775,miR-143,hsa-mir-143,MI0000459,Ribavirin,37542,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Resistant,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20969775,miR-145,hsa-mir-145,MI0000461,pegIFN/RBV therapy,-,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Resistant,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20969775,miR-145,hsa-mir-145,MI0000461,Ribavirin,37542,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Resistant,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20969775,miR-18a,hsa-mir-18a,MI0000072,pegIFN/RBV therapy,-,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Resistant,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20969775,miR-18a,hsa-mir-18a,MI0000072,Ribavirin,37542,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Resistant,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20969775,miR-27b,hsa-mir-27b,MI0000440,pegIFN/RBV therapy,-,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Sensitive,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20969775,miR-27b,hsa-mir-27b,MI0000440,Ribavirin,37542,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Sensitive,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20969775,miR-34b,hsa-mir-34b,MI0000742,pegIFN/RBV therapy,-,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Resistant,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20969775,miR-34b,hsa-mir-34b,MI0000742,Ribavirin,37542,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Resistant,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20969775,miR-378,hsa-mir-378a,MI0000786,pegIFN/RBV therapy,-,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Sensitive,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20969775,miR-378,hsa-mir-378a,MI0000786,Ribavirin,37542,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Sensitive,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20969775,miR-422b,hsa-mir-422b,MI0001443,pegIFN/RBV therapy,-,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Sensitive,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20969775,miR-422b,hsa-mir-422b,MI0001443,Ribavirin,37542,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Sensitive,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20969775,miR-652,hsa-mir-652,MI0003667,pegIFN/RBV therapy,-,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Resistant,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20969775,miR-652,hsa-mir-652,MI0003667,Ribavirin,37542,-,-,-,Patientss,chronic hepatitis (CH) C,in vivo,High,Resistant,-,-,2010,Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.,"To isolate the miRNAs that were associated with the drug response to the combination therapy, we chose miRNAs which had >/= 1.25 fold difference in the mean values of the gene expression level between at least two groups (p < 0.05)."
20978511,miR-21,hsa-mir-21,MI0000077,5-Fluorouracil,3385,PLC/PRF/5 and HepG2,-,Mice,-,hepatocellular carcinoma,in vitro and in vivo,Low,Resistant,PETN and PDCD4,-,2010,MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells.,"Transfection of anti-miR-21 rendered HCC cells sensitive to IFN-alpha/5-FU, and such sensitivity was weakened by transfection of siRNAs of target molecules, PETN and PDCD4."
20978511,miR-21,hsa-mir-21,MI0000077,Interferon-alpha,-,PLC/PRF/5 and HepG2,-,Mice,-,hepatocellular carcinoma,in vitro and in vivo,Low,Resistant,PETN and PDCD4,-,2010,MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells.,"Transfection of anti-miR-21 rendered HCC cells sensitive to IFN-alpha/5-FU, and such sensitivity was weakened by transfection of siRNAs of target molecules, PETN and PDCD4."
21029414,miR-24,hsa-mir-24-1,MI0000080,Docetaxel,148124,-,-,-,Patientss,"Gastric cancer, Lung cancer",in vivo,High,Resistant,-,-,2010,Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions,"miR-24, miR-26a and miR-30d were expressed significantly differently between groups (P =0.006, 0.021 and 0.011, respectively). "
21029414,miR-26a,hsa-mir-26a-1,MI0000083,Docetaxel,148124,-,-,-,Patientss,"Gastric cancer, Lung cancer",in vivo,High,Resistant,-,-,2010,Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions,"miR-24, miR-26a and miR-30d were expressed significantly differently between groups (P =0.006, 0.021 and 0.012, respectively)."
21029414,miR-30d,hsa-mir-30d,MI0000255,Docetaxel,148124,-,-,-,Patientss,"Gastric cancer, Lung cancer",in vivo,High,Resistant,-,-,2010,Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions,"miR-24, miR-26a and miR-30d were expressed significantly differently between groups (P =0.006, 0.021 and 0.013, respectively)."
21051560,miR-200c,hsa-mir-200c,MI0000650,Paclitaxel,36314,-,-,-,Patients,ovarian cancer ,in vivo,Low,Sensitive,Beta-tubulin,-,2010,The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer Patient.,The Patient who did not achieve a complete clinical response had lower miR-200c levels than those Patient with CRs.
21055388,miR-199a,hsa-mir-199a-1,MI0000242,Doxorubicin (Adriamycin),31703,SNU449,-,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,CD44,-,2010,miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines.,Transfection of miR-199a-3p into SNU449 cells reduced in vitro invasion and sensitized the cells to doxorubicin; both effects were enhanced when hyaluronic acid (HA) was added to the cell cultures.
21057537,miR-221,hsa-mir-221,MI0000298,Fulvestrant,104741,BT474,MCF-7 vs MCF-7/FUL,-,-,breast cancer,in vitro,Low,Resistant,b-Catenin,-,2011,MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.,"Taken together, these results indicate that miR-221/222 overexpression in ERa-positive cell lines counteracts the effects of E2 depletion or fulvestrant-induced cell death, thus also conferring hormone-independent growth and fulvestrant resistance."
21057537,miR-222,hsa-mir-222,MI0000299,Fulvestrant,104741,BT474,MCF-7 vs MCF-7/FUL,-,-,breast cancer,in vitro,Low,Resistant,beta-Catenin,-,2011,MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.,"Taken together, these results indicate that miR-221/222 overexpression in ERa-positive cell lines counteracts the effects of E2 depletion or fulvestrant-induced cell death, thus also conferring hormone-independent growth and fulvestrant resistance."
21067862,miR-34a,hsa-mir-34a,MI0000268,5-Fluorouracil,3385,-,DLD-1 vs DLD-1/5-FU,-,-,colon cancer,in vitro,Low,Sensitive,Sirt1 and E2F3,-,2011,Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells.,"The ectopic expression of miR-34a in the 5-FU-resistant cells inhibited growth, as in the parental cells, and attenuated the resistance to 5-FU through the down-regulation of Sirt1 and E2F3."
21070600,miR-27a,hsa-mir-27a,MI0000085,Doxorubicin (Adriamycin),31703,-,"K562 vs K562/ADR, HL60 vs HL60/ADR and NB4 vs NB4/ADR",-,Patients,leukaemia,in vitro and in vivo,Low,Sensitive,-,-,2011,Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia.,"Transfection of the K562 and, a human promyelocytic cell line (HL) HL60 DOX-resistant cells with miR-331-5p and miR-27a, separately or in combination, resulted in the increased sensitivity of cells to DOX"
21070600,miR-331,hsa-mir-331,MI0000812,Doxorubicin (Adriamycin),31703,-,"K562 vs K562/ADR, HL60 vs HL60/ADR and NB4 vs NB4/ADR",-,Patients,leukaemia,in vitro and in vivo,Low,Sensitive,-,-,2011,Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia.,"Transfection of the K562 and, a human promyelocytic cell line (HL) HL60 DOX-resistant cells with miR-331-5p and miR-27a, separately or in combination, resulted in the increased sensitivity of cells to DOX"
21078976,miR-21,hsa-mir-21,MI0000077,5-Fluorouracil,3385,Colo-320 DM and SW620,-,Mice,-,colorectal cancer,in vitro and in vivo,Low,Resistant,hMSH2,-,2010,MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2).,Cells that overproduce miR-21 exhibit significantly reduced 5-fluorouracil (5-FU)-induced G2/M damage arrest and apoptosis that is characteristic of defects in the core MMR component.
21114921,miR-200c,hsa-mir-200c,MI0000650,5-Fluorouracil,3385,-,SGC7901 vs SGC7901/CDDP,-,-,gastric cancer,in vitro,Low,Sensitive,"E-cadherin, Bcl-2 and Bax",-,2010,Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells.,The sensitivity of Pre-200c-transfected cells to chemotherapeutic drugs was increased.
21114921,miR-200c,hsa-mir-200c,MI0000650,Cisplatin,2767,-,SGC7901 vs SGC7901/CDDP,-,-,gastric cancer,in vitro,Low,Sensitive,"E-cadherin, Bcl-2 and Bax",-,2010,Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells.,The sensitivity of Pre-200c-transfected cells to chemotherapeutic drugs was increased.
21114921,miR-200c,hsa-mir-200c,MI0000650,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/CDDP,-,-,gastric cancer,in vitro,Low,Sensitive,"E-cadherin, Bcl-2 and Bax",-,2010,Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells.,The sensitivity of Pre-200c-transfected cells to chemotherapeutic drugs was increased.
21114921,miR-200c,hsa-mir-200c,MI0000650,Paclitaxel,36314,-,SGC7901 vs SGC7901/CDDP,-,-,gastric cancer,in vitro,Low,Sensitive,"E-cadherin, Bcl-2 and Bax",-,2010,Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells.,The sensitivity of Pre-200c-transfected cells to chemotherapeutic drugs was increased.
21122348,let-7f,hsa-let-7f-1,MI0000067,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,leukemia,in vitro,High,Resistant,-,-,2010,Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines,The differentially expressed microRNAs in K562 and K562/A02 cells were an alyzed by microarray technique and Real Time RT-PCR.
21122348,let-7g,hsa-let-7g,MI0000433,Doxorubicin (Adriamycin),31703,-,K562 vs K563/ADR,-,-,leukemia,in vitro,High,Sensitive,-,-,2010,Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines,The differentially expressed microRNAs in K562 and K562/A02 cells were an alyzed by microarray technique and Real Time RT-PCR.
21122348,miR-155,hsa-mir-155,MI0000681,Doxorubicin (Adriamycin),31703,-,K562 vs K564/ADR,-,-,leukemia,in vitro,High,Resistant,-,-,2010,Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines,The differentially expressed microRNAs in K562 and K562/A02 cells were an alyzed by microarray technique and Real Time RT-PCR.
21122348,miR-181a,hsa-mir-181a-2,MI0000269,Doxorubicin (Adriamycin),31703,-,K562 vs K565/ADR,-,-,leukemia,in vitro,High,Sensitive,-,-,2010,Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines,The differentially expressed microRNAs in K562 and K562/A02 cells were an alyzed by microarray technique and Real Time RT-PCR.
21122348,miR-221,hsa-mir-221,MI0000298,Doxorubicin (Adriamycin),31703,-,K562 vs K566/ADR,-,-,leukemia,in vitro,High,Sensitive,-,-,2010,Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines,The differentially expressed microRNAs in K562 and K562/A02 cells were an alyzed by microarray technique and Real Time RT-PCR.
21122348,miR-424,hsa-mir-424,MI0001446,Doxorubicin (Adriamycin),31703,-,K562 vs K567/ADR,-,-,leukemia,in vitro,High,Resistant,-,-,2010,Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines,The differentially expressed microRNAs in K562 and K562/A02 cells were an alyzed by microarray technique and Real Time RT-PCR.
21122348,miR-451,hsa-mir-451a,MI0001729,Doxorubicin (Adriamycin),31703,-,K562 vs K568/ADR,-,-,leukemia,in vitro,High,Sensitive,-,-,2010,Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines,The differentially expressed microRNAs in K562 and K562/A02 cells were an alyzed by microarray technique and Real Time RT-PCR.
21122348,miR-563,hsa-mir-563,MI0003569,Doxorubicin (Adriamycin),31703,-,K562 vs K569/ADR,-,-,leukemia,in vitro,High,Sensitive,-,-,2010,Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines,The differentially expressed microRNAs in K562 and K562/A02 cells were an alyzed by microarray technique and Real Time RT-PCR.
21122348,miR-98,hsa-mir-98,MI0000100,Doxorubicin (Adriamycin),31703,-,K562 vs K570/ADR,-,-,leukemia,in vitro,High,Sensitive,-,-,2010,Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines,The differentially expressed microRNAs in K562 and K562/A02 cells were an alyzed by microarray technique and Real Time RT-PCR.
21141738,miR-21 ,hsa-mir-21,MI0000077,SP600125,44259,"BSY-1, HBC-5, HT1080, MCF-7 and HeLa",-,-,-,cancer stem cell-like SP cells,in vitro,Low,Resistant,-,-,2010,AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells.,Treatment of the cells with the AP-1 inhibitor SP600125 attenuated miR-21 levels and increased topotecan sensitivity.
21172025,miR-342,hsa-mir-342,MI0000805,Tamoxifen,2733526,MCF-7,-,-,-,breast cancer,in vitro,Low,Sensitive,-,-,2010,Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.,"Consistent with these results, qRT-PCR analyses showed that miR-342 is suppressed in the tamoxifen resistant MCF-7/HER2delta16 and TAMR1 cell lines when compared to tamoxifen sensitive MCF-7/pcDNA cells."
21177782,miR-34a,hsa-mir-34a,MI0000268,Cisplatin,2767,"R262, UW228, UW426, R300, D556, D384Med, D425Med and HEK 293T/17",-,-,-,medulloblastoma,in vitro,Low,Sensitive,MAGE-A,p53/p21/WAF1/CIP1,2011,miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma.,"Additionally, the forced expression of miR-34a or the knockdown of MAGE-A genes by small interfering RNA similarly sensitizes medulloblastoma cells to several classes of chemotherapeutic agents, including mitomycin C and cisplatin."
21177782,miR-34a,hsa-mir-34a,MI0000268,Mitomycin C,5746,"R262, UW228, UW426, R300, D556, D384Med, D425Med and HEK 293T/17",-,-,-,medulloblastoma,in vitro,Low,Sensitive,MAGE-A,p53/p21/WAF1/CIP1,2011,miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma.,"Additionally, the forced expression of miR-34a or the knockdown of MAGE-A genes by small interfering RNA similarly sensitizes medulloblastoma cells to several classes of chemotherapeutic agents, including mitomycin C and cisplatin."
21187093,miR-21,hsa-mir-21,MI0000077,Daunorubicin,30323,-,K562 vs K562/DNR,-,-,leukaemia,in vitro,Low,Resistant,-,PTEN and PI3K/Akt pathway,2011,Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line.,"Stable transfection of miR-21 induced drug resistance in K562, while suppression of miR-21 in K562/DNR led to enhanced DNR cytotoxicity."
21195000,miR-182,hsa-mir-182,MI0000272,Olaparib,23725625,MDA-MB-231,-,Mice,-,breast cancer,in vitro and in vivo,Low,Sensitive,BRCA1,-,2011,miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.,"Conversely, antagonizing miR-182 enhances BRCA1 levels and induces resistance to PARP1 inhibitor."
21197560,miR-143,hsa-mir-143,MI0000459,Docetaxel,148124,DU145 and PC3,-,-,Patients,prostate cancer,in vitro and in vivo,Low,Sensitive,KRAS,EGFR/RAS/MAPK pathway,2011,miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS.,"Moreover, over-expression of miR-143 in prostate cancer cells suppressed their proliferation and migration and increased their sensitivity to docetaxel by targeting EGFR/RAS/MAPK pathway."
21219875,miR-328,hsa-mir-328,MI0000804,Mitoxantrone,4212,-,MCF-7 vs MCF-7/MIX,-,-,breast cancer,in vitro,Low,Sensitive,ABCG2,-,2011,"Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.","After successful creation of miRNA expression plasmids, drug-resistance MCF-7/MX100 cells over-expressing ABCG2 were transfected with control and individual miRNA expression plasmids. Compared with the control, transfection with miR-519c or miR-328 expression plasmids led to 30-35% reduction of ABCG2 protein expression in MCF-7/MX100 cells, whereas miR-520h had no significant impact on ABCG2 protein (Fig. 2A) or mRNA expression ."
21219875,miR-519c,hsa-mir-519c,MI0003148,Mitoxantrone,4212,-,MCF-7 vs MCF-7/MIX,-,-,breast cancer,in vitro,Low,Sensitive,ABCG2,-,2011,"Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.","After successful creation of miRNA expression plasmids, drug-resistance MCF-7/MX100 cells over-expressing ABCG2 were transfected with control and individual miRNA expression plasmids. Compared with the control, transfection with miR-519c or miR-328 expression plasmids led to 30-35% reduction of ABCG2 protein expression in MCF-7/MX100 cells, whereas miR-520h had no significant impact on ABCG2 protein (Fig. 2A) or mRNA expression ."
21224400,miR-376c,hsa-mir-376c,MI0000776,Cisplatin,2767,OV2008,-,-,Patients,ovarian cancer ,in vitro and in vivo,Low,Resistant,ALK7,-,2011,MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance.,Overexpression of miR-376c significantly reduced the effect of cisplatin.
21242186,let-7c,hsa-let-7c,MI0000064,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,let-7c,hsa-let-7c,MI0000064,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,let-7c,hsa-let-7c,MI0000064,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,let-7c,hsa-let-7c,MI0000064,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-100,hsa-mir-100,MI0000102,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-100,hsa-mir-100,MI0000102,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-100,hsa-mir-100,MI0000102,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-100,hsa-mir-100,MI0000102,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-125b,hsa-mir-125b-1,MI0000446,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-125b,hsa-mir-125b-1,MI0000446,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-125b,hsa-mir-125b-1,MI0000446,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-125b,hsa-mir-125b-1,MI0000446,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-125b,hsa-mir-125b-1,MI0000446,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-125b,hsa-mir-125b-1,MI0000446,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-125b,hsa-mir-125b-1,MI0000446,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-125b,hsa-mir-125b-1,MI0000446,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-126,hsa-mir-126,MI0000471,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-126,hsa-mir-126,MI0000471,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-126,hsa-mir-126,MI0000471,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-126,hsa-mir-126,MI0000471,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-126*,hsa-mir-126,MI0000471,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-126*,hsa-mir-126,MI0000471,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-126*,hsa-mir-126,MI0000471,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-126*,hsa-mir-126,MI0000471,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-141,hsa-mir-141,MI0000457,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-141,hsa-mir-141,MI0000457,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-141,hsa-mir-141,MI0000457,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-141,hsa-mir-141,MI0000457,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-199b*,hsa-mir-199b,MI0000282,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-199b*,hsa-mir-199b,MI0000282,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-199b*,hsa-mir-199b,MI0000282,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-199b*,hsa-mir-199b,MI0000282,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-200c,hsa-mir-200c,MI0000650,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-200c,hsa-mir-200c,MI0000650,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-200c,hsa-mir-200c,MI0000650,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-200c,hsa-mir-200c,MI0000650,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-203,hsa-mir-203a,MI0000283,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-203,hsa-mir-203a,MI0000283,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-203,hsa-mir-203a,MI0000283,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-203,hsa-mir-203a,MI0000283,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-335,hsa-mir-335,MI0000816,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-335,hsa-mir-335,MI0000816,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-335,hsa-mir-335,MI0000816,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-335,hsa-mir-335,MI0000816,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-383,hsa-mir-383,MI0000791,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-383,hsa-mir-383,MI0000791,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-383,hsa-mir-383,MI0000791,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-383,hsa-mir-383,MI0000791,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-454,hsa-mir-454,MI0003820,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-454,hsa-mir-454,MI0003820,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-454,hsa-mir-454,MI0003820,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-454,hsa-mir-454,MI0003820,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-625,hsa-mir-625,MI0003639,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-625,hsa-mir-625,MI0003639,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-625,hsa-mir-625,MI0003639,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-625,hsa-mir-625,MI0003639,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Sensitive,,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-629,hsa-mir-629,MI0003643,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-629,hsa-mir-629,MI0003643,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-629,hsa-mir-629,MI0003643,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-629,hsa-mir-629,MI0003643,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-9,hsa-mir-9-1,MI0000466,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-9,hsa-mir-9-1,MI0000466,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-9,hsa-mir-9-1,MI0000466,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-9,hsa-mir-9-1,MI0000466,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-99a,hsa-mir-99a,MI0000101,Daunorubicin,30323,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-99a,hsa-mir-99a,MI0000101,L-asparaginase,-,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-99a,hsa-mir-99a,MI0000101,Prednisolone,5755,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242186,miR-99a,hsa-mir-99a,MI0000101,Vincristine,5978,-,-,-,Patientss,lymphoblastic leukemia,in vivo,High,Resistant,-,-,2011,MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia,"Table 2 and Online Supplementary Table S9 show the fold-change for discriminative miRNA and their potential target genes, respectively."
21242194,miR-20a,hsa-mir-20a,MI0000076,5-Fluorouracil,3385,SW620 and SW480,-,-,-,colorectal adenocarcinoma,in vitro,Low,Resistant,BNIP2,-,2011,miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.,"Knockdown of miR-20 by ASO in SW620 cells resulted in increased cell death compared with control cells [Fig. 2(C,E,G)], demonstrating that inhibition of miR-20a-sensitized SW620 cells to these chemotherapeutic agents."
21242194,miR-20a,hsa-mir-20a,MI0000076,Oxaliplatin,5310940,SW620 and SW480,-,-,-,colorectal adenocarcinoma,in vitro,Low,Resistant,BNIP2,-,2011,miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.,"Knockdown of miR-20 by ASO in SW620 cells resulted in increased cell death compared with control cells [Fig. 2(C,E,G)], demonstrating that inhibition of miR-20a-sensitized SW620 cells to these chemotherapeutic agents."
21242194,miR-20a,hsa-mir-20a,MI0000076,Teniposide,452548,SW620 and SW480,-,-,-,colorectal adenocarcinoma,in vitro,Low,Resistant,BNIP2,-,2011,miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.,"Knockdown of miR-20 by ASO in SW620 cells resulted in increased cell death compared with control cells [Fig. 2(C,E,G)], demonstrating that inhibition of miR-20a-sensitized SW620 cells to these chemotherapeutic agents."
21246413,miR-148a,hsa-mir-148a,MI0000253,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,adenocarcinoma,in vitro,Low,Sensitive,-,-,2011,Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells.,"Furthermore, the effect of increased miR-148a levels was again more pronounced with cisplatin treatment, with the decrease in cell viability being -25.0 +/- 9.3% (cisplatin-resistant SCC: p = 0.009) and -30.6 +/- 6.4% (5-FU-resistant SCC: p = 0.014) after treatment."
21246413,miR-148a,hsa-mir-148a,MI0000253,5-Fluorouracil,3385,-,KYSE410 vs KYSE410/5-FU,-,-,squamous cell carcinoma,in vitro,Low,Sensitive,-,-,2011,Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells.,"Furthermore, the effect of increased miR-148a levels was again more pronounced with cisplatin treatment, with the decrease in cell viability being -25.0 +/- 9.3% (cisplatin-resistant SCC: p = 0.009) and -30.6 +/- 6.4% (5-FU-resistant SCC: p = 0.014) after treatment."
21246413,miR-148a,hsa-mir-148a,MI0000253,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,adenocarcinoma,in vitro,Low,Sensitive,-,-,2011,Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells.,"Furthermore, the effect of increased miR-148a levels was again more pronounced with cisplatin treatment, with the decrease in cell viability being -25.0 +/- 9.3% (cisplatin-resistant SCC: p = 0.009) and -30.6 +/- 6.4% (5-FU-resistant SCC: p = 0.014) after treatment."
21246413,miR-148a,hsa-mir-148a,MI0000253,Cisplatin,2767,-,KYSE410 vs KYSE410/CDDP,-,-,squamous cell carcinoma,in vitro,Low,Sensitive,-,-,2011,Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells.,"Furthermore, the effect of increased miR-148a levels was again more pronounced with cisplatin treatment, with the decrease in cell viability being -25.0 +/- 9.3% (cisplatin-resistant SCC: p = 0.009) and -30.6 +/- 6.4% (5-FU-resistant SCC: p = 0.014) after treatment."
21248297,miR-145,hsa-mir-145,MI0000461,5-Fluorouracil,3385,"TE-1, TE8-R, TE-8, TE-10, TE-13,and TE-15",-,-,Patientss,esophageal cancer,in vitro and in vivo,High,Resistant,PPP2R1B,-,2011,Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21248297,miR-145,hsa-mir-145,MI0000461,Cisplatin,2767,"TE-1, TE8-R, TE-8, TE-10, TE-13,and TE-15",-,-,Patientss,esophageal cancer,in vitro and in vivo,High,Resistant,PPP2R1B,-,2011,Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21248297,miR-145,hsa-mir-145,MI0000461,Doxorubicin (Adriamycin),31703,"TE-1, TE8-R, TE-8, TE-10, TE-13,and TE-15",-,-,Patientss,esophageal cancer,in vitro and in vivo,High,Resistant,PPP2R1B,-,2011,Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21248297,miR-200c,hsa-mir-200c,MI0000650,5-Fluorouracil,3385,"TE-1, TE8-R, TE-8, TE-10, TE-13,and TE-15",-,-,Patientss,esophageal cancer,in vitro and in vivo,High,Resistant,-,-,2011,Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21248297,miR-200c,hsa-mir-200c,MI0000650,Cisplatin,2767,-,TE8 vs TE8/CDDP,-,Patients,esophageal cancer,in vitro and in vivo,Low,Resistant,PPP2R1B,Akt pathway,2011,Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.,"In anti-miR-200c-transfected cells, chemosensitivity to cisplatin and apoptosis after exposure to cisplatin was found to increase as compared with the negative control."
21248297,miR-200c,hsa-mir-200c,MI0000650,Doxorubicin (Adriamycin),31703,"TE-1, TE8-R, TE-8, TE-10, TE-13,and TE-15",-,-,Patientss,esophageal cancer,in vitro and in vivo,High,Resistant,-,-,2011,Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21248297,miR-21,hsa-mir-21,MI0000077,5-Fluorouracil,3385,"TE-1, TE8-R, TE-8, TE-10, TE-13,and TE-15",-,-,Patientss,esophageal cancer,in vitro and in vivo,High,Sensitive,-,-,2011,Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21248297,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,"TE-1, TE8-R, TE-8, TE-10, TE-13,and TE-15",-,-,Patientss,esophageal cancer,in vitro and in vivo,High,Sensitive,-,-,2011,Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21248297,miR-21,hsa-mir-21,MI0000077,Doxorubicin (Adriamycin),31703,"TE-1, TE8-R, TE-8, TE-10, TE-13,and TE-15",-,-,Patientss,esophageal cancer,in vitro and in vivo,High,Sensitive,-,-,2011,Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21252292,miR-485,hsa-mir-485,MI0002469,Etoposide,36462,-,CEM  vs CEM/VM-1-5,-,-,lymphoblastic leukemia,in vitro,Low,Sensitive,NF-YB,Top2,2011,Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIalpha and drug responsiveness.,"To test this, we overexpressed miR-485-3p in CEM/VM-1-5 cells and found that this led to reduced expression of NF-YB, a corresponding up-regulation of Top2alpha, and increased sensitivity to the Top2 inhibitors."
21258880,miR-497,hsa-mir-497,MI0003138,Cisplatin,2767,-,SGC7901 vs SGC7901/VCR and A549 vs A549/CDDP,-,-,gastric cancer and lung cancer,in vitro,Low,Sensitive,BCL2,-,2012,miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.,"In vitro drug sensitivity assay demonstrated that overexpression of miR-497 sensitized SGC7901/VCR and A549/CDDP cells to anticancer drugs, respectively."
21258880,miR-497,hsa-mir-497,MI0003138,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung cancer,in vitro,Low,Sensitive,BCL2,-,2012,miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.,"In vitro drug sensitivity assay demonstrated that overexpression of miR-497 sensitized SGC7901/VCR and A549/CDDP cells to anticancer drugs, respectively."
21258880,miR-497,hsa-mir-497,MI0003138,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Sensitive,BCL2,-,2012,miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.,"In vitro drug sensitivity assay demonstrated that overexpression of miR-497 sensitized SGC7901/VCR and A549/CDDP cells to anticancer drugs, respectively."
21258880,miR-497,hsa-mir-497,MI0003138,Vincristine,5978,-,SGC7901 vs SGC7901/VCR and A549 vs A549/CDDP,-,-,gastric cancer and lung cancer,in vitro,Low,Sensitive,BCL2,-,2012,miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.,"In vitro drug sensitivity assay demonstrated that overexpression of miR-497 sensitized SGC7901/VCR and A549/CDDP cells to anticancer drugs, respectively."
21267675,miR-153,hsa-mir-153-1,MI0000463,Arsenic Trioxide,57347814,K562,-,-,-,leukemia,in vitro,Low,Sensitive,-,-,2012,miR-153 sensitized the K562 cells to As2O3-induced apoptosis.,"However, when cells were additionally treated with As2O3, significant greater apoptosis was observed in the miR-153 overexpressed group."
21289630,miR-141,hsa-mir-141,MI0000457,Cisplatin,2767,"KYSE890, KYSE960, KYSE520 and KYSE450",-,-,-,esophageal squamous cell carcinoma,in vitro,Low,Resistant,YAP1,-,2011,MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma.,miR-141 was upregulated the most in the cisplatin-resistant lines as in contrast with the cisplatin-sensitive lines
21289630,miR-19a ,hsa-mir-19a,MI0000073,Cisplatin,2767,"KYSE890, KYSE960, KYSE450, KYSE520, HEK293",-,-,-,esophageal squamous cell carcinoma,in vitro,High,Resistant,-,-,2011,MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21289630,miR-19b,hsa-mir-19b-1,MI0000074,Cisplatin,2767,"KYSE890, KYSE960, KYSE450, KYSE520, HEK293",-,-,-,esophageal squamous cell carcinoma,in vitro,High,Resistant,-,-,2011,MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21289630,miR-200a ,hsa-mir-200a,MI0000737,Cisplatin,2767,"KYSE890, KYSE960, KYSE450, KYSE520, HEK293",-,-,-,esophageal squamous cell carcinoma,in vitro,High,Resistant,-,-,2011,MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21289630,miR-205 ,hsa-mir-205,MI0000285,Cisplatin,2767,"KYSE890, KYSE960, KYSE450, KYSE520, HEK293",-,-,-,esophageal squamous cell carcinoma,in vitro,High,Resistant,-,-,2011,MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21289630,miR-20a ,hsa-mir-20a,MI0000076,Cisplatin,2767,"KYSE890, KYSE960, KYSE450, KYSE520, HEK293",-,-,-,esophageal squamous cell carcinoma,in vitro,High,Resistant,-,-,2011,MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21289630,miR-20b,hsa-mir-20b,MI0001519,Cisplatin,2767,"KYSE890, KYSE960, KYSE450, KYSE520, HEK293",-,-,-,esophageal squamous cell carcinoma,in vitro,High,Resistant,-,-,2011,MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21289630,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,"KYSE890, KYSE960, KYSE450, KYSE520, HEK293",-,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2011,MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21289630,miR-27a ,hsa-mir-27a,MI0000085,Cisplatin,2767,"KYSE890, KYSE960, KYSE450, KYSE520, HEK293",-,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2011,MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma.,"In this study, we used quantitative RT-PCR ( qRT-PCR ) to quantify the expression of 9 miRNAs ( let-7a, let-7g, miR-21, miR-134, miR-145, miR-155, miR-200c, miR-203, and miR-296 ) in esophageal cancer tissues harvested during surgery after a course of preoperative chemotherapy."
21293058,miR-193a,hsa-mir-193a,MI0000487,Cisplatin,2767,JHU-029 and A549,-,Mice,-,squamous cell carcinoma,in vitro and in vivo,Low,Resistant,P73,-,2011,A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.,"Furthermore, miR-193a antagomir expression increased chemosensitivity in response to cisplatin."
21293479,let-7g,hsa-let-7g,MI0000433,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Resistant,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-126,hsa-mir-126,MI0000471,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Resistant,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-132,hsa-mir-132,MI0000449,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Resistant,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-141,hsa-mir-141,MI0000457,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Resistant,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-196a,hsa-mir-196a-1,MI0000238,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Sensitive,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-196b,hsa-mir-196b,MI0001150,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Sensitive,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-19b,hsa-mir-19b-1,MI0000074,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Sensitive,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-200a,hsa-mir-200a,MI0000737,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Sensitive,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-200b,hsa-mir-200b,MI0000342,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Sensitive,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-200c,hsa-mir-200c,MI0000650,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Sensitive,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-224,hsa-mir-224,MI0000301,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Sensitive,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-27a,hsa-mir-27a,MI0000085,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Sensitive,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-31,hsa-mir-31,MI0000089,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Sensitive,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-338,hsa-mir-338,MI0000814,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Resistant,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-365,hsa-mir-365a,MI0000767,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Resistant,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-371,hsa-mir-371a,MI0000779,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Resistant,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-372,hsa-mir-372,MI0000780,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Resistant,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-373,hsa-mir-373,MI0000781,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Resistant,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-424,hsa-mir-424,MI0001446,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Sensitive,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-429,hsa-mir-429,MI0001641,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Resistant,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-452,hsa-mir-452,MI0001733,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Resistant,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-7,hsa-mir-7-1,MI0000263,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Sensitive,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-98,hsa-mir-98,MI0000100,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Resistant,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21293479,miR-99b,hsa-mir-99b,MI0000746,10-Hydroxycamptothecin (HCPT),97226,"BGC-823, SGC-7901, MGC-803, HGC-27, NCI-N87, AGS",,-,-,gastric cancer,in vitro,High,Sensitive,,-,2011,Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecinresistant gastric cancer cells,ANOVA analysis revealed that 137 miRNAs were differentially expressed between the BGC-823 (HCPT-resistant) and AGS (HCPTsensitive) cell lines with a more than 1.5-fold change (P<0.05)(Figure 2A).
21329503,miR-451,hsa-mir-451a,MI0001729,Cisplatin,2767,A549,-,-,Patients,non-small cell lung cancer,in vitro and in vivo,Low,Sensitive,-,Akt signaling pathway,2011,Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549).,"Finally, the effects of miR-451 upregulation on in vitro and in vivo sensitivity of A549 cells of DDP were also determined."
21347785,miR-125a,hsa-mir-125a,MI0000469,Gemcitabine,60750,SUIT-2 and CAPAN-1,-,-,-,pancreatic cancer,in vitro,High,Resistant,,-,2011,MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer,"To confirm our TaqMan miRNA array data, we subjected 11 of the differentially expressed miRNAs (5 upregulated miRNAs: miR-9, miR-27a, miR-424, miR-449b, and miR-34a; 6 downregulated miRNAs: miR-152, miR-181c, miR-518b, miR-125a, miR-142-5p, and miR-204), which were selected on the basis of expression levels and fold changes as promising candidate of clinical markers, to triplicate qRT-PCR analysis, and obtained consistent results (data not shown)."
21347785,miR-142,hsa-mir-142,MI0000458,Gemcitabine,60750,SUIT-2 and CAPAN-1,-,-,-,pancreatic cancer,in vitro,High,Resistant,,-,2011,MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer,"To confirm our TaqMan miRNA array data, we subjected 11 of the differentially expressed miRNAs (5 upregulated miRNAs: miR-9, miR-27a, miR-424, miR-449b, and miR-34a; 6 downregulated miRNAs: miR-152, miR-181c, miR-518b, miR-125a, miR-142-5p, and miR-204), which were selected on the basis of expression levels and fold changes as promising candidate of clinical markers, to triplicate qRT-PCR analysis, and obtained consistent results (data not shown)."
21347785,miR-152,hsa-mir-152,MI0000462,Gemcitabine,60750,SUIT-2 and CAPAN-1,-,-,-,pancreatic cancer,in vitro,High,Resistant,,-,2011,MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer,"To confirm our TaqMan miRNA array data, we subjected 11 of the differentially expressed miRNAs (5 upregulated miRNAs: miR-9, miR-27a, miR-424, miR-449b, and miR-34a; 6 downregulated miRNAs: miR-152, miR-181c, miR-518b, miR-125a, miR-142-5p, and miR-204), which were selected on the basis of expression levels and fold changes as promising candidate of clinical markers, to triplicate qRT-PCR analysis, and obtained consistent results (data not shown)."
21347785,miR-181c,hsa-mir-181c,MI0000271,Gemcitabine,60750,SUIT-2 and CAPAN-1,-,-,-,pancreatic cancer,in vitro,High,Resistant,,-,2011,MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer,"To confirm our TaqMan miRNA array data, we subjected 11 of the differentially expressed miRNAs (5 upregulated miRNAs: miR-9, miR-27a, miR-424, miR-449b, and miR-34a; 6 downregulated miRNAs: miR-152, miR-181c, miR-518b, miR-125a, miR-142-5p, and miR-204), which were selected on the basis of expression levels and fold changes as promising candidate of clinical markers, to triplicate qRT-PCR analysis, and obtained consistent results (data not shown)."
21347785,miR-204,hsa-mir-204,MI0000284,Gemcitabine,60750,SUIT-2 and CAPAN-1,-,-,-,pancreatic cancer,in vitro,High,Resistant,,-,2011,MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer,"To confirm our TaqMan miRNA array data, we subjected 11 of the differentially expressed miRNAs (5 upregulated miRNAs: miR-9, miR-27a, miR-424, miR-449b, and miR-34a; 6 downregulated miRNAs: miR-152, miR-181c, miR-518b, miR-125a, miR-142-5p, and miR-204), which were selected on the basis of expression levels and fold changes as promising candidate of clinical markers, to triplicate qRT-PCR analysis, and obtained consistent results (data not shown)."
21347785,miR-27a,hsa-mir-27a,MI0000085,Gemcitabine,60750,SUIT-2 and CAPAN-1,-,-,-,pancreatic cancer,in vitro,High,Sensitive,,-,2011,MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer,"To confirm our TaqMan miRNA array data, we subjected 11 of the differentially expressed miRNAs (5 upregulated miRNAs: miR-9, miR-27a, miR-424, miR-449b, and miR-34a; 6 downregulated miRNAs: miR-152, miR-181c, miR-518b, miR-125a, miR-142-5p, and miR-204), which were selected on the basis of expression levels and fold changes as promising candidate of clinical markers, to triplicate qRT-PCR analysis, and obtained consistent results (data not shown)."
21347785,miR-34a,hsa-mir-34a,MI0000268,Gemcitabine,60750,SUIT-2 and CAPAN-1,-,-,-,pancreatic cancer,in vitro,High,Sensitive,,-,2011,MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer,"To confirm our TaqMan miRNA array data, we subjected 11 of the differentially expressed miRNAs (5 upregulated miRNAs: miR-9, miR-27a, miR-424, miR-449b, and miR-34a; 6 downregulated miRNAs: miR-152, miR-181c, miR-518b, miR-125a, miR-142-5p, and miR-204), which were selected on the basis of expression levels and fold changes as promising candidate of clinical markers, to triplicate qRT-PCR analysis, and obtained consistent results (data not shown)."
21347785,miR-424,hsa-mir-424,MI0001446,Gemcitabine,60750,SUIT-2 and CAPAN-1,-,-,-,pancreatic cancer,in vitro,High,Sensitive,,-,2011,MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer,"To confirm our TaqMan miRNA array data, we subjected 11 of the differentially expressed miRNAs (5 upregulated miRNAs: miR-9, miR-27a, miR-424, miR-449b, and miR-34a; 6 downregulated miRNAs: miR-152, miR-181c, miR-518b, miR-125a, miR-142-5p, and miR-204), which were selected on the basis of expression levels and fold changes as promising candidate of clinical markers, to triplicate qRT-PCR analysis, and obtained consistent results (data not shown)."
21347785,miR-449b,hsa-mir-449b,MI0003673,Gemcitabine,60750,SUIT-2 and CAPAN-1,-,-,-,pancreatic cancer,in vitro,High,Sensitive,,-,2011,MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer,"To confirm our TaqMan miRNA array data, we subjected 11 of the differentially expressed miRNAs (5 upregulated miRNAs: miR-9, miR-27a, miR-424, miR-449b, and miR-34a; 6 downregulated miRNAs: miR-152, miR-181c, miR-518b, miR-125a, miR-142-5p, and miR-204), which were selected on the basis of expression levels and fold changes as promising candidate of clinical markers, to triplicate qRT-PCR analysis, and obtained consistent results (data not shown)."
21347785,miR-518b,hsa-mir-518b,MI0003156,Gemcitabine,60750,SUIT-2 and CAPAN-1,-,-,-,pancreatic cancer,in vitro,High,Sensitive,,-,2011,MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer,"To confirm our TaqMan miRNA array data, we subjected 11 of the differentially expressed miRNAs (5 upregulated miRNAs: miR-9, miR-27a, miR-424, miR-449b, and miR-34a; 6 downregulated miRNAs: miR-152, miR-181c, miR-518b, miR-125a, miR-142-5p, and miR-204), which were selected on the basis of expression levels and fold changes as promising candidate of clinical markers, to triplicate qRT-PCR analysis, and obtained consistent results (data not shown)."
21347785,miR-9,hsa-mir-9-1,MI0000466,Gemcitabine,60750,SUIT-2 and CAPAN-1,-,-,-,pancreatic cancer,in vitro,High,Sensitive,,-,2011,MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer,"To confirm our TaqMan miRNA array data, we subjected 11 of the differentially expressed miRNAs (5 upregulated miRNAs: miR-9, miR-27a, miR-424, miR-449b, and miR-34a; 6 downregulated miRNAs: miR-152, miR-181c, miR-518b, miR-125a, miR-142-5p, and miR-204), which were selected on the basis of expression levels and fold changes as promising candidate of clinical markers, to triplicate qRT-PCR analysis, and obtained consistent results (data not shown)."
21354697,miR-203,hsa-mir-203a,MI0000283,Paclitaxel,36314,"HCT-15, HT-29 and HTC-116",-,-,-,colon cancer,in vitro,Low,Sensitive,-,-,2011,miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression.,"Importantly, miR-203 overexpression increased the cytotoxic role of paclitaxel in the p53-mutated colon cancer cells, but not in the p53 wild-type cells."
21368878,miR-205,hsa-mir-205,MI0000285,Cisplatin,2767,WPE1-NA22 and WPE1-NB26,-,-,-,prostate cancer,in vitro,Low,Sensitive,BCL2L2,-,2010,Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells.,Overexpression of miR-205 sensitized WPE1-NB26 cells to apoptosis induced by both Docetaxel and Cisplatin (Figure 5a and b).
21368878,miR-205,hsa-mir-205,MI0000285,Docetaxel,148124,WPE1-NA22 and WPE1-NB26,-,-,-,prostate cancer,in vitro,Low,Sensitive,BCL2L2,-,2010,Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells.,Overexpression of miR-205 sensitized WPE1-NB26 cells to apoptosis induced by both Docetaxel and Cisplatin (Figure 5a and b).
21368878,miR-31,hsa-mir-31,MI0000089,Cisplatin,2767,WPE1-NA22 and WPE1-NB26,-,-,-,prostate cancer,in vitro,Low,Sensitive,E2F6,-,2010,Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells.,"Similarly, stable expression of miR-31 also sensitized WPE1-NB26 cells to apoptosis following exposure to these agents (Figure 5c and d)."
21368878,miR-31,hsa-mir-31,MI0000089,Docetaxel,148124,WPE1-NA22 and WPE1-NB26,-,-,-,prostate cancer,in vitro,Low,Sensitive,E2F6,-,2010,Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells.,"Similarly, stable expression of miR-31 also sensitized WPE1-NB26 cells to apoptosis following exposure to these agents (Figure 5c and d)."
21376256,miR-21,hsa-mir-21,MI0000077,Gemcitabine,60750,Mia-PaCa-2,-,-,-,pancreatic cancer,in vitro,Low,Resistant,Bcl-2,Bax,2011,Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells.,"Upregulation of Bcl-2 expression was detected in cells transfected with miR-21 mimics, accompanied by downregulated Bax expression, less apoptosis, lower caspase-3 activity, decreased chemosensitivity to gemcitabine and increased proliferation compared with the control cells."
21390040,miR-141,hsa-mir-141,MI0000457,Cisplatin,2767,Esophageal Squamous Cell Carcinoma Cells,-,-,-,esophageal squamous cell carcinoma,in vitro,Low,Resistant,YAP1,-,2011,A commentary on MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma.,"From these results, they conclude that miR-141 has an important regulatory function in the development of cisplatin resistance in ESCC."
21399894,miR-125,-,-,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Resistant," BCL-2, cyclin D1",-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-125a,hsa-mir-125a,MI0000469,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,ERBB3,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-126,hsa-mir-126,MI0000471,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-126,hsa-mir-126,MI0000471,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,VEGF,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-232)."
21399894,miR129,hsa-mir-129-1,MI0000252,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-129,hsa-mir-129-1,MI0000252,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-233)."
21399894,miR-138,hsa-mir-138-1,MI0000476,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-138,hsa-mir-138-1,MI0000476,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-234)."
21399894,miR-141,hsa-mir-141,MI0000457,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-141,hsa-mir-141,MI0000457,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Resistant,HMGB1,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-235)."
21399894,miR-149,hsa-mir-149,MI0000478,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-149 ,hsa-mir-149,MI0000478,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-236)."
21399894,miR-151,hsa-mir-151a,MI0000809,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-151,hsa-mir-151a,MI0000809,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-237)."
21399894,miR-16,hsa-mir-16-1,MI0000070,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-16,hsa-mir-16-1,MI0000070,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,"BCL2,CDK6,CCND1",-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-238)."
21399894,miR-190b,hsa-mir-190b,MI0005545,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-190b,hsa-mir-190b,MI0005545,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-239)."
21399894,miR-195,hsa-mir-195,MI0000489,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-195,hsa-mir-195,MI0000489,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-240)."
21399894,miR-203 ,hsa-mir-203a,MI0000283,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-241)."
21399894,miR-30a,hsa-mir-30a,MI0000088,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-30a,hsa-mir-30a,MI0000088,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,CDK6,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-242)."
21399894,miR-30d,hsa-mir-30d,MI0000255,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-30d,hsa-mir-30d,MI0000255,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-243)."
21399894,miR-34a,hsa-mir-34a,MI0000268,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Resistant,"BCL-2,CCND1,SIRT1,CDK6",-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-244)."
21399894,miR-34a,hsa-mir-34a,MI0000268,Docetaxel,148124,-,MCF-7 vs MCF7/DOC  and MDA-MB-231 vs MDA-MB-231/DOC,-,-,breast cancer,in vitro,Low,Resistant,BCL-2 and cyclin D1,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"Inhibition of miR-34a enhanced response to docetaxel in MCF-7 docetaxel-resistant cells, whereas overexpression of miR-34a conferred resistance in MCF-7 docetaxel-sensitive cells."
21399894,miR-361,hsa-mir-361,MI0000760,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-361 ,hsa-mir-361,MI0000760,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-245)."
21399894,miR-363,hsa-mir-363,MI0000764,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-363,hsa-mir-363,MI0000764,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-246)."
21399894,miR-429,hsa-mir-429,MI0001641,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Resistant,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-429,hsa-mir-429,MI0001641,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,TUBB2A,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-247)."
21399894,miR-532,hsa-mir-532,MI0003205,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-532,hsa-mir-532,MI0003205,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-248)."
21399894,miR-590,hsa-mir-590,MI0003602,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-590,hsa-mir-590,MI0003602,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-249)."
21399894,miR-7,hsa-mir-7-1,MI0000263,Docetaxel,148124,-,MDA-MB-231 vs MDA-MB-231/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-231)."
21399894,miR-7,hsa-mir-7-1,MI0000263,Docetaxel,148124,"MCF-7, MDA-MB-231",-,-,-,breast cancer,in vitro,High,Sensitive,RAF1,-,2012,miRNA-34a is associated with docetaxel resistance in human breast cancer cells.,"To identify changes in miRNA expression in docetaxelresistant human breast cancer cells, miRNA expression profiling of 376 human miRNAs was performed in two different in vitro breast cancer models of acquired docetaxel resistance (MCF-7, MDA-MB-250)."
21444672,miR-17,hsa-mir-17,MI0000071,Selumetinib,104842,Calu6 and H1437,-,-,-,lung cancer,in vitro,Low,Resistant,-,BIM,2011,STAT3 mediates resistance to MEK inhibitor through microRNA miR-17.,The result showed that overexpression of miR-17 in Calu6 and H1437 cells induced resistance to AZD6244.
21468550,miR-21,hsa-mir-21,MI0000077,Doxorubicin (Adriamycin),31703,T24,-,-,Patients,bladder cancer,in vitro and in vivo,Low,Resistant,PTEN,-,2011,microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells.,"BCL-2 up-regulation could be achieved by miR-21 overexpression, which prevented T24 cells from apoptosis induced by doxorubicin."
21471222,miR-21,hsa-mir-21,MI0000077,Trastuzumab,9903,-,"BT474 vs BT474/TRA, SKBR3 vs SKBR3/TRA and MDA-MB-453 vs MDA-MB-453/TRA",Mice,Patients,breast cancer,in vitro and in vivo,Low,Resistant,PTEN,-,2011,Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.,"Blocking the action of miR-21 with antisense oligonucleotides re-sensitized the resistant cells to the therapeutic activities of trastuzumab by inducing growth arrest, proliferation inhibition, and G(1)-S cell cycle checking in the presence of the antibody."
21531766,miR-9*,hsa-mir-9-1,MI0000466,Carmustine,2578,"A172, A1207, LN18, and LN229",-,-,Patients,glioma,in vitro and in vivo,Low,Sensitive,SOX2,ABCC3 and ABCC6,2011,ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2.,The ID4-miR-9*-SOX2 regulatory axis primes ABCC3/6-mediated chemoresistance in hGSCs derived from GBM Patient.
21552288,miR-135a,hsa-miR-135a-5p,MI0000452,Paclitaxel,36314,-,"MES-SA vs MES-SADX5, SKOV vs SKOVTR, A549 vs A549TR, PC-14 vs PC-14TXT",-,Patients,non-small cell lung carcinoma,in vitro and in vivo,Low,Resistant,-,adenomatous polyposis coli,2011,miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo.,"In paclitaxel-resistant cell lines, established either in vitro or in vivo, blockage of miR-135a sensitized resistant cell lines to paclitaxel-induced cell death."
21560177,miR-100,hsa-mir-100,MI0000102,Docetaxel,148124,-,"UMSCC-1 vs UMSCC-1/DOC, and SQ20B vs SQ20B/DOC",-,-,head and neck squamous cell carcinoma,in vitro,High,Sensitive,-,-,2010,microRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance,"After applying these criteria, the miRNA microarray initially indicated that the expression of 3 miRNAs (miR-100, miR-130a, and miR-197) were downregulated in both UMSC-1/DOC and SQ20B/DOC cells when compared to their parental cells, whereas 4 miRNAs (miR-101, miR-181b, miR-181d, and miR-195) were upregulated (data not shown)"
21560177,miR-101,hsa-mir-101-1,MI0000103,Docetaxel,148124,-,"UMSCC-1 vs UMSCC-1/DOC, and SQ20B vs SQ20B/DOC",-,-,head and neck squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,microRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance,"After applying these criteria, the miRNA microarray initially indicated that the expression of 3 miRNAs (miR-100, miR-130a, and miR-197) were downregulated in both UMSC-1/DOC and SQ20B/DOC cells when compared to their parental cells, whereas 4 miRNAs (miR-101, miR-181b, miR-181d, and miR-195) were upregulated (data not shown)"
21560177,miR-130a,hsa-mir-130a,MI0000448,Docetaxel,148124,-,"UMSCC-1 vs UMSCC-1/DOC, and SQ20B vs SQ20B/DOC",-,-,head and neck squamous cell carcinoma,in vitro,High,Sensitive,-,-,2010,microRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance,"After applying these criteria, the miRNA microarray initially indicated that the expression of 3 miRNAs (miR-100, miR-130a, and miR-197) were downregulated in both UMSC-1/DOC and SQ20B/DOC cells when compared to their parental cells, whereas 4 miRNAs (miR-101, miR-181b, miR-181d, and miR-195) were upregulated (data not shown)"
21560177,miR-181b,hsa-mir-181b-1,MI0000270,Docetaxel,148124,-,"UMSCC-1 vs UMSCC-1/DOC, and SQ20B vs SQ20B/DOC",-,-,head and neck squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,microRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance,"After applying these criteria, the miRNA microarray initially indicated that the expression of 3 miRNAs (miR-100, miR-130a, and miR-197) were downregulated in both UMSC-1/DOC and SQ20B/DOC cells when compared to their parental cells, whereas 4 miRNAs (miR-101, miR-181b, miR-181d, and miR-195) were upregulated (data not shown)"
21560177,miR-181d,hsa-mir-181d,MI0003139,Docetaxel,148124,-,"UMSCC-1 vs UMSCC-1/DOC, and SQ20B vs SQ20B/DOC",-,-,head and neck squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,microRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance,"After applying these criteria, the miRNA microarray initially indicated that the expression of 3 miRNAs (miR-100, miR-130a, and miR-197) were downregulated in both UMSC-1/DOC and SQ20B/DOC cells when compared to their parental cells, whereas 4 miRNAs (miR-101, miR-181b, miR-181d, and miR-195) were upregulated (data not shown)"
21560177,miR-195,hsa-mir-195,MI0000489,Docetaxel,148124,-,"UMSCC-1 vs UMSCC-1/DOC, and SQ20B vs SQ20B/DOC",-,-,head and neck squamous cell carcinoma,in vitro,High,Resistant,-,-,2010,microRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance,"After applying these criteria, the miRNA microarray initially indicated that the expression of 3 miRNAs (miR-100, miR-130a, and miR-197) were downregulated in both UMSC-1/DOC and SQ20B/DOC cells when compared to their parental cells, whereas 4 miRNAs (miR-101, miR-181b, miR-181d, and miR-195) were upregulated (data not shown)"
21560177,miR-197,hsa-mir-197,MI0000239,Docetaxel,148124,-,"UMSCC-1 vs UMSCC-1/DOC, and SQ20B vs SQ20B/DOC",-,-,head and neck squamous cell carcinoma,in vitro,High,Sensitive,-,-,2010,microRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance,"After applying these criteria, the miRNA microarray initially indicated that the expression of 3 miRNAs (miR-100, miR-130a, and miR-197) were downregulated in both UMSC-1/DOC and SQ20B/DOC cells when compared to their parental cells, whereas 4 miRNAs (miR-101, miR-181b, miR-181d, and miR-195) were upregulated (data not shown)"
21569481,miR-27a,hsa-mir-27a,MI0000085,5-Fluorouracil,3385,MKN45,-,-,-,gastric cancer,in vitro,Low,Resistant,-,-,2011,Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells.,"Down-regulation of miR-27a could also confer sensitivity of drugs on gastric cancer cells, and might increase accumulation and decrease releasing amount of adriamycin in gastric cancer cells."
21569481,miR-27a,hsa-mir-27a,MI0000085,Cisplatin,2767,MKN45,-,-,-,gastric cancer,in vitro,Low,Resistant,-,-,2011,Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells.,"Down-regulation of miR-27a could also confer sensitivity of drugs on gastric cancer cells, and might increase accumulation and decrease releasing amount of adriamycin in gastric cancer cells."
21569481,miR-27a,hsa-mir-27a,MI0000085,Doxorubicin (Adriamycin),31703,MKN45,-,-,-,gastric cancer,in vitro,Low,Resistant,-,-,2011,Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells.,"Down-regulation of miR-27a could also confer sensitivity of drugs on gastric cancer cells, and might increase accumulation and decrease releasing amount of adriamycin in gastric cancer cells."
21569481,miR-27a,hsa-mir-27a,MI0000085,Vincristine,5978,MKN45,-,-,-,gastric cancer,in vitro,Low,Resistant,-,-,2011,Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells.,"Down-regulation of miR-27a could also confer sensitivity of drugs on gastric cancer cells, and might increase accumulation and decrease releasing amount of adriamycin in gastric cancer cells."
21575166,miR-100,hsa-mir-100,MI0000102,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-10b,hsa-mir-10b,MI0000267,Cisplatin,2767,-,2102EP vs 2102EP/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-10b,hsa-mir-10b,MI0000267,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-125b,hsa-mir-125b-1,MI0000446,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-125b,hsa-mir-125b-1,MI0000446,Cisplatin,2767,-,"NTERA-2 vs NTERA-2/CDDP, NCCIT vs NCCIT/CDDP, 2102EP vs 2102EP/CDDP",-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-130b,hsa-mir-130b,MI0000748,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-145,hsa-mir-145,MI0000461,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-146,hsa-mir-146a,MI0000477,Cisplatin,2767,-,2102EP vs 2102EP/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-146a,hsa-mir-146a,MI0000477,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-192,hsa-mir-192,MI0000234,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-193a,hsa-mir-193a,MI0000487,Cisplatin,2767,-,"NTERA-2 vs NTERA-2/CDDP, NCCIT vs NCCIT/CDDP, 2102EP vs 2102EP/CDDP",-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-193b,hsa-mir-193b,MI0003137,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-194,hsa-mir-194-1,MI0000488,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-19b-1,hsa-mir-19b-1,MI0000074,Cisplatin,2767,-,2102EP vs 2102EP/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-205,hsa-mir-205,MI0000285,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-205,hsa-mir-205,MI0000285,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-218,hsa-mir-218-1,MI0000294,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-218,hsa-mir-218-1,MI0000294,Cisplatin,2767,-,"NTERA-2 vs NTERA-2/CDDP, NCCIT vs NCCIT/CDDP, 2102EP vs 2102EP/CDDP",-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-221,hsa-mir-221,MI0000298,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-296,hsa-mir-296,MI0000747,Cisplatin,2767,-,"NTERA-2 vs NTERA-2/CDDP, NCCIT vs NCCIT/CDDP, 2102EP vs 2102EP/CDDP",-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-302a,hsa-mir-302a,MI0000738,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-302b,hsa-mir-302b,MI0000772,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-302b,hsa-mir-302b,MI0000772,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-302d,hsa-mir-302d,MI0000774,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-335,hsa-mir-335,MI0000816,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-335*,hsa-mir-335,MI0000816,Cisplatin,2767,-,"NTERA-2 vs NTERA-2/CDDP, NCCIT vs NCCIT/CDDP, 2102EP vs 2102EP/CDDP",-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-34a,hsa-mir-34a,MI0000268,Cisplatin,2767,-,2102EP vs 2102EP/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-362,hsa-mir-362,MI0000762,Cisplatin,2767,-,2102EP vs 2102EP/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-362,hsa-mir-362,MI0000762,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-363,hsa-mir-363,MI0000764,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-365,hsa-mir-365a,MI0000767,Cisplatin,2767,-,"NTERA-2 vs NTERA-2/CDDP, NCCIT vs NCCIT/CDDP, 2102EP vs 2102EP/CDDP",-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-371,hsa-mir-371a,MI0000779,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-372,hsa-mir-372,MI0000780,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-373,hsa-mir-373,MI0000781,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-383,hsa-mir-383,MI0000791,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-424,hsa-mir-424,MI0001446,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-450b,hsa-mir-450b,MI0005531,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-455,hsa-mir-455,MI0003513,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-484,hsa-mir-484,MI0002468,Cisplatin,2767,-,"NTERA-2 vs NTERA-2/CDDP, NCCIT vs NCCIT/CDDP, 2102EP vs 2102EP/CDDP",-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-489,hsa-mir-489,MI0003124,Cisplatin,2767,-,"NTERA-2 vs NTERA-2/CDDP, NCCIT vs NCCIT/CDDP, 2102EP vs 2102EP/CDDP",-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-512,hsa-mir-512-1,MI0003140,Cisplatin,2767,-,2102EP vs 2102EP/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-512,hsa-mir-512-1,MI0003140,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-515,hsa-mir-515-1,MI0003144,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-516b,hsa-mir-516b-1,MI0003172,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-517a,hsa-mir-517a,MI0003161,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-517b,hsa-mir-517b,MI0003165,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-517c,hsa-mir-517c,MI0003174,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-518a,hsa-mir-518a-1,MI0003170,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-518b,hsa-mir-518b,MI0003156,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-518c,hsa-mir-518c,MI0003159,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-518d,hsa-mir-518d,MI0003171,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-518e,hsa-mir-518e,MI0003169,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-518f,hsa-mir-518f,MI0003154,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-519a,hsa-mir-519a-1,MI0003178,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-519b,hsa-mir-519b,MI0003151,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-519c,hsa-mir-519c,MI0003148,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-519d,hsa-mir-519d,MI0003162,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-520b,hsa-mir-520b,MI0003155,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-520c,hsa-mir-520c,MI0003158,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-520f,hsa-mir-520f,MI0003146,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-520g,hsa-mir-520g,MI0003166,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-520h,hsa-mir-520h,MI0003175,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-522,hsa-mir-522,MI0003177,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-523,hsa-mir-523,MI0003153,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-524,hsa-mir-524,MI0003160,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-525,hsa-mir-525,MI0003152,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-526,hsa-mir-526a-1,MI0003157,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-526b,hsa-mir-526b,MI0003150,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-576,hsa-mir-576,MI0003583,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-582,hsa-mir-582,MI0003589,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-708,hsa-mir-708,MI0005543,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-801,hsa-mir-801,MI0005202,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-923,hsa-mir-923,MI0005715,Cisplatin,2767,-,2102EP vs 2102EP/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-935,hsa-mir-935,MI0005757,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Resistant,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21575166,miR-99a,hsa-mir-99a,MI0000101,Cisplatin,2767,-,NTERA-2 vs NTERA-2/CDDP,-,-,germ cell tumor,in vitro,High,Sensitive,-,-,2011,Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.,Altogether 72 of 738 genes appeared differentially expressed (table 2)
21594648,miR-22,hsa-mir-22,MI0000078,Paclitaxel,36314,"HCT-15, HT-29 and HTC-116",-,-,-,colon cancer,in vitro,Low,Sensitive,-,-,2011,Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells.,"Importantly, miR-22 overexpression enhanced the cytotoxic role of paclitaxel in p53-mutated HT-29 and HCT-15 cells, but not in p53 wild-type HCT-116 cell."
21618519,let-7,-,-,Taxane,5394,-,OVCAR-8 vs OVCAR-8/ADR,-,-,ovarian cancer,in vitro,Low,Sensitive,IMP-1,MDR1,2012,Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.,"Introducing let-7g into ADR-RES cells expressing both IMP-1 and MDR1 reduced expression of both proteins rendering the cells more sensitive to treatment with either Taxol or vinblastine without affecting the sensitivity of the cells to carboplatin, a non-MDR1 substrate."
21618519,let-7,-,-,Vinblastine,241903,-,OVCAR-8 vsOVCAR-8/ADR,-,-,ovarian cancer,in vitro,Low,Sensitive,IMP-1,MDR1,2012,Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.,"Introducing let-7g into ADR-RES cells expressing both IMP-1 and MDR1 reduced expression of both proteins rendering the cells more sensitive to treatment with either Taxol or vinblastine without affecting the sensitivity of the cells to carboplatin, a non-MDR1 substrate."
21627863,miR-21,hsa-mir-21,MI0000077,Chemotherapy,-,-,-,-,Patients,non-small cell lung cancer,in vivo,Low,Resistant,-,-,2011,Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer.,The expression of plasma miR-21 was significantly higher in the PD plus SD group than in the PR group.
21652542,miR-10b,hsa-mir-10b,MI0000267,Chemotherapy,-,-,-,-,Patients,pancreatic ductal adenocarcinoma,in vivo,Low,Resistant,-,-,2011,MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma.,"In Patient with PDACs, lower levels of miR-10b were associated with improved response to multimodality neoadjuvant therapy, likelihood of surgical resection, delayed time to metastasis, and increased survival."
21666713,miR-451,hsa-mir-451a,MI0001729,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,Low,Sensitive,-,"HER2, EGFR and MAPK signaling",2012,Tamoxifen downregulation of miR-451 increases 14-3-3zeta and promotes breast cancer cell survival and endocrine resistance.,"Increasing the level of miR-451 by overexpression, which decreased 14-3-3zeta, suppressed cell proliferation and colony formation, markedly reduced activation of HER2, EGFR and MAPK signaling, increased apoptosis, and, importantly, restored the growth-inhibitory effectiveness of SERMs in endocrine-resistant cells."
21685938,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,HSC-3,-,-,-,head and neck squamous cell carcinoma,in vitro,Low,Sensitive,PDCD4,IAP,2012,Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells.,Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells.
21702042,miR-34a,hsa-mir-34a,MI0000268,Cisplatin,2767,"T24, TCCSUP and 5637",-,-,Patients,bladder cancer,in vitro and in vivo,Low,Sensitive,Cdk6 and SIRT-1,-,2012,MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status.,"We demonstrate that transfection of T24, TCCSUP and 5637 with pre-miR-34a followed by cisplatin treatment results in a dramatic reduction in clonogenic potential and induction of senescence compared to treatment with cisplatin alone."
21706050,miR-130a,hsa-mir-130a,MI0000448,TRAIL therapy,-,"A549, A459 and H1299",-,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,MET,"P27, PTEN and TIMP3",2012,miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222.,"Two microRNAs, miR-221 and miR-222, upregulated by the MET proto-oncogene, have been already described to enhance cell survival and to induce TNF-related apoptosis-inducing ligand (TRAIL) resistance in NSCLC cell lines."
21706050,miR-221,hsa-mir-221,MI0000298,TRAIL therapy,-,"A549, A459 and H1299",-,-,-,non-small cell lung cancer,in vitro,Low,Resistant,-,"P27, PTEN and TIMP3",2012,miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222.,"Here, we further investigated this pathway and showed that miR-130a, expressed at low level in lung cancer cell lines, by targeting MET was able to reduce TRAIL resistance in NSCLC cells through the c-Jun-mediated downregulation of miR-221 and miR-222."
21706050,miR-222,hsa-mir-222,MI0000299,TRAIL therapy,-,"A549, A459 and H1299",-,-,-,non-small cell lung cancer,in vitro,Low,Resistant,-,"P27, PTEN and TIMP3",2012,miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222.,"Here, we further investigated this pathway and showed that miR-130a, expressed at low level in lung cancer cell lines, by targeting MET was able to reduce TRAIL resistance in NSCLC cells through the c-Jun-mediated downregulation of miR-221 and miR-222."
21712475,miR-7,hsa-mir-7-1,MI0000263,Gefitinib,123631,H3255 and H1975,PC-9 vs PC-9/R,Mice,-,lung cancer,in vitro and in vivo,Low,Sensitive,EGFR,EGFR-AKT pathway,2011,Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells.,miR-7-expressing plasmid has antitumor effects against EGFR-TKI-resistant cell lines in vivo through multiple suppression of the EGFR-AKT and salvage pathway.
21725369,miR-15b,hsa-mir-15b,MI0000438,Cisplatin,2767,-,CAL27 vs CAL27/CDDP and SCC25 vs SCC25/CDDP,Mice,Patients,tongue cancer,in vitro and in vivo,Low,Sensitive,BMI1,-,2012,MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.,"Ectopic expression of miR-200b and miR-15b with miRNA mimics effectively reversed the phenotype of EMT in CAL27-res and SCC25-res cells, and sensitized them to chemotherapy, but inhibition of miR-200b and miR-15b in the sensitive lines with anti-sense oligonucleotides induced EMT and conferred chemoresistance."
21725369,miR-200b,hsa-mir-200b,MI0000342,Cisplatin,2767,-,CAL27 vs CAL27/CDDP and SCC25 vs SCC25/CDDP,Mice,Patients,tongue cancer,in vitro and in vivo,Low,Sensitive,BMI1,-,2012,MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.,"Ectopic expression of miR-200b and miR-15b with miRNA mimics effectively reversed the phenotype of EMT in CAL27-res and SCC25-res cells, and sensitized them to chemotherapy, but inhibition of miR-200b and miR-15b in the sensitive lines with anti-sense oligonucleotides induced EMT and conferred chemoresistance."
21725603,let-7d,hsa-let-7d,MI0000065,Cisplatin,2767,Oral Cancer Tumor Initiating Cells,-,-,-,oral cancer,in vitro,Low,Sensitive,"Twist, Snail, Vimentin and N-cadherin",-,2011,Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer.,"Notably, overexpression of let-7d effectively reversed the EMT phenotype, blocked migratory/invasive abilities, and further increased the chemosensitivity in oral cancer tumor initiating ALDH1+ cells."
21725603,let-7d,hsa-let-7d,MI0000065,Paclitaxel,36314,Oral Cancer Tumor Initiating Cells,-,-,-,oral cancer,in vitro,Low,Sensitive,"Twist, Snail, Vimentin and N-cadherin",-,2011,Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer.,"Notably, overexpression of let-7d effectively reversed the EMT phenotype, blocked migratory/invasive abilities, and further increased the chemosensitivity in oral cancer tumor initiating ALDH1+ cells."
21750653,miR-122,hsa-mir-122,MI0000442,Cisplatin,2767,Huh7,-,Mice,-,hepatocellular carcinoma,in vitro and in vivo,Low,Sensitive,PSMD10,unfolded protein response pathway,2011,Modulation of the unfolded protein response is the core of microRNA-122-involved sensitivity to chemotherapy in hepatocellular carcinoma.,"This result was confirmed using a gain-of-function analysis, which showed that miR-122 enhanced the sensitivity of HepG2 cells to cisplatin or DOX."
21750653,miR-122,hsa-mir-122,MI0000442,Doxorubicin (Adriamycin),31703,Huh7,-,Mice,-,hepatocellular carcinoma,in vitro and in vivo,Low,Sensitive,PSMD10,unfolded protein response pathway,2011,Modulation of the unfolded protein response is the core of microRNA-122-involved sensitivity to chemotherapy in hepatocellular carcinoma.,"This result was confirmed using a gain-of-function analysis, which showed that miR-122 enhanced the sensitivity of HepG2 cells to cisplatin or DOX."
21787234,miR-1228*,hsa-mir-1228,MI0006318,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2011,Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP),"The miRNA expression profile showed that 5 human miRNAs were down-regulated more than 2-fold in A549/DDP cells compared to A549 cells. In contrast, 9 human miRNAs were up-regulated more than 2-fold in A549/DDP cells (Table 1)."
21787234,miR-1246,hsa-mir-1246,MI0006381,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2011,Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP),"The miRNA expression profile showed that 5 human miRNAs were down-regulated more than 2-fold in A549/DDP cells compared to A549 cells. In contrast, 9 human miRNAs were up-regulated more than 2-fold in A549/DDP cells (Table 1)."
21787234,miR-138,hsa-miR-138-5p,MI0000455,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,-,ERCC1,2011,Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP).,"Up-regulation of miR-138 increased the sensitivity of A549/DDP cells to cisplatin in in vitro drug sensitivity assay, and increased apoptosis assessed by flow cytometry."
21787234,miR-1470,hsa-mir-1470,MI0007075,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2011,Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP),"The miRNA expression profile showed that 5 human miRNAs were down-regulated more than 2-fold in A549/DDP cells compared to A549 cells. In contrast, 9 human miRNAs were up-regulated more than 2-fold in A549/DDP cells (Table 1)."
21787234,miR-149*,hsa-mir-149,MI0000478,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2011,Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP),"The miRNA expression profile showed that 5 human miRNAs were down-regulated more than 2-fold in A549/DDP cells compared to A549 cells. In contrast, 9 human miRNAs were up-regulated more than 2-fold in A549/DDP cells (Table 1)."
21787234,miR-181a,hsa-mir-181a-2,MI0000269,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2011,Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP),"The miRNA expression profile showed that 5 human miRNAs were down-regulated more than 2-fold in A549/DDP cells compared to A549 cells. In contrast, 9 human miRNAs were up-regulated more than 2-fold in A549/DDP cells (Table 1)."
21787234,miR-1908,hsa-mir-1908,MI0008329,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2011,Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP),"The miRNA expression profile showed that 5 human miRNAs were down-regulated more than 2-fold in A549/DDP cells compared to A549 cells. In contrast, 9 human miRNAs were up-regulated more than 2-fold in A549/DDP cells (Table 1)."
21787234,miR-194,hsa-mir-194-1,MI0000488,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,Non-small Cell Lung Cancer,in vitro,High,Sensitive,-,-,2011,Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP),"The miRNA expression profile showed that 5 human miRNAs were down-regulated more than 2-fold in A549/DDP cells compared to A549 cells. In contrast, 9 human miRNAs were up-regulated more than 2-fold in A549/DDP cells (Table 1)."
21787234,miR-224,hsa-mir-224,MI0000301,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,Non-small Cell Lung Cancer,in vitro,High,Sensitive,-,-,2011,Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP),"The miRNA expression profile showed that 5 human miRNAs were down-regulated more than 2-fold in A549/DDP cells compared to A549 cells. In contrast, 9 human miRNAs were up-regulated more than 2-fold in A549/DDP cells (Table 1)."
21787234,miR-27b,hsa-mir-27b,MI0000440,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,Non-small Cell Lung Cancer,in vitro,High,Sensitive,-,-,2011,Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP),"The miRNA expression profile showed that 5 human miRNAs were down-regulated more than 2-fold in A549/DDP cells compared to A549 cells. In contrast, 9 human miRNAs were up-regulated more than 2-fold in A549/DDP cells (Table 1)."
21787234,miR-34a,hsa-mir-34a,MI0000268,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2011,Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP),"The miRNA expression profile showed that 5 human miRNAs were down-regulated more than 2-fold in A549/DDP cells compared to A549 cells. In contrast, 9 human miRNAs were up-regulated more than 2-fold in A549/DDP cells (Table 1)."
21787234,miR-638,hsa-mir-638,MI0003653,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2011,Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP),"The miRNA expression profile showed that 5 human miRNAs were down-regulated more than 2-fold in A549/DDP cells compared to A549 cells. In contrast, 9 human miRNAs were up-regulated more than 2-fold in A549/DDP cells (Table 1)."
21787234,miR-663,hsa-mir-663a,MI0003672,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2011,Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP),"The miRNA expression profile showed that 5 human miRNAs were down-regulated more than 2-fold in A549/DDP cells compared to A549 cells. In contrast, 9 human miRNAs were up-regulated more than 2-fold in A549/DDP cells (Table 1)."
21787234,miR-886,hsa-mir-886,MI0005527,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,Non-small Cell Lung Cancer,in vitro,High,Sensitive,-,-,2011,Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP),"The miRNA expression profile showed that 5 human miRNAs were down-regulated more than 2-fold in A549/DDP cells compared to A549 cells. In contrast, 9 human miRNAs were up-regulated more than 2-fold in A549/DDP cells (Table 1)."
21802841,miR-122,hsa-mir-122,MI0000442,Doxorubicin (Adriamycin),31703,"Hep3B, HepG2, Huh7, PLC/PRF/5 and HEK293",-,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,-,"MDR-1, GST-pie, MRP, Bcl-w and cyclin B1",2011,MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest.,"We further demonstrated that overexpression of miR-122 could modulate the sensitivity of the HCC cells to chemotherapeutic drugs through downregulating MDR related genes MDR-1, GST-pie, and MRP, antiapoptotic gene Bcl-w and cell cycle related gene cyclin B1."
21802841,miR-122,hsa-mir-122,MI0000442,Vincristine,5978,"Hep3B, HepG2, Huh7,PLC/PRF/5 and HEK293",-,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,-,"MDR-1, GST-pie, MRP, Bcl-w and cyclin B1",2011,MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest.,"We further demonstrated that overexpression of miR-122 could modulate the sensitivity of the HCC cells to chemotherapeutic drugs through downregulating MDR related genes MDR-1, GST-pie, and MRP, antiapoptotic gene Bcl-w and cell cycle related gene cyclin B1."
21807947,miR-199a,hsa-mir-199a-1,MI0000242,Docetaxel,148124,MT1,-,-,-,breast cancer,in vitro,Low,Sensitive,Caveolin-2,-,2011,MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2.,"However, overexpression of caveolin-2 completely counteracted the enhancement of miR-199a-3p-mediated activities on cell proliferation, survival and sensitivity of tumor cells to anticancer drugs."
21816906,miR-32,hsa-mir-32,MI0000090,Cytarabine,6253,HL60-G and U937,-,-,-,myeloid leukemia ,in vitro,Low,Resistant,Bim,-,2011,"MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis.",Inhibition of miR-32 expression by anti-miR-32 increases the toxicity of AraC to AML cells.
21820606,miR-21,hsa-mir-21,MI0000077,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Resistant,PTEN,-,2011,MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN.,MiR-21 mimic or inhibitor could obviously affect the sensitivity of breast cancer cells to ADR.
21823019,miR-125b,hsa-mir-125b-1,MI0000446,Cisplatin,2767,-,OV2008 vs OV2008/CDDP,-,-,ovarian cancer,in vitro,Low,Resistant,Bak1,-,2011,miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1.,This result also demonstrates that down-regulation of miR-125b may increase cisplatin sensitivity.
21826373,let-7b,hsa-let-7b,MI0000063,Tamoxifen,2733526,"184A1, ZR-75-1, T47D, HB3396, MDA-MB-231, MDA-MB-436, MDA-MB-468 and SK-BR-3",MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,Low,Sensitive,ER-alpha36 ,MAPK and Akt pathways,2011,let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor alpha signaling in breast cancer.,"Transfection of let-7 mimics to Tam-resistant MCF7 cells downregulated ER-alpha36 expression and enhanced the sensitivity of MCF7 cells to Tam in estrogen-free medium, which could be restored by overexpression of ER-alpha36 constructs without 3'UTR."
21826373,let-7i,hsa-let-7i,MI0000434,Tamoxifen,2733526,"184A1, ZR-75-1, T47D, HB3396, MDA-MB-231, MDA-MB-436, MDA-MB-468 and SK-BR-3",MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,Low,Sensitive,ER-alpha36 ,MAPK and Akt pathways,2011,let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor alpha signaling in breast cancer.,"Transfection of let-7 mimics to Tam-resistant MCF7 cells downregulated ER-alpha36 expression and enhanced the sensitivity of MCF7 cells to Tam in estrogen-free medium, which could be restored by overexpression of ER-alpha36 constructs without 3'UTR."
21853360,miR-19,-,-,Etoposide,36462,-,MCF-7 vs MCF-7/VP,-,-,breast cancer,in vitro,Low,Resistant,PTEN,-,2011,Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN.,"Inhibitor of miR-19a restored sensitivity of MDR cells to cytotoxic agents; administration of LNA-antimiR-19a, a chemo-modified miR-19a inhibitor, sensitized MDR cells to chemotherapeutic agents in vivo."
21853360,miR-19,-,-,Mitoxantrone,4212,Etoposide,MCF-7 vs MCF-7/MIX,-,-,breast cancer,in vitro,Low,Resistant,PTEN,-,2011,Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN.,"Inhibitor of miR-19a restored sensitivity of MDR cells to cytotoxic agents; administration of LNA-antimiR-19a, a chemo-modified miR-19a inhibitor, sensitized MDR cells to chemotherapeutic agents in vivo."
21853360,miR-19,-,-,Paclitaxel,36314,-,MCF-7 vs MCF-7/TX200,Mice,-,breast cancer,in vitro and in vivo,Low,Resistant,PTEN,-,2011,Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN.,"Inhibitor of miR-19a restored sensitivity of MDR cells to cytotoxic agents; administration of LNA-antimiR-19a, a chemo-modified miR-19a inhibitor, sensitized MDR cells to chemotherapeutic agents in vivo."
21864507,miR-149,hsa-mir-149,MI0000478,Methotrexate,126941,-,HT29 vs HT29/MTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-149,hsa-mir-149,MI0000478,Methotrexate,126941,HT29,-,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells.,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-193b,hsa-mir-193b,MI0003137,Methotrexate,126941,-,HT29 vs HT29/MTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-193b,hsa-mir-193b,MI0003137,Methotrexate,126941,HT29,-,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells.,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-210,hsa-mir-210,MI0000286,Methotrexate,126941,-,HT29 vs HT29/MTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-210,hsa-mir-210,MI0000286,Methotrexate,126941,HT29,-,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells.,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-224,hsa-mir-224,MI0000301,Methotrexate,126941,-,HT29 vs HT29/MTX,-,-,colon cancer,in vitro,High,Sensitive,CDS2,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-224,hsa-mir-224,MI0000301,Methotrexate,126941,CaCo-2 and K562,HT29 vs HT29/MET,-,-,colon cancer,in vitro,Low,Resistant,"CDS2, HSPC159, MYST3 and SLC4A4",-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells.,"Functional assays using an anti-miR against miR-224 desensitized the cells towards MTX, mimicking the resistant phenotype."
21864507,miR-27b,hsa-mir-27b,MI0000440,Methotrexate,126941,-,HT29 vs HT29/MTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-27b,hsa-mir-27b,MI0000440,Methotrexate,126941,HT29,-,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells.,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-320,hsa-mir-320a,MI0000542,Methotrexate,126941,-,HT29 vs HT29/MTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-320,hsa-mir-320a,MI0000542,Methotrexate,126941,HT29,-,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells.,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-361,hsa-mir-361,MI0000760,Methotrexate,126941,-,HT29 vs HT29/MTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-361,hsa-mir-361,MI0000760,Methotrexate,126941,HT29,-,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells.,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-365,hsa-mir-365a,MI0000767,Methotrexate,126941,-,HT29 vs HT29/MTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-365,hsa-mir-365a,MI0000767,Methotrexate,126941,HT29,-,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells.,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-455,hsa-mir-455,MI0003513,Methotrexate,126941,-,HT29 vs HT29/MTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-455,hsa-mir-455,MI0003513,Methotrexate,126941,HT29,-,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells.,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-615,hsa-mir-615,MI0003628,Methotrexate,126941,-,HT29 vs HT29/MTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21864507,miR-615,hsa-mir-615,MI0003628,Methotrexate,126941,HT29,-,-,-,colon cancer,in vitro,High,Resistant,-,-,2011,Underexpression of miR-224 in methotrexate resistant human colon cancer cells.,"These miRNAs were used for a Volcano plot analysis (Fig. 1B) where a filtering of p < 0.05 and a fold change  2, including multiple testing correction was applied. As a result, 10 miRNAs fulfilled these criteria (Table 3)."
21879257,miR-125b,hsa-mir-125b-1,MI0000446,Temozolomide,5394,Glioblastoma Stem Cells,-,-,-,glioblastoma,in vitro,Low,Resistant,-,-,2012,MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis.,Downregulation of miR-125b-2 expression in GBMSC could allow TMZ to induce GBMSC apoptosis.
21880154,miR-125b,hsa-mir-125b-1,MI0000446,Doxorubicin (Adriamycin),31703,-,HL60 vs HL60/ADR and K562 vs  K562/ADR,-,-,pediatric acute promyelocytic leukemia,in vitro,Low,Resistant,BAK1,-,2011,Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia.,"Remarkably, miR-125b was also found to be up-regulated in leukemic drug-resistant cells, and transfection of a miR-125b duplex into AML cells can increase their resistance to therapeutic drugs,"
21880154,miR-125b,hsa-mir-125b-1,MI0000446,Retinoic Acid,24801580,-,NB4 vs NB4-R1 and NB4 vs NB4-R2,-,-,pediatric acute promyelocytic leukemia,in vitro,Low,Resistant,BAK1,-,2011,Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia.,"Remarkably, miR-125b was also found to be up-regulated in leukemic drug-resistant cells, and transfection of a miR-125b duplex into AML cells can increase their resistance to therapeutic drugs,"
21893020,miR-193b,hsa-mir-193b,MI0003137,ABT-737,11228183,"Malme-3M, MeWo, SK-MEL-2, and SK-MEL-28",-,-,-,melanoma,in vitro,Low,Sensitive,Mcl-1,-,2011,miR-193b Regulates Mcl-1 in Melanoma.,"Similarly, overexpression of miR-193b restores ABT-737 sensitivity to ABT-737-resistant cells."
21899346,miR-125b,hsa-mir-125b-1,MI0000446,Cisplatin,2767,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Sensitive,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-125b,hsa-mir-125b-1,MI0000446,Doxorubicin (Adriamycin),31703,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Sensitive,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-135b,hsa-mir-135b,MI0000810,Cisplatin,2767,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Sensitive,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-135b,hsa-mir-135b,MI0000810,Doxorubicin (Adriamycin),31703,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Sensitive,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-141,hsa-mir-141,MI0000457,Cisplatin,2767,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Sensitive,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-141,hsa-mir-141,MI0000457,Doxorubicin (Adriamycin),31703,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Sensitive,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-182,hsa-mir-182,MI0000272,Cisplatin,2767,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Resistant,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-182,hsa-mir-182,MI0000272,Doxorubicin (Adriamycin),31703,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Resistant,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-183,hsa-mir-183,MI0000273,Cisplatin,2767,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Resistant,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-183,hsa-mir-183,MI0000273,Doxorubicin (Adriamycin),31703,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Resistant,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-200b,hsa-mir-200b,MI0000342,Cisplatin,2767,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Resistant,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-200b,hsa-mir-200b,MI0000342,Doxorubicin (Adriamycin),31703,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Resistant,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-210,hsa-mir-210,MI0000286,Cisplatin,2767,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Resistant,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-210,hsa-mir-210,MI0000286,Doxorubicin (Adriamycin),31703,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Resistant,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-27b,hsa-mir-27b,MI0000440,Cisplatin,2767,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Sensitive,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-27b,hsa-mir-27b,MI0000440,Doxorubicin (Adriamycin),31703,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Sensitive,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-30b,hsa-mir-30b,MI0000441,Cisplatin,2767,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Sensitive,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-30b,hsa-mir-30b,MI0000441,Doxorubicin (Adriamycin),31703,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Sensitive,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-30d,hsa-mir-30d,MI0000255,Cisplatin,2767,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Sensitive,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-30d,hsa-mir-30d,MI0000255,Doxorubicin (Adriamycin),31703,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Sensitive,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-429,hsa-mir-429,MI0001641,Cisplatin,2767,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Resistant,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-429,hsa-mir-429,MI0001641,Doxorubicin (Adriamycin),31703,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Resistant,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-881*,-,-,Cisplatin,2767,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Sensitive,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-881*,-,-,Doxorubicin (Adriamycin),31703,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Sensitive,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-96,hsa-mir-96,MI0000098,Cisplatin,2767,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Resistant,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21899346,miR-96,hsa-mir-96,MI0000098,Doxorubicin (Adriamycin),31703,"EHR2,P6, P12, P36, P72, EHR2/1.3",,-,-,ehrlich ascites tumor,in vitro,High,Resistant,-,-,2011,MicroRNA Expression Profiles Associated with Development of Drug Resistance in Ehrlich Ascites Tumor Cells,"We identified 13 miRNAs, listed in Table 1, with significant changes in expression pattern between sensitive (EHR2) and drug-resistant sublines."
21926415,let-7g,hsa-let-7g,MI0000433,modified ALLIC BFM 2002 protocol,-,-,-,-,Patientss,childhood acute lymphoblastic leukemia ,in vivo,High,Sensitive,,-,2011,A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL,"Among these miRNAs, miR-223, miR-23a and let-7g were downregulated with higher fold changes in the relapse samples compared with the samples of the same patients at CR, whereas miR-181 family, miR-708 and miR-130b were upregulated with higher fold changes in the relapse samples."
21926415,miR-130b,hsa-mir-130b,MI0000748,modified ALLIC BFM 2002 protocol,-,-,-,-,Patientss,childhood acute lymphoblastic leukemia ,in vivo,High,Sensitive,,-,2011,A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL,"Among these miRNAs, miR-223, miR-23a and let-7g were downregulated with higher fold changes in the relapse samples compared with the samples of the same patients at CR, whereas miR-181 family, miR-708 and miR-130b were upregulated with higher fold changes in the relapse samples."
21926415,miR-181,-,-,modified ALLIC BFM 2002 protocol,-,-,-,-,Patientss,childhood acute lymphoblastic leukemia ,in vivo,High,Sensitive,,-,2011,A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL,"Among these miRNAs, miR-223, miR-23a and let-7g were downregulated with higher fold changes in the relapse samples compared with the samples of the same patients at CR, whereas miR-181 family, miR-708 and miR-130b were upregulated with higher fold changes in the relapse samples."
21926415,miR-223,hsa-mir-223,MI0000300,modified ALLIC BFM 2002 protocol,-,-,-,-,Patientss,childhood acute lymphoblastic leukemia ,in vivo,High,Resistant,,-,2011,A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL,"Among these miRNAs, miR-223, miR-23a and let-7g were downregulated with higher fold changes in the relapse samples compared with the samples of the same patients at CR, whereas miR-181 family, miR-708 and miR-130b were upregulated with higher fold changes in the relapse samples."
21926415,miR-23a,hsa-mir-23a,MI0000079,modified ALLIC BFM 2002 protocol,-,-,-,-,Patientss,childhood acute lymphoblastic leukemia ,in vivo,High,Resistant,,-,2011,A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL,"Among these miRNAs, miR-223, miR-23a and let-7g were downregulated with higher fold changes in the relapse samples compared with the samples of the same patients at CR, whereas miR-181 family, miR-708 and miR-130b were upregulated with higher fold changes in the relapse samples."
21926415,miR-708,hsa-mir-708,MI0005543,modified ALLIC BFM 2002 protocol,-,-,-,-,Patientss,childhood acute lymphoblastic leukemia ,in vivo,High,Resistant,,-,2011,A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL,"Among these miRNAs, miR-223, miR-23a and let-7g were downregulated with higher fold changes in the relapse samples compared with the samples of the same patients at CR, whereas miR-181 family, miR-708 and miR-130b were upregulated with higher fold changes in the relapse samples."
21936961,miR-15a,hsa-mir-15a,MI0000069,Dexamethasone,5743,-,MM1S vs MM1R,-,-,myeloma,in vitro,Low,Sensitive,-,-,2011,Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells.,"Moreover, dexamethasone sensitive MM cell line, MM1S, expressed higher level of miRNA-15a than the resistant MM1R."
21936961,miR-15a,hsa-mir-15a,MI0000069,Melphalan,460612,U266 and NCI-H929,-,-,-,myeloma,in vitro,Low,Sensitive,-,-,2011,Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells.,"In this study, apoptosis analysis by flow cytometry showed that BMSCs protect U266 and NCI-H929 myeloma cells from apoptosis induced by melphalan and bortezomib."
21936961,miR-16,hsa-mir-16-1,MI0000070,Bortezomib,387447,U266 and NCI-H929,-,-,-,myeloma,in vitro,Low,Sensitive,-,-,2011,Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells.,"In this study, apoptosis analysis by flow cytometry showed that BMSCs protect U266 and NCI-H929 myeloma cells from apoptosis induced by melphalan and bortezomib."
21939554,let-7c,hsa-let-7c,MI0000064,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,,-,2011,MicroRNA signature of cis-platin resistant vs. cisplatin sensitive ovarian cancer cell lines,"miRNA analysis of the samples from A2780 and A2780/CP70 cell lines were screening for 1,500 miRNA sequences and a total of 11 miRNAs showed a difference in their expression levels between A2780 and A2780/CP70 cell lines."
21939554,miR-1299,hsa-mir-1299,MI0006359,Cisplatin,2767,-,A2780 vs A2781/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,,-,2011,MicroRNA signature of cis-platin resistant vs. cisplatin sensitive ovarian cancer cell lines,"miRNA analysis of the samples from A2780 and A2780/CP70 cell lines were screening for 1,500 miRNA sequences and a total of 11 miRNAs showed a difference in their expression levels between A2780 and A2780/CP70 cell lines."
21939554,miR-193b,hsa-mir-193b,MI0003137,Cisplatin,2767,-,A2780 vs A2782/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,,-,2011,MicroRNA signature of cis-platin resistant vs. cisplatin sensitive ovarian cancer cell lines,"miRNA analysis of the samples from A2780 and A2780/CP70 cell lines were screening for 1,500 miRNA sequences and a total of 11 miRNAs showed a difference in their expression levels between A2780 and A2780/CP70 cell lines."
21939554,miR-20b,hsa-mir-20b,MI0001519,Cisplatin,2767,-,A2780 vs A2783/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,,-,2011,MicroRNA signature of cis-platin resistant vs. cisplatin sensitive ovarian cancer cell lines,"miRNA analysis of the samples from A2780 and A2780/CP70 cell lines were screening for 1,500 miRNA sequences and a total of 11 miRNAs showed a difference in their expression levels between A2780 and A2780/CP70 cell lines."
21939554,miR-300,hsa-mir-300,MI0005525,Cisplatin,2767,-,A2780 vs A2784/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,,-,2011,MicroRNA signature of cis-platin resistant vs. cisplatin sensitive ovarian cancer cell lines,"miRNA analysis of the samples from A2780 and A2780/CP70 cell lines were screening for 1,500 miRNA sequences and a total of 11 miRNAs showed a difference in their expression levels between A2780 and A2780/CP70 cell lines."
21939554,miR-542,hsa-mir-542,MI0003686,Cisplatin,2767,-,A2780 vs A2785/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,,-,2011,MicroRNA signature of cis-platin resistant vs. cisplatin sensitive ovarian cancer cell lines,"miRNA analysis of the samples from A2780 and A2780/CP70 cell lines were screening for 1,500 miRNA sequences and a total of 11 miRNAs showed a difference in their expression levels between A2780 and A2780/CP70 cell lines."
21939554,miR-625,hsa-mir-625,MI0003639,Cisplatin,2767,-,A2780 vs A2786/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,,-,2011,MicroRNA signature of cis-platin resistant vs. cisplatin sensitive ovarian cancer cell lines,"miRNA analysis of the samples from A2780 and A2780/CP70 cell lines were screening for 1,500 miRNA sequences and a total of 11 miRNAs showed a difference in their expression levels between A2780 and A2780/CP70 cell lines."
21939554,miR-642,hsa-mir-642a,MI0003657,Cisplatin,2767,-,A2780 vs A2787/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,,-,2011,MicroRNA signature of cis-platin resistant vs. cisplatin sensitive ovarian cancer cell lines,"miRNA analysis of the samples from A2780 and A2780/CP70 cell lines were screening for 1,500 miRNA sequences and a total of 11 miRNAs showed a difference in their expression levels between A2780 and A2780/CP70 cell lines."
21939554,miRplus-F1064,-,-,Cisplatin,2767,-,A2780 vs A2788/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,,-,2011,MicroRNA signature of cis-platin resistant vs. cisplatin sensitive ovarian cancer cell lines,"miRNA analysis of the samples from A2780 and A2780/CP70 cell lines were screening for 1,500 miRNA sequences and a total of 11 miRNAs showed a difference in their expression levels between A2780 and A2780/CP70 cell lines."
21939554,miRPlus-F1147,-,-,Cisplatin,2767,-,A2780 vs A2789/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,,-,2011,MicroRNA signature of cis-platin resistant vs. cisplatin sensitive ovarian cancer cell lines,"miRNA analysis of the samples from A2780 and A2780/CP70 cell lines were screening for 1,500 miRNA sequences and a total of 11 miRNAs showed a difference in their expression levels between A2780 and A2780/CP70 cell lines."
21939554,miRPlus-F1231,-,-,Cisplatin,2767,-,A2780 vs A2790/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,,-,2011,MicroRNA signature of cis-platin resistant vs. cisplatin sensitive ovarian cancer cell lines,"miRNA analysis of the samples from A2780 and A2780/CP70 cell lines were screening for 1,500 miRNA sequences and a total of 11 miRNAs showed a difference in their expression levels between A2780 and A2780/CP70 cell lines."
21947305,miR-195,hsa-mir-195,MI0000489,5-Fluorouracil,3385,-,BEL-7402 vs BEL-7402/5-FU,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,Bcl-w,-,2012,miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w.,Overexpression of miRNA-195 sensitized BEL-7402/5-FU cells to anticancer drugs.
21948564,miR-451,hsa-mir-451a,MI0001729,Irinotecan,-,"SN38, LS513 and HT29",-,Mice,Patients,colorectal cancer,in vitro and in vivo,Low,Sensitive,-,COX-2 and ABCB1,2011,"MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells.","Furthermore, miR-451 restoration decreases expression of the ATP-binding cassette drug transporter ABCB1 and results in irinotecan sensitization."
21953503,miR-128,hsa-mir-128-1,MI0000447,Doxorubicin (Adriamycin),31703,SK-3rd cells and MCF-7 BT-ICs,-,-,-,breast tumor-initiating cells,in vitro,Low,Sensitive,BMI-1 and ABCC5,-,2011,Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5.,"Ectopic expression of miR-128 reduced the protein levels of Bmi-1 and ABCC5 in BT-ICs, along with decreased cell viability (P < 0.001) and increased apoptosis (P < 0.001) and DNA damage (P < 0.001) in the presence of doxorubicin."
21955614,ebv-miR-BART16,ebv-mir-BART16,MI0004989,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-100,hsa-mir-100,MI0000102,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-103,hsa-mir-103a-1,MI0000109,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-105,hsa-mir-105-1,MI0000111,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-106a,hsa-mir-106a,MI0000113,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-107,hsa-mir-107,MI0000114,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-10a,hsa-mir-10a,MI0000266,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-125a,hsa-mir-125a,MI0000469,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-125b,hsa-mir-125b-1,MI0000446,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-126,hsa-mir-126,MI0000471,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-141,hsa-mir-141,MI0000457,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-148b,hsa-mir-148b,MI0000811,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-149,hsa-mir-149,MI0000478,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-151,hsa-mir-151a,MI0000809,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-17,hsa-mir-17,MI0000071,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-181a*,hsa-mir-181a-2,MI0000269,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-182,hsa-mir-182,MI0000272,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-183,hsa-mir-183,MI0000273,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-185*,hsa-mir-185,MI0000482,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-18a,hsa-mir-18a,MI0000072,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-18b,hsa-mir-18b,MI0001518,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-193a,hsa-mir-193a,MI0000487,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-193b,hsa-mir-193b,MI0003137,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-196a,hsa-mir-196a-1,MI0000238,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-196a*,hsa-mir-196a-1,MI0000238,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-197,hsa-mir-197,MI0000239,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-19a,hsa-mir-19a,MI0000073,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-19b,hsa-mir-19b-1,MI0000074,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-200a,hsa-mir-200a,MI0000737,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-200b,hsa-mir-200b,MI0000342,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-200c,hsa-mir-200c,MI0000650,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-20a,hsa-mir-20a,MI0000076,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-20b*,hsa-mir-20b,MI0001519,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-21,hsa-mir-21,MI0000077,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-21*,hsa-mir-21,MI0000077,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-24-1*,hsa-mir-24-1,MI0000080,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-29b,hsa-mir-29b-1,MI0000105,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-324,hsa-mir-324,MI0000813,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-331,hsa-mir-331,MI0000812,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-339,hsa-mir-339,MI0000815,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-342,hsa-mir-342,MI0000805,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-345,hsa-mir-345,MI0000825,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-34a,hsa-mir-34a,MI0000268,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-361,hsa-mir-361,MI0000760,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-365,hsa-mir-365a,MI0000767,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-374a,hsa-mir-374a,MI0000782,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-374b,hsa-mir-374b,MI0005566,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-378,hsa-mir-378a,MI0000786,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-423,hsa-mir-423,MI0001445,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-425,hsa-mir-425,MI0001448,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-429,hsa-mir-429,MI0001641,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-450a,hsa-mir-450a-1,MI0001652,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-489,hsa-mir-489,MI0003124,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-510,hsa-mir-510,MI0003197,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-549,hsa-mir-549a,MI0003679,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-550,hsa-mir-550a-1,MI0003600,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-615,hsa-mir-615,MI0003628,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-625,hsa-mir-625,MI0003639,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-628,hsa-mir-628,MI0003642,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-665,hsa-mir-665,MI0005563,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-7,hsa-mir-7-1,MI0000263,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-744,hsa-mir-744,MI0005559,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-891a,hsa-mir-891a,MI0005524,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-939,hsa-mir-939,MI0005761,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Sensitive,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-96,hsa-mir-96,MI0000098,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-99b,hsa-mir-99b,MI0000746,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,miR-99b*,hsa-mir-99b,MI0000746,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,SNORD10,-,-,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,SNORD14B,-,-,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,SNORD2,-,-,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,SNORD3@,-,-,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21955614,SNORD4A,-,-,Tamoxifen,2733526,-,MCF-7 vs LY2,-,-,breast cancer,in vitro,High,Resistant,-,-,2011,Differential expression of microRNA expression in tamoxifensensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells,"A total of 97 miRNAs exhibited differential expression between TAM-sensitive MCF-7 and TAM-resistant LY2 cells with either EtOH or 4-OHT treatment (Figure 1, Tables 1 and 2)."
21960059,miR-34a,hsa-mir-34a,MI0000268,Doxorubicin (Adriamycin),31703,TC-71 and LAP-35,-,-,-,ewing sarcoma,in vitro,Low,Sensitive,-,-,2012,miR-34a predicts survival of Ewing's sarcoma Patient and directly influences cell chemo-sensitivity and malignancy.,"Functional analysis of miR-34a in EWS cell lines indicated that when miR-34a expression was enforced, cells were less proliferative, less malignant, and sensitized to doxorubicin and vincristine. "
21960059,miR-34a,hsa-mir-34a,MI0000268,Vincristine,5978,TC-71 and LAP-35,-,-,-,ewing sarcoma,in vitro ,Low,Sensitive,-,-,2012,miR-34a predicts survival of Ewing's sarcoma Patient and directly influences cell chemo-sensitivity and malignancy.,"Functional analysis of miR-34a in EWS cell lines indicated that when miR-34a expression was enforced, cells were less proliferative, less malignant, and sensitized to doxorubicin and vincristine. "
21982769,miR-146a,hsa-mir-146a,MI0000477,Interferon-alpha,-,-,PLC vs PLC/INF,-,-,hepatocellular carcinom,in vitro,Low,Resistant,-,SMAD4,2011,miR-146a suppresses the sensitivity to interferon-alpha in hepatocellular carcinoma cells.,miR-146a decreased the sensitivity to IFN-alpha through the suppression of apoptosis.
21993663,miR-200b,hsa-mir-200b,MI0000342,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung cancer,in vitro,Low,Sensitive,BCL2 and XIAP,-,2012,miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.,"Overexpression of miR-200bc/429 cluster sensitized SGC7901/VCR and A549/CDDP cells to anti-cancer drugs, respectively."
21993663,miR-200b,hsa-mir-200b,MI0000342,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Sensitive,BCL2 and XIAP,-,2012,miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.,"Overexpression of miR-200bc/429 cluster sensitized SGC7901/VCR and A549/CDDP cells to anti-cancer drugs, respectively."
21993663,miR-200c,hsa-mir-200c,MI0000650,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung cancer,in vitro,Low,Sensitive,BCL2 and XIAP,-,2012,miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.,"Overexpression of miR-200bc/429 cluster sensitized SGC7901/VCR and A549/CDDP cells to anti-cancer drugs, respectively."
21993663,miR-200c,hsa-mir-200c,MI0000650,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Sensitive,BCL2 and XIAP,-,2012,miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.,"Overexpression of miR-200bc/429 cluster sensitized SGC7901/VCR and A549/CDDP cells to anti-cancer drugs, respectively."
21993663,miR-429,hsa-mir-429,MI0001641,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung cancer,in vitro,Low,Sensitive,BCL2 and XIAP,-,2012,miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.,"Overexpression of miR-200bc/429 cluster sensitized SGC7901/VCR and A549/CDDP cells to anti-cancer drugs, respectively."
21993663,miR-429,hsa-mir-429,MI0001641,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Sensitive,BCL2 and XIAP,-,2012,miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.,"Overexpression of miR-200bc/429 cluster sensitized SGC7901/VCR and A549/CDDP cells to anti-cancer drugs, respectively."
22005523,miR-130b,hsa-mir-130b,MI0000748,Cisplatin,2767,-,A2780 vs A2780/CDDP and SKOV3 vs SKOV3/Taxol,-,-,ovarian cancer,in vitro,Low,Sensitive,CSF-1,-,2012,Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.,Restoration of miR-130b expression could sensitize these cells to anticancer drugs.
22005523,miR-130b,hsa-mir-130b,MI0000748,Paclitaxel,36314,-,A2780 vs A2780/CDDP and SKOV3 vs SKOV3/Taxol,-,-,ovarian cancer,in vitro,Low,Sensitive,CSF-1,-,2012,Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.,Restoration of miR-130b expression could sensitize these cells to anticancer drugs.
22015043,miR-200c,hsa-mir-200c,MI0000650,Cisplatin,2767,HEC-1A and Ishikawa,-,-,-,endometrial carcinoma,in vitro,Low,Resistant,-,BRD7,2012,The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma.,"Interestingly, anti-miR-200c showed addictive effect on the cisplatin cytotoxicity but not to the paclitaxel."
22036718,miR-506,hsa-mir-506,MI0003193,10-Hydroxycamptothecin (HCPT),97226,-,SW1116 vs SW1116/HCPT,-,-,colon cancer,in vitro,Low,Resistant,PPARalpha,-,2011,MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells.,"All together, our studies indicate that miR-506 over-expression in established HCPT-resistant colon cancer cell line confers resistance to HCPT by inhibiting PPARalpha expression, then providing a rationale for the development of miRNA-based strategies for reversing resistance in HCPT-resistant colon cancer cells."
22045191,miR-135b,hsa-mir-135b,MI0000810,Erlotinib,176870,"A549, UKY-29, H460, and H1975, H1650, H3255, PC-9, and H358",,-,-,epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)),in vitro,High,Resistant,-,-,2011,A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT,"Here, we measured the expression of 381 miRNA genes in the same resistant (A549, UKY-29, H460, and H1975) and sensitive (H1650, H3255, PC-9, and H358) cell lines using Taqman microRNA arrays."
22045191,miR-140,hsa-mir-140,MI0000456,Erlotinib,176870,"A549, UKY-29, H460, and H1975, H1650, H3255, PC-9, and H358",,-,-,epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)),in vitro,High,Resistant,-,-,2011,A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT,"Here, we measured the expression of 381 miRNA genes in the same resistant (A549, UKY-29, H460, and H1975) and sensitive (H1650, H3255, PC-9, and H358) cell lines using Taqman microRNA arrays."
22045191,miR-141,hsa-mir-141,MI0000457,Erlotinib,176870,"A549, UKY-29, H460, and H1975, H1650, H3255, PC-9, and H358",,-,-,epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)),in vitro,High,Sensitive,-,-,2011,A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT,"Here, we measured the expression of 381 miRNA genes in the same resistant (A549, UKY-29, H460, and H1975) and sensitive (H1650, H3255, PC-9, and H358) cell lines using Taqman microRNA arrays."
22045191,miR-197,hsa-mir-197,MI0000239,Erlotinib,176870,"A549, UKY-29, H460, and H1975, H1650, H3255, PC-9, and H358",,-,-,epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)),in vitro,High,Sensitive,-,-,2011,A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT,"Here, we measured the expression of 381 miRNA genes in the same resistant (A549, UKY-29, H460, and H1975) and sensitive (H1650, H3255, PC-9, and H358) cell lines using Taqman microRNA arrays."
22045191,miR-200b,hsa-mir-200b,MI0000342,Erlotinib,176870,"A549, UKY-29, H460, and H1975, H1650, H3255, PC-9, and H358",,-,-,epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)),in vitro,High,Sensitive,-,-,2011,A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT,"Here, we measured the expression of 381 miRNA genes in the same resistant (A549, UKY-29, H460, and H1975) and sensitive (H1650, H3255, PC-9, and H358) cell lines using Taqman microRNA arrays."
22045191,miR-200c,hsa-mir-200c,MI0000650,Erlotinib,176870,"A549, UKY-29, H460, and H1975, H1650, H3255, PC-9, and H358",,-,-,epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)),in vitro,High,Sensitive,-,-,2011,A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT,"Here, we measured the expression of 381 miRNA genes in the same resistant (A549, UKY-29, H460, and H1975) and sensitive (H1650, H3255, PC-9, and H358) cell lines using Taqman microRNA arrays."
22045191,miR-205,hsa-mir-205,MI0000285,Erlotinib,176870,"A549, UKY-29, H460, and H1975, H1650, H3255, PC-9, and H358",,-,-,epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)),in vitro,High,Sensitive,-,-,2011,A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT,"Here, we measured the expression of 381 miRNA genes in the same resistant (A549, UKY-29, H460, and H1975) and sensitive (H1650, H3255, PC-9, and H358) cell lines using Taqman microRNA arrays."
22045191,miR-224,hsa-mir-224,MI0000301,Erlotinib,176870,"A549, UKY-29, H460, and H1975, H1650, H3255, PC-9, and H358",,-,-,epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)),in vitro,High,Sensitive,-,-,2011,A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT,"Here, we measured the expression of 381 miRNA genes in the same resistant (A549, UKY-29, H460, and H1975) and sensitive (H1650, H3255, PC-9, and H358) cell lines using Taqman microRNA arrays."
22045191,miR-301a,hsa-mir-301a,MI0000745,Erlotinib,176870,"A549, UKY-29, H460, and H1975, H1650, H3255, PC-9, and H358",,-,-,epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)),in vitro,High,Sensitive,-,-,2011,A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT,"Here, we measured the expression of 381 miRNA genes in the same resistant (A549, UKY-29, H460, and H1975) and sensitive (H1650, H3255, PC-9, and H358) cell lines using Taqman microRNA arrays."
22045191,miR-34c,hsa-mir-34c,MI0000743,Erlotinib,176870,"A549, UKY-29, H460, and H1975, H1650, H3255, PC-9, and H358",,-,-,epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)),in vitro,High,Sensitive,-,-,2011,A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT,"Here, we measured the expression of 381 miRNA genes in the same resistant (A549, UKY-29, H460, and H1975) and sensitive (H1650, H3255, PC-9, and H358) cell lines using Taqman microRNA arrays."
22045191,miR-518f*,hsa-mir-518f,MI0003154,Erlotinib,176870,"A549, UKY-29, H460, and H1975, H1650, H3255, PC-9, and H358",,-,-,epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)),in vitro,High,Sensitive,-,-,2011,A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT,"Here, we measured the expression of 381 miRNA genes in the same resistant (A549, UKY-29, H460, and H1975) and sensitive (H1650, H3255, PC-9, and H358) cell lines using Taqman microRNA arrays."
22045191,miR-628 ,hsa-mir-628,MI0003642,Erlotinib,176870,"A549, UKY-29, H460, and H1975, H1650, H3255, PC-9, and H358",,-,-,epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)),in vitro,High,Sensitive,-,-,2011,A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT,"Here, we measured the expression of 381 miRNA genes in the same resistant (A549, UKY-29, H460, and H1975) and sensitive (H1650, H3255, PC-9, and H358) cell lines using Taqman microRNA arrays."
22045191,miR-636,hsa-mir-636,MI0003651,Erlotinib,176870,"A549, UKY-29, H460, and H1975, H1650, H3255, PC-9, and H358",,-,-,epithelial cancer(Non-small cell lung carcinoma (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)),in vitro,High,Sensitive,-,-,2011,A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT,"Here, we measured the expression of 381 miRNA genes in the same resistant (A549, UKY-29, H460, and H1975) and sensitive (H1650, H3255, PC-9, and H358) cell lines using Taqman microRNA arrays."
22069160,miR-433,hsa-mir-433,MI0001723,Paclitaxel,36314,A2780,-,-,-,serous epithelial ovarian cancer,in vitro,Low,Resistant,MAD2,-,2012,Low MAD2 expression levels associate with reduced progression-free survival in Patient with high-grade serous epithelial ovarian cancer.,"Importantly, reduced MAD2 protein expression in pre-miR-433-transfected A2780 cells rendered these cells less sensitive to paclitaxel."
22098779,miR-145,hsa-mir-145,MI0000461,Cisplatin,2767,GBM-CD133+,-,-,-,glioblastoma,in vitro,Low,Sensitive,Sox2 and Oct4,-,2012,Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI.,"Furthermore, PU-PEI-miR145-treated GBM-CD133(+) effectively suppressed the expression of drug-resistance and anti-apoptotic genes and increased the sensitivity of the cells to radiation and temozolomide."
22098779,miR-145,hsa-mir-145,MI0000461,Temozolomide,5394,GBM-CD133 ,-,Mice,-,glioblastoma,in vitro and in vivo,Low,Sensitive,Sox2 and Oct4,-,2012,Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI.,"Furthermore, PU-PEI-miR145-treated GBM-CD133(+) effectively suppressed the expression of drug-resistance and anti-apoptotic genes and increased the sensitivity of the cells to radiation and temozolomide."
22101791,miR-200c,hsa-mir-200c,MI0000650,Doxorubicin (Adriamycin),31703,MDA-MB-231,MCF-7 vs MCF-7/ADR,-,Patients,breast cancer,in vitro and in vivo,Low,Sensitive,-,-,2012,Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer.,Up-regulation of miR-200c with transfection of miR-200c mimics in breast cancer cells could enhance the chemosensitivity to epirubicin and reduce expression of multidrug resistance 1 mRNA and P-glycoprotein.
22112324,miR-363*,hsa-mir-363,MI0000764,5-Fluorouracil,3385,-,-,-,Patientss,gastric cancer,in vivo,High,Resistant,-,-,2011,miRNA signature associated with outcome of gastric cancer patients following chemotherapy,"Six *miRNAs that were associated with chemoresistance, including miR-518f*, miR-520a, miR-520d*, miR-519e*, miR-363*, and miR-517*, whereas no *miRNAs were associated with chemosensitivity."
22112324,miR-363*,hsa-mir-363,MI0000764,Cisplatin,2767,-,-,-,Patientss,gastric cancer,in vivo,High,Resistant,-,-,2011,miRNA signature associated with outcome of gastric cancer patients following chemotherapy,"Six *miRNAs that were associated with chemoresistance, including miR-518f*, miR-520a, miR-520d*, miR-519e*, miR-363*, and miR-517*, whereas no *miRNAs were associated with chemosensitivity."
22112324,miR-517*,hsa-mir-517a,MI0003161,5-Fluorouracil,3385,-,-,-,Patientss,gastric cancer,in vivo,High,Sensitive,-,-,2011,miRNA signature associated with outcome of gastric cancer patients following chemotherapy,"Six *miRNAs that were associated with chemoresistance, including miR-518f*, miR-520a, miR-520d*, miR-519e*, miR-363*, and miR-517*, whereas no *miRNAs were associated with chemosensitivity."
22112324,miR-517*,hsa-mir-517a,MI0003161,Cisplatin,2767,-,-,-,Patientss,gastric cancer,in vivo,High,Sensitive,-,-,2011,miRNA signature associated with outcome of gastric cancer patients following chemotherapy,"Six *miRNAs that were associated with chemoresistance, including miR-518f*, miR-520a, miR-520d*, miR-519e*, miR-363*, and miR-517*, whereas no *miRNAs were associated with chemosensitivity."
22112324,miR-518f*,hsa-mir-518f,MI0003154,5-Fluorouracil,3385,-,-,-,Patientss,gastric cancer,in vivo,High,Resistant,-,-,2011,miRNA signature associated with outcome of gastric cancer patients following chemotherapy,"Six *miRNAs that were associated with chemoresistance, including miR-518f*, miR-520a, miR-520d*, miR-519e*, miR-363*, and miR-517*, whereas no *miRNAs were associated with chemosensitivity."
22112324,miR-518f*,hsa-mir-518f,MI0003154,Cisplatin,2767,-,-,-,Patientss,gastric cancer,in vivo,High,Resistant,-,-,2011,miRNA signature associated with outcome of gastric cancer patients following chemotherapy,"Six *miRNAs that were associated with chemoresistance, including miR-518f*, miR-520a, miR-520d*, miR-519e*, miR-363*, and miR-517*, whereas no *miRNAs were associated with chemosensitivity."
22112324,miR-519e*,hsa-mir-519e,MI0003145,5-Fluorouracil,3385,-,-,-,Patientss,gastric cancer,in vivo,High,Resistant,-,-,2011,miRNA signature associated with outcome of gastric cancer patients following chemotherapy,"Six *miRNAs that were associated with chemoresistance, including miR-518f*, miR-520a, miR-520d*, miR-519e*, miR-363*, and miR-517*, whereas no *miRNAs were associated with chemosensitivity."
22112324,miR-519e*,hsa-mir-519e,MI0003145,Cisplatin,2767,-,-,-,Patientss,gastric cancer,in vivo,High,Resistant,-,-,2011,miRNA signature associated with outcome of gastric cancer patients following chemotherapy,"Six *miRNAs that were associated with chemoresistance, including miR-518f*, miR-520a, miR-520d*, miR-519e*, miR-363*, and miR-517*, whereas no *miRNAs were associated with chemosensitivity."
22112324,miR-520a,hsa-mir-520a,MI0003149,5-Fluorouracil,3385,-,-,-,Patientss,gastric cancer,in vivo,High,Resistant,-,-,2011,miRNA signature associated with outcome of gastric cancer patients following chemotherapy,"Six *miRNAs that were associated with chemoresistance, including miR-518f*, miR-520a, miR-520d*, miR-519e*, miR-363*, and miR-517*, whereas no *miRNAs were associated with chemosensitivity."
22112324,miR-520a,hsa-mir-520a,MI0003149,Cisplatin,2767,-,-,-,Patientss,gastric cancer,in vivo,High,Resistant,-,-,2011,miRNA signature associated with outcome of gastric cancer patients following chemotherapy,"Six *miRNAs that were associated with chemoresistance, including miR-518f*, miR-520a, miR-520d*, miR-519e*, miR-363*, and miR-517*, whereas no *miRNAs were associated with chemosensitivity."
22112324,miR-520d*,hsa-mir-520d,MI0003164,5-Fluorouracil,3385,-,-,-,Patientss,gastric cancer,in vivo,High,Resistant,-,-,2011,miRNA signature associated with outcome of gastric cancer patients following chemotherapy,"Six *miRNAs that were associated with chemoresistance, including miR-518f*, miR-520a, miR-520d*, miR-519e*, miR-363*, and miR-517*, whereas no *miRNAs were associated with chemosensitivity."
22112324,miR-520d*,hsa-mir-520d,MI0003164,Cisplatin,2767,-,-,-,Patientss,gastric cancer,in vivo,High,Resistant,-,-,2011,miRNA signature associated with outcome of gastric cancer patients following chemotherapy,"Six *miRNAs that were associated with chemoresistance, including miR-518f*, miR-520a, miR-520d*, miR-519e*, miR-363*, and miR-517*, whereas no *miRNAs were associated with chemosensitivity."
22116552,miR-17-92,-,-,Doxorubicin (Adriamycin),31703,Z138c and Granta,-,Mice,-,mantle cell lymphoma,in vitro and in vivo,Low,Resistant,PHLPP2,PI3K/AKT pathway,2012,The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.,Overexpression of miR-17-92 activated the PI3K/AKT pathway and inhibited chemotherapy-induced apoptosis in MCL cell lines.
22116552,miR-17-92,-,-,Etoposide,36462,Z138c and Granta,-,-,-,mantle cell lymphoma,in vitro,Low,Resistant,PHLPP2,PI3K/AKT pathway,2012,The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.,Overexpression of miR-17-92 activated the PI3K/AKT pathway and inhibited chemotherapy-induced apoptosis in MCL cell lines.
22116552,miR-17-92,-,-,Topotecan,60700,Z138c and Granta,-,-,-,mantle cell lymphoma,in vitro ,Low,Resistant,PHLPP2,PI3K/AKT pathway,2012,The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.,Overexpression of miR-17-92 activated the PI3K/AKT pathway and inhibited chemotherapy-induced apoptosis in MCL cell lines.
22117060,miR-193a,hsa-mir-193a,MI0000487,5-Fluorouracil,3385,QGY-7703 and SMMC-7721,-,Mice,-,hepatocellular carcinoma,in vitro and in vivo,Low,Resistant,SRSF2,-,2012,DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression.,"Forced changes of miR-193a-3p level reverse all of the phenotypic features examined, including cell proliferation, cell cycle progression, and 5-FU sensitivity, in cell culture and in nude mice."
22120675,miR-100,hsa-mir-100,MI0000102,Docetaxel,148124,-,SPC-A1 vs SPC-A1/DOC,Mice,Patients,lung adenocarcinoma,in vitro and in vivo,Low,Sensitive,PLK1,-,2012,MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1.,Ectopic miR-100 expression resensitized SPC-A1/DTX cells to docetaxel by suppression of cell proliferation and induction of cell arrest in G(2)/M phase and apoptosis.
22121083,miR-1202,hsa-mir-1202,MI0006334,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2011,miR-1915 Inhibits Bcl-2 to Modulate Multidrug Resistance by Increasing Drug-Sensitivity in Human Colorectal Carcinoma Cells,"Nine of miRNAs had shown obvious differential expression between HCT116/L-OHP cells and their parent cells (Table I, fold change  3)."
22121083,miR-1225,hsa-mir-1225,MI0006311,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2011,miR-1915 Inhibits Bcl-2 to Modulate Multidrug Resistance by Increasing Drug-Sensitivity in Human Colorectal Carcinoma Cells,"Nine of miRNAs had shown obvious differential expression between HCT116/L-OHP cells and their parent cells (Table I, fold change  3)."
22121083,miR-1274a,hsa-mir-1274a,MI0006410,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2011,miR-1915 Inhibits Bcl-2 to Modulate Multidrug Resistance by Increasing Drug-Sensitivity in Human Colorectal Carcinoma Cells,"Nine of miRNAs had shown obvious differential expression between HCT116/L-OHP cells and their parent cells (Table I, fold change  3)."
22121083,miR-1275,hsa-mir-1275,MI0006415,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2011,miR-1915 Inhibits Bcl-2 to Modulate Multidrug Resistance by Increasing Drug-Sensitivity in Human Colorectal Carcinoma Cells,"Nine of miRNAs had shown obvious differential expression between HCT116/L-OHP cells and their parent cells (Table I, fold change  3)."
22121083,miR-1915,hsa-mir-1915,MI0008336,5-Fluorouracil,3385,-,HCT-116 vs HCT-116/L-OHP,-,-,colorectal carcinoma,in vitro,Low,Sensitive,Bcl-2,-,2013,miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells.,"We found that elevated levels of miR-1915 in the mimics-transfected HCT116/L-OHP cells reduced Bcl-2 protein level and the luciferase activity of a Bcl-2 3'-untranslated region-based reporter, and also sensitized these cells to some anticancer drugs."
22121083,miR-1915,hsa-mir-1915,MI0008336,Doxorubicin (Adriamycin),31703,-,HCT-116 vs HCT-116/L-OHP,-,-,colorectal carcinoma,in vitro,Low,Sensitive,Bcl-2,-,2013,miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells.,"We found that elevated levels of miR-1915 in the mimics-transfected HCT116/L-OHP cells reduced Bcl-2 protein level and the luciferase activity of a Bcl-2 3'-untranslated region-based reporter, and also sensitized these cells to some anticancer drugs."
22121083,miR-1915,hsa-mir-1915,MI0008336,Mitomycin C,5746,-,HCT116 vs HCT116/L-OHP,-,-,colorectal carcinoma,in vitro,Low,Sensitive,Bcl-2,-,2013,miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells.,"We found that elevated levels of miR-1915 in the mimics-transfected HCT116/L-OHP cells reduced Bcl-2 protein level and the luciferase activity of a Bcl-2 3'-untranslated region-based reporter, and also sensitized these cells to some anticancer drugs."
22121083,miR-1915,hsa-mir-1915,MI0008336,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal carcinoma,in vitro,Low,Sensitive,Bcl-2,-,2013,miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells.,"We found that elevated levels of miR-1915 in the mimics-transfected HCT116/L-OHP cells reduced Bcl-2 protein level and the luciferase activity of a Bcl-2 3'-untranslated region-based reporter, and also sensitized these cells to some anticancer drugs."
22121083,miR-1915,hsa-mir-1915,MI0008336,Vincristine,5978,-,HCT116 vs HCT116/L-OHP,-,-,colorectal carcinoma,in vitro,Low,Sensitive,Bcl-2,-,2013,miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells.,"We found that elevated levels of miR-1915 in the mimics-transfected HCT116/L-OHP cells reduced Bcl-2 protein level and the luciferase activity of a Bcl-2 3'-untranslated region-based reporter, and also sensitized these cells to some anticancer drugs."
22121083,miR-297,hsa-mir-297,MI0005775,Doxorubicin (Adriamycin),31703,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,Bcl-2,-,2011,miR-1915 Inhibits Bcl-2 to Modulate Multidrug Resistance by Increasing Drug-Sensitivity in Human Colorectal Carcinoma Cells,"Nine of miRNAs had shown obvious differential expression between HCT116/L-OHP cells and their parent cells (Table I, fold change  3)."
22121083,miR-297,hsa-mir-297,MI0005775,Mitomycin C,5746,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,Bcl-2,-,2011,miR-1915 Inhibits Bcl-2 to Modulate Multidrug Resistance by Increasing Drug-Sensitivity in Human Colorectal Carcinoma Cells,"Nine of miRNAs had shown obvious differential expression between HCT116/L-OHP cells and their parent cells (Table I, fold change  3)."
22121083,miR-297,hsa-mir-297,MI0005775,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,Bcl-2,-,2011,miR-1915 Inhibits Bcl-2 to Modulate Multidrug Resistance by Increasing Drug-Sensitivity in Human Colorectal Carcinoma Cells,"Nine of miRNAs had shown obvious differential expression between HCT116/L-OHP cells and their parent cells (Table I, fold change  3)."
22121083,miR-326,hsa-mir-326,MI0000808,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2011,miR-1915 Inhibits Bcl-2 to Modulate Multidrug Resistance by Increasing Drug-Sensitivity in Human Colorectal Carcinoma Cells,"Nine of miRNAs had shown obvious differential expression between HCT116/L-OHP cells and their parent cells (Table I, fold change  3)."
22121083,miR-630,hsa-mir-630,MI0003644,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2011,miR-1915 Inhibits Bcl-2 to Modulate Multidrug Resistance by Increasing Drug-Sensitivity in Human Colorectal Carcinoma Cells,"Nine of miRNAs had shown obvious differential expression between HCT116/L-OHP cells and their parent cells (Table I, fold change  3)."
22121083,miR-892b,hsa-mir-892b,MI0005538,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2011,miR-1915 Inhibits Bcl-2 to Modulate Multidrug Resistance by Increasing Drug-Sensitivity in Human Colorectal Carcinoma Cells,"Nine of miRNAs had shown obvious differential expression between HCT116/L-OHP cells and their parent cells (Table I, fold change  3)."
22132977,miR-330,hsa-mir-330,MI0000803,Gemcitabine,60750,Colon and Lung Cancer Cells ,-,-,-,cancer,in vitro,Low,Resistant,dCK,-,2011,Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells.,"Expression of miR-330 in various colon and lung cancer cell lines, as measured by QRT-PCR, varied five-fold between samples and correlated with in-vitro gemcitabine resistance (R=0.82, p=0.04)."
22139708,miR-200b,hsa-mir-200b,MI0000342,Docetaxel,148124,-,SPC-A1 vs SPC-A1/DOC,Mice,Patients,lung adenocarcinoma,in vitro and in vivo,Low,Sensitive,E2F3,-,2012,MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3.,"Ectopic miR-200b expression reversed docetaxel chemoresistance of lung adenocarcinoma cells through cell proliferation inhibition, apoptosis enhancement, and G(2) /M cell cycle arrest."
22156446,miR-221,hsa-mir-221,MI0000298,Chemotherapy,-,-,-,-,Patients,breast cancer,in vivo,Low,Associated,-,-,2011,Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer Patient who previously received neoadjuvant chemotherapy.,Patient with different miR-221 levels had significant differences in the overall response rate (p = 0.044) but not in the pathologic complete response rate (p = 0.477).
22157765,miR-30a,hsa-mir-30a,MI0000088,Cisplatin,2767,SGC-7092 and SGC-7091,-,Mice,-,-,in vitro and in vivo,Low,Sensitive,beclin 1,-,2012,MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy.,"Finally, an in vivo tumor implantation mouse model clearly showed that elevation of miR-30a in implanted tumor cells by administration of the recombinant lentivirus expressing miR-30a strongly enhanced cis-DDP-induced apoptosis of tumor cells."
22174421,miR-21,hsa-mir-21,MI0000077,Gemcitabine,60750,BxPC-3 ,-,-,-,adenocarcinoma,in vitro,Low,Resistant,SIDT1,-,2012,Homo sapiens systemic RNA interference-defective-1 transmembrane family member 1 (SIDT1) protein mediates contact-dependent small RNA transfer and microRNA-21-driven chemoresistance.,Minority Subpopulation of miR-21-overexpressing Adenocarcinoma Cells Increases Global Cellular Chemoresistance to Gemcitabine
22193543,miR-128-2,hsa-mir-128-2,MI0000727,5-Fluorouracil,3385,"H1299, H1299 clone 41, H1299 clone 23 and H1299 clone pIND and A459",-,-,-,non-small-cell lung cancer,in vitro,Low,Resistant,E2F5,p21,2012,MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.,"miR-128-2 expression in lung cancer cells inhibits apoptosis and confers increased resistance to cisplatin, doxorubicin and 5-fluorouracyl treatments."
22193543,miR-128-2,hsa-mir-128-2,MI0000727,Cisplatin,2767,"H1299, H1299 clone 41, H1299 clone 23 and H1299 clone pIND and A459",-,-,-,non-small-cell lung cancer,in vitro,Low,Resistant,E2F5,p21,2012,MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.,"miR-128-2 expression in lung cancer cells inhibits apoptosis and confers increased resistance to cisplatin, doxorubicin and 5-fluorouracyl treatments."
22193543,miR-128-2,hsa-mir-128-2,MI0000727,Doxorubicin (Adriamycin),31703,"H1299, H1299 clone 41, H1299 clone 23, H1299 clone pIND and A459",-,-,-,non-small-cell lung cancer,in vitro,Low,Resistant,E2F5,p21,2012,MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.,"miR-128-2 expression in lung cancer cells inhibits apoptosis and confers increased resistance to cisplatin, doxorubicin and 5-fluorouracyl treatments."
22194984,miR-200b,hsa-mir-200b,MI0000342,Cisplatin,2767,HEC-1A,-,-,-,-,in vitro,Low,Associated,AP-2a,-,2011,A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2alpha gene is associated with cisplatin resistance.,A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2alpha gene is associated with cisplatin resistance.
22194984,miR-200c,hsa-mir-200c,MI0000650,Cisplatin,2767,HEC-1A,-,-,-,-,in vitro,Low,Associated,AP-2a,-,2011,A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2alpha gene is associated with cisplatin resistance.,A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2alpha gene is associated with cisplatin resistance.
22194984,miR-429,hsa-mir-429,MI0001641,Cisplatin,2767,HEC-1A,-,-,-,-,in vitro,Low,Associated,AP-2a,-,2011,A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2alpha gene is associated with cisplatin resistance.,A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2alpha gene is associated with cisplatin resistance.
22207897,miR-203,hsa-mir-203a,MI0000283,Cisplatin,2767,"MCF-7, ZR-75 and MDA-MB-231",-,-,-,breast cancer,in vitro,Low,Resistant,SOCS3,-,2011,Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity.,"Furthermore, knockdown of miR-203 sensitized human breast cancer MCF-7 cells to cisplatin-mediated apoptotic cell death, as evident from caspase-9 and caspase-7 activation, and poly(ADP-ribose) polymerase (PARP) cleavage."
22209977,miR-181a,hsa-mir-181a-2,MI0000269,Cytarabine,6253,-,HL-60 vs HL-60/Ara-C,-,-,leukaemia,in vitro,Low,Sensitive,Bcl-2,apoptosis pathway,2012,miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis.,Overexpression of miR-181a in HL-60/Ara-C cells sensitized the cells to Ara-C treatment.
22235305,miR-122,hsa-mir-122,MI0000442,Bortezomib,387447,SeAx and MyLa2000,-,-,-,cutaneous T-cell lymphoma,in vitro,Low,Resistant,-,Akt signalling pathway,2012,miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.,"Surprisingly, miR-122 overexpression decreased the sensitivity to the chemotherapy-induced apoptosis via a signaling circuit involving the activation of Akt and inhibition of p53."
22235305,miR-122,hsa-mir-122,MI0000442,Doxorubicin (Adriamycin),31703,SeAx and MyLa2000,-,-,-,cutaneous T-cell lymphoma,in vitro,Low,Resistant,-,Akt signalling pathway,2012,miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.,"Surprisingly, miR-122 overexpression decreased the sensitivity to the chemotherapy-induced apoptosis via a signaling circuit involving the activation of Akt and inhibition of p53."
22237007,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,-,A549 vs A549/CDDP,-,Patients,non-small cell lung cancer,in vitro and in vivo,Low,Resistant,-,PTEN and BCL-2,2012,MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in Patient with non-small cell lung cancer.,"Increased miR-21 expression significantly increased the resistance of A549 cell to platinum, whereas reduced miR-21 decreased the resistance of A549/CDDP cell."
22249446,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,CA-27,-,-,-,oral squamous cell carcinoma,in vitro,Low,Resistant,-,-,2012,miR-21 inhibitor sensitizes human OSCC cells to cisplatin.,"Moreover, downregulation of miR-21 could sensitize CA-27 cells to cisplatin possibly by increasing cisplatin induced apoptosis."
22260163,miR-142,hsa-mir-142,MI0000458,Dexamethasone,5743,MM.1S,-,-,-,multiple myeloma,in vitro,Low,Sensitive,-,-,2012,Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs.,"MicroRNA mimics and inhibitors inhibited or enhanced the synergistic effect between TPL and dexamethasone in inducing apoptosis in MM.1S cells, suggesting an important role of miR142 - 5p and miR181a in GR regulation by TPL."
22260163,miR-181a,hsa-mir-181a-2,MI0000269,Dexamethasone,5743,MM.1S,-,-,-,multiple myeloma,in vitro,Low,Sensitive,-,-,2012,Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs.,"MicroRNA mimics and inhibitors inhibited or enhanced the synergistic effect between TPL and dexamethasone in inducing apoptosis in MM.1S cells, suggesting an important role of miR142 - 5p and miR181a in GR regulation by TPL."
22285729,miR-181a,hsa-mir-181a-2,MI0000269,Daunorubicin,30323,-,K562 vs K562/DNR,-,-,leukemia,in vitro,Low,Sensitive,BCL-2,-,2012,miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2.,miR-181a could enhance DNR-induced apoptosis in K562/A02 cells.
22287315,miR-145 ,hsa-mir-145,MI0000461,Mitomycin C,5746,"HeLa, SiHa, CaSki and HaCaT",-,-,-,cervical cancer,in vitro,Low,Sensitive,-,-,2012,Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells.,Over-expression of miR-145 enhanced sensitivity to mitomycin and reversed the chemoresistance induced by glucocorticoids.
22289545,miR-21,hsa-mir-21,MI0000077,Chemotherapy,-,-,-,-,Patients,colorectal cancer,in vivo,Low,Associated,-,-,2011,Increased expression of microRNA-21and its association with chemotherapeutic response in human colorectal cancer.,"These data showed that miR-21 was significantly overexpressed in CRC tumour tissue and was associated with advanced CRC, and that miR-21 may be a potential candidate biomarker for predicting pathological tumour response to chemotherapy."
22312705,miR-122,hsa-mir-122,MI0000442,5-Fluorouracil,3385,-,BEL-7402 vs BEL-7402/5-FU ,-,-,hepatoblastoma,in vitro,Low,Sensitive,Bcl-2 and Bcl-XL,P53,2011,MiR-122 increases sensitivity of drug-resistant BEL-7402/5-FU cells to 5-fluorouracil via down-regulation of bcl-2 family proteins.,"MTT results showed that after incubation with 5-FU, miR-122 transfectants had higher cell inhibitory rates than negative miRNA or untreated cells."
22322955,miR-10b,hsa-mir-10b,MI0000267,5-Fluorouracil,3385,HCT-116,-,-,Patients,colorectal cancer,in vitro and in vivo,Low,Resistant,BIM,-,2012,MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells.,"In vitro studies revealed that miR-10b directly inhibits pro-apoptotic BIM, and the overexpression of miR-10b confers chemoresistance in colorectal cancer cells to 5-FU."
22354855,miR-21,hsa-mir-21,MI0000077,Chemotherapy,-,-,-,-,Patients,esophageal squamous cell carcinoma,in vivo,Low,Resistant,-,-,2012,Serum microRNA-21 is a novel biomarker in Patient with esophageal squamous cell carcinoma.,"Furthermore, miRNA-21 levels were significantly reduced in ESCC Patient who responded to chemotherapy (P = 0.003), whereas no significant change was observed in the non-responders."
22370637,miR-34c,hsa-mir-34c,MI0000743,Paclitaxel,36314,A549 and H460,-,-,-,lung cancer,in vitro,Low,Resistant,Bmf and C-myc,-,2013,miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis.,"We demonstrate that Bmf (Bcl-2-modifying factor) is a target of miR-34c-5p, and that its silencing, together with that of c-myc, a known target of miR-34c-5p, contributes to resistance to apoptosis induced by paclitaxel through p53 downregulation."
22370716,miR-210,hsa-mir-210,MI0000286,Trastuzumab,9903,BT474 and BTR65,-,-,Patients,breast cancer,in vitro and in vivo,Low,Resistant,-,-,2012,Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer Patient.,"At baseline before Patient received neoadjuvant chemotherapy combined with trastuzumab, circulating miR-210 levels were significantly higher in those who had residual disease than in those who achieved a pathologic complete response (P = .0359)."
22382630,let-7b,hsa-let-7b,MI0000063,5-Fluorouracil,3385,-,DLD-1 vs DLD-1/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU."
22382630,let-7c,hsa-let-7c,MI0000064,5-Fluorouracil,3385,-,DLD-1 vs DLD-1/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU."
22382630,let-7e,hsa-let-7e,MI0000066,5-Fluorouracil,3385,-,DLD-1 vs DLD-1/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU."
22382630,let-7g,hsa-let-7g,MI0000433,5-Fluorouracil,3385,-,DLD-1 vs DLD-1/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU."
22382630,miR-103,hsa-mir-103a-1,MI0000109,5-Fluorouracil,3385,-,DLD-1 vs DLD-1/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU."
22382630,miR-106b,hsa-mir-106b,MI0000734,5-Fluorouracil,3385,-,DLD-1 vs DLD-1/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-107,hsa-mir-107,MI0000114,5-Fluorouracil,3385,-,DLD-1 vs DLD-1/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-130b,hsa-mir-130b,MI0000748,5-Fluorouracil,3385,-,DLD-1 vs DLD-1/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-130b,hsa-mir-130b,MI0000748,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-141,hsa-mir-141,MI0000457,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-15a,hsa-mir-15a,MI0000069,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-15b,hsa-mir-15b,MI0000438,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-181a,hsa-mir-181a-2,MI0000269,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-19b,hsa-mir-19b-1,MI0000074,5-Fluorouracil,3385,-,DLD-1 vs DLD-1/5-FU and KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,Low,Associated,SFPQ and MYBL2,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In response to 5-FU, miR-19b and miR-21 were over-expressed in 5-FU-resistant cells. "
22382630,miR-200c,hsa-mir-200c,MI0000650,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-20b,hsa-mir-20b,MI0001519,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-21,hsa-mir-21,MI0000077,5-Fluorouracil,3385,-,DLD-1 vs DLD-1/5-FU and KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,Low,Associated,SFPQ and MYBL2,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In response to 5-FU, miR-19b and miR-21 were over-expressed in 5-FU-resistant cells. "
22382630,miR-24,hsa-mir-24-1,MI0000080,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-25,hsa-mir-25,MI0000082,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-26a,hsa-mir-26a-1,MI0000083,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-26b,hsa-mir-26b,MI0000084,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-29c,hsa-mir-29c,MI0000735,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-30b,hsa-mir-30b,MI0000441,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-30d,hsa-mir-30d,MI0000255,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-31,hsa-mir-31,MI0000089,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-365,hsa-mir-365a,MI0000767,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-425,hsa-mir-425,MI0001448,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-429,hsa-mir-429,MI0001641,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22382630,miR-96,hsa-mir-96,MI0000098,5-Fluorouracil,3385,-,KM12C vs KM12C/5-FU,-,-,colon cancer,in vitro,High,Resistant,-,-,2012,Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.,"In DLD-1 parental and resistant cells, a total of 47 microRNAs were differentially expressed by[2.0-fold after exposure to 5-FU. Eight microRNAs were specifically up-regulated in DLD-1/R cells (Table 1), whereas a total of 33 microRNAs were up-regulated in KM12C and KM12C/R cells, and 22 microRNAs were specifically up-regulated in KM12C/R cells (Table 1)."
22395361,miR-30a,hsa-mir-30a,MI0000088,Imatinib,5291,K562,-,-,Patients,chronic myeloid leukemia,in vitro and in vivo,Low,Sensitive,-,Beclin 1 and ATG5,2012,Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells.,"In contrast, knockdown of miR-30a by antagomir-30a increases the expression of Beclin 1 and ATG5, and inhibits imatinib-induced cytotoxicity."
22453125,miR-328,hsa-mir-328,MI0000804,10-Hydroxycamptothecin (HCPT),97226,Cancer Stem Cell-like SP cells,-,-,-,colorectal cancer,in vitro,Low,Sensitive,ABCG2 and MMP16,-,2012,MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer.,"In addition, miR-328 overexpression reversed drug resistance and inhibited cell invasion of SP cells."
22453125,miR-328,hsa-mir-328,MI0000804,5-Fluorouracil,3385,Cancer Stem Cell-like SP cells,-,-,-,colorectal cancer,in vitro,Low,Sensitive,ABCG2 and MMP16,-,2012,MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer.,"In addition, miR-328 overexpression reversed drug resistance and inhibited cell invasion of SP cells."
22455133,miR-130a,hsa-mir-130a,MI0000448,Cisplatin,2767,-,A2780 vs A2780/CDDP and SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer ,in vitro,Low,Associated,-,-,2012,Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer,"The expression of miR-130a was 30.51 times higher in A2780/CIS1, 4.87 times higher in A2780/CIS2 and 24.43 times higher in SKOV3/CIS than in their parental cell lines (P < 0.05), which was almost equally reflected in their resistance index."
22465665,miR-93,hsa-mir-93,MI0000095,Cisplatin,2767,-,OVCAR3 vs OVCAR3/CDDP and SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer ,in vitro,Low,Resistant,PTEN,AKT signaling pathway,2012,"Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells.","In vitro assays show that over-expression and knock-down of miR-93 regulate apoptotic activity, and thereby cisplatin chemosensitivity, in ovarian cells."
22498306,miR-199a,hsa-mir-199a-1,MI0000242,Cisplatin,2767,CD44+ ? CD117+,-,Mice,-,ovarian cancer,in vitro and in vivo,Low,Sensitive,CD44,ABCG2,2012,MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.,"miR-199a significantly increased the chemosensitivity of ovarian CICs to cisplatin, pacitaxel, and adriamycin, and reduced mRNA expression of the multidrug resistance gene ABCG2 as compared with miR-199a mutant-transfected and untransfected cells."
22498306,miR-199a,hsa-mir-199a-1,MI0000242,Doxorubicin (Adriamycin),31703,CD44+ ? CD117+,-,Mice,-,ovarian cancer,in vitro and in vivo,Low,Sensitive,CD44,ABCG2,2012,MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.,"miR-199a significantly increased the chemosensitivity of ovarian CICs to cisplatin, pacitaxel, and adriamycin, and reduced mRNA expression of the multidrug resistance gene ABCG2 as compared with miR-199a mutant-transfected and untransfected cells."
22498306,miR-199a,hsa-mir-199a-1,MI0000242,Paclitaxel,36314,CD44+ ? CD117+,-,Mice,-,ovarian cancer,in vitro and in vivo,Low,Sensitive,CD44,ABCG2,2012,MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.,"miR-199a significantly increased the chemosensitivity of ovarian CICs to cisplatin, pacitaxel, and adriamycin, and reduced mRNA expression of the multidrug resistance gene ABCG2 as compared with miR-199a mutant-transfected and untransfected cells."
22502680,miR-214,hsa-mir-214,MI0000290,Gefitinib,123631,-,HCC827 vs HCC827/GR,-,-,non-small cell lung cancer,in vitro,Low,Resistant,-,expression of PTEN and p-AKT,2012,MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.,Knockdown of miR-214 altered the expression of PTEN and p-AKT and re-sensitized HCC827/GR to gefitinib.
22508479,miR-375,hsa-mir-375,MI0000783,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,Low,Sensitive,MTDH,-,2013,Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer.,miRNA-375 is downregulated in TamR cells and its re-expression sensitizes cells to tamoxifen and reverts EMT-like properties.
22510476,miR-126,hsa-mir-126,MI0000471,Doxorubicin (Adriamycin),31703,A549,-,Mice,-,non-small cell lung cancer,in vitro and in vivo,Low,Sensitive,VEGFA and MRP1 ,VEGF/PI3K/Akt/MRP1 signaling pathway,2012,miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A.,"After transfected A549 cells with miR-126 mimic or inhibitor, we found that an elevated level of miR-126 was significantly associated with a decreased half maximal inhibitory concentration of adriamycin (ADM) and vincristine"
22510476,miR-126,hsa-mir-126,MI0000471,Vincristine,5978,A549,-,Mice,-,non-small cell lung cancer,in vitro and in vivo,Low,Sensitive,VEGFA and MRP1 ,VEGF/PI3K/Akt/MRP1 signaling pathway,2012,miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A.,"After transfected A549 cells with miR-126 mimic or inhibitor, we found that an elevated level of miR-126 was significantly associated with a decreased half maximal inhibitory concentration of adriamycin (ADM) and vincristine"
22521303,miR-298,hsa-mir-298,MI0005523,Doxorubicin (Adriamycin),31703,MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Resistant,MDR1,-,2012,Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298.,"Overexpression of miR-298 down-regulated P-gp expression, increasing nuclear accumulation of doxorubicin and cytotoxicity in doxorubicin-resistant breast cancer cells."
22523546,miR-125b,hsa-mir-125b-1,MI0000446,5-Fluorouracil,3385,"MCF-7, T47D, BT20 and MDA-MB-231",-,-,Patients,breast cancer,in vitro and in vivo,Low,Resistant,-,-,2012,Circulating MiR-125b as a marker predicting chemoresistance in breast cancer.,"Increased resistance to anticancer drug was observed in vitro in breast cancer cells with ectopic miR-125b expression; conversely, reducing miR-125b level sensitized breast cancer cells to chemotherapy."
22610076,miR-181a,hsa-mir-181a-2,MI0000269,Fludarabine,657237,-,-,-,Patients,chronic lymphocytic leukemia,in vivo,Low,Sensitive,"BCL-2, MCL-1 and X-linked inhibitor of apoptosis protein by direct binding to 3'UTR.",-,2012,miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.,MiR-181a/b significantly sensitizes CLL cells to fludarabine-induced apoptosis
22610076,miR-181b,hsa-mir-181b-1,MI0000270,Fludarabine,657237,-,-,-,Patients,chronic lymphocytic leukemia,in vivo,Low,Sensitive,"BCL-2, MCL-1 and X-linked inhibitor of apoptosis protein by direct binding to 3'UTR.",-,2012,miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.,MiR-181a/b significantly sensitizes CLL cells to fludarabine-induced apoptosis
22614869,let-7c,hsa-let-7c,MI0000064,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,let-7d,hsa-let-7d,MI0000065,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,let-7e,hsa-let-7e,MI0000066,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,let-7f,hsa-let-7f-1,MI0000067,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,let-7g,hsa-let-7g,MI0000433,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,let-7i,hsa-let-7i,MI0000434,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-106a,hsa-mir-106a,MI0000113,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-106b,hsa-mir-106b,MI0000734,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-1290,hsa-mir-1290,MI0006352,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-130a,hsa-mir-130a,MI0000448,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-130a,hsa-mir-130a,MI0000448,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,Low,Resistant,PTEN,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.,"We found that miR-130a was upregulated in SKOV3/CIS compared to the parental SKOV3 cells, and PTEN was predicted to be the potential target of miR-130a."
22614869,miR-133b,hsa-mir-133b,MI0000822,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-148b,hsa-mir-148b,MI0000811,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-15a,hsa-mir-15a,MI0000069,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-15b,hsa-mir-15b,MI0000438,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-16,hsa-mir-16-1,MI0000070,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-17,hsa-mir-17,MI0000071,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-181d,hsa-mir-181d,MI0003139,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-19a,hsa-mir-19a,MI0000073,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-20a,hsa-mir-20a,MI0000076,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-20b,hsa-mir-20b,MI0001519,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-22,hsa-mir-22,MI0000078,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-221,hsa-mir-221,MI0000298,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-222,hsa-mir-222,MI0000299,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-224,hsa-mir-224,MI0000301,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-23a,hsa-mir-23a,MI0000079,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-25,hsa-mir-25,MI0000082,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-26b,hsa-mir-26b,MI0000084,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-27a,hsa-mir-27a,MI0000085,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-29a,hsa-mir-29a,MI0000087,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-29b,hsa-mir-29b-1,MI0000105,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-30b,hsa-mir-30b,MI0000441,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-30e,hsa-mir-30e,MI0000749,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-3175,hsa-mir-3175,MI0014209,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-320a,hsa-mir-320a,MI0000542,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-320d,hsa-mir-320d-1,MI0008190,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-320e,hsa-mir-320e,MI0014234,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-331,hsa-mir-331,MI0000812,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-3607,hsa-mir-3607,MI0015997,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-365,hsa-mir-365a,MI0000767,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-3651,hsa-mir-3651,MI0016051,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-3653,hsa-mir-3653,MI0016053,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-374a,hsa-mir-374a,MI0000782,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-374b,hsa-mir-374b,MI0005566,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-378,hsa-mir-378a,MI0000786,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-423,hsa-mir-423,MI0001445,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-4284,hsa-mir-4284,MI0015893,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-4289,hsa-mir-4289,MI0015898,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-744,hsa-mir-744,MI0005559,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-92a,hsa-mir-92a-1,MI0000093,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-98,hsa-mir-98,MI0000100,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miR-99a,hsa-mir-99a,MI0000101,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miRPlus-A1015,-,-,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22614869,miRPlus-C1110,-,-,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2012,Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance,"Differentially expressed miRNAs with statistical significance were selected only when they were altered by at least 2-fold. With these strict criteria, 35 miRNAs exhibited lower expression and 54 miRNAs exhibited higher expression in SKOV3/CIS than those in SKOV3 cells (Tables II and III). "
22617440,miR-30a,hsa-mir-30a,MI0000088,Imatinib,5291,K562 and Primary CML Cells,-,-,-,chronic myelogenous leukemia,in vitro,Low,Sensitive,BECN1 and ATG5,-,2012,microRNA 30A promotes autophagy in response to cancer therapy.,"MIR30A mimics significantly decrease cell viability and enhance imatinib as well as other TKIs (e.g., nilotinib and dasatinib) induce apoptosis in CML cells."
22676135,miR-1202,hsa-mir-1202,MI0006334,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2,"A total of 16 miRNAs showed an obvious differential expression between HCT116/LOHP cells and their parent cells (fold change 3, Table 1)."
22676135,miR-1207,hsa-mir-1207,MI0006340,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2,"A total of 16 miRNAs showed an obvious differential expression between HCT116/LOHP cells and their parent cells (fold change 3, Table 1)."
22676135,miR-1225,hsa-mir-1225,MI0006311,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colon cancer,in vitro,High,Sensitive,MRP-2,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2,"A total of 16 miRNAs showed an obvious differential expression between HCT116/LOHP cells and their parent cells (fold change 3, Table 1)."
22676135,miR-1268,hsa-mir-1268a,MI0006405,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2,"A total of 16 miRNAs showed an obvious differential expression between HCT116/LOHP cells and their parent cells (fold change 3, Table 1)."
22676135,miR-1274a,hsa-mir-1274a,MI0006410,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2,"A total of 16 miRNAs showed an obvious differential expression between HCT116/LOHP cells and their parent cells (fold change 3, Table 1)."
22676135,miR-1275,hsa-mir-1275,MI0006415,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2,"A total of 16 miRNAs showed an obvious differential expression between HCT116/LOHP cells and their parent cells (fold change 3, Table 1)."
22676135,miR-1915,hsa-mir-1915,MI0008336,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2,"A total of 16 miRNAs showed an obvious differential expression between HCT116/LOHP cells and their parent cells (fold change 3, Table 1)."
22676135,miR-221,hsa-mir-221,MI0000298,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2,"A total of 16 miRNAs showed an obvious differential expression between HCT116/LOHP cells and their parent cells (fold change 3, Table 1)."
22676135,miR-222,hsa-mir-222,MI0000299,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2,"A total of 16 miRNAs showed an obvious differential expression between HCT116/LOHP cells and their parent cells (fold change 3, Table 1)."
22676135,miR-297,hsa-mir-297,MI0005775,Doxorubicin (Adriamycin),31703,-,HCT-116 vs HCT-116/L-OHP,Mice,-,colorectal carcinoma,in vitro and in vivo,Low,Sensitive,MRP-2,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2.,"Furthermore, we found that ectopic expression of miR-297 in MDR colorectal carcinoma cells reduced MRP-2 protein level and sensitized these cells to anti-cancer drugs in vitro and in vivo."
22676135,miR-297,hsa-mir-297,MI0005775,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,Mice,-,colorectal carcinoma,in vitro and in vivo,Low,Sensitive,MRP-2,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2.,"Furthermore, we found that ectopic expression of miR-297 in MDR colorectal carcinoma cells reduced MRP-2 protein level and sensitized these cells to anti-cancer drugs in vitro and in vivo."
22676135,miR-297,hsa-mir-297,MI0005775,Vincristine,5978,-,HCT116 vs HCT116/L-OHP,Mice,-,colorectal carcinoma,in vitro and in vivo,Low,Sensitive,MRP-2,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2.,"Furthermore, we found that ectopic expression of miR-297 in MDR colorectal carcinoma cells reduced MRP-2 protein level and sensitized these cells to anti-cancer drugs in vitro and in vivo."
22676135,miR-338,hsa-mir-338,MI0000814,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2,"A total of 16 miRNAs showed an obvious differential expression between HCT116/LOHP cells and their parent cells (fold change 3, Table 1)."
22676135,miR-513a,hsa-mir-513a-1,MI0003191,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2,"A total of 16 miRNAs showed an obvious differential expression between HCT116/LOHP cells and their parent cells (fold change 3, Table 1)."
22676135,miR-630,hsa-mir-630,MI0003644,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2,"A total of 16 miRNAs showed an obvious differential expression between HCT116/LOHP cells and their parent cells (fold change 3, Table 1)."
22676135,miR-638,hsa-mir-638,MI0003653,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2,"A total of 16 miRNAs showed an obvious differential expression between HCT116/LOHP cells and their parent cells (fold change 3, Table 1)."
22676135,miR-892b,hsa-mir-892b,MI0005538,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2,"A total of 16 miRNAs showed an obvious differential expression between HCT116/LOHP cells and their parent cells (fold change 3, Table 1)."
22676135,miR-939,hsa-mir-939,MI0005761,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2012,miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2,"A total of 16 miRNAs showed an obvious differential expression between HCT116/LOHP cells and their parent cells (fold change 3, Table 1)."
22677042,miR-222,hsa-mir-222,MI0000299,5-Fluorouracil,3385,-,HCT-8 vs HCT-8/VCR and HCT-116 vs HCT-116/L-OHP,-,-,colorectal carcinoma,in vitro,Low,Sensitive,ADAM-17,-,2012,MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17.,We found that elevated levels of miR-222 in the mimics-transfected HCT116/L-OHP and HCT-8/VCR cells reduced the ADAM-17 protein level and the luciferase activity of an ADAM-17 3' untranslated region-based reporter and sensitized these cells' apoptosis to some anticancer drugs.
22677042,miR-222,hsa-mir-222,MI0000299,Oxaliplatin,5310940,-,HCT-8 vs HCT-8/VCR and HCT-116 vs HCT-116/L-OHP,-,-,colorectal carcinoma,in vitro,Low,Sensitive,ADAM-17,-,2012,MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17.,We found that elevated levels of miR-222 in the mimics-transfected HCT116/L-OHP and HCT-8/VCR cells reduced the ADAM-17 protein level and the luciferase activity of an ADAM-17 3' untranslated region-based reporter and sensitized these cells' apoptosis to some anticancer drugs.
22677042,miR-222,hsa-mir-222,MI0000299,Vincristine,5978,-,HCT-8 vs HCT-8/VCR and HCT-116 vs HCT-116/L-OHP,-,-,colorectal carcinoma,in vitro,Low,Sensitive,ADAM-17,-,2012,MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17.,We found that elevated levels of miR-222 in the mimics-transfected HCT116/L-OHP and HCT-8/VCR cells reduced the ADAM-17 protein level and the luciferase activity of an ADAM-17 3' untranslated region-based reporter and sensitized these cells' apoptosis to some anticancer drugs.
22710713,miR-497,hsa-mir-497,MI0003138,5-Fluorouracil,3385,HCT-116,-,-,-,colorectal cancer,in vitro,Low,Sensitive,IGF1-R,-,2013,MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.,MiR-497 confers increased sensitivity of colon cancer cells to apoptosis.
22710713,miR-497,hsa-mir-497,MI0003138,Cisplatin,2767,HCT116,-,-,-,colorectal cancer,in vitro,Low,Sensitive,IGF1-R,-,2013,MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.,MiR-497 confers increased sensitivity of colon cancer cells to apoptosis.
22710713,miR-497,hsa-mir-497,MI0003138,TRAIL therapy,-,HCT116,-,-,-,colorectal cancer,in vitro,Low,Sensitive,IGF1-R,-,2013,MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.,MiR-497 confers increased sensitivity of colon cancer cells to apoptosis.
22713463,miR-199a,hsa-mir-199a-1,MI0000242,Cisplatin,2767,Huh7 and  HepG2,-,-,-,hepatocellular carcinoma,in vitro ,Low,Sensitive,ATG7,-,2012,Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell.,Forced expression of miR-199a-5p promoted cisplatin-induced inhibition of cell proliferation.
22723308,miR-708,hsa-mir-708,MI0005543,Doxorubicin (Adriamycin),31703,A673,-,-,-,ewing sarcoma,in vitro,Low,Associated,EYA3,-,2012,"EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.","EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance."
22723308,miR-708,hsa-mir-708,MI0005543,Etoposide,36462,A673,-,-,-,ewing sarcoma,in vitro,Low,Associated,EYA3,-,2012,"EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.","EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance."
22723956,miR-337,hsa-mir-337,MI0000806,Docetaxel,148124,NCI-H1155 ,-,-,-,non-small cell lung cancers,in vitro,Low,Sensitive,STAT3 and RAP1A,-,2012,miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers.,"Further investigation showed that miR-337-3p mimic also sensitizes cells to docetaxel, another member of the taxane family, and that STAT3 levels are significantly correlated with taxane resistance in lung cancer cell lines."
22723956,miR-337,hsa-mir-337,MI0000806,Paclitaxel,36314,NCI-H1155 ,-,-,-,non-small cell lung cancers,in vitro,Low,Sensitive,STAT3 and RAP1A,-,2012,miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers.,"We demonstrated that over-expression of the microRNA miR-337-3p sensitizes NCI-H1155 cells to paclitaxel, and that miR-337-3p mimic has a general effect on paclitaxel response in NSCLC cell lines."
22749944,miR-513a,hsa-mir-513a-1,MI0003191,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,Low,Sensitive,GSTP1,-,2012,miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1.,"Furthermore, CCK-8 assay showed that overexpression of miR-513a-3p could enhance cisplatin-induced apoptosis in human lung adenocarcinoma cell lines, A549/CDDP and SPC-A-1."
22752226,miR-193b,hsa-mir-193b,MI0003137,Carboplatin,38904,CEULCLs,-,-,-,cancer,in vitro,Low,Associated,-,-,2012,Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility.,"Examining the relationships among rs1649942, its gene expression targets, genome-wide miRNA expression, and cellular sensitivity to carboplatin and cisplatin, we identified 2 platinum-associated miRNAs (miR-193b* and miR-320) that inhibit the expression of 5 platinum-associated genes (CRIM1, IFIT2, OAS1, KCNMA1, and GRAMD1B)."
22752226,miR-193b,hsa-mir-193b,MI0003137,Cisplatin,2767,CEULCLs,-,-,-,cancer,in vitro,Low,Associated,-,-,2012,Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility.,"Examining the relationships among rs1649942, its gene expression targets, genome-wide miRNA expression, and cellular sensitivity to carboplatin and cisplatin, we identified 2 platinum-associated miRNAs (miR-193b* and miR-320) that inhibit the expression of 5 platinum-associated genes (CRIM1, IFIT2, OAS1, KCNMA1, and GRAMD1B)."
22753745,miR-21,hsa-mir-21,MI0000077,Temozolomide,5394,-,D54MG vs D54MG/TEM,-,-,glioblastoma,in vitro,Low,Resistant,-,-,2012,MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells.,Concomitant treatment with miR-21 inhibitor and TMZ resulted in a significantly higher apoptotic rate than TMZ treatment alone.
22761336,miR-96,hsa-mir-96,MI0000098,Cisplatin,2767,U2OS,-,Mice,-,cancer,in vitro and in vivo,Low,Sensitive,REV1 and RAD51,-,2012,MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition.,Overexpression of miR-96 decreased the efficiency of homologous recombination and enhanced sensitivity to the PARP inhibitor AZD2281 in vitro and to cisplatin both in vitro and in vivo.
22761336,miR-96,hsa-mir-96,MI0000098,Olaparib,23725625,"U2OS, HeLa, HCC1937, MDA-MB-231 and HCT116",PEO1 vs PEO1 C4-2,Mice,-,cancer,in vitro and in vivo,Low,Sensitive,REV1 and RAD51,-,2012,MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition.,Overexpression of miR-96 decreased the efficiency of homologous recombination and enhanced sensitivity to the PARP inhibitor AZD2281 in vitro and to cisplatin both in vitro and in vivo.
22768203,miR-1,hsa-mir-1-1,MI0000651,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Sensitive,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-1,hsa-mir-1-1,MI0000651,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Sensitive,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-10a,hsa-mir-10a,MI0000266,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Sensitive,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-10a,hsa-mir-10a,MI0000266,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Sensitive,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-10b,hsa-mir-10b,MI0000267,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Sensitive,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-10b,hsa-mir-10b,MI0000267,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Sensitive,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-125b,hsa-mir-125b-1,MI0000446,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Sensitive,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-125b,hsa-mir-125b-1,MI0000446,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Sensitive,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-126,hsa-mir-126,MI0000471,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Sensitive,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-126,hsa-mir-126,MI0000471,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Sensitive,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-138,hsa-mir-138-1,MI0000476,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Sensitive,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-138,hsa-mir-138-1,MI0000476,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Sensitive,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-144,hsa-mir-144,MI0000460,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Sensitive,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-144,hsa-mir-144,MI0000460,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Sensitive,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-146a,hsa-mir-146a,MI0000477,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-146a,hsa-mir-146a,MI0000477,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-155,hsa-mir-155,MI0000681,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-155,hsa-mir-155,MI0000681,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-17,hsa-mir-17,MI0000071,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-17,hsa-mir-17,MI0000071,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-18a,hsa-mir-18a,MI0000072,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-18a,hsa-mir-18a,MI0000072,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-193b,hsa-mir-193b,MI0003137,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-193b,hsa-mir-193b,MI0003137,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-200c,hsa-mir-200c,MI0000650,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-200c,hsa-mir-200c,MI0000650,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-23b,hsa-mir-23b,MI0000439,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-23b,hsa-mir-23b,MI0000439,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-29b,hsa-mir-29b-1,MI0000105,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-29b,hsa-mir-29b-1,MI0000105,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-30c,hsa-mir-30c-2,MI0000254,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-30c,hsa-mir-30c-2,MI0000254,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-34a,hsa-mir-34a,MI0000268,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-34a,hsa-mir-34a,MI0000268,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-373,hsa-mir-373,MI0000781,Cyclopamine,442972,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22768203,miR-373,hsa-mir-373,MI0000781,Paclitaxel,36314,-,"DU145 vs DU145-TXR, and PC3 vs PC3-TXR",-,-,prostate cancer,in vitro,Low,Resistant,-,-,2012,Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.,"As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTXresistant cells with respect to parental cells."
22781767,miR-15a,hsa-mir-15a,MI0000069,Bortezomib,387447,U266 and NCI-H929,-,-,-,myeloma ,in vitro,Low,Associated,-,-,2012,Regulation of miRNA-15a/-16 expression on the drug resistance of myeloma cells,"However, the miRNA-15a/-16 up-regulation by melphalan or bortezomib became inhibited when MM cells were co-cultured with MM-BMSCs."
22781767,miR-15a,hsa-mir-15a,MI0000069,Melphalan,460612,U266 and NCI-H929,-,-,-,myeloma ,in vitro,Low,Associated,-,-,2012,Regulation of miRNA-15a/-16 expression on the drug resistance of myeloma cells,"However, the miRNA-15a/-16 up-regulation by melphalan or bortezomib became inhibited when MM cells were co-cultured with MM-BMSCs."
22781767,miR-16,hsa-mir-16-1,MI0000070,Bortezomib,387447,U266 and NCI-H929,-,-,-,myeloma ,in vitro,Low,Associated,-,-,2012,Regulation of miRNA-15a/-16 expression on the drug resistance of myeloma cells,"However, the miRNA-15a/-16 up-regulation by melphalan or bortezomib became inhibited when MM cells were co-cultured with MM-BMSCs."
22781767,miR-16,hsa-mir-16-1,MI0000070,Melphalan,460612,U266 and NCI-H929,-,-,-,myeloma ,in vitro,Low,Associated,-,-,2012,Regulation of miRNA-15a/-16 expression on the drug resistance of myeloma cells,"However, the miRNA-15a/-16 up-regulation by melphalan or bortezomib became inhibited when MM cells were co-cultured with MM-BMSCs."
22808086,let-7a,hsa-let-7a-1,MI0000060,Paclitaxel,36314,SK-BR-3,-,-,-,breast cancer,in vitro,Low,Sensitive,-,-,2012,"Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells.",Transfection of cells with a Let-7 pre-miRNA significantly decreased the IC50 value of paclitaxel compared to that observed in the parental group or the pre-miRNA control group (p < 0.01).
22812695,let-7i,hsa-let-7i,MI0000434,Paclitaxel,36314,OVCAR-3,-,-,-,ovarian carcinoma,in vitro,Low,Sensitive,-,"downregulation of cyclin D1, cyclin D2, Dicer 1, and PGRMC1 expressions",2012,Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera.,"Results demonstrated that the chimera can specifically be delivered into OVCAR-3 cells and the released let-7i significantly sensitized the role of paclitaxel in inhibiting cell proliferation, inducing cell apoptosis, and decreasing long-term cell survival"
22842456,miR-144,hsa-mir-144,MI0000460,Imatinib,5291,-,K562 vs K562/IMA,-,-,chronic myelogenous leukemia,in vitro,Low,Sensitive,-,-,2012,Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562.,Knockdown of c-myc or restoration of miR-144/451 in the K562R cells sensitizes K562R cells to imatinib therapy.
22842456,miR-451,hsa-mir-451a,MI0001729,Imatinib,5291,-,K562 vs K562/IMA,-,-,chronic myelogenous leukemia,in vitro,Low,Sensitive,-,-,2012,Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562.,Knockdown of c-myc or restoration of miR-144/451 in the K562R cells sensitizes K562R cells to imatinib therapy.
22846564,miR-130a,hsa-mir-130a,MI0000448,Cisplatin,2767,-,Huh7 vs Huh7/CDDP,-,-,hepatocellular carcinoma ,in vitro,Low,Resistant,RUNX3,Wnt/Beta-catenin signaling pathway,2012,Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell.,"Overexpression of miR-130a contributed to cisplatin resistance in Huh7 cell, whereas knockdown of miR-130a overcame cisplatin resistance in cisplatin-resistant Huh7 cell"
22847005,miR-302 ,hsa-mir-302a,MI0000738,Cisplatin,2767,HSC-3,-,-,-,head and neck squamous cell carcinoma,in vitro,Low,Resistant,AOF1 and AOF2,-,2012,"Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.","Taken together, we believe that the miR-302 cluster plays a critical role in regulating HA-CD44-mediated chemotherapy resistance in these tumorigenic and CSC-like CD44v3 high ALDH1 high cell populations from head and neck cancer."
22847808,let-7b,hsa-let-7b,MI0000063,Cisplatin,2767,"TE1, TE5, TE8 vs TE8-R, TE9, TE10 vs TE10-R, TE11, TE13",-,-,Patientss,esophageal squamous cell carcinoma,in vitro and in vivo,High,Resistant,-,-,2012,Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma,"The miRNA microarray analysis in TE8/TE8-R and TE10/TE10-R cisplatin-resistant cells showed altered expression (by more than 1.7-fold) in 128 (35.0%) and 177 (48.5%) miRNAs among 365 miRNAs, respectively, compared with control cells. Among the miRNAs with altered expression in cisplatin-resistant cells, 15 miRNAs showed overlap in the 2 cell lines. Among these 15 miRNAs, miR135a, miR-96, miR-141, miR-101, miR-146a, miR-489, and miR-545 were upregulated, whereas miR-99a, let-7b, miR-204, let-7c, miR-202, miR-10a, miR-136, and miR-145 were downregulated in cisplatin-resistant cells, compared with control cells (Table 1)."
22847808,let-7c,hsa-let-7c,MI0000064,Cisplatin,2767,"TE1, TE5, TE8 vs TE8-R, TE9, TE10 vs TE10-R, TE11, TE13",-,-,Patientss,esophageal squamous cell carcinoma,in vitro and in vivo,High,Resistant,-,-,2012,Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma,"The miRNA microarray analysis in TE8/TE8-R and TE10/TE10-R cisplatin-resistant cells showed altered expression (by more than 1.7-fold) in 128 (35.0%) and 177 (48.5%) miRNAs among 365 miRNAs, respectively, compared with control cells. Among the miRNAs with altered expression in cisplatin-resistant cells, 15 miRNAs showed overlap in the 2 cell lines. Among these 15 miRNAs, miR135a, miR-96, miR-141, miR-101, miR-146a, miR-489, and miR-545 were upregulated, whereas miR-99a, let-7b, miR-204, let-7c, miR-202, miR-10a, miR-136, and miR-145 were downregulated in cisplatin-resistant cells, compared with control cells (Table 1)."
22847808,miR-101,hsa-mir-101-1,MI0000103,Cisplatin,2767,"TE1, TE5, TE8 vs TE8-R, TE9, TE10 vs TE10-R, TE11, TE13",-,-,Patientss,esophageal squamous cell carcinoma,in vitro and in vivo,High,Resistant,-,-,2012,Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma,"The miRNA microarray analysis in TE8/TE8-R and TE10/TE10-R cisplatin-resistant cells showed altered expression (by more than 1.7-fold) in 128 (35.0%) and 177 (48.5%) miRNAs among 365 miRNAs, respectively, compared with control cells. Among the miRNAs with altered expression in cisplatin-resistant cells, 15 miRNAs showed overlap in the 2 cell lines. Among these 15 miRNAs, miR135a, miR-96, miR-141, miR-101, miR-146a, miR-489, and miR-545 were upregulated, whereas miR-99a, let-7b, miR-204, let-7c, miR-202, miR-10a, miR-136, and miR-145 were downregulated in cisplatin-resistant cells, compared with control cells (Table 1)."
22847808,miR-10a,hsa-mir-10a,MI0000266,Cisplatin,2767,"TE1, TE5, TE8 vs TE8-R, TE9, TE10 vs TE10-R, TE11, TE13",-,-,Patientss,esophageal squamous cell carcinoma,in vitro and in vivo,High,Resistant,-,-,2012,Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma,"The miRNA microarray analysis in TE8/TE8-R and TE10/TE10-R cisplatin-resistant cells showed altered expression (by more than 1.7-fold) in 128 (35.0%) and 177 (48.5%) miRNAs among 365 miRNAs, respectively, compared with control cells. Among the miRNAs with altered expression in cisplatin-resistant cells, 15 miRNAs showed overlap in the 2 cell lines. Among these 15 miRNAs, miR135a, miR-96, miR-141, miR-101, miR-146a, miR-489, and miR-545 were upregulated, whereas miR-99a, let-7b, miR-204, let-7c, miR-202, miR-10a, miR-136, and miR-145 were downregulated in cisplatin-resistant cells, compared with control cells (Table 1)."
22847808,miR-135a,hsa-mir-135a-1,MI0000452,Cisplatin,2767,"TE1, TE5, TE8 vs TE8-R, TE9, TE10 vs TE10-R, TE11, TE13",-,-,Patientss,esophageal squamous cell carcinoma,in vitro and in vivo,High,Resistant,-,-,2012,Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma,"The miRNA microarray analysis in TE8/TE8-R and TE10/TE10-R cisplatin-resistant cells showed altered expression (by more than 1.7-fold) in 128 (35.0%) and 177 (48.5%) miRNAs among 365 miRNAs, respectively, compared with control cells. Among the miRNAs with altered expression in cisplatin-resistant cells, 15 miRNAs showed overlap in the 2 cell lines. Among these 15 miRNAs, miR135a, miR-96, miR-141, miR-101, miR-146a, miR-489, and miR-545 were upregulated, whereas miR-99a, let-7b, miR-204, let-7c, miR-202, miR-10a, miR-136, and miR-145 were downregulated in cisplatin-resistant cells, compared with control cells (Table 1)."
22847808,miR-136,hsa-mir-136,MI0000475,Cisplatin,2767,"TE1, TE5, TE8 vs TE8-R, TE9, TE10 vs TE10-R, TE11, TE13",-,-,Patientss,esophageal squamous cell carcinoma,in vitro and in vivo,High,Resistant,-,-,2012,Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma,"The miRNA microarray analysis in TE8/TE8-R and TE10/TE10-R cisplatin-resistant cells showed altered expression (by more than 1.7-fold) in 128 (35.0%) and 177 (48.5%) miRNAs among 365 miRNAs, respectively, compared with control cells. Among the miRNAs with altered expression in cisplatin-resistant cells, 15 miRNAs showed overlap in the 2 cell lines. Among these 15 miRNAs, miR135a, miR-96, miR-141, miR-101, miR-146a, miR-489, and miR-545 were upregulated, whereas miR-99a, let-7b, miR-204, let-7c, miR-202, miR-10a, miR-136, and miR-145 were downregulated in cisplatin-resistant cells, compared with control cells (Table 1)."
22847808,miR-141,hsa-mir-141,MI0000457,Cisplatin,2767,"TE1, TE5, TE8 vs TE8-R, TE9, TE10 vs TE10-R, TE11, TE13",-,-,Patientss,esophageal squamous cell carcinoma,in vitro and in vivo,High,Resistant,-,-,2012,Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma,"The miRNA microarray analysis in TE8/TE8-R and TE10/TE10-R cisplatin-resistant cells showed altered expression (by more than 1.7-fold) in 128 (35.0%) and 177 (48.5%) miRNAs among 365 miRNAs, respectively, compared with control cells. Among the miRNAs with altered expression in cisplatin-resistant cells, 15 miRNAs showed overlap in the 2 cell lines. Among these 15 miRNAs, miR135a, miR-96, miR-141, miR-101, miR-146a, miR-489, and miR-545 were upregulated, whereas miR-99a, let-7b, miR-204, let-7c, miR-202, miR-10a, miR-136, and miR-145 were downregulated in cisplatin-resistant cells, compared with control cells (Table 1)."
22847808,miR-145,hsa-mir-145,MI0000461,Cisplatin,2767,"TE1, TE5, TE8 vs TE8-R, TE9, TE10 vs TE10-R, TE11, TE13",-,-,Patientss,esophageal squamous cell carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma,"The miRNA microarray analysis in TE8/TE8-R and TE10/TE10-R cisplatin-resistant cells showed altered expression (by more than 1.7-fold) in 128 (35.0%) and 177 (48.5%) miRNAs among 365 miRNAs, respectively, compared with control cells. Among the miRNAs with altered expression in cisplatin-resistant cells, 15 miRNAs showed overlap in the 2 cell lines. Among these 15 miRNAs, miR135a, miR-96, miR-141, miR-101, miR-146a, miR-489, and miR-545 were upregulated, whereas miR-99a, let-7b, miR-204, let-7c, miR-202, miR-10a, miR-136, and miR-145 were downregulated in cisplatin-resistant cells, compared with control cells (Table 1)."
22847808,miR-146a,hsa-mir-146a,MI0000477,Cisplatin,2767,"TE1, TE5, TE8 vs TE8-R, TE9, TE10 vs TE10-R, TE11, TE13",-,-,Patientss,esophageal squamous cell carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma,"The miRNA microarray analysis in TE8/TE8-R and TE10/TE10-R cisplatin-resistant cells showed altered expression (by more than 1.7-fold) in 128 (35.0%) and 177 (48.5%) miRNAs among 365 miRNAs, respectively, compared with control cells. Among the miRNAs with altered expression in cisplatin-resistant cells, 15 miRNAs showed overlap in the 2 cell lines. Among these 15 miRNAs, miR135a, miR-96, miR-141, miR-101, miR-146a, miR-489, and miR-545 were upregulated, whereas miR-99a, let-7b, miR-204, let-7c, miR-202, miR-10a, miR-136, and miR-145 were downregulated in cisplatin-resistant cells, compared with control cells (Table 1)."
22847808,miR-202,hsa-mir-202,MI0003130,Cisplatin,2767,"TE1, TE5, TE8 vs TE8-R, TE9, TE10 vs TE10-R, TE11, TE13",-,-,Patientss,esophageal squamous cell carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma,"The miRNA microarray analysis in TE8/TE8-R and TE10/TE10-R cisplatin-resistant cells showed altered expression (by more than 1.7-fold) in 128 (35.0%) and 177 (48.5%) miRNAs among 365 miRNAs, respectively, compared with control cells. Among the miRNAs with altered expression in cisplatin-resistant cells, 15 miRNAs showed overlap in the 2 cell lines. Among these 15 miRNAs, miR135a, miR-96, miR-141, miR-101, miR-146a, miR-489, and miR-545 were upregulated, whereas miR-99a, let-7b, miR-204, let-7c, miR-202, miR-10a, miR-136, and miR-145 were downregulated in cisplatin-resistant cells, compared with control cells (Table 1)."
22847808,miR-204,hsa-mir-204,MI0000284,Cisplatin,2767,"TE1, TE5, TE8 vs TE8-R, TE9, TE10 vs TE10-R, TE11, TE13",-,-,Patientss,esophageal squamous cell carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma,"The miRNA microarray analysis in TE8/TE8-R and TE10/TE10-R cisplatin-resistant cells showed altered expression (by more than 1.7-fold) in 128 (35.0%) and 177 (48.5%) miRNAs among 365 miRNAs, respectively, compared with control cells. Among the miRNAs with altered expression in cisplatin-resistant cells, 15 miRNAs showed overlap in the 2 cell lines. Among these 15 miRNAs, miR135a, miR-96, miR-141, miR-101, miR-146a, miR-489, and miR-545 were upregulated, whereas miR-99a, let-7b, miR-204, let-7c, miR-202, miR-10a, miR-136, and miR-145 were downregulated in cisplatin-resistant cells, compared with control cells (Table 1)."
22847808,miR-489,hsa-mir-489,MI0003124,Cisplatin,2767,"TE1, TE5, TE8 vs TE8-R, TE9, TE10 vs TE10-R, TE11, TE13",-,-,Patientss,esophageal squamous cell carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma,"The miRNA microarray analysis in TE8/TE8-R and TE10/TE10-R cisplatin-resistant cells showed altered expression (by more than 1.7-fold) in 128 (35.0%) and 177 (48.5%) miRNAs among 365 miRNAs, respectively, compared with control cells. Among the miRNAs with altered expression in cisplatin-resistant cells, 15 miRNAs showed overlap in the 2 cell lines. Among these 15 miRNAs, miR135a, miR-96, miR-141, miR-101, miR-146a, miR-489, and miR-545 were upregulated, whereas miR-99a, let-7b, miR-204, let-7c, miR-202, miR-10a, miR-136, and miR-145 were downregulated in cisplatin-resistant cells, compared with control cells (Table 1)."
22847808,miR-545,hsa-mir-545,MI0003516,Cisplatin,2767,"TE1, TE5, TE8 vs TE8-R, TE9, TE10 vs TE10-R, TE11, TE13",-,-,Patientss,esophageal squamous cell carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma,"The miRNA microarray analysis in TE8/TE8-R and TE10/TE10-R cisplatin-resistant cells showed altered expression (by more than 1.7-fold) in 128 (35.0%) and 177 (48.5%) miRNAs among 365 miRNAs, respectively, compared with control cells. Among the miRNAs with altered expression in cisplatin-resistant cells, 15 miRNAs showed overlap in the 2 cell lines. Among these 15 miRNAs, miR135a, miR-96, miR-141, miR-101, miR-146a, miR-489, and miR-545 were upregulated, whereas miR-99a, let-7b, miR-204, let-7c, miR-202, miR-10a, miR-136, and miR-145 were downregulated in cisplatin-resistant cells, compared with control cells (Table 1)."
22847808,miR-96,hsa-mir-96,MI0000098,Cisplatin,2767,"TE1, TE5, TE8 vs TE8-R, TE9, TE10 vs TE10-R, TE11, TE13",-,-,Patientss,esophageal squamous cell carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma,"The miRNA microarray analysis in TE8/TE8-R and TE10/TE10-R cisplatin-resistant cells showed altered expression (by more than 1.7-fold) in 128 (35.0%) and 177 (48.5%) miRNAs among 365 miRNAs, respectively, compared with control cells. Among the miRNAs with altered expression in cisplatin-resistant cells, 15 miRNAs showed overlap in the 2 cell lines. Among these 15 miRNAs, miR135a, miR-96, miR-141, miR-101, miR-146a, miR-489, and miR-545 were upregulated, whereas miR-99a, let-7b, miR-204, let-7c, miR-202, miR-10a, miR-136, and miR-145 were downregulated in cisplatin-resistant cells, compared with control cells (Table 1)."
22847808,miR-99a,hsa-mir-99a,MI0000101,Cisplatin,2767,"TE1, TE5, TE8 vs TE8-R, TE9, TE10 vs TE10-R, TE11, TE13",-,-,Patientss,esophageal squamous cell carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma,"The miRNA microarray analysis in TE8/TE8-R and TE10/TE10-R cisplatin-resistant cells showed altered expression (by more than 1.7-fold) in 128 (35.0%) and 177 (48.5%) miRNAs among 365 miRNAs, respectively, compared with control cells. Among the miRNAs with altered expression in cisplatin-resistant cells, 15 miRNAs showed overlap in the 2 cell lines. Among these 15 miRNAs, miR135a, miR-96, miR-141, miR-101, miR-146a, miR-489, and miR-545 were upregulated, whereas miR-99a, let-7b, miR-204, let-7c, miR-202, miR-10a, miR-136, and miR-145 were downregulated in cisplatin-resistant cells, compared with control cells (Table 1)."
22871739,miR-205,hsa-mir-205,MI0000285,Cisplatin,2767,SK-Mel-147,-,-,-,-,in vitro,Low,Resistant,"Bcl-2, ABCA2 and ABCA5",-,2012,E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry.,"Finally, drug resistance associated to this genetic signature is mediated by removing the inhibitory effect of miR-205 on the expression of Bcl-2 and the ATP-binding cassette transporters A2 (ABCA2) and A5 (ABCA5) related to multi-drug resistance and malignant progression."
22883469,miR-133b,hsa-mir-133b,MI0000822,Gefitinib,123631,"H1650, A549, PC-9 and 293T",-,-,Patients,non-small-cell lung cancer,in vitro and in vivo,Low,Sensitive,EGFR,-,2012,MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor.,"Moreover, miR-133b transfection may modulate apoptosis, invasion and sensitivity to EGFR-TKI through the EGFR signaling pathways, especially in EGFR-addicted NSCLC cells."
22888524,miR-195,hsa-mir-195,MI0000489,5-Fluorouracil,3385,-,BEL-7402 vs BEL-7402/5-FU,-,-,hepatocellular carcinoma,in vitro,Low,Associated,LATS2,-,2012,MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2.,miR-195 over-expression inhibited the luciferase activity of a LATS2 3' untranslated region-based reporter construct in BEL-7402/5-FU cells. 
22892391,miR-24,hsa-mir-24-1,MI0000080,Cisplatin,2767,"Kelly, SK-NAS and SHSY-5Y",-,Mice,Patients,neuroblastoma,in vitro and in vivo,Low,Sensitive,BCL2 and NTRK2,-,2012,MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome.,Ectopic miR-204 expression significantly increased sensitivity to cisplatin and etoposide in vitro.
22892391,miR-24,hsa-mir-24-1,MI0000080,Etoposide,36462,"Kelly, SK-NAS and SHSY-5Y",-,Mice,Patients,neuroblastoma,in vitro and in vivo,Low,Sensitive,BCL2 and NTRK2,-,2012,MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome.,Ectopic miR-204 expression significantly increased sensitivity to cisplatin and etoposide in vitro.
22892985,miR-296,hsa-mir-296,MI0000747,Capecitabine,60953,-,-,-,Patients,colon cancer,in vivo,Low,Sensitive,-,-,2013,Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in Patient receiving systemic chemotherapy for metastatic colon cancer.,"Taken together, our results indicate that the decrease in circulating miR-296 is associated with shorter survival and poor response to treatment with Sunitinib and Capecitabine."
22892985,miR-296,hsa-mir-296,MI0000747,Sunitinib,5329102,-,-,-,Patients,colon cancer,in vivo,Low,Sensitive,-,-,2013,Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in Patient receiving systemic chemotherapy for metastatic colon cancer.,"Taken together, our results indicate that the decrease in circulating miR-296 is associated with shorter survival and poor response to treatment with Sunitinib and Capecitabine."
22903020,miR-199a,hsa-mir-199a-1,MI0000242,Doxorubicin (Adriamycin),31703,-,HCT-8 vs HCT-8/VCR,-,-,colorectal cancer,in vitro,Low,Sensitive,CAC1,CDK2,2012,The deoxycholic acid targets miRNA-dependent CAC1 gene expression in multidrug resistance of human colorectal cancer.,"Restoration of miR-199a-5p and/or CAC1 silencing in CRC cell lines reduces cell viability, promotes apoptosis, arrests the cell cycle and increases doxorubicin sensitivity in HCT-8/VCR cells."
22909203,hp-hsa-mir-146b,-,-,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,hp-hsa-mir-363,-,-,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,hp-hsa-mir-629,-,-,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,hp-hsa-mir-766,-,-,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,let-7b,hsa-let-7b,MI0000063,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,let-7c,hsa-let-7c,MI0000064,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,let-7d*,hsa-let-7d,MI0000065,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-124,hsa-mir-124-1,MI0000443,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-132,hsa-mir-132,MI0000449,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-148a*,hsa-mir-148a,MI0000253,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-151,hsa-mir-151a,MI0000809,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-181c*,hsa-mir-181c,MI0000271,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-192,hsa-mir-192,MI0000234,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-193a,hsa-mir-193a,MI0000487,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-194,hsa-mir-194-1,MI0000488,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-206,hsa-mir-206,MI0000490,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-20b*,hsa-mir-20b,MI0001519,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-21*,hsa-mir-212,MI0000288,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-212,hsa-mir-21,MI0000077,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Sensitive,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-30b,hsa-mir-30b,MI0000441,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-30b*,hsa-mir-30b,MI0000441,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-30d,hsa-mir-30d,MI0000255,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-328,hsa-mir-328,MI0000804,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-363*,hsa-mir-363,MI0000764,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-378*,hsa-mir-378a,MI0000786,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-425*,hsa-mir-425,MI0001448,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-4315,hsa-mir-4315-1,MI0015844,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-466,hsa-mir-466,MI0014157,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-485,hsa-mir-485,MI0002469,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-486,hsa-mir-486-1,MI0002470,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-500,hsa-mir-500a,MI0003184,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-501,hsa-mir-501,MI0003185,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-502,hsa-mir-502,MI0003186,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-625,hsa-mir-625,MI0003639,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-629,hsa-mir-629,MI0003643,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-629*,hsa-mir-629,MI0003643,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22909203,miR-671,hsa-mir-671,MI0003760,Paroxetine,43815,LCLs ( 80 ),-,-,-,lymphoblastoid,in vitro,High,Resistant,-,-,2012,Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,"The array experiments have identified 42 human miRNAs whose basal expression levels differed by >1.5-fold and p < 0.05 between the two phenotypic groups of LCLs. Of these miRNAs, 19 had higher expression levels in the LCLs with high paroxetine sensitivity (Supplementary table 1)."
22920753,miR-15b,hsa-mir-15b,MI0000438,Cisplatin,2767,Hela,-,-,-,cervical cancer,in vitro,Low,Associated,Bcl-2,-,2012,Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression.,"These data suggested that down-regulation of NDRG2 could enhance sensitivity of Hela cells to cisplatin through inhibiting Bcl-2 protein expression, which might be mediated by up-regulating miR-15b and miR-16."
22920753,miR-16,hsa-mir-16-1,MI0000070,Cisplatin,2767,Hela,-,-,-,cervical cancer,in vitro,Low,Associated,Bcl-2,-,2012,Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression.,"These data suggested that down-regulation of NDRG2 could enhance sensitivity of Hela cells to cisplatin through inhibiting Bcl-2 protein expression, which might be mediated by up-regulating miR-15b and miR-16."
22942255,miR-15,hsa-mir-15,MI0000069,Cisplatin,2767,"KB-3-1, KB-CP.5 and KB-CP20",-,-,-,"epidermoid carcinoma, ",in vitro,Low,Sensitive,WEE1 and CHK1,-,2012,Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.,miRNAs in the miR-15/16/195/424/497 family were found to sensitize cisplatin-resistant cells to apoptosis by targeting WEE1 and CHK1.
22942255,miR-155,hsa-mir-155,MI0000681,Cisplatin,2767,"KB-3-1, KB-CP.5 and KB-CP20",-,-,-,"epidermoid carcinoma, ",in vitro,Low,Sensitive,WEE1 and CHK1,-,2012,Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.,miRNAs in the miR-15/16/195/424/497 family were found to sensitize cisplatin-resistant cells to apoptosis by targeting WEE1 and CHK1.
22942255,miR-16,hsa-mir-16-1,MI0000070,Cisplatin,2767,"KB-3-1, KB-CP.5 and KB-CP20",-,-,-,"epidermoid carcinoma, ",in vitro,Low,Sensitive,WEE1 and CHK1,-,2012,Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.,miRNAs in the miR-15/16/195/424/497 family were found to sensitize cisplatin-resistant cells to apoptosis by targeting WEE1 and CHK1.
22942255,miR-195,hsa-mir-195,MI0000489,Cisplatin,2767,"KB-3-1, KB-CP.5 and KB-CP20",-,-,-,"epidermoid carcinoma, ",in vitro,Low,Sensitive,WEE1 and CHK1,-,2012,Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.,miRNAs in the miR-15/16/195/424/497 family were found to sensitize cisplatin-resistant cells to apoptosis by targeting WEE1 and CHK1.
22942255,miR-424,hsa-mir-424,MI0001446,Cisplatin,2767,"KB-3-1, KB-CP.5 and KB-CP20",-,-,-,"epidermoid carcinoma, ",in vitro,Low,Sensitive,WEE1 and CHK1,-,2012,Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.,miRNAs in the miR-15/16/195/424/497 family were found to sensitize cisplatin-resistant cells to apoptosis by targeting WEE1 and CHK1.
22942255,miR-497,hsa-mir-497,MI0003138,Cisplatin,2767,"KB-3-1, KB-CP.5 and KB-CP20",-,-,-,"epidermoid carcinoma, ",in vitro,Low,Sensitive,WEE1 and CHK1,-,2012,Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.,miRNAs in the miR-15/16/195/424/497 family were found to sensitize cisplatin-resistant cells to apoptosis by targeting WEE1 and CHK1.
22952996,miR-378,hsa-mir-378a,MI0000786,Epirubicin,41867,MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Resistant,-,-,2012,Ergosterol peroxide isolated from Ganoderma lucidum abolishes microRNA miR-378-mediated tumor cells on chemoresistance.,Cells expressing miR-378 displayed significant resistance to Epirubicin compared with the control cells.
22952996,miR-378,hsa-mir-378a,MI0000786,Methotrexate,126941,U87,-,-,-,brain tumour,in vitro,Low,Resistant,-,-,2012,Ergosterol peroxide isolated from Ganoderma lucidum abolishes microRNA miR-378-mediated tumor cells on chemoresistance.,"In addition, the miR-378 cells demonstrated resistance to cell death induced by different drugs."
22954303,miR-127,hsa-mir-127,MI0000472,Cisplatin,2767,"UMUC9, UMUC14, SLT4, 253JBV, RT4, CLR2169, HT1197, 575A",-,-,Patientss,Bladder Carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer,Seven patients experienced progression of disease (PD) and eight patients experienced complete responses (CR) according to the RECIST criteria [23]. Differentially expressed miRNAs (PD vs.CR) are listed in Table 2.
22954303,miR-142,hsa-mir-142,MI0000458,Cisplatin,2767,"UMUC9, UMUC14, SLT4, 253JBV, RT4, CLR2169, HT1197, 575A",-,-,Patientss,Bladder Carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer,Seven patients experienced progression of disease (PD) and eight patients experienced complete responses (CR) according to the RECIST criteria [23]. Differentially expressed miRNAs (PD vs.CR) are listed in Table 2.
22954303,miR-193a,hsa-mir-193a,MI0000487,Cisplatin,2767,"UMUC9, UMUC14, SLT4, 253JBV, RT4, CLR2169, HT1197, 575A",-,-,Patientss,Bladder Carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer,Seven patients experienced progression of disease (PD) and eight patients experienced complete responses (CR) according to the RECIST criteria [23]. Differentially expressed miRNAs (PD vs.CR) are listed in Table 2.
22954303,miR-218,hsa-mir-218-1,MI0000294,Cisplatin,2767,"UMUC9, UMUC14, SLT4, 253JBV, RT4, CLR2169, HT1197, 575A",-,-,Patientss,Bladder Carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer,Seven patients experienced progression of disease (PD) and eight patients experienced complete responses (CR) according to the RECIST criteria [23]. Differentially expressed miRNAs (PD vs.CR) are listed in Table 2.
22954303,miR-24,hsa-mir-24-1,MI0000080,Cisplatin,2767,"UMUC9, UMUC14, SLT4, 253JBV, RT4, CLR2169, HT1197, 575A",-,-,Patientss,Bladder Carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer,Seven patients experienced progression of disease (PD) and eight patients experienced complete responses (CR) according to the RECIST criteria [23]. Differentially expressed miRNAs (PD vs.CR) are listed in Table 2.
22954303,miR-27a,hsa-mir-27a,MI0000085,Cisplatin,2767,"UMUC9, UMUC14, SLT4, 253JBV, RT4, CLR2169, HT1197, 575A",-,-,Patientss,Bladder Carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer,Seven patients experienced progression of disease (PD) and eight patients experienced complete responses (CR) according to the RECIST criteria [23]. Differentially expressed miRNAs (PD vs.CR) are listed in Table 2.
22954303,miR-296,hsa-mir-296,MI0000747,Cisplatin,2767,"UMUC9, UMUC14, SLT4, 253JBV, RT4, CLR2169, HT1197, 575A",-,-,Patientss,Bladder Carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer,Seven patients experienced progression of disease (PD) and eight patients experienced complete responses (CR) according to the RECIST criteria [23]. Differentially expressed miRNAs (PD vs.CR) are listed in Table 2.
22954303,miR-492,hsa-mir-492,MI0003131,Cisplatin,2767,"UMUC9, UMUC14, SLT4, 253JBV, RT4, CLR2169, HT1197, 575A",-,-,Patientss,Bladder Carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer,Seven patients experienced progression of disease (PD) and eight patients experienced complete responses (CR) according to the RECIST criteria [23]. Differentially expressed miRNAs (PD vs.CR) are listed in Table 2.
22954303,miR-576,hsa-mir-576,MI0003583,Cisplatin,2767,"UMUC9, UMUC14, SLT4, 253JBV, RT4, CLR2169, HT1197, 575A",-,-,Patientss,Bladder Carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer,Seven patients experienced progression of disease (PD) and eight patients experienced complete responses (CR) according to the RECIST criteria [23]. Differentially expressed miRNAs (PD vs.CR) are listed in Table 2.
22954303,miR-625,hsa-mir-625,MI0003639,Cisplatin,2767,"UMUC9, UMUC14, SLT4, 253JBV, RT4, CLR2169, HT1197, 575A",-,-,Patientss,Bladder Carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer,Seven patients experienced progression of disease (PD) and eight patients experienced complete responses (CR) according to the RECIST criteria [23]. Differentially expressed miRNAs (PD vs.CR) are listed in Table 2.
22954303,miR-639,hsa-mir-639,MI0003654,Cisplatin,2767,"UMUC9, UMUC14, SLT4, 253JBV, RT4, CLR2169, HT1197, 575A",-,-,Patientss,Bladder Carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer,Seven patients experienced progression of disease (PD) and eight patients experienced complete responses (CR) according to the RECIST criteria [23]. Differentially expressed miRNAs (PD vs.CR) are listed in Table 2.
22954303,miR-642,hsa-mir-642a,MI0003657,Cisplatin,2767,"UMUC9, UMUC14, SLT4, 253JBV, RT4, CLR2169, HT1197, 575A",-,-,Patientss,Bladder Carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer,Seven patients experienced progression of disease (PD) and eight patients experienced complete responses (CR) according to the RECIST criteria [23]. Differentially expressed miRNAs (PD vs.CR) are listed in Table 2.
22954303,miR-886,hsa-mir-886,MI0005527,Cisplatin,2767,"UMUC9, UMUC14, SLT4, 253JBV, RT4, CLR2169, HT1197, 575A",-,-,Patientss,Bladder Carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer,Seven patients experienced progression of disease (PD) and eight patients experienced complete responses (CR) according to the RECIST criteria [23]. Differentially expressed miRNAs (PD vs.CR) are listed in Table 2.
22954303,miR-923,hsa-mir-923,MI0005715,Cisplatin,2767,"UMUC9, UMUC14, SLT4, 253JBV, RT4, CLR2169, HT1197, 575A",-,-,Patientss,Bladder Carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer,Seven patients experienced progression of disease (PD) and eight patients experienced complete responses (CR) according to the RECIST criteria [23]. Differentially expressed miRNAs (PD vs.CR) are listed in Table 2.
22954303,miR-944,hsa-mir-944,MI0005769,Cisplatin,2767,"UMUC9, UMUC14, SLT4, 253JBV, RT4, CLR2169, HT1197, 575A",-,-,Patientss,Bladder Carcinoma,in vitro and in vivo,High,Sensitive,-,-,2012,miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer,Seven patients experienced progression of disease (PD) and eight patients experienced complete responses (CR) according to the RECIST criteria [23]. Differentially expressed miRNAs (PD vs.CR) are listed in Table 2.
22956424,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,A549,-,-,-,non-small cell lung cancer,in vitro,Low,Resistant,PTEN,-,2013,"MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN.","In addition, we found that anti-miR-21 could significantly inhibit growth, migration and invasion, and reverse chemo- or radioresistance of NSCLC cells, while miR-21 mimics could increase growth, promote migration and invasion, and enhance chemo- or radioresistance of NSCLC cells."
22956424,miR-21,hsa-mir-21,MI0000077,Docetaxel,148124,A549,-,-,-,non-small cell lung cancer,in vitro,Low,Resistant,PTEN,-,2013,"MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN.","In addition, we found that anti-miR-21 could significantly inhibit growth, migration and invasion, and reverse chemo- or radioresistance of NSCLC cells, while miR-21 mimics could increase growth, promote migration and invasion, and enhance chemo- or radioresistance of NSCLC cells."
22957792,miR-21,hsa-mir-21,MI0000077,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic myeloid leukemia,in vitro,Low,Resistant,PTEN,-,2012,Triptolide modulates the sensitivity of K562/A02 cells to adriamycin by regulating miR-21 expression.,This result suggested that miR-21 contributes to adriamycin resistance in the K562 cells.
22982144,miR-23b,hsa-mir-23b,MI0000439,Temozolomide,5394,U87,-,-,-,glioma,in vitro,Low,Sensitive,-,-,2012,Methylation mediated silencing of miR-23b expression and its role in glioma stem cells.,These results suggest that upregulation of miR-23b can sensitize U87 GSCs to TMZ-induced proliferation inhibition.
22982443,miR-200c,hsa-mir-200c,MI0000650,Cisplatin,2767,WM115A,-,-,-,melanoma,in vitro,Low,Sensitive,BMI-1,-,2012,miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.,miR-200c over-expression resulted in a significant decrease in cell survival in all therapeutic agents tested.
22982443,miR-200c,hsa-mir-200c,MI0000650,PLX4720,24180719,WM115A,-,-,-,melanoma,in vitro,Low,Sensitive,BMI-1,-,2012,miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.,miR-200c over-expression resulted in a significant decrease in cell survival in all therapeutic agents tested.
22982443,miR-200c,hsa-mir-200c,MI0000650,U0126,3006531,WM115A,-,-,-,melanoma,in vitro,Low,Sensitive,BMI-1,-,2012,miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.,miR-200c over-expression resulted in a significant decrease in cell survival in all therapeutic agents tested.
22996741,miR-155,hsa-mir-155,MI0000681,Cisplatin,2767,A549,-,-,Patients,lung cancer,in vitro and in vivo,Low,Resistant,Apaf-1,-,2012,MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression.,Both the silencing of miR-155 and the overexpression Apaf-1 greatly increased the sensitivity of A549 cells to cisplatin treatment.
22999387,miR-296,hsa-mir-296,MI0000747,Imatinib,5291,-,U251 vs U251/IMA,-,-,glioblastoma,in vitro,Low,Sensitive,EAG1,-,2013,MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting (EAG1),"In vitro drug sensitivity assay demonstrated that over-expression of miR-296-3p sensitised glioblastoma (GBM) cells to anticancer drugs, whereas down-expression using antisense oligonucleotides conferred MDR."
23028896,miR-106a,hsa-mir-106a,MI0000113,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-129,hsa-mir-129-1,MI0000252,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-135a,hsa-mir-135a-1,MI0000452,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-150,hsa-mir-150,MI0000479,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-184,hsa-mir-184,MI0000481,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-198,hsa-mir-198,MI0000240,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-202,hsa-mir-202,MI0003130,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-218,hsa-mir-218-1,MI0000294,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-23b,hsa-mir-23b,MI0000439,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-298,hsa-mir-298,MI0005523,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-29b,hsa-mir-29b-1,MI0000105,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-31,hsa-mir-31,MI0000089,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-330,hsa-mir-330,MI0000803,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Resistant,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-342,hsa-mir-342,MI0000805,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-382,hsa-mir-382,MI0000790,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-455,hsa-mir-455,MI0003513,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-484,hsa-mir-484,MI0002468,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-487b,hsa-mir-487b,MI0003530,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-491,hsa-mir-491,MI0003126,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-503,hsa-mir-503,MI0003188,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-518d,hsa-mir-518d,MI0003171,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-518f,hsa-mir-518f,MI0003154,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-523,hsa-mir-523,MI0003153,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-542,hsa-mir-542,MI0003686,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-548d,hsa-mir-548d-1,MI0003668,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-758,hsa-mir-758,MI0003757,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23028896,miR-885,hsa-mir-885,MI0005560,Etoposide,36462,-,MCF7 vs MCF7/VP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2012,Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines,"Using miRNA microfluidic arrays from ABI, we determined the microRNA profile for MCF7VP cells compared to drug sensitive cells (Table 1, Data File S1)."
23036084,miR-34a,hsa-mir-34a,MI0000268,Cisplatin,2767,A549 and SBC-5,-,-,-,lung cancer,in vitro,Low,Sensitive,Sitr1,-,2013,microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status.,"Moreover, we demonstrated that pretransfection of miR-34a could increase the sensitivity of both lung cancer cell lines to cisplatin (DDP), and this could be reverted by the miR-34a inhibitor."
23036199,miR-155,hsa-mir-155,MI0000681,Cisplatin,2767,HT29,-,-,-,colon cancer,in vitro,Low,Resistant,NFKB,-,2012,Adrenaline promotes cell proliferation and increases chemoresistance in colon cancer HT29 cells through induction of miR-155.,HT29 cells overexpressing miR-155 had a higher cell growth rate and more resistance to cisplatin induced apoptosis.
23041061,miR-200c,hsa-mir-200c,MI0000650,Docetaxel,148124,-,PC3 vs PC3/DOC and DU-145 vs DU-145/DOC,-,-,prostate cancer,in vitro,Low,Associated,-,"E-cadherin, ZEB1 and ZEB2 ",2012,Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.,Screening for key regulators of an epithelial phenotype revealed a significantly reduced expression of microRNA (miR)-200c and miR-205 in docetaxel-resistant cells. 
23041061,miR-205,hsa-mir-205,MI0000285,Docetaxel,148124,-,PC3 vs PC3/DOC and DU-145 vs DU-145/DOC,-,-,prostate cancer,in vitro,Low,Associated,-,"E-cadherin, ZEB1 and ZEB2 ",2012,Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.,Screening for key regulators of an epithelial phenotype revealed a significantly reduced expression of microRNA (miR)-200c and miR-205 in docetaxel-resistant cells. 
23045278,miR-100,hsa-mir-100,MI0000102,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2017,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-10b,hsa-mir-10b,MI0000267,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-130a,hsa-mir-130a,MI0000448,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-135b*,hsa-mir-135b,MI0000810,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-141,hsa-mir-141,MI0000457,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer ,in vitro,Low,Resistant,KEAP1,NF--kappaB pathway,2013,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We demonstrate that miR-141 directly targets KEAP1, and that downregulation of KEAP1 induces cisplatin resistance."
23045278,miR-17,hsa-mir-17,MI0000071,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-186*,hsa-mir-186,MI0000483,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-18b,hsa-mir-18b,MI0001518,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-196a,hsa-mir-196a-1,MI0000238,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-199a,hsa-mir-199a-1,MI0000242,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-199b,hsa-mir-199b,MI0000282,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-19a,hsa-mir-19a,MI0000073,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-19b,hsa-mir-19b-1,MI0000074,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-200c,hsa-mir-200c,MI0000650,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-20b,hsa-mir-20b,MI0001519,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-214,hsa-mir-214,MI0000290,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-215,hsa-mir-215,MI0000291,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-222,hsa-mir-222,MI0000299,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-335,hsa-mir-335,MI0000816,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-338,hsa-mir-338,MI0000814,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-412,hsa-mir-412,MI0002464,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-421,hsa-mir-421,MI0003685,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-493*,hsa-mir-493,MI0003132,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2012,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-518e,hsa-mir-518e,MI0003169,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,KEAP1,-,2013,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-631,hsa-mir-631,MI0003645,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2014,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-645,hsa-mir-645,MI0003660,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2015,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23045278,miR-942,hsa-mir-942,MI0005767,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2016,miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.,"We identified 27 miRNAs to be differentially expressed (fold change X2.0), 22 of which were downregulated in the resistant A2780 DDP cell line and five were upregulated (Figure 1)."
23073476,miR-10a,hsa-mir-10a,MI0000266,Gemcitabine,60750,-,PaCa-2 vs PaCa-2/GR,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2012,miRNA profiling in pancreatic cancer and restoration of chemosensitivity.,"Fig. 5 shows the 14 differentially altered transcripts of which five (miR-15, 134, 205, 7 and 32) were downregulated in CSCs with miR-205-a tumor suppressor moleculeCthe most reduced transcript (6-fold). The nine upregulated transcripts were miR-143, 214,10a, 10b, 146a, 146b-5p, 34a and 100."
23073476,miR-10b,hsa-mir-10b,MI0000267,Gemcitabine,60750,-,PaCa-2 vs PaCa-2/GR,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2012,miRNA profiling in pancreatic cancer and restoration of chemosensitivity.,"Fig. 5 shows the 14 differentially altered transcripts of which five (miR-15, 134, 205, 7 and 32) were downregulated in CSCs with miR-205-a tumor suppressor moleculeCthe most reduced transcript (6-fold). The nine upregulated transcripts were miR-143, 214,10a, 10b, 146a, 146b-5p, 34a and 100."
23073476,miR-134,hsa-mir-134,MI0000474,Gemcitabine,60750,-,PaCa-2 vs PaCa-2/GR,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2012,miRNA profiling in pancreatic cancer and restoration of chemosensitivity.,"Fig. 5 shows the 14 differentially altered transcripts of which five (miR-15, 134, 205, 7 and 32) were downregulated in CSCs with miR-205-a tumor suppressor moleculeCthe most reduced transcript (6-fold). The nine upregulated transcripts were miR-143, 214,10a, 10b, 146a, 146b-5p, 34a and 100."
23073476,miR-143,hsa-mir-143,MI0000459,Gemcitabine,60750,-,PaCa-2 vs PaCa-2/GR,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2012,miRNA profiling in pancreatic cancer and restoration of chemosensitivity.,"Fig. 5 shows the 14 differentially altered transcripts of which five (miR-15, 134, 205, 7 and 32) were downregulated in CSCs with miR-205-a tumor suppressor moleculeCthe most reduced transcript (6-fold). The nine upregulated transcripts were miR-143, 214,10a, 10b, 146a, 146b-5p, 34a and 100."
23073476,miR-146a,hsa-mir-146a,MI0000477,Gemcitabine,60750,-,PaCa-2 vs PaCa-2/GR,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2012,miRNA profiling in pancreatic cancer and restoration of chemosensitivity.,"Fig. 5 shows the 14 differentially altered transcripts of which five (miR-15, 134, 205, 7 and 32) were downregulated in CSCs with miR-205-a tumor suppressor moleculeCthe most reduced transcript (6-fold). The nine upregulated transcripts were miR-143, 214,10a, 10b, 146a, 146b-5p, 34a and 100."
23073476,miR-146b,hsa-mir-146b,MI0003129,Gemcitabine,60750,-,PaCa-2 vs PaCa-2/GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2012,miRNA profiling in pancreatic cancer and restoration of chemosensitivity.,"Fig. 5 shows the 14 differentially altered transcripts of which five (miR-15, 134, 205, 7 and 32) were downregulated in CSCs with miR-205-a tumor suppressor moleculeCthe most reduced transcript (6-fold). The nine upregulated transcripts were miR-143, 214,10a, 10b, 146a, 146b-5p, 34a and 100."
23073476,miR-15,hsa-mir-15a,MI0000069,Gemcitabine,60750,-,PaCa-2 vs PaCa-2/GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2012,miRNA profiling in pancreatic cancer and restoration of chemosensitivity.,"Fig. 5 shows the 14 differentially altered transcripts of which five (miR-15, 134, 205, 7 and 32) were downregulated in CSCs with miR-205-a tumor suppressor moleculeCthe most reduced transcript (6-fold). The nine upregulated transcripts were miR-143, 214,10a, 10b, 146a, 146b-5p, 34a and 100."
23073476,miR-190b,hsa-mir-190b,MI0005545,Gemcitabine,60750,-,PaCa-2 vs PaCa-2/GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2012,miRNA profiling in pancreatic cancer and restoration of chemosensitivity.,"Fig. 5 shows the 14 differentially altered transcripts of which five (miR-15, 134, 205, 7 and 32) were downregulated in CSCs with miR-205-a tumor suppressor moleculeCthe most reduced transcript (6-fold). The nine upregulated transcripts were miR-143, 214,10a, 10b, 146a, 146b-5p, 34a and 100."
23073476,miR-205,hsa-mir-205,MI0000285,Gemcitabine,60750,-,PaCa-2 vs PaCa-2/GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2012,miRNA profiling in pancreatic cancer and restoration of chemosensitivity.,"Fig. 5 shows the 14 differentially altered transcripts of which five (miR-15, 134, 205, 7 and 32) were downregulated in CSCs with miR-205-a tumor suppressor moleculeCthe most reduced transcript (6-fold). The nine upregulated transcripts were miR-143, 214,10a, 10b, 146a, 146b-5p, 34a and 100."
23073476,miR-214,hsa-mir-214,MI0000290,Gemcitabine,60750,-,PaCa-2 vs PaCa-2/GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2012,miRNA profiling in pancreatic cancer and restoration of chemosensitivity.,"Fig. 5 shows the 14 differentially altered transcripts of which five (miR-15, 134, 205, 7 and 32) were downregulated in CSCs with miR-205-a tumor suppressor moleculeCthe most reduced transcript (6-fold). The nine upregulated transcripts were miR-143, 214,10a, 10b, 146a, 146b-5p, 34a and 100."
23073476,miR-32,hsa-mir-32,MI0000090,Gemcitabine,60750,-,PaCa-2 vs PaCa-2/GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2012,miRNA profiling in pancreatic cancer and restoration of chemosensitivity.,"Fig. 5 shows the 14 differentially altered transcripts of which five (miR-15, 134, 205, 7 and 32) were downregulated in CSCs with miR-205-a tumor suppressor moleculeCthe most reduced transcript (6-fold). The nine upregulated transcripts were miR-143, 214,10a, 10b, 146a, 146b-5p, 34a and 100."
23073476,miR-34a,hsa-mir-34a,MI0000268,Gemcitabine,60750,-,PaCa-2 vs PaCa-2/GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2012,miRNA profiling in pancreatic cancer and restoration of chemosensitivity.,"Fig. 5 shows the 14 differentially altered transcripts of which five (miR-15, 134, 205, 7 and 32) were downregulated in CSCs with miR-205-a tumor suppressor moleculeCthe most reduced transcript (6-fold). The nine upregulated transcripts were miR-143, 214,10a, 10b, 146a, 146b-5p, 34a and 100."
23073476,miR-7,hsa-mir-7-1,MI0000263,Gemcitabine,60750,-,PaCa-2 vs PaCa-2/GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2012,miRNA profiling in pancreatic cancer and restoration of chemosensitivity.,"Fig. 5 shows the 14 differentially altered transcripts of which five (miR-15, 134, 205, 7 and 32) were downregulated in CSCs with miR-205-a tumor suppressor moleculeCthe most reduced transcript (6-fold). The nine upregulated transcripts were miR-143, 214,10a, 10b, 146a, 146b-5p, 34a and 100."
23074172,miR-200c,hsa-mir-200c,MI0000650,Paclitaxel,36314,HeyTGL ,-,Mice,-,ovarian cancer,in vitro and in vivo,Low,Sensitive,TUBB3,-,2012,Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.,Our study suggests that restoration of miR-200c immediately before cytotoxic chemotherapy may allow for a better response or lower effective dose.
23084187,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,SH-SY5Y and BE(2)-M17,-,-,-,neuroblastoma ,in vitro,Low,Resistant,-,PTEN,2012,Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells.,Ectopic expression of pre-miR-21 in parental cells resulted in decreased sensitivity to cisplatin treatment.
23085450,miR-34a,hsa-mir-34a,MI0000268,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Sensitive,Notch1,-,2012,MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1.,Ectopic overexpression of miR-34a could sensitize MCF-7 breast cancer cells to ADR.
23085757,miR-181a,hsa-mir-181a-2,MI0000269,Trichostatin A,444732,C24B,-,-,-,cancer,in vitro,Low,Sensitive,GRP78,PARP-1,2013,"miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer.",The results indicate that restoring the expression of multiple miRNAs that target GRP78 can sensitize cancer cells to therapeutic epigenetic agents.
23085757,miR-199a,hsa-mir-199a-1,MI0000242,Trichostatin A,444732,C24B,-,-,-,cancer,in vitro,Low,Sensitive,GRP78,PARP-1,2013,"miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer.",The results indicate that restoring the expression of multiple miRNAs that target GRP78 can sensitize cancer cells to therapeutic epigenetic agents.
23085757,miR-30d,hsa-mir-30d,MI0000255,Trichostatin A,444732,C24B,-,-,-,cancer,in vitro,Low,Sensitive,GRP78,PARP-1,2013,"miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer.",The results indicate that restoring the expression of multiple miRNAs that target GRP78 can sensitize cancer cells to therapeutic epigenetic agents.
23107361,let-7i,hsa-let-7i,MI0000434,Chemotherapy,-,-,-,-,Patients,gastric cancer,in vivo,Low,Sensitive,-,-,2012,Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer.,Let-7i expression levels in pathologic responders were significantly higher than in non-responders.
23137650,miR-181a,hsa-mir-181a-2,MI0000269,Cisplatin,2767,"lineKB-3-1, KB-CP.5 and KB-CP20",-,-,-,adenocarcinoma,in vitro,Low,Resistant,-,-,2013,Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells.,"We found miR-181 expression differences in the cell lines using RT-PCR, with several members of the miR-181 family overexpressed in two KB cisplatin-resistant lines and in two cisplatin-resistant lung cancer lines, compared to their respective parental cells. "
23137650,miR-181a,hsa-mir-181a-2,MI0000269,Cisplatin,2767,-,PC-9 vs PC-9/CDDP and PC-14 vs PC-14/CDDP,-,-,lung cancer,in vitro,Low,Resistant,-,-,2013,Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells.,"We found miR-181 expression differences in the cell lines using RT-PCR, with several members of the miR-181 family overexpressed in two KB cisplatin-resistant lines and in two cisplatin-resistant lung cancer lines, compared to their respective parental cells. "
23137650,miR-181a*,hsa-mir-181a-2,MI0000290,Cisplatin,2767,"lineKB-3-1, KB-CP.5 and KB-CP20",-,-,-,adenocarcinoma,in vitro,Low,Resistant,-,-,2013,Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells.,"We found miR-181 expression differences in the cell lines using RT-PCR, with several members of the miR-181 family overexpressed in two KB cisplatin-resistant lines and in two cisplatin-resistant lung cancer lines, compared to their respective parental cells. "
23137650,miR-181a*,hsa-mir-181a-2,MI0000290,Cisplatin,2767,-,PC-9 vs PC-9/CDDP and PC-14 vs PC-14/CDDP,-,-,lung cancer,in vitro,Low,Resistant,-,-,2013,Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells.,"We found miR-181 expression differences in the cell lines using RT-PCR, with several members of the miR-181 family overexpressed in two KB cisplatin-resistant lines and in two cisplatin-resistant lung cancer lines, compared to their respective parental cells. "
23137650,miR-181b,hsa-mir-181b-1,MI0000270,Cisplatin,2767,"lineKB-3-1, KB-CP.5 and KB-CP20",-,-,-,adenocarcinoma,in vitro,Low,Resistant,-,-,2013,Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells.,"We found miR-181 expression differences in the cell lines using RT-PCR, with several members of the miR-181 family overexpressed in two KB cisplatin-resistant lines and in two cisplatin-resistant lung cancer lines, compared to their respective parental cells. "
23137650,miR-181b,hsa-mir-181b-1,MI0000270,Cisplatin,2767,-,PC-9 vs PC-9/CDDP and PC-14 vs PC-14/CDDP,-,-,lung cancer,in vitro,Low,Resistant,-,-,2013,Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells.,"We found miR-181 expression differences in the cell lines using RT-PCR, with several members of the miR-181 family overexpressed in two KB cisplatin-resistant lines and in two cisplatin-resistant lung cancer lines, compared to their respective parental cells. "
23142283,miR-29c ,hsa-mir-29c,MI0000735,Cisplatin,2767,CNE1 and CNE2,-,Mice,-,nasopharyngeal carcinoma ,in vitro and in vivo,Low,Sensitive,-,Mcl-1 and Bcl-2,2013,MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy.,Our further in vitro and in vivo studies illustrated ectopic restoration of miR-29c substantially enhanced the sensitivity of NPC cells to IR and cisplatin treatment by promoting apoptosis.
23152059,miR-204,hsa-mir-204,MI0000284,5-Fluorouracil,3385,"GTL-16, N87, HEK293 and H1299",-,-,Patients,gastric cancer,in vitro and in vivo,Low,Sensitive,Bcl-2 ,-,2012,miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer.,miR-204 targeted Bcl-2 messenger RNA and increased responsiveness of GC cells to 5-fluorouracil and oxaliplatin treatment.
23152059,miR-204,hsa-mir-204,MI0000284,Oxaliplatin,5310940,"GTL-16, N87, HEK293 and H1299",-,-,Patients,gastric cancer,in vitro and in vivo,Low,Sensitive,Bcl-2 ,-,2012,miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer.,miR-204 targeted Bcl-2 messenger RNA and increased responsiveness of GC cells to 5-fluorouracil and oxaliplatin treatment.
23167930,miR-146a,hsa-mir-146a,MI0000477,5-Fluorouracil,3385,-,-,-,Patientss,renal cancer,in vivo,High,Resistant,-,-,2012,MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients," Of these, miR-215, miR-190b and miR-29b-2 have been overexpressed, and let-7e, miR-196b, miR-450a, miR-450b-5p and miR-99a have shown lower expression levels in non-responders."
23167930,miR-146a,hsa-mir-146a,MI0000477,Capecitabine,60953,-,-,-,Patientss,renal cancer,in vivo,High,Resistant,-,-,2012,MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients," Of these, miR-215, miR-190b and miR-29b-2 have been overexpressed, and let-7e, miR-196b, miR-450a, miR-450b-5p and miR-99a have shown lower expression levels in non-responders."
23167930,miR-196b,hsa-mir-196b,MI0001150,5-Fluorouracil,3385,-,-,-,Patientss,renal cancer,in vivo,High,Sensitive,-,-,2012,MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients," Of these, miR-215, miR-190b and miR-29b-2 have been overexpressed, and let-7e, miR-196b, miR-450a, miR-450b-5p and miR-99a have shown lower expression levels in non-responders."
23167930,miR-196b,hsa-mir-196b,MI0001150,Capecitabine,60953,-,-,-,Patientss,renal cancer,in vivo,High,Sensitive,-,-,2012,MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients," Of these, miR-215, miR-190b and miR-29b-2 have been overexpressed, and let-7e, miR-196b, miR-450a, miR-450b-5p and miR-99a have shown lower expression levels in non-responders."
23167930,miR-215,hsa-mir-215,MI0000291,5-Fluorouracil,3385,-,-,-,Patientss,renal cancer,in vivo,High,Resistant,-,-,2012,MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients," Of these, miR-215, miR-190b and miR-29b-2 have been overexpressed, and let-7e, miR-196b, miR-450a, miR-450b-5p and miR-99a have shown lower expression levels in non-responders."
23167930,miR-215,hsa-mir-215,MI0000291,Capecitabine,60953,-,-,-,Patientss,renal cancer,in vivo,High,Resistant,-,-,2012,MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients," Of these, miR-215, miR-190b and miR-29b-2 have been overexpressed, and let-7e, miR-196b, miR-450a, miR-450b-5p and miR-99a have shown lower expression levels in non-responders."
23167930,miR-29b-2*,hsa-mir-29b-2,MI0000107,5-Fluorouracil,3385,-,-,-,Patientss,renal cancer,in vivo,High,Resistant,-,-,2012,MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients," Of these, miR-215, miR-190b and miR-29b-2 have been overexpressed, and let-7e, miR-196b, miR-450a, miR-450b-5p and miR-99a have shown lower expression levels in non-responders."
23167930,miR-29b-2*,hsa-mir-29b-2,MI0000107,Capecitabine,60953,-,-,-,Patientss,renal cancer,in vivo,High,Resistant,-,-,2012,MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients," Of these, miR-215, miR-190b and miR-29b-2 have been overexpressed, and let-7e, miR-196b, miR-450a, miR-450b-5p and miR-99a have shown lower expression levels in non-responders."
23177026,miR-21,hsa-mir-21,MI0000077,Gemcitabine,60750,PANC-1 and BxPC3,-,-,-,pancreatic cancer,in vitro,Low,Resistant,FasL,-,2013,"The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL.","The increased FasL expression following gemcitabine treatment induced cancer cell apoptosis, whereas the ectopic expression of miR-21 partially protected the cancer cells from gemcitabine-induced apoptosis."
23178755,miR-29b,hsa-mir-29b-1,MI0000105,Decitabine,451668,"Kasumi-1, NB4 and FDC-P1-KITmut",-,Mice,-,acute myeloid leukemia,in vitro and in vivo,Low,Sensitive,"DNMT1, DNMT3A, DNMT3B and SP1",-,2013,Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.,"Here, we show that AR-42 is a potent HDACI in AML, increasing miR-29b levels and sequential administration of AR-42 followed by decitabine resulted in a stronger anti-leukemic activity in vitro and in vivo than decitabine followed by AR-42 or either drug alone."
23178914,miR-137,hsa-mir-137,MI0000454,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR and MCF-7 vs MCF-7/PTX,-,Patients,breast cancer,in vitro and in vivo,Low,Sensitive,YB-1,P-gp,2013,miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1.,Overexpression of miR-137 partially sensitized the MCF-7/ADM cells to chemotherapeutic agents.
23178914,miR-137,hsa-mir-137,MI0000454,Paclitaxel,36314,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Sensitive,YB-1,P-gp,2013,miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1.,Overexpression of miR-137 partially sensitized the MCF-7/ADM cells to chemotherapeutic agents.
23178914,miR-137,hsa-mir-137,MI0000454,Vincristine,5978,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Sensitive,YB-1,P-gp,2013,miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1.,Overexpression of miR-137 partially sensitized the MCF-7/ADM cells to chemotherapeutic agents.
23183822,miR-211,hsa-mir-211,MI0000287,Temozolomide,5394,Cancer Stem Cells,-,-,-,glioma,in vitro,Low,Sensitive,MMP-9,-,2012,"Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity.",Our study indicates that miR-211 or pM in combination with ionizing radiation (IR) and temozolomide significantly induces apoptosis and DNA fragmentation.
23206420,miR-141,hsa-mir-141,MI0000457,Sunitinib,5329102,-,-,-,Patients,clear cell renal cell carcinoma,in vivo,Low,Sensitive,-,-,2013,A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance.,MiR-141 was significantly down-regulated in tumours of poor responders to sunitinib therapy as compared to good responders.
23209748,miR-200c,hsa-mir-200c,MI0000650,Doxorubicin (Adriamycin),31703,BT474,-,-,-,breast cancer,in vitro,Low,Sensitive,TrkB and Bmi1,-,2012,miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression.,"To investigate the involvement of miR-200c in resistance formation, we inhibited and overexpressed miR-200c in different cell lines. Thereby, the cells were rendered more resistant or susceptible to doxorubicin treatment."
23229111,miR-146a ,hsa-mir-146a,MI0000477,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2015,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-146a ,hsa-mir-146a,MI0000477,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2015,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-146a ,hsa-mir-146a,MI0000477,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2015,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-146a ,hsa-mir-146a,MI0000477,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2015,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-146a ,hsa-mir-146a,MI0000477,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2015,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-146b,hsa-mir-146b,MI0003129,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-146b,hsa-mir-146b,MI0003129,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-146b,hsa-mir-146b,MI0003129,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-146b,hsa-mir-146b,MI0003129,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-146b,hsa-mir-146b,MI0003129,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-181a,hsa-mir-181a-2,MI0000269,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-181a,hsa-mir-181a-2,MI0000269,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-181a,hsa-mir-181a-2,MI0000269,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-181a,hsa-mir-181a-2,MI0000269,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-181a,hsa-mir-181a-2,MI0000269,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-181d,hsa-mir-181d,MI0003139,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-181d,hsa-mir-181d,MI0003139,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-181d,hsa-mir-181d,MI0003139,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-181d,hsa-mir-181d,MI0003139,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-181d,hsa-mir-181d,MI0003139,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-186*,hsa-mir-186,MI0000483,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-186*,hsa-mir-186,MI0000483,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-186*,hsa-mir-186,MI0000483,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-186*,hsa-mir-186,MI0000483,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-186*,hsa-mir-186,MI0000483,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-1908,hsa-mir-1908,MI0008329,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-1908,hsa-mir-1908,MI0008329,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-1908,hsa-mir-1908,MI0008329,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-1908,hsa-mir-1908,MI0008329,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-1908,hsa-mir-1908,MI0008329,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-1915,hsa-mir-1915,MI0008336,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-1915,hsa-mir-1915,MI0008336,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-1915,hsa-mir-1915,MI0008336,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-1915,hsa-mir-1915,MI0008336,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-1915,hsa-mir-1915,MI0008336,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-193b*,hsa-mir-193b,MI0003137,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-193b*,hsa-mir-193b,MI0003137,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-193b*,hsa-mir-193b,MI0003137,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-193b*,hsa-mir-193b,MI0003137,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-193b*,hsa-mir-193b,MI0003137,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-194,hsa-mir-194-1,MI0000488,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-194,hsa-mir-194-1,MI0000488,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-194,hsa-mir-194-1,MI0000488,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-194,hsa-mir-194-1,MI0000488,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-194,hsa-mir-194-1,MI0000488,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-22,hsa-mir-22,MI0000078,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-22,hsa-mir-22,MI0000078,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-22,hsa-mir-22,MI0000078,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-22,hsa-mir-22,MI0000078,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-22,hsa-mir-22,MI0000078,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-23a,hsa-mir-23a,MI0000079,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-23a,hsa-mir-23a,MI0000079,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-23a,hsa-mir-23a,MI0000079,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-23a,hsa-mir-23a,MI0000079,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-23a,hsa-mir-23a,MI0000079,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-26b,hsa-mir-26b,MI0000084,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-26b,hsa-mir-26b,MI0000084,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-26b,hsa-mir-26b,MI0000084,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-26b,hsa-mir-26b,MI0000084,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-26b,hsa-mir-26b,MI0000084,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-27b,hsa-mir-27b,MI0000440,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-27b,hsa-mir-27b,MI0000440,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-27b,hsa-mir-27b,MI0000440,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-27b,hsa-mir-27b,MI0000440,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-27b,hsa-mir-27b,MI0000440,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-300,hsa-mir-300,MI0005525,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-300,hsa-mir-300,MI0005525,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-300,hsa-mir-300,MI0005525,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-300,hsa-mir-300,MI0005525,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-300,hsa-mir-300,MI0005525,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-30b,hsa-mir-30b,MI0000441,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-30b,hsa-mir-30b,MI0000441,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-30b,hsa-mir-30b,MI0000441,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-30b,hsa-mir-30b,MI0000441,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-30b,hsa-mir-30b,MI0000441,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-30c,hsa-mir-30c-2,MI0000254,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-30c,hsa-mir-30c-2,MI0000254,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-30c,hsa-mir-30c-2,MI0000254,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-30c,hsa-mir-30c-2,MI0000254,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-30c,hsa-mir-30c-2,MI0000254,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-3183,hsa-mir-3183,MI0014225,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-3183,hsa-mir-3183,MI0014225,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-3183,hsa-mir-3183,MI0014225,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-3183,hsa-mir-3183,MI0014225,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-3183,hsa-mir-3183,MI0014225,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-4258,hsa-mir-4258,MI0015857,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-4258,hsa-mir-4258,MI0015857,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-4258,hsa-mir-4258,MI0015857,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-4258,hsa-mir-4258,MI0015857,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-4258,hsa-mir-4258,MI0015857,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-4285,hsa-mir-4285,MI0015891,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-4285,hsa-mir-4285,MI0015891,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-4285,hsa-mir-4285,MI0015891,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-4285,hsa-mir-4285,MI0015891,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-4285,hsa-mir-4285,MI0015891,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-4311,hsa-mir-4311,MI0015841,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-4311,hsa-mir-4311,MI0015841,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-4311,hsa-mir-4311,MI0015841,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-4311,hsa-mir-4311,MI0015841,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-4311,hsa-mir-4311,MI0015841,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-485,hsa-mir-485,MI0002469,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-485,hsa-mir-485,MI0002469,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-485,hsa-mir-485,MI0002469,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-485,hsa-mir-485,MI0002469,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-485,hsa-mir-485,MI0002469,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-584,hsa-mir-584,MI0003591,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-584,hsa-mir-584,MI0003591,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-584,hsa-mir-584,MI0003591,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-584,hsa-mir-584,MI0003591,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-584,hsa-mir-584,MI0003591,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-612,hsa-mir-612,MI0003625,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-612,hsa-mir-612,MI0003625,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-612,hsa-mir-612,MI0003625,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-612,hsa-mir-612,MI0003625,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-612,hsa-mir-612,MI0003625,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2012,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-630,hsa-mir-630,MI0003644,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-630,hsa-mir-630,MI0003644,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-630,hsa-mir-630,MI0003644,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-630,hsa-mir-630,MI0003644,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-630,hsa-mir-630,MI0003644,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-99b*,hsa-mir-99b,MI0000746,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2014,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-99b*,hsa-mir-99b,MI0000746,Cisplatin,2767,-,Huh-7 vs Huh-7/CDDP,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2014,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-99b*,hsa-mir-99b,MI0000746,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2014,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-99b*,hsa-mir-99b,MI0000746,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2014,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23229111,miR-99b*,hsa-mir-99b,MI0000746,Vincristine,5978,-,Huh-7 vs Huh-10/VCR,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2014,Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines,"Fig. 4 shows the normalized value of these differentially expressed miRNAs between Huh-7 cells and the Huh-7/ADM, Huh-7/CBP, Huh-7/DDP, Huh-7/MMC and Huh-7/VCR sublines."
23255607,miR-125b,hsa-mir-125b-1,MI0000446,Gemcitabine,60750,HMLE,-,-,-,breast cancer,in vitro,Low,Resistant,bak1,-,2013,miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance.,"Restoring the expression of Bak1 or depleting miR-125b re-sensitizes Snail-expressing cancer cells to Taxol, indicating that miR-125b is critical in Snail-induced chemoresistance."
23255607,miR-125b,hsa-mir-125b-1,MI0000446,Paclitaxel,36314,-,"MDA-MB-435 vs MDA-MB-435/Taxol,  SKBR3 vs SKBR3/Taxol and HMLE vs HMLE/Taxol",-,-,breast cancer,in vitro,Low,Resistant,bak1,-,2013,miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance.,"Restoring the expression of Bak1 or depleting miR-125b re-sensitizes Snail-expressing cancer cells to Taxol, indicating that miR-125b is critical in Snail-induced chemoresistance."
23270413,miR-155,hsa-mir-155,MI0000681,Fulvestrant,104741,-,MCF7 vs MCF7/FUL,-,-,breast cancer,in vitro,Low,Sensitive, BRCA1/2,-,2012,"An integrative analysis of cellular contexts, miRNAs and mRNAs reveals network clusters associated with antiestrogen-resistant breast cancer cells","Mir-146a was down-regulated in both drug resistant cell lines, and its targets, BRCA1/2, were up-regulated in the cluster."
23270413,miR-155,hsa-mir-155,MI0000681,Tamoxifen,2733526,-,MCF7 vs MCF7/TAM,-,-,breast cancer,in vitro,Low,Sensitive, BRCA1/2,-,2012,"An integrative analysis of cellular contexts, miRNAs and mRNAs reveals network clusters associated with antiestrogen-resistant breast cancer cells","Mir-146a was down-regulated in both drug resistant cell lines, and its targets, BRCA1/2, were up-regulated in the cluster."
23270413,miR-196a,hsa-mir-196a-1,MI0000238,Fulvestrant,104741,-,MCF7 vs MCF7/FUL,-,-,breast cancer,in vitro,Low,Resistant,-,-,2012,"An integrative analysis of cellular contexts, miRNAs and mRNAs reveals network clusters associated with antiestrogen-resistant breast cancer cells",mir-155 and its targets showed opposite expression patterns in MCF7-T and MCF7-F and thus could contribute to the different drug-resistant states
23270413,miR-196a,hsa-mir-196a-1,MI0000238,Tamoxifen,2733526,-,MCF7 vs MCF7/TAM,-,-,breast cancer,in vitro,Low,Resistant,-,-,2012,"An integrative analysis of cellular contexts, miRNAs and mRNAs reveals network clusters associated with antiestrogen-resistant breast cancer cells",mir-155 and its targets showed opposite expression patterns in MCF7-T and MCF7-F and thus could contribute to the different drug-resistant states
23275230,miR-21,hsa-mir-21,MI0000077,Cyclophosphamide,2907,CRL2631,-,-,-,diffuse large B-cell lymphoma,in vitro,Low,Resistant,PTEN,PI3K/AKT signaling,2013,MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen.,Knockdown of miR-21 with antisense oligonucleotides significantly increased the cytotoxic effects of the CHOP regimen in CRL2631 cells.
23275230,miR-21,hsa-mir-21,MI0000077,Doxorubicin (Adriamycin),31703,CRL2631,-,-,-,diffuse large B-cell lymphoma,in vitro,Low,Resistant,PTEN,PI3K/AKT signaling,2013,MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen.,Knockdown of miR-21 with antisense oligonucleotides significantly increased the cytotoxic effects of the CHOP regimen in CRL2631 cells.
23275230,miR-21,hsa-mir-21,MI0000077,Prednisone (R-CHOP),5865,CRL2631,-,-,-,diffuse large B-cell lymphoma,in vitro,Low,Resistant,PTEN,PI3K/AKT signaling,2013,MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen.,Knockdown of miR-21 with antisense oligonucleotides significantly increased the cytotoxic effects of the CHOP regimen in CRL2631 cells.
23275230,miR-21,hsa-mir-21,MI0000077,Vincristine,5978,CRL2631,-,-,-,diffuse large B-cell lymphoma,in vitro,Low,Resistant,PTEN,PI3K/AKT signaling,2013,MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen.,Knockdown of miR-21 with antisense oligonucleotides significantly increased the cytotoxic effects of the CHOP regimen in CRL2631 cells.
23284982,miR-155,hsa-mir-155,MI0000681,Cisplatin,2767,Caski Cells,-,-,-,caski cervical cancer,in vitro,Low,Sensitive,"SMAD2, TCF4 and CCND1",-,2012,Up-regulated miR155 reverses the epithelial-mesenchymal transition induced by EGF and increases chemo-sensitivity to cisplatin in human Caski cervical cancer cells.,"In this study, we reported that miR155 overexpression suppressed EGF-induced EMT, decreased migration/invasion capacities, inhibited cell proliferation and increased the chemo-sensitivity to DDP in human Caski cervical cancer cells."
23293055,miR-125a,hsa-mir-125a,MI0000469,Gemcitabine,60750,-,BxPC-3 and Panc-1,-,-,pancreatic cancer,in vitro,Low,Resistant,-,-,2012,Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures,"To evaluate the correlation in expression pattern between the two analytical methods, a statistical analysis was done and an R2 value of 0.73, 0.90, 0.81, 0.78, 0.74, and 0.92 was obtained for expression of miR-196a, miR-495, miR-21, miR-453, miR-638, and miR-605, respectively (Fig. 4); suggesting average to good correlation between the two analytical methods."
23293055,miR-21,hsa-mir-21,MI0000077,Gemcitabine,60750,-,BxPC-3 and Panc-1,-,-,pancreatic cancer,in vitro,Low,Resistant,-,-,2012,Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures,"To evaluate the correlation in expression pattern between the two analytical methods, a statistical analysis was done and an R2 value of 0.73, 0.90, 0.81, 0.78, 0.74, and 0.92 was obtained for expression of miR-196a, miR-495, miR-21, miR-453, miR-638, and miR-605, respectively (Fig. 4); suggesting average to good correlation between the two analytical methods."
23293055,miR-453,hsa-mir-453,MI0001728,Gemcitabine,60750,-,BxPC-3 and Panc-1,-,-,pancreatic cancer,in vitro,Low,Resistant,-,-,2012,Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures,"To evaluate the correlation in expression pattern between the two analytical methods, a statistical analysis was done and an R2 value of 0.73, 0.90, 0.81, 0.78, 0.74, and 0.92 was obtained for expression of miR-196a, miR-495, miR-21, miR-453, miR-638, and miR-605, respectively (Fig. 4); suggesting average to good correlation between the two analytical methods."
23293055,miR-495,hsa-mir-495,MI0003135,Gemcitabine,60750,-,BxPC-3 and Panc-1,-,-,pancreatic cancer,in vitro,Low,Sensitive,-,-,2012,Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures,"To evaluate the correlation in expression pattern between the two analytical methods, a statistical analysis was done and an R2 value of 0.73, 0.90, 0.81, 0.78, 0.74, and 0.92 was obtained for expression of miR-196a, miR-495, miR-21, miR-453, miR-638, and miR-605, respectively (Fig. 4); suggesting average to good correlation between the two analytical methods."
23293055,miR-605,hsa-mir-605,MI0003618,Gemcitabine,60750,-,BxPC-3 and Panc-1,-,-,pancreatic cancer,in vitro,Low,Sensitive,-,-,2012,Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures,"To evaluate the correlation in expression pattern between the two analytical methods, a statistical analysis was done and an R2 value of 0.73, 0.90, 0.81, 0.78, 0.74, and 0.92 was obtained for expression of miR-196a, miR-495, miR-21, miR-453, miR-638, and miR-605, respectively (Fig. 4); suggesting average to good correlation between the two analytical methods."
23293055,miR-638,hsa-mir-638,MI0003653,Gemcitabine,60750,-,BxPC-3 and Panc-1,-,-,pancreatic cancer,in vitro,Low,Sensitive,-,-,2012,Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures,"To evaluate the correlation in expression pattern between the two analytical methods, a statistical analysis was done and an R2 value of 0.73, 0.90, 0.81, 0.78, 0.74, and 0.92 was obtained for expression of miR-196a, miR-495, miR-21, miR-453, miR-638, and miR-605, respectively (Fig. 4); suggesting average to good correlation between the two analytical methods."
23300087,miR-17-92,-,-,Sirolimus,5284616,-,BC3H1 vs BC3H1/RAP and RR1 vs RR1/RAP,-,-,brain tumour,in vitro,Low,Resistant,TGFB,-,2013,Reprogramming of the microRNA transcriptome mediates resistance to rapamycin.,Inhibition of members of the miR-17-92 clusters or delivery of tumor suppressor miRNAs restored sensitivity to rapamycin.
23308047,miR-1250,hsa-mir-1250,MI0006385,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Sensitive,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-1308,hsa-mir-1308,MI0006441,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Resistant,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-139,hsa-mir-139,MI0000261,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Resistant,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-141,hsa-mir-141,MI0000457,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Resistant,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-145,hsa-mir-145,MI0000461,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Resistant,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-150,hsa-mir-150,MI0000479,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Resistant,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-181a*,hsa-mir-181a-2,MI0000269,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Resistant,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-1825,hsa-mir-1825,MI0008193,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Resistant,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-192,hsa-mir-192,MI0000234,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Resistant,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-193a,hsa-mir-193a,MI0000487,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Resistant,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-199a,hsa-mir-199a-1,MI0000242,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Resistant,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-29a,hsa-mir-29a,MI0000087,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Resistant,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-30b*,hsa-mir-30b,MI0000441,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Resistant,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-31,hsa-mir-31,MI0000089,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Resistant,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-34a,hsa-mir-34a,MI0000268,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Resistant,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-362,hsa-mir-362,MI0000762,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Resistant,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-370,hsa-mir-370,MI0000778,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Sensitive,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-501,hsa-mir-501,MI0003185,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Sensitive,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-505*,hsa-mir-505,MI0003190,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Sensitive,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-516a,hsa-mir-516a-1,MI0003180,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Sensitive,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-564,hsa-mir-564,MI0003570,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Sensitive,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-582,hsa-mir-582,MI0003589,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Sensitive,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-624*,hsa-mir-624,MI0003638,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Sensitive,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-629,hsa-mir-629,MI0003643,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Sensitive,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-659,hsa-mir-659,MI0003683,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Sensitive,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308047,miR-933,hsa-mir-933,MI0005755,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Sensitive,-,-,2012,"MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients1,2","Comparison of the poor response and response groups found significant differences in the expressions of 28 miRNAs of the 287 evaluated when L2 boosting was applied to filtered miRNA expression data obtained from basal blood. Additionally, L2 boosting identified 28 variables related to prolonged response to sunitinib."
23308219,miR-193a,hsa-mir-193a,MI0000487,SIOP treatment protocol,-,-,-,-,Patientss,neuroblastoma,in vivo,High,Resistant,-,-,2013,miRNA Profiles as a Predictor of Chemoresponsiveness in Wilms' Tumor Blastema,"We investigated for representation of these miRNAs at the biopsy stage, through comparison of pre-treatment biopsies originating from intermediate risk cases [Pre-IR], to pre-treatment biopsies from high risk cases [Pre-HR]. Interestingly, 7 miRNAs from the post-treatment analysis were also differentially expressed at the biopsy stage (Table 4)."
23308219,miR-27a,hsa-mir-27a,MI0000085,SIOP treatment protocol,-,-,-,-,Patientss,neuroblastoma,in vivo,High,Resistant,-,-,2013,miRNA Profiles as a Predictor of Chemoresponsiveness in Wilms' Tumor Blastema,"We investigated for representation of these miRNAs at the biopsy stage, through comparison of pre-treatment biopsies originating from intermediate risk cases [Pre-IR], to pre-treatment biopsies from high risk cases [Pre-HR]. Interestingly, 7 miRNAs from the post-treatment analysis were also differentially expressed at the biopsy stage (Table 4)."
23308219,miR-302a,hsa-mir-302a,MI0000738,SIOP treatment protocol,-,-,-,-,Patientss,neuroblastoma,in vivo,High,Sensitive,-,-,2013,miRNA Profiles as a Predictor of Chemoresponsiveness in Wilms' Tumor Blastema,"We investigated for representation of these miRNAs at the biopsy stage, through comparison of pre-treatment biopsies originating from intermediate risk cases [Pre-IR], to pre-treatment biopsies from high risk cases [Pre-HR]. Interestingly, 7 miRNAs from the post-treatment analysis were also differentially expressed at the biopsy stage (Table 4)."
23308219,miR-367,hsa-mir-367,MI0000775,SIOP treatment protocol,-,-,-,-,Patientss,neuroblastoma,in vivo,High,Sensitive,-,-,2013,miRNA Profiles as a Predictor of Chemoresponsiveness in Wilms' Tumor Blastema,"We investigated for representation of these miRNAs at the biopsy stage, through comparison of pre-treatment biopsies originating from intermediate risk cases [Pre-IR], to pre-treatment biopsies from high risk cases [Pre-HR]. Interestingly, 7 miRNAs from the post-treatment analysis were also differentially expressed at the biopsy stage (Table 4)."
23308219,miR-483,hsa-mir-483,MI0002467,SIOP treatment protocol,-,-,-,-,Patientss,neuroblastoma,in vivo,High,Sensitive,-,-,2013,miRNA Profiles as a Predictor of Chemoresponsiveness in Wilms' Tumor Blastema,"We investigated for representation of these miRNAs at the biopsy stage, through comparison of pre-treatment biopsies originating from intermediate risk cases [Pre-IR], to pre-treatment biopsies from high risk cases [Pre-HR]. Interestingly, 7 miRNAs from the post-treatment analysis were also differentially expressed at the biopsy stage (Table 4)."
23308219,miR-590,hsa-mir-590,MI0003602,SIOP treatment protocol,-,-,-,-,Patientss,neuroblastoma,in vivo,High,Sensitive,-,-,2013,miRNA Profiles as a Predictor of Chemoresponsiveness in Wilms' Tumor Blastema,"We investigated for representation of these miRNAs at the biopsy stage, through comparison of pre-treatment biopsies originating from intermediate risk cases [Pre-IR], to pre-treatment biopsies from high risk cases [Pre-HR]. Interestingly, 7 miRNAs from the post-treatment analysis were also differentially expressed at the biopsy stage (Table 4)."
23308219,miR-628,hsa-mir-628,MI0003642,SIOP treatment protocol,-,-,-,-,Patientss,neuroblastoma,in vivo,High,Sensitive,-,-,2013,miRNA Profiles as a Predictor of Chemoresponsiveness in Wilms' Tumor Blastema,"We investigated for representation of these miRNAs at the biopsy stage, through comparison of pre-treatment biopsies originating from intermediate risk cases [Pre-IR], to pre-treatment biopsies from high risk cases [Pre-HR]. Interestingly, 7 miRNAs from the post-treatment analysis were also differentially expressed at the biopsy stage (Table 4)."
23318422,miR-152,hsa-mir-152,MI0000462,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP and A2780 vs A2780/CDDP,Mice,-,ovarian cancer,in vitro and in vivo,Low,Sensitive,DNMT1 ,-,2014,MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.,The overexpression of miR-152 or miR-185 increased cisplatin sensitivity of SKOV3/DDP and A2780/DDP cells by inhibiting proliferation and promoting apoptosis
23318422,miR-185,hsa-mir-185,MI0000482,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP and A2780 vs A2780/CDDP,Mice,-,ovarian cancer,in vitro and in vivo,Low,Sensitive,DNMT1 ,-,2014,MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.,The overexpression of miR-152 or miR-185 increased cisplatin sensitivity of SKOV3/DDP and A2780/DDP cells by inhibiting proliferation and promoting apoptosis
23321165,miR-21,hsa-mir-21,MI0000077,Chemotherapy,-,-,-,-,Patients,osteosarcoma,in vivo,Low,Associated,-,-,2012,Identification of serum microRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma.,High serum miR-21 was significantly correlated with advanced Enneking stage and chemotherapeutic resistance.
23327190,miR-125a,hsa-mir-125a,MI0000469,Paclitaxel,36314,-,HT29 vs HT29/Taxol,Mice,-,colon cancer,in vitro and in vivo,Low,Sensitive,-,ALDH1A3 and Mcl1 expression,2013,MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer.,Injection of miR-125a/b expression vector inhibited tumor growth in xenograft HT29-taxol mouse model.
23327190,miR-125b,hsa-mir-125b-1,MI0000446,Paclitaxel,36314,-,HT29 vs HT29/Taxol,Mice,-,colon cancer,in vitro and in vivo,Low,Sensitive,-,ALDH1A3 and Mcl1 expression,2013,MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer.,Injection of miR-125a/b expression vector inhibited tumor growth in xenograft HT29-taxol mouse model.
23335963,let-7a,hsa-let-7a-1,MI0000060,Gemcitabine,60750,Mia-PaCa-2,-,-,-,pancreatic cancer,in vitro,Low,Resistant,RRM2,-,2013,Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.,"Intriguingly, overexpression of human precursor-let-7 miRNAs led to differential RRM2 expression and chemosensitivity responses in a poorly differentiated pancreatic cancer cell line, MIA PaCa-2."
23337879,miR-214,hsa-mir-214,MI0000290,Cisplatin,2767,HeLa and C-33A,-,-,-,cervical cancer,in vitro,Low,Sensitive,Bcl2l2,"Bax, caspase-9, caspase-8 and caspase-3",2013,MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells.,"Here we demonstrate that ectopic expression of miR-214 reduces cell survival, induces apoptosis and enhances sensitivity to cisplatin through directly inhibiting Bcl2l2 expression in cervical cancer HeLa and C-33A cells."
23340433,miR-30a*,hsa-mir-30a,MI0000088,Doxorubicin (Adriamycin),31703,MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Sensitive,-,-,2013,MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.,"In addition, miR-30a* sensitized the drug response of breast cancer cells to doxorubicin (200nM) and paclitaxel at relatively high doses."
23340433,miR-30a*,hsa-mir-30a,MI0000088,Paclitaxel,36314,MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Sensitive,-,-,2013,MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.,"In addition, miR-30a* sensitized the drug response of breast cancer cells to doxorubicin (200nM) and paclitaxel at relatively high doses."
23340433,miR-30c,hsa-mir-30c-1,MI0000736,Doxorubicin (Adriamycin),31703,MDA-MB-231 and BT-20,-,-,-,breast cancer,in vitro,Low,Sensitive,TWF1,IL-11,2013,MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.,Elevated miR-30c also sensitized the drug response of a second breast cancer cell line BT-20 to paclitaxel and doxorubicin.
23340433,miR-30c,hsa-mir-30c-1,MI0000736,Paclitaxel,36314,MDA-MB-231 and BT-20,-,-,-,breast cancer,in vitro,Low,Sensitive,TWF1,IL-11,2013,MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.,Elevated miR-30c also sensitized the drug response of a second breast cancer cell line BT-20 to paclitaxel and doxorubicin.
23359607,hsa-novel-miR-12,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,hsa-novel-miR-13,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2014,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-14,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2015,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-mir-15,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2016,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-17,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2017,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-19,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2018,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-25,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2019,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-26,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2020,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-mir-27,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2021,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novelmiR-35,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2022,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-41,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2023,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-43,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2024,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-5,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2025,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-50,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2026,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-51,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2027,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-57,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2028,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-58,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2029,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-64,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2030,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-65,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2031,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-71,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2032,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-miR-72,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2033,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,hsa-novel-mir-8,-,-,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2034,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"A total of 71,596 and 41,059 sequence tags were identified to be 70 and 59 novel miRNAs in HepG2 and HepG2/DOX, respectively, of which 26 miRNAs were shared by both cells. Compared to HepG2 cells, 9 and 13 novel miRNAs were significantly up-expressed and downexpressed in HepG2/DOX cells, respectively (Figure 2D, Table 2, adjusted P<0.05)."
23359607,miR-1255a,hsa-mir-1255a,MI0006389,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-1269b,hsa-mir-1269b,MI0016888,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-1277,hsa-mir-1277,MI0006419,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-1293,hsa-mir-1293,MI0006355,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-139,hsa-mir-139,MI0000261,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-181a,hsa-mir-181a-2,MI0000269,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-196a,hsa-mir-196a-1,MI0000238,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-203,hsa-mir-203a,MI0000283,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-21,hsa-mir-21,MI0000077,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-2116,hsa-mir-2116,MI0010635,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-2277,hsa-mir-2277,MI0011284,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-2682,hsa-mir-2682,MI0012063,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-296,hsa-mir-296,MI0000747,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-302b,hsa-mir-302a,MI0000738,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2035,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-3117,hsa-mir-3117,MI0014130,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-3186,hsa-mir-3186,MI0014229,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-335,hsa-mir-335,MI0000816,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-338,hsa-mir-338,MI0000814,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-362,hsa-mir-3622a,MI0016013,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-3622a,hsa-mir-362,MI0000762,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-3654,hsa-mir-3654,MI0016054,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-365a,hsa-mir-365a,MI0000767,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-365b,hsa-mir-365b,MI0000769,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-3660,hsa-mir-3660,MI0016061,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-3674,hsa-mir-3674,MI0016075,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-3679,hsa-mir-3679,MI0016080,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-3687,hsa-mir-3687-1,MI0016088,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-3910,hsa-mir-3910-1,MI0016414,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-4426,hsa-mir-4426,MI0016765,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-4427,hsa-mir-4427,MI0016766,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-4448,hsa-mir-4448,MI0016791,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-4454,hsa-mir-4454,MI0016800,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-4485,hsa-mir-4485,MI0016846,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-4488,hsa-mir-4488,MI0016849,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-4501,hsa-mir-4501,MI0016864,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-4508,hsa-mir-450a-1,MI0001652,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-4687,hsa-mir-4687,MI0017319,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-486,hsa-mir-486-1,MI0002470,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-500a,hsa-mir-500a,MI0003184,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-500b,hsa-mir-500b,MI0015903,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-548h,hsa-mir-548h-1,MI0006411,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-551b,hsa-mir-551b,MI0003575,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-577,hsa-mir-577,MI0003584,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-642a,hsa-mir-642a,MI0003657,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-720,hsa-mir-720,MI0006654,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-877,hsa-mir-877,MI0005561,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23359607,miR-944,hsa-mir-944,MI0005769,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/DOX ,-,-,hepatocellular cancer,in vitro,High,Sensitive,-,-,2013,Genome-Wide Analysis of miRNA Signature Differentially Expressed in Doxorubicin-Resistant and Parental Human Hepatocellular Carcinoma Cell Lines,"In all the 360 known miRNAs shared by both cells, 23 miRNAs were over-expressed and 246 miRNAs were down-expressed significantly (adjusted P,0.05) in the HepG2/DOX cells (Figure 2A). Among these differentially expressed miRNAs, HepG2/DOX cells had a total of 12 miRNAs with elevated expression levels >16-fold and 30 miRNAs with reduced expression levels >16-fold of the corresponding miRNAs in HepG2 cells (Table 1)."
23364795,miR-31,hsa-mir-31,MI0000089,Doxorubicin (Adriamycin),31703,"MDA-MB-231, MCF-7, MCF10A and HEK293FT",-,-,-,breast cancer,in vitro,Low,Sensitive,PRKCE,-,2013,MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon).,"We identified protein kinase C epsilon (PKC-Epsilon encoded by the PRKCE gene) as a novel direct target of miR-31 and show that down-regulation of PKC-Epsilon results in impaired NF--kappaB signaling, enhanced apoptosis, and increased sensitivity of MCF10A breast epithelial and MDA-MB-231 triple-negative breast cancer cells toward ionizing radiation as well as treatment with chemotherapeutics."
23364795,miR-31,hsa-mir-31,MI0000089,Staurosporine,5329102,"MDA-MB-231, MCF-7,  MCF10A and HEK293FT",-,-,-,breast cancer,in vitro,Low,Sensitive,PRKCE,-,2013,MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon).,"We identified protein kinase C epsilon (PKC-Epsilon encoded by the PRKCE gene) as a novel direct target of miR-31 and show that down-regulation of PKC-Epsilon results in impaired NF--kappaB signaling, enhanced apoptosis, and increased sensitivity of MCF10A breast epithelial and MDA-MB-231 triple-negative breast cancer cells toward ionizing radiation as well as treatment with chemotherapeutics."
23372675,miR-221,hsa-mir-221,MI0000298,Cisplatin,2767,SOSP-9607 and MG63,-,-,-,osteosarcoma,in vitro,Low,Resistant,PTEN,PI3K/Akt pathway,2013,MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma.,"In addition, knockdown of miR-221 inhibited cell growth and cisplatin resistance and induced cell apoptosis."
23391506,miR-17,hsa-mir-17,MI0000071,Docetaxel,148124,U87,-,-,-,glioblastoma,in vitro,Low,Resistant,MDM2,-,2012,Stress response of glioblastoma cells mediated by miR-17-5p targeting PTEN and the passenger strand miR-17-3p targeting MDM2.,"Finally, we demonstrated that miR-17 could repress MDM2 levels, resulting in decreased cell proliferation and drug-resistance."
23423488,miR-34c,hsa-mir-34c,MI0000743,Paclitaxel,36314,-,SGC7901 and  SGC7901/VCR,-,Patients,gastric cancer,in vitro and in vivo,Low,Sensitive,MAPT,-,2013,Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel.,Overexpression of miR-34c-5p significantly downregulated MAPT protein expression and increased the chemosensitivity of paclitaxel-resistant gastric cancer cells.
23436656,miR-663,hsa-mir-663a,MI0003672,Cyclophosphamide,2907,-,MDA-MB-231 vs MDA-MB-231/ADR,-,Patients,breast cancer,in vitro and in vivo,Low,Resistant,HSPG2,-,2013,The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2).,"We found that miR-663 was significantly elevated in MDA-MB-231/ADM cells, and the down-regulation of miR-663 sensitized MDA-MB-231/ADM cells to both cyclophosphamide and docetaxel."
23436656,miR-663,hsa-mir-663a,MI0003672,Docetaxel,148124,-,MDA-MB-231 vs MDA-MB-231/ADR,-,Patients,breast cancer,in vitro and in vivo,Low,Resistant,HSPG2,-,2013,The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2).,"We found that miR-663 was significantly elevated in MDA-MB-231/ADM cells, and the down-regulation of miR-663 sensitized MDA-MB-231/ADM cells to both cyclophosphamide and docetaxel."
23438844,miR-135,-,-,5-Fluorouracil,3385,"HeLa, SW480, 293, A375 and PANC-1",-,-,-,"cervical carcinoma, colon cancer",in vitro,Low,Sensitive,focal adhesion kinase,-,2014,"MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells.","Moreover, stable expression of MiR-138 and MiR-135 in 293 and HeLa cells decreased cell invasion and increased sensitivity to 5- fluorouracil (5-FU), FAK inhibitor, Y15, and doxorubicin."
23438844,miR-135,-,-,Doxorubicin (Adriamycin),31703,"HeLa, SW480, 293, A375 and PANC-1",-,-,-,"cervical carcinoma, colon cancer",in vitro,Low,Sensitive,focal adhesion kinase,-,2014,"MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells.","Moreover, stable expression of MiR-138 and MiR-135 in 293 and HeLa cells decreased cell invasion and increased sensitivity to 5- fluorouracil (5-FU), FAK inhibitor, Y15, and doxorubicin."
23438844,miR-135,-,-,FAK inhibitor,-,"HeLa, SW480, 293, A375 and PANC-1",-,-,-,"cervical carcinoma, colon cancer",in vitro,Low,Sensitive,focal adhesion kinase,-,2014,"MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells.","Moreover, stable expression of MiR-138 and MiR-135 in 293 and HeLa cells decreased cell invasion and increased sensitivity to 5- fluorouracil (5-FU), FAK inhibitor, Y15, and doxorubicin."
23438844,miR-135,-,-,Y15,-,"HeLa, SW480, 293, A375 and Panc-1",-,-,-,"cervical carcinoma, colon cancer",in vitro,Low,Sensitive,focal adhesion kinase,-,2014,"MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells.","Moreover, stable expression of MiR-138 and MiR-135 in 293 and HeLa cells decreased cell invasion and increased sensitivity to 5- fluorouracil (5-FU), FAK inhibitor, Y15, and doxorubicin."
23438844,miR-138,hsa-miR-138-5p,MI0000455,5-Fluorouracil,3385,"HeLa, SW480, 293, A375 and PANC-1",-,-,-,"cervical carcinoma, colon cancer",in vitro,Low,Sensitive,focal adhesion kinase,-,2014,"MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells.","Moreover, stable expression of MiR-138 and MiR-135 in 293 and HeLa cells decreased cell invasion and increased sensitivity to 5- fluorouracil (5-FU), FAK inhibitor, Y15, and doxorubicin."
23438844,miR-138,hsa-miR-138-5p,MI0000455,Doxorubicin (Adriamycin),31703,"HeLa, SW480, 293, A375 and PANC-1",-,-,-,"cervical carcinoma, colon cancer",in vitro,Low,Sensitive,focal adhesion kinase,-,2014,"MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells.","Moreover, stable expression of MiR-138 and MiR-135 in 293 and HeLa cells decreased cell invasion and increased sensitivity to 5- fluorouracil (5-FU), FAK inhibitor, Y15, and doxorubicin."
23438844,miR-138,hsa-miR-138-5p,MI0000455,FAK inhibitor,-,"HeLa, SW480, 293, A375 and PANC-1",-,-,-,"cervical carcinoma, colon cancer",in vitro,Low,Sensitive,focal adhesion kinase,-,2014,"MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells.","Moreover, stable expression of MiR-138 and MiR-135 in 293 and HeLa cells decreased cell invasion and increased sensitivity to 5- fluorouracil (5-FU), FAK inhibitor, Y15, and doxorubicin."
23438844,miR-138,hsa-miR-138-5p,MI0000455,Y15,-,"HeLa, SW480, 293, A375 and Panc-1",-,-,-,"cervical carcinoma, colon cancer",in vitro,Low,Sensitive,focal adhesion kinase,-,2014,"MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells.","Moreover, stable expression of MiR-138 and MiR-135 in 293 and HeLa cells decreased cell invasion and increased sensitivity to 5- fluorouracil (5-FU), FAK inhibitor, Y15, and doxorubicin."
23440261,miR-181b,hsa-mir-181b-1,MI0000270,Gemcitabine,60750,-,SW1990 vs SW1990/GR and CFPAC-1 vs CFPAC-1/GR,Mice,-,pancreatic ductal adenocarcinoma,in vitro and in vivo,Low,Sensitive,BCL-2,-,2013,miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.,The data showed that miRNA-181b expression sensitized PDAC cells to gemcitabine treatment.
23442794,let-7,-,-,Sirolimus,5284616,RR1 and BC3H1,-,-,-,brain tumour,in vitro,Low,Sensitive,PTEN,-,2013,MicroRNAs and the cellular response to rapamycin: potential role in diagnosis and therapy.,"Upregulation of let-7 or downregulation of mir-19 or mir-17, members of mir-17-92 cluster, restored sensitivity to rapamycin."
23442794,miR-17,hsa-mir-17,MI0000071,Sirolimus,5284616,RR1 and BC3H1,-,-,-,brain tumour,in vitro,Low,Resistant,PTEN,-,2013,MicroRNAs and the cellular response to rapamycin: potential role in diagnosis and therapy.,"Upregulation of let-7 or downregulation of mir-19 or mir-17, members of mir-17-92 cluster, restored sensitivity to rapamycin."
23442794,miR-19,-,-,Sirolimus,5284616,RR1 and BC3H1,-,-,-,brain tumour,in vitro,Low,Resistant,PTEN,-,2013,MicroRNAs and the cellular response to rapamycin: potential role in diagnosis and therapy.,"Upregulation of let-7 or downregulation of mir-19 or mir-17, members of mir-17-92 cluster, restored sensitivity to rapamycin."
23443110,miR-218,hsa-mir-218-1,MI0000294,Cisplatin,2767,HeLa,-,-,-,cervical cancer,in vitro,Low,Sensitive,-,-,2012,MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer.,"Furthermore, miR-218 increased chemosensitivity to cisplatin (CDDP) in vitro."
23447575,miR-205,hsa-mir-205,MI0000285,Cisplatin,2767,SK-Mel-147,-,-,-,melanoma,in vitro,Low,Sensitive,ERBB3,-,2013,Kinetic modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-p73/DNp73-miR-205 network.,We identified a signature composed of high E2F1 and low miR-205 expression that promotes resistance to genotoxic drugs.
23447575,miR-205,hsa-mir-205,MI0000285,Doxorubicin (Adriamycin),31703,SK-Mel-147,-,-,-,melanoma,in vitro,Low,Sensitive,ERBB3,-,2013,Kinetic modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-p73/DNp73-miR-205 network.,We identified a signature composed of high E2F1 and low miR-205 expression that promotes resistance to genotoxic drugs.
23447575,miR-205,hsa-mir-205,MI0000285,Erlotinib,176870,SK-Mel-147,-,-,-,melanoma,in vitro,Low,Sensitive,ERBB3,-,2013,Kinetic modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-p73/DNp73-miR-205 network.,We identified a signature composed of high E2F1 and low miR-205 expression that promotes resistance to genotoxic drugs.
23447575,miR-205,hsa-mir-205,MI0000285,Lapatinib,25183872,SK-Mel-147,-,-,-,melanoma,in vitro,Low,Sensitive,ERBB3,-,2013,Kinetic modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-p73/DNp73-miR-205 network.,We identified a signature composed of high E2F1 and low miR-205 expression that promotes resistance to genotoxic drugs.
23466500,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,-,SGC7901 vs SGC7901/CDDP,-,-,gastric cancer,in vitro,Low,Resistant,PTEN,Akt pathway,2013,miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN.,"In addition, miR-21 induced cell survival and cisplatin resistance through downregulating the expression of phosphatase and tension homolog deleted on chromosome 10 (PTEN) and activation of Akt pathway."
23471579,miR-216a,hsa-mir-216a,MI0000292,Sorafenib,216239,"HepG2, Hep3B, Huh-7, PLC/PRF/5, HCCLM3, Bel-7404, HLE, SK-HEP-1 and SNU-449",-,-,Patients,liver cancer,in vitro and in vivo,Low,Resistant,PTEN and SMAD7,TGF-Beta pathway and the canonical pathway,2013,MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.,"Additionally, activation of the TGF-Beta- and PI3K/Akt-signaling pathways in HCC cells resulted in an acquired resistance to sorafenib, whereas blocking activation of the TGF-Beta pathway overcame miR-216a/217-induced sorafenib resistance and prevented tumor metastases in HCC."
23471579,miR-217,hsa-mir-217,MI0000293,Sorafenib,216239,"HepG2, Hep3B, Huh-7, PLC/PRF/5, HCCLM3, Bel-7404, HLE, SK-HEP-1 and SNU-449",-,-,Patients,liver cancer,in vitro and in vivo,Low,Resistant,PTEN and SMAD7,TGF-Beta pathway and the canonical pathway,2013,MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.,"Additionally, activation of the TGF-Beta- and PI3K/Akt-signaling pathways in HCC cells resulted in an acquired resistance to sorafenib, whereas blocking activation of the TGF-Beta pathway overcame miR-216a/217-induced sorafenib resistance and prevented tumor metastases in HCC."
23484053,miR-10b,hsa-mir-10b,MI0000267,Cisplatin,2767,-,-,mice,Patientss,ovarian cancer,in vitro and in vivo,Low,Sensitive,HDAC4,-,2013,Increased Sensitivity to Chemotherapy Induced by CpGODN Treatment Is Mediated by microRNA Modulation,"Both HDAC4 mRNA and protein levels were significantly reduced in IGROV-1 cells overexpressing hsa-miR-302b. Altogether, these findings indicate that hsa-miR-302b acts as a chemosensitizer in humanovarian carcinoma cells and may represent a biomarker able to predict response to cisplatin treatment. "
23497288,let-7c,hsa-let-7c,MI0000064,Doxorubicin (Adriamycin),31703,-,"VH-64 vs VH-64/ADR, WE-68 vs WE-68/ADR",-,-,The Ewing sarcoma/primitive neuroectodermal tumor,in vitro,High,Resistant,-,-,2013,miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor.,"Among the 46 different miRNAs examined, miR-125b was the most highly upregulated miRNA in the VH-64/ADR cells compared to the parental cells (Figure 1A)."
23497288,miR-125b,hsa-mir-125b-1,MI0000446,Doxorubicin (Adriamycin),31703,-,VH-64 vs VH-64/ADR and WE-68 vs WE-68/ADR,-,-,ewing sarcoma,in vitro,Low,Resistant,p53 and bak,-,2013,contribute to hepatocellular carcinoma ,"When miR-125b was knocked down in EWS cells, both the Dox-resistant and parental cells showed an enhanced sensitivity to doxorubicin."
23497288,miR-125b,hsa-mir-125b-1,MI0000446,Etoposide,36462,-,VH-64 vs VH-64/ADR and WE-68 vs WE-68/ADR,-,-,ewing sarcoma,in vitro,Low,Resistant,p53 and bak,-,2013,miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor.,"When miR-125b was knocked down in EWS cells, both the Dox-resistant and parental cells showed an enhanced sensitivity to doxorubicin."
23497288,miR-125b,hsa-mir-125b-1,MI0000446,Mafosfamide,104746,-,"VH-64 vs VH-64/ADR, WE-68 vs WE-68/ADR",-,-,ewing sarcoma/primitive neuroectodermal tumor,in vitro,High,Resistant,"p53, Bak",-,2013,miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor.,"Among the 46 different miRNAs examined, miR-125b was the most highly upregulated miRNA in the VH-64/ADR cells compared to the parental cells (Figure 1A)."
23497288,miR-125b,hsa-mir-125b-1,MI0000446,Vincristine,5978,-,VH-64 vs VH-64/ADR and WE-68 vs WE-68/ADR,-,-,ewing sarcoma,in vitro,Low,Resistant,p53 and bak,-,2013,miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor.,"When miR-125b was knocked down in EWS cells, both the Dox-resistant and parental cells showed an enhanced sensitivity to doxorubicin."
23497288,miR-93,hsa-mir-93,MI0000095,Doxorubicin (Adriamycin),31703,-,"VH-64 vs VH-64/ADR, WE-68 vs WE-68/ADR",-,-,The Ewing sarcoma/primitive neuroectodermal tumor,in vitro,High,Resistant,-,-,2013,miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor.,"Among the 46 different miRNAs examined, miR-125b was the most highly upregulated miRNA in the VH-64/ADR cells compared to the parental cells (Figure 1A)."
23498169,miR-223,hsa-mir-223,MI0000300,Clopidogrel,60606,-,-,-,Patients,coronary heart disease,in vivo,Low,Sensitive,-,-,2013,Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity.,"Compared with PRI-determined normal-responders, miR-223 expression, but not miR-96, was significantly decreased in low-responders (P = 0.037)."
23506979,miR-181b,hsa-mir-181b-1,MI0000270,Oxaliplatin,5310940,-,HCT116 vs HCT116/OXP and LoVo vs LoVo/OXP,-,Patients,colorectal cancer,in vitro and in vivo,Low,Associated,-,-,2013,High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.,"miR-625-3p, miR-27b and miR-181b are upregulated in oxPt-resistant cells in vitro."
23506979,miR-27b,hsa-mir-27b,MI0000440,Oxaliplatin,5310940,-,HCT116 vs HCT116/OXP and LoVo vs LoVo/OXP,-,Patients,colorectal cancer,in vitro and in vivo,Low,Associated,-,-,2013,High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.,"miR-625-3p, miR-27b and miR-181b are upregulated in oxPt-resistant cells in vitro."
23506979,miR-625,hsa-mir-625,MI0003639,Oxaliplatin,5310940,-,HCT116 vs HCT116/OXP and LoVo vs LoVo/OXP,-,Patients,colorectal cancer,in vitro and in vivo,Low,Associated,-,-,2013,High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.,"miR-625-3p, miR-27b and miR-181b are upregulated in oxPt-resistant cells in vitro."
23525256,miR-1224,hsa-mir-1224,MI0003764,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-1224,hsa-mir-1224,MI0003764,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-1224,hsa-mir-1224,MI0003764,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-1224,hsa-mir-1224,MI0003764,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-1229,hsa-mir-1229,MI0006319,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-1229,hsa-mir-1229,MI0006319,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-1229,hsa-mir-1229,MI0006319,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-1229,hsa-mir-1229,MI0006319,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-1238,hsa-mir-1238,MI0006328,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-1238,hsa-mir-1238,MI0006328,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-1238,hsa-mir-1238,MI0006328,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-1238,hsa-mir-1238,MI0006328,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-1273d,hsa-mir-1273d,MI0014254,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-1273d,hsa-mir-1273d,MI0014254,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-1273d,hsa-mir-1273d,MI0014254,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-1273d,hsa-mir-1273d,MI0014254,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-129,hsa-mir-129-1,MI0000252,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-129,hsa-mir-129-1,MI0000252,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-129,hsa-mir-129-1,MI0000252,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-129,hsa-mir-129-1,MI0000252,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-133b,hsa-mir-133b,MI0000822,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-133b,hsa-mir-133b,MI0000822,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-133b,hsa-mir-133b,MI0000822,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-133b,hsa-mir-133b,MI0000822,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-190,hsa-mir-190a,MI0000486,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-190,hsa-mir-190a,MI0000486,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-190,hsa-mir-190a,MI0000486,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-190,hsa-mir-190a,MI0000486,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-197,hsa-mir-197,MI0000239,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-197,hsa-mir-197,MI0000239,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-197,hsa-mir-197,MI0000239,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-197,hsa-mir-197,MI0000239,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-210,hsa-mir-210,MI0000286,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-210,hsa-mir-210,MI0000286,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-210,hsa-mir-210,MI0000286,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-210,hsa-mir-210,MI0000286,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-22,hsa-mir-22,MI0000078,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-22,hsa-mir-22,MI0000078,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-22,hsa-mir-22,MI0000078,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-22,hsa-mir-22,MI0000078,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-31,hsa-mir-31,MI0000089,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-31,hsa-mir-31,MI0000089,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-31,hsa-mir-31,MI0000089,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-31,hsa-mir-31,MI0000089,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-3131,hsa-mir-3131,MI0014151,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-3131,hsa-mir-3131,MI0014151,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-3131,hsa-mir-3131,MI0014151,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-3131,hsa-mir-3131,MI0014151,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-3149,hsa-mir-3149,MI0014176,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-3149,hsa-mir-3149,MI0014176,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-3149,hsa-mir-3149,MI0014176,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-3149,hsa-mir-3149,MI0014176,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-3162,hsa-mir-3162,MI0014192,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-3162,hsa-mir-3162,MI0014192,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-3162,hsa-mir-3162,MI0014192,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-3162,hsa-mir-3162,MI0014192,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-32,hsa-mir-32,MI0000090,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-32,hsa-mir-32,MI0000090,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-32,hsa-mir-32,MI0000090,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-32,hsa-mir-32,MI0000090,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-4701,hsa-mir-4701,MI0017334,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-4701,hsa-mir-4701,MI0017334,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-4701,hsa-mir-4701,MI0017334,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-4701,hsa-mir-4701,MI0017334,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-4728,hsa-mir-4728,MI0017365,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-4728,hsa-mir-4728,MI0017365,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-4728,hsa-mir-4728,MI0017365,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-4728,hsa-mir-4728,MI0017365,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-4763,hsa-mir-4763,MI0017404,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-4763,hsa-mir-4763,MI0017404,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-4763,hsa-mir-4763,MI0017404,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-4763,hsa-mir-4763,MI0017404,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-486,hsa-mir-486-1,MI0002470,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-486,hsa-mir-486-1,MI0002470,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-486,hsa-mir-486-1,MI0002470,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-486,hsa-mir-486-1,MI0002470,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-501,hsa-mir-501,MI0003185,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-501,hsa-mir-501,MI0003185,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-501,hsa-mir-501,MI0003185,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-501,hsa-mir-501,MI0003185,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-5096,hsa-mir-5096,MI0018004,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-5096,hsa-mir-5096,MI0018004,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-5096,hsa-mir-5096,MI0018004,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-5096,hsa-mir-5096,MI0018004,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-532,hsa-mir-532,MI0003205,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-532,hsa-mir-532,MI0003205,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-532,hsa-mir-532,MI0003205,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-532,hsa-mir-532,MI0003205,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-615,hsa-mir-615,MI0003628,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-615,hsa-mir-615,MI0003628,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-615,hsa-mir-615,MI0003628,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-615,hsa-mir-615,MI0003628,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-766,hsa-mir-766,MI0003836,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-766,hsa-mir-766,MI0003836,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-766,hsa-mir-766,MI0003836,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-766,hsa-mir-766,MI0003836,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-877,hsa-mir-877,MI0005561,5-Fluorouracil,3385,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-877,hsa-mir-877,MI0005561,Cisplatin,2767,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-877,hsa-mir-877,MI0005561,Doxorubicin (Adriamycin),31703,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23525256,miR-877,hsa-mir-877,MI0005561,Vincristine,5978,-,SGC-7901 vs SGC?7901/5?FU,-,-,gastric cancer,in vitro,High,Resistant,-,-,2013,microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line,"The results revealed that 18 miRNAs were downregulated >2-fold in the SGC-7901/5-Fu cells compared with the SGC-7901 cells, while 9 miRNAs were upregulated >2-fold in the SGC-7901/5-Fu cells (Table II). "
23526568,miR-195,hsa-mir-195,MI0000489,Doxorubicin (Adriamycin),31703,-,HT-29 vs HT-29/ADR and LOVO vs LOVO/ADR,-,-,colon cancer,in vitro,Low,Sensitive,BCL2L2,-,2015,MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA.,"Furthermore, down-regulation of miR-195 conferred DOX resistance in parental cells and reduced cell apoptosis activity, while over-expression of miR-195 sensitized resistant cells to DOX and enhanced cell apoptosis activity, all of which can be partly rescued by BCL2L2 siRNA and cDNA expression."
23526655,miR-128,hsa-mir-128-1,MI0000447,Doxorubicin (Adriamycin),31703,MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Resistant,Bax,-,2013,Downregulation of miRNA-128 sensitises breast cancer cell to chemodrugs by targeting Bax.,Inhibition of miR-128 in breast cancer cells was sufficient to sensitise them to drugs and activate caspase and the apoptotic pathway.
23526655,miR-128,hsa-mir-128-1,MI0000447,Etoposide,36462,MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Resistant,Bax,-,2013,Downregulation of miRNA-128 sensitises breast cancer cell to chemodrugs by targeting Bax.,Inhibition of miR-128 in breast cancer cells was sufficient to sensitise them to drugs and activate caspase and the apoptotic pathway.
23527180,miR-125b,hsa-mir-125b-1,MI0000446,Bortezomib,387447,SeAx and MyLa,-,-,-,cutaneous T-cell lymphomas,in vitro,Low,Resistant,MAD4,-,2013,cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas.,Overexpression of cMyc repressed miR-125b-5p transcription and sensitized lymphoma cells to bortezomib. 
23527297,miR-21,hsa-mir-21,MI0000077,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Resistant,-,-,2013,Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro.,The co-delivery of anti-miR-21 and ADR was expected to enhance the anticancer activity of ADR through efficient inhibition of miR-21 expression and efficient delivery of ADR
23546450,miR-200c,hsa-mir-200c,MI0000650,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Sensitive,-,"ZEB1, E-cadherin, PTEN and Akt signaling",2013,miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling.,"More importantly, we demonstrated that the gain of miRNA-200c results in an increased sensitivity of cells to ADR, downregulation of ZEB1, upregulation of E-cadherin and PTEN, and inactivation of Akt signaling."
23554878,miR-146a,hsa-mir-146a,MI0000477,Cisplatin,2767,OVCAR-8 and SKOV-3,-,-,-,ovarian cancer,in vitro,Low,Resistant,-,-,2013,Identification of ovarian cancer metastatic miRNAs.,Both miR-146a and miR-150 increase the number of residual surviving cells by 2-4 fold when challenged with lethal cisplatin concentrations.
23554878,miR-150,hsa-mir-150,MI0000479,Cisplatin,2767,OVCAR-8 and SKOV-3,-,-,-,ovarian cancer,in vitro,Low,Resistant,-,-,2013,Identification of ovarian cancer metastatic miRNAs.,Both miR-146a and miR-150 increase the number of residual surviving cells by 2-4 fold when challenged with lethal cisplatin concentrations.
23555954,miR-146a,hsa-mir-146a,MI0000477,Afatinib,10184653,"H358, H1650 and H1975",-,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,EGFR,-,2013,"miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells.","On the other hand, miR-146a enhanced the inhibition of cell proliferation by drugs targeting EGFR, including both TKIs (gefitinib, erlotinib, and afatinib) and a monoclonal antibody (cetuximab)."
23555954,miR-146a,hsa-mir-146a,MI0000477,Cetuximab,91820602,"H358, H1650 and H1975",-,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,EGFR,-,2013,"miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells.","On the other hand, miR-146a enhanced the inhibition of cell proliferation by drugs targeting EGFR, including both TKIs (gefitinib, erlotinib, and afatinib) and a monoclonal antibody (cetuximab)."
23555954,miR-146a,hsa-mir-146a,MI0000477,Erlotinib,176870,"H358, H1650 and H1975",-,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,EGFR,-,2013,"miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells.","On the other hand, miR-146a enhanced the inhibition of cell proliferation by drugs targeting EGFR, including both TKIs (gefitinib, erlotinib, and afatinib) and a monoclonal antibody (cetuximab)."
23555954,miR-146a,hsa-mir-146a,MI0000477,Gefitinib,123631,"H358, H1650 and H1975",-,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,EGFR,-,2013,"miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells.","On the other hand, miR-146a enhanced the inhibition of cell proliferation by drugs targeting EGFR, including both TKIs (gefitinib, erlotinib, and afatinib) and a monoclonal antibody (cetuximab)."
23562878,let-7c,hsa-let-7c,MI0000064,Docetaxel,148124,-,SPC-A1 vs SPC-A1/DOC and H1299 vs H1299/DOC,Mice,Patients,lung adenocarcinoma,in vitro and in vivo,Low,Sensitive,Bcl-xL,-,2013,Let-7c governs the acquisition of chemo- or radioresistance and epithelial-to-mesenchymal transition phenotypes in docetaxel-resistant lung adenocarcinoma.,Ectopic let-7c expression increased the in vitro and in vivo chemo- or radiosensitivity of DTX-resistant LAD cells through enhanced apoptosis.
23564788,miR-21,hsa-mir-21,MI0000077,Gemcitabine,60750,Panc-1,-,-,-,pancreatic cancer,in vitro,Low,Resistant,-,PDCD4,2013,Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol.,Transfection of miR-21 mimic abrogated I3C-induced sensitivity to gemcitabine.
23574723,miR-143,hsa-mir-143,MI0000459,Oxaliplatin,5310940,SW1116 and HEK293T,-,-,-,colorectal cancer,in vitro,Low,Sensitive,IGF-IR,-,2013,MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers.,"Overexpression of miR-143 inhibited cell proliferation, migration, tumor growth and angiogenesis and increased chemosensitivity to oxaliplatin treatment in an IGF-IR-dependent manner."
23584479,miR-223,hsa-mir-223,MI0000300,5-Fluorouracil,3385,MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Sensitive,STMN-1,-,2014,Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.,We found that miR-223 exogenous expression sensitizes breast and colon cancer cell lines expressing mutant p53 to treatment with DNA-damaging drugs.
23584479,miR-223,hsa-mir-223,MI0000300,5-Fluorouracil,3385,SW480,-,-,-,colon cancer,in vitro,Low,Sensitive,STMN-1,-,2014,Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.,We found that miR-223 exogenous expression sensitizes breast and colon cancer cell lines expressing mutant p53 to treatment with DNA-damaging drugs.
23584479,miR-223,hsa-mir-223,MI0000300,Cisplatin,2767,MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Sensitive,STMN-1,-,2014,Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.,We found that miR-223 exogenous expression sensitizes breast and colon cancer cell lines expressing mutant p53 to treatment with DNA-damaging drugs.
23584479,miR-223,hsa-mir-223,MI0000300,Cisplatin,2767,SW480,-,-,-,colon cancer,in vitro,Low,Sensitive,STMN-1,-,2014,Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.,We found that miR-223 exogenous expression sensitizes breast and colon cancer cell lines expressing mutant p53 to treatment with DNA-damaging drugs.
23603256,miR-19a,hsa-mir-19a,MI0000073,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/VCR and SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,Low,Resistant,PTEN,mdr1 and P-gp,2013,MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN.,Our results also showed that miR-19a/b upregulation decreased the sensitivity of gastric cancer cells to anticancer drugs.
23603256,miR-19a,hsa-mir-19a,MI0000073,Vincristine,5978,-,SGC7901 vs SGC7901/VCR and SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,Low,Resistant,PTEN,mdr1 and P-gp,2013,MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN.,Our results also showed that miR-19a/b upregulation decreased the sensitivity of gastric cancer cells to anticancer drugs.
23603256,miR-19b,hsa-mir-19b-1,MI0000074,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/VCR and SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,Low,Resistant,PTEN,mdr1 and P-gp,2013,MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN.,Our results also showed that miR-19a/b upregulation decreased the sensitivity of gastric cancer cells to anticancer drugs.
23603256,miR-19b,hsa-mir-19b-1,MI0000074,Vincristine,5978,-,SGC7901 vs SGC7901/VCR and SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,Low,Resistant,PTEN,mdr1 and P-gp,2013,MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN.,Our results also showed that miR-19a/b upregulation decreased the sensitivity of gastric cancer cells to anticancer drugs.
23606360,miR-125b,hsa-mir-125b-1,MI0000446,Chemotherapy,-,-,-,-,Patients,breast cancer,in vivo,Low,Resistant,-,-,2013,miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype.,These data indicate that SP cells overexpress miR-125b and the high miR-125b expression in chemoresistant cancer cells is dueto high percentage of SP cells.
23610125,miR-221,hsa-mir-221,MI0000298,AGRO100,56842234,MCF-7,-,-,-,breast cancer,in vitro,Low,Resistant,-,-,2013,In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.,Reexpression of exogenous miR-221 and miR-222 in MCF-7 cells partially abrogated the inhibitory effect of AS1411 on cell growth.
23610125,miR-221,hsa-mir-221,MI0000298,Fulvestrant,104741,-,MCF-7 vs MCF-7/FUL,-,-,breast cancer,in vitro,Low,Resistant,-,-,2013,In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.,Knockdown of miR-221 and miR-222 by 2-O-methyl-antagonist reduced the growth of MCF-7F to the same extent as NCL-targeting treatment.
23610125,miR-222,hsa-mir-222,MI0000299,AGRO100,56842234,MCF-7,-,-,-,breast cancer,in vitro,Low,Resistant,-,-,2013,In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.,Reexpression of exogenous miR-221 and miR-222 in MCF-7 cells partially abrogated the inhibitory effect of AS1411 on cell growth.
23610125,miR-222,hsa-mir-222,MI0000299,Fulvestrant,104741,-,MCF-7 vs MCF-7/FUL,-,-,breast cancer,in vitro,Low,Resistant,-,-,2013,In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.,Knockdown of miR-221 and miR-222 by 2-O-methyl-antagonist reduced the growth of MCF-7F to the same extent as NCL-targeting treatment.
23613588,miR-122,hsa-mir-122,MI0000442,pegIFN/RBV therapy,-,-,-,-,Patients,chronic hepatitis (CH) C,in vivo,Low,Sensitive,-,-,2013,Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C.,"In conclusion, serum miR-122 may serve as a surrogate of hepatic miR-122, and a higher pretreatment serum miR-122 level can help predict virologic responses to pegylated IFN plus ribavirin therapy."
23613938,miR-16,hsa-mir-16-1,MI0000070,Vincristine,5978,-,NF-3xmir16 vs NF-3xmir16/VCR,Mice,-,gastric cancer,in vitro and in vivo,Low,Associated,-,-,2013,Noninvasive visualization of microRNA-16 in the chemoresistance of gastric cancer using a dual reporter gene imaging system.,"In accordance with the reporter gene system data, Q-PCR showed decreased miRNA-16 levels in NF-3xmir16/VCR compared to its counterpart NF-3xmir16 cells."
23613955,miR-203,hsa-mir-203a,MI0000283,Imatinib,5291,BaF3-BCR/ABL and BaF3-BCR/ABL(T315I),-,-,-,chronic myelogenous leukemia,in vitro,Low,Sensitive,-,BCR/ABL,2013,Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate.,"Furthermore, miR-203 increased sensitivity to imatinib in BaF3-BCR/ABL(T315I) cells, thereby antagonizing the main mechanism of resistance to imatinib."
23619912,miR-142,hsa-mir-142,MI0000458,5-Fluorouracil,3385,Caco2 and SW1116,-,-,-,colon cancer,in vitro,Low,Sensitive,"CD133, ABCG2 and Lgr5",-,2013,"MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells.","Transfection of miR-142-3p mimics in colon cancer cells downregulated cyclin D1 expression, induced G1 phase cell cycle arrest, and elevated the sensitivity of the cells to 5-fluorouracil."
23625774,miR-302a,hsa-mir-302a,MI0000738,Cisplatin,2767,NT2 and NCCIT,-,-,-,testicular embryonal carcinoma,in vitro,Low,Sensitive,-,"P21, Oct4, Sox2, and Nanog",2013,MicroRNA-302a sensitizes testicular embryonal carcinoma cells to cisplatin-induced cell death.,Up-regulation of miR-302a significantly increased the sensitivity of NT2 cells to cisplatin by enhancing cisplatin-induced G2/M phase arrest and the subsequent progression to apoptosis. 
23626803,miR-200b,hsa-mir-200b,MI0000342,Fulvestrant,104741,"MCF-7, LCC1, LCC2, LCC9, and LY2",-,-,-,breast cancer,in vitro,Low,Sensitive,ZEB1 ,-,2013,Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.,"Further, miR-200b and miR-200c overexpression sensitized LY2 cells to growth inhibition by estrogen receptor (ER) antagonists TAM and fulvestrant."
23626803,miR-200b,hsa-mir-200b,MI0000342,Tamoxifen,2733526,"MCF-7, LCC1, LCC2, LCC9, and LY2",-,-,-,breast cancer,in vitro,Low,Sensitive,ZEB1 ,-,2013,Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.,"Further, miR-200b and miR-200c overexpression sensitized LY2 cells to growth inhibition by estrogen receptor (ER) antagonists TAM and fulvestrant."
23626803,miR-200b,hsa-mir-200b,MI0000342,Tamoxifen,2733526,"MCF-7, LCC1, LCC2, LCC9 and LY2",-,-,-,breast cancer,in vitro,Low,Sensitive,ZEB1 ,-,2013,Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.,"Further, miR-200b and miR-200c overexpression sensitized LY2 cells to growth inhibition by estrogen receptor (ER) antagonists TAM and fulvestrant."
23626803,miR-200c,hsa-mir-200c,MI0000650,Fulvestrant,104741,"MCF-7, LCC1, LCC2, LCC9, and LY2",-,-,-,breast cancer,in vitro,Low,Sensitive,ZEB1 ,-,2013,Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.,"Further, miR-200b and miR-200c overexpression sensitized LY2 cells to growth inhibition by estrogen receptor (ER) antagonists TAM and fulvestrant."
23626803,miR-200c,hsa-mir-200c,MI0000650,Tamoxifen,2733526,"MCF-7, LCC1, LCC2, LCC9, and LY2",-,-,-,breast cancer,in vitro,Low,Sensitive,ZEB1 ,-,2013,Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.,"Further, miR-200b and miR-200c overexpression sensitized LY2 cells to growth inhibition by estrogen receptor (ER) antagonists TAM and fulvestrant."
23626803,miR-200c,hsa-mir-200c,MI0000650,Tamoxifen,2733526,"MCF-7, LCC1, LCC2, LCC9 and LY2",-,-,-,breast cancer,in vitro,Low,Sensitive,ZEB1 ,-,2013,Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.,"Further, miR-200b and miR-200c overexpression sensitized LY2 cells to growth inhibition by estrogen receptor (ER) antagonists TAM and fulvestrant."
23627607,miR-155,hsa-mir-155,MI0000681,Paclitaxel,36314,-,SKOV3 vs SKOV3-TR30,-,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples,The miRNA microarray revealed that 39 miRNAs showed more than 1.5 fold deregulation between the pacilitaxel resistant and sensitive cell lines (Figure 1A).
23627607,miR-22,hsa-mir-22,MI0000078,Paclitaxel,36314,-,SKOV3 vs SKOV3-TR30,-,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples,The miRNA microarray revealed that 39 miRNAs showed more than 1.5 fold deregulation between the pacilitaxel resistant and sensitive cell lines (Figure 1A).
23627607,miR-320,hsa-mir-320a,MI0000542,Paclitaxel,36314,-,SKOV3 vs SKOV3-TR30,-,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples,The miRNA microarray revealed that 39 miRNAs showed more than 1.5 fold deregulation between the pacilitaxel resistant and sensitive cell lines (Figure 1A).
23627607,miR-640,hsa-mir-640,MI0003655,Paclitaxel,36314,-,SKOV3 vs SKOV3-TR30,-,Patientss,ovarian cancer,in vitro and in vivo,High,Resistant,-,-,2013,MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples,The miRNA microarray revealed that 39 miRNAs showed more than 1.5 fold deregulation between the pacilitaxel resistant and sensitive cell lines (Figure 1A).
23627607,miR-9,hsa-mir-9-1,MI0000466,Paclitaxel,36314,-,SKOV3 vs SKOV3-TR30,-,Patientss,ovarian cancer,in vitro and in vivo,High,Resistant,-,-,2013,MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples,The miRNA microarray revealed that 39 miRNAs showed more than 1.5 fold deregulation between the pacilitaxel resistant and sensitive cell lines (Figure 1A).
23640248,miR-135a,hsa-miR-135a-5p,MI0000452,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung cancer,in vitro,Low,Sensitive,MCL1,-,2013,miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1.,In vitro drug sensitivity assay demonstrated that overexpression of miR-135a/b sensitized A549/CDDP cells to cisplatin.
23640248,miR-135b,hsa-mir-135b,MI0000810,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung cancer,in vitro,Low,Sensitive,MCL1,-,2013,miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1.,In vitro drug sensitivity assay demonstrated that overexpression of miR-135a/b sensitized A549/CDDP cells to cisplatin.
23645289,miR-181b,hsa-mir-181b-1,MI0000270,Temozolomide,5394,U87 and U251,-,-,Patients,glioma,in vitro and in vivo,Low,Sensitive,MEK1,-,2013,miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1.,miR-181b combined with temozolomide enhanced glioma cell sensitivity and apoptosis.
23676502,let-7a,hsa-let-7a-1,MI0000060,Cytarabine,6253,OCI-AML3,-,Mice,-,acute myeloid leukemia,in vitro and in vivo,Low,Sensitive,-,-,2013,CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.,"Overexpression of let-7a in AML cell lines was associated with decreased c-Myc and BCL-XL protein expression and enhanced chemosensitivity, both in vitro and in vivo."
23686318,miR-1291,hsa-mir-1291,MI0006353,Doxorubicin (Adriamycin),31703,PANC-1,-,-,-,-,in vitro,Low,Sensitive,ABCC1,-,2013,Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1.,"In addition, hsa-miR-1291-directed downregulation of ABCC1 led to a greater intracellular drug accumulation and sensitized the cells to doxorubicin."
23689423,miR-181a,hsa-mir-181a-2,MI0000269,intensive induction chemotherapy based on cytarabine and idarubicine,-,-,-,-,Patientss,acute myeloid leukemia,in vivo,High,Resistant,-,-,2013,MicroRNA Profiling in Chemoresistant and Chemosensitive Acute Myeloid Leukemia,"We found 3 upregulated miRNAs, miR-363 (FC = 4.2,q = 0.007), miR-532-5p (FC = 2.7, q = 0.007) and miR-342-3p (FC = 2.02, q = 0.02), which showed a significant difference in chemorefractory compared to chemosensitive patients ( table 2 )"
23689423,miR-342,hsa-mir-342,MI0000805,Paclitaxel,36314,-,SKOV3 vs SKOV3-TR30,-,Patientss,ovarian cancer,in vitro and in vivo,High,Resistant,-,-,2013,MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples,The miRNA microarray revealed that 39 miRNAs showed more than 1.5 fold deregulation between the pacilitaxel resistant and sensitive cell lines (Figure 1A).
23689423,miR-363,hsa-mir-363,MI0000764,intensive induction chemotherapy based on cytarabine and idarubicine,-,-,-,-,Patientss,acute myeloid leukemia,in vivo,High,Resistant,-,-,2013,MicroRNA Profiling in Chemoresistant and Chemosensitive Acute Myeloid Leukemia,"We found 3 upregulated miRNAs, miR-363 (FC = 4.2,q = 0.007), miR-532-5p (FC = 2.7, q = 0.007) and miR-342-3p (FC = 2.02, q = 0.02), which showed a significant difference in chemorefractory compared to chemosensitive patients ( table 2 )"
23689423,miR-532,hsa-mir-532,MI0003205,intensive induction chemotherapy based on cytarabine and idarubicine,-,-,-,-,Patientss,acute myeloid leukemia,in vivo,High,Resistant,-,-,2013,MicroRNA Profiling in Chemoresistant and Chemosensitive Acute Myeloid Leukemia,"We found 3 upregulated miRNAs, miR-363 (FC = 4.2,q = 0.007), miR-532-5p (FC = 2.7, q = 0.007) and miR-342-3p (FC = 2.02, q = 0.02), which showed a significant difference in chemorefractory compared to chemosensitive patients ( table 2 )"
23696927,miR-375,hsa-mir-375,MI0000783,RAWQ01 (Ruthenium),444795,"OVCAR3, HO-8910 and SK-OV-3",-,Mice,-,ovarian cancer,in vitro and in vivo,Low,Sensitive,-,-,2013,Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancer.,Mir-375 enhanced the in vitro sensitivity of ovarian cancer cells to RAWQ01 by inducing apoptosis. Mir-375 also increased the in vivo chemosensitivity of ovarian cancer cells to RAWQ01.
23697367,miR-106b*,hsa-mir-106b,MI0000734,Carboplatin,38904,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-106b*,hsa-mir-106b,MI0000734,Paclitaxel,36314,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-19a,hsa-mir-19a,MI0000073,Carboplatin,38904,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Resistant,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-19a,hsa-mir-19a,MI0000073,Paclitaxel,36314,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Resistant,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-217,hsa-mir-217,MI0000293,Carboplatin,38904,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Resistant,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-217,hsa-mir-217,MI0000293,Paclitaxel,36314,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Resistant,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-302d,hsa-mir-302d,MI0000774,Carboplatin,38904,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-302d,hsa-mir-302d,MI0000774,Paclitaxel,36314,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-483,hsa-mir-483,MI0002467,Carboplatin,38904,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-483,hsa-mir-483,MI0002467,Paclitaxel,36314,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-484,hsa-mir-484,MI0002468,Carboplatin,38904,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-484,hsa-mir-484,MI0002468,Paclitaxel,36314,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-491,hsa-mir-491,MI0003126,Carboplatin,38904,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-491,hsa-mir-491,MI0003126,Paclitaxel,36314,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-592,hsa-mir-592,MI0003604,Carboplatin,38904,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-592,hsa-mir-592,MI0003604,Paclitaxel,36314,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-642,hsa-mir-642a,MI0003657,Carboplatin,38904,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive, VEGFB,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-642,hsa-mir-642a,MI0003657,Paclitaxel,36314,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive, VEGFB,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-653,hsa-mir-653,MI0003674,Carboplatin,38904,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-653,hsa-mir-653,MI0003674,Paclitaxel,36314,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-671,hsa-mir-671,MI0003760,Carboplatin,38904,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-671,hsa-mir-671,MI0003760,Paclitaxel,36314,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-744,hsa-mir-744,MI0005559,Carboplatin,38904,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23697367,miR-744,hsa-mir-744,MI0005559,Paclitaxel,36314,"MDAH-2274, and SKOV-3",-,mice,Patientss,ovarian cancer,in vitro and in vivo,High,Sensitive,-,-,2013,A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis,"To investigate whether miRs could predict serous ovarian carcinoma (EOC) chemoresistance, we analyzed the expression of 676 miRs in the training set (Table S1)."
23700794,miR-10a*,hsa-mir-10a,MI0000266,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-125a,hsa-mir-125a,MI0000469,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-132*,hsa-mir-132,MI0000449,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-136,hsa-mir-136,MI0000475,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-147,hsa-mir-147a,MI0000262,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-155*,hsa-mir-155,MI0000681,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-181d,hsa-mir-181d,MI0003139,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-183,hsa-mir-183,MI0000273,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-186*,hsa-mir-186,MI0000483,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-195*,hsa-mir-195,MI0000489,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-198,hsa-mir-198,MI0000240,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-320,hsa-mir-320a,MI0000542,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-374a,hsa-mir-374a,MI0000782,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-375,hsa-mir-375,MI0000783,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-518c*,hsa-mir-518c,MI0003159,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-541*,hsa-mir-541,MI0005539,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-551b*,hsa-mir-551b,MI0003575,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Resistant,"HMGA2, Bcl-XL and Bcl-2",-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-601,hsa-mir-601,MI0003614,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-876,hsa-mir-876,MI0005542,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-886,hsa-mir-886,MI0005527,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2012,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2,Every sample was repeated four times to improve miChip accuracy. Fourteen upregulated miRNAs (> 2) and 8 downregulated miRNAs (< 0.5) were observed in A549 cells compared to that in 549/DDP.
23700794,miR-98,hsa-mir-98,MI0000100,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,Low,Sensitive,HMGA2,Bcl-XL and Bcl-2,2013,MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2.,"We found that elevated expression of miR-98 led to a higher sensitivity of A549/DDP cells to cisplatin, and the protein level of HMGA2, was clearly up-regulated in both A549/DDP and A549 cells by miR-98."
23721345,miR-214,hsa-mir-214,MI0000290,Doxorubicin (Adriamycin),31703,ECA109,-,-,-,esophageal squamous cell carcinoma,in vitro,Low,Resistant,-,-,2013,Prediction value of miR-483 and miR-214 in prognosis and multidrug resistance of esophageal squamous cell carcinoma.,"Downregulation of miR-483 and miR-214 could confer sensitivity of both P-glycoprotein-related and P-glycoprotein-nonrelated drugs to esophageal cancer cells, and it might induce increased accumulation of adriamycin (ADR) and decreased amount of ADR released."
23721345,miR-483,hsa-mir-483,MI0002467,Doxorubicin (Adriamycin),31703,ECA109,-,-,-,esophageal squamous cell carcinoma,in vitro,Low,Resistant,-,-,2013,Prediction value of miR-483 and miR-214 in prognosis and multidrug resistance of esophageal squamous cell carcinoma.,"Downregulation of miR-483 and miR-214 could confer sensitivity of both P-glycoprotein-related and P-glycoprotein-nonrelated drugs to esophageal cancer cells, and it might induce increased accumulation of adriamycin (ADR) and decreased amount of ADR released."
23734815,miR-485,hsa-mir-485,MI0002469,Fludarabine,657237,DU-145,-,-,-,prostate cancer,in vitro,Low,Resistant,NF-YB,CCNB2 and MDR1,2013,Fludarabine treatment favors the retention of miR-485-3p by prostate cancer cells: implications for survival.,We speculate that the retention of miR-485-3p was a side effect of fludarabine treatment in that the high intracellular level of miR-485-3p plays a role in the sensitivity to fludarabine.
23744359,miR-129,hsa-mir-129-1,MI0000252,5-Fluorouracil,3385,HCT-116,-,Mice,-,colorectal cancer,in vitro and in vivo,Low,Sensitive,BCL2,-,2013,miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer.,"More importantly, we demonstrated that miR-129 enhanced the cytotoxic effect of 5-fluorouracil both in vitro and in vivo."
23750239,miR-26a,hsa-mir-26a-1,MI0000083,Paclitaxel,36314,"MDA-MB-231, MCF-7, MDA-MB-435, MDA-MB-468, MCF-10A and 184A1",-,-,-,breast cancer,in vitro,Low,Sensitive,MCL-1,-,2013,MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1.,It was further explored that miR-26a increased sensitivity of breast cancer cells to paclitaxel in which MCL-1 was involved.
23757351,miR-223,hsa-mir-223,MI0000300,Cisplatin,2767,OE33 and  JHesoAD1,-,-,Patients,esophageal adenocarcinoma,in vitro and in vivo,Low,Sensitive,PARP1,-,2013,MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1.,Increased sensitivity to chemotherapy was observed in cells with enforced miR-223 expression and reduced PARP1.
23757351,miR-223,hsa-mir-223,MI0000300,Doxorubicin (Adriamycin),31703,OE33 and JHesoAD1,-,-,Patients,esophageal adenocarcinoma,in vitro and in vivo,Low,Sensitive,PARP1,-,2013,MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1.,Increased sensitivity to chemotherapy was observed in cells with enforced miR-223 expression and reduced PARP1.
23757351,miR-223,hsa-mir-223,MI0000300,Mitomycin C,5746,OE33 and  JHesoAD1,-,-,Patients,esophageal adenocarcinoma,in vitro and in vivo,Low,Sensitive,PARP1,-,2013,MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1.,Increased sensitivity to chemotherapy was observed in cells with enforced miR-223 expression and reduced PARP1.
23759586,miR-125b,hsa-mir-125b-1,MI0000446,Dexamethasone,5743,-,MM vs MM.1S and MM vs MM.1R,-,-,multiple myeloma,in vitro,Low,Resistant,-,-,2013,Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression.,"Use of antisense miR-125b transcripts enhanced expression of pro-apoptotic p53, repressed expression of anti-apoptotic SIRT1 and, importantly, significantly enhanced dexamethasone-induced cell death responses in MM."
23760062,miR-195,hsa-mir-195,MI0000489,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,Patients,breast cancer,in vitro and in vivo,Low,Sensitive,Raf-1,-,2013,Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1.,"Induction of miR-195 expression promoted tumor cell apoptosis and inhibited breast cancer cell viability, but induced the sensitivity of breast cancer cells to Adriamycin treatment"
23760980,miR-200a,hsa-mir-200a,MI0000737,Curcumin,969516,HepG2 and HepJ5,-,-,-,hepatocellular carcinoma,in vitro,Low,Resistant,-,-,2013,MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells.,The MTT assay revealed that the overexpression of miR-200a/b in HepJ5 cells conferred enhanced resistance to curcumin treatment compared with the control cells.
23760980,miR-200b,hsa-mir-200b,MI0000342,Curcumin,969516,HepG2 and HepJ5,-,-,-,hepatocellular carcinoma,in vitro,Low,Resistant,-,-,2013,MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells.,The MTT assay revealed that the overexpression of miR-200a/b in HepJ5 cells conferred enhanced resistance to curcumin treatment compared with the control cells.
23778521,miR-210,hsa-mir-210,MI0000286,Paclitaxel,36314,SiHa and Cask,-,mice,Patientss,cervical cancer,in vitro and in vivo,Low,Resistant,-,-,2013,miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer,Forced overexpression of miR-375 in cervical cancer cells decreased paclitaxel sensitivity in vitro and in vivo.
23778521,miR-375,hsa-mir-375,MI0000783,Paclitaxel,36314,SiHa and Caski-blank,-,Mice,-,cervical cancer,in vitro and in vivo,Low,Resistant,-,-,2013,miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer.,Forced overexpression of miR-375 in cervical cancer cells decreased paclitaxel sensitivity in vitro and in vivo.
23780424,miR-10b*,hsa-mir-10b,MI0000267,5-Fluorouracil,3385,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Sensitive,-,-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-10b*,hsa-mir-10b,MI0000267,Cisplatin,2767,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Sensitive,-,-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-10b*,hsa-mir-10b,MI0000267,Vincristine,5978,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Sensitive,-,-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-25*,hsa-mir-25,MI0000082,5-Fluorouracil,3385,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Resistant,"NUPR1, HTRA1, and RGS10",-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-25*,hsa-mir-25,MI0000082,Cisplatin,2767,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Resistant,"NUPR1, HTRA1, and RGS10",-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-25*,hsa-mir-25,MI0000082,Vincristine,5978,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Resistant,"NUPR1, HTRA1, and RGS10",-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-424*,hsa-mir-424,MI0001446,5-Fluorouracil,3385,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Resistant,NUPR1,-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-424*,hsa-mir-424,MI0001446,Cisplatin,2767,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Resistant,NUPR1,-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-424*,hsa-mir-424,MI0001446,Vincristine,5978,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Resistant,NUPR1,-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-494,hsa-mir-494,MI0003134,5-Fluorouracil,3385,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Sensitive,"HTRA1, and RGS10",-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-494,hsa-mir-494,MI0003134,Cisplatin,2767,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Sensitive,"HTRA1, and RGS10",-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-494,hsa-mir-494,MI0003134,Vincristine,5978,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Sensitive,"HTRA1, and RGS10",-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-923,hsa-mir-923,MI0005715,5-Fluorouracil,3385,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Sensitive,-,-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-923,hsa-mir-923,MI0005715,Cisplatin,2767,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Sensitive,-,-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-923,hsa-mir-923,MI0005715,Vincristine,5978,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Sensitive,-,-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-93,hsa-mir-93,MI0000095,5-Fluorouracil,3385,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Sensitive,-,-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-93,hsa-mir-93,MI0000095,Cisplatin,2767,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Sensitive,-,-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-93,hsa-mir-93,MI0000095,Vincristine,5978,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Sensitive,-,-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-93*,hsa-mir-93,MI0000095,5-Fluorouracil,3385,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Sensitive,-,-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-93*,hsa-mir-93,MI0000095,Cisplatin,2767,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Sensitive,-,-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780424,miR-93*,hsa-mir-93,MI0000095,Vincristine,5978,-,Hep2 vs Hep2/v,-,-,laryngeal cancer ,in vitro,High,Sensitive,-,-,2013,Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells,A total of 7 differentially expressed miRNAs were identified when Hep-2 and Hep-2/v cells were compared by microarray analysis (Table 1 and Figure 3A).
23780685,miR-181a,hsa-mir-181a-2,MI0000269,Mitoxantrone,4212,-,MCF-7 vs MCF-7/MIX,Mice,-,breast cancer,in vitro and in vivo,Low,Sensitive,BCRP and ABCG2,-,2013,MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).,"Overexpression of miR-181a down-regulated BCRP expression, and sensitized MX-resistant MCF-7/MX cells to MX."
23792642,miR-17,hsa-mir-17,MI0000071,Temozolomide,5394,T98G,-,-,-,glioblastoma,in vitro,Low,Resistant,ATG7,-,2013,"microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells.","Furthermore, the autophagy activation by anti-miR-17 resulted in a decrease of the threshold resistance at temozolomide doses in T98G cells, while miR-17 modulation in U373-MG glioblastoma cells resulted in a sensitization to low ionizing radiation doses."
23794259,miR-22,hsa-mir-22,MI0000078,Pemetrexed,446556,-,-,-,Patients,non-small cell lung cancer,in vivo,Low,Resistant,-,-,2014,"Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer.",The correlation between high expression of miR-22 in whole blood and the lack of response in pemetrexed treated NSCLC Patient indicates that miR-22 could represent a novel predictive biomarker for pemetrexed-based treatment.
23799850,miR-320c,hsa-mir-320c-1,MI0003778,Gemcitabine,60750,-,MiaPaCa2 vs MiaPaCa2/GEM and PSN1 vs PSN1/GEM,-,Patients,pancreatic cancer,in vitro and in vivo,Low,Resistant,SMARCC1,-,2013,miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.,miR-320c induced resistance to gemcitabine in MiaPaCa2.
23806108,let-7b,hsa-let-7b,MI0000063,Cisplatin,2767,-,U251 vs U251/CDDP,-,-,glioblastoma,in vitro,Low,Sensitive,cyclin D1,-,2013,Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma.,"Transfection of Let-7b mimics greatly re-sensitized U251R cells to cisplatin, while transfection of other miRNAs has no effect or slightly effect."
23806972,miR-200c,hsa-mir-200c,MI0000650,Docetaxel,148124,BGC-823,-,Mice,-,gastric cancer,in vitro and in vivo,Low,Sensitive,TUBB3,CD44,2013,Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles.,The miR-200c/DOC NPs prominently suppressed in vivo tumor growth with elevated miR-200c and E-cadherin levels and down-regulated TUBB3 and CD44 expressions. 
23807165,miR-106a,hsa-mir-106a,MI0000113,Paclitaxel,36314,"SKOV3 and Skpac( SKpac-8, -10, -11, and -12 )",-,-,-,ovarian cancer,in vitro,Low,Resistant,"ZEB1, BCL10 and caspase-7",-,2013,Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.,"Transfection with anti-miR-106a or pre-miR-591 resensitized PTX-resistant SKpac cells to PTX by enhancing apoptosis (23 and 42% increase), and inhibited their cell migration (43 and 56% decrease) and proliferation (64 and 65% decrease)."
23807165,miR-591,hsa-mir-591,MI0003603,Paclitaxel,36314,"SKOV3 and Skpac( SKpac-8, -10, -11, and -12 )",-,-,-,ovarian cancer,in vitro,Low,Resistant,"ZEB1, BCL10 and caspase-7",-,2013,Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.,"Transfection with anti-miR-106a or pre-miR-591 resensitized PTX-resistant SKpac cells to PTX by enhancing apoptosis (23 and 42% increase), and inhibited their cell migration (43 and 56% decrease) and proliferation (64 and 65% decrease)."
23816136,miR-381,hsa-mir-381,MI0000789,5-Fluorouracil,3385,HK-2 and 786-O,-,-,-,renal cancer,in vitro,Low,Sensitive,WEE1,-,2013,"miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O.",We showed that miR-381 combined with 5-FU inhibited proliferation and potentiated the anti-tumour efficacies of 5-FU at tolerated concentration in vitro.
23818358,miR-17,hsa-mir-17,MI0000071,Dasatinib,3062316,K562 and IMA-3,-,-,-,chronic myeloid leukemia,in vitro,Low,Associated,-,-,2013,miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells.,"The results revealed significant increase in the expression levels of miR-17 in imatinib sensitive and resistant cells compared to peripheral blood mononuclear cells (PBMCs). On the other hand, significant decrease was observed in miR-17 levels in response to imatinib, nilotinib and dasatinib."
23818358,miR-17,hsa-mir-17,MI0000071,Imatinib,5291,-,K562 vs K562/IMA,-,-,chronic myeloid leukemia,in vitro,Low,Sensitive,-,-,2013,miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells.,"The results revealed significant increase in the expression levels of miR-17 in imatinib sensitive and resistant cells compared to peripheral blood mononuclear cells (PBMCs). On the other hand, significant decrease was observed in miR-17 levels in response to imatinib, nilotinib and dasatinib."
23818358,miR-17,hsa-mir-17,MI0000071,Nilotinib,644241, K562,-,-,-,chronic myeloid leukemia,in vitro,Low,Associated,-,-,2013,miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells.,"The results revealed significant increase in the expression levels of miR-17 in imatinib sensitive and resistant cells compared to peripheral blood mononuclear cells (PBMCs). On the other hand, significant decrease was observed in miR-17 levels in response to imatinib, nilotinib and dasatinib."
23821457,miR-200c,hsa-mir-200c,MI0000650,Cisplatin,2767,-,SGC7901 vs SGC7901/CDDP,-,-,gastric cancer,in vitro,Low,Sensitive,RhoE,-,2014,MicroRNA-200c regulates the sensitivity of chemotherapy of gastric cancer SGC7901/DDP cells by directly targeting RhoE.,These suggested that miRNA-200c regulated the sensitivity of chemotherapy to cisplatin (DDP) in gastric cancer by possibly targeting RhoE.
23824073,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,OVCAR3 and SKOV3,-,-,-,ovarian cancer,in vitro,Low,Resistant,PDCD4,-,2013,Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis.,The results suggested that berberine could modulate the sensitivity of cisplatin via regulating miR-21/PDCD4 axis in the ovarian cancer cells.
23826416,let-7b,hsa-let-7b,MI0000063,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-1197,hsa-mir-1197,MI0006656,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-1200,hsa-mir-1200,MI0006332,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,INSIG1,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-124*,hsa-mir-124-1,MI0000443,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-1250,hsa-mir-1250,MI0006385,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-1264,hsa-mir-1264,MI0003758,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-1265,hsa-mir-1265,MI0006401,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-1268,hsa-mir-1268a,MI0006405,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-1277,hsa-mir-1277,MI0006419,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-1291,hsa-mir-1291,MI0006353,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-130a,hsa-mir-130a,MI0000448,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-130b*,hsa-mir-130b,MI0000748,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-140,hsa-mir-140,MI0000456,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-15a,hsa-mir-15a,MI0000069,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-188,hsa-mir-188,MI0000484,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-193b*,hsa-mir-193b,MI0003137,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-195,hsa-mir-195,MI0000489,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-199a,hsa-mir-199a-1,MI0000242,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-200a,hsa-mir-200a,MI0000737,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-200b*,hsa-mir-200b,MI0000342,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,INSIG1,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-20b*,hsa-mir-20b,MI0001519,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-210,hsa-mir-210,MI0000286,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-2114,hsa-mir-2114,MI0010633,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-214,hsa-mir-214,MI0000290,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-219-2,-,-,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant," INSIG1 , FASN and INSIG1",-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-221,hsa-mir-221,MI0000298,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-2277,hsa-mir-2277,MI0011284,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Resistant,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-2278,hsa-mir-2278,MI0011285,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-23c,hsa-mir-23c,MI0016010,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-27b,hsa-mir-27b,MI0000440,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-28,hsa-mir-28,MI0000086,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-296,hsa-mir-296,MI0000747,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-2964a,-,-,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-29c,hsa-mir-29c,MI0000735,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-302b*,hsa-mir-302b,MI0000772,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-3065,hsa-mir-3065,MI0014228,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-3074,hsa-mir-3074,MI0014181,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-30a,hsa-mir-30a,MI0000088,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-31*,hsa-mir-31,MI0000089,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-3144,hsa-mir-3144,MI0014169,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-3150b,hsa-mir-3150b,MI0016426,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-3153,hsa-mir-3153,MI0014180,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-3161,hsa-mir-3161,MI0014191,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-3163,hsa-mir-3163,MI0014193,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-3164,hsa-mir-3164,MI0014194,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-3167,hsa-mir-3167,MI0014198,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-3168,hsa-mir-3168,MI0014199,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23826416,miR-3173,hsa-mir-3173,MI0014204,Paclitaxel,36314,Hep2,-,-,-,laryngeal cancer,in vitro,High,Sensitive,-,-,2013,Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line,"According to this criterion (FDR<10%), 27 miRs showed increased expression and 22 miRs showed decreased expression (Table 4). Within these miRs, the most significantly expression-altered were miR-31-star, miR-1264, miR-3150b-5p and miR-210."
23831023,miR-101,hsa-mir-101-1,MI0000103,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-146b,hsa-mir-146b,MI0003129,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-148a,hsa-mir-148a,MI0000253,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-155,hsa-mir-155,MI0000681,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-181a,hsa-mir-181a-2,MI0000269,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-183,hsa-mir-183,MI0000273,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-185,hsa-mir-185,MI0000482,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Sensitive,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-18a,hsa-mir-18a,MI0000072,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-194,hsa-mir-194-1,MI0000488,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Sensitive,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-199b,hsa-mir-199b,MI0000282,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-203a,hsa-mir-203a,MI0000283,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-206,hsa-mir-206,MI0000490,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-214,hsa-mir-214,MI0000290,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-22,hsa-mir-22,MI0000078,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-221,hsa-mir-221,MI0000298,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-25,hsa-mir-25,MI0000082,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,CDKN1C,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-27a,hsa-mir-27a,MI0000085,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-296,hsa-mir-296,MI0000747,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Sensitive,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-297,hsa-mir-297,MI0005775,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Sensitive,"ATM,ATG5",-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-29c,hsa-mir-29c,MI0000735,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,CDK2,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-339,hsa-mir-339,MI0000815,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-34c,hsa-mir-34c,MI0000743,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-362,hsa-mir-362,MI0000762,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-374a,hsa-mir-374a,MI0000782,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-382,hsa-mir-382,MI0000790,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Sensitive,CDK1,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-429,hsa-mir-429,MI0001641,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-429,hsa-mir-429,MI0001641,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,"NFYA,CASP2,CDKN2B,CDK2",-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-455,hsa-mir-455,MI0003513,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-485,hsa-mir-485,MI0002469,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-485,hsa-mir-485,MI0002469,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Sensitive,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-519a,hsa-mir-519a-1,MI0003178,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-574,hsa-mir-574,MI0003581,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Sensitive,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-603,hsa-mir-603,MI0003616,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-610,hsa-mir-610,MI0003623,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Sensitive,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-630,hsa-mir-630,MI0003644,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Sensitive,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-637,hsa-mir-637,MI0003652,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Sensitive,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-659,hsa-mir-659,MI0003683,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-7,hsa-mir-7-1,MI0000263,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-760,hsa-mir-760,MI0005567,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Sensitive,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-885,hsa-mir-885,MI0005560,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Sensitive,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-920,hsa-mir-920,MI0005712,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Sensitive,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-92b,hsa-mir-92b,MI0003560,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Sensitive,-,-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23831023,miR-98,hsa-mir-98,MI0000100,Cisplatin,2767,-,SCC-11 vs  SCC-11/CDDP,-,-,squamous cell carcinoma, in vitro,High,Resistant,"CASP3,ATG10",-,2013,Phospho-delta-Np63alpha-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.,"By global analysis of microRNA expression [16], we showed that the cisplatin exposure led to a down regulation of twenty-eight microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p, miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206, miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p) for  3.44C19.26  fold (Supplementary Table SI) and up regulation of fifteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p, miR-297, miR-194-3p, miR-885-3p and miR-630) for  3.36C7.46  fold (Supplementary Table SII) in SCC-11 cells compared to SCC-11M cells upon cisplatin exposure [16]."
23834154,miR-21,hsa-mir-21,MI0000077,Doxorubicin (Adriamycin),31703,K562 and KYO-1 ,-,-,-,chronic myeloid leukemia,in vitro,Low,Resistant,Bcl-2,"Beclin-1, Vps34 and LC3-II",2013,Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells.,"Additionally, miR-21 downregulation increased K562 and KYO-1 cellular sensitivity to etoposide or doxorubicin."
23834154,miR-21,hsa-mir-21,MI0000077,Etoposide,36462,K562 and KYO-1 ,-,-,-,chronic myeloid leukemia,in vitro,Low,Resistant,Bcl-2,"Beclin-1, Vps34 and LC3-II",2013,Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells.,"Additionally, miR-21 downregulation increased K562 and KYO-1 cellular sensitivity to etoposide or doxorubicin."
23838916,miR-200c,hsa-mir-200c,MI0000650,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,Patients,esophageal cancer,in vitro and in vivo,Low,Resistant,-,-,2013,Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of Patient undergoing neoadjuvant chemotherapy for esophageal cancer.,High expression of miR-200c correlated significantly with poor response to chemotherapy (p = 0.0211).
23856992,miR-503,hsa-mir-503,MI0003188,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,Bcl-2,-,2013,miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2.,"The overexpression of miR-503 sensitized the A549/CDDP cells to cisplatin, whereas the inhibition of miR-503 in the A549 cells increased resistance to cisplatin."
23857508,miR-125b,hsa-mir-125b-1,MI0000446,Temozolomide,5394,Primary Glioblastoma Cell,-,Mice,-,glioblastoma,in vitro and in vivo,Low,Resistant,PIAS3,"STAT3, MMP-2 and MMP-9",2014,miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3.,Further research into the underlying mechanism demonstrated that the miR-125b inhibitor enhanced the invasion-prevention activity of temozolomide in GSCs through targeting PIAS3.
23862748,miR-34a,hsa-mir-34a,MI0000268,Sorafenib,216239,"HL-7702, Huh-7 and MHCC97H",-,-,Patients,hepatocellular carcinoma,in vitro and in vivo,Low,Sensitive,Bcl-2,-,2014,MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.,"Functional analyses indicated that the restoration of miR-34a reduced cell viability, promoted cell apoptosis and potentiated sorafenib-induced apoptosis and toxicity in HCC cell lines by inhibiting Bcl-2 expression."
23866735,miR-181c,hsa-mir-181c,MI0000271,Imatinib,5291,-,-,-,Patients,chronic myeloid leukemia,in vivo,Low,Sensitive,-,-,2013,Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia.,"Only one differentially expressed miRNA, miR-181c, was found when the imatinib-resistant group was compared with imatinib-responders. Significant down-regulation of miR-181c in imatinib-resistant versus imatinib-responders was confirmed by qRT-PCR."
23879965,miR-487a,hsa-mir-487a,MI0002471,Mitoxantrone,4212,-,MCF-7 vs MCF-7/MIX,Mice,-,breast cancer,in vitro and in vivo,Low,Sensitive,BCRP,-,2013,MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).,"Moreover, ectopic miR-487a down-regulated BCRP expression at the mRNA and protein levels, increasing the intracellular accumulation and cytotoxicity of MX in resistant MCF-7/MX breast cancer cells."
23888996,miR-335,hsa-mir-335,MI0000816,Prednisolone,5755,"697, RS4:11 and Sup-B15",-,-,-,paediatric acute lymphoblastic leukaemia,in vitro,Low,Sensitive,MAPK1,-,2013,Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia.,These results indicate that ectopic expression of MIR335 can confer an enhanced sensitivity specifically to PRED.
23893241,miR-508,hsa-mir-508,MI0003195,5-Fluorouracil,3385,-,SGC7901 vs SGC7901/ADR and SGC7901 vs SGC7901/VCR,Mice,-,gastric cancer,in vitro and in vivo,Low,Sensitive,ABCB1 and ZNRD1,-,2014,miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1.,The overexpression of miR-508-5p was sufficient to reverse cancer cell resistance to multiple chemotherapeutics in vitro and sensitize tumours to chemotherapy in vivo.
23893241,miR-508,hsa-mir-508,MI0003195,Cisplatin,2767,-,SGC7901 vs SGC7901/ADR and SGC7901 vs SGC7901/VCR,Mice,-,gastric cancer,in vitro and in vivo,Low,Sensitive,ABCB1 and ZNRD1,-,2014,miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1.,The overexpression of miR-508-5p was sufficient to reverse cancer cell resistance to multiple chemotherapeutics in vitro and sensitize tumours to chemotherapy in vivo.
23893241,miR-508,hsa-mir-508,MI0003195,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR and SGC7901 vs SGC7901/VCR,Mice,-,gastric cancer,in vitro and in vivo,Low,Sensitive,ABCB1 and ZNRD1,-,2014,miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1.,The overexpression of miR-508-5p was sufficient to reverse cancer cell resistance to multiple chemotherapeutics in vitro and sensitize tumours to chemotherapy in vivo.
23893241,miR-508,hsa-mir-508,MI0003195,Vincristine,5978,-,SGC7901 vs SGC7901/VCR and SGC7901 vs SGC7901/ADR,Mice,-,gastric cancer,in vitro and in vivo,Low,Sensitive,ABCB1 and ZNRD1,-,2014,miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1.,The overexpression of miR-508-5p was sufficient to reverse cancer cell resistance to multiple chemotherapeutics in vitro and sensitize tumours to chemotherapy in vivo.
23894315,miR-21,hsa-mir-21,MI0000077,5-Fluorouracil,3385,"HCT-116, HT-29 and SW620",-,-,-,colon cancer,in vitro,Low,Sensitive,PTEN,-,2013,Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21.,"Difluorinated curcumin (CDF), a novel analog of the dietary ingredient curcumin, which has been shown to inhibit the growth of 5-Flurouracil + Oxaliplatin resistant colon cancer cells, downregulated miR-21 in chemo-resistant colon cancer HCT116 and HT-29 cells and restored PTEN levels with subsequent reduction in Akt phosphorylation."
23894315,miR-21,hsa-mir-21,MI0000077,Oxaliplatin,5310940,"HCT116, HT-29 and SW620",-,-,-,colon cancer,in vitro,Low,Sensitive,PTEN,-,2013,Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21.,"Difluorinated curcumin (CDF), a novel analog of the dietary ingredient curcumin, which has been shown to inhibit the growth of 5-Flurouracil + Oxaliplatin resistant colon cancer cells, downregulated miR-21 in chemo-resistant colon cancer HCT116 and HT-29 cells and restored PTEN levels with subsequent reduction in Akt phosphorylation."
23900458,miR-29a,hsa-mir-29a,MI0000087,Gemcitabine,60750,"MIAPaCa-2, PSN-1, BxPC-3 and Panc-1",-,-,-,pancreatic cancer,in vitro,Low,Sensitive,-,Wnt/Beta-catenin signaling pathway,2013,MicroRNA-29a induces resistance to gemcitabine through the Wnt/Beta-catenin signaling pathway in pancreatic cancer cells.,"These findings suggest that activation of the Wnt/Beta-catenin signaling mediates, at least in part, the miR-29a-induced resistance to GEM."
23904094,miR-29,hsa-mir-29a,MI0000087,Cisplatin,2767,SKOV3 and HeyC2,CP70 vs CP70/CDDP,Mice,-,ovarian cancer,in vitro and in vivo,Low,Sensitive,COL1A1,-,2014,Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells.,Knockdown of miR-29a/b/c increased the ability of cells to escape cisplatin-induced cell death partly through upregulation of collagen type I alpha 1 (COL1A1) and increased the activation of extracellular signal-regulated kinase 1/2 and inactivation of glycogen synthase kinase 3 beta.
23904379,miR-106a,hsa-mir-106a,MI0000113,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,Low,Sensitive,Mcl-1,-,2013,MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.,"Furthermore, miR-106a inhibited cell survival and cisplatin resistance through downregulating the expression of Mcl-1."
23915286,miR-433,hsa-mir-433,MI0001723,5-Fluorouracil,3385,HeLa,-,-,-,cervical cancer,in vitro,Low,Sensitive,TYMS ,-,2013,MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells.,"The results indicate that miR-433 post-transcriptionally regulates the expression of TYMS mRNA and protein, and increases sensitivity to 5-FU in HeLa cells."
23915977,miR-100,hsa-mir-100,MI0000102,Vincristine,5978,Reh,-,-,Patients,childhood acute lymphoblastic leukemia,in vitro and in vivo,Low,Resistant,-,-,2013,"MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia.","Cellular viability of ETV6-RUNX1-positive Reh cells significantly increased in presence of 9 ng/mL vincristine upon co-expression of miR-125b/miR-99a (91 +/- 4%), miR-125b/miR-100 (93 +/- 5%) or miR-125b/miR-99a/miR-100 (82 +/- 17%) compared with miR-125b-transduced cells (38 +/- 13%, P<0.05)."
23915977,miR-125b,hsa-mir-125b-1,MI0000446,Vincristine,5978,Reh,-,-,Patients,childhood acute lymphoblastic leukemia,in vitro and in vivo,Low,Resistant,-,-,2013,"MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia.","Cellular viability of ETV6-RUNX1-positive Reh cells significantly increased in presence of 9 ng/mL vincristine upon co-expression of miR-125b/miR-99a (91 +/- 4%), miR-125b/miR-100 (93 +/- 5%) or miR-125b/miR-99a/miR-100 (82 +/- 17%) compared with miR-125b-transduced cells (38 +/- 13%, P<0.05)."
23915977,miR-99a,hsa-mir-99a,MI0000101,Vincristine,5978,Reh,-,-,Patients,childhood acute lymphoblastic leukemia,in vitro and in vivo,Low,Resistant,-,-,2013,"MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia.","Cellular viability of ETV6-RUNX1-positive Reh cells significantly increased in presence of 9 ng/mL vincristine upon co-expression of miR-125b/miR-99a (91 +/- 4%), miR-125b/miR-100 (93 +/- 5%) or miR-125b/miR-99a/miR-100 (82 +/- 17%) compared with miR-125b-transduced cells (38 +/- 13%, P<0.05)."
23918833,miR-135b,hsa-mir-135b,MI0000810,Erlotinib,176870,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23918833,miR-135b,hsa-mir-135b,MI0000810,PD-0325901,9826528,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23918833,miR-139,hsa-mir-139,MI0000261,Erlotinib,176870,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23918833,miR-139,hsa-mir-139,MI0000261,PD-0325901,9826528,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23918833,miR-141,hsa-mir-141,MI0000457,Erlotinib,176870,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23918833,miR-141,hsa-mir-141,MI0000457,PD-0325901,9826528,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23918833,miR-155,hsa-mir-155,MI0000681,Erlotinib,176870,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23918833,miR-155,hsa-mir-155,MI0000681,PD-0325901,9826528,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23918833,miR-200a,hsa-mir-200a,MI0000737,Erlotinib,176870,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23918833,miR-200a,hsa-mir-200a,MI0000737,PD-0325901,9826528,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23918833,miR-200b,hsa-mir-200b,MI0000342,Erlotinib,176870,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23918833,miR-200b,hsa-mir-200b,MI0000342,PD-0325901,9826528,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23918833,miR-200c,hsa-mir-200c,MI0000650,Erlotinib,176870,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23918833,miR-200c,hsa-mir-200c,MI0000650,PD-0325901,9826528,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23918833,miR-429,hsa-mir-429,MI0001641,Erlotinib,176870,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23918833,miR-429,hsa-mir-429,MI0001641,PD-0325901,9826528,"Panc8.13, DANG, BxPC-3, HPAC, HPAF-II, CFPAC-1, PA-TU8988T, Panc-1, Panc2.13, MiaPaCa-2, HcG25 and Hs766T",-,-,-,pancreatic adenocarcinoma,in vitro,High,Sensitive,-,-,2013,Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.,"We found that all 5 members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and in addition, miR-155, -139-5p, and 135b, were markedly upregulated in sensitive, but almost not expressed in resistant cell lines."
23924943,miR-20a,hsa-mir-20a,MI0000076,Cisplatin,2767,"GES-1, SGC7901, MKN45 and NUGC-3",-,-,-,gastric cancer,in vitro,Low,Resistant,EGR2,-,2013,Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2).,"miR-20a promoted the growth, migration and invasion of GC cells, enhanced the chemoresistance of GC cells to cisplatin and docetaxel."
23924943,miR-20a,hsa-mir-20a,MI0000076,Docetaxel,148124,"GES-1, SGC7901, MKN45 and NUGC-3",-,-,-,gastric cancer,in vitro,Low,Resistant,EGR2,-,2013,Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2).,"miR-20a promoted the growth, migration and invasion of GC cells, enhanced the chemoresistance of GC cells to cisplatin and docetaxel."
23925649,miR-223,hsa-mir-223,MI0000300,Doxorubicin (Adriamycin),31703,"Hep3B, HCC3, LM-6, SMMC7721, Huh-7, SK-Hep-1, HepG2 and BEL-7402",-,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,ABCB1,-,2013,MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells.,"Finally, we found that the over-expression of miR-223 increased the HCC cell sensitivity to anticancer drugs, and the inhibition of miR-223 had the opposite effect."
23925649,miR-223,hsa-mir-223,MI0000300,Paclitaxel,36314,"Hep3B, HCC3, LM-6, SMMC7721, Huh-7, SK-Hep-1, HepG2 and BEL-7402",-,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,ABCB1,-,2013,MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells.,"Finally, we found that the over-expression of miR-223 increased the HCC cell sensitivity to anticancer drugs, and the inhibition of miR-223 had the opposite effect."
23932924,miR-106a,hsa-mir-106a,MI0000113,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR and SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Resistant,RUNX3,-,2013,MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3.,"miR-106a promotes chemo-resistance of GC cells, accelerates ADR efflux, and suppresses drug-induced apoptosis."
23932924,miR-106a,hsa-mir-106a,MI0000113,Vincristine,5978,-,SGC7901 vs SGC7901/VCR and SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,Low,Resistant,RUNX3,-,2013,MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3.,"miR-106a promotes chemo-resistance of GC cells, accelerates ADR efflux, and suppresses drug-induced apoptosis."
23934188,miR-137,hsa-mir-137,MI0000454,Doxorubicin (Adriamycin),31703,HepG2 and LS174T,UKF-NB3 vs UKF-NB3/ADR,Mice,-,neuroblastoma,in vitro and in vivo,Low,Sensitive,CAR,constitutive androstane receptor,2014,miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells.,"miR-137 overexpression resulted in downregulation of CAR protein and mRNA (via mRNA degradation); it sensitized doxorubicin-resistant cells to doxorubicin (as shown by reduced proliferation, increased apoptosis and increased G2-phase cell cycle arrest) and reduced the in vivo growth rate of neuroblastoma xenografts."
23946872,let-7i,hsa-let-7i,MI0000434,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-100,hsa-mir-100,MI0000102,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-106a,hsa-mir-106a,MI0000113,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-1246,hsa-mir-1246,MI0006381,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-125a,hsa-mir-125a,MI0000469,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-125b,hsa-mir-125b-1,MI0000446,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-1275,hsa-mir-1275,MI0006415,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-129*,hsa-mir-1290,MI0006352,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-1290,hsa-mir-129-1,MI0000252,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-130a,hsa-mir-130a,MI0000448,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-130b,hsa-mir-130b,MI0000748,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-138,hsa-mir-138-1,MI0000476,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-151,hsa-mir-151a,MI0000809,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-15a,hsa-mir-15a,MI0000069,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-16,hsa-mir-16-1,MI0000070,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-17,hsa-mir-17,MI0000071,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-1826,hsa-mir-1826,MI0008194,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-18a,hsa-mir-18a,MI0000072,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-18b,hsa-mir-18b,MI0001518,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-194,hsa-mir-194-1,MI0000488,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-195,hsa-mir-195,MI0000489,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-19a,hsa-mir-19a,MI0000073,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-19b,hsa-mir-19b-1,MI0000074,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-208a,hsa-mir-208a,MI0000251,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-20a,hsa-mir-20a,MI0000076,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-20b,hsa-mir-20b,MI0001519,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-21,hsa-mir-21,MI0000077,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-22,hsa-mir-22,MI0000078,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-221,hsa-mir-221,MI0000298,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-222,hsa-mir-222,MI0000299,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-28,hsa-mir-28,MI0000086,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,mucin-4,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-29b,hsa-mir-29b-1,MI0000105,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-29c,hsa-mir-29c,MI0000735,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-301a,hsa-mir-301a,MI0000745,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-487b,hsa-mir-487b,MI0003530,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-513a,hsa-mir-513a-1,MI0003191,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-549,hsa-mir-549a,MI0003679,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-602,hsa-mir-602,MI0003615,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-665,hsa-mir-665,MI0005563,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-765,hsa-mir-765,MI0005116,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23946872,miR-99b,hsa-mir-99b,MI0000746,Gemcitabine,60750,"RT4, J82,TCCSUP, UM-UC-3,RT112,CUBIII",-,-,-,Bladder Carcinoma,in vitro,High,Resistant,-,-,2013,MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines,The microarray data identified 41 human miRNAs (Table 1) and 25 human miRPlus sequences that were differentially expressed between all of the sensitive and resistant cell lines.
23950211,miR-153,hsa-mir-153-1,MI0000463,Cisplatin,2767,SW480 and SW620,-,-,-,colorectal cancer,in vitro,Low,Resistant,FOXO3a,-,2013,miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance.,Functional studies revealed that miR-153 upregulation increased colorectal cancer invasiveness and resistance to oxaliplatin and cisplatin both in vitro and in vivo.
23950211,miR-153,hsa-mir-153-1,MI0000463,Oxaliplatin,5310940,SW480 and SW620,-,-,-,colorectal cancer,in vitro,Low,Resistant,FOXO3a,-,2013,miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance.,Functional studies revealed that miR-153 upregulation increased colorectal cancer invasiveness and resistance to oxaliplatin and cisplatin both in vitro and in vivo.
23963283,miR-200c,hsa-mir-200c,MI0000650,Erlotinib,176870,PC-9 and Erl-R,-,Mice,-,non-small cell lung cancer ,in vitro and in vivo,Low,Resistant,ZEB1 and ZEB2,-,2013,Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo.,Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo.
23963283,miR-21,hsa-mir-21,MI0000077,Erlotinib,176870,PC-9 and Erl-R,-,Mice,-,non-small cell lung cancer ,in vitro and in vivo,Low,Sensitive,SNAIL1,-,2013,Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo.,Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo.
23969999,miR-133a,hsa-mir-133a-1,MI0000450,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,Low,Sensitive,FTL ,-,2013,Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin.,"Additionally, we demonstrate that targeted downregulation of FTL protein by the microRNA miR-133a increases sensitivity of MCF-7/DOX and MCF-7/CDDP cells to doxorubicin and cisplatin."
23969999,miR-133a,hsa-mir-133a-1,MI0000450,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Sensitive,FTL ,-,2013,Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin.,"Additionally, we demonstrate that targeted downregulation of FTL protein by the microRNA miR-133a increases sensitivity of MCF-7/DOX and MCF-7/CDDP cells to doxorubicin and cisplatin."
23977446,miR-146a,hsa-mir-146a,MI0000477,Paclitaxel,36314,10A-iK8,-,-,-,tumorigenic mammary stem cell,in vitro,Low,Sensitive,NUMB,-,2013,Kruppel-like factor 8 promotes tumorigenic mammary stem cell induction by targeting miR-146a.,These results strongly suggested that KLF8-induced miR-146a-dependent stem cell traits are a major contribution to the resistance of the cells to the cytotoxic effect of the drug.
23981989,miR-126,hsa-mir-126,MI0000471,Oxaliplatin,5310940,SW480 and 293T,-,-,-,colon cancer,in vitro,Low,Sensitive,"IRS1, SLC75A and TOM1",-,2013,"miR-126 inhibits colon cancer proliferation and invasion through targeting IRS1, SLC7A5 and TOM1 gene",MiR-126 significantly enhanced the sensitivity of the colon cancer cell to chemotherapeutic drug.
23991130,miR-650,hsa-mir-650,MI0003665,Docetaxel,148124,-,SPC-A1 vs SPC-A1/DOC and H1299 vs H1299/DOC,-,Patients,lung adenocarcinoma,in vitro and in vivo,Low,Resistant,ING4,Bcl-2/Bax,2013,MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression.,"Silencing of miR-650 could increase the in vitro sensitivity of docetaxel-resistant LAD cells to docetaxel, while upregulation of miR-650 decreased the sensitivity of parental LAD cells to docetaxel both in vitro and in vivo."
23994196,miR-196a,hsa-mir-196a-1,MI0000238,Docetaxel,148124,-,MCF-7/S vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Resistant,-,-,2013,miR-222 and miR-29a Contribute to the Drug-resistance of Breast Cancer Cells,"Here, 183 differentially expressed miRNAs were identified in the two resistant sublines compared to MCF-7/S.Then, five up-regulated miRNAs (miR-100, miR-29a, miR-196a, miR-222 and miR-30a)in both MCF-7/Adr and MCF-7/Doc were selected to explore their roles in acquisition of drug-resistance using transfection experiment."
23994196,miR-196a,hsa-mir-196a-1,MI0000238,Doxorubicin (Adriamycin),31703,-,MCF-7/S vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2013,miR-222 and miR-29a Contribute to the Drug-resistance of Breast Cancer Cells,"Here, 183 differentially expressed miRNAs were identified in the two resistant sublines compared to MCF-7/S.Then, five up-regulated miRNAs (miR-100, miR-29a, miR-196a, miR-222 and miR-30a)in both MCF-7/Adr and MCF-7/Doc were selected to explore their roles in acquisition of drug-resistance using transfection experiment."
23994196,miR-222,hsa-mir-222,MI0000299,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,Low,Resistant,-,PTEN,2013,MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.,"Western blot results suggested that miR-222 and -29a could regulate the expression of PTEN, maybe through which the two miRNAs conferred Adr and Doc resistance in MCF-7 cells."
23994196,miR-222,hsa-mir-222,MI0000299,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Resistant,-,PTEN,2013,MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.,"Western blot results suggested that miR-222 and -29a could regulate the expression of PTEN, maybe through which the two miRNAs conferred Adr and Doc resistance in MCF-7 cells."
23994196,miR-29a,hsa-mir-29a,MI0000087,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,Low,Resistant,-,PTEN,2013,MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.,"Western blot results suggested that miR-222 and -29a could regulate the expression of PTEN, maybe through which the two miRNAs conferred Adr and Doc resistance in MCF-7 cells."
23994196,miR-29a,hsa-mir-29a,MI0000087,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Resistant,-,PTEN,2013,MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.,"Western blot results suggested that miR-222 and -29a could regulate the expression of PTEN, maybe through which the two miRNAs conferred Adr and Doc resistance in MCF-7 cells."
23994196,miR-30a,hsa-mir-30a,MI0000088,Docetaxel,148124,-,MCF-7/S vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Resistant,PTEN,-,2013,miR-222 and miR-29a Contribute to the Drug-resistance of Breast Cancer Cells,"Here, 183 differentially expressed miRNAs were identified in the two resistant sublines compared to MCF-7/S.Then, five up-regulated miRNAs (miR-100, miR-29a, miR-196a, miR-222 and miR-30a)in both MCF-7/Adr and MCF-7/Doc were selected to explore their roles in acquisition of drug-resistance using transfection experiment."
23994196,miR-30a,hsa-mir-30a,MI0000088,Doxorubicin (Adriamycin),31703,-,MCF-7/S vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,PTEN,-,2013,miR-222 and miR-29a Contribute to the Drug-resistance of Breast Cancer Cells,"Here, 183 differentially expressed miRNAs were identified in the two resistant sublines compared to MCF-7/S.Then, five up-regulated miRNAs (miR-100, miR-29a, miR-196a, miR-222 and miR-30a)in both MCF-7/Adr and MCF-7/Doc were selected to explore their roles in acquisition of drug-resistance using transfection experiment."
24007627,miR-149,hsa-mir-149,MI0000478,Docetaxel,148124,-,MCF-7/S vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Resistant,-,-,2013,miR-222 and miR-29a Contribute to the Drug-resistance of Breast Cancer Cells,"Here, 183 differentially expressed miRNAs were identified in the two resistant sublines compared to MCF-7/S.Then, five up-regulated miRNAs (miR-100, miR-29a, miR-196a, miR-222 and miR-30a)in both MCF-7/Adr and MCF-7/Doc were selected to explore their roles in acquisition of drug-resistance using transfection experiment."
24007627,miR-149,hsa-mir-149,MI0000478,Doxorubicin (Adriamycin),31703,-,MCF-7/S vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2013,miR-222 and miR-29a Contribute to the Drug-resistance of Breast Cancer Cells,"Here, 183 differentially expressed miRNAs were identified in the two resistant sublines compared to MCF-7/S.Then, five up-regulated miRNAs (miR-100, miR-29a, miR-196a, miR-222 and miR-30a)in both MCF-7/Adr and MCF-7/Doc were selected to explore their roles in acquisition of drug-resistance using transfection experiment."
24007863,miR-520,-,-,5-Fluorouracil,3385,Huh7 and SMMC,-,Mice,-,hepatocellular carcinoma,in vitro and in vivo,Low,Associated,E2F-1,-,2014,The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.,"We observed that EGFRvIII expression can induce miR-520d-3p downregulation and the ensuing upregulation of the transcription factor E2F-1 and the enzyme thymidylate synthase (TS), which may lead to drug resistance."
24007863,miR-520,-,-,CH12,-,Huh7 and SMMC,-,Mice,-,hepatocellular carcinoma,in vitro and in vivo,Low,Associated,E2F-1,-,2014,The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.,"We observed that EGFRvIII expression can induce miR-520d-3p downregulation and the ensuing upregulation of the transcription factor E2F-1 and the enzyme thymidylate synthase (TS), which may lead to drug resistance."
24009080,miR-34,hsa-mir-34a,MI0000268,5-Fluorouracil,3385,"SW480, DLD-1, Colo320 and HCT-15",-,-,-,colorectal cancer,in vitro,Low,Sensitive,c-Kit,-,2013,"Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness.","Furthermore, ectopic expression of c-Kit conferred resistance of colorectal cancer (CRC) cells to treatment with 5-fluorouracil (5-FU), whereas ectopic miR-34a sensitized the cells to 5-FU."
24009080,miR-34,hsa-mir-34a,MI0000268,Doxycycline,54671203,"SW480, DLD-1, Colo320 and HCT15",-,-,-,colorectal cancer,in vitro,Low,Sensitive,c-Kit,-,2013,"Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness.","Furthermore, ectopic expression of c-Kit conferred resistance of colorectal cancer (CRC) cells to treatment with 5-fluorouracil (5-FU), whereas ectopic miR-34a sensitized the cells to 5-FU."
24018051,miR-27a,hsa-mir-27a,MI0000085,5-Fluorouracil,3385,-,BEL-7402 vs BEL-7402/5-FU,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,-,MDR1,2013,MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/Beta-catenin pathway in hepatocellular carcinoma cells.,"Overexpression of miR-27a by transfecting with miR-27a mimics in the BEL/5-FU cells could reduce the MDR1/P-glycoprotein and Beta-catenin expressions, enhance the sensitivity of these cells to 5-fluorouracil and 5-fluorouracil-induced apoptosis."
24026012,miR-34a,hsa-mir-34a,MI0000268,Erlotinib,176870,-,HN5 vs HN5/ER,-,-,head and neck cancer,in vitro,Low,Sensitive,-,-,2013,Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.,Expression of the tumor suppressor miR-34a was reduced in HN5-ER cells and increasing its expression abrogated Axl expression and reversed erlotinib resistance.
24038379,miR-495,hsa-mir-495,MI0003135,Carboplatin,38904,H1299,A549 vs A549/CDDP,-,Patients,non-small cell lung cancer,in vitro and in vivo,Low,Sensitive,ATP7A,-,2014,"In conclusion, our data demonstrate that miR-495 regulates the multi-drug resistance by modulation of ATP7A expression in NSCLC and suggest that miR-495 may serve as a potential biomarker for the treatment of multi-drug resistant NSCLC Patient with high ATP7A levels.",we discovered that the inhibition of miR-495 increased the IC50 of both CBDCA and L-OHP in A549 and H1299 cells compared to the control.
24038379,miR-495,hsa-mir-495,MI0003135,Cisplatin,2767,H1299,A549 vs A549/CDDP,-,Patients,non-small cell lung cancer,in vitro and in vivo,Low,Sensitive,ATP7A,-,2014,"In conclusion, our data demonstrate that miR-495 regulates the multi-drug resistance by modulation of ATP7A expression in NSCLC and suggest that miR-495 may serve as a potential biomarker for the treatment of multi-drug resistant NSCLC Patient with high ATP7A levels.","The drug sensitivity assay indicated that miR-495 enhanced the cell response to cisplatin (CDDP) in NSCLC cells, while inhibition of miR-495 led to the opposite effects."
24038379,miR-495,hsa-mir-495,MI0003135,Oxaliplatin,5310940,H1299,A549 vs A549/CDDP,-,Patients,non-small cell lung cancer,in vitro and in vivo,Low,Sensitive,ATP7A,-,2014,"In conclusion, our data demonstrate that miR-495 regulates the multi-drug resistance by modulation of ATP7A expression in NSCLC and suggest that miR-495 may serve as a potential biomarker for the treatment of multi-drug resistant NSCLC Patient with high ATP7A levels.",we discovered that the inhibition of miR-495 increased the IC50 of both CBDCA and L-OHP in A549 and H1299 cells compared to the control.
24039897,miR-200c,hsa-mir-200c,MI0000650,5-Fluorouracil,3385,MDA-MB-231 and MDA-MB-453,MCF-7 vs MCF-7/5-FU,-,-,breast cancer,in vitro,Low,Sensitive,Bmi1,-,2013,A Bmi1-miRNAs cross-talk modulates chemotherapy response to 5-fluorouracil in breast cancer cells.,MiR-200c and miR-203 overexpression in breast cancer cells downregulated Bmi1 expression accompanied with reversion of resistance to 5-Fu mediated by Bmi1.
24039897,miR-203,hsa-mir-203a,MI0000283,5-Fluorouracil,3385,MDA-MB-231 and MDA-MB-453,MCF-7 vs MCF-7/5-FU,-,-,breast cancer,in vitro,Low,Sensitive,Bmi1,-,2013,A Bmi1-miRNAs cross-talk modulates chemotherapy response to 5-fluorouracil in breast cancer cells.,MiR-200c and miR-203 overexpression in breast cancer cells downregulated Bmi1 expression accompanied with reversion of resistance to 5-Fu mediated by Bmi1.
24040438,miR-10a ,hsa-mir-10a,MI0000266,Cisplatin,2767,-,-,-,Patientss,Non-small Cell Lung Cancer,in vivo,High,Resistant,-,-,2013,Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study,"Here, 183 differentially expressed miRNAs were identified in the two resistant sublines compared to MCF-7/S.Then, five up-regulated miRNAs (miR-100, miR-29a, miR-196a, miR-222 and miR-30a)in both MCF-7/Adr and MCF-7/Doc were selected to explore their roles in acquisition of drug-resistance using transfection experiment."
24040438,miR-10a ,hsa-mir-10a,MI0000266,Vinorelbine,60780,-,-,-,Patientss,Non-small Cell Lung Cancer,in vivo,High,Resistant,-,-,2013,Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study,"Here, 183 differentially expressed miRNAs were identified in the two resistant sublines compared to MCF-7/S.Then, five up-regulated miRNAs (miR-100, miR-29a, miR-196a, miR-222 and miR-30a)in both MCF-7/Adr and MCF-7/Doc were selected to explore their roles in acquisition of drug-resistance using transfection experiment."
24040438,miR-125a,hsa-mir-125a,MI0000469,Gemcitabine,60750,"SK-MES-1, NCI-H1975, NCI-H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2013,Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines,Differential expression analysis showed that there were only 10 miRs whose expression altered higher than 100% (p<0.05) gradually from NCI-H1975 to NCI-H460 to SK-MES-1(Table 4).
24040438,miR-130a,hsa-mir-130a,MI0000448,Gemcitabine,60750,"SK-MES-1, NCI-H1975, NCI-H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2013,Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines,Differential expression analysis showed that there were only 10 miRs whose expression altered higher than 100% (p<0.05) gradually from NCI-H1975 to NCI-H460 to SK-MES-1(Table 4).
24040438,miR-195,hsa-mir-195,MI0000489,Gemcitabine,60750,"SK-MES-1, NCI-H1975, NCI-H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Sensitive,-,-,2013,Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines,Differential expression analysis showed that there were only 10 miRs whose expression altered higher than 100% (p<0.05) gradually from NCI-H1975 to NCI-H460 to SK-MES-1(Table 4).
24040438,miR-200c,hsa-mir-200c,MI0000650,Gemcitabine,60750,"SK-MES-1, NCI-H1975, NCI-H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Sensitive,-,-,2013,Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines,Differential expression analysis showed that there were only 10 miRs whose expression altered higher than 100% (p<0.05) gradually from NCI-H1975 to NCI-H460 to SK-MES-1(Table 4).
24040438,miR-203,hsa-mir-203a,MI0000283,Gemcitabine,60750,"SK-MES-1, NCI-H1975, NCI-H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Sensitive,-,-,2013,Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines,Differential expression analysis showed that there were only 10 miRs whose expression altered higher than 100% (p<0.05) gradually from NCI-H1975 to NCI-H460 to SK-MES-1(Table 4).
24040438,miR-24-2*,hsa-mir-24-2,MI0000081,Gemcitabine,60750,"SK-MES-1, NCI-H1975, NCI-H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Sensitive,-,-,2013,Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines,Differential expression analysis showed that there were only 10 miRs whose expression altered higher than 100% (p<0.05) gradually from NCI-H1975 to NCI-H460 to SK-MES-1(Table 4).
24040438,miR-25*,hsa-mir-25,MI0000082,Gemcitabine,60750,"SK-MES-1, NCI-H1975, NCI-H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Sensitive,-,-,2013,Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines,Differential expression analysis showed that there were only 10 miRs whose expression altered higher than 100% (p<0.05) gradually from NCI-H1975 to NCI-H460 to SK-MES-1(Table 4).
24040438,miR-30a,hsa-mir-30a,MI0000088,Gemcitabine,60750,"SK-MES-1, NCI-H1975, NCI-H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2013,Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines,Differential expression analysis showed that there were only 10 miRs whose expression altered higher than 100% (p<0.05) gradually from NCI-H1975 to NCI-H460 to SK-MES-1(Table 4).
24040438,miR-30c-2*,hsa-mir-30c-2,MI0000254,Gemcitabine,60750,"SK-MES-1, NCI-H1975, NCI-H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2013,Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines,Differential expression analysis showed that there were only 10 miRs whose expression altered higher than 100% (p<0.05) gradually from NCI-H1975 to NCI-H460 to SK-MES-1(Table 4).
24040438,miR-375,hsa-mir-375,MI0000783,Cisplatin,2767,-,-,-,Patientss,Non-small Cell Lung Cancer,in vivo,High,Resistant,-,-,2013,Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study,"Here, 183 differentially expressed miRNAs were identified in the two resistant sublines compared to MCF-7/S.Then, five up-regulated miRNAs (miR-100, miR-29a, miR-196a, miR-222 and miR-30a)in both MCF-7/Adr and MCF-7/Doc were selected to explore their roles in acquisition of drug-resistance using transfection experiment."
24040438,miR-375,hsa-mir-375,MI0000783,Vinorelbine,60780,-,-,-,Patientss,Non-small Cell Lung Cancer,in vivo,High,Resistant,-,-,2013,Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study,"Here, 183 differentially expressed miRNAs were identified in the two resistant sublines compared to MCF-7/S.Then, five up-regulated miRNAs (miR-100, miR-29a, miR-196a, miR-222 and miR-30a)in both MCF-7/Adr and MCF-7/Doc were selected to explore their roles in acquisition of drug-resistance using transfection experiment."
24040438,miR-885,hsa-mir-885,MI0005560,Gemcitabine,60750,"SK-MES-1, NCI-H1975, NCI-H460",-,-,-,Non-small Cell Lung Cancer,in vitro,High,Resistant,-,-,2013,Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines,Differential expression analysis showed that there were only 10 miRs whose expression altered higher than 100% (p<0.05) gradually from NCI-H1975 to NCI-H460 to SK-MES-1(Table 4).
24054006,miR-29c ,hsa-mir-29c,MI0000735,Docetaxel,148124,"GES-1, SGC-7901 and BGC-823 ",-,-,Patients,gastric cancer,in vitro and in vivo,Low,Sensitive,Mcl-1,-,2013,Relationship between the expression level of miR-29c and biological behavior of gastric cancer,"Overexpression of miR-29c in gastric cancer BGC-823 cells suppressed cell proliferation, stimulated cell apoptosis, induced cell cycle arrest in S phase and increased the chemotherapy sensitivity to drug docetaxel (all were P < 0.05)."
24068565,miR-34a,hsa-mir-34a,MI0000268,Cisplatin,2767,-,SGC-7901 vs SGC-7901/CDDP,-,-,gastric cancer,in vitro,Low,Sensitive,-,PI3K/AKT/survivin pathway,2014,miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway.,"miR-34a over-expression could improve the sensitivity of gastric cancer cells against cisplatin-based chemotherapies, with PI3K/AKT/survivin signaling pathway possibly involved in the mechanism."
24075517,miR-181b,hsa-mir-181b-1,MI0000270,Gemcitabine,60750,"BxPC3, MiaPaCa2, Panc1 and PSN1",-,-,-,pancreatic cancer,in vitro,Low,Resistant,CYLD,CYLD and NF--kappaB,2013,Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells.,"Pre-miR-181b transfection into MiaPaCa2 cells increased their gemcitabine resistance, whereas anti-miR-181b transfection into the other pancreatic cancer cell lines reduced their resistance to gemcitabine and led to the induction of apoptosis."
24084846,miR-9,hsa-mir-9-1,MI0000466,Temozolomide,5394,"U87, T98G, BT145 and BT164",-,-,-,glioblastoma multiforme,in vitro,Low,Resistant,-,P-glycoprotein,2013,Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity.,"The delivery of anti-miR-9 to the resistant GBM cells reversed the expression of the multidrug transporter and sensitized the GBM cells to TMZ, as shown by increased cell death and caspase activity."
24084898,miR-205,hsa-mir-205,MI0000285,Cisplatin,2767,"A549, SPC-A1, SK-MES-1 and 16HBE",-,-,-,non-small cell lung cancer,in vitro,Low,Resistant,PTEN,-,2013,"miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN.","Overexpression of miR-205 promoted growth, migration and invasion, and enhanced the chemoresistance of NSCLC cells."
24088786,miR-103,hsa-mir-103a-1,MI0000109,Camptothecin,24360,U2OS,-,-,-,-,in vitro,Low,Sensitive,RAD51D,-,2013,Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity.,"As expected, miR-103/107 overexpression sensitized U2OS, HeLa, and PEO1 C4-2 cells to cisplatin and a PARP inhibitor, AZD2281."
24088786,miR-103,hsa-mir-103a-1,MI0000109,Cisplatin,2767,"U2OS, HeLa and PEO1 C4-2",-,-,-,-,in vitro,Low,Sensitive,RAD51D,-,2013,Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity.,Overexpression of miR-103/107 also sensitized U2OS cells to camptothecin and etoposide.
24088786,miR-103,hsa-mir-103a-1,MI0000109,Etoposide,36462,U2OS,-,-,-,-,in vitro,Low,Sensitive,RAD51D,-,2013,Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity.,"As expected, miR-103/107 overexpression sensitized U2OS, HeLa, and PEO1 C4-2 cells to cisplatin and a PARP inhibitor, AZD2281."
24088786,miR-103,hsa-mir-103a-1,MI0000109,Olaparib,23725625,"U2OS, HeLa and PEO1 C4-2",-,-,-,-,in vitro,Low,Sensitive,RAD51D,-,2013,Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity.,Overexpression of miR-103/107 also sensitized U2OS cells to camptothecin and etoposide.
24088786,miR-107,hsa-mir-107,MI0000114,Camptothecin,24360,U2OS,-,-,-,-,in vitro,Low,Sensitive,RAD51D,-,2013,Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity.,"As expected, miR-103/107 overexpression sensitized U2OS, HeLa, and PEO1 C4-2 cells to cisplatin and a PARP inhibitor, AZD2281."
24088786,miR-107,hsa-mir-107,MI0000114,Cisplatin,2767,"U2OS, HeLa and PEO1 C4-2",-,-,-,-,in vitro,Low,Sensitive,RAD51D,-,2013,Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity.,Overexpression of miR-103/107 also sensitized U2OS cells to camptothecin and etoposide.
24088786,miR-107,hsa-mir-107,MI0000114,Etoposide,36462,U2OS,-,-,-,-,in vitro,Low,Sensitive,RAD51D,-,2013,Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity.,"As expected, miR-103/107 overexpression sensitized U2OS, HeLa, and PEO1 C4-2 cells to cisplatin and a PARP inhibitor, AZD2281."
24088786,miR-107,hsa-mir-107,MI0000114,Olaparib,23725625,"U2OS, HeLa and PEO1 C4-2",-,-,-,-,in vitro,Low,Sensitive,RAD51D,-,2013,Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity.,Overexpression of miR-103/107 also sensitized U2OS cells to camptothecin and etoposide.
24099768,miR-92b,hsa-mir-92b,MI0003560,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,non-small cell lung cancer,in vitro,Low,Resistant,PTEN,-,2013,"MiR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN.",In vitro assay demonstrated that knock-down of miR-92b inhabits cell growth and sensitized the A549/CDDP cells to CDDP. 
24099915,miR-31 ,hsa-mir-31,MI0000089,Cisplatin,2767,NCI-H1299 and SPC-A-1,-,-,-,non-small cell lung cancer ,in vitro,Low,Resistant,ABCB9,-,2014,MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9.,MiR-31 overexpression induces DDP resistance and miR-31 knockdown rescues DDP sensitivity.
24100610,let-7e,hsa-let-7e,MI0000066,Cisplatin,2767,-,A2780 vs A2780/CDDP,Mice,-,ovarian cancer,in vitro and in vivo,Low,Sensitive,EZH2 and CCND1,EZH2 and CCND1,2013,Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin.,"Overexpression of let-7e by transfection of agomir could resensitize A2780/CP and reduce the expression of cisplatin-resistant-related proteins enhancer of zeste 2 (EZH2) and cyclin D1 (CCND1), whereas let-7e inhibitors increased resistance to cisplatin in parental A2780 cells."
24103454,miR-23a,hsa-mir-23a,MI0000079,Etoposide,36462,HepG2,-,Mice,-,hepatocellular carcinoma,in vitro and in vivo,Low,Sensitive,TOP1 ,-,2013,MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma.,Overexpression of mir-23a could significantly potentiate the in vitro and in vivo anti-tumor effect of etoposide;
24104394,miR-187,hsa-mir-187,MI0000274,Bortezomib,387447,pEZX-187 and pEZX-ct,-,-,-,peripheral T-cell lymphoma,in vitro,Low,Sensitive,-,-,2014,MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.,MiR187-overexpressing T-lymphoma cells were resistant to chemotherapeutic agents but sensitive to the proteasome inhibitor bortezomib.
24104394,miR-187,hsa-mir-187,MI0000274,Cisplatin,2767,pEZX-187 and pEZX-ct,-,-,-,peripheral T-cell lymphoma,in vitro,Low,Resistant,-,-,2014,MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.,MiR187-overexpressing T-lymphoma cells were resistant to chemotherapeutic agents but sensitive to the proteasome inhibitor bortezomib.
24104394,miR-187,hsa-mir-187,MI0000274,Cyclophosphamide,2907,pEZX-187 and pEZX-ct,-,-,-,peripheral T-cell lymphoma,in vitro,Low,Resistant,-,-,2014,MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.,MiR187-overexpressing T-lymphoma cells were resistant to chemotherapeutic agents but sensitive to the proteasome inhibitor bortezomib.
24104394,miR-187,hsa-mir-187,MI0000274,Doxorubicin (Adriamycin),31703,pEZX-187 and pEZX-ct,-,-,-,peripheral T-cell lymphoma,in vitro,Low,Resistant,-,-,2014,MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.,MiR187-overexpressing T-lymphoma cells were resistant to chemotherapeutic agents but sensitive to the proteasome inhibitor bortezomib.
24104394,miR-187,hsa-mir-187,MI0000274,Gemcitabine,60750,pEZX-187 and pEZX-ct,-,-,-,peripheral T-cell lymphoma,in vitro,Low,Resistant,-,-,2014,MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.,MiR187-overexpressing T-lymphoma cells were resistant to chemotherapeutic agents but sensitive to the proteasome inhibitor bortezomib.
24108762,miR-106a,hsa-mir-106a,MI0000113,Cisplatin,2767,-,SGC7901 vs SGC7901/CDDP,-,-,gastric cancer,in vitro,Low,Resistant,PTEN,PTEN/Akt pathway,2013,miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells.,"Transfection of miR-106a induced DDP resistance in SGC7901, while suppression of miR-106a in SGC7901/DDP led to enhanced DDP cytotoxicity."
24122631,miR-21,hsa-mir-21,MI0000077,Chemotherapy,-,-,-,-,Patients,colon cancer,in vivo,Low,Associated,-,-,2014,High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer.,These results demonstrate the potential for miR-21 expression to be used to identify Patient who can benefit from adjuvant chemotherapy.
24122958,miR-1,hsa-mir-1-1,MI0000651,Fluoropyrimidine,-,-,-,-,Patients,gastric cancer,in vivo,Low,Resistant,-,-,2014,miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer.,"Among the 27 Patient with high miR-1 expression, only 3 Patient showed partial response to fluoropyrimidine-based treatment, whereas the remaining 26 Patient showed stable or progressive disease."
24122958,miR-27a,hsa-mir-27a,MI0000085,Fluoropyrimidine,-,-,-,-,Patients,gastric cancer,in vivo,Low,Resistant,-,-,2014,miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer.,"The partial response rates of the Patient with high miRNA1 expression and low miRNA1 expression were 11.1% and 23.1%, respectively (P?=?0.048). Similar results were observed for miRNA27a."
24145123,let-7a,hsa-let-7a-1,MI0000060,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,let-7a,hsa-let-7a-1,MI0000060,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,let-7a2,hsa-let-7a-2,MI0000061,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,let-7c,hsa-let-7c,MI0000064,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,let-7d,hsa-let-7d,MI0000065,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,let-7d-v2,let-7d-v2-P,-,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,let-7e,hsa-let-7e,MI0000066,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,let-7e*,hsa-let-7e,MI0000066,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,let-7i,hsa-let-7i,MI0000434,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1,hsa-mir-1-1,MI0000651,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-100,hsa-mir-100,MI0000102,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-102,hsa-mir-29b-3,MI0000106,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-103,hsa-mir-103a-1,MI0000109,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-106a,hsa-mir-106a,MI0000113,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-106a,hsa-mir-106a,MI0000113,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-106b,hsa-mir-106b,MI0000734,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-107,hsa-mir-107,MI0000114,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-10a*,hsa-mir-10a,MI0000266,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-10b,hsa-mir-10b,MI0000267,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1178,hsa-mir-1178,MI0006271,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1179,hsa-mir-1179,MI0006272,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1181,hsa-mir-1181,MI0006274,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1182,hsa-mir-1182,MI0006275,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1182,hsa-mir-1182,MI0006275,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1183,hsa-mir-1183,MI0006276,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1183,hsa-mir-1183,MI0006276,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1183,hsa-mir-1183,MI0006276,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1200,hsa-mir-1200,MI0006332,Oxaliplatin,5310940,-,"RKO vs RKO/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1206,hsa-mir-1206,MI0006339,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1207,hsa-mir-1207,MI0006340,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-122,hsa-mir-122,MI0000442,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-122,hsa-mir-122,MI0000442,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-122*,hsa-mir-122,MI0000442,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1224,hsa-mir-1224,MI0003764,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1229,hsa-mir-1229,MI0006319,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1229,hsa-mir-1229,MI0006319,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1233,hsa-mir-1233-1,MI0006323,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1236,hsa-mir-1236,MI0006326,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1236,hsa-mir-1236,MI0006326,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1238,hsa-mir-1238,MI0006328,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-123-A,-,-,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1246,hsa-mir-1246,MI0006381,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1247,hsa-mir-1247,MI0006382,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1250,hsa-mir-1250,MI0006385,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1255b,hsa-mir-1255b-1,MI0006435,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1255b1,hsa-mir-1255b-1,MI0006435,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1257,hsa-mir-1257,MI0006391,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1257,hsa-mir-1257,MI0006391,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1257,hsa-mir-1257,MI0006391,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1258,hsa-mir-1258,MI0006392,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1258,hsa-mir-1258,MI0006392,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-125b,hsa-mir-125b-1,MI0000446,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-126*,hsa-mir-126,MI0000471,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-126*,hsa-mir-126,MI0000471,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1264,hsa-mir-1264,MI0003758,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1264,hsa-mir-1264,MI0003758,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1265,hsa-mir-1265,MI0006401,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1265,hsa-mir-1265,MI0006401,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1267,hsa-mir-1267,MI0006404,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1267,hsa-mir-1267,MI0006404,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-127,hsa-mir-127,MI0000472,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1270,hsa-mir-1270,MI0006407,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1270,hsa-mir-1270,MI0006407,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1273,hsa-mir-1273a,MI0006409,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1274a,hsa-mir-1274a,MI0006410,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1274a,hsa-mir-1274a,MI0006410,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1274b,hsa-mir-1274b,MI0006427,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1274b,hsa-mir-1274b,MI0006427,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1275,hsa-mir-1275,MI0006415,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-128,hsa-mir-128-1,MI0000447,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-128,hsa-mir-128-1,MI0000447,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1281,hsa-mir-1281,MI0006428,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1285,hsa-mir-1285-1,MI0006346,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1285-1,hsa-mir-1285-1,MI0006346,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1285-1,hsa-mir-1285-1,MI0006346,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1287,hsa-mir-1287,MI0006349,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-128a,hsa-mir-128-1,MI0000447,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-129*,hsa-mir-129-1,MI0000252,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1290,hsa-mir-1290,MI0006352,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1292,hsa-mir-1292,MI0006433,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1293,hsa-mir-1293,MI0006355,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1293,hsa-mir-1293,MI0006355,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1297,hsa-mir-1297,MI0006358,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1297,hsa-mir-1297,MI0006358,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1299,hsa-mir-1299,MI0006359,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1300,hsa-mir-1300,MI0006360,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1301,hsa-mir-1301,MI0003815,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1303,hsa-mir-1303,MI0006370,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1303,hsa-mir-1303,MI0006370,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1304,hsa-mir-1304,MI0006371,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1306,hsa-mir-1306,MI0006443,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1306,hsa-mir-1306,MI0006443,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1308,hsa-mir-1308,MI0006441,Oxaliplatin,5310940,-,"RKO vs RKO/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-130a,hsa-mir-130a,MI0000448,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-130a,hsa-mir-130a,MI0000448,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1321,hsa-mir-1321,MI0006652,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1323,hsa-mir-1323,MI0003786,Oxaliplatin,5310940,-,"RKO vs RKO/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-135a,hsa-mir-135a-1,MI0000452,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-138-1*,hsa-mir-138-1,MI0000476,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-142,hsa-mir-142,MI0000458,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP,",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1468,hsa-mir-1468,MI0003782,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1468,hsa-mir-1468,MI0003782,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-147,hsa-mir-147a,MI0000262,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-147,hsa-mir-147a,MI0000262,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-150,hsa-mir-150,MI0000479,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-151,hsa-mir-151a,MI0000809,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP, RKO vs RKO/L-OHP",-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-153-2,hsa-mir-153-2,MI0000464,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-155*,hsa-mir-155,MI0000681,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-15a,hsa-mir-15a,MI0000069,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-15b,hsa-mir-15b,MI0000438,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-16,hsa-mir-16-1,MI0000070,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-16-2*,hsa-mir-16-2,MI0000115,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-17,hsa-mir-17,MI0000071,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-17,hsa-mir-17,MI0000071,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-181a,hsa-mir-181a-2,MI0000269,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-181a-2*,hsa-mir-181a-2,MI0000269,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-181a-2*,hsa-mir-181a-2,MI0000269,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-181b,hsa-mir-181b-1,MI0000270,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-181d,hsa-mir-181d,MI0003139,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-182,hsa-mir-182,MI0000272,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-182,hsa-mir-182,MI0000272,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1826,hsa-mir-1826,MI0008194,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1826,hsa-mir-1826,MI0008194,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP, RKO vs RKO/L-OHP ",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1826,hsa-mir-1826,MI0008194,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-184,hsa-mir-184,MI0000481,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-185,hsa-mir-185,MI0000482,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-185,hsa-mir-185,MI0000482,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-186*,hsa-mir-186,MI0000483,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1908,hsa-mir-1908,MI0008329,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1908,hsa-mir-1908,MI0008329,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-191,hsa-mir-191,MI0000465,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-191,hsa-mir-191,MI0000465,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1910,hsa-mir-1910,MI0008331,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-1910,hsa-mir-1910,MI0008331,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-192,hsa-mir-192,MI0000234,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-193a,hsa-mir-193a,MI0000487,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-193b,hsa-mir-193b,MI0003137,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-195,hsa-mir-195,MI0000489,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-196a,hsa-mir-196a-1,MI0000238,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-196a1,hsa-mir-196a-1,MI0000238,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-196b,hsa-mir-196b,MI0001150,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-197,hsa-mir-197,MI0000239,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-197,hsa-mir-197,MI0000239,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-198,hsa-mir-198,MI0000240,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-199b,hsa-mir-199b,MI0000282,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-199b,hsa-mir-200a,MI0000737,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-200a,hsa-mir-200a,MI0000737,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-200a,hsa-mir-200a,MI0000737,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-200b,hsa-mir-200b,MI0000342,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-200c,hsa-mir-200c,MI0000650,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-202*,hsa-mir-202,MI0003130,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-203,hsa-mir-203a,MI0000283,Oxaliplatin,5310940,-,"HT29 vs HT29/OXP, RKO vs RKO/OXP and HCT116 vs HCT116/OXP",-,-,colorectal cancer,in vitro,Low,Resistant,ATM,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,Exogenous expression of miR-203 in chemo-naive CRC cells induced oxaliplatin resistance. Knockdown of miR-203 sensitized chemoresistant CRC cells to oxaliplatin.
24145123,miR-205,hsa-mir-205,MI0000285,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-205,hsa-mir-205,MI0000285,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-206,hsa-mir-206,MI0000490,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-206,hsa-mir-206,MI0000490,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-20a,hsa-mir-20a,MI0000076,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-20a,hsa-mir-20a,MI0000076,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-20b,hsa-mir-20b,MI0001519,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-20b,hsa-mir-20b,MI0001519,Oxaliplatin,5310940,-,"RKO vs RKO/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-21,hsa-mir-21,MI0000077,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-214,hsa-mir-214,MI0000290,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-215,hsa-mir-215,MI0000291,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-219-1,hsa-mir-219a-1,MI0000296,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-219-1,hsa-mir-219a-1,MI0000296,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-221,hsa-mir-221,MI0000298,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP, RKO vs RKO/L-OHP",-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-222,hsa-mir-222,MI0000299,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP, RKO vs RKO/L-OHP",-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-224,hsa-mir-224,MI0000301,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-25,hsa-mir-25,MI0000082,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-25,hsa-mir-25,MI0000082,Oxaliplatin,5310940,-,"RKO vs RKO/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-26a,hsa-mir-26a-1,MI0000083,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-26b,hsa-mir-26b,MI0000084,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-27a,hsa-mir-27a,MI0000085,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-29a,hsa-mir-29a,MI0000087,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-29b,hsa-mir-29b-1,MI0000105,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-29b-1*,hsa-mir-29b-1,MI0000105,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-29c,hsa-mir-29c,MI0000735,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-301a,hsa-mir-301a,MI0000745,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-30a,hsa-mir-30a,MI0000088,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-30b,hsa-mir-30b,MI0000441,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-30b*,hsa-mir-30b,MI0000441,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-30c,hsa-mir-30c-2,MI0000254,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-30c-2*,hsa-mir-30c-2,MI0000254,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-30d,hsa-mir-30d,MI0000255,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP, RKO vs RKO/L-OHP",-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-30e,hsa-mir-30e,MI0000749,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-31,hsa-mir-31,MI0000089,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-32,hsa-mir-32,MI0000090,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-32*,hsa-mir-32,MI0000090,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-32*,hsa-mir-32,MI0000090,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-320a,hsa-mir-320a,MI0000542,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-320a,hsa-mir-320a,MI0000542,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-320b,hsa-mir-320b-1,MI0003776,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-320c,hsa-mir-320c-1,MI0003778,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-320c,hsa-mir-320c-1,MI0003778,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-320d,hsa-mir-320d-1,MI0008190,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-320d,hsa-mir-320d-1,MI0008190,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-324,hsa-mir-324,MI0000813,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-324,hsa-mir-324,MI0000813,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-326,hsa-mir-326,MI0000808,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-326,hsa-mir-326,MI0000808,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-328,hsa-mir-328,MI0000804,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-335*,hsa-mir-335,MI0000816,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-335*,hsa-mir-335,MI0000816,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-339,hsa-mir-339,MI0000815,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-33b,hsa-mir-33b,MI0003646,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-33b*,hsa-mir-33b,MI0003646,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-33b*,hsa-mir-33b,MI0003646,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-342,hsa-mir-342,MI0000805,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-342,hsa-mir-342,MI0000805,Oxaliplatin,5310940,-,"RKO vs RKO/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-345,hsa-mir-345,MI0000825,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-34a,hsa-mir-34a,MI0000268,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-34a,hsa-mir-34a,MI0000268,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-34b,hsa-mir-34b,MI0000742,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-34b,hsa-mir-34b,MI0000742,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-34c,hsa-mir-34c,MI0000743,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-361,hsa-mir-361,MI0000760,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-361,hsa-mir-361,MI0000760,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-362,hsa-mir-362,MI0000762,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-363*,hsa-mir-363,MI0000764,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-365-1,hsa-mir-365a,MI0000767,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-371,hsa-mir-371a,MI0000779,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-373,hsa-mir-373,MI0000781,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-375,hsa-mir-375,MI0000783,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-375,hsa-mir-375,MI0000783,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-382,hsa-mir-382,MI0000790,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-382,hsa-mir-382,MI0000790,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-383,hsa-mir-383,MI0000791,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-383,hsa-mir-383,MI0000791,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-412,hsa-mir-412,MI0002464,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-412,hsa-mir-412,MI0002464,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-421,hsa-mir-421,MI0003685,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-421,hsa-mir-421,MI0003685,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-423,hsa-mir-423,MI0001445,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-425,hsa-mir-425,MI0001448,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-429,hsa-mir-429,MI0001641,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-429,hsa-mir-429,MI0001641,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-433,hsa-mir-433,MI0001723,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-449b,hsa-mir-449b,MI0003673,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-449b,hsa-mir-449b,MI0003673,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-450a2,hsa-mir-450a-2,MI0003187,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-453,hsa-mir-453,MI0001728,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-483,hsa-mir-483,MI0002467,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-483,hsa-mir-483,MI0002467,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-494,hsa-mir-494,MI0003134,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-499,hsa-mir-499a,MI0003183,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-502,hsa-mir-502,MI0003186,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-504,hsa-mir-504,MI0003189,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-504,hsa-mir-504,MI0003189,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-541,hsa-mir-541,MI0005539,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-541,hsa-mir-541,MI0005539,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-548a1,hsa-mir-548a-1,MI0003593,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-548a2,hsa-mir-548a-2,MI0003598,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-548a2,hsa-mir-548a-2,MI0003598,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-548h2,hsa-mir-548h-2,MI0006412,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-548m,hsa-mir-548m,MI0006400,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-550,hsa-mir-550a-1,MI0003600,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-550,hsa-mir-550a-1,MI0003600,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-557,hsa-mir-557,MI0003563,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-558,hsa-mir-558,MI0003564,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-558,hsa-mir-558,MI0003564,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-561,hsa-mir-561,MI0003567,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-566,hsa-mir-566,MI0003572,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-572,hsa-mir-572,MI0003579,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-576,hsa-mir-576,MI0003583,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-576,hsa-mir-576,MI0003583,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-581,hsa-mir-581,MI0003588,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-584,hsa-mir-584,MI0003591,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-584,hsa-mir-584,MI0003591,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-585,hsa-mir-585,MI0003592,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-585,hsa-mir-585,MI0003592,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-587,hsa-mir-587,MI0003595,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-591,hsa-mir-591,MI0003603,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-593,hsa-mir-593,MI0003605,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-595,hsa-mir-595,MI0003607,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-595,hsa-mir-595,MI0003607,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-595,hsa-mir-595,MI0003607,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-598,hsa-mir-598,MI0003610,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-601,hsa-mir-601,MI0003614,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-601,hsa-mir-601,MI0003614,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-602,hsa-mir-602,MI0003615,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-603,hsa-mir-603,MI0003616,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-609,hsa-mir-609,MI0003622,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-609,hsa-mir-609,MI0003622,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-609,hsa-mir-609,MI0003622,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-611,hsa-mir-611,MI0003624,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-613,hsa-mir-613,MI0003626,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-613,hsa-mir-613,MI0003626,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-616,hsa-mir-616,MI0003629,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-619,hsa-mir-619,MI0003633,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-619,hsa-mir-619,MI0003633,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-625*,hsa-mir-625,MI0003639,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-627,hsa-mir-627,MI0003641,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-631,hsa-mir-631,MI0003645,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-634,hsa-mir-634,MI0003649,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-639,hsa-mir-639,MI0003654,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-657,hsa-mir-657,MI0003681,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-657,hsa-mir-657,MI0003681,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-657,hsa-mir-657,MI0003681,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-658,hsa-mir-658,MI0003682,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-660,hsa-mir-660,MI0003684,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-661,hsa-mir-661,MI0003669,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-661,hsa-mir-661,MI0003669,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-663,hsa-mir-663a,MI0003672,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-663b,hsa-mir-663b,MI0006336,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-664,hsa-mir-664a,MI0006442,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-664,hsa-mir-664a,MI0006442,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-675,hsa-mir-675,MI0005416,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-675,hsa-mir-675,MI0005416,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-7,hsa-mir-7-1,MI0000263,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-7-1*,hsa-mir-7-1,MI0000263,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-7-3,hsa-mir-7-3,MI0000265,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-7-3,hsa-mir-7-3,MI0000265,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-760,hsa-mir-760,MI0005567,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-765,hsa-mir-765,MI0005116,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-765,hsa-mir-765,MI0005116,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-766,hsa-mir-766,MI0003836,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-769,hsa-mir-769,MI0003834,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-770,hsa-mir-770,MI0005118,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-770,hsa-mir-770,MI0005118,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-876,hsa-mir-876,MI0005542,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-876,hsa-mir-876,MI0005542,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-877,hsa-mir-877,MI0005561,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-877*,hsa-mir-877,MI0005561,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-877*,hsa-mir-877,MI0005561,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-885,hsa-mir-885,MI0005560,Oxaliplatin,5310940,-,"RKO vs RKO/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-9*,hsa-mir-9-1,MI0000466,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-923,hsa-mir-923,MI0005715,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-923,hsa-mir-923,MI0005715,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-92a,hsa-mir-92a-1,MI0000093,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-92b,hsa-mir-92b,MI0003560,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-92b,hsa-mir-92b,MI0003560,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-92b*,hsa-mir-92b,MI0003560,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-93,hsa-mir-93,MI0000095,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-93,hsa-mir-93,MI0000095,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-93*,hsa-mir-93,MI0000095,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-935,hsa-mir-935,MI0005757,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-936,hsa-mir-936,MI0005758,Oxaliplatin,5310940,-,"HT29 vs HT29/L-OHP,HCT116 vs HCT116/L-OHP",-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-936,hsa-mir-936,MI0005758,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-940,hsa-mir-940,MI0005762,Oxaliplatin,5310940,-,RKO vs RKO/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-99a,hsa-mir-99a,MI0000101,Oxaliplatin,5310940,-,HCT116 vs HCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145123,miR-99b,hsa-mir-99b,MI0000746,Oxaliplatin,5310940,-,HT29 vs HT29/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,,-,2014,miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.,"We compared the miRNA expression profiles of the three parental (chemo-naive) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells by using miRNA microarray chip analysis with about 1200 premiRNA and mature human miRNA probes (Suppl. Table S1-S3)."
24145606,miR-130a,hsa-mir-130a,MI0000448,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer ,in vitro,Low,Sensitive,XIAP,-,2013,Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.,"MTT assay and flow cytometry (FCM) results showed that over-expression of miR-130a regulated apoptotic activity, and thereby cisplatin chemosensitivity, in ovarian cancer cells."
24147037,let-7a*,hsa-let-7a-1,MI0000060,Gemcitabine,60750,-,HuCCT1 vs HuH28,-,-,cholangiocarcinoma,in vitro,High,Resistant,-,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Because HuCCT1 cells were more sensitive to Gem than were HuH28 cells, HuCCT1 cells were used as the standard in this comparison; expression of 10 miRNAs (miR-29b, 130a, 141, 200a, 200b, 200c, 205, 221, 222 and 429) was downregulated in HuH28 cells, while expression of eight others (miR-99b, 125a-5p, 143, 377, 452, 589, 597, and 708) was upregulated."
24147037,let-7f-2*,hsa-let-7f-2,MI0000068,Gemcitabine,60750,-,HuCCT1 vs HuH28,-,-,cholangiocarcinoma,in vitro,High,Resistant,-,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Because HuCCT1 cells were more sensitive to Gem than were HuH28 cells, HuCCT1 cells were used as the standard in this comparison; expression of 10 miRNAs (miR-29b, 130a, 141, 200a, 200b, 200c, 205, 221, 222 and 429) was downregulated in HuH28 cells, while expression of eight others (miR-99b, 125a-5p, 143, 377, 452, 589, 597, and 708) was upregulated."
24147037,miR-141,hsa-mir-141,MI0000457,Gemcitabine,60750,-,HuCCT1 vs HuH28,-,-,cholangiocarcinoma,in vitro,High,Sensitive,"PIK3R1, MMP-2",-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Because HuCCT1 cells were more sensitive to Gem than were HuH28 cells, HuCCT1 cells were used as the standard in this comparison; expression of 10 miRNAs (miR-29b, 130a, 141, 200a, 200b, 200c, 205, 221, 222 and 429) was downregulated in HuH28 cells, while expression of eight others (miR-99b, 125a-5p, 143, 377, 452, 589, 597, and 708) was upregulated."
24147037,miR-143,hsa-mir-143,MI0000459,Gemcitabine,60750,-,HuCCT1 vs HuH28,-,-,cholangiocarcinoma,in vitro,High,Sensitive,-,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Because HuCCT1 cells were more sensitive to Gem than were HuH28 cells, HuCCT1 cells were used as the standard in this comparison; expression of 10 miRNAs (miR-29b, 130a, 141, 200a, 200b, 200c, 205, 221, 222 and 429) was downregulated in HuH28 cells, while expression of eight others (miR-99b, 125a-5p, 143, 377, 452, 589, 597, and 708) was upregulated."
24147037,miR-200a,hsa-mir-200a,MI0000737,Gemcitabine,60750,-,HuCCT1 vs HuH28,-,-,cholangiocarcinoma,in vitro,High,Sensitive,-,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Because HuCCT1 cells were more sensitive to Gem than were HuH28 cells, HuCCT1 cells were used as the standard in this comparison; expression of 10 miRNAs (miR-29b, 130a, 141, 200a, 200b, 200c, 205, 221, 222 and 429) was downregulated in HuH28 cells, while expression of eight others (miR-99b, 125a-5p, 143, 377, 452, 589, 597, and 708) was upregulated."
24147037,miR-200b,hsa-mir-200b,MI0000342,Gemcitabine,60750,-,HuCCT1 vs HuH28,-,-,cholangiocarcinoma,in vitro,High,Sensitive,-,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Because HuCCT1 cells were more sensitive to Gem than were HuH28 cells, HuCCT1 cells were used as the standard in this comparison; expression of 10 miRNAs (miR-29b, 130a, 141, 200a, 200b, 200c, 205, 221, 222 and 429) was downregulated in HuH28 cells, while expression of eight others (miR-99b, 125a-5p, 143, 377, 452, 589, 597, and 708) was upregulated."
24147037,miR-200c,hsa-mir-200c,MI0000650,Gemcitabine,60750,-,HuCCT1 vs HuH28,-,-,cholangiocarcinoma,in vitro,High,Sensitive,-,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Because HuCCT1 cells were more sensitive to Gem than were HuH28 cells, HuCCT1 cells were used as the standard in this comparison; expression of 10 miRNAs (miR-29b, 130a, 141, 200a, 200b, 200c, 205, 221, 222 and 429) was downregulated in HuH28 cells, while expression of eight others (miR-99b, 125a-5p, 143, 377, 452, 589, 597, and 708) was upregulated."
24147037,miR-205,hsa-mir-205,MI0000285,Gemcitabine,60750,HuCCT1 and HuH28,-,-,-,cholangiocarcinoma,in vitro,Low,Sensitive,-,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Ectopic overexpression of each of three downregulated miRNAs in HuH28 (miR-29b, miR-205, miR-221) restored Gem sensitivity to HuH28."
24147037,miR-221,hsa-mir-221,MI0000298,Gemcitabine,60750,HuCCT1 and HuH28,-,-,-,cholangiocarcinoma,in vitro,Low,Sensitive,PIK3R1,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Ectopic overexpression of each of three downregulated miRNAs in HuH28 (miR-29b, miR-205, miR-221) restored Gem sensitivity to HuH28."
24147037,miR-222,hsa-mir-222,MI0000299,Gemcitabine,60750,-,HuCCT1 vs HuH28,-,-,cholangiocarcinoma,in vitro,High,Sensitive,PIK3R1,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Because HuCCT1 cells were more sensitive to Gem than were HuH28 cells, HuCCT1 cells were used as the standard in this comparison; expression of 10 miRNAs (miR-29b, 130a, 141, 200a, 200b, 200c, 205, 221, 222 and 429) was downregulated in HuH28 cells, while expression of eight others (miR-99b, 125a-5p, 143, 377, 452, 589, 597, and 708) was upregulated."
24147037,miR-29b,hsa-mir-29b-1,MI0000105,Gemcitabine,60750,HuCCT1 and HuH28,-,-,-,cholangiocarcinoma,in vitro,Low,Sensitive,PIK3R1 and MMP-2,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Ectopic overexpression of each of three downregulated miRNAs in HuH28 (miR-29b, miR-205, miR-221) restored Gem sensitivity to HuH28."
24147037,miR-377,hsa-mir-377,MI0000785,Gemcitabine,60750,-,HuCCT1 vs HuH28,-,-,cholangiocarcinoma,in vitro,High,Sensitive,-,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Because HuCCT1 cells were more sensitive to Gem than were HuH28 cells, HuCCT1 cells were used as the standard in this comparison; expression of 10 miRNAs (miR-29b, 130a, 141, 200a, 200b, 200c, 205, 221, 222 and 429) was downregulated in HuH28 cells, while expression of eight others (miR-99b, 125a-5p, 143, 377, 452, 589, 597, and 708) was upregulated."
24147037,miR-429,hsa-mir-429,MI0001641,Gemcitabine,60750,-,HuCCT1 vs HuH28,-,-,cholangiocarcinoma,in vitro,High,Resistant,-,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Because HuCCT1 cells were more sensitive to Gem than were HuH28 cells, HuCCT1 cells were used as the standard in this comparison; expression of 10 miRNAs (miR-29b, 130a, 141, 200a, 200b, 200c, 205, 221, 222 and 429) was downregulated in HuH28 cells, while expression of eight others (miR-99b, 125a-5p, 143, 377, 452, 589, 597, and 708) was upregulated."
24147037,miR-452,hsa-mir-452,MI0001733,Gemcitabine,60750,-,HuCCT1 vs HuH28,-,-,cholangiocarcinoma,in vitro,High,Resistant,-,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Because HuCCT1 cells were more sensitive to Gem than were HuH28 cells, HuCCT1 cells were used as the standard in this comparison; expression of 10 miRNAs (miR-29b, 130a, 141, 200a, 200b, 200c, 205, 221, 222 and 429) was downregulated in HuH28 cells, while expression of eight others (miR-99b, 125a-5p, 143, 377, 452, 589, 597, and 708) was upregulated."
24147037,miR-589,hsa-mir-589,MI0003599,Gemcitabine,60750,-,HuCCT1 vs HuH28,-,-,cholangiocarcinoma,in vitro,High,Resistant,-,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Because HuCCT1 cells were more sensitive to Gem than were HuH28 cells, HuCCT1 cells were used as the standard in this comparison; expression of 10 miRNAs (miR-29b, 130a, 141, 200a, 200b, 200c, 205, 221, 222 and 429) was downregulated in HuH28 cells, while expression of eight others (miR-99b, 125a-5p, 143, 377, 452, 589, 597, and 708) was upregulated."
24147037,miR-597,hsa-mir-597,MI0003609,Gemcitabine,60750,-,HuCCT1 vs HuH28,-,-,cholangiocarcinoma,in vitro,High,Resistant,-,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Because HuCCT1 cells were more sensitive to Gem than were HuH28 cells, HuCCT1 cells were used as the standard in this comparison; expression of 10 miRNAs (miR-29b, 130a, 141, 200a, 200b, 200c, 205, 221, 222 and 429) was downregulated in HuH28 cells, while expression of eight others (miR-99b, 125a-5p, 143, 377, 452, 589, 597, and 708) was upregulated."
24147037,miR-708,hsa-mir-708,MI0005543,Gemcitabine,60750,-,HuCCT1 vs HuH28,-,-,cholangiocarcinoma,in vitro,High,Resistant,-,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Because HuCCT1 cells were more sensitive to Gem than were HuH28 cells, HuCCT1 cells were used as the standard in this comparison; expression of 10 miRNAs (miR-29b, 130a, 141, 200a, 200b, 200c, 205, 221, 222 and 429) was downregulated in HuH28 cells, while expression of eight others (miR-99b, 125a-5p, 143, 377, 452, 589, 597, and 708) was upregulated."
24147037,miR-99b,hsa-mir-99b,MI0000746,Gemcitabine,60750,-,HuCCT1 vs HuH28,-,-,cholangiocarcinoma,in vitro,High,Resistant,-,-,2013,"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.","Because HuCCT1 cells were more sensitive to Gem than were HuH28 cells, HuCCT1 cells were used as the standard in this comparison; expression of 10 miRNAs (miR-29b, 130a, 141, 200a, 200b, 200c, 205, 221, 222 and 429) was downregulated in HuH28 cells, while expression of eight others (miR-99b, 125a-5p, 143, 377, 452, 589, 597, and 708) was upregulated."
24148180,miR-370,hsa-mir-370,MI0000778,Homoharringtonine,285033,K562,-,-,Patients,chronic myeloid leukemia,in vitro and in vivo,Low,Sensitive,FoxM1,-,2013,MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1.,miR-370 significantly promoted HHT-mediated cell apoptosis and miR-370 and HHT cooperated in affecting FoxM1 expression.
24148247,miR-181a,hsa-mir-181a-2,MI0000269,Cisplatin,2767,-,CAL27 vs CAL27/CDDP,-,-,tongue squamous cell carcinoma,in vitro,Low,Sensitive,Twist1,-,2013,miR-181a-Twist1 pathway in the chemoresistance of tongue squamous cell carcinoma.,"Functional analyses indicated that miR-181a reversed chemoresistance, inhibited EMT and metastatic potential in TSCC cells."
24148817,miR-16,hsa-mir-16-1,MI0000070,Gemcitabine,60750,MSTO-211H and MM05,-,-,-,malignant pleural mesothelioma,in vitro,Low,Sensitive,Bcl-2 and CCND1,-,2013,Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.,"Growth inhibition caused by miR-16 correlated with downregulation of target genes including Bcl-2 and CCND1, and miR-16 re-expression sensitised MPM cells to pemetrexed and gemcitabine."
24148817,miR-16,hsa-mir-16-1,MI0000070,Pemetrexed,446556,MSTO-211H and MM05,-,-,-,malignant pleural mesothelioma,in vitro,Low,Sensitive,Bcl-2 and CCND1,-,2013,Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.,"Growth inhibition caused by miR-16 correlated with downregulation of target genes including Bcl-2 and CCND1, and miR-16 re-expression sensitised MPM cells to pemetrexed and gemcitabine."
24154840,miR-21,hsa-mir-21,MI0000077,Trastuzumab,9903,NUGC4 and NCI-N87,-,-,-,gastric cancer,in vitro,Low,Resistant,PTEN,-,2014,The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.,"Overexpression of miR-21 decreased the sensitivity of GC cells to trastuzumab, while suppression of miR-21 expression restored the resistance of GC cells to trastuzumab."
24157646,hsa-miRPlus-A1098,-,-,Paclitaxel,36314,"H1993, H1155",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,hsa-miRPlus-C1005,-,-,Paclitaxel,36314,"H1993, H1155",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,hsa-miRPlus-C1040,-,-,Paclitaxel,36314,"H1993, H1155",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,hsa-miRPlus-C1049,-,-,Paclitaxel,36314,"H1993, H1155",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,hsa-miRPlus-C1100,-,-,Paclitaxel,36314,"H1993, H1155",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,let-7i,hsa-let-7i,MI0000434,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-103-2*,hsa-mir-103a-2,MI0000108,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-106b,hsa-mir-106b,MI0000734,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-10a,hsa-mir-10a,MI0000266,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-10b,hsa-mir-10b,MI0000267,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-1204,hsa-mir-1204,MI0006337,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-125a,hsa-mir-125a,MI0000469,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-126,hsa-mir-126,MI0000471,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-127,hsa-mir-127,MI0000472,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-128,hsa-mir-128-1,MI0000447,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-129,hsa-mir-129-1,MI0000252,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-1296,hsa-mir-1296,MI0003780,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-130b*,hsa-mir-130b,MI0000748,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-130b*,hsa-mir-130b,MI0000748,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-132,hsa-mir-132,MI0000449,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-133a,hsa-mir-133a-1,MI0000450,Paclitaxel,36314,"H1155, H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-133a,hsa-mir-133a-1,MI0000450,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-133b,hsa-mir-133b,MI0000822,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-134,hsa-mir-134,MI0000474,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-139,hsa-mir-139,MI0000261,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-141,hsa-mir-141,MI0000457,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-143,hsa-mir-143,MI0000459,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-143*,hsa-mir-143,MI0000459,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-145*,hsa-mir-145,MI0000461,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-155*,hsa-mir-155,MI0000681,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-182,hsa-mir-182,MI0000272,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-187,hsa-mir-187,MI0000274,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-18a*,hsa-mir-18a,MI0000072,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-1908,hsa-mir-1908,MI0008329,Paclitaxel,36314,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-1908,hsa-mir-1908,MI0008329,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-197,hsa-mir-197,MI0000239,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24157646,miR-199a,hsa-mir-199a-1,MI0000242,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-199b,hsa-mir-199b,MI0000282,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-200c*,hsa-mir-200c,MI0000650,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-23b,hsa-mir-23b,MI0000439,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-346,hsa-mir-346,MI0000826,Paclitaxel,36314,"H1155, H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-34c,hsa-mir-34c,MI0000743,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-361,hsa-mir-361,MI0000760,Paclitaxel,36314,"H1155, H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-363*,hsa-mir-363,MI0000764,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-374a,hsa-mir-374a,MI0000782,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-432*,hsa-mir-432,MI0003133,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-486,hsa-mir-486-1,MI0002470,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-512,hsa-mir-512-1,MI0003140,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-513b,hsa-mir-513b,MI0006648,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-515,hsa-mir-515-1,MI0003144,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-516a,hsa-mir-516a-1,MI0003180,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-517a,hsa-mir-517a,MI0003161,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-517b,hsa-miR-517b,MI0003165,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-517c,hsa-mir-517c,MI0003174,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-518e*,hsa-mir-518e,MI0003169,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-518f,hsa-mir-518f,MI0003154,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-519a*,hsa-mir-519a-1,MI0003178,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-519b,hsa-mir-519b,MI0003151,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-519c,hsa-mir-519c,MI0003148,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-519e*,hsa-mir-519e,MI0003145,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-522*,hsa-mir-522,MI0003177,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-523*,hsa-mir-523,MI0003153,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-582,hsa-mir-582,MI0003589,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-585,hsa-mir-585,MI0003592,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-586,hsa-mir-586,MI0003594,Vinorelbine,60780,"H358, H1993",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-605,hsa-mir-605,MI0003618,Paclitaxel,36314,"H358, H1155",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-610,hsa-mir-610,MI0003623,Paclitaxel,36314,"H358, H1155",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-615,hsa-mir-615,MI0003628,Paclitaxel,36314,"H358, H1155",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-625*,hsa-mir-625,MI0003639,Paclitaxel,36314,"H358, H1155",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-671,hsa-mir-671,MI0003760,Paclitaxel,36314,"H358, H1155",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-767,hsa-mir-767,MI0003763,Paclitaxel,36314,"H358, H1155",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-768,hsa-mir-768,MI0005117,Paclitaxel,36314,"H358, H1155",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-769,hsa-mir-769,MI0003834,Paclitaxel,36314,"H358, H1155",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-875,hsa-mir-875,MI0005541,Paclitaxel,36314,"H358, H1155",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-885,hsa-mir-885,MI0005560,Paclitaxel,36314,"H358, H1155",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-920,hsa-mir-920,MI0005712,Paclitaxel,36314,"H358, H1155",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-922,hsa-mir-922,MI0005714,Paclitaxel,36314,"H358, H1155",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-923,hsa-mir-923,MI0005715,Paclitaxel,36314,"H358, H1155",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-933,hsa-mir-933,MI0005755,Paclitaxel,36314,"H358, H1155",-,-,-,lung cancer,in vitro,High,Resistant,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24157646,miR-938,hsa-mir-938,MI0005760,Paclitaxel,36314,"H358, H1155",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24168967,miR-9,hsa-mir-9-1,MI0000466,AG014699,9931953,C13,-,Mice,-,ovarian cancer,in vitro and in vivo,Low,Sensitive,BRCA1,-,2013,miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.,Treatment with miR-9 agomiR sensitized BRCA1-proficient C13* xenograft tumors to cisplatin and AG014699.
24168967,miR-9,hsa-mir-9-1,MI0000466,Cisplatin,2767,"C13, OV2008 and A2780",-,Mice,-,ovarian cancer,in vitro and in vivo,Low,Sensitive,BRCA1,-,2013,miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.,Treatment with miR-9 agomiR sensitized BRCA1-proficient C13* xenograft tumors to cisplatin and AG014699.
24169343,miR-200b,hsa-mir-200b,MI0000342,5-Fluorouracil,3385,TFK-1,-,-,-,cholangiocarcinoma,in vitro,Low,Sensitive,SUZ12 and ROCK2,-,2013,Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis.,These data illustrate that miR-200b/c significantly enhances the cytotoxic effect of 5-fluorouracil on cholangiocarcinoma cells.
24169343,miR-200c,hsa-mir-200c,MI0000650,5-Fluorouracil,3385,TFK-1,-,-,-,cholangiocarcinoma,in vitro,Low,Sensitive,SUZ12 and ROCK2,-,2013,Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis.,These data illustrate that miR-200b/c significantly enhances the cytotoxic effect of 5-fluorouracil on cholangiocarcinoma cells.
24174534,miR-200b,hsa-mir-200b,MI0000342,Celastrol,122724,-,Malme3M  vs Malme3M/CEL,-,-,melanoma,in vitro,Low,Sensitive,CAGE,-,2013,miR-200b and cancer/testis antigen CAGE form a feedback loop to regulate the invasion and tumorigenic and angiogenic responses of a cancer cell line to microtubule-targeting drugs.,miR-200b also enhanced the sensitivities to microtubule-targeting drugs in vitro.
24183997,miR-181a,hsa-mir-181a-2,MI0000269,Cisplatin,2767,SiHa and Me180,-,Mice,-,cervical squamous cell carcinoma,in vitro and in vivo,Low,Resistant,PRKCD,-,2014,MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.,"Two human cervical squamous cancer cell lines, SiHa and Me180, were used. Enforced expression of miR-181a enhanced chemoresistance to cisplatin in cervical cancer cells through apoptosis reversion. In a nude mouse xenograft model, the overexpression of miR-181a markedly inhibited the therapeutic response to cisplatin."
24186202,let-7,-,-,Paclitaxel,36314,-,O432 vs O432/Taxol,-,-,ovarian cancer,in vitro,Low,Sensitive,-,-,2014,PSP94 contributes to chemoresistance and its peptide derivative PCK3145 represses tumor growth in ovarian cancer.,"We found that Let-7 (family) miRNA levels were significantly decreased in O432-RP-psp-O cells, when compared to control O432-RP-C cells."
24194922,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,CNE2,-,-,-,nasopharyngeal carcinoma,in vitro,Low,Resistant,PDCD4 and Fas-L,-,2013,Epstein-Barr Virus_Encoded LMP1 upregulates microRNA-21 to promote the resistance of nasopharyngeal carcinoma cells to cisplatin-induced Apoptosis by suppressing PDCD4 and Fas-L.,The enforced expression of miR-21 reduced sensitivity to the growth inhibition effects of cisplatin.
24198203,miR-10b,hsa-mir-10b,MI0000267,Gefitinib,123631,-,-,-,Patientss,Non-small Cell Lung Cancer,in vivo,High,Resistant,-,-,2013,"microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation","Additionally, miR-10b is highly expressed in progressive disease compared with complete remission or stable disease (Fig. 2b, D, P<0.001)."
24198203,miR-21,hsa-mir-21,MI0000077,Gefitinib,123631,-,-,-,Patientss,Non-small Cell Lung Cancer,in vivo,High,Resistant,-,-,2013,"microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation","Patients with reduced miR-21 expression after receiving adjuvant therapy with gefitinib had a significant improvement in overall survival (28.3 months), as compared with those with a high expression level (24.4 months) (P = 0.0045) (Fig. 2b, A)."
24199791,let-7c,hsa-let-7c,MI0000064,Erlotinib,176870,-,A549 vs A549/ER,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,-,-,2013,Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.,"Ectopic up-regulation of miRNAs, especially miR-200b and let-7c, significantly diminished the erlotinib resistance of A549M cells."
24199791,miR-200b,hsa-mir-200b,MI0000342,Erlotinib,176870,-,A549 vs A549/ER,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,-,-,2013,Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.,"Ectopic up-regulation of miRNAs, especially miR-200b and let-7c, significantly diminished the erlotinib resistance of A549M cells."
24210072,miR-29a,hsa-mir-29a,MI0000087,Cisplatin,2767,SCC-9 and SCC-25,-,-,-,oral squamous cell carcinoma,in vitro,Low,Sensitive,MMP2,-,2014,MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis.,"Exogenous overexpression of miR-29a inhibited OSCC cell invasion and anti-apoptosis significantly in vitro. Whereas, knockdown of miR-29a promoted OSCC cell invasion and induced drug-resistance in vitro."
24211739,miR-101,hsa-mir-101-1,MI0000103,5-Fluorouracil,3385,HepG2,-,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,EZH2 ,-,2014,MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.,Tumor suppressor miR-101 represses HCC progression through directly targeting EZH2 oncogene and sensitizes liver cancer cells to chemotherapeutic treatment.
24211739,miR-101,hsa-mir-101-1,MI0000103,Doxorubicin (Adriamycin),31703,HepG2,-,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,EZH2 ,-,2014,MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.,Tumor suppressor miR-101 represses HCC progression through directly targeting EZH2 oncogene and sensitizes liver cancer cells to chemotherapeutic treatment.
24216611,miR-365,hsa-mir-365a,MI0000767,Gemcitabine,60750,Panc-1 and AsPC-1,-,-,-,pancreatic cancer,in vitro,Low,Resistant,SHC1 and BAX,-,2014,MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX.,The introduction of miR-365 to Panc-1 and AsPC-1 cells significantly increased cell viability after gemcitabine treatment up to 2-fold.
24217767,miR-1280,hsa-mir-1280,MI0006437,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.,"Compared with the primary GISTs,the levels of eight genes (hsa-miR-1280,hsa-miR-140-5p,hsa-miR-320a,hsa-miR-135b,hsa-miR-664*,hsa-miR-483-5p,hsa-miR-140-3p,and hsa-miR-574-3p)were downregulated in imatinib-resistant GISTs"
24217767,miR-135b,hsa-mir-135b,MI0000810,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.,"Compared with the primary GISTs,the levels of eight genes (hsa-miR-1280,hsa-miR-140-5p,hsa-miR-320a,hsa-miR-135b,hsa-miR-664*,hsa-miR-483-5p,hsa-miR-140-3p,and hsa-miR-574-3p)were downregulated in imatinib-resistant GISTs"
24217767,miR-140,hsa-mir-140,MI0000456,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.,"Compared with the primary GISTs,the levels of eight genes (hsa-miR-1280,hsa-miR-140-5p,hsa-miR-320a,hsa-miR-135b,hsa-miR-664*,hsa-miR-483-5p,hsa-miR-140-3p,and hsa-miR-574-3p)were downregulated in imatinib-resistant GISTs"
24217767,miR-151,hsa-mir-151a,MI0000809,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.,"Compared with the primary GISTs, the expression levels of five genes (hsa-miR-15a,hsa-miR-16,hsa-miR-195 ,hsa-miR-335,and hsa-miR-151-5p) were upregulated in imatinib-resistant GISTs"
24217767,miR-15a,hsa-mir-15a,MI0000069,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.,"Compared with the primary GISTs, the expression levels of five genes (hsa-miR-15a,hsa-miR-16,hsa-miR-195 ,hsa-miR-335,and hsa-miR-151-5p) were upregulated in imatinib-resistant GISTs"
24217767,miR-16,hsa-mir-16-1,MI0000070,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.,"Compared with the primary GISTs, the expression levels of five genes (hsa-miR-15a,hsa-miR-16,hsa-miR-195 ,hsa-miR-335,and hsa-miR-151-5p) were upregulated in imatinib-resistant GISTs"
24217767,miR-195,hsa-mir-195,MI0000489,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.,"Compared with the primary GISTs, the expression levels of five genes (hsa-miR-15a,hsa-miR-16,hsa-miR-195 ,hsa-miR-335,and hsa-miR-151-5p) were upregulated in imatinib-resistant GISTs"
24217767,miR-320a,hsa-mir-320a,MI0000542,Imatinib,5291,-,-,-,Patients,gastrointestinal stromal tumors,in vivo,Low,Sensitive,-,-,2014,MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.,"We examined the miR-320a expression level by qRT-PCR in 12 cases of GISTs, and confirmed that miR-320a expression tended to be lower in imatinib-resistant samples."
24217767,miR-335,hsa-mir-335,MI0000816,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.,"Compared with the primary GISTs, the expression levels of five genes (hsa-miR-15a,hsa-miR-16,hsa-miR-195 ,hsa-miR-335,and hsa-miR-151-5p) were upregulated in imatinib-resistant GISTs"
24217767,miR-483,hsa-mir-483,MI0002467,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.,"Compared with the primary GISTs,the levels of eight genes (hsa-miR-1280,hsa-miR-140-5p,hsa-miR-320a,hsa-miR-135b,hsa-miR-664*,hsa-miR-483-5p,hsa-miR-140-3p,and hsa-miR-574-3p) were downregulated in imatinib-resistant GISTs"
24217767,miR-574,hsa-mir-574,MI0003581,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.,"Compared with the primary GISTs,the levels of eight genes (hsa-miR-1280,hsa-miR-140-5p,hsa-miR-320a,hsa-miR-135b,hsa-miR-664*,hsa-miR-483-5p,hsa-miR-140-3p,and hsa-miR-574-3p) were downregulated in imatinib-resistant GISTs"
24217767,miR-664*,hsa-mir-664a,MI0006442,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.,"Compared with the primary GISTs,the levels of eight genes (hsa-miR-1280,hsa-miR-140-5p,hsa-miR-320a,hsa-miR-135b,hsa-miR-664*,hsa-miR-483-5p,hsa-miR-140-3p,and hsa-miR-574-3p) were downregulated in imatinib-resistant GISTs"
24220856,let-7e,hsa-let-7e,MI0000066,Paclitaxel,36314,"H1155, H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,"In order to identify miRNA inhibitors that affect viability and response to paclitaxel of NSCLC cells, we combined an HTS platform with a library of inhibitors for 747 human miRNAs."
24220856,let-7e,hsa-let-7e,MI0000066,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-106a,hsa-mir-106a,MI0000113,Paclitaxel,36314,"H1155, H358, H1993",-,-,-,lung cancer,in vitro,High,Sensitive,-,-,2013,A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel,We further identified miRNA inhibitors that have effects on cell viability or paclitaxel response in more than one cell line.
24220856,miR-106a,hsa-mir-106a,MI0000113,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-125a,hsa-mir-125a,MI0000469,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-126 ,hsa-mir-126,MI0000471,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-130a,hsa-mir-130a,MI0000448,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-130b ,hsa-mir-130b,MI0000748,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-134 ,hsa-mir-134,MI0000474,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-141,hsa-mir-141,MI0000457,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-142 ,hsa-mir-142,MI0000458,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-148a ,hsa-mir-148a,MI0000253,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-17,hsa-mir-17,MI0000071,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-17 ,hsa-mir-17,MI0000071,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-192,hsa-mir-192,MI0000234,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-193b ,hsa-mir-193b,MI0003137,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-195,hsa-mir-195,MI0000489,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-19b ,hsa-mir-19b-1,MI0000074,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-218,hsa-mir-218-1,MI0000294,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-29c,hsa-mir-29c,MI0000735,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-30a,hsa-mir-30a,MI0000088,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-30a ,hsa-mir-30a,MI0000088,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-30c ,hsa-mir-30c-2,MI0000254,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-32,hsa-mir-320a,MI0000542,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-338,hsa-mir-338,MI0000814,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-367,hsa-mir-367,MI0000775,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-373* ,hsa-mir-373,MI0000781,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-374 ,hsa-mir-374a,MI0000782,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-376b ,hsa-mir-376b,MI0002466,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-377,hsa-mir-377,MI0000785,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-452-AS ,-,-,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-489,hsa-mir-489,MI0003124,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-515,hsa-mir-515-1,MI0003144,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-516 ,hsa-mir-516a-1,MI0003180,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-7 ,hsa-mir-7-1,MI0000263,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-95,hsa-mir-95,MI0000097,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Resistant,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24220856,miR-99b ,hsa-mir-99b,MI0000746,Paclitaxel,36314,NCI60 cell lines (40 ccls),-,-,-,Cancer,in vitro,High,Sensitive,-,-,2013,Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel,"Based on miRNA expression and GI50 data, Pearson's correlation test identified 35 miRNAs associated with in vitro paclitaxel sensitivity (P<0.05)."
24223174,miR-27a,hsa-mir-27a,MI0000085,Chemotherapy,-,-,-,-,Patients,non-small cell lung cancer,in vivo,Low,Associated,-,-,2013,A genetic polymorphism in pre-miR-27a confers clinical outcome of non-small cell lung cancer in a Chinese population.,"Moreover, multivariate logistic regression analysis showed that the subjects with AG/GG genotypes of rs895819 had significantly decreased response rate to platinum-based chemotherapy compared to those with the AA genotype."
24248543,miR-145,hsa-mir-145,MI0000461,Vemurafenib,42611257,-,colo205 vs colo205/VEM,Mice,-,colorectal cancer,in vitro and in vivo,Low,Sensitive,-,-,2014,Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line.,"Moreover, the overexpression of miR-145 could increase the sensitivity of colo205/V cells to vemurafenib both in vitro and in vivo."
24249161,miR-23a,hsa-mir-23a,MI0000079,5-fluorouracil,3385,HCT-116 and HT-29,-,Mice,-,colorectal cancer,in vitro and in vivo,Low,Resistant,Apaf-1,-,2014,MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells.,The overexpression of miR-23a antisense up-regulated the 5-FU induced apoptosis in colon cancer cells.
24258346,miR-134,hsa-mir-134,MI0000474,Gefitinib,123631,A549,-,-,-,lung adenocarcinoma,in vitro,Low,Resistant,MAGI2,-,2014,MiR-134/487b/655 cluster regulates TGF-Beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.,"Overexpression of miR-134 and miR-487b promoted the EMT phenomenon and affected the drug resistance to gefitinib, whereas knockdown of these miRNAs inhibited the EMT process and reversed TGF-Beta1-induced resistance to gefitinib."
24258346,miR-487b,hsa-mir-487b,MI0003530,Gefitinib,123631,A549,-,-,-,lung adenocarcinoma,in vitro,Low,Resistant,MAGI2,-,2014,MiR-134/487b/655 cluster regulates TGF-Beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.,"Overexpression of miR-134 and miR-487b promoted the EMT phenomenon and affected the drug resistance to gefitinib, whereas knockdown of these miRNAs inhibited the EMT process and reversed TGF-Beta1-induced resistance to gefitinib."
24268810,let-7c,hsa-let-7c,MI0000064,Gefitinib,123631,-,H1975 vs H1975/FUL,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,-,PI3K/AKT and MEK/ERK signaling pathways,2014,Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression.,"Taken together, our findings suggest that let-7c plays an important role in fulvestrant-induced upregulation of gefitinib sensitivity in H1975 cells."
24275137,miR-21,hsa-mir-21,MI0000077,5-Fluorouracil,3385,-,HT-29 vs HT-29/5-FU,-,-,colon cancer,in vitro,Low,Resistant,hMSH2,TP and DPD,2014,Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro.,"Furthermore, knockdown of miR-21 reversed these effects on HT-29 cells and increased the sensitivity of HT-29/5-FU to 5-FU chemotherapy."
24286315,miR-221,hsa-mir-221,MI0000298,Trastuzumab,9903,SKBr-3,-,-,-,breast cancer,in vitro,Low,Resistant,PTEN,-,2014,MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN.,"Here, we found that the oncogenic miRNA, miR-221, inhibited apoptosis, induced trastuzumab resistance and promoted metastasis of HER2-positive breast cancers."
24286402,miR-30b,hsa-mir-30b,MI0000441,Erlotinib,176870,-,-,-,Patients,non-small cell lung cancer,in vivo,Low,Associated,-,-,2013,miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer.,Expression of both miR-30b and miR-30c were significantly correlated with the short-term response (P <0.05).
24286402,miR-30b,hsa-mir-30b,MI0000441,Gefitinib,123631,-,-,-,Patients,non-small cell lung cancer,in vivo,Low,Associated,-,-,2013,miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer.,Expression of both miR-30b and miR-30c were significantly correlated with the short-term response (P <0.05).
24303078,miR-1269,hsa-mir-1269a,MI0006406,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-127,hsa-mir-127,MI0000472,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-135b,hsa-mir-135b,MI0000810,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-146a,hsa-mir-146a,MI0000477,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-149,hsa-mir-149,MI0000478,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-184,hsa-mir-184,MI0000481,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-202*,hsa-mir-202,MI0003130,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-299,hsa-mir-299,MI0000744,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-3117,hsa-mir-3117,MI0014130,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-323,hsa-mir-323a,MI0000807,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-338,hsa-mir-338,MI0000814,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-3681,hsa-mir-3681,MI0016082,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-3681*,hsa-mir-3681,MI0016082,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-369,hsa-mir-369,MI0000777,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-375,hsa-mir-375,MI0000783,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-376a,hsa-mir-376a-1,MI0000784,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-376b,hsa-mir-376b,MI0002466,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-376c,hsa-mir-376c,MI0000776,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-377,hsa-mir-377,MI0000785,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-379,hsa-mir-379,MI0000787,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-380,hsa-mir-380,MI0000788,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-381,hsa-mir-381,MI0000789,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,leukemia,in vitro,Low,Sensitive,MDR1,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"These miRs are located within a miR cluster located at chromosome region 14q32.31, and all miRs in this cluster appear to be down-regulated in K562/ADM cells."
24303078,miR-383*,hsa-mir-383,MI0000791,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-409,hsa-mir-409,MI0001735,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-410,hsa-mir-410,MI0002465,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-411,hsa-mir-411,MI0003675,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-485,hsa-mir-485,MI0002469,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-487b,hsa-mir-487b,MI0003530,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-488,hsa-mir-488,MI0003123,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-489,hsa-mir-489,MI0003124,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-494,hsa-mir-494,MI0003134,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24303078,miR-495,hsa-mir-495,MI0003135,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,leukemia,in vitro,Low,Sensitive,MDR1,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"These miRs are located within a miR cluster located at chromosome region 14q32.31, and all miRs in this cluster appear to be down-regulated in K562/ADM cells."
24303078,miR-508,hsa-mir-508,MI0003195,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-509,hsa-mir-509-1,MI0003196,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-514,hsa-mir-514a-1,MI0003198,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-584,hsa-mir-584,MI0003591,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Resistant,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,"In addition, up-regulated miRs with fold-changes > 10 are listed in Table S5"
24303078,miR-889,hsa-mir-889,MI0005540,Doxorubicin (Adriamycin),31703,-,K562 vs K562/ADR,-,-,chronic  myelogenous  leukemia,in vitro,High,Sensitive,-,-,2013,Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.,miRs with >50-fold reduction in expression in K563/ADM cells
24304648,miR-122,hsa-mir-122,MI0000442,5-Fluorouracil,3385,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-122,hsa-mir-122,MI0000442,Oxaliplatin,5310940,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-130,-,-,5-Fluorouracil,3385,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-130,-,-,Oxaliplatin,5310940,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-145,hsa-mir-145,MI0000461,5-Fluorouracil,3385,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-145,hsa-mir-145,MI0000461,Oxaliplatin,5310940,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-185,hsa-mir-185,MI0000482,5-Fluorouracil,3385,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-185,hsa-mir-185,MI0000482,Oxaliplatin,5310940,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-191,hsa-mir-191,MI0000465,5-Fluorouracil,3385,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-191,hsa-mir-191,MI0000465,Oxaliplatin,5310940,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-20a,hsa-mir-20a,MI0000076,5-Fluorouracil,3385,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-20a,hsa-mir-20a,MI0000076,Oxaliplatin,5310940,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-21,hsa-mir-21,MI0000077,5-Fluorouracil,3385,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-21,hsa-mir-21,MI0000077,Oxaliplatin,5310940,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-216,hsa-mir-216a,MI0000292,5-Fluorouracil,3385,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-216,hsa-mir-216a,MI0000292,Oxaliplatin,5310940,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-24,hsa-mir-24-1,MI0000080,5-Fluorouracil,3385,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-24,hsa-mir-24-1,MI0000080,Oxaliplatin,5310940,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-25,hsa-mir-25,MI0000082,5-Fluorouracil,3385,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-25,hsa-mir-25,MI0000082,Oxaliplatin,5310940,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-372,hsa-mir-372,MI0000780,5-Fluorouracil,3385,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-372,hsa-mir-372,MI0000780,Oxaliplatin,5310940,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-483,hsa-mir-483,MI0002467,5-Fluorouracil,3385,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-483,hsa-mir-483,MI0002467,Oxaliplatin,5310940,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-618,hsa-mir-618,MI0003632,5-Fluorouracil,3385,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-618,hsa-mir-618,MI0003632,Oxaliplatin,5310940,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-92a,hsa-mir-92a-1,MI0000093,5-Fluorouracil,3385,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-92a,hsa-mir-92a-1,MI0000093,Oxaliplatin,5310940,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-99a,hsa-mir-99a,MI0000101,5-Fluorouracil,3385,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24304648,miR-99a,hsa-mir-99a,MI0000101,Oxaliplatin,5310940,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy,"Individual miRNA was considered to be differentially expressed only if there was a larger than two-fold change in its expression level between the responders and nonresponders to chemotherapy. On the basis of these criteria, 14 miRNAs were found to be differentially expressed between the two groups, analysed by qRT-PCR for individuals of the 20 pool samples, as shown in Supplementary Table 1"
24314246,miR-146a,hsa-mir-146a,MI0000477,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-146a,hsa-mir-146a,MI0000477,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-146a,hsa-mir-146a,MI0000477,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-146b,hsa-mir-146b,MI0003129,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-146b,hsa-mir-146b,MI0003129,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-146b,hsa-mir-146b,MI0003129,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-15a,hsa-mir-15a,MI0000069,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-15a,hsa-mir-15a,MI0000069,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-15a,hsa-mir-15a,MI0000069,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-16,hsa-mir-16-1,MI0000070,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-16,hsa-mir-16-1,MI0000070,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-16,hsa-mir-16-1,MI0000070,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-181a,hsa-mir-181a-2,MI0000269,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-181a,hsa-mir-181a-2,MI0000269,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-181a,hsa-mir-181a-2,MI0000269,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-181d,hsa-mir-181d,MI0003139,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-181d,hsa-mir-181d,MI0003139,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-181d,hsa-mir-181d,MI0003139,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-194,hsa-mir-194-1,MI0000488,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-194,hsa-mir-194-1,MI0000488,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-194,hsa-mir-194-1,MI0000488,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-27b ,hsa-mir-27b,MI0000440,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-27b ,hsa-mir-27b,MI0000440,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-27b ,hsa-mir-27b,MI0000440,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-30b,hsa-mir-30b,MI0000441,Carboplatin,38904,-,Huh-7 vs Huh-7/CBP,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-30b,hsa-mir-30b,MI0000441,Doxorubicin (Adriamycin),31703,-,Huh-7 vs Huh-7/ADR,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24314246,miR-30b,hsa-mir-30b,MI0000441,Mitomycin C,5746,-,Huh-7 vs Huh-7/MMC,-,-,hepatocellular cancer,in vitro,High,Resistant,-,-,2013,Morphology and microRNA expression profiles of drug-resistant cells in hepatocellular carcinoma,"MiRNA microarray was used to analyze the differential miRNA expression profiles in these cells (Huh-7, Huh-7/ADM, Huh-7/CBP. Huh-7/MMC) followed by real time quantitative PCR validation."
24316511,miR-520h,hsa-mir-520h,MI0003175,Doxorubicin (Adriamycin),31703,MKN45 and MKN28,-,-,-,gastric cancer,in vitro,Low,Sensitive,HDAC-1,-,2014,Downregulation of histone deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin.,Doxorubicin-induced cell death was impaired by exogenous HDAC1 or by miR-520h inhibitor.
24317363,miR-200b,hsa-mir-200b,MI0000342,Docetaxel,148124,PC3 and DU-145,-,-,-,prostate cancer,in vitro,Low,Sensitive,Bmi-1,-,2014,"miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1.",Enforced miR-200b expression suppressed PCa cell proliferation and migration and enhanced chemosensitivity to docetaxel by targeting B-cell-specific Moloney murine leukemia virus insertion site 1 (Bmi-1).
24318997,miR-328,hsa-mir-328,MI0000804,Cisplatin,2767,HCT-116,-,-,-,colorectal cancer,in vitro,Low,Sensitive,CD44,-,2014,Macrophage-derived reactive oxygen species suppress miR-328 targeting CD44 in cancer cells and promote redox adaptation.,HCT116 cells transfected with miR-328 mimics were significantly less resistant to H2O2 and CDDP than control HCT116 cells.
24318997,miR-328,hsa-mir-328,MI0000804,Hydrogen Peroxide (H2O2),784,HCT116,-,-,-,colorectal cancer,in vitro,Low,Sensitive,CD44,-,2014,Macrophage-derived reactive oxygen species suppress miR-328 targeting CD44 in cancer cells and promote redox adaptation.,HCT116 cells transfected with miR-328 mimics were significantly less resistant to H2O2 and CDDP than control HCT116 cells.
24324033,miR-221,hsa-mir-221,MI0000298,Doxorubicin (Adriamycin),31703,HepG2 and SNU449,-,-,-,hepatocellular carcinoma,in vitro,Low,Resistant,MDM2,-,2014,p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.,"In these cell lines, miR-221 silencing determined an increased sensitization to doxorubicin challenge in terms of caspase-3/7 activity assay."
24330517,miR-223,hsa-mir-223,MI0000300,Praziquantel,4891,-,-,mice,-,Schistosoma japonicum infection,in vivo,Low,Sensitive,-,-,2013,Host serum miR-223 is a potential new biomarker for Schistosoma japonicum infection and the response to chemotherapy,"We showed both hydroxyproline content and the circulating miR-223 were returned to near normality within one month after PZQ treatment, indicating the serum miR-223 marker is sensitive to chemotherapy and could be potentially developed as new tool for measurement of the response to chemotherapy."
24331411,miR-21,hsa-mir-21,MI0000077,Gefitinib,123631,-,PC-9 vs PC-9/R,Mice,-,non-small cell lung cancer,in vitro and in vivo,Low,Resistant,PTEN and PDCD4,-,2014,MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.,"Furthermore, serum miR-21 expression in NSCLC Patient treated with EGFR-TKI was significantly higher at the time of acquiring resistance than at baseline (p<0.01)."
24335172,miR-181a,hsa-mir-181a-2,MI0000269,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Sensitive,Bcl-2 ,-,2013,The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells.,The down-regulation of miR-181a decreased adriamycin-induced apoptosis in MCF-7 cells. 
24345332,miR-30d,hsa-mir-30d,MI0000255,Cisplatin,2767,SW3716 and 8305C,-,Mice,-,anaplastic thyroid carcinoma,in vitro and in vivo,Low,Sensitive,beclin 1,-,2014,Regulation of autophagy by miR-30d impacts sensitivity of anaplastic thyroid carcinoma to cisplatin.,We further showed that inhibition of the beclin 1-mediated autophagy by the miR-30d mimic sensitized ATC cells to cisplatin both in vitro (cell culture) and in vivo (animal xenograft model). 
24348845,miR-106a,hsa-mir-106a,MI0000113,Cisplatin,2767,-,OVCAR3 vs OVCAR3/CDDP,-,-,ovarian cancer,in vitro,Low,Resistant,PDCD4,-,2014,microRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells.,The expression of the PDCD4 protein and the sensitivity to CDDP was decreased in the OVCAR3 cells that were transfected with the mimics of miR-106a.
24350829,miR-217,hsa-mir-217,MI0000293,Dasatinib,3062316,-,K562 vs K562/DAS,-,-,leukemia,in vitro,Low,Sensitive,DNMT3A,-,2014,Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors.,Forced expression of miR-217 in K562DR cells sensitized these cells to thyrosine kinase inhibitors via downregulation of DNMT3A.
24370341,miR-205,hsa-mir-205,MI0000285,Cisplatin,2767,DU145 and  PC-3,-,Mice,-,prostate cancer,in vitro and in vivo,Low,Sensitive,RAB27A and LAMP3,-,2014,miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells.,"In the present study, we show that miR-205 replacement in castration-resistant mesenchymal prostate cancer cells caused an enhancement of cisplatin cytotoxic activity in vitro and in vivo, as a consequence of autophagy impairment."
24377569,miR-126,hsa-mir-126,MI0000471,Bleomicin,5360373,Siha,-,-,-,cervical cancer,in vitro,Low,Sensitive,-,-,2014,miR-126 Suppresses the proliferation of cervical cancer cells and alters cell sensitivity to the chemotherapeutic drug bleomycin.,Upregulation of miR-126 inhibited cervical cancer cell proliferation and enhanced the sensitivity to BLM.
24394555,miR-181a,hsa-mir-181a-2,MI0000269,Cisplatin,2767,-,-,-,Patients,ovarian cancer,in vivo,Low,Resistant,Smad7,-,2014,microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition.,"Furthermore, ectopic expression of miR-181a results in increased cellular survival, migration, invasion, drug resistance and in vivo tumour burden and dissemination."
24398307,miR-503,hsa-mir-503,MI0003188,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung cancer,in vitro,Low,Sensitive,-,"MDR1, MRP1, ERCC1, Survivin and Bcl-2",2014,The reversing and molecular mechanisms of miR-503 on the drug-resistance to cisplatin in A549/DDP cells,MiR-503 was able to increase the cisplatin sensitivity of A549/DDP.
24400121,miR-223,hsa-mir-223,MI0000300,Doxorubicin (Adriamycin),31703,MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Sensitive,STAT5A,-,2014,miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions.,"we obtained elevated levels of miR-223 in tumor cells and observed decreased migration, increased cell death in anoikis conditions and augmented sensitivity to chemotherapy but no effect on adhesion and proliferation."
24400121,miR-223,hsa-mir-223,MI0000300,Paclitaxel,36314,MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Sensitive,STAT5A,-,2014,miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions.,"we obtained elevated levels of miR-223 in tumor cells and observed decreased migration, increased cell death in anoikis conditions and augmented sensitivity to chemotherapy but no effect on adhesion and proliferation."
24400442,let-7c,hsa-let-7c,MI0000064,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,ABCC2 and Bcl-XL ,-,2013,Let-7c sensitizes acquired cisplatin-resistant A549 cells by targeting ABCC2 and Bcl-XL.,"In conclusion, our findings suggested for the first time that let-7c modulate DDP response in A549/DDP cells, and one of the mechanisms was through targeting ABCC2 and Bcl-XL."
24412084,miR-137,hsa-mir-137,MI0000454,Cisplatin,2767,-,H446 vs H446/CDDP,-,-,small cell lung cancer,in vitro,Low,Sensitive,-,KIT,2014,MicroRNA-137 down-regulates KIT and inhibits small cell lung cancer cell proliferation.,"Results indicated that sensitivity of H446 cells to cisplatin significantly decreased after transfected with miR-137 inhibitor, while miR-137 mimics transfection increased drug sensitivity of H446/CDDP cells and deregulated KIT expression."
24423412,miR-34a,hsa-mir-34a,MI0000268,Cisplatin,2767,"5637, T24 and HT-1376",-,-,-,bladder cancer,in vitro,Low,Sensitive,CD44,-,2014,Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy.,Increased miR-34a expression significantly sensitized MIBC cells to cisplatin and inhibited the tumorigenicity and proliferation of cancer cells in vitro and in vivo.
24425875,miR-146a,hsa-mir-146a,MI0000477,Cisplatin,2767,A549 and H460,-,-,-,lung cancer,in vitro,Low,Sensitive,RIP1,-,2014,Receptor-interacting protein 1 increases chemoresistance by maintaining inhibitor of apoptosis protein levels and reducing reactive oxygen species through a microRNA-146a-mediated catalase pathway.,"Inhibition of microRNA-146a restored catalase expression, suppressed ROS induction, and protected against cytotoxicity in cisplatin-treated RIP1 knockdown cells"
24444609,miR-34a,hsa-mir-34a,MI0000268,Capsaicin,1548943,A549,-,-,-,non-small cell lung carcinoma,in vitro,Low,Sensitive,BCL2,-,2014,Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells.,"Further exploration revealed that over-expression of miR-34a augmented capsaicin-induced apoptosis, while inhibition of miR-34a significantly favored survival benefit by increasing Bcl-2 level."
24447717,miR-182,hsa-mir-182,MI0000272,Cisplatin,2767,-,HepG2 vs HepG2/CDDP,-,-,hepatocellular carcinoma,in vitro,Low,Resistant,TP53INP1,-,2014,Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.,"Upregulated miR-182 significantly increased the cell viability, whereas miR-182 knockdown reduced the cell viability during cisplatin treatment."
24447928,miR-145,hsa-mir-145,MI0000461,5-Fluorouracil,3385,-,DLD-1 vs DLD-1/5-FU,-,-,colon cancer,in vitro,Low,Associated,-,-,2014,Extracellular disposal of tumor-suppressor miRs-145 and -34a via microvesicles and 5-FU resistance of human colon cancer cells.,"Thus, the intra- and extracellular miR-145 and -34a were closely associated with 5-FU resistance, and the resistance was in part due to the enhanced secretion of miR-145 and -34a via MVs, resulting in low intracellular levels of both miRNAs."
24447928,miR-34a,hsa-mir-34a,MI0000268,5-Fluorouracil,3385,-,DLD-1 vs DLD-1/5-FU,-,-,colon cancer,in vitro,Low,Associated,-,-,2014,Extracellular disposal of tumor-suppressor miRs-145 and -34a via microvesicles and 5-FU resistance of human colon cancer cells.,"Thus, the intra- and extracellular miR-145 and -34a were closely associated with 5-FU resistance, and the resistance was in part due to the enhanced secretion of miR-145 and -34a via MVs, resulting in low intracellular levels of both miRNAs."
24454732,miR-147,hsa-mir-147a,MI0000262,Gefitinib,123631,HCT116 and SW480,-,-,-,colorectal cancer,in vitro,Low,Sensitive,-,-,2014,MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance.,This supports the hypothesis that miR-147 reverses cell resistance to EGFR inhibitor gefitinib following a mesenchymal to epithelial transition.
24454901,miR-142,hsa-mir-142,MI0000458,Levetiracetam(LEV),5284583,-,-,mice,-,seizure,in vivo,High,Resistant,-,-,2014,Unique Behavioral Characteristics and microRNA Signatures in a Drug Resistant Epilepsy Model,"Expression of miRNA was altered in LS and MDR groups, and we identified 4 miRNAs (miR-206, miR-374, miR-468, and miR-142-5p), which were differently modulated in the MDR group versus both control and LS groups."
24454901,miR-142,hsa-mir-142,MI0000458,Valproate(VAP),-,-,-,mice,-,seizure,in vivo,High,Resistant,-,-,2014,Unique Behavioral Characteristics and microRNA Signatures in a Drug Resistant Epilepsy Model,"Expression of miRNA was altered in LS and MDR groups, and we identified 4 miRNAs (miR-206, miR-374, miR-468, and miR-142-5p), which were differently modulated in the MDR group versus both control and LS groups."
24454901,miR-206,hsa-mir-206,MI0000490,Levetiracetam(LEV),5284583,-,-,mice,-,seizure,in vivo,High,Sensitive,-,-,2014,Unique Behavioral Characteristics and microRNA Signatures in a Drug Resistant Epilepsy Model,"Expression of miRNA was altered in LS and MDR groups, and we identified 4 miRNAs (miR-206, miR-374, miR-468, and miR-142-5p), which were differently modulated in the MDR group versus both control and LS groups."
24454901,miR-206,hsa-mir-206,MI0000490,Valproate(VAP),-,-,-,mice,-,seizure,in vivo,High,Sensitive,-,-,2014,Unique Behavioral Characteristics and microRNA Signatures in a Drug Resistant Epilepsy Model,"Expression of miRNA was altered in LS and MDR groups, and we identified 4 miRNAs (miR-206, miR-374, miR-468, and miR-142-5p), which were differently modulated in the MDR group versus both control and LS groups."
24454901,miR-374,hsa-mir-374a,MI0000782,Levetiracetam(LEV),5284583,-,-,mice,-,seizure,in vivo,High,Sensitive,-,-,2014,Unique Behavioral Characteristics and microRNA Signatures in a Drug Resistant Epilepsy Model,"Expression of miRNA was altered in LS and MDR groups, and we identified 4 miRNAs (miR-206, miR-374, miR-468, and miR-142-5p), which were differently modulated in the MDR group versus both control and LS groups."
24454901,miR-374,hsa-mir-374a,MI0000782,Valproate(VAP),-,-,-,mice,-,seizure,in vivo,High,Sensitive,-,-,2014,Unique Behavioral Characteristics and microRNA Signatures in a Drug Resistant Epilepsy Model,"Expression of miRNA was altered in LS and MDR groups, and we identified 4 miRNAs (miR-206, miR-374, miR-468, and miR-142-5p), which were differently modulated in the MDR group versus both control and LS groups."
24454901,miR-468,-,-,Levetiracetam(LEV),5284583,-,-,mice,-,seizure,in vivo,High,Resistant,-,-,2014,Unique Behavioral Characteristics and microRNA Signatures in a Drug Resistant Epilepsy Model,"Expression of miRNA was altered in LS and MDR groups, and we identified 4 miRNAs (miR-206, miR-374, miR-468, and miR-142-5p), which were differently modulated in the MDR group versus both control and LS groups."
24454901,miR-468,-,-,Valproate(VAP),-,-,-,mice,-,seizure,in vivo,High,Resistant,-,-,2014,Unique Behavioral Characteristics and microRNA Signatures in a Drug Resistant Epilepsy Model,"Expression of miRNA was altered in LS and MDR groups, and we identified 4 miRNAs (miR-206, miR-374, miR-468, and miR-142-5p), which were differently modulated in the MDR group versus both control and LS groups."
24460313,let-7g,hsa-let-7g,MI0000433,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,let-7i,hsa-let-7i,MI0000434,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-101,hsa-mir-101-1,MI0000103,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-103_1,hsa-mir-103a-1,MI0000109,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-103_2,hsa-mir-103a-2,MI0000108,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-103-2*,hsa-mir-103a-2,MI0000108,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-106a,hsa-mir-106a,MI0000113,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-107,hsa-mir-107,MI0000114,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-10a,hsa-mir-10a,MI0000266,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-10b,hsa-mir-10b,MI0000267,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-122,hsa-mir-122,MI0000442,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,8 serum samples from response-phase (n=8) and 8 from resistance-phase (n=8) were evaluated bymicroarrays. 168 miRNA primer sets were integrated into the miRNA microarray each.
24460313,miR-122,hsa-mir-122,MI0000442,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-125b,hsa-mir-125b-1,MI0000446,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-133b,hsa-mir-133b,MI0000822,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-142,hsa-mir-142,MI0000458,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-144,hsa-mir-144,MI0000460,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,8 serum samples from response-phase (n=8) and 8 from resistance-phase (n=8) were evaluated bymicroarrays. 168 miRNA primer sets were integrated into the miRNA microarray each.
24460313,miR-144,hsa-mir-144,MI0000460,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-146a,hsa-mir-146a,MI0000477,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-148a,hsa-mir-148a,MI0000253,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-148b,hsa-mir-148b,MI0000811,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-151-59p,-,-,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-15a,hsa-mir-15a,MI0000069,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-181a,hsa-mir-181a-2,MI0000269,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-185,hsa-mir-185,MI0000482,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-18a,hsa-mir-18a,MI0000072,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-18a*,hsa-mir-18a,MI0000072,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-192,hsa-mir-192,MI0000234,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-193b,hsa-mir-193b,MI0003137,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-199a,hsa-mir-199a-1,MI0000242,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-19a,hsa-mir-19a,MI0000073,Chemotherapy,-,-,-,-,Patients,colorectal cancer,in vivo,Low,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,Expression level of miR-19a in serum was significantly up-regulated in resistance-phase Patient than in response-phase Patient. 
24460313,miR-19a,hsa-mir-19a,MI0000073,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,8 serum samples from response-phase (n=8) and 8 from resistance-phase (n=8) were evaluated bymicroarrays. 168 miRNA primer sets were integrated into the miRNA microarray each.
24460313,miR-19b,hsa-mir-19b-1,MI0000074,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-205,hsa-mir-205,MI0000285,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-20a,hsa-mir-20a,MI0000076,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-20b,hsa-mir-20b,MI0001519,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-21,hsa-mir-21,MI0000077,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-210,hsa-mir-210,MI0000286,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-215,hsa-mir-215,MI0000291,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-22,hsa-mir-22,MI0000078,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-221,hsa-mir-221,MI0000298,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,8 serum samples from response-phase (n=8) and 8 from resistance-phase (n=8) were evaluated bymicroarrays. 168 miRNA primer sets were integrated into the miRNA microarray each.
24460313,miR-221,hsa-mir-221,MI0000298,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-222,hsa-mir-222,MI0000299,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,8 serum samples from response-phase (n=8) and 8 from resistance-phase (n=8) were evaluated bymicroarrays. 168 miRNA primer sets were integrated into the miRNA microarray each.
24460313,miR-222,hsa-mir-222,MI0000299,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-26b,hsa-mir-26b,MI0000084,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-29a,hsa-mir-29a,MI0000087,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-29b,hsa-mir-29b-1,MI0000105,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-29c,hsa-mir-29c,MI0000735,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-30a,hsa-mir-30a,MI0000088,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-30e,hsa-mir-30e,MI0000749,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-32,hsa-mir-32,MI0000090,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-324,hsa-mir-324,MI0000813,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-331,hsa-mir-331,MI0000812,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-335,hsa-mir-335,MI0000816,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-339,hsa-mir-339,MI0000815,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-34a,hsa-mir-34a,MI0000268,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-365,hsa-mir-365a,MI0000767,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-409,hsa-mir-409,MI0001735,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-423,hsa-mir-423,MI0001445,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-451,hsa-mir-451a,MI0001729,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-501,hsa-mir-501,MI0003185,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-502,hsa-mir-502,MI0003186,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-543,hsa-mir-543,MI0005565,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-652,hsa-mir-652,MI0003667,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-660,hsa-mir-660,MI0003684,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-720,hsa-mir-720,MI0006654,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460313,miR-99a,hsa-mir-99a,MI0000101,FOLFOX Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2013,Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.,62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis
24460329,miR-21,hsa-mir-21,MI0000077,Gemcitabine,60750,HPAC and PANC-1,-,-,Patients,pancreatic cancer,in vitro and in vivo,Low,Resistant,PTEN,-,2013,MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.,The serum miRNA-21 level in gemcitabine-resistant Patient was significantly higher than in gemcitabine-sensitive Patient.
24462518,miR-16,hsa-mir-16-1,MI0000070,Cisplatin,2767,H460 (HTB-177),-,-,-,lung adenocarcinoma,in vitro,Low,Sensitive,-,-,2013,DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity,"MiR-382 and miR-21 overexpression had no effect or resulted in resistance, while miR-16 promoted sensitivity to cisplatin and doxorubicin (Figure 5A). "
24462518,miR-16,hsa-mir-16-1,MI0000070,Doxorubicin (Adriamycin),31703,H460 (HTB-177),-,-,-,lung adenocarcinoma,in vitro,Low,Sensitive,-,-,2013,DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity,"MiR-382 and miR-21 overexpression had no effect or resulted in resistance, while miR-16 promoted sensitivity to cisplatin and doxorubicin (Figure 5A). "
24462518,miR-183,hsa-mir-183,MI0000273,Cisplatin,2767,MDA-MB-231 (HTB-26),-,-,-,breast cancer,in vitro,Low,Sensitive,-,-,2013,DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity,"MiR-296-5p and miR-193a-3p overexpression consistently induced resistance to cisplatin, whereas miR-183 overexpression induced sensitivity. MiR-296-5p overexpression also led to resistance for doxorubicin and paclitaxel, while let-7a overexpression did not modulate chemotherapy sensitivity (Figure 5A). "
24462518,miR-193a,hsa-mir-193a,MI0000487,Cisplatin,2767,MDA-MB-157 (HTB-24),-,-,-,breast cancer,in vitro,Low,Resistant,-,-,2013,DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity,"MiR-296-5p and miR-193a-3p overexpression consistently induced resistance to cisplatin, whereas miR-183 overexpression induced sensitivity. MiR-296-5p overexpression also led to resistance for doxorubicin and paclitaxel, while let-7a overexpression did not modulate chemotherapy sensitivity (Figure 5A). "
24462518,miR-296,hsa-mir-296,MI0000747,Cisplatin,2767,MDA-MB-157 (HTB-24),-,-,-,breast cancer,in vitro,Low,Resistant,-,-,2013,DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity,"MiR-296-5p and miR-193a-3p overexpression consistently induced resistance to cisplatin, whereas miR-183 overexpression induced sensitivity. MiR-296-5p overexpression also led to resistance for doxorubicin and paclitaxel, while let-7a overexpression did not modulate chemotherapy sensitivity (Figure 5A). "
24462518,miR-296,hsa-mir-296,MI0000747,Doxorubicin (Adriamycin),31703,MDA-MB-157 (HTB-24),-,-,-,breast cancer,in vitro,Low,Resistant,-,-,2013,DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity,"MiR-296-5p and miR-193a-3p overexpression consistently induced resistance to cisplatin, whereas miR-183 overexpression induced sensitivity. MiR-296-5p overexpression also led to resistance for doxorubicin and paclitaxel, while let-7a overexpression did not modulate chemotherapy sensitivity (Figure 5A). "
24462518,miR-296,hsa-mir-296,MI0000747,Paclitaxel,36314,MDA-MB-157 (HTB-24),-,-,-,breast cancer,in vitro,Low,Resistant,-,-,2013,DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity,"MiR-296-5p and miR-193a-3p overexpression consistently induced resistance to cisplatin, whereas miR-183 overexpression induced sensitivity. MiR-296-5p overexpression also led to resistance for doxorubicin and paclitaxel, while let-7a overexpression did not modulate chemotherapy sensitivity (Figure 5A). "
24468065,miR-132,hsa-mir-132,MI0000449,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Resistant,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-140,hsa-mir-140,MI0000456,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Resistant,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-143,hsa-mir-143,MI0000459,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Sensitive,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-145,hsa-mir-145,MI0000461,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Sensitive,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-15b,hsa-mir-15b,MI0000438,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Sensitive,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-17,hsa-mir-17,MI0000071,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Resistant,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-181a,hsa-mir-181a-2,MI0000269,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Resistant,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-200a,hsa-mir-200a,MI0000737,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Sensitive,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-200c,hsa-mir-200c,MI0000650,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Resistant,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-21,hsa-mir-21,MI0000077,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Resistant,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-215,hsa-mir-215,MI0000291,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Resistant,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-221,hsa-mir-221,MI0000298,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Resistant,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-23a,hsa-mir-23a,MI0000079,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Resistant,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-25,hsa-mir-25,MI0000082,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Resistant,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-26b,hsa-mir-26b,MI0000084,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Resistant,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-30a,hsa-mir-30a,MI0000088,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Resistant,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-33a,hsa-mir-33a,MI0000091,Cisplatin,2767,Saos-2 and MG-63,-,-,Patients,osteosarcoma,in vitro and in vivo,Low,Resistant,TWIST,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"In Saos-2 cells treated with cisplatin, inhibition of miR-33a by antagomir-33a markedly increased cell apoptosis, which was enhanced by overexpression of TWIST."
24468065,miR-34c,hsa-mir-34c,MI0000743,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Sensitive,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-363,hsa-mir-363,MI0000764,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Resistant,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-375,hsa-mir-375,MI0000783,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Resistant,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-422a,hsa-mir-422a,MI0001444,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Sensitive,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-451,hsa-mir-451a,MI0001729,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Sensitive,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-611,hsa-mir-611,MI0003624,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Sensitive,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-625,hsa-mir-625,MI0003639,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Resistant,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24468065,miR-92a,hsa-mir-92a-1,MI0000093,Chemotherapy,-,-,-,-,Patientss,osteosarcoma,in vivo,High,Sensitive,,-,2014,miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.,"All patients had OS in the long tubular bones. As the inclusion rate for adult OS patients was low, we only performed this study with pediatric OS patients. miRNA microarray analyses showed that 25 miRNAs were differentially expressed in OS tissues from the chemoresistant OS patients compared with those from the control OS patients, 16 being up-regulated (Table 2) and 9 down-regulated (Table 3)."
24469837,miR-17-92,-,-,Staurosporine,5329102,"H157, H460 and RH2",-,-,-,non-small cell lung cancer,in vitro,Low,Resistant,-,-,2014,PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC.,Suppression of miR-19b sensitizes NSCLC cells to apoptosis.
24472409,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,SKOV3,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,Low,Resistant,PDCD4,-,2014,The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.,"Using anti-microRNA inhibitors, we demonstrated that miR-21 attenuation reversed the drug resistant phenotype in both the resistant and parental cell lines."
24475095,miR-133a,hsa-mir-133a-1,MI0000450,Sunitinib,5329102,-,Caki-2 vs SRCaki-2,-,Patientss,metastatic renal cell carcinoma,in vitro and in vivo,High,Resistant,-,-,2013,Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma,"Increased levels of miR-942, miR-133a, miR-628-5p and miR-484 were observed in resistant phenotypes as compared with sensitive phenotypes (Figure 1)"
24475095,miR-484,hsa-mir-484,MI0002468,Sunitinib,5329102,-,Caki-2 vs SRCaki-2,-,Patientss,metastatic renal cell carcinoma,in vitro and in vivo,High,Resistant,-,-,2013,Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma,"Increased levels of miR-942, miR-133a, miR-628-5p and miR-484 were observed in resistant phenotypes as compared with sensitive phenotypes (Figure 1)"
24475095,miR-628,hsa-mir-628,MI0003642,Sunitinib,5329102,-,Caki-2 vs SRCaki-2,-,Patientss,metastatic renal cell carcinoma,in vitro and in vivo,High,Resistant,-,-,2013,Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma,"Increased levels of miR-942, miR-133a, miR-628-5p and miR-484 were observed in resistant phenotypes as compared with sensitive phenotypes (Figure 1)"
24475095,miR-942,hsa-mir-942,MI0005767,Sunitinib,5329102,-,Caki-2 vs SRCaki-2,-,Patientss,metastatic renal cell carcinoma,in vitro and in vivo,High,Resistant, MMP-9 and VEGF,-,2013,Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma,"Increased levels of miR-942, miR-133a, miR-628-5p and miR-484 were observed in resistant phenotypes as compared with sensitive phenotypes (Figure 1)"
24486548,miR-503,hsa-mir-503,MI0003188,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,non-small cell lung cancer,in vitro,Low,Associated,FANCA,-,2014,Epigenetic silencing of MicroRNA-503 regulates FANCA expression in non-small cell lung cancer cell.,"Our result found that the level of DNMT1 was enhanced in cisplatin resistant cells when compared to parental cells, suggesting that increased expression of DNMT1 would be implicated in methylation of miR-503"
24490491,miR-130a,hsa-mir-130a,MI0000448,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,Low,Resistant,-,MDR1 and PTEN,2013,Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines,"Down-regulated miR-130a did not affect cell proliferations, but enhanced the sensitivity of the cells to cisplatin, inhibited the expressions of MDR1 mRNA and P-gp and increased the expression of PTEN proteins."
24510775,miR-145,hsa-mir-145,MI0000461,Paclitaxel,36314,-,SKOV3 vs SKOV3/Taxol and A2780 vs A2780/Taxol,Mice,Patients ,ovarian cancer,in vitro and in vivo,Low,Sensitive,Sp1 and Cdk6,-,2014,miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.,"These changes resulted in increased accumulation of antineoplastic drugs and G1 cell cycle arrest, which rendered the cells more sensitive to paclitaxel in vitro and in vivo."
24516043,miR-27a,hsa-mir-27a,MI0000085,Cisplatin,2767,-,EJ vs EJ/CDDP and RT112 vs RT112/CDDP,-,-,bladder cancer,in vitro,Low,Sensitive,SLC7A11,-,2014,Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.,Resistant cell lines were resensitized by restoring miRNA-27a expression or reducing SLC7A11 activity with siRNA or with sulfasalazine.
24519092,miR-30c,hsa-mir-30c-1,MI0000736,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR and MDA-MB-231 vs MDA-MB-231/ADR,-,-,breast cancer,in vitro,Low,Sensitive,YWHAZ,p38MAPK pathway,2014,Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells.,"Furthermore, we observed that transfection of an miR-30c mimic significantly suppressed the ability of MCF-7/ADR to resist doxorubicin."
24551227,miR-34a,hsa-mir-34a,MI0000268,Erlotinib,176870,"A549, H460, H1299 and H226",HCC827 vs HCC827/ER,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,-,-,2014,In-depth analysis shows synergy between erlotinib and miR-34a.,The data suggest that a majority of NSCLC and other cancers previously not suited for erlotinib may prove sensitive to the drug when used in combination with a miR-34a-based therapy.
24554719,miR-29b,hsa-mir-29b-1,MI0000105,Ethanol,702,-,-,Mice,-,cerebellum granule neuron,in vivo,Low,Resistant,SP1,RAX and PKR,2014,MicroRNA-29b regulates ethanol-induced neuronal apoptosis in the developing cerebellum through SP1/RAX/PKR cascade.,Overexpression of miR-29b rendered neurons protection against ethanol-induced apoptosis.
24559685,miR-100,hsa-mir-100,MI0000102,Cisplatin,2767,-,H69 vs H69/CDDP,-,Patients,small cell lung cancer,in vitro and in vivo,Low,Resistant,HOXA1,-,2014,Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100.,Our data suggested that HOXA1-mediated SCLC chemoresistance is under the regulation of miR-100.
24559685,miR-100,hsa-mir-100,MI0000102,Doxorubicin (Adriamycin),31703,-,H69 vs H69/ADR,-,Patients,small cell lung cancer,in vitro and in vivo,Low,Resistant,HOXA1,-,2014,Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100.,Our data suggested that HOXA1-mediated SCLC chemoresistance is under the regulation of miR-100.
24559685,miR-100,hsa-mir-100,MI0000102,Etoposide,36462,-,H69 vs H69/ET,-,Patients,small cell lung cancer,in vitro and in vivo,Low,Resistant,HOXA1,-,2014,Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100.,Our data suggested that HOXA1-mediated SCLC chemoresistance is under the regulation of miR-100.
24565101,miR-26b,hsa-mir-26b,MI0000084,Doxorubicin (Adriamycin),31703,QGY-7703 and MHCC-97H,-,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,TAK1 and TAB3,-,2014,MicroRNA-26b suppresses the NF-kappaB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3.,"Furthermore, the ectopic expression of miR-26b dramatically sensitized HCC cells to the doxorubicin-induced apoptosis, whereas the antagonism of miR-26b attenuated cell apoptosis."
24565525,miR-34a,hsa-mir-34a,MI0000268,Doxorubicin (Adriamycin),31703,MDA-MB-231,-,Mice,-,triple negative breast cancer,in vitro and in vivo,Low,Sensitive,BCL-2,-,2014,Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.,In vitro and in vivo experiments showed that miR-34a and DOX can be efficiently encapsulated into HA-CS NPs and delivered into tumor cells or tumor tissues and enhance anti-tumor effects of DOX by suppressing the expression of non-pump resistance and anti-apoptosis proto-oncogene Bcl-2.
24568519,miR-100,hsa-mir-100,MI0000102,Cisplatin,2767,"CHON-001, C-28/l2 and C-12710",CH-2879 vs CH-2879/CDDP,-,-,chondrosarcoma,in vitro,Low,Sensitive,mTOR,-,2014,MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR.,"Overexpression of miR-100 complementary pairs to the 3' untranslated region (UTR) of mTOR, resulted in sensitization of cisplatin resistant cells to cisplatin."
24571711,miR-375,hsa-mir-375,MI0000783,Trastuzumab,9903,-,SKBr-3 vs SKBr-3/TRA,Mice,-,breast cancer,in vitro and in vivo,Low,Sensitive,IGF1R,-,2014,Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.,"Overexpression of miR-375 restored the sensitivity of cells to trastuzumab, while inhibition of miR-375 conferred trastuzumab resistance on HER2-positive breast cancer cells. "
24573637,miR-181,-,-,Temozolomide,5394,U251 and U87,-,-,-,glioblastoma,in vitro,Low,Sensitive,Rap1B,-,2014,miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells.,"TMZ as a standard chemotherapeutic agent for GBM inhibited the Rap1B expression and actin cytoskeleton remodeling to exert its cell killing by upregulating miR-181a/b/c/d subunits; conversely, each miR-181a/b/c/d subunit enhanced the chemosensitivity of TMZ in glioblastoma cells."
24582749,miR-138,hsa-miR-138-5p,MI0000455,Gefitinib,123631,-,PC-9 vs PC-9/GR,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,GPR124,-,2014,miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.,"Re-expression of miR-138-5p was sufficient to sensitize PC9GR cells and another gefitinib-resistant NSCLC cell line, H1975, to gefitinib."
24589211,let-7c,hsa-let-7c,MI0000064,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells,"Among the 663 miRNAs analyzed, 13 miRNAs were significantly differentially expressed between the two sample groups, with fold change > 2 and P < 0.05. Of those 13 miRNAs, 11 were up-regulated and 2 were downregulated in SKOV3/DDP cells as compared to SKOV3 cells (Table 2). "
24589211,miR-100,hsa-mir-100,MI0000102,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells,"Among the 663 miRNAs analyzed, 13 miRNAs were significantly differentially expressed between the two sample groups, with fold change > 2 and P < 0.05. Of those 13 miRNAs, 11 were up-regulated and 2 were downregulated in SKOV3/DDP cells as compared to SKOV3 cells (Table 2). "
24589211,miR-100* ,hsa-mir-100,MI0000102,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells,"Among the 663 miRNAs analyzed, 13 miRNAs were significantly differentially expressed between the two sample groups, with fold change > 2 and P < 0.05. Of those 13 miRNAs, 11 were up-regulated and 2 were downregulated in SKOV3/DDP cells as compared to SKOV3 cells (Table 2). "
24589211,miR-10a ,hsa-mir-10a,MI0000266,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells,"Among the 663 miRNAs analyzed, 13 miRNAs were significantly differentially expressed between the two sample groups, with fold change > 2 and P < 0.05. Of those 13 miRNAs, 11 were up-regulated and 2 were downregulated in SKOV3/DDP cells as compared to SKOV3 cells (Table 2). "
24589211,miR-125b,hsa-mir-125b-1,MI0000446,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells,"Among the 663 miRNAs analyzed, 13 miRNAs were significantly differentially expressed between the two sample groups, with fold change > 2 and P < 0.05. Of those 13 miRNAs, 11 were up-regulated and 2 were downregulated in SKOV3/DDP cells as compared to SKOV3 cells (Table 2). "
24589211,miR-133a,hsa-mir-133a-1,MI0000450,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells,"Among the 663 miRNAs analyzed, 13 miRNAs were significantly differentially expressed between the two sample groups, with fold change > 2 and P < 0.05. Of those 13 miRNAs, 11 were up-regulated and 2 were downregulated in SKOV3/DDP cells as compared to SKOV3 cells (Table 2). "
24589211,miR-139 ,hsa-mir-139,MI0000261,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells,"Among the 663 miRNAs analyzed, 13 miRNAs were significantly differentially expressed between the two sample groups, with fold change > 2 and P < 0.05. Of those 13 miRNAs, 11 were up-regulated and 2 were downregulated in SKOV3/DDP cells as compared to SKOV3 cells (Table 2). "
24589211,miR-181c* ,hsa-mir-181c,MI0000271,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells,"Among the 663 miRNAs analyzed, 13 miRNAs were significantly differentially expressed between the two sample groups, with fold change > 2 and P < 0.05. Of those 13 miRNAs, 11 were up-regulated and 2 were downregulated in SKOV3/DDP cells as compared to SKOV3 cells (Table 2). "
24589211,miR-27b ,hsa-mir-27b,MI0000440,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells,"Among the 663 miRNAs analyzed, 13 miRNAs were significantly differentially expressed between the two sample groups, with fold change > 2 and P < 0.05. Of those 13 miRNAs, 11 were up-regulated and 2 were downregulated in SKOV3/DDP cells as compared to SKOV3 cells (Table 2). "
24589211,miR-33a* ,hsa-mir-33a,MI0000091,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells,"Among the 663 miRNAs analyzed, 13 miRNAs were significantly differentially expressed between the two sample groups, with fold change > 2 and P < 0.05. Of those 13 miRNAs, 11 were up-regulated and 2 were downregulated in SKOV3/DDP cells as compared to SKOV3 cells (Table 2). "
24589211,miR-34a,hsa-mir-34a,MI0000268,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells,"Among the 663 miRNAs analyzed, 13 miRNAs were significantly differentially expressed between the two sample groups, with fold change > 2 and P < 0.05. Of those 13 miRNAs, 11 were up-regulated and 2 were downregulated in SKOV3/DDP cells as compared to SKOV3 cells (Table 2). "
24589211,miR-383,hsa-mir-383,MI0000791,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells,"Among the 663 miRNAs analyzed, 13 miRNAs were significantly differentially expressed between the two sample groups, with fold change > 2 and P < 0.05. Of those 13 miRNAs, 11 were up-regulated and 2 were downregulated in SKOV3/DDP cells as compared to SKOV3 cells (Table 2). "
24589211,miR-486,hsa-mir-486-1,MI0002470,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells,"Among the 663 miRNAs analyzed, 13 miRNAs were significantly differentially expressed between the two sample groups, with fold change > 2 and P < 0.05. Of those 13 miRNAs, 11 were up-regulated and 2 were downregulated in SKOV3/DDP cells as compared to SKOV3 cells (Table 2). "
24589600,miR-221,hsa-mir-221,MI0000298,Chemotherapy,-,"Z1, Z2 and Z2-BCNU",-,-,-,glioma,in vitro,Low,Resistant,PTEN,-,2014,miR-221 mediates epithelial-mesenchymal transition-related gene expressions via regulation of PTEN/Akt signaling in drug-resistant glioma cells,miR-221 mediates epithelial-mesenchymal transition-related gene expressions via regulation of PTEN/Akt signaling in drug-resistant glioma cells
24591819,hs-160,-,-,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,hs-188,-,-,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,hs-254,-,-,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,hs-279-a,-,-,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,hs-303-b,-,-,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,miR-107,hsa-mir-107,MI0000114,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,miR-187,hsa-mir-187,MI0000274,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,miR-195,hsa-mir-195,MI0000489,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,miR-363,hsa-mir-363,MI0000764,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,miR-376a*,hsa-mir-376a-1,MI0000784,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,miR-411,hsa-mir-411,MI0003675,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,miR-497,hsa-mir-497,MI0003138,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,miR-517*,hsa-mir-517a,MI0003161,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,miR-589,hsa-mir-589,MI0003599,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,miR-622,hsa-mir-622,MI0003636,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,miR-647,hsa-mir-647,MI0003662,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24591819,miR-663,hsa-mir-663a,MI0003672,Paclitaxel,36314,"IOSE386, IOSE397, (A2780,KF, SKOV3, TOUS3,TU-OC-1, OVCAR-3, OV2008, CI3) vs (A2780Tax, KFrTax, SKOV3Tax, TOUS4, KK KOC-7C, OVCAR3-Tx)",-,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2014,Differential microrna expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells,We first analyzed the detection P-value of Illumina Expression BeadChips to determine differentially expressed changes in the Taxol-sensitive and -resistant ovarian cancer cells. 
24596420,miR-10a,hsa-mir-10a,MI0000266,Cytarabine,6253,"KG-1a, Kasumi-1, K562 and OCI-AML3",-,-,Patients,acute myeloid leukemia,in vitro and in vivo,Low,Sensitive,-,-,2014,Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML.,We found that high baseline miR-10 family expression in 54 untreated cytogenetically heterogeneous AML Patient was associated with achieving CR.
24596420,miR-10b,hsa-mir-10b,MI0000267,Cytarabine,6253,"KG-1a, Kasumi-1, K562 and OCI-AML3",-,-,Patients,acute myeloid leukemia,in vitro and in vivo,Low,Sensitive,-,-,2014,Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML.,We found that high baseline miR-10 family expression in 54 untreated cytogenetically heterogeneous AML Patient was associated with achieving CR.
24604579,miR-125b,hsa-mir-125b-1,MI0000446,Daunorubicin,30323,"K562, THP?1, Jurkat, REH and HEK293T",-,-,-,leukemia,in vitro,Low,Resistant,GRK2 and PUMA,-,2014,microRNA?125b promotes leukemia cell resistance to daunorubicin by inhibiting apoptosis.,"The overexpression of miR-125b was observed to induce DNR resistance in K562, THP?1 and Jurkat cells by reducing apoptosis, whereas the suppression of miR-125b was found to enhance DNR cytotoxicity in REH cells."
24606471,miR-130a,hsa-mir-130a,MI0000448,Gefitinib,123631,A549 and H1975,PC-9 vs PC-9/GR,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,MET,-,2014,MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines.,"Further analysis revealed that over-expression of miR-130a increased cell apoptosis and inhibited proliferation of NSCLC cells treated with gefitinib, whereas lowering the expression of miR-130a decreased cell apoptosis and promoted cell proliferation after treatment with gefitinib in both gefitinib-sensitive and -resistant NSCLC cell lines, suggesting that miR-130a overcomes gefitinib resistance."
24606718,miR-21,hsa-mir-21,MI0000077,Doxorubicin (Adriamycin),31703,MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Resistant,BCL2,-,2014,Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells.,"Moreover, downregulation of c-Jun or miR-21 effectively attenuates HA-mediated tumor cell growth/anti-apoptosis/survival and enhances chemotherapy sensitivity in MDA-MB-231 cells."
24609901,miR-22,hsa-mir-22,MI0000078,Cisplatin,2767,U2OS,-,-,-,osteosarcoma,in vitro,Low,Sensitive,HMGB1,-,2014,miR-22 targets the 3' UTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy.,These results reveal novel potential role of miR-22 against chemotherapy resistance during the treatment of osteosarcoma.
24609901,miR-22,hsa-mir-22,MI0000078,Doxorubicin (Adriamycin),31703,U2OS,-,-,-,osteosarcoma,in vitro,Low,Sensitive,HMGB1,-,2014,miR-22 targets the 3' UTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy.,These results reveal novel potential role of miR-22 against chemotherapy resistance during the treatment of osteosarcoma.
24609942,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,Tca8113 and CAL-27,-,-,-,tongue squamous cell carcinoma,in vitro,Low,Resistant,PDCD4,-,2014,MiR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4.,Transfection of miR-21 inhibitor induced sensitivity of TSCC cells (Tca8113 and CAL-27) to cisplatin.
24615544,miR-200c,hsa-mir-200c,MI0000650,Trastuzumab,9903,SKBr-3,-,Mice,-,breast cancer,in vitro and in vivo,Low,Sensitive,ZNF217 and ZEB1,-,2014,MiR-200c suppresses TGF-Beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.,"Restoration of miR-200c, silencing of ZEB1 or ZNF217 or blockade of TGF-Beta signaling increased trastuzumab sensitivity and suppressed invasiveness of breast cancer cells."
24628843,miR-141,hsa-mir-141,MI0000457,Cisplatin,2767,-,7901 vs 7901/CDDP,-,Patients,gastric cancer,in vitro and in vivo,Low,Resistant,KEAP1,-,2014,Helicobacter pylori modulates cisplatin sensitivity in gastric cancer by down-regulating miR-141 expression.,We found that H. pylori infection can significantly down-regulate miR-141 expression. Knockdown miR-141 expression in 7901/DDP and 7901 cells could significantly improve cisplatin sensitivity.
24629639,miR-130b,hsa-mir-130b,MI0000748,Imatinib,5291,-,-,-,Patientss,Chronic myeloid leukemia,in vivo,High,Sensitive,-,-,2014,ApoptomiRs expression modulated by BCRCABL is linked to CML progression and imatinib resistance,"Low expression of miR-26a (median = 22483); miR-29c (m = 4105); miR-130b (1320) and miR-146a (7671) was observed in CCR patients in comparison to IM-resistant patients (m =86939; 12226; 2535 and 17898, respectively) (Figs. 5A to D)."
24629639,miR-146a,hsa-mir-146a,MI0000477,Imatinib,5291,-,-,-,Patientss,Chronic myeloid leukemia,in vivo,High,Sensitive,-,-,2014,ApoptomiRs expression modulated by BCRCABL is linked to CML progression and imatinib resistance,"Low expression of miR-26a (median = 22483); miR-29c (m = 4105); miR-130b (1320) and miR-146a (7671) was observed in CCR patients in comparison to IM-resistant patients (m =86939; 12226; 2535 and 17898, respectively) (Figs. 5A to D)."
24629639,miR-26a,hsa-mir-26a-1,MI0000083,Imatinib,5291,-,-,-,Patientss,Chronic myeloid leukemia,in vivo,High,Sensitive,-,-,2014,ApoptomiRs expression modulated by BCRCABL is linked to CML progression and imatinib resistance,"Low expression of miR-26a (median = 22483); miR-29c (m = 4105); miR-130b (1320) and miR-146a (7671) was observed in CCR patients in comparison to IM-resistant patients (m =86939; 12226; 2535 and 17898, respectively) (Figs. 5A to D)."
24629639,miR-29c,hsa-mir-29c,MI0000735,Imatinib,5291,-,-,-,Patientss,Chronic myeloid leukemia,in vivo,High,Sensitive,-,-,2014,ApoptomiRs expression modulated by BCRCABL is linked to CML progression and imatinib resistance,"Low expression of miR-26a (median = 22483); miR-29c (m = 4105); miR-130b (1320) and miR-146a (7671) was observed in CCR patients in comparison to IM-resistant patients (m =86939; 12226; 2535 and 17898, respectively) (Figs. 5A to D)."
24643683,miR-125b,hsa-mir-125b-1,MI0000446,Temozolomide,5394,CD133/1 and CD133/2-PE,-,Mice,Patients,glioblastoma,in vitro and in vivo,Low,Resistant,Bak1,-,2014,miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1.,"In this study, we found that miR-125b was up-regulated in TMZ-resistant cells, inhibition of which caused a marked increase of TMZ-induced cytotoxicity and apoptosis and a subsequent decrease in the resistance to TMZ in GSCs."
24648265,miR-452,hsa-mir-452,MI0001733,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,Low,Resistant,APC4,-,2014,MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells.,"Dysregulation of miRNA-452 involved in the DOC resistance formation of breast cancer cells may be, in part, via targeting APC4."
24655723,miR-630,hsa-mir-630,MI0003644,Lapatinib,25183872,MDA-MB-453,HCC1954 vs HCC1954-LR and SKBR3 vs SKBR3-LR,-,-,breast cancer,in vitro,Low,Sensitive,IGF1R,-,2014,miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.,miR-630 mimic was found to further enhance the anti-proliferative effects of all drugs assessed in HCC1954-LR and SKBR3-LR as well as innately-resistant MDA-MB-453
24655723,miR-630,hsa-mir-630,MI0003644,Neratinib,9915743,-,HCC1954 vs HCC1954/NR,-,-,breast cancer,in vitro,Low,Associated,IGF1R,-,2014,miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.,Changes in both intracellular and extracellular miR-630 levels are associated with acquired-resistance to HER-targeting drugs.
24659709,let-7a,hsa-let-7a-1,MI0000060,Cisplatin,2767,"A2780s, OV2008, A2780cp, C13*","A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,let-7b,hsa-let-7b,MI0000063,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch2 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,let-7d,hsa-let-7d,MI0000065,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch3 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,let-7f,hsa-let-7f-1,MI0000067,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch4 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,let-7g,hsa-let-7g,MI0000433,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch5 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-10b,hsa-mir-10b,MI0000267,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch22 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-1275,hsa-mir-1275,MI0006415,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch28 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-138,hsa-mir-138-1,MI0000476,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch11 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-141,hsa-mir-141,MI0000457,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch12 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-199a,hsa-mir-199a-1,MI0000242,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch24 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-199b,hsa-mir-199b,MI0000282,Cisplatin,2767,"A2780cp, C13, SKOV3, ES-2 and OVCA433",-,Mice,-,ovarian cancer,in vitro and in vivo,Low,Sensitive,JAG1,-,2014,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.,These results indicate that miR-199b-5p is capable of suppressing ovarian cancer cell growth and sensitizing ovarian cancer cells to be cisplatin-induced cytotoxicity.
24659709,miR-200a,hsa-mir-200a,MI0000737,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch13 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-200c,hsa-mir-200c,MI0000650,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch14 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-205,hsa-mir-205,MI0000285,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch15 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch6 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-221,hsa-mir-221,MI0000298,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch16 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-222,hsa-mir-222,MI0000299,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch17 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-23a,hsa-mir-23a,MI0000079,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch7 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-27a,hsa-mir-27a,MI0000085,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch8 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-31,hsa-mir-31,MI0000089,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch9 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-363,hsa-mir-363,MI0000764,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch25 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-452,hsa-mir-452,MI0001733,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch18 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-542,hsa-mir-542,MI0003686,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch27 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-675,hsa-mir-675,MI0005416,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch26 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-886,hsa-mir-886,MI0005527,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch19 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-98,hsa-mir-98,MI0000100,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch10 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-99a,hsa-mir-99a,MI0000101,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch23 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-Plus B1114,-,-,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch29 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-Plus C1115,-,-,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch30 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-PlusA1087,-,-,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch20 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24659709,miR-PlusC1049,-,-,Cisplatin,2767,-,"A2780 vs A2780/CDDP, OV2008 vs C13*",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch21 signaling in ovarian cancer.,Our results revealed that there were 35 upregulated miRNAs (>2-fold) and 45 downregulated miRNAs (<0.5-fold) with statistical significance (data not shown). 
24667580,miR-497,hsa-mir-497,MI0003138,Gemcitabine,60750,BxPC-3 and AsPC-1,-,-,-,pancreatic cancer,in vitro,Low,Sensitive,IGF-1R ,-,2014,Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer.,Cells transfected with miR-497 inhibitor were more resistant to gemcitabine treatment than cells transfected with inhibitor control.
24675421,miR-940,hsa-mir-940,MI0005762,Cisplatin,2767,A549 and H460,-,-,-,lung cancer,in vitro,Low,-,-,RIP1/miR-940/MKP1/JNK pathway,2014,Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition.,"Altogether, our results suggest that RIP1 contributes to cisplatin resistance by suppressing JNK activation that involves releasing miR-940-mediated inhibition of MKP1 and suppressing activation of MKK4."
24680705,miR-199b,hsa-mir-199b,MI0000282,Imatinib,5291,-,-,-,Patients,chronic myeloid leukemia,in vivo,Low,Sensitive,-,-,2014,Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML Patient.,The miR-199b was significantly down-regulated in 15 Patient with imatinib resistance.
24686007,miR-489,hsa-mir-489,MI0003124,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP and OVCAR3 vs OVCAR3/CDDP,-,-,ovarian cancer,in vitro,Low,Sensitive,Akt3,-,2014,MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3.,"In addition, miR-489 overexpression increases the sensitivity of SKOV3/CDDP and OVCAR3/CDDP cells to CDDP and inhibits their colony number."
24690174,miR-21,hsa-mir-21,MI0000077,Teniposide,452548,U373MG and U251,-,-,-,glioblastoma multiforme,in vitro,Low,Resistant,LRRFIP1,-,2014,"Higher LRRFIP1 expression in glioblastoma multiforme is associated with better response to teniposide, a type II topoisomerase inhibitor.",Growth inhibition in the cells transfected with pcDNA3/miRNA-21 was significantly lower than in the cells transfected with the control vector pcDNA3.
24699530,let-7i,hsa-let-7i,MI0000434,Tamoxifen,2733526,"HapMap LCLs, YRI LCLs, ZR-75-1",-,-,-,breast cancer,in vitro,Low,Sensitive,,-,2014,Integrative Omic Analysis for Tamoxifen Sensitivity through Cell Based Models,"he same phenotype is also associated with hsa-let-7i expression at p = 0.006, with higher hsalet-7i expression corresponding to higher cellular sensitivity to endoxifen (Figure 2B)."
24714754,miR-100,hsa-mir-100,MI0000102,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-100,hsa-mir-100,MI0000102,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-105,hsa-mir-105-1,MI0000111,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-125a,hsa-mir-125a,MI0000469,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-1267,hsa-mir-1267,MI0006404,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-135b,hsa-mir-135b,MI0000810,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-135b,hsa-mir-135b,MI0000810,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-146a,hsa-mir-146a,MI0000477,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-146a,hsa-mir-146a,MI0000477,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-146b,hsa-mir-146b,MI0003129,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-151,hsa-mir-151a,MI0000809,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-152,hsa-mir-152,MI0000462,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-15a,hsa-mir-15a,MI0000069,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-191,hsa-mir-191,MI0000465,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-191,hsa-mir-191,MI0000465,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-194,hsa-mir-194-1,MI0000488,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-196b,hsa-mir-196b,MI0001150,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-200a,hsa-mir-200a,MI0000737,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-200a,hsa-mir-200a,MI0000737,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-200b,hsa-mir-200b,MI0000342,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-200b,hsa-mir-200b,MI0000342,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-200c,hsa-mir-200c,MI0000650,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-203,hsa-mir-203a,MI0000283,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-205,hsa-mir-205,MI0000285,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-20b,hsa-mir-20b,MI0001519,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-210,hsa-mir-210,MI0000286,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-24,hsa-mir-24-1,MI0000080,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-25,hsa-mir-25,MI0000082,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-26b,hsa-mir-26b,MI0000084,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-27a,hsa-mir-27a,MI0000085,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-301a,hsa-mir-301a,MI0000745,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-301a,hsa-mir-301a,MI0000745,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-301b,hsa-mir-301b,MI0005568,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-30a,hsa-mir-30a,MI0000088,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-30e,hsa-mir-30e,MI0000749,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-342,hsa-mir-342,MI0000805,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-34a,hsa-mir-34a,MI0000268,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-34b,hsa-mir-34b,MI0000742,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-375,hsa-mir-375,MI0000783,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-429,hsa-mir-429,MI0001641,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-429,hsa-mir-429,MI0001641,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-454,hsa-mir-454,MI0003820,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-455,hsa-mir-455,MI0003513,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-486,hsa-mir-486-1,MI0002470,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-489,hsa-mir-489,MI0003124,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-590,hsa-mir-590,MI0003602,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-598,hsa-mir-598,MI0003610,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-767,hsa-mir-767,MI0003763,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-9,hsa-mir-9-1,MI0000466,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-95,hsa-mir-95,MI0000097,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-96,hsa-mir-96,MI0000098,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-99a,hsa-mir-99a,MI0000101,Docetaxel,148124,-,DU145 vs DU145/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24714754,miR-99b,hsa-mir-99b,MI0000746,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,"Eight differentially expressed microRNAs were in common for both cell line models, in the comparisons between docetaxelresistant and sensitive cell lines, suggesting their regulation of common docetaxel-resistance pathways (Table 1). "
24720529,miR-210,hsa-mir-210,MI0000286,Asparaginase,-,Reh cells and RS4,-,-,-,pediatric acute lymphoblastic leukemia,in vitro,Low,Sensitive,-,-,2014,Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia.,"Taken together, these results indicate that increased intracellular level of miR-210 enhances the sensitivity of leukemic cells to common chemotherapeutic drugs and decreases their viability."
24720529,miR-210,hsa-mir-210,MI0000286,Daunorubicin,30323,Reh cells,-,-,-,pediatric acute lymphoblastic leukemia,in vitro,Low,Sensitive,-,-,2014,Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia.,"Taken together, these results indicate that increased intracellular level of miR-210 enhances the sensitivity of leukemic cells to common chemotherapeutic drugs and decreases their viability."
24720529,miR-210,hsa-mir-210,MI0000286,Dexamethasone,5743,Reh cells,-,-,-,pediatric acute lymphoblastic leukemia,in vitro,Low,Sensitive,-,-,2014,Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia.,"Taken together, these results indicate that increased intracellular level of miR-210 enhances the sensitivity of leukemic cells to common chemotherapeutic drugs and decreases their viability."
24722426,miR-17,hsa-mir-17,MI0000071,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,non-small-cell lung cancer,in vitro,Low,Sensitive,TGFbetaR2,-,2014,MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC.,"Over-expression of miR-17, 20a, 20b can not only decrease cisplatin-resistant but also reduce migration by inhibiting epithelial-to-mesenchymal transition (EMT) in A549/DDP cells."
24722426,miR-20a,hsa-mir-20a,MI0000076,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,non-small-cell lung cancer,in vitro,Low,Sensitive,TGFbetaR2,-,2014,MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC.,"Over-expression of miR-17, 20a, 20b can not only decrease cisplatin-resistant but also reduce migration by inhibiting epithelial-to-mesenchymal transition (EMT) in A549/DDP cells."
24722426,miR-20b,hsa-mir-20b,MI0001519,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,non-small-cell lung cancer,in vitro,Low,Sensitive,TGFbetaR2,-,2014,MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC.,"Over-expression of miR-17, 20a, 20b can not only decrease cisplatin-resistant but also reduce migration by inhibiting epithelial-to-mesenchymal transition (EMT) in A549/DDP cells."
24723223,miR-221,hsa-mir-221,MI0000298,Gefitinib,123631,-,PC-9 vs PC-9/GR,-,-,lung cancer,in vitro,Low,Resistant,-,-,2014,Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells.,"Silencing of Dicer induces sensitivity to gefitinib in NSCLC cells through the downregulation of miR-30b/c and miR-221/222 to increase the protein level of caspase-3, resulting in an increase in gefitinib-induced apoptosis."
24723223,miR-222,hsa-mir-222,MI0000299,Gefitinib,123631,-,PC-9 vs PC-9/GR,-,-,lung cancer,in vitro,Low,Resistant,-,-,2014,Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells.,"Silencing of Dicer induces sensitivity to gefitinib in NSCLC cells through the downregulation of miR-30b/c and miR-221/222 to increase the protein level of caspase-3, resulting in an increase in gefitinib-induced apoptosis."
24723223,miR-30b,hsa-mir-30b,MI0000441,Gefitinib,123631,-,PC-9 vs PC-9/GR,-,-,lung cancer,in vitro,Low,Resistant,-,-,2014,Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells.,"Silencing of Dicer induces sensitivity to gefitinib in NSCLC cells through the downregulation of miR-30b/c and miR-221/222 to increase the protein level of caspase-3, resulting in an increase in gefitinib-induced apoptosis."
24723223,miR-30c,hsa-mir-30c-1,MI0000736,Gefitinib,123631,-,PC-9 vs PC-9/GR,-,-,lung cancer,in vitro,Low,Resistant,-,-,2014,Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells.,"Silencing of Dicer induces sensitivity to gefitinib in NSCLC cells through the downregulation of miR-30b/c and miR-221/222 to increase the protein level of caspase-3, resulting in an increase in gefitinib-induced apoptosis."
24727676,miR-223,hsa-mir-223,MI0000300,DAPT (GSI-IX),5311272,"DND41, Molt3 and Jurkat",-,-,-,T-cell acute lymphoblastic leukemia,in vitro,Low,Resistant,FBXW7,-,2014,Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia.,"Finally, we show that miR-223 inhibition prevents T-ALL resistance to gamma-secretase inhibitor (GSI) treatment, suggesting that miR-223 could be involved in GSI sensitivity and its inhibition may be exploited in target therapy protocols."
24740415,miR-100,hsa-mir-100,MI0000102,Docetaxel,148124,-,MCF-7/S vs MCF-7/DOC,-,-,breast cancer,in vitro,Low,Resistant,-,-,2014,Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs,"Five miRNAs were selected for validation, all of which (miR-100, miR-17, miR-222, miR-342-3p and miR-451) were elevated in both A/exo and D/exo. "
24740415,miR-100,hsa-mir-100,MI0000102,Doxorubicin (Adriamycin),31703,-,MCF-7/S vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Resistant,-,-,2014,Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs,"Five miRNAs were selected for validation, all of which (miR-100, miR-17, miR-222, miR-342-3p and miR-451) were elevated in both A/exo and D/exo. "
24740415,miR-17,hsa-mir-17,MI0000071,Docetaxel,148124,-,MCF-7/S vs MCF-7/DOC,-,-,breast cancer,in vitro,Low,Resistant,-,-,2014,Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs,"Five miRNAs were selected for validation, all of which (miR-100, miR-17, miR-222, miR-342-3p and miR-451) were elevated in both A/exo and D/exo. "
24740415,miR-17,hsa-mir-17,MI0000071,Doxorubicin (Adriamycin),31703,-,MCF-7/S vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Resistant,-,-,2014,Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs,"Five miRNAs were selected for validation, all of which (miR-100, miR-17, miR-222, miR-342-3p and miR-451) were elevated in both A/exo and D/exo. "
24740415,miR-222,hsa-mir-222,MI0000299,Docetaxel,148124,-,MCF-7/S vs MCF-7/DOC,-,-,breast cancer,in vitro,Low,Resistant,PTEN,-,2014,Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs,"Five miRNAs were selected for validation, all of which (miR-100, miR-17, miR-222, miR-342-3p and miR-451) were elevated in both A/exo and D/exo. "
24740415,miR-222,hsa-mir-222,MI0000299,Doxorubicin (Adriamycin),31703,-,MCF-7/S vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Resistant,PTEN,-,2014,Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs,"Five miRNAs were selected for validation, all of which (miR-100, miR-17, miR-222, miR-342-3p and miR-451) were elevated in both A/exo and D/exo. "
24740415,miR-342,hsa-mir-342,MI0000805,Docetaxel,148124,-,MCF-7/S vs MCF-7/DOC,-,-,breast cancer,in vitro,Low,Resistant,-,-,2014,Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs,"Five miRNAs were selected for validation, all of which (miR-100, miR-17, miR-222, miR-342-3p and miR-451) were elevated in both A/exo and D/exo. "
24740415,miR-342,hsa-mir-342,MI0000805,Doxorubicin (Adriamycin),31703,-,MCF-7/S vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Resistant,-,-,2014,Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs,"Five miRNAs were selected for validation, all of which (miR-100, miR-17, miR-222, miR-342-3p and miR-451) were elevated in both A/exo and D/exo. "
24740415,miR-451,hsa-mir-451a,MI0001729,Docetaxel,148124,-,MCF-7/S vs MCF-7/DOC,-,-,breast cancer,in vitro,Low,Resistant,-,-,2014,Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs,"Five miRNAs were selected for validation, all of which (miR-100, miR-17, miR-222, miR-342-3p and miR-451) were elevated in both A/exo and D/exo. "
24740415,miR-451,hsa-mir-451a,MI0001729,Doxorubicin (Adriamycin),31703,-,MCF-7/S vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Resistant,-,-,2014,Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs,"Five miRNAs were selected for validation, all of which (miR-100, miR-17, miR-222, miR-342-3p and miR-451) were elevated in both A/exo and D/exo. "
24740829,miR-302,hsa-mir-302a,MI0000738,Interferon-alpha,-,-,PLC vs PLC/INF,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,Mcl-1,-,2014,Reprogramming using microRNA-302 improves drug sensitivity in hepatocellular carcinoma cells.,"Twenty days after miR-302 transfection into PLC-R cells, round colonies appeared (similar to parental PLC cells)."
24752803,miR-181C*,hsa-mir-181c,MI0000271,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-181d,hsa-mir-181d,MI0003139,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-199a,hsa-mir-199a-1,MI0000242,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-220b,hsa-mir-220b,MI0005529,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-300,hsa-mir-300,MI0005525,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-330,hsa-mir-330,MI0000803,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-512,hsa-mir-512-1,MI0003140,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-515,hsa-mir-515-1,MI0003144,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-516a,hsa-mir-516a-1,MI0003180,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-517c,hsa-mir-517c,MI0003174,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-518b,hsa-mir-518b,MI0003156,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-518c,hsa-mir-518c,MI0003159,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-518e*,hsa-mir-518e,MI0003169,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-518f,hsa-mir-518f,MI0003154,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-519a,hsa-mir-513a-1,MI0003191,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,Patients,breast cancer,in vitro and in vivo,Low,Resistant,"CDKN1A, RB1 and PTEN",-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"We could demonstrate that miRNA-519a regulates tamoxifen resistance using gain- and loss-of-function testing. By combining functional enrichment analysis and prediction algorithms, we identified three central tumour-suppressor genes (TSGs) in PI3K signalling and the cell cycle network as direct target genes of miR-519a."
24752803,miR-519c,hsa-mir-519c,MI0003148,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-519d,hsa-mir-519d,MI0003162,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-519e,hsa-mir-519e,MI0003145,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-520,-,-,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-520b,hsa-mir-520b,MI0003155,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-520h,hsa-mir-520h,MI0003175,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-521,hsa-mir-521-1,MI0003176,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-522,hsa-mir-522,MI0003177,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-642,hsa-mir-642a,MI0003657,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-7,hsa-mir-7-1,MI0000263,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-769,hsa-mir-769,MI0003834,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24752803,miR-935,hsa-mir-935,MI0005757,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.,"In total, 18 members of C19MC were co-upregulated in TamR cells (Figure 1b). We selected four of the top up-regulated miRNAs from the cluster and validated their overexpression in TamR cells with qRT-PCR (Figure 1c)."
24755562,let-7a,hsa-let-7a-1,MI0000060,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-101,hsa-mir-101-1,MI0000103,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-106a,hsa-mir-106a,MI0000113,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-1246,hsa-mir-1246,MI0006381,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-1275,hsa-mir-1275,MI0006415,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-1290,hsa-mir-1290,MI0006352,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-16,hsa-mir-16-1,MI0000070,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-17,hsa-mir-17,MI0000071,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung cancer,in vitro,Low,Sensitive,Beclin 1 ,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression.,We found that overexpression of miR-17-5p sensitized paclitaxel resistant lung cancer cells to paclitaxel induced apoptotic cell death.
24755562,miR-1973,hsa-mir-1973,MI0009983,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-19a,hsa-mir-19a,MI0000073,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-20a,hsa-mir-20a,MI0000076,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-27a,hsa-mir-27a,MI0000085,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-3074,hsa-mir-3074,MI0014181,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-31*,hsa-mir-31,MI0000089,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-3196,hsa-mir-3196,MI0014241,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-365,hsa-mir-365a,MI0000767,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-374-a,hsa-mir-374a,MI0000782,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-4284,hsa-mir-4284,MI0015893,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-4288,hsa-mir-4288,MI0015896,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-483,hsa-mir-483,MI0002467,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-513a,hsa-mir-513a-1,MI0003191,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miR-676*,hsa-mir-676,MI0016436,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24755562,miRPlus-A1086,-,-,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,,-,2014,miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin 1 expression.,From the array results it was identified that 23 miRNAs were differentially expressed in A549-T24 cells than A549 cells (Fig. 1).
24756163,miR-181b,hsa-mir-181b-1,MI0000270,Cytarabine,6253,-,K562/A02 and HL-60/ADM,-,-,acute myeloid leukemia,in vitro,Low,Sensitive,HMGB1 and Mcl-1,-,2014,miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1.,Overexpression of miR-181b increased the sensitivity of leukemia cells to cytotoxic chemotherapeutic agents and promoted drug-induced apoptosis.
24756163,miR-181b,hsa-mir-181b-1,MI0000270,Doxorubicin (Adriamycin),31703,-,K562/A02 and HL-60/ADM,-,-,acute myeloid leukemia,in vitro,Low,Sensitive,HMGB1 and Mcl-1,-,2014,miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1.,Overexpression of miR-181b increased the sensitivity of leukemia cells to cytotoxic chemotherapeutic agents and promoted drug-induced apoptosis.
24759738,let-7e,hsa-let-7e,MI0000066,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,Low,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,let-7e,hsa-let-7e,MI0000066,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-100,hsa-mir-100,MI0000102,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,Low,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-100,hsa-mir-100,MI0000102,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-1246,hsa-mir-1246,MI0006381,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-1246,hsa-mir-1246,MI0006381,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-125a,hsa-mir-125a,MI0000469,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,Low,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-125a,hsa-mir-125a,MI0000469,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-1273g,hsa-mir-1273g,MI0018003,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,Low,Resistant,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-1273g,hsa-mir-1273g,MI0018003,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Resistant,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-148a,hsa-mir-148a,MI0000253,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-148a,hsa-mir-148a,MI0000253,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-181a,hsa-mir-181a-2,MI0000269,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,Low,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-181a,hsa-mir-181a-2,MI0000269,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-181b,hsa-mir-181b-1,MI0000270,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-181b,hsa-mir-181b-1,MI0000270,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-342,hsa-mir-342,MI0000805,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-342,hsa-mir-342,MI0000805,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-378a,hsa-mir-378a,MI0000786,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,Low,Resistant,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-378a,hsa-mir-378a,MI0000786,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Resistant,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-425,hsa-mir-425,MI0001448,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,Low,Resistant,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-425,hsa-mir-425,MI0001448,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Resistant,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-4430,hsa-mir-4430,MI0016769,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-4430,hsa-mir-4430,MI0016769,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-494,hsa-mir-494,MI0003134,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-494,hsa-mir-494,MI0003134,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-7,hsa-mir-7-1,MI0000263,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-7,hsa-mir-7-1,MI0000263,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-99b,hsa-mir-99b,MI0000746,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,Low,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24759738,miR-99b,hsa-mir-99b,MI0000746,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,-,-,gastric cancer,in vitro,Low,Sensitive,-,-,2014,Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling,"Between the dysregulated microRNAs in SGC7901/VCR cells and the dysregulated microRNAs in SGC7901/ADR cells, 15 were overlapping. Of these overlapping microRNAs, 9 were commonly down-regulated and 6 were commonly up-regulated in the two drug resistant sublines (Table 2). "
24763054,miR-185,hsa-mir-185,MI0000482,Cisplatin,2767,SGC-7901 and  MGC-803,-,Mice,-,gastric cancer,in vitro and in vivo,Low,Sensitive,ARC,-,2014,MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain.,"Taken together, these results suggest that miR-185 reduces chemotherapy resistance in gastric cancer."
24763054,miR-185,hsa-mir-185,MI0000482,Doxorubicin (Adriamycin),31703,SGC-7901 and  MGC-803,-,Mice,-,gastric cancer,in vitro and in vivo,Low,Sensitive,ARC,-,2014,MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain.,"Taken together, these results suggest that miR-185 reduces chemotherapy resistance in gastric cancer."
24767251,miR-29b,hsa-mir-29b-1,MI0000105,chemotherapy,-,-,-,-,Patients,ovarian carcinoma,in vivo,Low,Sensitive,"MCL-1, MAPK10 and ATG9A",-,2014,Involvement of miR-29b signaling in the sensitivity to chemotherapy in Patient with ovarian carcinoma.,"Therefore, the correlation of miR-29b expression with progression-free survival suggests that miR-29b is a marker for chemosensitivity."
24769353,miR-200b,hsa-mir-200b,MI0000342,Cisplatin,2767,-,H69 vs H69/CDDP,-,-,small cell lung cancer,in vitro,Low,Sensitive,ZEB2,-,2014,Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by miR-200b contributes to multi-drug resistance of small cell lung cancer.,Our results suggest that ZEB2 modulates drug resistance and is regulated by miR-200b.
24769353,miR-200b,hsa-mir-200b,MI0000342,Doxorubicin (Adriamycin),31703,-,H69 vs H69/ADR,-,-,small cell lung cancer,in vitro,Low,Sensitive,ZEB2,-,2014,Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by miR-200b contributes to multi-drug resistance of small cell lung cancer.,Our results suggest that ZEB2 modulates drug resistance and is regulated by miR-200b.
24769353,miR-200b,hsa-mir-200b,MI0000342,Etoposide,36462,-,H69 vs H69/ET,-,-,small cell lung cancer,in vitro,Low,Sensitive,ZEB2,-,2014,Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by miR-200b contributes to multi-drug resistance of small cell lung cancer.,Our results suggest that ZEB2 modulates drug resistance and is regulated by miR-200b.
24778468,miR-125b,hsa-mir-125b-1,MI0000446,Rituximab,24801582,-,-,-,Patients,rheumatoid arthritis,in vivo,Low,Sensitive,-,-,2014,Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis,Our results identify circulating miR-125b as a novel miRNA over expressed in RA and suggest that serum level of miR-125b is potential predictive biomarker of response to rituximab treatment.
24780067,miR-221,hsa-mir-221,MI0000298,Carmustine,2578,U87,SWOZ2 vs SWOZ2/BCNU,-,-,glioblastoma,in vitro,Low,Resistant,PTEN,p27,2014,Involvement of miR-29b signaling in the sensitivity to chemotherapy in Patient with ovarian carcinoma.,"Collectively, these results further demonstrate that PTEN/Akt signaling axis is a predominant target of miR-221 and mediates BCNU resistance in glioma cells."
24786471,miR-489,hsa-mir-489,MI0003124,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,Mice,-,breast cancer,in vitro and in vivo,Low,Sensitive,SMAD3,-,2014,MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway.,Forced-expression of miR-489 reversed chemoresistance. 
24788655,miR-130a,hsa-mir-130a,MI0000448,Doxorubicin (Adriamycin),31703,MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Sensitive,-,-,2014,MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer,"We found that overexpression of either miR-130a-3p or miR-451a in MDA-MB-231 cells could significantly decrease cells viability, and increase cells apoptotic rate compared with the doxorubicin group (Figures 5C and 5D)."
24788655,miR-451a,hsa-mir-451a,MI0001729,Doxorubicin (Adriamycin),31703,MDA-MB-231 ,-,-,-,breast cancer,in vitro,Low,Sensitive,-,-,2014,MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer,"We found that overexpression of either miR-130a-3p or miR-451a in MDA-MB-231 cells could significantly decrease cells viability, and increase cells apoptotic rate compared with the doxorubicin group (Figures 5C and 5D)."
24791593,let-7g,hsa-let-7g,MI0000433,5-Fluorouracil,3385,-,Bel-7402 vs Bel-7402/5-FU,-,-,hepatoma,in vitro,Low,Sensitive,HMGA2,-,2014,Let-7 g microRNA sensitizes fluorouracil-resistant human hepatoma cells.,"The results showed that let-7 g microRNA contributed to an increase of 5-Fu-induced cell cycle inhibit in human hepatoma cell and sensitized cells to 5-Fu, leading to increased the effectiveness of the drug in treating hepatoma cancer."
24802328,miR-34c,hsa-mir-34c,MI0000743,Cisplatin,2767,U2OS and MG63,-,-,Patients,osteosarcoma,in vitro and in vivo,Low,Sensitive,Notch1 and LEF1,-,2014,MiR-34c inhibits osteosarcoma metastasis and chemoresistance.,"Taken together, our data indicate that miR-34c suppresses OS metastasis and chemoresistance by targeting Notch1 and LEF1."
24802328,miR-34c,hsa-mir-34c,MI0000743,Doxorubicin (Adriamycin),31703,U2OS and MG63,-,-,Patients,osteosarcoma,in vitro and in vivo,Low,Sensitive,Notch1 and LEF1,-,2014,MiR-34c inhibits osteosarcoma metastasis and chemoresistance.,"Taken together, our data indicate that miR-34c suppresses OS metastasis and chemoresistance by targeting Notch1 and LEF1."
24802328,miR-34c,hsa-mir-34c,MI0000743,Methotrexate,126941,U2OS and MG63,-,-,Patients,osteosarcoma,in vitro and in vivo,Low,Sensitive,Notch1 and LEF1,-,2014,MiR-34c inhibits osteosarcoma metastasis and chemoresistance.,"Taken together, our data indicate that miR-34c suppresses OS metastasis and chemoresistance by targeting Notch1 and LEF1."
24802724,miR-429,hsa-mir-429,MI0001641,Cisplatin,2767,OCI-984,-,-,-,ovarian cancer,in vitro,Low,Sensitive,-,-,2014,Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells.,The results demonstrate that the ectopic over-expression of miR-429 significantly increased sensitivity to cisplatin relative to the negative control.
24805828,miR-106b,hsa-mir-106b,MI0000734,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,Low,Sensitive,-,-,2014,Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer,"The miRNA- normalized correlation values between drugresistant and drug-sensitive tissues were compared usinge Students t test and fold change test, and P values less than 0.05 and fold change values more than 2 are considered as statistically significant (Table 2). "
24805828,miR-152,hsa-mir-152,MI0000462,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,Low,Resistant,-,-,2014,Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer,"The miRNA- normalized correlation values between drugresistant and drug-sensitive tissues were compared usinge Students t test and fold change test, and P values less than 0.05 and fold change values more than 2 are considered as statistically significant (Table 2). "
24805828,miR-200a,hsa-mir-200a,MI0000737,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,Low,Sensitive,-,-,2014,Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer,"The miRNA- normalized correlation values between drugresistant and drug-sensitive tissues were compared usinge Students t test and fold change test, and P values less than 0.05 and fold change values more than 2 are considered as statistically significant (Table 2). "
24805828,miR-381,hsa-mir-381,MI0000789,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,Low,Resistant,-,-,2014,Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer,"The miRNA- normalized correlation values between drugresistant and drug-sensitive tissues were compared usinge Students t test and fold change test, and P values less than 0.05 and fold change values more than 2 are considered as statistically significant (Table 2). "
24805828,miR-429,hsa-mir-429,MI0001641,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,Low,Sensitive,-,-,2014,Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer,"The miRNA- normalized correlation values between drugresistant and drug-sensitive tissues were compared usinge Students t test and fold change test, and P values less than 0.05 and fold change values more than 2 are considered as statistically significant (Table 2). "
24817940,miR-1287,hsa-mir-1287,MI0006349,Paclitaxel,36314,"BGC-823, HGC-27, and NCI-N87",,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel,"The expression of 10 miRs was more than 50% higher in BGC-823 compared to HGC-27 and in HGC-27 compared to NCI-N87. Among these miRs, 7 (miR-224, miR-424-3p, miR-130a, miR-224-star, miR-452, miR-181a-2-star, and miR-193b-5p) were downregulated in the PTX-resistant GC cell line, whereas the other 3 miRs (miR-3127-5p, miR-1287, and miR-4713-5p) were upregulated in the PTX-resistant GC cell line compared to the PTX-sensitive GC cell line (Table 2)."
24817940,miR-130a,hsa-mir-130a,MI0000448,Paclitaxel,36314,"BGC-823, HGC-27, and NCI-N87",,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel,"The expression of 10 miRs was more than 50% higher in BGC-823 compared to HGC-27 and in HGC-27 compared to NCI-N87. Among these miRs, 7 (miR-224, miR-424-3p, miR-130a, miR-224-star, miR-452, miR-181a-2-star, and miR-193b-5p) were downregulated in the PTX-resistant GC cell line, whereas the other 3 miRs (miR-3127-5p, miR-1287, and miR-4713-5p) were upregulated in the PTX-resistant GC cell line compared to the PTX-sensitive GC cell line (Table 2)."
24817940,miR-181a-2*,hsa-mir-181a-2,MI0000269,Paclitaxel,36314,"BGC-823, HGC-27, and NCI-N87",,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel,"The expression of 10 miRs was more than 50% higher in BGC-823 compared to HGC-27 and in HGC-27 compared to NCI-N87. Among these miRs, 7 (miR-224, miR-424-3p, miR-130a, miR-224-star, miR-452, miR-181a-2-star, and miR-193b-5p) were downregulated in the PTX-resistant GC cell line, whereas the other 3 miRs (miR-3127-5p, miR-1287, and miR-4713-5p) were upregulated in the PTX-resistant GC cell line compared to the PTX-sensitive GC cell line (Table 2)."
24817940,miR-193b*,hsa-mir-193b,MI0003137,Paclitaxel,36314,"BGC-823, HGC-27, and NCI-N87",,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel,"The expression of 10 miRs was more than 50% higher in BGC-823 compared to HGC-27 and in HGC-27 compared to NCI-N87. Among these miRs, 7 (miR-224, miR-424-3p, miR-130a, miR-224-star, miR-452, miR-181a-2-star, and miR-193b-5p) were downregulated in the PTX-resistant GC cell line, whereas the other 3 miRs (miR-3127-5p, miR-1287, and miR-4713-5p) were upregulated in the PTX-resistant GC cell line compared to the PTX-sensitive GC cell line (Table 2)."
24817940,miR-224,hsa-mir-224,MI0000301,Paclitaxel,36314,"BGC-823, HGC-27, and NCI-N87",,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel,"The expression of 10 miRs was more than 50% higher in BGC-823 compared to HGC-27 and in HGC-27 compared to NCI-N87. Among these miRs, 7 (miR-224, miR-424-3p, miR-130a, miR-224-star, miR-452, miR-181a-2-star, and miR-193b-5p) were downregulated in the PTX-resistant GC cell line, whereas the other 3 miRs (miR-3127-5p, miR-1287, and miR-4713-5p) were upregulated in the PTX-resistant GC cell line compared to the PTX-sensitive GC cell line (Table 2)."
24817940,miR-224*,hsa-mir-224,MI0000301,Paclitaxel,36314,"BGC-823, HGC-27, and NCI-N87",,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel,"The expression of 10 miRs was more than 50% higher in BGC-823 compared to HGC-27 and in HGC-27 compared to NCI-N87. Among these miRs, 7 (miR-224, miR-424-3p, miR-130a, miR-224-star, miR-452, miR-181a-2-star, and miR-193b-5p) were downregulated in the PTX-resistant GC cell line, whereas the other 3 miRs (miR-3127-5p, miR-1287, and miR-4713-5p) were upregulated in the PTX-resistant GC cell line compared to the PTX-sensitive GC cell line (Table 2)."
24817940,miR-3127,hsa-mir-3127,MI0014144,Paclitaxel,36314,"BGC-823, HGC-27, and NCI-N87",,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel,"The expression of 10 miRs was more than 50% higher in BGC-823 compared to HGC-27 and in HGC-27 compared to NCI-N87. Among these miRs, 7 (miR-224, miR-424-3p, miR-130a, miR-224-star, miR-452, miR-181a-2-star, and miR-193b-5p) were downregulated in the PTX-resistant GC cell line, whereas the other 3 miRs (miR-3127-5p, miR-1287, and miR-4713-5p) were upregulated in the PTX-resistant GC cell line compared to the PTX-sensitive GC cell line (Table 2)."
24817940,miR-424*,hsa-mir-424,MI0001446,Paclitaxel,36314,"BGC-823, HGC-27, and NCI-N87",,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel,"The expression of 10 miRs was more than 50% higher in BGC-823 compared to HGC-27 and in HGC-27 compared to NCI-N87. Among these miRs, 7 (miR-224, miR-424-3p, miR-130a, miR-224-star, miR-452, miR-181a-2-star, and miR-193b-5p) were downregulated in the PTX-resistant GC cell line, whereas the other 3 miRs (miR-3127-5p, miR-1287, and miR-4713-5p) were upregulated in the PTX-resistant GC cell line compared to the PTX-sensitive GC cell line (Table 2)."
24817940,miR-452,hsa-mir-452,MI0001733,Paclitaxel,36314,"BGC-823, HGC-27, and NCI-N87",,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel,"The expression of 10 miRs was more than 50% higher in BGC-823 compared to HGC-27 and in HGC-27 compared to NCI-N87. Among these miRs, 7 (miR-224, miR-424-3p, miR-130a, miR-224-star, miR-452, miR-181a-2-star, and miR-193b-5p) were downregulated in the PTX-resistant GC cell line, whereas the other 3 miRs (miR-3127-5p, miR-1287, and miR-4713-5p) were upregulated in the PTX-resistant GC cell line compared to the PTX-sensitive GC cell line (Table 2)."
24817940,miR-4713,hsa-mir-4713,MI0017347,Paclitaxel,36314,"BGC-823, HGC-27, and NCI-N87",,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel,"The expression of 10 miRs was more than 50% higher in BGC-823 compared to HGC-27 and in HGC-27 compared to NCI-N87. Among these miRs, 7 (miR-224, miR-424-3p, miR-130a, miR-224-star, miR-452, miR-181a-2-star, and miR-193b-5p) were downregulated in the PTX-resistant GC cell line, whereas the other 3 miRs (miR-3127-5p, miR-1287, and miR-4713-5p) were upregulated in the PTX-resistant GC cell line compared to the PTX-sensitive GC cell line (Table 2)."
24830600,miR-200b,hsa-mir-200b,MI0000342,Docetaxel,148124,-,SPC-A1 vs SPC-A1/DOC and H1299 vs H1299/DOC,Mice,Patients,lung adenocarcinoma,in vitro and in vivo,Low,Sensitive,E2F3,survivin and Aurora-A,2014,HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells.,"Furthermore, silencing of HDAC1/4 suppressed cell proliferation, promoted cell apoptosis, induced G2/M cell cycle arrest and ultimately reversed in vitro and in vivo chemoresistance of docetaxel-resistant LAD cells, at least partially in a miR-200b-dependent manner."
24830724,miR-200,-,-,Erlotinib,176870,"JHU011, JHU028, H358, H1703,Calu3 and Calu6",SCC vs SCC/ER,Mice,Patients,cancer,in vitro and in vivo,Low,Sensitive,MIG6,-,2014,The TGFBeta-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.,"Although erlotinib-sensitive cells demonstrated a high level of miR200 and a low level of MIG6, most of the erlotinib-resistant cells showed decreased levels of miR200 miRNAs and elevated MIG6 expression."
24832599,miR-374a,hsa-mir-374a,MI0000782,Gefitinib,123631,Calu1,HCC827 vs HCC827/GR,Mice,-,lung cancer,in vitro and in vivo,Low,Resistant,Wnt5a,-,2014,Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.,"In this study, we validate and report that miR-374a and miR-548b modulated by Axl have essential roles in cell cycle arrest, gefitinib-induced apoptosis, epithelial-to-mesenchymal transition, migration and tumorigenesis of gefitinib-resistant lung cancer cells in vitro and in vivo by targeting Wnt5a and CCNB1 genes, respectively."
24832599,miR-548b ,hsa-mir-548b,MI0003596,Gefitinib,123631,Calu1,HCC827 vs HCC827/GR,Mice,-,lung cancer,in vitro and in vivo,Low,Resistant,CCNB1,-,2014,Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.,"In this study, we validate and report that miR-374a and miR-548b modulated by Axl have essential roles in cell cycle arrest, gefitinib-induced apoptosis, epithelial-to-mesenchymal transition, migration and tumorigenesis of gefitinib-resistant lung cancer cells in vitro and in vivo by targeting Wnt5a and CCNB1 genes, respectively."
24836307,miR-205,hsa-mir-205,MI0000285,Gemcitabine,60750,-,Mia-PaCa-2 vs Mia-PaCa-2/GEM and CAPAN-1 vs CAPAN-1/GEM,Mice,-,pancreatic cancer,in vitro and in vivo,Low,Sensitive,-,-,2014,Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer.,Immuno-hiostochemical analysis revealed decreased tumor cell proliferation with increased apoptosis in the animals treated with miR-205 and gemcitabine combination.
24846940,miR-125b,hsa-mir-125b-1,MI0000446,5-Fluorouracil,3385,-,BGC823 vs BGC823/5-FU,-,-,gastric cancer,in vitro,Low,Associated,-,-,2014,Expression profiling and functional analysis of hsa-miR-125b and its target genes in drug-resistant cell line of human gastric cancer,The expression of hsa-miR-125b is significantly downregulated in the fluorouracil-resistant cell line of human gastric cancer (BGC823/Fu).
24848511,miR-10b,hsa-mir-10b,MI0000267,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-10b*,hsa-mir-10b,MI0000267,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-1233,hsa-mir-1233-1,MI0006323,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Resistant,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-129,hsa-mir-129-1,MI0000252,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-135b,hsa-mir-135b,MI0000810,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-148a,hsa-mir-148a,MI0000253,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-182,hsa-mir-182,MI0000272,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-183,hsa-mir-183,MI0000273,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-193a,hsa-mir-193a,MI0000487,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Resistant,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-200b,hsa-mir-200b,MI0000342,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-22,hsa-mir-22,MI0000078,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Resistant,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-302b,hsa-mir-302a,MI0000738,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-30a*,hsa-mir-30a,MI0000088,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-33b,hsa-mir-33b,MI0003646,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Resistant,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-34b,hsa-mir-34b,MI0000742,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-371,hsa-mir-371a,MI0000779,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-424,hsa-mir-424,MI0001446,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-431*,hsa-mir-431,MI0001721,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-488,hsa-mir-488,MI0003123,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-491,hsa-mir-491,MI0003126,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-492,hsa-mir-492,MI0003131,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-498,hsa-mir-498,MI0003142,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-509-3,hsa-mir-509-3,MI0005717,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-513a,hsa-mir-513a-1,MI0003191,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-517b,hsa-mir-517b,MI0003165,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-545,hsa-mir-545,MI0003516,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-592,hsa-mir-592,MI0003604,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-597,hsa-mir-597,MI0003609,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-625*,hsa-mir-625,MI0003639,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-628,hsa-mir-628,MI0003642,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-629*,hsa-mir-629,MI0003643,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-641,hsa-mir-641,MI0003656,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-7,hsa-mir-7-1,MI0000263,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-708,hsa-mir-708,MI0005543,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-7-1*,hsa-mir-7-1,MI0000263,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24848511,miR-96,hsa-mir-96,MI0000098,Chemotherapy,-,-,-,-,Patientss,epithelial ovarian cancer,in vivo,High,Sensitive,-,-,2014,Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data,"As previously, differentially miRNA expression was performed in 455 patients with available high-throughput data and information about chemoresponse. A heatmap of the 38 miRNA differentially expressed between the CR and IR groups is represented in Supplementary Fig. S4D. "
24854555,miR-192,hsa-mir-192,MI0000234,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung cancer,in vitro,Low,Resistant,Bim,-,2014,MiR-192 confers cisplatin resistance by targeting Bim in lung cancer,Overexpression of miR-192 in A549 cells significantly conferred resistance to Cisplatin and inhibited apoptosis.
24858372,miR-1236,hsa-mir-1236,MI0006326,Doxorubicin (Adriamycin),31703,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-1236,hsa-mir-1236,MI0006326,Prednisone (R-CHOP),5865,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-1236,hsa-mir-1236,MI0006326,Vincristine,5978,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-1256,hsa-mir-1256,MI0006390,Doxorubicin (Adriamycin),31703,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-1256,hsa-mir-1256,MI0006390,Prednisone (R-CHOP),5865,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-1256,hsa-mir-1256,MI0006390,Vincristine,5978,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-129,hsa-mir-129-1,MI0000252,Doxorubicin (Adriamycin),31703,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Sensitive,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-129,hsa-mir-129-1,MI0000252,Prednisone (R-CHOP),5865,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Sensitive,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-129,hsa-mir-129-1,MI0000252,Vincristine,5978,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Sensitive,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-138-1*,hsa-mir-138-1,MI0000476,Doxorubicin (Adriamycin),31703,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-138-1*,hsa-mir-138-1,MI0000476,Prednisone (R-CHOP),5865,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-138-1*,hsa-mir-138-1,MI0000476,Vincristine,5978,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-187,hsa-mir-187,MI0000274,Doxorubicin (Adriamycin),31703,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-187,hsa-mir-187,MI0000274,Prednisone (R-CHOP),5865,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-187,hsa-mir-187,MI0000274,Vincristine,5978,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-191*,hsa-mir-191,MI0000465,Doxorubicin (Adriamycin),31703,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-191*,hsa-mir-191,MI0000465,Prednisone (R-CHOP),5865,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-191*,hsa-mir-191,MI0000465,Vincristine,5978,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-214*,hsa-mir-214,MI0000290,Doxorubicin (Adriamycin),31703,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-214*,hsa-mir-214,MI0000290,Prednisone (R-CHOP),5865,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-214*,hsa-mir-214,MI0000290,Vincristine,5978,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-224,hsa-mir-224,MI0000301,Doxorubicin (Adriamycin),31703,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-224,hsa-mir-224,MI0000301,Prednisone (R-CHOP),5865,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-224,hsa-mir-224,MI0000301,Vincristine,5978,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-29b-2*,hsa-mir-29b-2,MI0000107,Doxorubicin (Adriamycin),31703,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-29b-2*,hsa-mir-29b-2,MI0000107,Prednisone (R-CHOP),5865,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-29b-2*,hsa-mir-29b-2,MI0000107,Vincristine,5978,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-33a,hsa-mir-33a,MI0000091,Doxorubicin (Adriamycin),31703,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Sensitive,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-33a,hsa-mir-33a,MI0000091,Prednisone (R-CHOP),5865,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Sensitive,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-33a,hsa-mir-33a,MI0000091,Vincristine,5978,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Sensitive,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-455,hsa-mir-455,MI0003513,Doxorubicin (Adriamycin),31703,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Sensitive,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-455,hsa-mir-455,MI0003513,Prednisone (R-CHOP),5865,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Sensitive,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-455,hsa-mir-455,MI0003513,Vincristine,5978,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Sensitive,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-520,-,-,Doxorubicin (Adriamycin),31703,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-520,-,-,Prednisone (R-CHOP),5865,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-520,-,-,Vincristine,5978,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-542,hsa-mir-542,MI0003686,Doxorubicin (Adriamycin),31703,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Sensitive,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-542,hsa-mir-542,MI0003686,Prednisone (R-CHOP),5865,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Sensitive,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-542,hsa-mir-542,MI0003686,Vincristine,5978,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Sensitive,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-876,hsa-mir-876,MI0005542,Doxorubicin (Adriamycin),31703,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Sensitive,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-876,hsa-mir-876,MI0005542,Prednisone (R-CHOP),5865,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Sensitive,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-876,hsa-mir-876,MI0005542,Vincristine,5978,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Sensitive,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-Plus-A1031,-,-,Doxorubicin (Adriamycin),31703,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-Plus-A1031,-,-,Prednisone (R-CHOP),5865,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24858372,miR-Plus-A1031,-,-,Vincristine,5978,-,-,-,Patientss,diffuse large B cell lymphoma (DLBCL) ,in vivo,High,Resistant,-,-,2014,Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients,"One hundred fifty-nine miRNAs were >2-fold upregulated in the primary refractory group, whereas 63 miRNAs were >2-fold upregulated in the complete remission group. "
24865582,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,SKOV3ip1 and HEYA8,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,Low,Sensitive,PDCD4,-,2014,Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway.,Overexpression of miR-21 in cisplatin sensitive cells decreased PDCD4 levels and increased cell proliferation.
24865963,miR-125b,hsa-mir-125b-1,MI0000446,5-Fluorouracil,3385,-,HepG3 vs HepG3/5-FU,-,-,hepatocellular carcinoma ,in vitro,Low,Sensitive,Hexokinase 2,-,2014,Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II.,"In conclusion, the results suggested that the overexpression of miR-125b sensitized HCC cells to 5-FU through inhibition of HK II."
24870597,miR-520a,hsa-mir-520a,MI0003149,Capsaicin,1548943,K562,-,-,-,chronic myelogenous leukemia,in vitro,Low,Sensitive,STAT3,-,2014,MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin.,"Taken together, our findings indicate that capsaicin, potentially through the miR-520a-5p/STAT3 interaction, inhibits K562 leukemic cell proliferation."
24872388,miR-17,hsa-mir-17,MI0000071,Etoposide,36462,-,K562 vs K562/ADR and HL60 vs HL60/ADR,Mice,-,leukemia,in vitro and in vivo,Low,Resistant,-,BIM-S,2014,Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S.,"Notably, silencing miR-17 or miR-20a expression by treatment with microRNA (miRNA; miR) inhibitors or oridonin restored sensitivity of K562 cells to VP-16."
24872388,miR-20a,hsa-mir-20a,MI0000076,Etoposide,36462,-,K562 vs K562/ADR and HL60 vs HL60/ADR,Mice,-,leukemia,in vitro and in vivo,Low,Resistant,-,BIM-S,2014,Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S.,"Notably, silencing miR-17 or miR-20a expression by treatment with microRNA (miRNA; miR) inhibitors or oridonin restored sensitivity of K562 cells to VP-16."
24875127,miR-1271,hsa-mir-1271,MI0003814,Cisplatin,2767,-,SGC7901 vs SGC7901/CDDP,-,-,gastric cancer,in vitro,Low,Sensitive,"IGF1R, IRS1, mTOR, and BCL2",-,2014,"miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.","Overall, on the basis of the results of our study, we proposed that miR-1271 could regulate cisplatin resistance in human gastric cancer cells, at least partially, via targeting the IGF1R/IRS1 pathway."
24898807,miR-122,hsa-mir-122,MI0000442,5-Fluorouracil,3385,-,HCT-116 vs HCT-116/5-FU and HCT-29 vs HCT-29/5-FU,Mice,-,colon cancer,in vitro and in vivo,Low,Sensitive,PKM2,-,2014,Overexpression of microRNA-122 re-sensitizes 5-FU-resistant colon cancer cells to 5-FU through the inhibition of PKM2 in vitro and in vivo.,"Importantly, overexpression of miR-122 in 5-FU-resistant cells resensitizes 5-FU resistance through the inhibition of PKM2 both in vitro and in vivo."
24901050,miR-125b,hsa-mir-125b-1,MI0000446,Temozolomide,5394,U87 and LN-18 ,-,-,-,glioblastoma,in vitro,Low,Sensitive,TNFAIP3 ,NF--kappaB signaling pathway,2014,miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas.,"Conversely, overexpression of anti-miR-125b resulted in cell cycle arrest, increased apoptosis and increased sensitivity to TMZ, indicating that endogenous miR-125b is sufficient to control these processes."
24906642,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,A549 and SK-MES-1,-,Mice,-,non-small-cell lung cancer,in vitro and in vivo,Low,Resistant,-,-,2014,Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.,Our findings demonstrate that miR-21 suppression enhances the sensitivity of lung cancer cells to DDP in vitro and in vivo.
24912422,miR-17,hsa-mir-17,MI0000071,5-Fluorouracil,3385,COLO205,-,-,Patients,colorectal cancer,in vitro and in vivo,Low,Resistant,PTEN ,-,2014,MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression.,"After 12 hour treatment, miR-17-transfected cells showed greater resistance towards these chemotherapeutic agents, with more cells surviving after the treatment"
24912422,miR-17,hsa-mir-17,MI0000071,Irinotecan,-,COLO205,-,-,Patients,colorectal cancer,in vitro and in vivo,Low,Resistant,PTEN ,-,2014,MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression.,"After 12 hour treatment, miR-17-transfected cells showed greater resistance towards these chemotherapeutic agents, with more cells surviving after the treatment"
24912422,miR-17,hsa-mir-17,MI0000071,Oxaliplatin,5310940,COLO205,-,-,Patients,colorectal cancer,in vitro and in vivo,Low,Resistant,PTEN ,-,2014,MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression.,"After 12 hour treatment, miR-17-transfected cells showed greater resistance towards these chemotherapeutic agents, with more cells surviving after the treatment"
24921394,miR-342,hsa-mir-342,MI0000805,Cisplatin,2767,MDA-MB-231,-,-,-,breast cancer,in vitro ,Low,Sensitive,-,-,2014,Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer,"TNBC with high expression of miR-342-3p are more sensitive to chemotherapy. miRNA-342-3p may regulate the sensitivity of breast cancer cell line MDA-MB-231 to chemotherapy drugs paclitaxel and cisplatin, but can not affect the chemotherapy sensitivity of doxorubicin."
24921394,miR-342,hsa-mir-342,MI0000805,Paclitaxel,36314,MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Sensitive,-,-,2014,Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer,"TNBC with high expression of miR-342-3p are more sensitive to chemotherapy. miRNA-342-3p may regulate the sensitivity of breast cancer cell line MDA-MB-231 to chemotherapy drugs paclitaxel and cisplatin, but can not affect the chemotherapy sensitivity of doxorubicin."
24921914,miR-224,hsa-mir-224,MI0000301,Cisplatin,2767,-,A549 vs A549/CDDP and SPC-A1 vs SPC-A1/CDDP,Mice,-,lung adenocarcinoma,in vitro and in vivo,Low,Resistant,p21,-,2014,MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G1/S transition and apoptosis by targeting p21(WAF1/CIP1).,Overexpression of p21(WAF1/CIP1) could phenocopy the effect of miR-224 downregulation and silencing of p21(WAF1/CIP1) could partially reverse the effect of miR-224 downregulation on DDP resistance of DDP-resistant LA cells.
24924200,miR-221,hsa-mir-221,MI0000298,Tamoxifen,2733526,MCF-7 and MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Resistant,TIMP3,-,2014,Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3.,We have demonstrated for the first time that suppression of miRNA-221/222 increases the sensitivity of ER-positive MCF-7 breast cancer cells to tamoxifen. This effect is mediated through upregulation of TIMP3.
24924200,miR-222,hsa-mir-222,MI0000299,Tamoxifen,2733526,MCF-7 and MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Resistant,TIMP3,-,2014,Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3.,We have demonstrated for the first time that suppression of miRNA-221/222 increases the sensitivity of ER-positive MCF-7 breast cancer cells to tamoxifen. This effect is mediated through upregulation of TIMP3.
24931256,miR-503,hsa-mir-503,MI0003188,Cisplatin,2767,-,SGC7901 vs SGC7901/CDDP,-,-,gastric cancer,in vitro ,Low,Sensitive,IGF1R and BCL2,-,2014,MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2.,An in vitro drug sensitivity assay showed that overexpression of miR-503 sensitized SGC7901/DDP cells to cisplatin.
24940696,miR-211,hsa-mir-211,MI0000287,Gemcitabine,60750,SUIT2-007 and SUIT2-028,-,-,-,pancreatic cancer,in vitro,Low,Sensitive,RRM2,-,2014,miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells.,"Moreover, we demonstrated that induction of the miR-211 expression in the cells increased the sensitivity to gemcitabine and reduced the expression of its target ribonucleotide reductase subunit 2 (RRM2). "
24967963,miR-424,hsa-mir-424,MI0001446,Doxorubicin (Adriamycin),31703,HCT-116 and A375,-,Mice,-,cancer,in vitro and in vivo,Low,Resistant,PDCD4,-,2014,Hypoxia-induced miR-424 decreases tumor sensitivity to chemotherapy by inhibiting apoptosis.,"In contrast, the inhibition of miR-424 enhanced apoptosis and increased the sensitivity of cancer cells to Dox. In a xenograft tumor model, miR-424 overexpression promoted tumor growth following Dox treatment, suggesting that miR-424 promotes tumor cell resistance to Dox."
24967963,miR-424,hsa-mir-424,MI0001446,Etoposide,36462,HCT116 and A375,-,Mice,-,cancer,in vitro and in vivo,Low,Resistant,PDCD4,-,2014,Hypoxia-induced miR-424 decreases tumor sensitivity to chemotherapy by inhibiting apoptosis.,"In contrast, the inhibition of miR-424 enhanced apoptosis and increased the sensitivity of cancer cells to Dox. In a xenograft tumor model, miR-424 overexpression promoted tumor growth following Dox treatment, suggesting that miR-424 promotes tumor cell resistance to Dox."
24969560,miR-196a,hsa-mir-196a-1,MI0000238,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,Patientss,breast cancer,in vitro and in vivo,Low,Resistant,-,-,2014,Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs,"Additionally, we were able to detect a group of miRNAs that resulted unique for D/exo compared to the donor cells whereas some miRNAs expressed by MCF-7/Doc were absent in the corresponding exosomes (Fig. 2c). The miRNA microarray data was further validated by qRT-PCR using the following selected miRNAs, namely, miR-196a, miR-21, miR-222, and miR-29a (Fig. 2d). "
24969560,miR-21,hsa-mir-21,MI0000077,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,Low,Resistant,-,-,2014,Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs,"Additionally, we were able to detect a group of miRNAs that resulted unique for D/exo compared to the donor cells whereas some miRNAs expressed by MCF-7/Doc were absent in the corresponding exosomes (Fig. 2c). The miRNA microarray data was further validated by qRT-PCR using the following selected miRNAs, namely, miR-196a, miR-21, miR-222, and miR-29a (Fig. 2d). "
24969560,miR-222,hsa-mir-222,MI0000299,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,Low,Resistant,-,-,2014,Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs,"Additionally, we were able to detect a group of miRNAs that resulted unique for D/exo compared to the donor cells whereas some miRNAs expressed by MCF-7/Doc were absent in the corresponding exosomes (Fig. 2c). The miRNA microarray data was further validated by qRT-PCR using the following selected miRNAs, namely, miR-196a, miR-21, miR-222, and miR-29a (Fig. 2d). "
24969560,miR-29a,hsa-mir-29a,MI0000087,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,Low,Resistant,-,-,2014,Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs,"Additionally, we were able to detect a group of miRNAs that resulted unique for D/exo compared to the donor cells whereas some miRNAs expressed by MCF-7/Doc were absent in the corresponding exosomes (Fig. 2c). The miRNA microarray data was further validated by qRT-PCR using the following selected miRNAs, namely, miR-196a, miR-21, miR-222, and miR-29a (Fig. 2d). "
24970027,let-7,-,-,Paclitaxel,36314,-,Hep3B vs Hep3B/Taxol,-,-,hepatocellular carcinoma,in vitro,Low,Associated,Bcl-xL,-,2014,Lin28/let-7/Bcl-xL pathway: the underlying mechanism of drug resistance in Hep3B cells.,Lin28/let-7/Bcl-xL is associated with drug resistance in Hep3B cells.
24970682,miR-34a,hsa-mir-34a,MI0000268,TRAIL therapy,-,MCF-7,-,-,-,breast cancer,in vitro,Low,Associated,Sirt1,Pgc-1alpha alpha and Nrf2,2014,"Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1alpha/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents.",Our results indicated that the activation of the p53/miR-34a signaling pathway and down-regulation of Sirt1 expression play an important role for enhancing sensitivity of wild-type p53 MCF-7 cells to oxidative stress or TRAIL-induced apoptosis.
24970806,miR-942,hsa-mir-942,MI0005767,TRAIL therapy,-,"LH86, HLCZ02, Huh7, HGC-27 and BGC-823",-,-,-,hepatocellular carcinoma,in vitro,Low,Resistant,ISG12a,-,2014,miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT.,Knockdown of miR-942 expression in TRAIL-resistant cells restores the expression of ISG12a and sensitizes the cells to TRAIL treatment.
24977712,miR-146a,hsa-mir-146a,MI0000477,Paclitaxel,36314,SKOV-3,-,-,-,epithelial ovarian cancer,in vitro,Low,Associated,TLR4 ,MyD88,2014,The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.,"However, the reduced level of TLR4 expression significantly affected the response of the SKOV-3 towards paclitaxel."
24977712,miR-21,hsa-mir-21,MI0000077,Paclitaxel,36314,SKOV-3,-,-,-,epithelial ovarian cancer,in vitro,Low,Associated,TLR4 ,MyD88,2014,The MyD88 phenotype is an adverse prognostic factor in epithelial ovarian cancer.,"However, the reduced level of TLR4 expression significantly affected the response of the SKOV-3 towards paclitaxel."
24983493,miR-34a,hsa-mir-34a,MI0000268,Gefitinib,123631,HCC827 and PC-9,-,Mice,-,non-small-cell lung cancer,in vitro and in vivo,Low,Sensitive,MET,-,2014,MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.,"In our study, we found that the forced expression of miR-34a inhibited cell growth and induced apoptosis partly by targeting MET in HGF-induced gefitinib-resistant HCC827 and PC-9 cells. "
24989082,miR-17,hsa-mir-17,MI0000071,Doxorubicin (Adriamycin),31703,Fuji,-,-,-,synovial sarcoma,in vitro,Low,Resistant,p21,-,2014,SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.,It is noteworthy that miR-17 succeeded in suppressing doxorubicin-evoked higher expression of p21 and conferred the drug resistance.
24992675,miR-29b,hsa-mir-29b-1,MI0000105,Paclitaxel,36314,ES2 and AMOC2,-,-,-,ovarian cancer,in vitro,Low,Sensitive,Mcl-1,Mcl-1,2014,BAG3 upregulates Mcl-1 through downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer.,"BAG3 knockdown appears to downregulate expression of Mcl-1 through upregulation of miR-29b, thereby increasing the chemosensitivity of ovarian clear cell carcinoma cells."
25004126,miR-203,hsa-mir-203a,MI0000283,AG1478,2051,DU145 and RasB1,-,-,-,prostate cancer bone metastasis,in vitro,Low,Sensitive,"AREG, EREG, and TGFA",-,2014,Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance,These results suggest that the effects of miR-203 on TKIs sensitivity are due to directly regulating the anti-apoptotic signaling-related genes mediated by miR-203.
25004126,miR-203,hsa-mir-203a,MI0000283,Canertinib HCl,156413,DU145 and RasB1,-,-,-,prostate cancer bone metastasis,in vitro,Low,Sensitive,"AREG, EREG, and TGFA",-,2014,Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance,These results suggest that the effects of miR-203 on TKIs sensitivity are due to directly regulating the anti-apoptotic signaling-related genes mediated by miR-203.
25007959,miR-221,hsa-mir-221,MI0000298,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,Low,Resistant,p27 and Era,-,2014,Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells.,"And the elevated miR-221/222 effectively reduced the target genes expression of P27 and ERalpha, which enhanced tamoxifen resistance in recipient cells."
25007959,miR-222,hsa-mir-222,MI0000299,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,Low,Resistant,p27 and Era,-,2014,Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells.,"And the elevated miR-221/222 effectively reduced the target genes expression of P27 and ERalpha, which enhanced tamoxifen resistance in recipient cells."
25009614,miR-155,hsa-mir-155,MI0000681,Doxorubicin (Adriamycin),31703,Saos-2 and MG-63,-,-,-,osteosarcoma,in vitro,Low,Sensitive,-,-,2014,miR-155 mediates drug resistance in osteosarcoma cells via inducing autophagy.,The increased miR-155 expression levels upregulated anticancer drug-induced autophagy in osteosarcoma cells and ameliorated the anticancer drug-induced cell proliferation and viability decrease. 
25012722,miR-182,hsa-mir-182,MI0000272,Cisplatin,2767,A549 and NHBE,-,-,-,non-small cell lung cancer ,in vitro,Low,Resistant,PDCD4,PDCD4,2014,MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4.,Transfection of miR-182 inhibitor induced sensitivity of A549 cells to cisplatin.
25013866,miR-101,hsa-mir-101-1,MI0000103,Doxorubicin (Adriamycin),31703,U2OS,-,-,-,osteosarcoma,in vitro,Low,Resistant,-,-,2014,Blocked autophagy by miR-101 enhances osteosarcoma cell chemosensitivity in vitro.,These results show miR-101 blocked chemotherapy-induced autophagy and expression of autophagy-related proteins in OS cells.
25013866,miR-101,hsa-mir-101-1,MI0000103,Sirolimus,5284616,U2OS,-,-,-,osteosarcoma,in vitro,Low,Resistant,-,-,2014,Blocked autophagy by miR-101 enhances osteosarcoma cell chemosensitivity in vitro.,These results show miR-101 blocked chemotherapy-induced autophagy and expression of autophagy-related proteins in OS cells.
25014664,let-7f-1,hsa-let-7f-1,MI0000067,Cisplatin,2767,D425 and UW228,-,-,-,medulloblastoma ,in vitro,Low,Resistant,HMGB1,SPARC,2014,miR-let-7f-1 regulates SPARC mediated cisplatin resistance in medulloblastoma cells.,We also show that HMGB1 is a direct target of miR-let-7f-1 and forced expression of HMGB1 cDNA enhanced cisplatin sensitivity in SPARC expressed cells.
25015549,miR-135a,hsa-miR-135a-5p,MI0000452,TRAIL therapy,-,PC-3 and DU145,-,-,-,prostate cancer,in vitro,Low,Sensitive,-,-,2014,Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis.,MiR135a-3p mimic enhanced cytotoxicity by combination with Tanshinone I and TRAIL in PC-3 or DU145 cells compared to Tanshinone I or TRAIL alone.
25017423,miR-224,hsa-mir-224,MI0000301,Cisplatin,2767,-,OV2008 vs OV2008/CDDP and A2780S vs A2780S/CDDP,-,Patients,ovarian papillary serous carcinoma,in vitro and in vivo,Low,Resistant,PRKCD,-,2014,Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.,"miR-224-5p expression in different chemoresistant ovarian cancer cell lines, and upregulation of miR-224-5p increases cell survival of chemosensitive cell lines to cisplatin."
25017996,miR-128,hsa-mir-128-1,MI0000447,Temozolomide,5394,U251,-,-,-,glioblastoma,in vitro,Low,Sensitive,Rap1B,-,2014,miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.,miR-128 and miR-149 increase the chemosensitivity of TMZ in glioblastoma cells.
25017996,miR-149,hsa-mir-149,MI0000478,Temozolomide,5394,U251,-,-,-,glioblastoma,in vitro,Low,Sensitive,Rap1B,-,2014,miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.,miR-128 and miR-149 increase the chemosensitivity of TMZ in glioblastoma cells.
25026296,miR-25,hsa-mir-25,MI0000082,Epirubicin,41867,-,MCF-7 vs MCF-7/ADR,Mice,-,breast cancer,in vitro and in vivo,Low,Resistant,ULK-1,-,2014,"MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin.",miR-25 overexpression was demonstrated to block ISL-induced autophagy and chemosensitization.
25031750,miR-204,hsa-mir-204,MI0000284,5-Fluorouracil,3385,-,-,-,Patients,breast cancer,in vivo,Low,Associated,-,-,2014,Decreased expression of miR-204 is associated with poor prognosis in Patient with breast cancer.,"The result showed that miR-204 was significantly associated with therapeutic response, exhibiting lower expression in non-responsive Patient"
25031750,miR-204,hsa-mir-204,MI0000284,Cyclophosphamide,2907,-,-,-,Patients,breast cancer,in vivo,Low,Associated,-,-,2014,Decreased expression of miR-204 is associated with poor prognosis in Patient with breast cancer.,"The result showed that miR-204 was significantly associated with therapeutic response, exhibiting lower expression in non-responsive Patient"
25031750,miR-204,hsa-mir-204,MI0000284,Epirubicin,41867,-,-,-,Patients,breast cancer,in vivo,Low,Associated,-,-,2014,Decreased expression of miR-204 is associated with poor prognosis in Patient with breast cancer.,"The result showed that miR-204 was significantly associated with therapeutic response, exhibiting lower expression in non-responsive Patient"
25034398,miR-193b,hsa-mir-193b,MI0003137,Sorafenib,216239,-,HepG2 vs HepG2.2.15 (HBV),-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,MCL-1,-,2014,Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.,Restoring the expression of miR-193b sensitized HBV-associated HCC cells to sorafenib treatment and facilitated sorafenib-induced apoptosis.
25038915,miR-34a,hsa-mir-34a,MI0000268,Cisplatin,2767,A549,-,-,-,lung cancer,in vitro,Low,Associated,PEBP4,-,2014,"Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells.","In conclusion, overexpression of PEBP4 reduced the sensitivity of A549 cells to DDP-induced cytotoxicity, mainly through the altered expression of the p53 protein or the modulation of miR-34a."
25040368,miR-425,hsa-mir-425,MI0001448,Sorafenib,216239,HuH-7 and HepG2,-,-,Patients,hepatocellular carcinoma,in vitro and in vivo,Low,Sensitive,-,-,2015,MicroRNA-425-3p predicts response to sorafenib therapy in Patient with hepatocellular carcinoma.,"Furthermore, an association between increased miR-425-3p, cell death and reduced cell motility was defined in vitro in HCC cell lines treated with sorafenib."
25040964,miR-452,hsa-mir-452,MI0001733,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Sensitive,-,-,2014,Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells.,These results suggested that miR-452 could confer ADR resistance in breast cancer MCF-7 cells by inhibiting ADR-induced apoptosis.
25047724,miR-181 ,-,-,Temozolomide,5394,-,U87MG vs U87MG/TEM,Mice,-,glioma,in vitro and in vivo,Low,Sensitive,MeK1,Bcl-2,2014,Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.,The data indicated that mir-181 overexpression is required for the synergistic anti-tumor activity of aplysin and temozolomide on glioma cells.
25053345,miR-135a,hsa-mir-135a-1,MI0000452,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,miR-34a is an Intracellular and Exosomal Predictive Biomarker for Response to Docetaxel with Clinical Relevance to Prostate Cancer Progression,"To confirm the results from global miRNA profiling, four miRNAs found to be decreased in the cells and exosomes of at least two of the three docetaxelresistant cell line variants were selected for validation by qPCR. The expression of miR-598, miR-148a, miR-34a, and miR-146a confirmed the sametrends as demonstrated in the global profiling (Table II)."
25053345,miR-146a,hsa-mir-146a,MI0000477,Docetaxel,148124,"22Rv1, DU145, PC3,22Rv1RD, DU145RD, and PC3RD",,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profile of bromocriptine-resistant prolactinomas,"The expression of these seven decreased miRNAs in docetaxel-resistant cell line variants compared to their sensitive parent cell lines, as identified from the global profiling, is shown in Figure 3B. "
25053345,miR-146a,hsa-mir-146a,MI0000477,Docetaxel,148124,"22Rv1, DU145, PC3,22Rv1RD, DU145RD, and PC3RD",,-,-,prostate cancer,in vitro,High,Resistant,-,-,2014,MicroRNA expression profile of bromocriptine-resistant prolactinomas,"The expression of these seven decreased miRNAs in docetaxel-resistant cell line variants compared to their sensitive parent cell lines, as identified from the global profiling, is shown in Figure 3B. "
25053345,miR-146a,hsa-mir-146a,MI0000477,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,"SNCA, SCL7A5",-,2014,miR-34a is an Intracellular and Exosomal Predictive Biomarker for Response to Docetaxel with Clinical Relevance to Prostate Cancer Progression,"To confirm the results from global miRNA profiling, four miRNAs found to be decreased in the cells and exosomes of at least two of the three docetaxelresistant cell line variants were selected for validation by qPCR. The expression of miR-598, miR-148a, miR-34a, and miR-146a confirmed the sametrends as demonstrated in the global profiling (Table II)."
25053345,miR-148a,hsa-mir-148a,MI0000253,Docetaxel,148124,"22Rv1, DU145, PC3,22Rv1RD, DU145RD, and PC3RD",,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profile of bromocriptine-resistant prolactinomas,"The expression of these seven decreased miRNAs in docetaxel-resistant cell line variants compared to their sensitive parent cell lines, as identified from the global profiling, is shown in Figure 3B. "
25053345,miR-148a,hsa-mir-148a,MI0000253,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,"SNCA, SCL7A5",-,2014,miR-34a is an Intracellular and Exosomal Predictive Biomarker for Response to Docetaxel with Clinical Relevance to Prostate Cancer Progression,"To confirm the results from global miRNA profiling, four miRNAs found to be decreased in the cells and exosomes of at least two of the three docetaxelresistant cell line variants were selected for validation by qPCR. The expression of miR-598, miR-148a, miR-34a, and miR-146a confirmed the sametrends as demonstrated in the global profiling (Table II)."
25053345,miR-203,hsa-mir-203a,MI0000283,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,miR-34a is an Intracellular and Exosomal Predictive Biomarker for Response to Docetaxel with Clinical Relevance to Prostate Cancer Progression,"To confirm the results from global miRNA profiling, four miRNAs found to be decreased in the cells and exosomes of at least two of the three docetaxelresistant cell line variants were selected for validation by qPCR. The expression of miR-598, miR-148a, miR-34a, and miR-146a confirmed the sametrends as demonstrated in the global profiling (Table II)."
25053345,miR-34a,hsa-mir-34a,MI0000268,Docetaxel,148124,"22Rv1, DU145, PC3,22Rv1RD, DU145RD, and PC3RD",,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profile of bromocriptine-resistant prolactinomas,"The expression of these seven decreased miRNAs in docetaxel-resistant cell line variants compared to their sensitive parent cell lines, as identified from the global profiling, is shown in Figure 3B. "
25053345,miR-34a,hsa-mir-34a,MI0000268,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,"BCL-2,SNCA, SCL7A5",-,2014,miR-34a is an Intracellular and Exosomal Predictive Biomarker for Response to Docetaxel with Clinical Relevance to Prostate Cancer Progression,"To confirm the results from global miRNA profiling, four miRNAs found to be decreased in the cells and exosomes of at least two of the three docetaxelresistant cell line variants were selected for validation by qPCR. The expression of miR-598, miR-148a, miR-34a, and miR-146a confirmed the sametrends as demonstrated in the global profiling (Table II)."
25053345,miR-34a,hsa-mir-34a,MI0000268,Docetaxel,148124,-,"PC3 vs PC3/DOC, DU145 vs DU145/DOC and 22Rv1 vs 22Rv1/DOC",-,-,prostate cancer,in vitro,Low,Associated,BCL-2,-,2014,miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.,"Using miR-34a as example, we showed that biomarkers identified in this manner may also hold functional relevance."
25053345,miR-383,hsa-mir-383,MI0000791,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,miR-34a is an Intracellular and Exosomal Predictive Biomarker for Response to Docetaxel with Clinical Relevance to Prostate Cancer Progression,"To confirm the results from global miRNA profiling, four miRNAs found to be decreased in the cells and exosomes of at least two of the three docetaxelresistant cell line variants were selected for validation by qPCR. The expression of miR-598, miR-148a, miR-34a, and miR-146a confirmed the sametrends as demonstrated in the global profiling (Table II)."
25053345,miR-598,hsa-mir-598,MI0003610,Docetaxel,148124,"22Rv1, DU145, PC3,22Rv1RD, DU145RD, and PC3RD",,-,-,prostate cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profile of bromocriptine-resistant prolactinomas,"The expression of these seven decreased miRNAs in docetaxel-resistant cell line variants compared to their sensitive parent cell lines, as identified from the global profiling, is shown in Figure 3B. "
25053345,miR-598,hsa-mir-598,MI0003610,Docetaxel,148124,-,PC3 vs PC3/DOC,-,-,prostate cancer,in vitro,High,Sensitive,"SNCA, SCL7A5",-,2014,miR-34a is an Intracellular and Exosomal Predictive Biomarker for Response to Docetaxel with Clinical Relevance to Prostate Cancer Progression,"To confirm the results from global miRNA profiling, four miRNAs found to be decreased in the cells and exosomes of at least two of the three docetaxelresistant cell line variants were selected for validation by qPCR. The expression of miR-598, miR-148a, miR-34a, and miR-146a confirmed the sametrends as demonstrated in the global profiling (Table II)."
25058005,miR-21,hsa-mir-21,MI0000077,Gefitinib,123631,-,PC-9 vs PC-9/GR,Mice,-,non-small cell lung cancer,in vitro and in vivo,Low,Resistant,PTEN,Akt and ERK pathways,2014,Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer.,"Moreover, over-expression of miR-21 significantly decreased gefitinib sensitivity by down-regulating Pten expression and activating Akt and ERK pathways in pc-9 cells, while miR-21 knockdown dramatically restored gefitinib sensitivity of pc-9/GR cells by up-regulation of Pten expression and inactivation of AKT and ERK pathways, in vivo and in vitro."
25063739,miR-370,hsa-mir-370,MI0000778,Cisplatin,2767,IGROV1 and TOV112D,-,-,-,endometrioid ovarian cancer ,in vitro,Low,Sensitive,ENG,-,2014,MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG.,"miR-370 reduced the cDDP but not the Taxol IC 50 in the two endometrioid ovarian cancer cell lines, further suggesting the enhancement of cDDP chemosensitivity by miR-370 in endometrioid ovarian cancer."
25080009,miR-497,hsa-mir-497,MI0003138,Temozolomide,5394,U87 and U251,-,-,-,glioma,in vitro,Low,Resistant,PDCD4,-,2014,Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis.,"Ectopic overexpression of miR-497 promotes chemotherapy resistance in glioma cells by targeting PDCD4, a tumor suppressor that is involved in apoptosis."
25085901,miR-551b,hsa-mir-551b,MI0003575,Cisplatin,2767,-,A549 vs A549/CDDP and H460 vs H460/CDDP,-,-,lung cancer,in vitro,Low,Associated,Catalase,ROS and MUC1,2014,"A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance.","Thus, our results establish a pathway consisting of miR-551b/catalase/ROS that results in MUC1 overexpression, and intervention against this pathway could be exploited to overcome acquired chemoresistance."
25085901,miR-551b,hsa-mir-551b,MI0003575,Doxorubicin (Adriamycin),31703,-,A549 vs A549/ADR and H460 vs H460/ADR,-,-,lung cancer,in vitro,Low,Associated,Catalase,ROS and MUC1,2014,"A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance.","Thus, our results establish a pathway consisting of miR-551b/catalase/ROS that results in MUC1 overexpression, and intervention against this pathway could be exploited to overcome acquired chemoresistance."
25085901,miR-551b,hsa-mir-551b,MI0003575,TRAIL therapy,-,-,A549 vs A549/TRAIL and H460 vs H460/TRAIL,-,-,lung cancer,in vitro,Low,Associated,Catalase,ROS and MUC1,2014,"A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance.","Thus, our results establish a pathway consisting of miR-551b/catalase/ROS that results in MUC1 overexpression, and intervention against this pathway could be exploited to overcome acquired chemoresistance."
25096647,miR-222,hsa-mir-222,MI0000299,Sorafenib,216239,HepG2,-,-,-,hepatocellular carcinoma,in vitro,Low,Resistant,-,PI3K and AKT,2014,miR?222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma.,"In addition, we investigated whether miR?222 confers SOR resistance in HepG2 cells to explore it roles in acquisition of drug resistance."
25103640,miR-502,hsa-mir-502,MI0003186,Cisplatin,2767,OVCAR-3,-,-,-,ovarian cancer,in vitro,Low,Associated,IFI27,-,2015,Interferon alpha-inducible protein 27 promotes epithelial-mesenchymal transition and induces ovarian tumorigenicity and stemness.,"When IFI27 was stable overexpressed, the sensitivity of ovarian cancer cells to cisplatin was significantly decreased compared with pcDNA3-controletransfected cells"
25109742,miR-101,hsa-mir-101-1,MI0000103,Cisplatin,2767,-,T24 vs T24/CDDP,Mice,-,bladder cancer,in vitro and in vivo,Low,Sensitive,COX?2,-,2014,Enforced expression of miR-101 enhances cisplatin sensitivity in human bladder cancer cells by modulating the cyclooxygenase-2 pathway.,"Furthermore, overexpression of miR?101 significantly increased the anti?proliferative effects and apoptosis induced by cisplatin, whereas knockdown of miR?101 significantly decreased the anti?proliferative effects and apoptosis induced by cisplatin."
25117811,let-7d,hsa-let-7d,MI0000065,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,let-7d,hsa-let-7d,MI0000065,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,let-7f-1*,hsa-let-7f-1,MI0000067,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,let-7f-1*,hsa-let-7f-1,MI0000067,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,let-7i,hsa-let-7i,MI0000434,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,let-7i,hsa-let-7i,MI0000434,Gemcitabine,60750,-,"Panc1-P vs Panc1-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-101,hsa-mir-101-1,MI0000103,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-101,hsa-mir-101-1,MI0000103,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-106a,hsa-mir-106a,MI0000113,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-106a,hsa-mir-106a,MI0000113,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1202,hsa-mir-1202,MI0006334,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1202,hsa-mir-1202,MI0006334,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1226,hsa-mir-1226,MI0006313,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1226,hsa-mir-1226,MI0006313,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1228,hsa-mir-1228,MI0006318,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1228,hsa-mir-1228,MI0006318,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1228*,hsa-mir-1228,MI0006318,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1228*,hsa-mir-1228,MI0006318,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1234,hsa-mir-1234,MI0006324,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1234,hsa-mir-1234,MI0006324,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1236,hsa-mir-1236,MI0006326,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1236,hsa-mir-1236,MI0006326,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1237,hsa-mir-1237,MI0006327,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1237,hsa-mir-1237,MI0006327,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1246,hsa-mir-1246,MI0006381,5-Fluorouracil,3385,MiaPaCa2,PANC-1 vs PANC-1/GR,-,-,pancreatic cancer,in vitro,Low,Resistant,CCNG2,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Similarly, pre-miR-1246 significantly reduced the early and late apoptosis in MiaPaCa2 cells"
25117811,miR-1246,hsa-mir-1246,MI0006381,Gemcitabine,60750,MiaPaCa2,PANC-1 vs PANC-1/GR,-,-,pancreatic cancer,in vitro,Low,Resistant,CCNG2,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Similarly, pre-miR-1246 significantly reduced the early and late apoptosis in MiaPaCa2 cells"
25117811,miR-1249,hsa-mir-1249,MI0006384,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1249,hsa-mir-1249,MI0006384,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1260,hsa-mir-1260a,MI0006394,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1260,hsa-mir-1260a,MI0006394,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1260b,hsa-mir-1260b,MI0014197,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-GR, Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1260b,hsa-mir-1260b,MI0014197,Gemcitabine,60750,-,"Panc1-P vs Panc1-GR, Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1268,hsa-mir-1268a,MI0006405,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1268,hsa-mir-1268a,MI0006405,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1273c,hsa-mir-1273c,MI0014171,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1273c,hsa-mir-1273c,MI0014171,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1280,hsa-mir-1280,MI0006437,5-Fluorouracil,3385,-,Panc1-P vs Panc89-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1280,hsa-mir-1280,MI0006437,Gemcitabine,60750,-,Panc1-P vs Panc89-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1285,hsa-mir-1285-1,MI0006346,5-Fluorouracil,3385,-,Panc1-P vs Panc71-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1285,hsa-mir-1285-1,MI0006346,Gemcitabine,60750,-,Panc1-P vs Panc71-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1288,hsa-mir-1288,MI0006432,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1288,hsa-mir-1288,MI0006432,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1290,hsa-mir-1290,MI0006352,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1290,hsa-mir-1290,MI0006352,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1307,hsa-mir-1307,MI0006444,5-Fluorouracil,3385,-,Panc1-P vs Panc84-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1307,hsa-mir-1307,MI0006444,Gemcitabine,60750,-,Panc1-P vs Panc84-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-130a,hsa-mir-130a,MI0000448,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-130a,hsa-mir-130a,MI0000448,5-Fluorouracil,3385,-,Panc1-P vs Panc74-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-130a,hsa-mir-130a,MI0000448,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-130a,hsa-mir-130a,MI0000448,Gemcitabine,60750,-,Panc1-P vs Panc74-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-132,hsa-mir-132,MI0000449,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-132,hsa-mir-132,MI0000449,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1343,hsa-mir-1343,MI0017320,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1343,hsa-mir-1343,MI0017320,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-138,hsa-mir-138-1,MI0000476,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-138,hsa-mir-138-1,MI0000476,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-140,hsa-mir-140,MI0000456,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-140,hsa-mir-140,MI0000456,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-141*,hsa-mir-141,MI0000457,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-141*,hsa-mir-141,MI0000457,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1469,hsa-mir-1469,MI0007074,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1469,hsa-mir-1469,MI0007074,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-146a,hsa-mir-146a,MI0000477,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-146a,hsa-mir-146a,MI0000477,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-147b,hsa-mir-147b,MI0005544,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-147b,hsa-mir-147b,MI0005544,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-148b,hsa-mir-148b,MI0000811,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-148b,hsa-mir-148b,MI0000811,Gemcitabine,60750,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-149,hsa-mir-149,MI0000478,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-149,hsa-mir-149,MI0000478,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-155,hsa-mir-15b,MI0000438,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-155,hsa-mir-155,MI0000681,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-155,hsa-mir-15b,MI0000438,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-155,hsa-mir-155,MI0000681,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-15b,hsa-mir-15b,MI0000438,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-15b,hsa-mir-15b,MI0000438,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-17,hsa-mir-17,MI0000071,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-GR, Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-17,hsa-mir-17,MI0000071,Gemcitabine,60750,-,"Panc1-P vs Panc1-GR, Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-17*,hsa-mir-17,MI0000071,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-17*,hsa-mir-17,MI0000071,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-181a*,hsa-mir-181a-2,MI0000269,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-181a*,hsa-mir-181a-2,MI0000269,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-181a-2*,hsa-mir-181a-2,MI0000269,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-181a-2*,hsa-mir-181a-2,MI0000269,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-181d,hsa-mir-181d,MI0003139,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-181d,hsa-mir-181d,MI0003139,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1825,hsa-mir-1825,MI0008193,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1825,hsa-mir-1825,MI0008193,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-187*,hsa-mir-187,MI0000274,5-Fluorouracil,3385,-,Panc1-P vs Panc86-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-187*,hsa-mir-187,MI0000274,Gemcitabine,60750,-,Panc1-P vs Panc86-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-188,hsa-mir-188,MI0000484,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-188,hsa-mir-188,MI0000484,Gemcitabine,60750,-,"Panc1-P vs Panc1-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-18a,hsa-mir-18a,MI0000072,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-18a,hsa-mir-18a,MI0000072,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-18b,hsa-mir-18b,MI0001518,5-Fluorouracil,3385,-,Panc1-P vs Panc78-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-18b,hsa-mir-18b,MI0001518,Gemcitabine,60750,-,Panc1-P vs Panc78-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1908,hsa-mir-1908,MI0008329,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1908,hsa-mir-1908,MI0008329,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-191,hsa-mir-191,MI0000465,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-191,hsa-mir-191,MI0000465,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1913,hsa-mir-1913,MI0008334,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1913,hsa-mir-1913,MI0008334,Gemcitabine,60750,-,"Panc1-P vs Panc1-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1914*,hsa-mir-1914,MI0008335,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1914*,hsa-mir-1914,MI0008335,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1915,hsa-mir-1915,MI0008336,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1915,hsa-mir-1915,MI0008336,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-193a,hsa-mir-193a,MI0000487,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-193a,hsa-mir-193a,MI0000487,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-193b*,hsa-mir-193b,MI0003137,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-193b*,hsa-mir-193b,MI0003137,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-196b,hsa-mir-196b,MI0001150,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-196b,hsa-mir-196b,MI0001150,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1972,hsa-mir-1972-1,MI0009982,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1972,hsa-mir-1972-1,MI0009982,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1976,hsa-mir-1976,MI0009986,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-1976,hsa-mir-1976,MI0009986,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-19b,hsa-mir-19b-1,MI0000074,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-19b,hsa-mir-19b-1,MI0000074,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-19b-1*,hsa-mir-19b-1,MI0000074,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-19b-1*,hsa-mir-19b-1,MI0000074,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-200a,hsa-mir-200a,MI0000737,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-200a,hsa-mir-200a,MI0000737,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-200b*,hsa-mir-200b,MI0000342,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-200b*,hsa-mir-200b,MI0000342,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-200c*,hsa-mir-200c,MI0000650,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-200c*,hsa-mir-200c,MI0000650,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-205,hsa-mir-205,MI0000285,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-205,hsa-mir-205,MI0000285,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-20a,hsa-mir-20a,MI0000076,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-20a,hsa-mir-20a,MI0000076,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-20b,hsa-mir-20b,MI0001519,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-GR, Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-20b,hsa-mir-20b,MI0001519,Gemcitabine,60750,-,"Panc1-P vs Panc1-GR, Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-21*,hsa-mir-21,MI0000077,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-21*,hsa-mir-21,MI0000077,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-210,hsa-mir-210,MI0000286,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-210,hsa-mir-210,MI0000286,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-218,hsa-mir-218-1,MI0000294,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-218,hsa-mir-218-1,MI0000294,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-22*,hsa-mir-22,MI0000078,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-22*,hsa-mir-22,MI0000078,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-221*,hsa-mir-221,MI0000298,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-221*,hsa-mir-221,MI0000298,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-222*,hsa-mir-222,MI0000299,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-222*,hsa-mir-222,MI0000299,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-224*,hsa-mir-224,MI0000301,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-224*,hsa-mir-224,MI0000301,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-2355,hsa-mir-2355,MI0015873,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-2355,hsa-mir-2355,MI0015873,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-2467,hsa-mir-2467,MI0017432,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-2467,hsa-mir-2467,MI0017432,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-2861,hsa-mir-2861,MI0013006,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-2861,hsa-mir-2861,MI0013006,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-29a*,hsa-mir-29a,MI0000087,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-29a*,hsa-mir-29a,MI0000087,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-29b,hsa-mir-29b-1,MI0000105,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-29b,hsa-mir-29b-1,MI0000105,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-29b-1*,hsa-mir-29b-1,MI0000105,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-29b-1*,hsa-mir-29b-1,MI0000105,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-301a,hsa-mir-301a,MI0000745,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-301a,hsa-mir-301a,MI0000745,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-301b,hsa-mir-301b,MI0005568,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-301b,hsa-mir-301b,MI0005568,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3064,hsa-mir-3064,MI0017375,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3064,hsa-mir-3064,MI0017375,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3065,hsa-mir-3065,MI0014228,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3065,hsa-mir-3065,MI0014228,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-30a,hsa-mir-30a,MI0000088,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-30a,hsa-mir-30a,MI0000088,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-30d,hsa-mir-30d,MI0000255,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-30d,hsa-mir-30d,MI0000255,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-30e,hsa-mir-30e,MI0000749,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-30e,hsa-mir-30e,MI0000749,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-31*,hsa-mir-31,MI0000089,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-31*,hsa-mir-31,MI0000089,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3126,hsa-mir-3126,MI0014143,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3126,hsa-mir-3126,MI0014143,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3130,hsa-mir-3130-1,MI0014147,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3130,hsa-mir-3130-1,MI0014147,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3131,hsa-mir-3131,MI0014151,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3131,hsa-mir-3131,MI0014151,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3141,hsa-mir-3141,MI0014165,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3141,hsa-mir-3141,MI0014165,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3147,hsa-mir-3147,MI0014173,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3147,hsa-mir-3147,MI0014173,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3154,hsa-mir-3154,MI0014182,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3154,hsa-mir-3154,MI0014182,Gemcitabine,60750,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3173,hsa-mir-3173,MI0014204,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3173,hsa-mir-3173,MI0014204,Gemcitabine,60750,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3177,hsa-mir-3177,MI0014211,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3177,hsa-mir-3177,MI0014211,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3178,hsa-mir-3178,MI0014212,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3178,hsa-mir-3178,MI0014212,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3180,hsa-mir-3180-1,MI0014214,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3180,hsa-mir-3180-1,MI0014214,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3184,hsa-mir-3184,MI0014226,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3184,hsa-mir-3184,MI0014226,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3186,hsa-mir-3186,MI0014229,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3186,hsa-mir-3186,MI0014229,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3187,hsa-mir-3187,MI0014231,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3187,hsa-mir-3187,MI0014231,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3188,hsa-mir-3188,MI0014232,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3188,hsa-mir-3188,MI0014232,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3193,hsa-mir-3193,MI0014238,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3193,hsa-mir-3193,MI0014238,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3194,hsa-mir-3194,MI0014239,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3194,hsa-mir-3194,MI0014239,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3195,hsa-mir-3195,MI0014240,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3195,hsa-mir-3195,MI0014240,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-32,hsa-mir-32,MI0000090,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-32,hsa-mir-32,MI0000090,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3200,hsa-mir-3200,MI0014249,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3200,hsa-mir-3200,MI0014249,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-323,hsa-mir-323a,MI0000807,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-323,hsa-mir-323a,MI0000807,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-324,hsa-mir-324,MI0000813,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-324,hsa-mir-324,MI0000813,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-324,hsa-mir-324,MI0000813,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-324,hsa-mir-324,MI0000813,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-328,hsa-mir-328,MI0000804,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-GR, Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-328,hsa-mir-328,MI0000804,Gemcitabine,60750,-,"Panc1-P vs Panc1-GR, Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-330,hsa-mir-330,MI0000803,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-330,hsa-mir-330,MI0000803,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-330,hsa-mir-330,MI0000803,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-330,hsa-mir-330,MI0000803,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-338,hsa-mir-338,MI0000814,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-338,hsa-mir-338,MI0000814,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-339,hsa-mir-339,MI0000815,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-339,hsa-mir-339,MI0000815,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-33a*,hsa-mir-33a,MI0000091,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-33a*,hsa-mir-33a,MI0000091,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-345,hsa-mir-345,MI0000825,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-345,hsa-mir-345,MI0000825,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-346,hsa-mir-346,MI0000826,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-346,hsa-mir-346,MI0000826,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3607,hsa-mir-3607,MI0015997,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3607,hsa-mir-3607,MI0015997,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-361,hsa-mir-361,MI0000760,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-361,hsa-mir-361,MI0000760,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3619,hsa-mir-3619,MI0016009,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3619,hsa-mir-3619,MI0016009,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-362,hsa-mir-362,MI0000762,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-362,hsa-mir-362,MI0000762,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3620,hsa-mir-3620,MI0016011,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3620,hsa-mir-3620,MI0016011,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3621,hsa-mir-3621,MI0016012,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3621,hsa-mir-3621,MI0016012,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3647,hsa-mir-3647,MI0016047,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3647,hsa-mir-3647,MI0016047,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3653,hsa-mir-3653,MI0016053,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3653,hsa-mir-3653,MI0016053,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3665,hsa-mir-3665,MI0016066,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3665,hsa-mir-3665,MI0016066,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3676,hsa-mir-3676,MI0016077,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3676,hsa-mir-3676,MI0016077,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3682,hsa-mir-3682,MI0016083,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3682,hsa-mir-3682,MI0016083,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3687,hsa-mir-3687-1,MI0016088,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3687,hsa-mir-3687-1,MI0016088,Gemcitabine,60750,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-370,hsa-mir-370,MI0000778,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-370,hsa-mir-370,MI0000778,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-371,hsa-mir-371a,MI0000779,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-371,hsa-mir-371a,MI0000779,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-373*,hsa-mir-373,MI0000781,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-373*,hsa-mir-373,MI0000781,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-378,hsa-mir-378a,MI0000786,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-378,hsa-mir-378a,MI0000786,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-378c,hsa-mir-378c,MI0015825,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-378c,hsa-mir-378c,MI0015825,Gemcitabine,60750,-,"Panc1-P vs Panc1-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-378d,hsa-mir-378d-1,MI0016749,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-378d,hsa-mir-378d-1,MI0016749,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-378e,hsa-mir-378e,MI0016750,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-378e,hsa-mir-378e,MI0016750,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-378f,hsa-mir-378f,MI0016756,5-Fluorouracil,3385,-,"Panc1-P vs Panc82-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-378f,hsa-mir-378f,MI0016756,Gemcitabine,60750,-,"Panc1-P vs Panc82-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-378g,hsa-mir-378g,MI0016761,5-Fluorouracil,3385,-,"Panc1-P vs Panc81-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-378g,hsa-mir-378g,MI0016761,Gemcitabine,60750,-,"Panc1-P vs Panc81-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-378i,hsa-mir-378i,MI0016902,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-GR, Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-378i,hsa-mir-378i,MI0016902,Gemcitabine,60750,-,"Panc1-P vs Panc1-GR, Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3917,hsa-mir-3917,MI0016423,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3917,hsa-mir-3917,MI0016423,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3937,hsa-mir-3937,MI0016593,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3937,hsa-mir-3937,MI0016593,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3940,hsa-mir-3940,MI0016597,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3940,hsa-mir-3940,MI0016597,Gemcitabine,60750,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3960,hsa-mir-3940,MI0016597,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-3960,hsa-mir-3940,MI0016597,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-421,hsa-mir-421,MI0003685,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-421,hsa-mir-421,MI0003685,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-422a,hsa-mir-422a,MI0001444,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-422a,hsa-mir-422a,MI0001444,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-423,hsa-mir-423,MI0001445,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-423,hsa-mir-423,MI0001445,Gemcitabine,60750,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-424,hsa-mir-424,MI0001446,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-424,hsa-mir-424,MI0001446,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-424,hsa-mir-424,MI0001446,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-424,hsa-mir-424,MI0001446,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-425,hsa-mir-425,MI0001448,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-425,hsa-mir-425,MI0001448,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-425*,hsa-mir-425,MI0001448,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-425*,hsa-mir-425,MI0001448,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4257,hsa-mir-4257,MI0015856,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4257,hsa-mir-4257,MI0015856,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4258,hsa-mir-4258,MI0015857,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4258,hsa-mir-4258,MI0015857,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4261,hsa-mir-4261,MI0015868,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4261,hsa-mir-4261,MI0015868,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4279,hsa-mir-4279,MI0015887,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4279,hsa-mir-4279,MI0015887,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4284,hsa-mir-4284,MI0015893,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4284,hsa-mir-4284,MI0015893,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4286,hsa-mir-4286,MI0015894,5-Fluorouracil,3385,-,Panc1-P vs Panc72-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4286,hsa-mir-4286,MI0015894,Gemcitabine,60750,-,Panc1-P vs Panc72-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4288,hsa-mir-4288,MI0015896,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4288,hsa-mir-4288,MI0015896,5-Fluorouracil,3385,-,Panc1-P vs Panc79-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4288,hsa-mir-4288,MI0015896,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4288,hsa-mir-4288,MI0015896,Gemcitabine,60750,-,Panc1-P vs Panc79-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-429,hsa-mir-429,MI0001641,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-429,hsa-mir-429,MI0001641,Gemcitabine,60750,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4319,hsa-mir-4319,MI0015848,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4319,hsa-mir-4319,MI0015848,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4419b,hsa-mir-4419b,MI0016861,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4419b,hsa-mir-4419b,MI0016861,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4428,hsa-mir-4428,MI0016767,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4428,hsa-mir-4428,MI0016767,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4454,hsa-mir-4454,MI0016800,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4454,hsa-mir-4454,MI0016800,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4455,hsa-mir-4455,MI0016801,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4455,hsa-mir-4455,MI0016801,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4463,hsa-mir-4463,MI0016811,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4463,hsa-mir-4463,MI0016811,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4465,hsa-mir-4465,MI0016816,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4465,hsa-mir-4465,MI0016816,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4466,hsa-mir-4466,MI0016817,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4466,hsa-mir-4466,MI0016817,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4467,hsa-mir-4467,MI0016818,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4467,hsa-mir-4467,MI0016818,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4476,hsa-mir-4476,MI0016828,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4476,hsa-mir-4476,MI0016828,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4478,hsa-mir-4478,MI0016831,5-Fluorouracil,3385,-,Panc1-P vs Panc80-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4478,hsa-mir-4478,MI0016831,Gemcitabine,60750,-,Panc1-P vs Panc80-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4484,hsa-mir-4484,MI0016845,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4484,hsa-mir-4484,MI0016845,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4485,hsa-mir-4485,MI0016846,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4485,hsa-mir-4485,MI0016846,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4487,hsa-mir-4487,MI0016848,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4487,hsa-mir-4487,MI0016848,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4488,hsa-mir-4488,MI0016849,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4488,hsa-mir-4488,MI0016849,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4492,hsa-mir-4492,MI0016854,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4492,hsa-mir-4492,MI0016854,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4497,hsa-mir-4497,MI0016859,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4497,hsa-mir-4497,MI0016859,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-449b*,hsa-mir-449b,MI0003673,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-449b*,hsa-mir-449b,MI0003673,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4508,hsa-mir-4508,MI0016872,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4508,hsa-mir-4508,MI0016872,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-450a,hsa-mir-450a-1,MI0001652,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-450a,hsa-mir-450a-1,MI0001652,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4516,hsa-mir-4516,MI0016882,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4516,hsa-mir-4516,MI0016882,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4521,hsa-mir-4521,MI0016887,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4521,hsa-mir-4521,MI0016887,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4530,hsa-mir-4530,MI0016897,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4530,hsa-mir-4530,MI0016897,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4532,hsa-mir-4532,MI0016899,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4532,hsa-mir-4532,MI0016899,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4535,hsa-mir-4535,MI0016903,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4535,hsa-mir-4535,MI0016903,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-454,hsa-mir-454,MI0003820,5-Fluorouracil,3385,-,Panc1-P vs Panc83-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-454,hsa-mir-454,MI0003820,Gemcitabine,60750,-,Panc1-P vs Panc83-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4638,hsa-mir-4638,MI0017265,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4638,hsa-mir-4638,MI0017265,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4640,hsa-mir-4640,MI0017267,5-Fluorouracil,3385,-,Panc1-P vs Panc87-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4640,hsa-mir-4640,MI0017267,Gemcitabine,60750,-,Panc1-P vs Panc87-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4646,hsa-mir-4646,MI0017273,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4646,hsa-mir-4646,MI0017273,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4655,hsa-mir-4655,MI0017283,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4655,hsa-mir-4655,MI0017283,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4665,hsa-mir-4665,MI0017295,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4665,hsa-mir-4665,MI0017295,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4669,hsa-mir-4669,MI0017300,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4669,hsa-mir-4669,MI0017300,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4674,hsa-mir-4674,MI0017305,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4674,hsa-mir-4674,MI0017305,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4675,hsa-mir-4675,MI0017306,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4675,hsa-mir-4675,MI0017306,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4685,hsa-mir-4685,MI0017317,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4685,hsa-mir-4685,MI0017317,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4685,hsa-mir-4685,MI0017317,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4685,hsa-mir-4685,MI0017317,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4685,hsa-mir-4685,MI0017317,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4685,hsa-mir-4685,MI0017317,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4687,hsa-mir-4687,MI0017319,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4687,hsa-mir-4687,MI0017319,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4689,hsa-mir-4689,MI0017322,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4689,hsa-mir-4689,MI0017322,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4695,hsa-mir-4695,MI0017328,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4695,hsa-mir-4695,MI0017328,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4706,hsa-mir-4706,MI0017339,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4706,hsa-mir-4706,MI0017339,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4707,hsa-mir-4707,MI0017340,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4707,hsa-mir-4707,MI0017340,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4710,hsa-mir-4710,MI0017344,5-Fluorouracil,3385,-,Panc1-P vs Panc77-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4710,hsa-mir-4710,MI0017344,Gemcitabine,60750,-,Panc1-P vs Panc77-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4711,hsa-mir-4711,MI0017345,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4711,hsa-mir-4711,MI0017345,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4713,hsa-mir-4713,MI0017347,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4713,hsa-mir-4713,MI0017347,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4716,hsa-mir-4716,MI0017350,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4716,hsa-mir-4716,MI0017350,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4721,hsa-mir-4721,MI0017356,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4721,hsa-mir-4721,MI0017356,Gemcitabine,60750,-,"Panc1-P vs Panc1-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4722,hsa-mir-4722,MI0017357,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4722,hsa-mir-4722,MI0017357,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4723,hsa-mir-4723,MI0017359,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4723,hsa-mir-4723,MI0017359,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4725,hsa-mir-4725,MI0017362,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4725,hsa-mir-4725,MI0017362,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4731,hsa-mir-4731,MI0017368,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4731,hsa-mir-4731,MI0017368,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4732,hsa-mir-4732,MI0017369,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4732,hsa-mir-4732,MI0017369,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4739,hsa-mir-4739,MI0017377,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4739,hsa-mir-4739,MI0017377,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4745,hsa-mir-4745,MI0017384,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4745,hsa-mir-4745,MI0017384,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4749,hsa-mir-4749,MI0017388,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4749,hsa-mir-4749,MI0017388,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4750,hsa-mir-4750,MI0017389,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4750,hsa-mir-4750,MI0017389,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4758,hsa-mir-4758,MI0017399,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4758,hsa-mir-4758,MI0017399,Gemcitabine,60750,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4783,hsa-mir-4783,MI0017428,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4783,hsa-mir-4783,MI0017428,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4787,hsa-mir-4787,MI0017434,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-4787,hsa-mir-4787,MI0017434,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-483,hsa-mir-483,MI0002467,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-483,hsa-mir-483,MI0002467,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-484,hsa-mir-484,MI0002468,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-484,hsa-mir-484,MI0002468,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-486,hsa-mir-486-1,MI0002470,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-486,hsa-mir-486-1,MI0002470,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-487b,hsa-mir-487b,MI0003530,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-487b,hsa-mir-487b,MI0003530,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-491,hsa-mir-491,MI0003126,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-491,hsa-mir-491,MI0003126,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-500a,hsa-mir-500a,MI0003184,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-500a,hsa-mir-500a,MI0003184,Gemcitabine,60750,-,"Panc1-P vs Panc1-GR,Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-500a*,hsa-mir-500a,MI0003184,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-500a*,hsa-mir-500a,MI0003184,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-500b,hsa-mir-500b,MI0015903,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-500b,hsa-mir-500b,MI0015903,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-503,hsa-mir-503,MI0003188,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-503,hsa-mir-503,MI0003188,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-518b,hsa-mir-518b,MI0003156,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-518b,hsa-mir-518b,MI0003156,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-532,hsa-mir-532,MI0003205,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-532,hsa-mir-532,MI0003205,Gemcitabine,60750,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-557,hsa-mir-557,MI0003563,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-557,hsa-mir-557,MI0003563,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-584,hsa-mir-584,MI0003591,5-Fluorouracil,3385,-,Panc1-P vs Panc85-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-584,hsa-mir-584,MI0003591,Gemcitabine,60750,-,Panc1-P vs Panc85-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-590,hsa-mir-590,MI0003602,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-590,hsa-mir-590,MI0003602,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-593,hsa-mir-593,MI0003605,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-593,hsa-mir-593,MI0003605,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-614,hsa-mir-614,MI0003627,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-614,hsa-mir-614,MI0003627,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-615,hsa-mir-615,MI0003628,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-615,hsa-mir-615,MI0003628,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-622,hsa-mir-622,MI0003636,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-622,hsa-mir-622,MI0003636,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-624*,hsa-mir-624,MI0003638,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-624*,hsa-mir-624,MI0003638,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-625*,hsa-mir-627,MI0003641,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-625*,hsa-mir-627,MI0003641,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-629,hsa-mir-629,MI0003643,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-629,hsa-mir-629,MI0003643,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-658,hsa-mir-658,MI0003682,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-658,hsa-mir-658,MI0003682,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-660,hsa-mir-660,MI0003684,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-660,hsa-mir-660,MI0003684,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-663,hsa-mir-663a,MI0003672,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-663,hsa-mir-663a,MI0003672,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-665,hsa-mir-665,MI0005563,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-665,hsa-mir-665,MI0005563,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-670,hsa-mir-670,MI0003933,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-670,hsa-mir-670,MI0003933,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-671,hsa-mir-671,MI0003760,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-671,hsa-mir-671,MI0003760,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-675,hsa-mir-675,MI0005416,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-675,hsa-mir-675,MI0005416,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-675*,hsa-mir-675,MI0005416,5-Fluorouracil,3385,-,Panc1-P vs Panc88-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-675*,hsa-mir-675,MI0005416,Gemcitabine,60750,-,Panc1-P vs Panc88-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-7,hsa-mir-7-1,MI0000263,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-7,hsa-mir-7-1,MI0000263,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-718,hsa-mir-718,MI0012489,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-718,hsa-mir-718,MI0012489,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-720,hsa-mir-720,MI0006654,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-720,hsa-mir-720,MI0006654,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-762,hsa-mir-762,MI0003892,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-762,hsa-mir-762,MI0003892,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-766,hsa-mir-766,MI0003836,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-766,hsa-mir-766,MI0003836,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-873,hsa-mir-873,MI0005564,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-873,hsa-mir-873,MI0005564,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-874,hsa-mir-874,MI0005532,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-874,hsa-mir-874,MI0005532,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-887,hsa-mir-887,MI0005562,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-887,hsa-mir-887,MI0005562,Gemcitabine,60750,-,"Panc1-P vs Panc1-P(Sp),Panc1-P vs Panc76-GR",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-920,hsa-mir-920,MI0005712,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-920,hsa-mir-920,MI0005712,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-921,hsa-mir-921,MI0005713,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-921,hsa-mir-921,MI0005713,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-92b,hsa-mir-92b,MI0003560,5-Fluorouracil,3385,-,"Panc1-P vs Panc1-GR, Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-92b,hsa-mir-92b,MI0003560,Gemcitabine,60750,-,"Panc1-P vs Panc1-GR, Panc1-P vs Panc1-P(Sp)",-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-939,hsa-mir-939,MI0005761,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-939,hsa-mir-939,MI0005761,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-940,hsa-mir-940,MI0005762,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-940,hsa-mir-940,MI0005762,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-96,hsa-mir-96,MI0000098,5-Fluorouracil,3385,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-96,hsa-mir-96,MI0000098,Gemcitabine,60750,-,Panc1-P vs Panc1-P(Sp),-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-98,hsa-mir-98,MI0000100,5-Fluorouracil,3385,-,Panc1-P vs Panc70-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-98,hsa-mir-98,MI0000100,Gemcitabine,60750,-,Panc1-P vs Panc70-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-99a,hsa-mir-99a,MI0000101,5-Fluorouracil,3385,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25117811,miR-99a,hsa-mir-99a,MI0000101,Gemcitabine,60750,-,Panc1-P vs Panc1-GR,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer,"Compared with the Panc1-P cells, the Panc1-GR cells were significantly more resistant to GEM (Figure 1A) and showed significantly more drug resistance to 5-FU at three densities (Supplementary Figure 1A)."
25132574,miR-21,hsa-mir-21,MI0000077,5-Fluorouracil,3385,-,-,-,Patients,pancreatic cancer,in vivo,Low,Associated,-,-,2014,Stromal microRNA-21 levels predict response to 5-fluorouracil in Patient with pancreatic cancer.,"MiR-21 expression in CAFs was associated with decreased OS in PDAC patients who received 5-FU, but not gemcitabine."
25137037,miR-520f,hsa-mir-520f,MI0003146,Cisplatin,2767,-,SK-N-AS vs SK-N-As/CDDP,-,Patients,neuroblastoma,in vitro and in vivo,Low,Resistant,NAIP,-,2015,Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f.,This finding supports the hypothesis that a reduction of miR-520f contributes to drug resistance in vivo through reduced targeting of NAIP.
25137071,hsa-1274A,-,-,Epirubicin,41867,-,-,-,Patientss,breast cancer,in vivo,High,Resistant,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25137071,hsa-1274A,-,-,Paclitaxel,36314,-,-,-,Patientss,breast cancer,in vivo,High,Resistant,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25137071,let-7b,hsa-let-7b,MI0000063,Epirubicin,41867,-,-,-,Patientss,breast cancer,in vivo,High,Sensitive,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25137071,let-7b,hsa-let-7b,MI0000063,Paclitaxel,36314,-,-,-,Patientss,breast cancer,in vivo,High,Sensitive,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25137071,miR-1290,hsa-mir-1290,MI0006352,Epirubicin,41867,-,-,-,Patientss,breast cancer,in vivo,High,Resistant,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25137071,miR-1290,hsa-mir-1290,MI0006352,Paclitaxel,36314,-,-,-,Patientss,breast cancer,in vivo,High,Resistant,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25137071,miR-194,hsa-mir-194-1,MI0000488,Epirubicin,41867,-,-,-,Patientss,breast cancer,in vivo,High,Sensitive,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25137071,miR-194,hsa-mir-194-1,MI0000488,Paclitaxel,36314,-,-,-,Patientss,breast cancer,in vivo,High,Sensitive,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25137071,miR-19a,hsa-mir-19a,MI0000073,Epirubicin,41867,-,-,-,Patientss,breast cancer,in vivo,High,Resistant,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25137071,miR-19a,hsa-mir-19a,MI0000073,Paclitaxel,36314,-,-,-,Patientss,breast cancer,in vivo,High,Resistant,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25137071,miR-205,hsa-mir-205,MI0000285,Epirubicin,41867,-,-,-,Patientss,breast cancer,in vivo,High,Resistant,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25137071,miR-205,hsa-mir-205,MI0000285,Paclitaxel,36314,-,-,-,Patientss,breast cancer,in vivo,High,Resistant,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25137071,miR-28,hsa-mir-28,MI0000086,Epirubicin,41867,-,-,-,Patientss,breast cancer,in vivo,High,Resistant,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25137071,miR-28,hsa-mir-28,MI0000086,Paclitaxel,36314,-,-,-,Patientss,breast cancer,in vivo,High,Resistant,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25137071,miR-375,hsa-mir-375,MI0000783,Epirubicin,41867,-,-,-,Patientss,breast cancer,in vivo,High,Resistant,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25137071,miR-375,hsa-mir-375,MI0000783,Paclitaxel,36314,-,-,-,Patientss,breast cancer,in vivo,High,Resistant,-,-,2014,Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel,"Of those 8 miRNAs, 6 were up-regulated and 2 were down-regulated in the resistant group compared with the sensitive group (Table 2)"
25138213,miR-200b,hsa-mir-200b,MI0000342,Celastrol,122724,-,Malme3M  vs Malme3M/CEL,-,-,melanoma,in vitro,Low,Sensitive,-,-,2014,miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs.,"Overexpression of miR-200b, miR-217, or miR-335 Enhances the Response of Anti-cancer Drug-resistant Cancer Cell Line to Anti-cancerDrugs."
25138213,miR-200b,hsa-mir-200b,MI0000342,Paclitaxel,36314,-,Malme3M  vs Malme3M/CEL,-,-,melanoma,in vitro,Low,Sensitive,-,-,2014,miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs.,"Overexpression of miR-200b, miR-217, or miR-335 Enhances the Response of Anti-cancer Drug-resistant Cancer Cell Line to Anti-cancerDrugs."
25138213,miR-217,hsa-mir-217,MI0000293,Celastrol,122724,-,Malme3M  vs Malme3M/CEL,-,-,melanoma,in vitro,Low,Sensitive,-,-,2014,miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs.,"Overexpression of miR-200b, miR-217, or miR-335 Enhances the Response of Anti-cancer Drug-resistant Cancer Cell Line to Anti-cancerDrugs."
25138213,miR-217,hsa-mir-217,MI0000293,Paclitaxel,36314,-,Malme3M  vs Malme3M/CEL,-,-,melanoma,in vitro,Low,Sensitive,-,-,2014,miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs.,"Overexpression of miR-200b, miR-217, or miR-335 Enhances the Response of Anti-cancer Drug-resistant Cancer Cell Line to Anti-cancerDrugs."
25138213,miR-326,hsa-mir-326,MI0000808,Celastrol,122724,-,Malme3M  vs Malme3M/CEL,-,-,melanoma,in vitro,Low,Sensitive,HDAC3,-,2014,miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs.,"miR-326 decreased the apoptotic effect of anti-cancer drugs, and the miR-326 inhibitor increased the apoptotic effect of anti-cancer drugs."
25138213,miR-326,hsa-mir-326,MI0000808,Paclitaxel,36314,-,Malme3M  vs Malme3M/CEL,-,-,melanoma,in vitro,Low,Sensitive,HDAC3,-,2014,miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs.,"miR-326 decreased the apoptotic effect of anti-cancer drugs, and the miR-326 inhibitor increased the apoptotic effect of anti-cancer drugs."
25138213,miR-335,hsa-mir-335,MI0000816,Celastrol,122724,-,Malme3M  vs Malme3M/CEL,-,-,melanoma,in vitro,Low,Sensitive,-,-,2014,miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs.,"Overexpression of miR-200b, miR-217, or miR-335 Enhances the Response of Anti-cancer Drug-resistant Cancer Cell Line to Anti-cancerDrugs."
25138213,miR-335,hsa-mir-335,MI0000816,Paclitaxel,36314,-,Malme3M  vs Malme3M/CEL,-,-,melanoma,in vitro,Low,Sensitive,-,-,2014,miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs.,"Overexpression of miR-200b, miR-217, or miR-335 Enhances the Response of Anti-cancer Drug-resistant Cancer Cell Line to Anti-cancerDrugs."
25139024,miR-136,hsa-mir-136,MI0000475,Cisplatin,2767,U87,U251 vs U251/CDDP ,-,-,glioma,in vitro,Low,Sensitive,E2F1,-,2014,MiR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells.,Both gain- and loss-of-function experiments showed that miR-136 expression can reverse cisplatin resistance and enhance the response to cisplatin treatment.
25142144,let-7a,hsa-let-7a-1,MI0000060,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,let-7b,hsa-let-7b,MI0000063,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-1,hsa-mir-1-1,MI0000651,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,Low,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-1181,hsa-mir-1181,MI0006274,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,Low,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-1246,hsa-mir-1246,MI0006381,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-1290,hsa-mir-1290,MI0006352,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,Low,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-130b,hsa-mir-130b,MI0000748,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-135a,hsa-mir-135a-1,MI0000452,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,Low,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-139,hsa-mir-139,MI0000261,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-144,hsa-mir-144,MI0000460,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,Low,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-1471,hsa-mir-1471,MI0007076,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-150,hsa-mir-150,MI0000479,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-181c,hsa-mir-181c,MI0000271,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-186,hsa-mir-186,MI0000483,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-18a,hsa-mir-18a,MI0000072,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-18b,hsa-mir-18b,MI0001518,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-193a,hsa-mir-193a,MI0000487,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-195,hsa-mir-195,MI0000489,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-196b,hsa-mir-196b,MI0001150,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,Low,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-23b,hsa-mir-23b,MI0000439,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-24,hsa-mir-24-1,MI0000080,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-26a,hsa-mir-26a-1,MI0000083,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-27b,hsa-mir-27b,MI0000440,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-29c,hsa-mir-29c,MI0000735,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-3065,hsa-mir-3065,MI0014228,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-30c,hsa-mir-30c-2,MI0000254,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-30e,hsa-mir-30e,MI0000749,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-31,hsa-mir-31,MI0000089,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,Low,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-3137,hsa-mir-3137,MI0014160,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-3195,hsa-mir-3195,MI0014240,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-3198,hsa-mir-3198-1,MI0014246,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-328,hsa-mir-328,MI0000804,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-331,hsa-mir-331,MI0000812,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-34a,hsa-mir-34a,MI0000268,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-34b,hsa-mir-34b,MI0000742,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,Low,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-34b,hsa-mir-34b,MI0000742,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-361,hsa-mir-361,MI0000760,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-3648,hsa-mir-3648-1,MI0016048,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-3663,hsa-mir-3663,MI0016064,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-3667,hsa-mir-3667,MI0016068,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-3926,hsa-mir-3926-1,MI0016434,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-3934,hsa-mir-3934,MI0016590,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-4271,hsa-mir-4271,MI0015879,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-4291,hsa-mir-4291,MI0015900,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-4327,hsa-mir-4327,MI0015867,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-449a,hsa-mir-449a,MI0001648,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,Low,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-483,hsa-mir-483,MI0002467,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-497,hsa-mir-497,MI0003138,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-500a,hsa-mir-500a,MI0003184,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-598,hsa-mir-598,MI0003610,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,Low,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-628,hsa-mir-628,MI0003642,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,Low,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-630,hsa-mir-630,MI0003644,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-642b,hsa-mir-642b,MI0016685,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-663a,hsa-mir-663a,MI0003672,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25142144,miR-7,hsa-mir-7-1,MI0000263,platinum-based doublet chemotherapy ,-,-,-,-,Patientss,lung adenocarcinoma,in vivo,High,Sensitive,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"Fifty-nine miRNAs were identified (P < 0.05; Welch t test; Supplementary Table S2). Of these, 28 were upregulated in responders and 31 were downregulated."
25149530,HA-22.1,HA-22.1,-,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,HS-169,-,-,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-1248,hsa-mir-1248,MI0006383,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-125a,hsa-mir-125a,MI0000469,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-125b,hsa-miR-125b,MI0000446,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-1285,hsa-mir-1285-1,MI0006346,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-129*,hsa-mir-129-1,MI0000252,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-139,hsa-miR-542-139-3p,-,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-19b-1*,hsa-miR-542-19b-1*,-,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-205,hsa-miR-205,MI0000285,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-25*,hsa-mir-25,MI0000082,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-26a-1*,hsa-mir-26a-1,MI0000083,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-30c-1*,hsa-mir-30c-1,MI0000736,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-369,hsa-mir-369,MI0000777,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-374b,hsa-mir-374b,MI0005566,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-494,hsa-mir-494,MI0003134,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-497,hsa-mir-497,MI0003138,Erlotinib,176870,MiaPaCa-2,-,-,-,pancreatic cancer,in vitro,Low,Sensitive,FGF2 and FGFR1,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"Further studies focusing on miR-497 demonstrated that miR-497 suppressed cells proliferation, decreased the percentage of S phase cells, re-sensitized cells to gemcitabine and erlotinib, and attenuated migration and invasion capacities."
25149530,miR-497,hsa-mir-497,MI0003138,Gemcitabine,60750,MiaPaCa-2,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,Low,Sensitive,FGF2 and FGFR1,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"Further studies focusing on miR-497 demonstrated that miR-497 suppressed cells proliferation, decreased the percentage of S phase cells, re-sensitized cells to gemcitabine and erlotinib, and attenuated migration and invasion capacities."
25149530,miR-503,hsa-mir-503,MI0003188,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-508,hsa-mir-508,MI0003195,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-515,hsa-mir-515-1,MI0003144,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-518f,hsa-mir-518f,MI0003154,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-519d,hsa-mir-519d,MI0003162,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-542,hsa-mir-542,MI0003686,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-542-32,-,-,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-542-33a,-,-,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-542-33b,-,-,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-579,hsa-mir-579,MI0003586,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-647,hsa-mir-647,MI0003662,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-935,hsa-mir-935,MI0005757,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,miR-99b*,hsa-mir-99b,MI0000746,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,solexa-3277-272,-,-,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,solexa-578-1915,-,-,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25149530,solexa-826-1288,-,-,Gemcitabine,60750,-,SW1990 vs SW199/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2014,MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.,"A total of 33 miRNAs out of 1146 miRNAs probes in the Illumina microarray platform were identified, including 13 downregulated miRNAs and 20 upregulated miRNAs (Figure 1A)."
25150313,miR-200c,hsa-mir-200c,MI0000650,Imatinib,5291,786-O and Caki-1,-,-,-,clear-cell renal cell carcinoma,in vitro,Low,Sensitive,HO-1,-,2014,MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1.,"We provided evidences to elucidate that miR-200c could sensitize ccRCC cells to sorafenib or imatinib to inhibit cell proliferation, at least partly by targeting HO-1."
25150313,miR-200c,hsa-mir-200c,MI0000650,Sorafenib,216239,786-O and Caki-1,-,-,-,clear-cell renal cell carcinoma,in vitro,Low,Sensitive,HO-1,-,2014,MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1.,"We provided evidences to elucidate that miR-200c could sensitize ccRCC cells to sorafenib or imatinib to inhibit cell proliferation, at least partly by targeting HO-1."
25151861,miR-181b,hsa-mir-181b-1,MI0000270,Teniposide,452548,U87,-,-,-,glioma,in vitro,Low,Sensitive,MDM2,-,2014,MiR-181b sensitizes glioma cells to teniposide by targeting MDM2.,Overexpression of miR-181b increased glioma cell sensitivity to teniposide.
25155039,miR-130b,hsa-mir-130b,MI0000748,Cisplatin,2767,-,A2780 vs A2780/Taxol,-,-,ovarian cancer,in vitro,Low,Resistant,-,1/P-gp and GST-pie,2014,MicroRNA 130b enhances drug resistance in human ovarian cancer cells.,The sensitivity of A2780 cells transfected with miR-130b mimics to paclitaxel and cisplatin was decreased compared with negative control (NC) or mock-transfected cells.
25155039,miR-130b,hsa-mir-130b,MI0000748,Paclitaxel,36314,-,A2780 vs A2780/Taxol,-,-,ovarian cancer,in vitro,Low,Resistant,-,1/P-gp and GST-pie,2014,MicroRNA 130b enhances drug resistance in human ovarian cancer cells.,The sensitivity of A2780 cells transfected with miR-130b mimics to paclitaxel and cisplatin was decreased compared with negative control (NC) or mock-transfected cells.
25156775,miR-149,hsa-mir-149,MI0000478,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,Patients,breast cancer,in vitro and in vivo,Low,Sensitive,NSTD1,-,2014,Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer.,"Furthermore, we found that miR-149 modulated chemoresistance through targeting the expression of GlcNAc N-deacetylase/N-sulfotransferase-1 (NDST1)."
25156775,miR-149,hsa-mir-149,MI0000478,Paclitaxel,36314,-,MCF-7 vs MCF-7/ADR and MCF-7 vs MCF-7/PTX,-,Patients,breast cancer,in vitro and in vivo,Low,Sensitive,NSTD1,-,2014,Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer.,"Furthermore, we found that miR-149 modulated chemoresistance through targeting the expression of GlcNAc N-deacetylase/N-sulfotransferase-1 (NDST1)."
25159093,miR-320a,hsa-mir-320a,MI0000542,5-Fluorouracil,3385,-,HCT-8 vs HCT-8/5-FU,-,-,breast cancer,in vitro,Low,Sensitive,TRPC5 and NFATC3,-,2014,A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer.,Restoring the activity of miR-320a markedly decreased the chemoresistance in MCF-7/PTX cells (Fig. 5B) but only slightly decreased in HCT-8/5-FU cells.
25159093,miR-320a,hsa-mir-320a,MI0000542,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Sensitive,TRPC5 and NFATC3,-,2014,A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer.,We found that overexpression of miR-320a sensitized the cells to ADM.
25159093,miR-320a,hsa-mir-320a,MI0000542,Paclitaxel,36314,-,MCF-7 vs MCF-7/Taxol,-,-,breast cancer,in vitro,Low,Sensitive,TRPC5 and NFATC3,-,2014,A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer.,Restoring the activity of miR-320a markedly decreased the chemoresistance in MCF-7/PTX cells (Fig. 5B) but only slightly decreased in HCT-8/5-FU cells.
25159729,miR-223,hsa-mir-223,MI0000300,Trastuzumab,9903,-,NCI-N87 vs NCI-N87/TRA,-,-,gastric cancer,in vitro,Low,Resistant,FBXW7,-,2015,The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway.,"Overexpression of miR-223 decreased FBXW7 expression and the sensitivity of GC cells to trastuzumab, while suppression of miR-223 restored FBXW7 expression and the sensitivity of GC cells to trastuzumab."
25170221,miR-218,hsa-mir-218-1,MI0000294,Cisplatin,2767,SGC7901,-,Mice,-,gastric cancer,in vitro and in vivo,Low,Sensitive,-,-,2014,MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin.,"Furthermore, miR-218 increased gastric cancer cell chemosensitivity to cisplatin in vitro and inhibited gastric cell tumor growth in nude mice in vivo (0.5 vs 0.78, P < 0.05)."
25174983,miR-29b-1,hsa-mir-29b-1,MI0000105,Cisplatin,2767,3AB-OS,-,-,-,osteosarcoma,in vitro,Low,Sensitive,-,-,2014,"MicroRNA-29b-1 impairs in vitro cell proliferation, self-renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells.","In addition, while miR-29b-1 overexpression sensitized 3AB-OS cells to chemotherapeutic drug-induced apoptosis, it did not influence their migratory and invasive capacities, thus suggesting a context-depending role of miR-29b-1."
25174983,miR-29b-1,hsa-mir-29b-1,MI0000105,Doxorubicin (Adriamycin),31703,3AB-OS,-,-,-,osteosarcoma,in vitro,Low,Sensitive,-,-,2014,"MicroRNA-29b-1 impairs in vitro cell proliferation, self-renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells.","In addition, while miR-29b-1 overexpression sensitized 3AB-OS cells to chemotherapeutic drug-induced apoptosis, it did not influence their migratory and invasive capacities, thus suggesting a context-depending role of miR-29b-1."
25179844,miR-449a,hsa-mir-449a,MI0001648,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP and A2780 vs A2780/CDDP,Mice,-,ovarian cancer,in vitro and in vivo,Low,Sensitive,NOTCH1 ,-,2014,MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells.,The overexpression of miR-449a increased cisplatin sensitivity of SKOV3/DDP and A2780/DDP cells by inhibiting proliferation and promoting apoptosis.
25184537,miR-100,hsa-mir-100,MI0000102,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,Patientss,pancreatic ductal adenocarcinoma,in vitro and in vivo,High,Resistant,-,-,2014,A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-1246,hsa-mir-1246,MI0006381,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-125b,hsa-mir-125b-1,MI0000446,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Resistant,"PUMA, Neu1",-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-155,hsa-mir-155,MI0000681,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Resistant,-,-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-15b,hsa-mir-15b,MI0000438,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Resistant,-,-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-205,hsa-mir-205,MI0000285,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-21,hsa-mir-21,MI0000077,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Resistant,-,-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-25,hsa-mir-25,MI0000082,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Resistant,-,-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-27b,hsa-mir-27b,MI0000440,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-30d,hsa-mir-30d,MI0000255,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-378*,hsa-mir-378a,MI0000786,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-424*,hsa-mir-424,MI0001446,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Resistant,-,-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-4324,hsa-mir-4324,MI0015854,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Resistant,-,-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-4443,hsa-mir-4443,MI0016786,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-4485,hsa-mir-4485,MI0016846,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-455*,hsa-mir-455,MI0003513,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25184537,miR-99b,hsa-mir-99b,MI0000746,Gemcitabine,60750,-,BxPC3 vs BxPC3/GEM,-,-,pancreatic ductal adenocarcinoma,in vitro,High,Resistant,-,-,2014,A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer,"The expression level of miRNA was compared in BxPC3 and BxPC3-GZR cells by mParaflo microfluidic chip miRNA profiling. After calculation and eliminating non-significant miRNAs (in terms of expression), a highly significant miRNA profile was established that distinguished BxPC3-GZR cells from parental BxPC3 cells (Fig. 2, Table 1). "
25188512,miR-193a,hsa-mir-193a,MI0000487,Paclitaxel,36314,5637 and H-bc,-,Mice,-,bladder cancer,in vitro and in vivo,Low,Resistant,"SRSF2, PLAUand HIC2",-,2014,The DNA methylation-regulated miR-193a-3p dictates the multi-chemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2 expression.,miR-193a-3p promotes both growth and Pa chemoresistance of the 5637- and H-bc-derived tumor xenografts in nude mice.
25197016,let-7g*,hsa-let-7g,MI0000433,Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Sensitive,-,-,2014,MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer,"The relative miRNA expression levels for patients that achieved an objective response to chemotherapy (R) versus those that did not (NR) are represented in Additional file 1: Figure S1. Of the 667 miRNAs assessed, 7% (N = 46) were differentially expressed (p < 0.05) among these two subgroups described (R versus NR). However, only eight of these 46 miRNAs were detected in at least 50% of tested samples (let-7 g*, miR-107, miR-299-5p, miR-337-5p, miR-370, miR-505*, miR-889 and miR-99a-3p) (Table 2), and were therefore considered to be representative of the general behaviour of the study population."
25197016,miR-107,hsa-mir-107,MI0000114,Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Sensitive,CCND1,-,2014,MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer,"The relative miRNA expression levels for patients that achieved an objective response to chemotherapy (R) versus those that did not (NR) are represented in Additional file 1: Figure S1. Of the 667 miRNAs assessed, 7% (N = 46) were differentially expressed (p < 0.05) among these two subgroups described (R versus NR). However, only eight of these 46 miRNAs were detected in at least 50% of tested samples (let-7 g*, miR-107, miR-299-5p, miR-337-5p, miR-370, miR-505*, miR-889 and miR-99a-3p) (Table 2), and were therefore considered to be representative of the general behaviour of the study population."
25197016,miR-299,hsa-mir-299,MI0000744,Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Sensitive,-,-,2014,MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer,"The relative miRNA expression levels for patients that achieved an objective response to chemotherapy (R) versus those that did not (NR) are represented in Additional file 1: Figure S1. Of the 667 miRNAs assessed, 7% (N = 46) were differentially expressed (p < 0.05) among these two subgroups described (R versus NR). However, only eight of these 46 miRNAs were detected in at least 50% of tested samples (let-7 g*, miR-107, miR-299-5p, miR-337-5p, miR-370, miR-505*, miR-889 and miR-99a-3p) (Table 2), and were therefore considered to be representative of the general behaviour of the study population."
25197016,miR-337,hsa-mir-337,MI0000806,Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Sensitive,-,-,2014,MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer,"The relative miRNA expression levels for patients that achieved an objective response to chemotherapy (R) versus those that did not (NR) are represented in Additional file 1: Figure S1. Of the 667 miRNAs assessed, 7% (N = 46) were differentially expressed (p < 0.05) among these two subgroups described (R versus NR). However, only eight of these 46 miRNAs were detected in at least 50% of tested samples (let-7 g*, miR-107, miR-299-5p, miR-337-5p, miR-370, miR-505*, miR-889 and miR-99a-3p) (Table 2), and were therefore considered to be representative of the general behaviour of the study population."
25197016,miR-370,hsa-mir-370,MI0000778,Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Sensitive,-,-,2014,MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer,"The relative miRNA expression levels for patients that achieved an objective response to chemotherapy (R) versus those that did not (NR) are represented in Additional file 1: Figure S1. Of the 667 miRNAs assessed, 7% (N = 46) were differentially expressed (p < 0.05) among these two subgroups described (R versus NR). However, only eight of these 46 miRNAs were detected in at least 50% of tested samples (let-7 g*, miR-107, miR-299-5p, miR-337-5p, miR-370, miR-505*, miR-889 and miR-99a-3p) (Table 2), and were therefore considered to be representative of the general behaviour of the study population."
25197016,miR-505*,hsa-mir-505,MI0003190,Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Sensitive,-,-,2014,MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer,"The relative miRNA expression levels for patients that achieved an objective response to chemotherapy (R) versus those that did not (NR) are represented in Additional file 1: Figure S1. Of the 667 miRNAs assessed, 7% (N = 46) were differentially expressed (p < 0.05) among these two subgroups described (R versus NR). However, only eight of these 46 miRNAs were detected in at least 50% of tested samples (let-7 g*, miR-107, miR-299-5p, miR-337-5p, miR-370, miR-505*, miR-889 and miR-99a-3p) (Table 2), and were therefore considered to be representative of the general behaviour of the study population."
25197016,miR-889,hsa-mir-889,MI0005540,Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Resistant,-,-,2014,MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer,"The relative miRNA expression levels for patients that achieved an objective response to chemotherapy (R) versus those that did not (NR) are represented in Additional file 1: Figure S1. Of the 667 miRNAs assessed, 7% (N = 46) were differentially expressed (p < 0.05) among these two subgroups described (R versus NR). However, only eight of these 46 miRNAs were detected in at least 50% of tested samples (let-7 g*, miR-107, miR-299-5p, miR-337-5p, miR-370, miR-505*, miR-889 and miR-99a-3p) (Table 2), and were therefore considered to be representative of the general behaviour of the study population."
25197016,miR-99a,hsa-mir-99a,MI0000101,Chemotherapy,-,-,-,-,Patientss,colorectal cancer,in vivo,High,Sensitive,-,-,2014,MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer,"The relative miRNA expression levels for patients that achieved an objective response to chemotherapy (R) versus those that did not (NR) are represented in Additional file 1: Figure S1. Of the 667 miRNAs assessed, 7% (N = 46) were differentially expressed (p < 0.05) among these two subgroups described (R versus NR). However, only eight of these 46 miRNAs were detected in at least 50% of tested samples (let-7 g*, miR-107, miR-299-5p, miR-337-5p, miR-370, miR-505*, miR-889 and miR-99a-3p) (Table 2), and were therefore considered to be representative of the general behaviour of the study population."
25205654,miR-1207,hsa-mir-1207,MI0006340,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-1207,hsa-mir-1207,MI0006340,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-141,hsa-mir-141,MI0000457,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-141,hsa-mir-141,MI0000457,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-155,hsa-mir-155,MI0000681,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-155,hsa-mir-155,MI0000681,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-15a,hsa-mir-15a,MI0000069,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-15a,hsa-mir-15a,MI0000069,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-1915,hsa-mir-1915,MI0008336,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-1915,hsa-mir-1915,MI0008336,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-200a,hsa-mir-200a,MI0000737,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-200a,hsa-mir-200a,MI0000737,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-200c,hsa-mir-200c,MI0000650,5-Fluorouracil,3385,-,HCT-8 vs HCT-8/V and HCT116 vs HCT116/MDR,-,-,colorectal cancer,in vitro,Low,Sensitive,JNK2,"p-c-Jun, P-gp, and MMP-2/-9",2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"In summary, our data purported that in vivo tumor growth and metastasis of MDR colorectal cancer were inhibited by miR200c reconstitution via repressing JNK2/c-Jun/P-gp signaling."
25205654,miR-200c,hsa-mir-200c,MI0000650,Cisplatin,2767,-,HCT8 vs HCT8/V and HCT116 vs HCT116/MDR,-,-,colorectal cancer,in vitro,Low,Sensitive,JNK2,"p-c-Jun, P-gp, and MMP-2/-9",2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"In summary, our data purported that in vivo tumor growth and metastasis of MDR colorectal cancer were inhibited by miR200c reconstitution via repressing JNK2/c-Jun/P-gp signaling."
25205654,miR-200c,hsa-mir-200c,MI0000650,Methylmethcathinone,45266826,-,HCT8 vs HCT8/MMC and HCT116 vs HCT116/MDR,-,-,colorectal cancer,in vitro,Low,Sensitive,JNK2,"p-c-Jun, P-gp, and MMP-2/-9",2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"In summary, our data purported that in vivo tumor growth and metastasis of MDR colorectal cancer were inhibited by miR200c reconstitution via repressing JNK2/c-Jun/P-gp signaling."
25205654,miR-200c,hsa-mir-200c,MI0000650,Tetrahydropalmatine,72301,-,HCT8 vs HCT8/THP and HCT116 vs HCT116/MDR,-,-,colorectal cancer,in vitro,Low,Sensitive,JNK2,"p-c-Jun, P-gp, and MMP-2/-9",2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"In summary, our data purported that in vivo tumor growth and metastasis of MDR colorectal cancer were inhibited by miR200c reconstitution via repressing JNK2/c-Jun/P-gp signaling."
25205654,miR-221,hsa-mir-221,MI0000298,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-221,hsa-mir-221,MI0000298,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-222,hsa-mir-222,MI0000299,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-222,hsa-mir-222,MI0000299,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-23a,hsa-mir-23a,MI0000079,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-23a,hsa-mir-23a,MI0000079,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-23b,hsa-mir-23b,MI0000439,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-23b,hsa-mir-23b,MI0000439,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-275,-,-,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-275,-,-,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-27a,hsa-mir-27a,MI0000085,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-27a,hsa-mir-27a,MI0000085,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-336,-,-,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-336,-,-,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-424,hsa-mir-424,MI0001446,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-424,hsa-mir-424,MI0001446,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-497,hsa-mir-497,MI0003138,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-497,hsa-mir-497,MI0003138,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Sensitive,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-638,hsa-mir-638,MI0003653,Oxaliplatin,5310940,-,HCT116 vsHCT116/L-OHP,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25205654,miR-638,hsa-mir-638,MI0003653,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colorectal cancer,in vitro,High,Resistant,-,-,2014,miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.,"First, we compared levels of miRNAs in the colorectal cancer MDR cells with their parental cells using miRNA microarray analysis. In total, 13 miRNAs were found to be significantly upregulated and four were downregulated (Supplementary Fig. S1). "
25226615,miR-494,hsa-mir-494,MI0003134,Doxorubicin (Adriamycin),31703,-,H69 vs H69/ADR and H446 vs H446/ADR,-,Patients,small cell lung cancer,in vitro and in vivo,Low,Sensitive,SCGN,-,2014,Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494.,"SCGN as a novel target of miR-494 by luciferase reporter assay, up-regulation of miR-494 can sensitize H69AR cells to chemotherapeutic drugs. "
25228385,miR-638,hsa-mir-638,MI0003653,Cisplatin,2767,"MDA-MB-231, Hs578T, MCF-7, T47D and MCF-10A",-,-,-,triple-negative breast cancer,in vitro,Low,Sensitive,BRCA1,-,2014,miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.,"Furthermore, miR-638 overexpression increased sensitivity to DNA-damaging agents, ultraviolet (UV) and cisplatin, but not to 5-fluorouracil (5-FU) and epirubicin exposure in TNBC cells."
25228385,miR-638,hsa-mir-638,MI0003653,Ultraviolet,-,"MDA-MB-231, Hs578T, MCF-7, T47D and MCF-10A",-,-,-,triple-negative breast cancer,in vitro,Low,Sensitive,BRCA1,-,2014,miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.,"Furthermore, miR-638 overexpression increased sensitivity to DNA-damaging agents, ultraviolet (UV) and cisplatin, but not to 5-fluorouracil (5-FU) and epirubicin exposure in TNBC cells."
25231602,miR-379,hsa-mir-379,MI0000787,Vorinostat,5311,MESO1,-,-,-,malignant pleural mesothelioma,in vitro,Low,Sensitive,IL-18,-,2014,MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.,miR-379 and miR-411 inhibit the invasive activity in MPM cells and improve sensitivity to SAHA.
25231602,miR-411 ,hsa-mir-411,MI0003675,Vorinostat,5311,MESO1,-,-,-,malignant pleural mesothelioma,in vitro,Low,Sensitive,IL-18,-,2014,MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.,miR-379 and miR-411 inhibit the invasive activity in MPM cells and improve sensitivity to SAHA.
25234165,miR-1202,hsa-mir-1202,MI0006334,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-1207,hsa-mir-1207,MI0006340,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-1246,hsa-mir-1246,MI0006381,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-129,hsa-mir-129-1,MI0000252,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-1290,hsa-mir-1290,MI0006352,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-1469,hsa-mir-146a,MI0000477,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-149*,hsa-mir-149,MI0000478,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-1908,hsa-mir-1908,MI0008329,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-1915,hsa-mir-1915,MI0008336,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-192,hsa-mir-192,MI0000234,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Sensitive,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-19a,hsa-mir-19a,MI0000073,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Sensitive,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-21,hsa-mir-21,MI0000077,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Sensitive,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-27a,hsa-mir-27a,MI0000085,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Sensitive,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-2861,hsa-mir-2861,MI0013006,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-29b,hsa-mir-29b-1,MI0000105,Bortezomib,387447,-,RPMI8226 vs RPMI8226/BOR,-,-,melanoma,in vitro,Low,Sensitive,PSME4,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,MiR-29b was significantly reduced in bortezomib-resistant cells as well as in cells resistant to second-generation PIs carfilzomib and ixazomib.
25234165,miR-29b,hsa-mir-29b-1,MI0000105,Carfilzomib,11556711,-,RPMI8226 vs RPMI8226/BOR,-,-,melanoma,in vitro,Low,Sensitive,PSME4,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,MiR-29b was significantly reduced in bortezomib-resistant cells as well as in cells resistant to second-generation PIs carfilzomib and ixazomib.
25234165,miR-29b,hsa-mir-29b-1,MI0000105,Ixazomib,25183872,-,RPMI8226 vs RPMI8226/BOR,-,-,melanoma,in vitro,Low,Sensitive,PSME4,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,MiR-29b was significantly reduced in bortezomib-resistant cells as well as in cells resistant to second-generation PIs carfilzomib and ixazomib.
25234165,miR-29c,hsa-mir-29c,MI0000735,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Sensitive,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-301a,hsa-mir-301a,MI0000745,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Sensitive,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-30e,hsa-mir-30e,MI0000749,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Sensitive,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-3185,hsa-mir-3185,MI0014227,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-3196,hsa-mir-3196,MI0014241,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-638,hsa-mir-638,MI0003653,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-660,hsa-mir-660,MI0003684,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Sensitive,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-762,hsa-mir-762,MI0003892,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-92-1,hsa-mir-92a-1,MI0000093,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Sensitive,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-92b,hsa-mir-92b,MI0003560,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234165,miR-939,hsa-mir-939,MI0005761,Bortezomib,387447,MM cell lines ,-,-,-,multiple myeloma,in vitro,High,Resistant,-,-,2015,MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.,"We then identified miRs differentially expressed in the bortezomibresistant cells. Over 415 000 pre-miR and mature miR were screened; however, only 26 human miRs were expressed with statistical difference between bortezomib-resistant and parental cells (Supplementary Table 1). "
25234467,miR-217,hsa-mir-217,MI0000293,Cisplatin,2767,SPC-A-1 and A549,-,-,-,lung cancer,in vitro,Low,Sensitive,KRAS,-,2014,MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer.,The up-regulation of miR-217 enhanced the sensitivity of SPC-A-1 and A549 cells to cisplatin.
25248111,miR-128,hsa-mir-128-1,MI0000447,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,Mice,-,ovarian cancer,in vitro and in vivo,Low,Sensitive,-,ABCC5 and Bmi-1,2014,Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance.,"Overexpression of miR-128 resensitized SKOV3/CP cells to cisplatin and reduced the expression of cisplatin-resistant-related proteins ABCC5 and Bmi-1, whereas miR-128 inhibitors increased cisplatin resistance in SKOV3 cells."
25249558,miR-145,hsa-mir-145,MI0000461,5-fluorouracil,3385,-,DLD-1 vs DLD-1/5-FU,-,Patients,colorectal cancer,in vitro and in vivo,Low,Sensitive,-,-,2014,SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression.,miR145 expression restores sensitivity to 5FU and augments CSC transcription factor expression
25250818,miR-34a,hsa-mir-34a,MI0000268,Etoposide,36462,-,D283-MED vs MEB-Med8A,-,-,brain tumour,in vitro,Low,Associated,SIRT1,-,2014,Mir-34a mimics are potential therapeutic agents for p53-mutated and chemoresistant brain tumour cells.,"Treatment with etoposide, increased miR-34a levels in a p53-dependent fashion and the level of miR-34a transcription was correlated with the cell sensitivity to etoposide."
25260883,miR-101,hsa-mir-101-1,MI0000103,Cisplatin,2767,-,A2780 vs A2780/CDDP and SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,Low,Sensitive,EZH2,-,2014,miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer.,"miR-101 overexpression decreased the expression of EZH2, reduced proliferation and migration of ovarian cancer cells, and resensitized drug-resistant cancer cells to cisplatin-induced cytotoxicity, suggesting the important role miR-101 plays in ovarian cancer that may be associated with its function as a regulator targeting EZH2."
25269574,miR-503,hsa-mir-503,MI0003188,Doxorubicin (Adriamycin),31703,-,HepG2 vs HepG2/ADR,-,-,hepatocellular cancer,in vitro,Low,Sensitive,-,"including multidrug resistance 1, multi drug resistance?associated protein 1, DNA excision repair protein ERCC?1, survivin and B?cell lymphoma 2;the phosphorylation of Akt was decreased and expression of cyclin?dependent kinase 1 was decreased by miR?503 overexpression.",2014,Role and mechanisms of microRNA-503 in drug resistance reversal in HepG2/ADM human hepatocellular carcinoma cells.,HepG2/ADM cells overexpressing miR?503 demonstrated an enhanced sensitivity to ADM.
25277203,miR-200c,hsa-mir-200c,MI0000650,Gefitinib,123631,"A549, H1299, H23, H460 and H1975",PC-9 vs PC-9/GR,-,Patients,non-small cell lung cancer,in vitro and in vivo,Low,Sensitive,ZEB1,PI3K/AKT and MEK/ERK pathways,2014,miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer Patient with EGFR wild-type.,Up-regulated miR-200c could regain the sensitivity to gefitinib in the EGFR wild-type cell lines and miR-200c could regulate epithelial to mesenchymal transition through PI3K/AKT and MEK/ERK pathways.
25280517,miR-133a,hsa-mir-133a-1,MI0000450,Paclitaxel,36314,-,-,-,Patients,esophageal squamous cell carcinoma,in vivo,Low,Resistant,-,-,2014,Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of Patient with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy.,"Moreover, the response rate of ESCC Patient to paclitaxel-based chemotherapy was significantly higher in combined miR-133a/b downregulation group compared with other groups (P = 0.02)."
25280517,miR-133b,hsa-mir-133b,MI0000822,Paclitaxel,36314,-,-,-,Patients,esophageal squamous cell carcinoma,in vivo,Low,Resistant,-,-,2014,Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of Patient with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy.,"Moreover, the response rate of ESCC Patient to paclitaxel-based chemotherapy was significantly higher in combined miR-133a/b downregulation group compared with other groups (P = 0.02)."
25284075,miR-3127,hsa-mir-3127,MI0014144,Dasatinib,3062316,A549 and H292,-,-,-,non-small cell lung cancer,in vitro,Low,Resistant,ABL1,c-Abl/Ras/ERK pathway,2014,Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway.,"Overexpression of miR-3127-5p in A549 or H292 cells resulted in enhanced resistance to dasatinib, an Abl/src tyrosine kinase inhibitor."
25287716,miR-150,hsa-mir-150,MI0000479,Cisplatin,2767,5637 and T24,-,-,-,bladder cancer,in vitro,Low,Resistant,PDCD4,-,2014,miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro.,"miR-150 expression was found to be significantly increased in both MIBC cell lines, and treatment with a miR-150 inhibitor significantly sensitized MIBC cells to cisplatin and inhibited MIBC cell invasiveness. "
25289099,miR-7,hsa-mir-7-1,MI0000263,Paclitaxel,36314,"A549, H1395, 95C and 95D",-,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,-,EGFR,2014,MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel.,"Upregulation of miR-7 enhanced the PTX-sensitivity of NSCLC cells by suppressing cell proliferation and promoting cell apoptosis, while the inhibition of miR-7 abrogated the antiproliferative proapoptotic effects of PTX."
25294901,miR-204,hsa-mir-204,MI0000284,5-Fluorouracil,3385,HCT-116 and LoVo,-,-,-,colorectal cancer,in vitro,Low,Sensitive,RAB22A,-,2014,miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A.,"Moreover, restoring miR-204-5p expression inhibited colorectal cancer migration and invasion and promoted tumor sensitivity to chemotherapy."
25294901,miR-204,hsa-mir-204,MI0000284,Cisplatin,2767,HCT-116 and LoVo,-,-,-,colorectal cancer,in vitro,Low,Sensitive,RAB22A,-,2014,miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A.,"Moreover, restoring miR-204-5p expression inhibited colorectal cancer migration and invasion and promoted tumor sensitivity to chemotherapy."
25294901,miR-204,hsa-mir-204,MI0000284,Oxaliplatin,5310940,HCT116 and LoVo,-,-,-,colorectal cancer,in vitro,Low,Sensitive,RAB22A,-,2014,miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A.,"Moreover, restoring miR-204-5p expression inhibited colorectal cancer migration and invasion and promoted tumor sensitivity to chemotherapy."
25297343,miR-490,hsa-mir-490,MI0003125,Paclitaxel,36314,-,A2780 vs A2780/Taxol,-,-,ovarian cancer,in vitro,Low,Resistant,-,MDR1 and GST-pie,2014,microRNA 490-3P enhances the drug-resistance of human ovarian cancer cells.,"Following miR-490-3P transfection, both A2780 and A2780/Taxol cells showed decreased sensitivity to paclitaxel."
25305453,miR-30e ,hsa-mir-30e,MI0000749,Imatinib,5291,K562,-,-,-,chronic myeloid leukemia,in vitro,Low,Sensitive,ABL,-,2015,MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.,Enforced expression of miR-30e in K562 cells suppressed proliferation and induced apoptosis of these cells and sensitized them to imatinib treatment.
25310895,miR-451,hsa-mir-451a,MI0001729,Docetaxel,148124,-,SPC-A1 vs SPC-A1/DOC and H1299 vs H1299/DOC,Mice,Patients,lung adenocarcinoma,in vitro and in vivo,Low,Sensitive,c-Myc,-,2014,MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc.,"This study first reported the involvement of miR-451/c-Myc/ERK/GSK-3Beta signalling axis in the acquisition of EMT phenotype in docetaxel-resistant LAD cells, suggesting that re-expression of miR-451 or targeting c-Myc will be a potential strategy for the treatment of chemoresistant LAD Patient."
25311867,miR-193a,hsa-mir-193a,MI0000487,Paclitaxel,36314,5637 and H-bc,-,-,Patients,bladder cancer,in vitro and in vivo,Low,Resistant,LOXL4,oxidative stress pathway,2014,miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the oxidative stress pathway.,"From the detailed studies of a multi-chemosensitive (5637) versus a chemoresistant (H-bc) bladder cancer cell lines, we showed that miR-193a-3p promotes the multi-chemoresistance of bladder cancer cells."
25322930,miR-135a,hsa-miR-135a-5p,MI0000452,Doxorubicin (Adriamycin),31703,BGC-823,-,-,-,gastric cancer,in vitro,Low,Resistant,AP-2alpha,BCL-2,2014,Regulation of BGC-823 cell sensitivity to adriamycin via miRNA-135a-5p.,"Therefore, miRNA-135a-5p increased BCL-2 via AP-2alpha and consequently enhanced cell resistance to apoptosis."
25323306,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung cancer,in vitro,Low,Resistant,-,"GST-pie, MDR1 and MPR1",2015,Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells.,miR-21 increases cisplatin resistance in tumor cells by inhibiting apoptosis and blocking the cell cycle.
25327162,miR-16,hsa-mir-16-1,MI0000070,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,Mice ,-,gastric cancer,in vitro and in vivo,Low,Sensitive,-,-,2014,In vivo multimodality imaging of miRNA-16 iron nanoparticle reversing drug resistance to chemotherapy in a mouse gastric cancer model.,"Results showed that miR16/MNPs were able to significantly suppress SGC7901/ADR tumor growth, probably through increasing SGC7901/ADR cells' sensitivity to ADR."
25330011,miR-375,hsa-mir-375,MI0000783,Paclitaxel,36314,SiHa and CaSki,-,-,-,cervical cancer,in vitro,Low,Resistant,Ecadherin,-,2014,miR-375 mediated acquired chemoresistance in cervical cancer by facilitating EMT.,"Forced over-expression of miR-375 may suppress Ecadherin expression by a directly targeting pathway, which led to paclitaxel resistance. "
25333257,miR-145,hsa-mir-145,MI0000461,SN-38,104842,"SW480, DLD1 and AGS",-,-,-,gastrointestinal cancer,in vitro,Low,Associated,P-glycoprotein,-,2014,Fas signaling promotes chemoresistance in gastrointestinal cancer by up-regulating P-glycoprotein.,FasL promoted chemoresistance of GI cancer cell via upregulation of P-gp by increasing Beta-catenin and decreasing miR-145.
25333573,miR-34a,hsa-mir-34a,MI0000268,5-Fluorouracil,3385,DLD-1,-,-,-,colon cancer,in vitro,Low,Sensitive,LDHA,-,2015,Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil.,"Overexpression of miR-34a reduced the expression of LDHA, probably through binding to the 3' untranslated region, leading to the re-sensitization of 5-FU-resistant cancer cells to 5-FU."
25333670,let-7b,hsa-let-7b,MI0000063,5-Fluorouracil,3385,BEL-7402,-,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,Bcl-xl,-,2015,Let-7b binding site polymorphism in the B-cell lymphoma-extra large 3'UTR is associated with fluorouracil resistance of hepatocellular carcinoma.,Let-7b downregulates endogenous Bcl-xl expression and sensitizes BEL-7402 cells to 5-FU.
25339370,miR-106a,hsa-mir-106a,MI0000113,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,non-small cell lung cancer,in vitro,Low,Resistant,ABCA1,-,2015,MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.,miR-106a is upregulated in DDP-resistant A549/DDP cells and involved in conferring DDP resistance to A549 cells.
25339453,let-7e,hsa-let-7e,MI0000066,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-100,hsa-mir-100,MI0000102,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-122,hsa-mir-122,MI0000442,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-124c,-,-,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,Low,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-125,-,-,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-125b,hsa-mir-125b-1,MI0000446,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-126,hsa-mir-126,MI0000471,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-127,hsa-mir-127,MI0000472,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-130a,hsa-mir-130a,MI0000448,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-132,hsa-mir-132,MI0000449,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-140,hsa-mir-140,MI0000456,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-142,hsa-mir-142,MI0000458,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,Low,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-143,hsa-mir-143,MI0000459,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-145,hsa-mir-145,MI0000461,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-146a,hsa-mir-146a,MI0000477,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,Low,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-148a,hsa-mir-148a,MI0000253,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-155,hsa-mir-155,MI0000681,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-181,-,-,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,Low,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-21,hsa-mir-21,MI0000077,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,Low,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-214,hsa-mir-214,MI0000290,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-22,hsa-mir-22,MI0000078,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-224,hsa-mir-224,MI0000301,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-24-1,hsa-mir-24-1,MI0000080,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-299,hsa-mir-299,MI0000744,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-31,hsa-mir-31,MI0000089,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-375,hsa-mir-375,MI0000783,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-376a,hsa-mir-376a-1,MI0000784,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-423,hsa-mir-423,MI0001445,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-424,hsa-mir-424,MI0001446,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-483,hsa-mir-483,MI0002467,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-494,hsa-mir-494,MI0003134,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-497,hsa-mir-497,MI0003138,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-505,hsa-mir-505,MI0003190,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-572,hsa-mir-572,MI0003579,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-638,hsa-mir-638,MI0003653,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-660,hsa-mir-660,MI0003684,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-7,hsa-mir-7-1,MI0000263,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,Low,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-720,hsa-mir-720,MI0006654,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-744,hsa-mir-744,MI0005559,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-762,hsa-mir-762,MI0003892,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-766,hsa-mir-766,MI0003836,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-92a,hsa-mir-92a-1,MI0000093,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25339453,miR-99a,hsa-mir-99a,MI0000101,Gefitinib,123631,-,A549  vs  A549/GR,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.,"The expression profiles of 43 miRNAs changed significantly (2.0-14.0 fold), with 25 upregulated miRNAs and 18 downregulated miRNAs detected in the resistant cells, as compared with the parent cells (Table I). "
25341040,miR-205,hsa-mir-205,MI0000285,Docetaxel,148124,"WPE1-NA22, PC-3 and DU-145",-,-,-,prostate cancer,in vitro,Low,Sensitive,E2F6,-,2014,Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.,"SiRNA knockdown of EZH2 increased miR-31 expression and decreased the antiapoptotic protein E2F6 (E2F transcription factor 6) (a target of miR-31), resulting in the sensitization of prostate cancer cells to docetaxel-induced apoptosis."
25341040,miR-31,hsa-mir-31,MI0000089,Docetaxel,148124,"WPE1-NA22, PC-3 and DU-145",-,-,-,prostate cancer,in vitro,Low,Sensitive,E2F6,-,2014,Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.,"SiRNA knockdown of EZH2 increased miR-31 expression and decreased the antiapoptotic protein E2F6 (E2F transcription factor 6) (a target of miR-31), resulting in the sensitization of prostate cancer cells to docetaxel-induced apoptosis."
25344675,miR-100,hsa-mir-100,MI0000102,Cisplatin,2767,MIA PaCa-2 and CFPAC-1,-,-,-,pancreatic cancer,in vitro,Low,Sensitive,FGFR3,-,2014,MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3.,Overexpression of miR-100 increased cisplatin sensitivity of pancreatic cancer cells
25344865,miR-382,hsa-mir-382,MI0000790,Cisplatin,2767,U2OS and MG63,-,-,Patients,osteosarcoma,in vitro and in vivo,Low,Sensitive,KLF12 and HIPK3,-,2014,miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma.,"Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting KLF12 and HIPK3, respectively."
25344865,miR-382,hsa-mir-382,MI0000790,Doxorubicin (Adriamycin),31703,U2OS and MG63,-,-,Patients,osteosarcoma,in vitro and in vivo,Low,Sensitive,KLF12 and HIPK3,-,2014,miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma.,"Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting KLF12 and HIPK3, respectively."
25344865,miR-382,hsa-mir-382,MI0000790,Methotrexate,126941,U2OS and MG63,-,-,Patients,osteosarcoma,in vitro and in vivo,Low,Sensitive,KLF12 and HIPK3,-,2014,miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma.,"Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting KLF12 and HIPK3, respectively."
25344911,miR-129,hsa-mir-129-1,MI0000252,Decitabine,451668,-,SGC7901 vs SGC7901/VCR and SGC7901 vs SGC7901/ADR,Mice,-,gastric cancer,in vitro and in vivo,Low,Sensitive,"ABCB1, ABCC5 and ABCG1",-,2014,Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters.,"Using gain or loss of function assays, we found the over-expressed miR-129-5p reduced the chemo-resistance of SGC7901/VCR and SGC7901/ADR cells, while down-regulation of miR-129-5p had an opposite effect."
25344911,miR-129,hsa-mir-129-1,MI0000252,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/VCR and SGC7901 vs SGC7901/ADR,Mice,-,gastric cancer,in vitro and in vivo,Low,Sensitive,"ABCB1, ABCC5 and ABCG1",-,2014,Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters.,"Using gain or loss of function assays, we found the over-expressed miR-129-5p reduced the chemo-resistance of SGC7901/VCR and SGC7901/ADR cells, while down-regulation of miR-129-5p had an opposite effect."
25344911,miR-129,hsa-mir-129-1,MI0000252,Vincristine,5978,-,SGC7901 vs SGC7901/VCR and SGC7901 vs SGC7901/ADR,Mice,-,gastric cancer,in vitro and in vivo,Low,Sensitive,"ABCB1, ABCC5 and ABCG1",-,2014,Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters.,"Using gain or loss of function assays, we found the over-expressed miR-129-5p reduced the chemo-resistance of SGC7901/VCR and SGC7901/ADR cells, while down-regulation of miR-129-5p had an opposite effect."
25349971,let-7a,hsa-let-7a-1,MI0000060,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,let-7d,hsa-let-7d,MI0000065,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,let-7e,hsa-let-7e,MI0000066,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,let-7f,hsa-let-7f-1,MI0000067,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,let-7i,hsa-let-7i,MI0000434,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-103,hsa-mir-103a-1,MI0000109,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-107,hsa-mir-107,MI0000114,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-1207,hsa-mir-1207,MI0006340,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-1224,hsa-mir-1224,MI0003764,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-1225,hsa-mir-1225,MI0006311,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-1228,hsa-mir-1228,MI0006318,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-1249,hsa-mir-1249,MI0006384,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-125a,hsa-mir-125a,MI0000469,Imatinib,5291,-,GIST882 vs GIST48,-,Patientss,gastrointestinal stromal tumors,in vitro and in vivo,Low,Resistant,PTPN18,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-1268,hsa-mir-1268a,MI0006405,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-130b,hsa-mir-130b,MI0000748,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-134,hsa-mir-134,MI0000474,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-139,hsa-mir-139,MI0000261,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-143,hsa-mir-143,MI0000459,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-146b,hsa-mir-146b,MI0003129,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-150,hsa-mir-150,MI0000479,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-151,hsa-mir-151a,MI0000809,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-15b,hsa-mir-15b,MI0000438,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-188,hsa-mir-188,MI0000484,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-1915,hsa-mir-1915,MI0008336,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-193b,hsa-mir-193b,MI0003137,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-214,hsa-mir-214,MI0000290,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-25,hsa-mir-25,MI0000082,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-296,hsa-mir-296,MI0000747,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-301a,hsa-mir-301a,MI0000745,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-30a,hsa-mir-30a,MI0000088,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-30b,hsa-mir-30b,MI0000441,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-30c,hsa-mir-30c-2,MI0000254,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-324,hsa-mir-324,MI0000813,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-362,hsa-mir-362,MI0000762,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-365,hsa-mir-365a,MI0000767,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-483,hsa-mir-483,MI0002467,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-532,hsa-mir-532,MI0003205,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-574,hsa-mir-574,MI0003581,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-638,hsa-mir-638,MI0003653,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-660,hsa-mir-660,MI0003684,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Resistant,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-663,hsa-mir-663a,MI0003672,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-762,hsa-mir-762,MI0003892,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25349971,miR-939,hsa-mir-939,MI0005761,Imatinib,5291,-,-,-,Patientss,gastrointestinal stromal tumors,in vivo,High,Sensitive,-,-,2014,microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome," Using SAM analysis on the microarray data, we found 27 overexpressed and 17 underexpressed miRNAs with a false discovery rate (FDR) <15% in the imatinib-resistant GISTs compared with imatinibsensitive GISTs (Supplementary Table S4)."
25356050,let-7a,hsa-let-7a-1,MI0000060,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,let-7e,hsa-let-7e,MI0000066,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-1226,hsa-mir-1226,MI0006313,5-Fluorouracil,3385,-,KYSE410 vs KYSE410/5-FU,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-125a,hsa-mir-125a,MI0000469,5-Fluorouracil,3385,-,KYSE410 vs KYSE410/5-FU,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-125a,hsa-mir-125a,MI0000469,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-1268a,hsa-mir-1268a,MI0006405,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-1275,hsa-mir-1275,MI0006415,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-1292,hsa-mir-1292,MI0006433,5-Fluorouracil,3385,-,KYSE410 vs KYSE410/5-FU,-,-,esophageal squamous cell carcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-130a,hsa-mir-130a,MI0000448,Cisplatin,2767,-,KYSE410 vs KYSE410/CDDP,-,-,esophageal squamous cell carcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-17,hsa-mir-17,MI0000071,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-181a,hsa-mir-181a-2,MI0000269,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-181b,hsa-mir-181b-1,MI0000270,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-18a,hsa-mir-18a,MI0000072,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-18a,hsa-mir-18a,MI0000072,5-Fluorouracil,3385,-,KYSE410 vs KYSE410/5-FU,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-18a,hsa-mir-18a,MI0000072,Cisplatin,2767,-,KYSE410 vs KYSE410/CDDP,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-191,hsa-mir-191,MI0000465,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-192,hsa-mir-192,MI0000234,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-193b,hsa-mir-193b,MI0003137,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-193b,hsa-mir-193b,MI0003137,Cisplatin,2767,-,KYSE410 vs KYSE410/CDDP,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-194,hsa-mir-194-1,MI0000488,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-196b,hsa-mir-196b,MI0001150,5-Fluorouracil,3385,-,KYSE410 vs KYSE410/5-FU,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-200a,hsa-mir-200a,MI0000737,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-200b,hsa-mir-200b,MI0000342,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-203a,hsa-mir-203a,MI0000283,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-203a,hsa-mir-203a,MI0000283,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-21,hsa-mir-21,MI0000077,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-210,hsa-mir-210,MI0000286,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-222,hsa-mir-222,MI0000299,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-23a,hsa-mir-23a,MI0000079,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-25,hsa-mir-25,MI0000082,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-25,hsa-mir-25,MI0000082,Cisplatin,2767,-,KYSE410 vs KYSE410/CDDP,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-27b,hsa-mir-27b,MI0000440,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-296,hsa-mir-296,MI0000747,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-31,hsa-mir-31,MI0000089,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-31,hsa-mir-31,MI0000089,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-320a,hsa-mir-320a,MI0000542,Cisplatin,2767,-,KYSE410 vs KYSE410/CDDP,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-320b,hsa-mir-320b-1,MI0003776,Cisplatin,2767,-,KYSE410 vs KYSE410/CDDP,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-320c,hsa-mir-320c-1,MI0003778,Cisplatin,2767,-,KYSE410 vs KYSE410/CDDP,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-331,hsa-mir-331,MI0000812,5-Fluorouracil,3385,-,KYSE410 vs KYSE410/5-FU,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-339,hsa-mir-339,MI0000815,Cisplatin,2767,-,KYSE410 vs KYSE410/CDDP,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-378a,hsa-mir-378a,MI0000786,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-410,hsa-mir-410,MI0002465,5-Fluorouracil,3385,-,KYSE410 vs KYSE410/5-FU,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-455,hsa-mir-455,MI0003513,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-455,hsa-mir-455,MI0003513,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-532,hsa-mir-532,MI0003205,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-550a,hsa-mir-550a-1,MI0003600,5-Fluorouracil,3385,-,KYSE410 vs KYSE410/5-FU,-,-,esophageal squamous cell carcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-638,hsa-mir-638,MI0003653,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-663a,hsa-mir-663a,MI0003672,5-Fluorouracil,3385,-,OE19 vs OE19/5-FU,-,-,esophageal adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-663a,hsa-mir-663a,MI0003672,5-Fluorouracil,3385,-,KYSE410 vs KYSE410/5-FU,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-663a,hsa-mir-663a,MI0003672,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-744,hsa-mir-744,MI0005559,Cisplatin,2767,-,KYSE410 vs KYSE410/CDDP,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-92a,hsa-mir-92a-1,MI0000093,Cisplatin,2767,-,KYSE410 vs KYSE410/CDDP,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-92b,hsa-mir-92b,MI0003560,Cisplatin,2767,-,OE19 vs OE19/CDDP,-,-,esophageal adenocarcinoma,in vitro,High,Resistant,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-935,hsa-mir-935,MI0005757,5-Fluorouracil,3385,-,KYSE410 vs KYSE410/5-FU,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-99b,hsa-mir-99b,MI0000746,5-Fluorouracil,3385,-,KYSE410 vs KYSE410/5-FU,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25356050,miR-99b,hsa-mir-99b,MI0000746,Cisplatin,2767,-,KYSE410 vs KYSE410/CDDP,-,-,esophageal squamous cell carcinoma,in vitro,High,Sensitive,-,-,2014,MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines,"In cisplatin resistant EAC cells, 18 miRNAs were significantly dysregulated compared to controls (13 downregulated, 5 upregulated).In cisplatin resistant ESCC cells, 8 miRNAs were significantly dysregulated (all 8 downregulated). In 5-FU resistant EAC cells, 18 miRNAs were significantly dysregulated (10 downregulated, 8 upregulated). In 5-FU resistant ESCC cells, 5 miRNAs were significantly dysregulated (3 downregulated, 2 upregulated)."
25368020,miR-34a,hsa-mir-34a,MI0000268,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,Mice,-,breast cancer,in vitro and in vivo,Low,Sensitive,NOTCH1,-,2014,Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance.,Ectopic miR34a expression reduced cancer stem cell properties and increased sensitivity to doxorubicin treatment by directly targeting NOTCH1.
25381586,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,MG-63,-,-,-,osteosarcoma,in vitro,Low,Resistant,-,-,2016,MicroRNA-21 regulates the sensitivity to cisplatin in a human osteosarcoma cell line.,"Osteosarcoma cells transfected with miR-21 mimics were significantly resistant to CDDP, while suppression of miR-21 in osteosarcoma cells led to enhanced CDDP cytotoxicity."
25394901,miR-125a,hsa-mir-125a,MI0000469,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-129,hsa-mir-129-1,MI0000252,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-15a,hsa-mir-15a,MI0000069,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-181b,hsa-mir-181b-1,MI0000270,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-182,hsa-mir-182,MI0000272,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-185,hsa-mir-185,MI0000482,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-200b,hsa-mir-200b,MI0000342,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-205,hsa-mir-205,MI0000285,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-214,hsa-mir-214,MI0000290,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-218,hsa-mir-218-1,MI0000294,Cisplatin,2767,-,MCF-7 vs MCF-7/CDDP,-,Patients,breast cancer,in vitro and in vivo,Low,Sensitive,BRCA1,-,2015,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"In vivo assay also demonstrated that restoring miR-218 expression in MCF-7/DDP cell line could sensitize cells against cisplatin, thereby increasing cisplatin-mediated tumor cell apoptosis and reducing DNA repair."
25394901,miR-222,hsa-mir-222,MI0000299,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-302c,hsa-mir-302c,MI0000773,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-30c,hsa-mir-30c-2,MI0000254,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-331,hsa-mir-331,MI0000812,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-33a,hsa-mir-33a,MI0000091,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-374b,hsa-mir-374b,MI0005566,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-375,hsa-mir-375,MI0000783,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25394901,miR-663,hsa-mir-663a,MI0003672,Cisplatin,2767,HEK-293,MCF-7 vs MCF-7/CDDP,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.,"As shown in Table 1, a total of 18 miRNA genes (8 upregulated and 10 downregulated) were identified as differently expressed in MCF-7/DDP cells compared with parental MCF-7 cells."
25400759,miR-100,hsa-mir-100,MI0000102,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Sensitive,-,-,2014,MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo,"Compared to the parental CNE-1 cells, there were 7 upregulated (miR-4788, miR-802, miR-3146, miR-4678, miR-377-3p, miR-208b, miR-22-5p) and 6 downregulated (miR-100-5p, miR-4478, miR-1204, miR-634, miR-4653-3p, miR-3198) miRNAs screened in CNE-1/Taxol cells (Figure 1A)."
25400759,miR-1204,hsa-mir-1204,MI0006337,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Sensitive,-,-,2014,MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo,"Compared to the parental CNE-1 cells, there were 7 upregulated (miR-4788, miR-802, miR-3146, miR-4678, miR-377-3p, miR-208b, miR-22-5p) and 6 downregulated (miR-100-5p, miR-4478, miR-1204, miR-634, miR-4653-3p, miR-3198) miRNAs screened in CNE-1/Taxol cells (Figure 1A)."
25400759,miR-208b,hsa-mir-208a,MI0000251,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Resistant,-,-,2014,MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo,"Compared to the parental CNE-1 cells, there were 7 upregulated (miR-4788, miR-802, miR-3146, miR-4678, miR-377-3p, miR-208b, miR-22-5p) and 6 downregulated (miR-100-5p, miR-4478, miR-1204, miR-634, miR-4653-3p, miR-3198) miRNAs screened in CNE-1/Taxol cells (Figure 1A)."
25400759,miR-22,hsa-mir-22,MI0000078,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Resistant,-,-,2014,MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo,"Compared to the parental CNE-1 cells, there were 7 upregulated (miR-4788, miR-802, miR-3146, miR-4678, miR-377-3p, miR-208b, miR-22-5p) and 6 downregulated (miR-100-5p, miR-4478, miR-1204, miR-634, miR-4653-3p, miR-3198) miRNAs screened in CNE-1/Taxol cells (Figure 1A)."
25400759,miR-3146,hsa-mir-3146,MI0014172,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Resistant,-,-,2014,MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo,"Compared to the parental CNE-1 cells, there were 7 upregulated (miR-4788, miR-802, miR-3146, miR-4678, miR-377-3p, miR-208b, miR-22-5p) and 6 downregulated (miR-100-5p, miR-4478, miR-1204, miR-634, miR-4653-3p, miR-3198) miRNAs screened in CNE-1/Taxol cells (Figure 1A)."
25400759,miR-3198,hsa-mir-3198-1,MI0014246,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Sensitive,-,-,2014,MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo,"Compared to the parental CNE-1 cells, there were 7 upregulated (miR-4788, miR-802, miR-3146, miR-4678, miR-377-3p, miR-208b, miR-22-5p) and 6 downregulated (miR-100-5p, miR-4478, miR-1204, miR-634, miR-4653-3p, miR-3198) miRNAs screened in CNE-1/Taxol cells (Figure 1A)."
25400759,miR-377,hsa-mir-377,MI0000785,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Resistant,-,-,2014,MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo,"Compared to the parental CNE-1 cells, there were 7 upregulated (miR-4788, miR-802, miR-3146, miR-4678, miR-377-3p, miR-208b, miR-22-5p) and 6 downregulated (miR-100-5p, miR-4478, miR-1204, miR-634, miR-4653-3p, miR-3198) miRNAs screened in CNE-1/Taxol cells (Figure 1A)."
25400759,miR-4478,hsa-mir-4478,MI0016831,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Sensitive,-,-,2014,MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo,"Compared to the parental CNE-1 cells, there were 7 upregulated (miR-4788, miR-802, miR-3146, miR-4678, miR-377-3p, miR-208b, miR-22-5p) and 6 downregulated (miR-100-5p, miR-4478, miR-1204, miR-634, miR-4653-3p, miR-3198) miRNAs screened in CNE-1/Taxol cells (Figure 1A)."
25400759,miR-4653,hsa-mir-4653,MI0017281,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Sensitive,-,-,2014,MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo,"Compared to the parental CNE-1 cells, there were 7 upregulated (miR-4788, miR-802, miR-3146, miR-4678, miR-377-3p, miR-208b, miR-22-5p) and 6 downregulated (miR-100-5p, miR-4478, miR-1204, miR-634, miR-4653-3p, miR-3198) miRNAs screened in CNE-1/Taxol cells (Figure 1A)."
25400759,miR-4678,hsa-mir-4678,MI0017309,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Resistant,-,-,2014,MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo,"Compared to the parental CNE-1 cells, there were 7 upregulated (miR-4788, miR-802, miR-3146, miR-4678, miR-377-3p, miR-208b, miR-22-5p) and 6 downregulated (miR-100-5p, miR-4478, miR-1204, miR-634, miR-4653-3p, miR-3198) miRNAs screened in CNE-1/Taxol cells (Figure 1A)."
25400759,miR-4788,hsa-mir-4788,MI0017435,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Resistant,-,-,2014,MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo,"Compared to the parental CNE-1 cells, there were 7 upregulated (miR-4788, miR-802, miR-3146, miR-4678, miR-377-3p, miR-208b, miR-22-5p) and 6 downregulated (miR-100-5p, miR-4478, miR-1204, miR-634, miR-4653-3p, miR-3198) miRNAs screened in CNE-1/Taxol cells (Figure 1A)."
25400759,miR-634,hsa-mir-634,MI0003649,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,Low,Sensitive,-,-,2014,MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo,"Compared to the parental CNE-1 cells, there were 7 upregulated (miR-4788, miR-802, miR-3146, miR-4678, miR-377-3p, miR-208b, miR-22-5p) and 6 downregulated (miR-100-5p, miR-4478, miR-1204, miR-634, miR-4653-3p, miR-3198) miRNAs screened in CNE-1/Taxol cells (Figure 1A)."
25400759,miR-634,hsa-mir-634,MI0003649,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,Mice,-,nasopharyngeal carcinoma,in vitro and in vivo,Low,Sensitive,-,-,2014,MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo.,"We restored miR-634 expression in the CNE-1/Taxol cells by lentivirus infection, and found restoration of miR-634 re-sensitized the CNE-1/Taxol cells to paclitaxel in vitro by MTT assay and colony formation assay. In xenograft mouse model, we found that miR-634 inhibited tumor growth and enhanced paclitaxel sensitivity. "
25400759,miR-802,hsa-mir-802,MI0003906,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Resistant,-,-,2014,MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo,"Compared to the parental CNE-1 cells, there were 7 upregulated (miR-4788, miR-802, miR-3146, miR-4678, miR-377-3p, miR-208b, miR-22-5p) and 6 downregulated (miR-100-5p, miR-4478, miR-1204, miR-634, miR-4653-3p, miR-3198) miRNAs screened in CNE-1/Taxol cells (Figure 1A)."
25400821,miR-107,hsa-mir-107,MI0000114,Cisplatin,2767,A549,-,-,-,non small cell lung cancer ,in vitro,Low,Sensitive,CDK8,-,2014,miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8.,"In conclusion, the present study provides the first evidence that miR-107 plays a key role in cisplatin resistance by targeting the CDK8 protein in NSCLC cell lines."
25407491,miR-103,hsa-mir-103a-1,MI0000109,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,Mice,-,gastric carcinoma,in vitro and in vivo,Low,Sensitive,Cav-1,inhibited P-gp function,2015,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Overexpression of miR-103/107 sensitized SGC7901/ADR cells to doxorubicin (DOX), as demonstrated by in vitro and in vivo drug sensitivity assay."
25407491,miR-107,hsa-mir-107,MI0000114,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,Mice,-,gastric carcinoma,in vitro and in vivo,Low,Sensitive,Cav-1,inhibited P-gp function,2015,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Overexpression of miR-103/107 sensitized SGC7901/ADR cells to doxorubicin (DOX), as demonstrated by in vitro and in vivo drug sensitivity assay."
25407491,miR-10a,hsa-mir-10a,MI0000266,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-1224,hsa-mir-1224,MI0003764,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-1254,hsa-mir-1254-1,MI0006388,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-145,hsa-mir-145,MI0000461,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-17,hsa-mir-17,MI0000071,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-297,hsa-mir-297,MI0005775,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-30b,hsa-mir-30b,MI0000441,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-30e,hsa-mir-30e,MI0000749,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-338,hsa-mir-338,MI0000814,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-361,hsa-mir-361,MI0000760,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-424,hsa-mir-424,MI0001446,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-487b,hsa-mir-487b,MI0003530,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-519b,hsa-mir-519b,MI0003151,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-520f,hsa-mir-520f,MI0003146,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-523,hsa-mir-523,MI0003153,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Resistant,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-587,hsa-mir-587,MI0003595,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-593,hsa-mir-593,MI0003605,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-628,hsa-mir-628,MI0003642,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-675,hsa-mir-675,MI0005416,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-760,hsa-mir-760,MI0005567,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25407491,miR-92b,hsa-mir-92b,MI0003560,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR,-,-,gastric cancer,in vitro,High,Sensitive,-,-,2014,miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.,"Thirteen of miRNAs had shown obvious differential expression between SGC7901/ADR cells and their parent cells (Table 1, fold change >2.5)."
25416050,miR-363,hsa-mir-363,MI0000764,Cisplatin,2767,"MDA-MB-231, MDA-MB-435, MCF-7 and MCF-10A",-,-,-,breast cancer,in vitro,Low,Sensitive,Mcl-1 ,-,2014,MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer.,Our study indicated that miR-363 reversed the resistance of the breast cancer cell line MDA-MB-231 to the chemotherapeutic agent cisplatin (CDDP).
25432132,miR-25,hsa-mir-25,MI0000082,Cisplatin,2767,A549,-,Mice,-,non-small cell lung cancer,in vitro and in vivo,Low,Resistant,CDC42,-,2015,Downregulation of miR-25 modulates non-small cell lung cancer cells by targeting CDC42.,"Downregulation of miR-25 markedly inhibited A549 cell proliferation, induced G1 cell cycle arrest, increased cisplatin sensitivity, and suppressed the growth of caner cell xenograft in vivo."
25435430,miR-16,hsa-mir-16-1,MI0000070,Paclitaxel,36314,"A549, NCI-H596, NCI-H1734 and NCI-H1299",-,-,-,lung cancer,in vitro,Low,Sensitive,BCL-2,-,2015,MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis.,"miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1, whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2."
25444900,miR-193a,hsa-mir-193a,MI0000487,Paclitaxel,36314,5637 and H-bc,-,Mice,-,bladder cancer,in vitro and in vivo,Low,Resistant,HOXC9,DNA damage response and oxidative stress pathways,2015,MiR-193a-3p promotes the multi-chemoresistance of bladder cancer by targeting the HOXC9 gene.,"Here, we showed that as a new direct target, the homeobox C9 (HOXC9) gene also executes the promoting effect of miR-193a-3p on the bladder cancer chemoresistance from a systematic study of multi-chemosensitive (5637) and resistant (H-bc) bladder cancer cell lines in both cell culture and tumor-xenograft/nude mice system. "
25446103,miR-320,hsa-mir-320a,MI0000542,5-Fluorouracil,3385,HCT-116 and HT-29,-,-,-,colon cancer,in vitro,Low,Sensitive,FOXM1,Wnt/Beta-catenin pathway,2015,miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1.,"In this study, we demonstrated that ectopic expression of miR-320 led to inhibit HCT-116 cell proliferation, invasion and hypersensitivity to 5-Fu and Oxaliplatin. Also, knockdown of miR-320 reversed these effects in HT-29 cells."
25446103,miR-320,hsa-mir-320a,MI0000542,Oxaliplatin,5310940,HCT116 and HT-29,-,-,-,colon cancer,in vitro,Low,Sensitive,FOXM1,Wnt/Beta-catenin pathway,2015,miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1.,"In this study, we demonstrated that ectopic expression of miR-320 led to inhibit HCT-116 cell proliferation, invasion and hypersensitivity to 5-Fu and Oxaliplatin. Also, knockdown of miR-320 reversed these effects in HT-29 cells."
25449431,miR-22,hsa-mir-22,MI0000078,5-Fluorouracil,3385,SW620,-,Mice,-,colorectal cancer,in vitro and in vivo,Low,Sensitive,BTG1,-,2015,MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells.,"Thus, miR-22 may function as an important switch between autophagy and apoptosis to regulate 5-FU sensitivity through post-transcriptional silencing of BTG1."
25451164,let-7e,hsa-let-7e,MI0000066,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-/ADR,-,Patientss,breast cancer,in vitro and in vivo,Low,Sensitive,-,-,2014,miRNA expression patterns in chemoresistant breast cancer tissues,"As illustrated in Fig. 4, compared to the parental MCF-7 cell line, 6 miRNAs (miR-200a, miR-141, miR-200c, miR-31, miR-429, and miR-196b) were up-regulated, and 7 miRNAs (let-7e, miR-576-3p, miR-125b-1, miR-370, miR-145, miR-765, and miR-760) were down-regulated in MCF-7/Adr cells."
25451164,miR-125-1,-,-,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-/ADR,-,Patientss,breast cancer,in vitro and in vivo,Low,Sensitive,-,-,2014,miRNA expression patterns in chemoresistant breast cancer tissues,"As illustrated in Fig. 4, compared to the parental MCF-7 cell line, 6 miRNAs (miR-200a, miR-141, miR-200c, miR-31, miR-429, and miR-196b) were up-regulated, and 7 miRNAs (let-7e, miR-576-3p, miR-125b-1, miR-370, miR-145, miR-765, and miR-760) were down-regulated in MCF-7/Adr cells."
25451164,miR-141,hsa-mir-141,MI0000457,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-/ADR,-,Patientss,breast cancer,in vitro and in vivo,Low,Resistant,-,-,2014,miRNA expression patterns in chemoresistant breast cancer tissues,"As illustrated in Fig. 4, compared to the parental MCF-7 cell line, 6 miRNAs (miR-200a, miR-141, miR-200c, miR-31, miR-429, and miR-196b) were up-regulated, and 7 miRNAs (let-7e, miR-576-3p, miR-125b-1, miR-370, miR-145, miR-765, and miR-760) were down-regulated in MCF-7/Adr cells."
25451164,miR-145,hsa-mir-145,MI0000461,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-/ADR,-,Patientss,breast cancer,in vitro and in vivo,Low,Sensitive,-,-,2014,miRNA expression patterns in chemoresistant breast cancer tissues,"As illustrated in Fig. 4, compared to the parental MCF-7 cell line, 6 miRNAs (miR-200a, miR-141, miR-200c, miR-31, miR-429, and miR-196b) were up-regulated, and 7 miRNAs (let-7e, miR-576-3p, miR-125b-1, miR-370, miR-145, miR-765, and miR-760) were down-regulated in MCF-7/Adr cells."
25451164,miR-196b,hsa-mir-196b,MI0001150,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-/ADR,-,Patientss,breast cancer,in vitro and in vivo,Low,Resistant,-,-,2014,miRNA expression patterns in chemoresistant breast cancer tissues,"As illustrated in Fig. 4, compared to the parental MCF-7 cell line, 6 miRNAs (miR-200a, miR-141, miR-200c, miR-31, miR-429, and miR-196b) were up-regulated, and 7 miRNAs (let-7e, miR-576-3p, miR-125b-1, miR-370, miR-145, miR-765, and miR-760) were down-regulated in MCF-7/Adr cells."
25451164,miR-200a,hsa-mir-200a,MI0000737,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-/ADR,-,Patientss,breast cancer,in vitro and in vivo,Low,Resistant,-,-,2014,miRNA expression patterns in chemoresistant breast cancer tissues,"As illustrated in Fig. 4, compared to the parental MCF-7 cell line, 6 miRNAs (miR-200a, miR-141, miR-200c, miR-31, miR-429, and miR-196b) were up-regulated, and 7 miRNAs (let-7e, miR-576-3p, miR-125b-1, miR-370, miR-145, miR-765, and miR-760) were down-regulated in MCF-7/Adr cells."
25451164,miR-200c,hsa-mir-200c,MI0000650,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-/ADR,-,Patientss,breast cancer,in vitro and in vivo,Low,Resistant,-,-,2014,miRNA expression patterns in chemoresistant breast cancer tissues,"As illustrated in Fig. 4, compared to the parental MCF-7 cell line, 6 miRNAs (miR-200a, miR-141, miR-200c, miR-31, miR-429, and miR-196b) were up-regulated, and 7 miRNAs (let-7e, miR-576-3p, miR-125b-1, miR-370, miR-145, miR-765, and miR-760) were down-regulated in MCF-7/Adr cells."
25451164,miR-31,hsa-mir-31,MI0000089,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-/ADR,-,Patientss,breast cancer,in vitro and in vivo,Low,Resistant,-,-,2014,miRNA expression patterns in chemoresistant breast cancer tissues,"As illustrated in Fig. 4, compared to the parental MCF-7 cell line, 6 miRNAs (miR-200a, miR-141, miR-200c, miR-31, miR-429, and miR-196b) were up-regulated, and 7 miRNAs (let-7e, miR-576-3p, miR-125b-1, miR-370, miR-145, miR-765, and miR-760) were down-regulated in MCF-7/Adr cells."
25451164,miR-370,hsa-mir-370,MI0000778,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-/ADR,-,Patientss,breast cancer,in vitro and in vivo,Low,Sensitive,-,-,2014,miRNA expression patterns in chemoresistant breast cancer tissues,"As illustrated in Fig. 4, compared to the parental MCF-7 cell line, 6 miRNAs (miR-200a, miR-141, miR-200c, miR-31, miR-429, and miR-196b) were up-regulated, and 7 miRNAs (let-7e, miR-576-3p, miR-125b-1, miR-370, miR-145, miR-765, and miR-760) were down-regulated in MCF-7/Adr cells."
25451164,miR-429,hsa-mir-429,MI0001641,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-/ADR,-,Patientss,breast cancer,in vitro and in vivo,Low,Resistant,-,-,2014,miRNA expression patterns in chemoresistant breast cancer tissues,"As illustrated in Fig. 4, compared to the parental MCF-7 cell line, 6 miRNAs (miR-200a, miR-141, miR-200c, miR-31, miR-429, and miR-196b) were up-regulated, and 7 miRNAs (let-7e, miR-576-3p, miR-125b-1, miR-370, miR-145, miR-765, and miR-760) were down-regulated in MCF-7/Adr cells."
25451164,miR-576,hsa-mir-576,MI0003583,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-/ADR,-,Patientss,breast cancer,in vitro and in vivo,Low,Sensitive,-,-,2014,miRNA expression patterns in chemoresistant breast cancer tissues,"As illustrated in Fig. 4, compared to the parental MCF-7 cell line, 6 miRNAs (miR-200a, miR-141, miR-200c, miR-31, miR-429, and miR-196b) were up-regulated, and 7 miRNAs (let-7e, miR-576-3p, miR-125b-1, miR-370, miR-145, miR-765, and miR-760) were down-regulated in MCF-7/Adr cells."
25451164,miR-760,hsa-mir-760,MI0005567,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-/ADR,-,Patientss,breast cancer,in vitro and in vivo,Low,Sensitive,-,-,2014,miRNA expression patterns in chemoresistant breast cancer tissues,"As illustrated in Fig. 4, compared to the parental MCF-7 cell line, 6 miRNAs (miR-200a, miR-141, miR-200c, miR-31, miR-429, and miR-196b) were up-regulated, and 7 miRNAs (let-7e, miR-576-3p, miR-125b-1, miR-370, miR-145, miR-765, and miR-760) were down-regulated in MCF-7/Adr cells."
25451164,miR-765,hsa-mir-765,MI0005116,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-/ADR,-,Patientss,breast cancer,in vitro and in vivo,Low,Sensitive,-,-,2014,miRNA expression patterns in chemoresistant breast cancer tissues,"As illustrated in Fig. 4, compared to the parental MCF-7 cell line, 6 miRNAs (miR-200a, miR-141, miR-200c, miR-31, miR-429, and miR-196b) were up-regulated, and 7 miRNAs (let-7e, miR-576-3p, miR-125b-1, miR-370, miR-145, miR-765, and miR-760) were down-regulated in MCF-7/Adr cells."
25465153,miR-96,hsa-mir-96,MI0000098,Cisplatin,2767,"TE-1, ECa-109 and EC-9706",-,-,-,esophageal cancer,in vitro,Low,Resistant,RECK,-,2014,MiR-96 promotes proliferation and chemo- or radioresistance by down-regulating RECK in esophageal cancer.,Up-regulation of miR-96 promotes the chemo- or radioresistance of EC cells.
25474084,miR-222,hsa-mir-222,MI0000299,Cisplatin,2767,UM1,-,-,-,oral squamous cell carcinoma,in vitro,Low,Resistant,PUMA,-,2014,MiR-222 targeted PUMA to improve sensitization of UM1 cells to cisplatin.,"Analysis of the above data suggested that, in UM1 cells, there might be a regulatory loop between miR-222 and PUMA, and that miR-222 inhibition increased the chemosensitivity to CDDP."
25482209,miR-136,hsa-mir-136,MI0000475,Cisplatin,2767,OV2008 and C13,-,-,Patients,ovarian cancer,in vitro and in vivo,Low,Sensitive,-,-,2015,Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer.,Our findings suggest that miR-136 may function as an anti-oncogene and deficiency of miR-136 expression in ovarian cancer can induce chemoresistance at least in part by downregulating apoptosis and promoting the repair of cisplatin-induced DNA damage.
25492481,miR-143,hsa-mir-143,MI0000459,Cisplatin,2767,-,SGC7901 vs SGC7901/CDDP,-,-,gastric cancer,in vitro,Low,Sensitive,IGF1R and BCL2,-,2015,Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2.,Our findings suggested that hsa-miR-143 could modulate cisplatin resistance of human gastric cancer cell line at least in part by targeting IGF1R and BCL2.
25501015,miR-23a,hsa-mir-23a,MI0000079,Cisplatin,2767,SCC-4 and Tca8113,-,-,-,tongue squamous cell carcinoma,in vitro,Low,Resistant,Twist,-,2015,miR-23a promotes cisplatin chemoresistance and protects against cisplatin-induced apoptosis in tongue squamous cell carcinoma cells through Twist.,"In conclusion, the present study for the first time demonstrates that miR-23a promotes cisplatin chemoresistance and protects cisplatin-induced apoptosis in TSCC cells through inducing Twist expression by a JNK-dependent mechanism."
25502560,miR-96,hsa-mir-96,MI0000098,5-Fluorouracil,3385,"HT-29, DLD-1 and HCT-116",-,-,-,colorectal cancer,in vitro,Low,Sensitive,-,XIAP and UBE2N,2015,Indirect modulation of sensitivity to 5-fluorouracil by microRNA-96 in human colorectal cancer cells.,"When the level of miR-96 increased, the expression of the anti-apoptotic regulator XIAP and p53 stability regulator UBE2N decreased, resulting in increased apoptosis and growth inhibition following 5-FU exposure."
25503932,miR-7,hsa-mir-7-1,MI0000263,Cetuximab,91820602,"HCT116, SW480 and HT29",-,-,-,colorectal cancer,in vitro,Low,Sensitive,EGFR and RAF-1,-,2015,MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation.,miR-7 regulates cetuximab sensitivity in cetuximab-resistant HCT116 and SW480 cells with a KRAS mutation and HT29 cells with a BRAF mutation.
25510179,miR-126,hsa-mir-126,MI0000471,Epigallocatechin Gallate,65064,MG63 and U2OS,-,-,-,osteosarcoma,in vitro,Low,Sensitive,-,-,2014,Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate.,Overexpression of miR-126 enhanced the inhibitory effects of EGCG on proliferation in U2OS cells via promotion of apoptosis.
25514838,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,-,Tca8113 vs Tca8113/CDDP,Mice,Patients,oral squamous cell carcinoma,in vitro and in vivo,Low,Associated,"PTEN, TIMP3 and PDCD4",-,2014,WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis.,"STAT3 mediated OSCC cell survival and DDP resistance through upregulating the expression of miR-21 and downregulating miR-21 downstream targets, including PTEN, TIMP3 and PDCD4. "
25515700,miR-203,hsa-mir-203a,MI0000283,Temozolomide,5394,U87MG,-,-,-,glioma,in vitro,Low,Sensitive,E2F3,-,2015,MiR-203 sensitizes glioma cells to temozolomide and inhibits glioma cell invasion by targeting E2F3.,Restoration of miR-203 expression additionally sensitized the cells to temozolomide (TMZ) as determined by MTS assay.
25515961,miR-486,hsa-mir-486-1,MI0002470,Imatinib,5291,TF1-Ba and TF1,-,-,-,chronic myeloid leukemia,in vitro,Low,Sensitive,"FoxO1, PTEN, ARID4B, and PI3KP",-,2016,MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors,Inhibition of miR-486-5p enhances the sensitivity of CML progenitors to IM-mediated apoptosis.
25531114,miR-338,hsa-mir-338,MI0000814,Sorafenib,216239,"HepG2, SMMC7721, Huh-7; Mice",-,-,-,hepatocarcinoma,in vitro,Low,Sensitive,HIF-1alpha,-,2014,MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1alpha.,"Furthermore, miR-338-3p sensitized HCC cells to sorafenib in vitro and in a HCC subcutaneous nude mice tumor model by inhibiting HIF-1alpha."
25531331,miR-873,-,-,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM,-,-,breast cancer,in vitro,Low,Sensitive,CDK3,-,2015,MiR-873 regulates ERalpha transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells.,"More importantly, re-expression of miR-873 reversed tamoxifen resistance in MCF-7/TamR cells."
25532106,miR-7,hsa-mir-7-1,MI0000263,Trastuzumab,9903,MCF-7,-,-,-,breast cancer,in vitro,Low,Sensitive,-,EGFR and Src kinase,2014,MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2delta16 mediated breast tumorigenesis and reverse trastuzumab resistance.,Our results demonstrate that reestablished miR-7 expression abolishes HER2delta16 induced cell proliferation and migration while sensitizing HER2delta16 expressing cells to trastuzumab therapy.
25542424,miR-193a,hsa-mir-193a,MI0000487,Cisplatin,2767,5637 and H-bc,-,-,-,bladder cancer,in vitro,Low,Resistant,PSEN1,DNA damage response pathway,2015,The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer.,"As a direct target of microRNA-193a-3p that promotes the multi-chemoresistance of the bladder cancer cell, PSEN1 acts as an important executor for the microRNA-193a-3p's positive impact on the multi-chemoresistance of bladder cancer, probably via its activating effect on DNA damage response pathway."
25542424,miR-193a,hsa-mir-193a,MI0000487,Doxorubicin (Adriamycin),31703,5637 and H-bc,-,-,-,bladder cancer,in vitro,Low,Resistant,PSEN1,DNA damage response pathway,2015,The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer.,"As a direct target of microRNA-193a-3p that promotes the multi-chemoresistance of the bladder cancer cell, PSEN1 acts as an important executor for the microRNA-193a-3p's positive impact on the multi-chemoresistance of bladder cancer, probably via its activating effect on DNA damage response pathway."
25542424,miR-193a,hsa-mir-193a,MI0000487,Epirubicin HCl,65348,5637 and H-bc,-,-,-,bladder cancer,in vitro,Low,Resistant,PSEN1,DNA damage response pathway,2015,The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer.,"As a direct target of microRNA-193a-3p that promotes the multi-chemoresistance of the bladder cancer cell, PSEN1 acts as an important executor for the microRNA-193a-3p's positive impact on the multi-chemoresistance of bladder cancer, probably via its activating effect on DNA damage response pathway."
25542424,miR-193a,hsa-mir-193a,MI0000487,Paclitaxel,36314,5637 and H-bc,-,-,-,bladder cancer,in vitro,Low,Resistant,PSEN1,DNA damage response pathway,2015,The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer.,"As a direct target of microRNA-193a-3p that promotes the multi-chemoresistance of the bladder cancer cell, PSEN1 acts as an important executor for the microRNA-193a-3p's positive impact on the multi-chemoresistance of bladder cancer, probably via its activating effect on DNA damage response pathway."
25542424,miR-193a,hsa-mir-193a,MI0000487,Pirarubicin,636397,5637 and H-bc,-,-,-,bladder cancer,in vitro,Low,Resistant,PSEN1,DNA damage response pathway,2015,The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer.,"As a direct target of microRNA-193a-3p that promotes the multi-chemoresistance of the bladder cancer cell, PSEN1 acts as an important executor for the microRNA-193a-3p's positive impact on the multi-chemoresistance of bladder cancer, probably via its activating effect on DNA damage response pathway."
25551563,miR-145,hsa-mir-145,MI0000461,Cisplatin,2767,FLO-1,-,-,-,esophageal adenocarcinoma,in vitro,Low,Sensitive,-,-,2014,MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance.,"In FLO-1 cells, miR-145 enhanced the effect of cisplatin but had no effect on 5-FU resistance."
25551563,miR-145,hsa-mir-145,MI0000461,Cisplatin,2767,SK-GT-4,-,-,-,esophageal adenocarcinoma,in vitro,Low,Resistant,-,-,2014,MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance.,"However, miR-145 protected SK-GT-4 cells against cisplatin but not against 5-FU."
25556489,miR-340,hsa-mir-340,MI0000802,Cisplatin,2767,-,HepG2 vs HepG2/ CDDP,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,Nrf2,-,2014,miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway.,miR-340 mimics suppressing Nrf2-dependent antioxidant pathway and enhancing the sensitivity of HepG2/ CDDP cells to cisplatin.
25560734,miR-574,hsa-mir-574,MI0003581,Tamoxifen,2733526,MCF-7,-,-,-,breast cancer,in vitro,Low,Sensitive,CLTC,-,2015,"MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer.",Knockdown of miR-574-3p reverses tamoxifen-dependent suppression of cell growth in MCF-7 cells.
25562151,miR-125b,hsa-mir-125b-1,MI0000446,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-125b,hsa-mir-125b-1,MI0000446,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-145,hsa-mir-145,MI0000461,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-145,hsa-mir-145,MI0000461,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-152,hsa-mir-152,MI0000462,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-152,hsa-mir-152,MI0000462,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-155,hsa-mir-155,MI0000681,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-155,hsa-mir-155,MI0000681,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-181a,hsa-mir-181a-2,MI0000269,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-181a,hsa-mir-181a-2,MI0000269,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-193b,hsa-mir-193b,MI0003137,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-193b,hsa-mir-193b,MI0003137,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-200c,hsa-mir-200c,MI0000650,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-200c,hsa-mir-200c,MI0000650,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-222,hsa-mir-222,MI0000299,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-222,hsa-mir-222,MI0000299,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-29a,hsa-mir-29a,MI0000087,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-29a,hsa-mir-29a,MI0000087,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-320d,hsa-mir-320d-1,MI0008190,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-320d,hsa-mir-320d-1,MI0008190,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-34a,hsa-mir-34a,MI0000268,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-34a,hsa-mir-34a,MI0000268,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-424,hsa-mir-424,MI0001446,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-424,hsa-mir-424,MI0001446,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-4284,hsa-mir-4284,MI0015893,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-4284,hsa-mir-4284,MI0015893,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-452,hsa-mir-452,MI0001733,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-452,hsa-mir-452,MI0001733,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-455,hsa-mir-455,MI0003513,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-455,hsa-mir-455,MI0003513,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-500,hsa-mir-500a,MI0003184,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-500,hsa-mir-500a,MI0003184,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Resistant,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-503,hsa-mir-503,MI0003188,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-503,hsa-mir-503,MI0003188,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-767,hsa-mir-767,MI0003763,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25562151,miR-767,hsa-mir-767,MI0003763,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,High,Sensitive,-,-,2014,beta-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression,"Among the 322 miRNAs, 6 miRNAs were up-regulated, and 12 miRNAs were downregulated in both MCF-7/Adr and MCF-7/Doc cells significantly (criteria differences for Ratio > 4.0 or < 0.2, compared to MCF-7) (Table 1)."
25563770,miR-21,hsa-mir-21,MI0000077,Dibenziodolium,3101,A549 and 95D,-,Mice,-,lung cancer,in vitro and in vivo,Low,Resistant,PTEN,-,2015,Inhibition of NADPH oxidase protects against metastasis of human lung cancer by decreasing microRNA-21.,Increased expression of miR-21 abrogated the effect of NOX inhibitor on metastasis of human lung cancer in vitro and in vivo.
25576341,miR-143,hsa-mir-143,MI0000459,Doxorubicin (Adriamycin),31703,-,SAOS-2 vs SAOS-2/ADR and U2OS vs U2OS/ADR,Mice,-,osteosarcoma,in vitro and in vivo,Low,Sensitive,-,"ATG2B, Bcl-2, and LC3-I",2015,microRNA-143 is associated with the survival of ALDH1+CD133+ osteosarcoma cells and the chemoresistance of osteosarcoma.,"The chemoresistance of osteosarcoma tumor cells to doxorubicin is associated with the downregulation of miR-143 expression, activation of ALDH1(+)CD133(+) cells, activation of autophagy, and inhibition of cell death."
25579119,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,"A2780, CP70, OVCAR5, OVCAR8 and IGROV1",-,-,-,ovarian cancer,in vitro,Low,Resistant,NAV3,-,2015,"The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.","Our data suggest that miR-21-3p can induce cisplatin resistance in ovarian tumours, potentially by targeting the NAV3 gene."
25586125,miR-542,hsa-mir-542,MI0003686,Trastuzumab,9903,SKBr-3 and MCF-7,-,-,-,breast cancer,in vitro,Low,Sensitive,-,PI3K?akt pathway,2015,MiRNA?542?3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation.,"Furthermore, knockdown of miRNA?542?3p in the two cell lines resulted in decreased drug sensitivity to trastuzumab and cell apoptosis. "
25586740,miR-10a,hsa-mir-10a,MI0000266,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung cancer,in vitro,Low,Resistant,-,"Bcl-2, Survivin, RhoE and caspase-3/8",2015,MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-Beta/Smad2/STAT3/STAT5 pathway.,"In the present study, miR?10a silencing in human DDP-resistant lung cancer A549/DDP cells was demonstrated to improve DDP sensitivity."
25592039,miR-29b,hsa-mir-29b-1,MI0000105,Interferon-gamma,-,"HCT116, HT29, LS174T, SW480,SW620 and HEK293",-,-,-,colorectal cancer,in vitro,Low,Sensitive,IGF1,-,2015,IFN-gamma-mediated IRF1/miR-29b feedback loop suppresses colorectal cancer cell growth and metastasis by repressing IGF1.,"Moreover, miR-29b increased IRF1 expression, and the inhibition of miR-29b suppressed IFN-gamma-induced apoptosis."
25595896,miR-9,hsa-mir-9-1,MI0000466,Temozolomide,5394,U87 and T98G,-,-,-,glioblastoma,in vitro,Low,Resistant,PTCH1,-,2015,"Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.","Taken together, miR-9 targets PTCH1 in GBM cells by a SHH-independent method in GBM cells for TMZ resistance."
25613625,miR-23a,hsa-mir-23a,MI0000079,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,Low,Resistant,-,the cellular expression of P-gp protein was significantly reduced as the cisplatin doses increased,2015,Inhibition of microRNA-23a increases cisplatin sensitivity of ovarian cancer cells: the possible molecular mechanisms,Inhibition of miR-23a expression increases the sensitivity of A2780 cells to cisplatin possibly by inhibiting the negative regulation by miR-23a target genes that causes inhibition of P-gp protein expression.
25616665,miR-27a,hsa-mir-27a,MI0000085,5-Fluorouracil,3385,"RKO, HCT-116, FET and GEO",-,Mice,-,bladder cancer,in vitro and in vivo,Low,Sensitive,RUNX-1,-,2015,rs11671784 G/A variation in miR-27a decreases chemo-sensitivity of bladder cancer by decreasing miR-27a and increasing the target RUNX-1 expression.,"This study identified a causative relationship between rs11671784 G/A variation, lowered miR-27a expression, increased RUNX-1 expression and following weakened chemo-sensitivity."
25623761,miR-34a,hsa-mir-34a,MI0000268,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR ,-,-,breast cancer,in vitro,Low,Sensitive,Notch1,-,2014,miR-34a may regulate sensitivity of breast cancer cells to adriamycin via targeting Notch1,"Further, overexpression of miR-34a significantly enhanced apoptosis in the ADR-treated MCF-7/ADR cells, and miR-34a inhibitor reduced apoptosis in the ADR-treated MCF-7 cells."
25623762,miR-15a,hsa-mir-15a,MI0000069,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colon cancer,in vitro,Low,Sensitive,Bcl-2,-,2014,miR-15a and miR-16 modulate drug resistance by targeting bcl-2 in human colon cancer cells,"The survival rates of HCT8/VCR cells were basically the same in the blank control group, negative control group, miR-15a mimic group and miR-16 mimic group, but the survival rate of HCT8/VCR cells was significantly decreased after transfection of mimics."
25623762,miR-16,hsa-mir-16-1,MI0000070,Vincristine,5978,-,HCT8 vs HCT8/VCR,-,-,colon cancer,in vitro,Low,Sensitive,Bcl-2,-,2014,miR-15a and miR-16 modulate drug resistance by targeting bcl-2 in human colon cancer cells,"The survival rates of HCT8/VCR cells were basically the same in the blank control group, negative control group, miR-15a mimic group and miR-16 mimic group, but the survival rate of HCT8/VCR cells was significantly decreased after transfection of mimics."
25625875,miR-21,hsa-mir-21,MI0000077,Doxorubicin (Adriamycin),31703,"U87, U87 EGFRvIII and LN229",-,-,-,glioblastoma,in vitro,Low,Resistant,-,"E-cadherin, RECK, PTEN and VHL",2015,Combination treatment with doxorubicin and microRNA-21 inhibitor synergistically augments anticancer activity through upregulation of tumor suppressing genes.,"Moreover, we demonstrate that combining DOX and miR-21i significantly reduced tumor cell proliferation, invasion and migration in vitro."
25628933,miR-21,hsa-mir-21,MI0000077,Doxorubicin (Adriamycin),31703,"A172, U87MG and T98G",-,-,-,glioblastoma,in vitro,Low,Resistant,-,-,2014,Anti-miR21 oligonucleotide enhances chemosensitivity of T98G cell line to doxorubicin by inducing apoptosis.,"Transfected cells showed a high apoptotic rate compared to control after Dox treatment by TUNEL assay, suggesting that combined Dox and miR-21 inhibitor therapy can sensitize GBM resistant cells to anthracyclines by enhancing apoptosis."
25638153,miR-223,hsa-mir-223,MI0000300,Gemcitabine,60750,-,AsPC-1 vs AsPC-1/GR and PANC-1 vs PANC-1/GR,-,-,pancreatic cancer,in vitro,Low,Resistant,Fbw7,Notch-1,2015,Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.,Down-regulation of miR-223 enhances GR cells to gemcitabine sensitivity.
25641148,miR-181a,hsa-mir-181a-2,MI0000269,Camptothecin,24360,CEM-C1,-,-,-,pediatric acute lymphoblastic leukemia,in vitro,Low,Resistant,-,-,2015,The expression and functional study of miR-181a in pediatric acute lymphoblastic leukemia,"Upregulation of miR-181a might play an important role in the development of drug resistance in CEM-C1 cells, and knockdown of miR-181a could sensitize CEM-C1 cells to camptothecin"
25656571,miR-27a,hsa-mir-27a,MI0000085,Cisplatin,2767,"UM-UC-3, H-bc, RT-4, T24 and 5637",-,-,Patients,bladder cancer,in vitro and in vivo,Low,Sensitive,RUNX-1,-,2015,rs11671784 G/A variation in miR-27a decreases chemo-sensitivity of bladder cancer by decreasing miR-27a and increasing the target RUNX-1 expression.,miR-27a mediates chemotherapy at least partially through reducing P-gp expression and increasing apoptosis.
25656571,miR-27a,hsa-mir-27a,MI0000085,Doxorubicin (Adriamycin),31703,"UM-UC-3, H-bc, RT-4, T24 and 5637",-,-,Patients,bladder cancer,in vitro and in vivo,Low,Sensitive,RUNX-1,-,2015,rs11671784 G/A variation in miR-27a decreases chemo-sensitivity of bladder cancer by decreasing miR-27a and increasing the target RUNX-1 expression.,miR-27a mediates chemotherapy at least partially through reducing P-gp expression and increasing apoptosis.
25656571,miR-27a,hsa-mir-27a,MI0000085,Paclitaxel,36314,"UM-UC-3, H-bc, RT-4, T24 and 5637",-,-,Patients,bladder cancer,in vitro and in vivo,Low,Sensitive,RUNX-1,-,2015,rs11671784 G/A variation in miR-27a decreases chemo-sensitivity of bladder cancer by decreasing miR-27a and increasing the target RUNX-1 expression.,miR-27a mediates chemotherapy at least partially through reducing P-gp expression and increasing apoptosis.
25661353,miR-760,hsa-mir-760,MI0005567,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Sensitive,-,-,2015,Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin.,"Compared to parental cell line MCF-7, miR-760 was downregulated by 6.15 folds in MCF-7/Adr cells. "
25661374,miR-145,hsa-mir-145,MI0000461,chemotherapy,-,-,-,-,Patients,non-small cell lung cancer,in vivo,Low,Sensitive,-,-,2015,Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer.,"Down-regulation of miR-145 was correlated with late clinical stage and poorly differentiated carcinoma, and, low expression level of miR-145 could also predict chemotherapy resistance and shorter disease-free survival (DFS)."
25669981,let-7a,hsa-let-7a-1,MI0000060,Doxorubicin (Adriamycin),31703,MDA-MB-231,-,-,-,breast cancer,in vitro,Low,Sensitive,-,redox pathway,2015,Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA.,We combined let-7a transfection with the chemotherapeutic drug doxorubicin. In both cancer types let-7a increased cell sensitivity to doxorubicin.
25669981,let-7a,hsa-let-7a-1,MI0000060,Doxorubicin (Adriamycin),31703,WM239,-,-,-,melanoma,in vitro,Low,Sensitive,-,redox pathway,2015,Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA.,We combined let-7a transfection with the chemotherapeutic drug doxorubicin. In both cancer types let-7a increased cell sensitivity to doxorubicin.
25687041,miR-10a,hsa-mir-10a,MI0000266,Doxorubicin (Adriamycin),31703,-,HL-60 vs HL-60/ADR,-,Patients,acute myeloid leukemia,in vitro and in vivo,Low,Resistant,-,-,2015,MicroRNA-10a expression in FAB different subtype of acute myeloid leukemia and its relationship with drug resistance,HL-60/ADR cell line showed higher miR-10a expression than that in HL-60 cell line.
25698578,miR-101,hsa-mir-101-1,MI0000103,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-10a*,hsa-mir-10a,MI0000266,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-1226,hsa-mir-1226,MI0006313,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-1226*,hsa-mir-1226,MI0006313,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-1228*,hsa-mir-1228,MI0006318,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-1233,hsa-mir-1233-1,MI0006323,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-1234,hsa-mir-1234,MI0006324,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-124,hsa-mir-124-1,MI0000443,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-1253,hsa-mir-1253,MI0006387,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-1265,hsa-mir-1265,MI0006401,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-127,hsa-mir-127,MI0000472,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-129,hsa-mir-129-1,MI0000252,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-1299,hsa-mir-1299,MI0006359,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-137,hsa-mir-137,MI0000454,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-138,hsa-mir-138-1,MI0000476,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-139,hsa-mir-139,MI0000261,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-140,hsa-mir-140,MI0000456,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-148a,hsa-mir-148a,MI0000253,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-1538,hsa-mir-1538,MI0007259,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-1539,hsa-mir-1539,MI0007260,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-15a*,hsa-mir-15a,MI0000069,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-17*,hsa-mir-17,MI0000071,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-183,hsa-mir-183,MI0000273,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-185,hsa-mir-185,MI0000482,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-18b,hsa-mir-18b,MI0001518,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-1911,hsa-mir-1911,MI0008332,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-1911*,hsa-mir-1911,MI0008332,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-1915,hsa-mir-1915,MI0008336,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-1915*,hsa-mir-1915,MI0008336,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-193b,hsa-mir-193b,MI0003137,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-203,hsa-mir-203a,MI0000283,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-20a,hsa-mir-20a,MI0000076,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-20a*,hsa-mir-20a,MI0000076,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-20b,hsa-mir-20b,MI0001519,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-20b*,hsa-mir-20b,MI0001519,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-21*,hsa-mir-21,MI0000077,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-210,hsa-mir-210,MI0000286,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-211,hsa-mir-211,MI0000287,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-214,hsa-mir-214,MI0000290,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-215,hsa-mir-215,MI0000291,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-23b*,hsa-mir-23b,MI0000439,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-25*,hsa-mir-25,MI0000082,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-27b,hsa-mir-27b,MI0000440,Cisplatin,2767,ACHN,-,-,-,kidney cancer,in vitro,Low,Sensitive,CCNG1,P53 and CYP1B1,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. Notably, miR-27b promotes drug response specifically in Patient carrying p53-wild-type or CYP1B1-high signature."
25698578,miR-27b,hsa-mir-27b,MI0000440,Cisplatin,2767,HepG2,-,-,-,liver cancer,in vitro,Low,Sensitive,CCNG1,P53 and CYP1B1,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. Notably, miR-27b promotes drug response specifically in Patient carrying p53-wild-type or CYP1B1-high signature."
25698578,miR-27b,hsa-mir-27b,MI0000440,Doxorubicin (Adriamycin),31703,"ACHN, 786-O, 769-P and Caki-1",-,Mice,-,kidney cancer,in vitro and in vivo,Low,Sensitive,CCNG1,P53 and CYP1B1,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. Notably, miR-27b promotes drug response specifically in Patient carrying p53-wild-type or CYP1B1-high signature."
25698578,miR-27b,hsa-mir-27b,MI0000440,Doxorubicin (Adriamycin),31703,"HepG2, SNU-182, SNU-739 and Tong",-,Mice,Patients,liver cancer,in vitro and in vivo,Low,Sensitive,CCNG1,P53 and CYP1B1,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. Notably, miR-27b promotes drug response specifically in Patient carrying p53-wild-type or CYP1B1-high signature."
25698578,miR-27b,hsa-mir-27b,MI0000440,Epirubicin,41867,ACHN,-,-,-,kidney cancer,in vitro,Low,Sensitive,CCNG1,P53 and CYP1B1,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. Notably, miR-27b promotes drug response specifically in Patient carrying p53-wild-type or CYP1B1-high signature."
25698578,miR-27b,hsa-mir-27b,MI0000440,Epirubicin,41867,HepG2,-,-,-,liver cancer,in vitro,Low,Sensitive,CCNG1,P53 and CYP1B1,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. Notably, miR-27b promotes drug response specifically in Patient carrying p53-wild-type or CYP1B1-high signature."
25698578,miR-27b,hsa-mir-27b,MI0000440,Etoposide,36462,ACHN,-,-,-,kidney cancer,in vitro,Low,Sensitive,CCNG1,P53 and CYP1B1,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. Notably, miR-27b promotes drug response specifically in Patient carrying p53-wild-type or CYP1B1-high signature."
25698578,miR-27b,hsa-mir-27b,MI0000440,Etoposide,36462,HepG2,-,-,-,liver cancer,in vitro,Low,Sensitive,CCNG1,P53 and CYP1B1,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. Notably, miR-27b promotes drug response specifically in Patient carrying p53-wild-type or CYP1B1-high signature."
25698578,miR-27b,hsa-mir-27b,MI0000440,Gefitinib,123631,ACHN,-,-,-,kidney cancer,in vitro,Low,Sensitive,CCNG1,P53 and CYP1B1,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. Notably, miR-27b promotes drug response specifically in Patient carrying p53-wild-type or CYP1B1-high signature."
25698578,miR-27b,hsa-mir-27b,MI0000440,Gefitinib,123631,HepG2,-,-,-,liver cancer,in vitro,Low,Sensitive,CCNG1,P53 and CYP1B1,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. Notably, miR-27b promotes drug response specifically in Patient carrying p53-wild-type or CYP1B1-high signature."
25698578,miR-27b,hsa-mir-27b,MI0000440,Sorafenib,216239,ACHN,-,-,-,kidney cancer,in vitro,Low,Sensitive,CCNG1,P53 and CYP1B1,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. Notably, miR-27b promotes drug response specifically in Patient carrying p53-wild-type or CYP1B1-high signature."
25698578,miR-27b,hsa-mir-27b,MI0000440,Sorafenib,216239,HepG2,-,-,-,liver cancer,in vitro,Low,Sensitive,CCNG1,P53 and CYP1B1,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"Functionally, miR-27b enhances drug response by activating p53-dependent apoptosis and reducing CYP1B1-mediated drug detoxification. Notably, miR-27b promotes drug response specifically in Patient carrying p53-wild-type or CYP1B1-high signature."
25698578,miR-28,hsa-mir-28,MI0000086,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-326,hsa-mir-326,MI0000808,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-338,hsa-mir-338,MI0000814,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-342,hsa-mir-342,MI0000805,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-34c,hsa-mir-34c,MI0000743,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-367,hsa-mir-367,MI0000775,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-371,hsa-mir-371a,MI0000779,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-372,hsa-mir-372,MI0000780,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-379,hsa-mir-379,MI0000787,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-380,hsa-mir-380,MI0000788,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-409,hsa-mir-409,MI0001735,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-455,hsa-mir-455,MI0003513,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-485,hsa-mir-485,MI0002469,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-495,hsa-mir-495,MI0003135,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-503,hsa-mir-503,MI0003188,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-513a,hsa-mir-513a-1,MI0003191,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-513c,hsa-mir-513c,MI0006649,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-520c,hsa-mir-519b,MI0003151,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-526a,hsa-mir-526a-1,MI0003157,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-577,hsa-mir-577,MI0003584,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-606,hsa-mir-606,MI0003619,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-620,hsa-mir-620,MI0003634,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-621,hsa-mir-621,MI0003635,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-625,hsa-mir-626,MI0003640,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-634,hsa-mir-634,MI0003649,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-635,hsa-mir-635,MI0003650,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-639,hsa-mir-639,MI0003654,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-642a,hsa-mir-642a,MI0003657,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-664*,hsa-mir-664a,MI0006442,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-708,hsa-mir-708,MI0005543,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Sensitive,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,33 miRNAs with Z-scores below -1.65 enhanced the sensitivity of HepG2 cells to doxorubicin (P<0.1)
25698578,miR-769,hsa-mir-769,MI0003834,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-802,hsa-mir-802,MI0003906,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-885,hsa-mir-885,MI0005560,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-886,hsa-mir-886,MI0005527,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-891b,hsa-mir-891b,MI0005534,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-892b,hsa-mir-892b,MI0005538,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-920,hsa-mir-920,MI0005712,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-922,hsa-mir-922,MI0005714,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-924,hsa-mir-924,MI0005716,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-933,hsa-mir-933,MI0005755,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-934,hsa-mir-934,MI0005756,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-935,hsa-mir-935,MI0005757,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25698578,miR-98,hsa-mir-98,MI0000100,Doxorubicin (Adriamycin),31703,HepG2,-,-,Patientss,liver cancer,in vitro and in vivo,High,Resistant,-,-,2015,miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.,"55 miRNAs increased the resistance of HepG2 cells to doxorubicin (Z-score >1.65,P< 0.1)"
25712526,miR-30a,hsa-mir-30a,MI0000088,Sorafenib,216239,"786-0, A498, SK-RC-44 and HK-2",-,-,-,renal cell carcinoma,in vitro,Low,Sensitive,-,-,2015,MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.,Exogenously expressing miR-30a in 786-0 or A489 cells inhibited Beclin-1 expression and enhanced sorafenib-induced cytotoxicity.
25714665,miR-133a,hsa-mir-133a-1,MI0000450,Doxorubicin (Adriamycin),31703,HepG2,-,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,-,ABCC1,2015,Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1.,"Compared with mock transfection, miR-133a or miR-326 mimics transfection sensitized these cells to ADM."
25714665,miR-326,hsa-mir-326,MI0000808,Doxorubicin (Adriamycin),31703,HepG2,-,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,-,ABCC1,2015,Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1.,"Compared with mock transfection, miR-133a or miR-326 mimics transfection sensitized these cells to ADM."
25722110,miR-1247,hsa-mir-1247,MI0006382,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-126,hsa-mir-126,MI0000471,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-1260b,hsa-mir-1260b,MI0014197,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-1261,hsa-mir-1261,MI0006396,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-1287,hsa-mir-1287,MI0006349,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-1301,hsa-mir-1301,MI0003815,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-141,hsa-mir-141,MI0000457,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-1468,hsa-mir-146a,MI0000477,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-146a,hsa-mir-146a,MI0000477,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-152,hsa-mir-152,MI0000462,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-15b,hsa-mir-15b,MI0000438,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-181a-2,hsa-mir-181a-2,MI0000269,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-192,hsa-mir-192,MI0000234,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-193a,hsa-mir-193a,MI0000487,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-210,hsa-mir-210,MI0000286,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-2113,hsa-mir-2113,MI0003939,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-224,hsa-mir-224,MI0000301,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-3139,hsa-mir-3139,MI0014162,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-33b,hsa-mir-33b,MI0003646,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-34c,hsa-mir-34c,MI0000743,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-3611,hsa-mir-3611,MI0016001,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-3676,hsa-mir-3676,MI0016077,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-371a,hsa-mir-371a,MI0000779,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-371b,hsa-mir-371b,MI0017393,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-372,hsa-mir-372,MI0000780,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-373,hsa-mir-373,MI0000781,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-378a,hsa-mir-378a,MI0000786,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-378c,hsa-mir-378c,MI0015825,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-3960,hsa-mir-3960,MI0016964,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-4447,hsa-mir-4447,MI0016790,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-4455,hsa-mir-4455,MI0016801,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-4483,hsa-mir-4483,MI0016844,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-450b,hsa-mir-450b,MI0005531,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-4516,hsa-mir-4516,MI0016882,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-452,hsa-mir-452,MI0001733,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-4521,hsa-mir-4521,MI0016887,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-4644,hsa-mir-4644,MI0017271,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-4650,hsa-mir-4650-1,MI0017277,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-4739,hsa-mir-4739,MI0017377,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-4791,hsa-mir-4791,MI0017438,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-4800,hsa-mir-4800,MI0017448,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-483,hsa-mir-483,MI0002467,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-542,hsa-mir-542,MI0003686,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-576,hsa-mir-576,MI0003583,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-589,hsa-mir-589,MI0003599,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-6087,hsa-mir-6087,MI0020364,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-6134,hsa-mir-6134,MI0021279,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-643,hsa-mir-643,MI0003658,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-675,hsa-mir-675,MI0005416,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Sensitive,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25722110,miR-92b,hsa-mir-92b,MI0003560,Gemcitabine,60750,-,SW1990 vs SW1990/GEM,-,-,pancreatic cancer,in vitro,High,Resistant,-,-,2015,Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells,"Consequently, compared with SW1990 cells, 28 microRNAs were upregulated and 28 microRNAs were decreased (fold change 2) in SW1990/GEM cells (Fig. 3a, Table S2). "
25727016,miR-301a,hsa-mir-301a,MI0000745,Doxorubicin (Adriamycin),31703,U2OS and MG-63,-,-,-,osteosarcoma,in vitro,Low,Resistant,AMPKa1,-,2015,MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1.,"Notably, miR-301a reduced doxorubicin-induced cell apoptosis whereas anti-miR-301a enhanced apoptosis in OS cells, suggesting that up-regulation of miR-301a contributed to chemoresistance of OS cells."
25738863,miR-141,hsa-mir-141,MI0000457,Epoxomicin,11226684,-,Ishikawa vs Ish/EXM ,-,-,endometrial carcinoma,in vitro,Low,Associated,ZEB1,E-cadherin,2015,Proteasome inhibitor-resistant cells cause EMT-induction via suppression of E-cadherin by miR-200 and ZEB1.,"Furthermore, expression of the miR-200 family (miR-200a, miR-200b, miR-200c and miR-141) found in Ishikawa cells was suppressed in Ish/EXM cells."
25738863,miR-200a,hsa-mir-200a,MI0000737,Epoxomicin,11226684,-,Ishikawa vs Ish/EXM ,-,-,endometrial carcinoma,in vitro,Low,Associated,ZEB1,E-cadherin,2015,Proteasome inhibitor-resistant cells cause EMT-induction via suppression of E-cadherin by miR-200 and ZEB1.,"Furthermore, expression of the miR-200 family (miR-200a, miR-200b, miR-200c and miR-141) found in Ishikawa cells was suppressed in Ish/EXM cells."
25738863,miR-200b,hsa-mir-200b,MI0000342,Epoxomicin,11226684,-,Ishikawa vs Ish/EXM ,-,-,endometrial carcinoma,in vitro,Low,Associated,ZEB1,E-cadherin,2015,Proteasome inhibitor-resistant cells cause EMT-induction via suppression of E-cadherin by miR-200 and ZEB1.,"Furthermore, expression of the miR-200 family (miR-200a, miR-200b, miR-200c and miR-141) found in Ishikawa cells was suppressed in Ish/EXM cells."
25738863,miR-200c,hsa-mir-200c,MI0000650,Epoxomicin,11226684,-,Ishikawa vs Ish/EXM ,-,-,endometrial carcinoma,in vitro,Low,Associated,ZEB1,E-cadherin,2015,Proteasome inhibitor-resistant cells cause EMT-induction via suppression of E-cadherin by miR-200 and ZEB1.,"Furthermore, expression of the miR-200 family (miR-200a, miR-200b, miR-200c and miR-141) found in Ishikawa cells was suppressed in Ish/EXM cells."
25756509,miR-100,hsa-mir-100,MI0000102,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Sensitive,-,-,2015,MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo,"Overall, compared to the parental CNE-1 cells, 7 upregulated and 6 downregulated miRNAs were found in CNE-1/Taxol cells (Fig. 2A)."
25756509,miR-1204,hsa-mir-1204,MI0006337,Paclitaxel,36314,-,"CNE-1 vs CNE-1/Taxol, HNE-2 vs HNE-2/Taxol and 5-8F vs 5-8F/Taxol",Mice,-,nasopharyngeal carcinoma,in vitro and in vivo,Low,Sensitive,-,-,2015,MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo.,"We restored miR-1204 expression in the CNE-1/Taxol, HNE-2/Taxol and 5-8F/Taxol cells and found that restoration of miR-1204 re-sensitized the paclitaxel-resistant CNE-1/Taxol, HNE-2/Taxol and 5-8F/Taxol cells to paclitaxel both in vitro."
25756509,miR-208b,hsa-mir-208a,MI0000251,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Resistant,-,-,2015,MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo,"Overall, compared to the parental CNE-1 cells, 7 upregulated and 6 downregulated miRNAs were found in CNE-1/Taxol cells (Fig. 2A)."
25756509,miR-22,hsa-mir-22,MI0000078,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Resistant,-,-,2015,MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo,"Overall, compared to the parental CNE-1 cells, 7 upregulated and 6 downregulated miRNAs were found in CNE-1/Taxol cells (Fig. 2A)."
25756509,miR-3146,hsa-mir-3146,MI0014172,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Resistant,-,-,2015,MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo,"Overall, compared to the parental CNE-1 cells, 7 upregulated and 6 downregulated miRNAs were found in CNE-1/Taxol cells (Fig. 2A)."
25756509,miR-3198,hsa-mir-3198-1,MI0014246,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Sensitive,-,-,2015,MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo,"Overall, compared to the parental CNE-1 cells, 7 upregulated and 6 downregulated miRNAs were found in CNE-1/Taxol cells (Fig. 2A)."
25756509,miR-377,hsa-mir-377,MI0000785,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Resistant,-,-,2015,MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo,"Overall, compared to the parental CNE-1 cells, 7 upregulated and 6 downregulated miRNAs were found in CNE-1/Taxol cells (Fig. 2A)."
25756509,miR-4478,hsa-mir-4478,MI0016831,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Sensitive,-,-,2015,MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo,"Overall, compared to the parental CNE-1 cells, 7 upregulated and 6 downregulated miRNAs were found in CNE-1/Taxol cells (Fig. 2A)."
25756509,miR-4653,hsa-mir-4653,MI0017281,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Sensitive,-,-,2015,MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo,"Overall, compared to the parental CNE-1 cells, 7 upregulated and 6 downregulated miRNAs were found in CNE-1/Taxol cells (Fig. 2A)."
25756509,miR-4678,hsa-mir-4678,MI0017309,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Resistant,-,-,2015,MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo,"Overall, compared to the parental CNE-1 cells, 7 upregulated and 6 downregulated miRNAs were found in CNE-1/Taxol cells (Fig. 2A)."
25756509,miR-4788,hsa-mir-4788,MI0017435,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Resistant,-,-,2015,MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo,"Overall, compared to the parental CNE-1 cells, 7 upregulated and 6 downregulated miRNAs were found in CNE-1/Taxol cells (Fig. 2A)."
25756509,miR-634,hsa-mir-634,MI0003649,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Sensitive,-,-,2015,MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo,"Overall, compared to the parental CNE-1 cells, 7 upregulated and 6 downregulated miRNAs were found in CNE-1/Taxol cells (Fig. 2A)."
25756509,miR-802,hsa-mir-802,MI0003906,Paclitaxel,36314,-,CNE-1 vs CNE-1/Taxol,-,-,nasopharyngeal carcinoma,in vitro,High,Resistant,-,-,2015,MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo,"Overall, compared to the parental CNE-1 cells, 7 upregulated and 6 downregulated miRNAs were found in CNE-1/Taxol cells (Fig. 2A)."
25757925,miR-141,hsa-mir-141,MI0000457,Oxaliplatin,5310940,-,SW620 vs SW620/L-OHP,-,-,colorectal cancer,in vitro,Low,Associated,ZEB1,-,2015,Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells.,The expression levels of miR-200c and miR-141 were markedly lower in L-OHP-resistant SW620 cells than in control SW620 cells.
25757925,miR-200c,hsa-mir-200c,MI0000650,Oxaliplatin,5310940,-,SW620 vs SW620/L-OHP,-,-,colorectal cancer,in vitro,Low,Associated,ZEB1,-,2015,Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells.,The expression levels of miR-200c and miR-141 were markedly lower in L-OHP-resistant SW620 cells than in control SW620 cells.
25759982,miR-126,hsa-mir-126,MI0000471,Cytarabine,6253,KG-1,-,-,-,acute myeloid leukemia,in vitro,Low,Resistant,-,expression of Klotho and phosphorylation of Akt,2015,Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML Patient.,"Transfection of the mimic miR-126-5p into the AML cell line, KG-1, resulted in a decrease in the sensitivity to cytarabin and the expression level of Klotho mRNA as well as the elevation in the phosphorylation of Akt."
25783790,miR-34a,hsa-mir-34a,MI0000268,Paclitaxel,36314,MCF-7,-,-,-,breast cancer,in vitro,Low,Sensitive,Notch1,Notch1 pathway,2015,MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway.,"Furthermore, overexpression of miR-34a increased chemosensitivity of breast cancer cells to paclitaxel (PTX) by downregulating the Notch1 pathway."
25811198,miR-122,hsa-mir-122,MI0000442,Interferon,-,-,-,-,Patients,hepatitis c virus injection,in vivo,Low,Sensitive,-,-,2015,MicroRNAs as predictor markers for response to interferon treatment of chronic hepatitis C genotype-4 in Egyptian Patient.,The expression levels of miR-21 and miR-122 were significantly different between the SVR and NR groups.
25811198,miR-21 ,hsa-mir-21,MI0000077,Interferon,-,-,-,-,Patients,hepatitis c virus injection,in vivo,Low,Sensitive,-,-,2015,MicroRNAs as predictor markers for response to interferon treatment of chronic hepatitis C genotype-4 in Egyptian Patient.,The expression levels of miR-21 and miR-122 were significantly different between the SVR and NR groups.
25813250,miR-141,hsa-mir-141,MI0000457,Docetaxel,148124,-,MCF-7 vs MCF-7/DOC and MDA-MB-231 vs MDA-MB-231/DOC,-,-,breast cancer,in vitro,Low,Resistant,EIF4E,-,2015,miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression.,"By directly targeting the eukaryotic translation initiation factor 4E (EIF4E) mRNA, miR-141 acts on genes that are necessary for drug induced apoptosis rendering the cells drug resistant."
25831546,miR-93,hsa-mir-93,MI0000095,Cisplatin,2767,"2008, C13 and SKOV3",-,-,-,ovarian cancer stem cells,in vitro,Low,Sensitive,Pol-eta,-,2015,Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells.,Enforced expression of miR-93 in ovarian CSCs reduced Pol-eta expression and increased their sensitivity to cisplatin.
25833695,miR-197,hsa-mir-197,MI0000239,Paclitaxel,36314,"SKOV3, IOSE386 and IOSE397",A2780 vs A2780/Taxol,-,-,ovarian cancer,in vitro,Low,Resistant,NLK,-,2015,MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK.,"Meanwhile, repression of miR-197 in ovarian cancer cells can sensitize its response to Taxol and also induced attenuated cell proliferation and invasion ability."
25838542,miR-182,hsa-mir-182,MI0000272,Temozolomide,5394,"U87MG, LNZ308 and LN229",-,-,-,glioblastoma,in vitro,Low,Sensitive,Bcl2L12,-,2015,"miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma.","Repression of Bcl2-like12 (Bcl2L12), c-Met, and hypoxia-inducible factor 2alpha (HIF2A) is of central importance to miR-182 anti-tumor activity, as it results in enhanced therapy susceptibility, decreased GIC sphere size, expansion, and stemness in vitro."
25843291,miR-483,hsa-mir-483,MI0002467,Cisplatin,2767,CAL27 and SCC9,-,Mice,Patients,tongue squamous cell carcinoma,in vitro and in vivo,Low,Resistant,FIS1,-,2015,miR-483-5p determines mitochondrial fission and cisplatin sensitivity in tongue squamous cell carcinoma by targeting FIS1.,We found that FIS1 is a direct target of miR-483-5p and that miR-483-5p can inhibit mitochondrial fission and cisplatin sensitivity in vitro and in vivo.
25846727,miR-21,hsa-mir-21,MI0000077,Gemcitabine,60750,"Mia-PaCa-2, PANC-1 and Hs766T",-,-,-,pancreatic cancer,in vitro,Low,Resistant,p85alpha,PI3K-AKT signaling pathway,2015,p85alpha is a microRNA target and affects chemosensitivity in pancreatic cancer.,"Our results demonstrate that p85alpha expression is a determinant of chemosensitivity in PDAC. Additionally, we provide novel evidence that miR-21 can influence PI3K-AKT signaling via its direct regulation of p85alpha."
25846738,miR-145,hsa-mir-145,MI0000461,Cisplatin,2767,Primary Epithelial Ovarian Cancer Single Cells,-,-,-,primary epithelial ovarian cancer,in vitro,Low,Sensitive,-,-,2015,MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.,"MiR-9, miR-145, and miR-429 were expressed significantly higher in drug-sensitive Patient (n = 26) than in drug-resistant ones (n = 20)."
25846738,miR-429,hsa-mir-429,MI0001641,Cisplatin,2767,Primary Epithelial Ovarian Cancer Single Cells,-,-,-,primary epithelial ovarian cancer,in vitro,Low,Sensitive,-,-,2015,MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.,"MiR-9, miR-145, and miR-429 were expressed significantly higher in drug-sensitive Patient (n?=?26) than in drug-resistant ones (n?=?20)."
25846738,miR-9,hsa-mir-9-1,MI0000466,Cisplatin,2767,Primary Epithelial Ovarian Cancer Single Cells,-,-,-,primary epithelial ovarian cancer,in vitro,Low,Sensitive,-,-,2015,MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.,"Specific anti-miRs were then employed to downregulate the expression of microRNAs in primary tumor cells. Inhibition of miR-9 resulted in decreased clonal formation and sensitivity to cisplatin, while the knockdown of other three microRNAs did not show any influence in tumorigenesis and drug sensitivity."
25871397,miR-203,hsa-mir-203a,MI0000283,Imatinib,5291,-,U251 vs U251/IMA and U87 vs U87/IMA,-,-,glioblastoma,in vitro,Low,Sensitive,SNAI2,-,2015,MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.,"Ectopic expression of miR-203 with miRNA mimics effectively reversed EMT in U251AR and U87AR cells, and sensitized them to chemotherapy"
25872328,hsa-3149,-,-,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,let-7g,hsa-let-7g,MI0000433,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,let-7i,hsa-let-7i,MI0000434,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,miR-1290,hsa-mir-1290,MI0006352,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,miR-141,hsa-mir-141,MI0000457,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,miR-149,hsa-mir-149,MI0000478,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,miR-195,hsa-mir-195,MI0000489,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,miR-1973,hsa-mir-1973,MI0009983,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,miR-200c,hsa-mir-200c,MI0000650,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,miR-3135a,hsa-mir-3135a,MI0014156,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,miR-3621,hsa-mir-3621,MI0016012,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,miR-3687,hsa-mir-3687-1,MI0016088,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,miR-491,hsa-mir-491,MI0003126,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,miR-636,hsa-mir-636,MI0003651,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,miR-933,hsa-mir-933,MI0005755,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,miR-96,hsa-mir-96,MI0000098,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25872328,miRPlus-G1246-3p,-,-,Cisplatin,2767,-,COC1 vs COC1/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2013,MicroRNA signatures of platinum-resistance in ovarian cancer,"Seventeen miRNAs were differentially expressed between COC1 and COC1/DDP. The up-regulted miRNA ( n=13 ) were hsa-miR-1290, hsa-miR-141-3p, hsa-miR-491-3p, hsa-3135a, hsa-miR-141-3p, and hsa-3149. The dowmregulated miRNAs ( n=4 ) were hsa-miR-933, hsa-let-7g-5p,hsa-let-7i-5p, hsa-miRPlus-G1246-3p."
25873402,miR-494,hsa-mir-494,MI0003134,5-Fluorouracil,3385,-,SW480 vs SW480/5-FU,Mice,-,colon cancer,in vitro and in vivo,Low,Sensitive,DPYD ,-,2015,MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD.,"miR-494 level was found to be correlated with 5-Fu sensitivity in colon cancer cells, and artificial alteration of miR-494 affects the sensitivity of colon cancer cell lines to 5-Fu."
25880778,miR-7,hsa-mir-7-1,MI0000263,Cisplatin,2767,-,H446 vs H446/ADR and H69 vs H69/ADR,-,-,small cell lung cancer,in vitro,Low,Sensitive,KCNJ2,-,2015,Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.,"These results demonstrated that the upregulation of miR-7 expression sensitized the SCLC cells to all three chemotherapeutic drugs, whereas the downregulation of miR-7 desensitized the SCLC cells."
25880778,miR-7,hsa-mir-7-1,MI0000263,Doxorubicin (Adriamycin),31703,-,H446 vs H446/ADR and H69 vs H69/ADR,-,-,small cell lung cancer,in vitro,Low,Sensitive,KCNJ2,-,2015,Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.,"These results demonstrated that the upregulation of miR-7 expression sensitized the SCLC cells to all three chemotherapeutic drugs, whereas the downregulation of miR-7 desensitized the SCLC cells."
25880778,miR-7,hsa-mir-7-1,MI0000263,Etoposide,36462,-,H446 vs H446/VP and H69 vs H69/VP,-,-,small cell lung cancer,in vitro,Low,Sensitive,KCNJ2,-,2015,Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.,"These results demonstrated that the upregulation of miR-7 expression sensitized the SCLC cells to all three chemotherapeutic drugs, whereas the downregulation of miR-7 desensitized the SCLC cells."
25887381,miR-17-92,-,-,Gemcitabine,60750,Pancreatic Cancer Stem Cells,-,Mice,-,pancreatic cancer,in vitro and in vivo,Low,Sensitive,"P21, P57 and TBX3",-,2015,The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.,"In particular, overexpression of miR-17-92 reduced CSC self-renewal capacity, in vivo tumourigenicity and chemoresistance."
25889892,miR-196b,hsa-mir-196b,MI0001150,Etoposide,36462,HepG2,-,-,-,HepG2,in vitro,Low,Sensitive,IGF2BP1,-,2015,miRNA-196b inhibits cell proliferation and induces apoptosis in HepG2 cells by targeting IGF2BP1.,miR-196b overexpression increased the etoposide-induced apoptosis and reversed the protection of cell death observed under hypoxia.
25900794,miR-218,hsa-mir-218-1,MI0000294,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR and Cal51 vs Cal51/ADR,Mice,-,breast cancer,in vitro and in vivo,Low,Sensitive,BIRC5,-,2015,miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.,"Experimental down-regulation of survivin by RNA interference in drug-resistant cells did mimic the sensitization observed when miRNA-218 was up-regulated. In addition, resensitization to taxol was also observed in mouse tumor xenografts from cells over-expressing miR-218."
25900794,miR-218,hsa-mir-218-1,MI0000294,Paclitaxel,36314,-,MCF-7 vs MCF-7/ADR and Cal51 vs Cal51/DOX,Mice,-,breast cancer,in vitro and in vivo,Low,Sensitive,BIRC5,-,2015,miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.,"Experimental down-regulation of survivin by RNA interference in drug-resistant cells did mimic the sensitization observed when miRNA-218 was up-regulated. In addition, resensitization to taxol was also observed in mouse tumor xenografts from cells over-expressing miR-218."
25908215,miR-218,hsa-mir-218-1,MI0000294,Sirolimus,5284616,"HeLa, SiHa, Caski and C33A",-,Mice,-,cervical cancer,in vitro and in vivo,Low,Sensitive,Rictor,-,2015,MicroRNA-218 increases cellular sensitivity to Rapamycin via targeting Rictor in cervical cancer.,"In conclusion, we demonstrated that microRNA-218 could re-sensitize cervical cancer to Rapamycin through targeting Rictor."
25910754,miR-101,hsa-mir-101-1,MI0000103,Cisplatin,2767,-,SCC-11 vs SCC-11/CDDP and SCC-25 vs SCC-25/CDDP,-,-,squamous cell carcinoma,in vitro,Low,Resistant,RIPK1,-,2015,Phospho-deltaNp63alpha-responsive microRNAs contribute to the regulation of necroptosis in squamous cell carcinoma upon cisplatin exposure.,Both miR-101-3p mimic and RIPK1 siRNA partially increased the resistance of sensitive SCC cells to cisplatin treatment.
25913620,miR-145,hsa-mir-145,MI0000461,5-Fluorouracil,3385,-,SW620 vs SW620/5-FU,-,-,colorectal cancer,in vitro,Low,Sensitive,RAD18,-,2015,Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer.,"Taken together, these results suggest that miR-145 can act as an RAD18 inhibitor and contribute as an important factor in reversing drug resistance after chemotherapy."
25916297,miR-27a,hsa-mir-27a,MI0000085,Doxorubicin (Adriamycin),31703,-,Raji vs Raji/ADR,-,-,cancer,in vitro,Low,Resistant,-,-,2015,The establishment of Raji drug-resistant cell line and analyses of prohibitin and miR-27a expression,"By building the experimental model of Raji ADR-resistant cell lines, high expression level of PHB1 and miR-27a were detected in the cell lines, indicating that PHB1 and miR-27a may be associated with ADR-resistance of Raji cells."
25919696,miR-224,hsa-mir-224,MI0000301,5-fluorouracil,3385,HCT116 and NIH3T3,-,-,-,"colorectal cancer, mouce",in vitro,Low,Resistant,-,-,2015,MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.,"5-FU chemosensitivity was significantly increased in miR-224 knockdown cells, and in NIH3T3 cells expressing KRAS and BRAF mutant proteins."
25921099,miR-128,hsa-mir-128-1,MI0000447,Cisplatin,2767,DU-145 and LNCaP,-,-,-,prostate cancer,in vitro,Low,Sensitive,ZEB1,-,2015,miR-128 modulates chemosensitivity and invasion of prostate cancer cells through targeting ZEB1.,Restored miR-128 expression sensitized prostate cancer cells to cisplatin and inhibited the invasion.
25927928,miR-148b,hsa-mir-148b,MI0000811,Cisplatin,2767,-,A549 vs A549/CDDP and SPC-A1 vs SPC-A1/CDDP,-,-,non-small cell cancer,in vitro,Low,Resistant,DNMT1,-,2015,miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.,"miR-148b mimics reduced the DNMT1 expression, as well as enhanced the sensitivity of cells to cisplatin and cisplatin-induced apoptosis in A549/DDP or SPC-A1/DDP cells."
25929865,miR-497,hsa-mir-497,MI0003138,5-Fluorouracil,3385,SW480 and LoVo,-,-,Patients,colorectal cancer,in vitro and in vivo,Low,Sensitive,Smurf1,-,2015,miRNA-497 Enhances the Sensitivity of Colorectal Cancer Cells to Neoadjuvant Chemotherapeutic Drug.,Functional studies showed that restoration of miRNA-497 expression inhibited cell viability and enhanced 5-FU sensitivity in SW480 cells.
25934574,miR-1291,hsa-mir-1291,MI0006353,Doxorubicin (Adriamycin),31703,MCF-7,-,-,-,breast cancer,in vitro,Low,Sensitive,-,-,2015,Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity.,"In addition, tRNA-carried pre-miR-1291 suppressed the growth of MCF-7 and PANC-1 cells in a dose-dependent manner, and significantly enhanced the sensitivity of ABCC1-overexpressing PANC-1 cells to doxorubicin."
25934574,miR-1291,hsa-mir-1291,MI0006353,Doxorubicin (Adriamycin),31703,PANC-1,-,-,-,pancreatic carcinoma,in vitro,Low,Sensitive,-,-,2015,Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity.,"In addition, tRNA-carried pre-miR-1291 suppressed the growth of MCF-7 and PANC-1 cells in a dose-dependent manner, and significantly enhanced the sensitivity of ABCC1-overexpressing PANC-1 cells to doxorubicin."
25946136,let-7,-,-,Gemcitabine,60750,"A549, PANC-1 and MDA-MB-231",-,-,-,KRAS mutation cancer,in vitro,Low,Sensitive,TUBB3 and RRM2,MEK/ERK and PI3K/AKT signaling pathway,2015,Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy.,We found that let-7b repletion selectively sensitized KRAS mutant tumor cells to the cytotoxicity of paclitaxel and gemcitabine.
25946136,let-7,-,-,Paclitaxel,36314,"A549, Panc-1 and MDA-MB-231",-,-,-,KRAS mutation cancer,in vitro,Low,Sensitive,TUBB3 and RRM2,MEK/ERK and PI3K/AKT signaling pathway,2015,Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy.,We found that let-7b repletion selectively sensitized KRAS mutant tumor cells to the cytotoxicity of paclitaxel and gemcitabine.
25953263,miR-2278,hsa-mir-2278,MI0011285,Imatinib,5291,-,K562 vs K562/IMA,-,-,chronic myeloid leukemia,in vitro,Low,Sensitive,"AKT2, STAM2, and STAT5A",-,2015,Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted hsa-miR-2278 as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.,"Upregulating miR-2278 expression resulted in the inhibition of resistant leukemic cell proliferation and induced apoptosis, whereas miR-1245b-3p did not exhibit therapeutic results. "
25972604,miR-155,hsa-mir-155,MI0000681,Cisplatin,2767,SK-N-BE(2) and CHLA-255,-,Mice,-,neuroblastoma,in vitro and in vivo,Low,Resistant,TERF1,-,2015,Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy.,When SK-N-BE(2) and CHLA-255 cells were treated with Dotap-Scrambled or Dotap-miR-155 in presence of CDDP a statistically significantly increased growth and telomere length in the Dotap-miR-155 treated group was observed.
25973145,miR-125b-1,hsa-mir-125b-1,MI0000446,Doxorubicin (Adriamycin),31703,-,SH-SY5Y vs SH-SY5Y/ADR,-,-,neuroblastoma,in vitro,High,Sensitive,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-125b-1,hsa-mir-125b-1,MI0000446,Doxorubicin (Adriamycin),31703,-,UKF-NB-3/ADR,-,-,neuroblastoma,in vitro,High,Sensitive,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-125b-1,hsa-mir-125b-1,MI0000446,Etoposide,36462,-,SH-SY5Y vs SH-SY5Y/ET,-,-,neuroblastoma,in vitro,High,Sensitive,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-150,hsa-mir-150,MI0000479,Doxorubicin (Adriamycin),31703,-,SH-SY5Y vs SH-SY5Y/ADR,-,-,neuroblastoma,in vitro,High,Resistant,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-150,hsa-mir-150,MI0000479,Doxorubicin (Adriamycin),31703,-,UKF-NB-3/ADR,-,-,neuroblastoma,in vitro,High,Resistant,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-150,hsa-mir-150,MI0000479,Etoposide,36462,-,SH-SY5Y vs SH-SY5Y/ET,-,-,neuroblastoma,in vitro,High,Resistant,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-188,hsa-mir-188,MI0000484,Doxorubicin (Adriamycin),31703,-,SH-SY5Y vs SH-SY5Y/ADR,-,-,neuroblastoma,in vitro,High,Resistant,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-188,hsa-mir-188,MI0000484,Doxorubicin (Adriamycin),31703,-,UKF-NB-3/ADR,-,-,neuroblastoma,in vitro,High,Resistant,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-188,hsa-mir-188,MI0000484,Etoposide,36462,-,SH-SY5Y vs SH-SY5Y/ET,-,-,neuroblastoma,in vitro,High,Resistant,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-204,hsa-mir-204,MI0000284,Doxorubicin (Adriamycin),31703,-,SH-SY5Y vs SH-SY5Y/ADR,-,-,neuroblastoma,in vitro,High,Sensitive,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-204,hsa-mir-204,MI0000284,Doxorubicin (Adriamycin),31703,-,UKF-NB-3/ADR,-,-,neuroblastoma,in vitro,High,Sensitive,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-204,hsa-mir-204,MI0000284,Etoposide,36462,-,SH-SY5Y vs SH-SY5Y/ET,-,-,neuroblastoma,in vitro,High,Sensitive,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-501-5P,hsa-mir-501,MI0003185,Doxorubicin (Adriamycin),31703,-,SH-SY5Y vs SH-SY5Y/ADR,-,-,neuroblastoma,in vitro,High,Resistant,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-501-5P,hsa-mir-501,MI0003185,Doxorubicin (Adriamycin),31703,-,UKF-NB-3/ADR,-,-,neuroblastoma,in vitro,High,Resistant,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-501-5P,hsa-mir-501,MI0003185,Etoposide,36462,-,SH-SY5Y vs SH-SY5Y/ET,-,-,neuroblastoma,in vitro,High,Resistant,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-519,hsa-mir-519a-1,MI0003178,Doxorubicin (Adriamycin),31703,-,SH-SY5Y vs SH-SY5Y/ADR,-,-,neuroblastoma,in vitro,High,Resistant,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-519,hsa-mir-519a-1,MI0003178,Doxorubicin (Adriamycin),31703,-,UKF-NB-3/ADR,-,-,neuroblastoma,in vitro,High,Resistant,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-519,hsa-mir-519a-1,MI0003178,Etoposide,36462,-,SH-SY5Y vs SH-SY5Y/ET,-,-,neuroblastoma,in vitro,High,Resistant,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-769,hsa-mir-769,MI0003834,Doxorubicin (Adriamycin),31703,-,SH-SY5Y vs SH-SY5Y/ADR,-,-,neuroblastoma,in vitro,High,Sensitive,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-769,hsa-mir-769,MI0003834,Doxorubicin (Adriamycin),31703,-,UKF-NB-3/ADR,-,-,neuroblastoma,in vitro,High,Sensitive,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25973145,miR-769,hsa-mir-769,MI0003834,Etoposide,36462,-,SH-SY5Y vs SH-SY5Y/ET,-,-,neuroblastoma,in vitro,High,Sensitive,-,-,2015,Identification of miRNAs contributing to neuroblastoma chemoresistance,The results of the miRNA expression profiling revealed that a putative chemoresistance signature expression of seven miRNAs was present in all three NB chemoresistance cell line models (see Fig. 8).
25975752,miR-33b,hsa-mir-33b,MI0003646,Bortezomib,387447,-,-,-,Patients,multiple myeloma,in vivo,Low,Sensitive,-,-,2015,Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma.,"Strikingly, bortezomib-based treatment did not significantly extend PFS and OS of Patient with miR-33b low expression, suggesting Patient with miR-33b down-regulation could be resistant to bortezomib-based treatment."
25982274,miR-520h,hsa-mir-520h,MI0003175,Paclitaxel,36314,"Hs578T, MDA-MB-231 and MDA-MB-468 ",-,-,-,breast cancer,in vitro,Low,Resistant,DAPK2,-,2016,miR-520h is crucial for DAPK2 regulation and breast cancer progression.,"Through protecting cells from paclitaxel-induced apoptosis, expression of miR-520h promoted the drug resistance of human breast cancer cells. "
25984652,miR-194,hsa-mir-194-1,MI0000488,AED therapy,-,-,-,-,Patientss,epilepsy,in vivo,High,Sensitive,-,-,2015,Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy,"According to these criteria, we found that 12 miRNAs were downregulated (miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p, -3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p and novel-mir-451) and 3 were upregulated(miR-574-5p, novel-mir-67 and novel-mir-9) in drug-resistant group compared to drug-responsive group(Supplementary Table S1). "
25984652,miR-204,hsa-mir-204,MI0000284,AED therapy,-,-,-,-,Patientss,epilepsy,in vivo,High,Sensitive,-,-,2015,Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy,"According to these criteria, we found that 12 miRNAs were downregulated (miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p, -3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p and novel-mir-451) and 3 were upregulated(miR-574-5p, novel-mir-67 and novel-mir-9) in drug-resistant group compared to drug-responsive group(Supplementary Table S1). "
25984652,miR-221,hsa-mir-221,MI0000298,AED therapy,-,-,-,-,Patientss,epilepsy,in vivo,High,Sensitive,-,-,2015,Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy,"According to these criteria, we found that 12 miRNAs were downregulated (miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p, -3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p and novel-mir-451) and 3 were upregulated(miR-574-5p, novel-mir-67 and novel-mir-9) in drug-resistant group compared to drug-responsive group(Supplementary Table S1). "
25984652,miR-301a,hsa-mir-301a,MI0000745,AED therapy,-,-,-,-,Patientss,epilepsy,in vivo,High,Sensitive,-,-,2015,Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy,"According to these criteria, we found that 12 miRNAs were downregulated (miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p, -3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p and novel-mir-451) and 3 were upregulated(miR-574-5p, novel-mir-67 and novel-mir-9) in drug-resistant group compared to drug-responsive group(Supplementary Table S1). "
25984652,miR-30b,hsa-mir-30b,MI0000441,AED therapy,-,-,-,-,Patientss,epilepsy,in vivo,High,Sensitive,-,-,2015,Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy,"According to these criteria, we found that 12 miRNAs were downregulated (miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p, -3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p and novel-mir-451) and 3 were upregulated(miR-574-5p, novel-mir-67 and novel-mir-9) in drug-resistant group compared to drug-responsive group(Supplementary Table S1). "
25984652,miR-342,hsa-mir-342,MI0000805,AED therapy,-,-,-,-,Patientss,epilepsy,in vivo,High,Sensitive,-,-,2015,Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy,"According to these criteria, we found that 12 miRNAs were downregulated (miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p, -3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p and novel-mir-451) and 3 were upregulated(miR-574-5p, novel-mir-67 and novel-mir-9) in drug-resistant group compared to drug-responsive group(Supplementary Table S1). "
25984652,miR-3605,hsa-mir-3605,MI0015995,AED therapy,-,-,-,-,Patientss,epilepsy,in vivo,High,Sensitive,-,-,2015,Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy,"According to these criteria, we found that 12 miRNAs were downregulated (miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p, -3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p and novel-mir-451) and 3 were upregulated(miR-574-5p, novel-mir-67 and novel-mir-9) in drug-resistant group compared to drug-responsive group(Supplementary Table S1). "
25984652,miR-4446,hsa-mir-4446,MI0016789,AED therapy,-,-,-,-,Patientss,epilepsy,in vivo,High,Sensitive,-,-,2015,Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy,"According to these criteria, we found that 12 miRNAs were downregulated (miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p, -3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p and novel-mir-451) and 3 were upregulated(miR-574-5p, novel-mir-67 and novel-mir-9) in drug-resistant group compared to drug-responsive group(Supplementary Table S1). "
25984652,miR-574,hsa-mir-574,MI0003581,AED therapy,-,-,-,-,Patientss,epilepsy,in vivo,High,Resistant,-,-,2015,Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy,"According to these criteria, we found that 12 miRNAs were downregulated (miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p, -3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p and novel-mir-451) and 3 were upregulated(miR-574-5p, novel-mir-67 and novel-mir-9) in drug-resistant group compared to drug-responsive group(Supplementary Table S1). "
25984652,miR-598,hsa-mir-598,MI0003610,AED therapy,-,-,-,-,Patientss,epilepsy,in vivo,High,Sensitive,-,-,2015,Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy,"According to these criteria, we found that 12 miRNAs were downregulated (miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p, -3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p and novel-mir-451) and 3 were upregulated(miR-574-5p, novel-mir-67 and novel-mir-9) in drug-resistant group compared to drug-responsive group(Supplementary Table S1). "
25984652,miR-874,hsa-mir-874,MI0005532,AED therapy,-,-,-,-,Patientss,epilepsy,in vivo,High,Sensitive,-,-,2015,Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy,"According to these criteria, we found that 12 miRNAs were downregulated (miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p, -3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p and novel-mir-451) and 3 were upregulated(miR-574-5p, novel-mir-67 and novel-mir-9) in drug-resistant group compared to drug-responsive group(Supplementary Table S1). "
25984652,miR-889,hsa-mir-889,MI0005540,AED therapy,-,-,-,-,Patientss,epilepsy,in vivo,High,Sensitive,-,-,2015,Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy,"According to these criteria, we found that 12 miRNAs were downregulated (miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p, -3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p and novel-mir-451) and 3 were upregulated(miR-574-5p, novel-mir-67 and novel-mir-9) in drug-resistant group compared to drug-responsive group(Supplementary Table S1). "
25984652,novel-mir-451,-,-,AED therapy,-,-,-,-,Patientss,epilepsy,in vivo,High,Sensitive,-,-,2015,Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy,"According to these criteria, we found that 12 miRNAs were downregulated (miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p, -3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p and novel-mir-451) and 3 were upregulated(miR-574-5p, novel-mir-67 and novel-mir-9) in drug-resistant group compared to drug-responsive group(Supplementary Table S1). "
25984652,novel-mir-67,-,-,AED therapy,-,-,-,-,Patientss,epilepsy,in vivo,High,Sensitive,-,-,2015,Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy,"According to these criteria, we found that 12 miRNAs were downregulated (miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p, -3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p and novel-mir-451) and 3 were upregulated(miR-574-5p, novel-mir-67 and novel-mir-9) in drug-resistant group compared to drug-responsive group(Supplementary Table S1). "
25984652,novel-mir-9,-,-,AED therapy,-,-,-,-,Patientss,epilepsy,in vivo,High,Resistant,-,-,2015,Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy,"According to these criteria, we found that 12 miRNAs were downregulated (miR-194-5p, -204-5p, -221-5p, -301a-3p, -30b-5p, -342-5p, -3605-5p, -4446-3p, -598-3p, -874-3p, -889-3p and novel-mir-451) and 3 were upregulated(miR-574-5p, novel-mir-67 and novel-mir-9) in drug-resistant group compared to drug-responsive group(Supplementary Table S1). "
25986891,miR-150,hsa-mir-150,MI0000479,Pertuzumab,-,SKOV3 and SNU119,-,-,-,ovarian cancer ,in vitro,Low,Sensitive,-,PI3K-akt pathway,2015,miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation.,"Furthermore, suppression of miRNA-150 in both cell lines resulted in decreased drug sensitivity to pertuzumab and cell apoptosis."
25991372,miR-21,hsa-mir-21,MI0000077,Temozolomide,5394,LN229 and U251,-,Mice,-,glioblastoma,in vitro and in vivo,Low,Sensitive,-,Wnt/Beta-catenin signaling,2015,Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/Beta-catenin signaling in glioblastoma.,"Finally, we observed that SFN strengthened TMZ-mediated apoptosis in a miR-21-dependent manner."
25995442,miR-506,hsa-mir-506,MI0003193,Cisplatin,2767,HeyA8 and SKOV3,-,Mice,Patients,ovarian cancer,in vitro and in vivo,Low,Sensitive,RAD51,-,2015,Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.,MiR-506 sensitized cells to DNA damage through directly targeting the double-strand DNA damage repair gene RAD51.
25995442,miR-506,hsa-mir-506,MI0003193,Olaparib,23725625,HeyA8 and SKOV3,-,Mice,Patients,ovarian cancer,in vitro and in vivo,Low,Sensitive,RAD51,-,2015,Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.,MiR-506 sensitized cells to DNA damage through directly targeting the double-strand DNA damage repair gene RAD51.
25996293,miR-23b,hsa-mir-23b,MI0000439,5-Fluorouracil,3385,-,SGC7901 vs SGC7901/VCR,Mice,-,gastric cancer,in vitro and in vivo,Low,Sensitive,ATG12 and HMGB2,-,2015,miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2.,"Overexpression of miR-23b-3p dramatically enhanced the sensitivity of SGC7901/VCR cells to 5-fluorouracil (5-FU), VCR and CDDP."
25996293,miR-23b,hsa-mir-23b,MI0000439,Cisplatin,2767,-,SGC7901 vs SGC7901/VCR,Mice,-,gastric cancer,in vitro and in vivo,Low,Sensitive,ATG12 and HMGB2,-,2015,miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2.,"Overexpression of miR-23b-3p dramatically enhanced the sensitivity of SGC7901/VCR cells to 5-fluorouracil (5-FU), VCR and CDDP."
25996293,miR-23b,hsa-mir-23b,MI0000439,Vincristine,5978,-,SGC7901 vs SGC7901/VCR,Mice,-,gastric cancer,in vitro and in vivo,Low,Sensitive,ATG12 and HMGB2,-,2015,miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2.,"Overexpression of miR-23b-3p dramatically enhanced the sensitivity of SGC7901/VCR cells to 5-fluorouracil (5-FU), VCR and CDDP."
25997740,miR-335,hsa-mir-335,MI0000816,Celastrol,122724,-,SNU387 vs SNU387/CEL and Malme3M/CEL,-,-,cancer,in vitro,Low,Sensitive,SIAH2,HDAC3,2015,miR-335 Targets SIAH2 and Confers Sensitivity to Anti-Cancer Drugs by Increasing the Expression of HDAC3.,The results of the study indicated that the miR-335/SIAH2/HDAC3 axis regulates the response to anti-cancer drugs.
25997740,miR-335,hsa-mir-335,MI0000816,Paclitaxel,36314,-,SNU387 vs SNU387/Taxol and Malme3M vs Malme3M/Taxol,-,-,cancer,in vitro,Low,Sensitive,SIAH2,HDAC3,2015,miR-335 Targets SIAH2 and Confers Sensitivity to Anti-Cancer Drugs by Increasing the Expression of HDAC3.,The results of the study indicated that the miR-335/SIAH2/HDAC3 axis regulates the response to anti-cancer drugs.
25997962,miR-200a,hsa-mir-200a,MI0000737,Paclitaxel,36314,OVCAR-3 and SDCs,-,-,-,ovarian cancer,in vitro,Low,Sensitive,-,-,2015,"Upregulation of microRNA-200a associates with tumor proliferation, CSCs phenotype and chemosensitivity in ovarian cancer.","Finally, we invalidated that miR-200a significantly enhanced the chemosensitivity of paclitaxel but not cisplatin in both adherent culture and sphere culture."
26017674,miR-125a,hsa-mir-126a,MI0000470,Cisplatin,2767,-,TW03 vs TW03/CDDP,-,-,nasopharyngeal carcinoma,in vitro,Low,Resistant,p53 ,-,2015,Hsa-miR-25a and 125b are induced by treatment with cisplatin in nasopharyngeal carcinoma and inhibit apoptosis in a p53-dependent manner by targeting p53 mRNA.,Induction of the expression of miR-125a and miR-125b by treatment with cisplatin resulted in resistance to the cisplatin drug in the NPC cells.
26017674,miR-125b,hsa-mir-125b-1,MI0000446,Cisplatin,2767,-,TW03 vs TW03/CDDP,-,-,nasopharyngeal carcinoma,in vitro,Low,Resistant,p53 ,-,2015,Hsa-miR-125a and 125b are induced by treatment with cisplatin in nasopharyngeal carcinoma and inhibit apoptosis in a p53-dependent manner by targeting p53 mRNA.,"Taken together, the present study revealed for the first time, to the best of our knowledge, that induction of the expression of miR-125a and miR-125b by treatment with cisplatin resulted in resistance to the cisplatin drug in the NPC cells."
26025631,miR-200,-,-,Carboplatin,38904,-,OVCAR-3 vs OVCAR-3/CBDCA and MES-OV vs MES-OV/CBDCA,-,-,ovarian carcinoma,in vitro,Low,Resistant,-,-,2015,The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.,"MiR-200c and miR-141 mimics conferred resistance to carboplatin in MES-OV/TP cells, similar to OVCAR-3/TP, but sensitized MES-OV to paclitaxel."
26025631,miR-200,-,-,Paclitaxel,36314,-,OVCAR-3 vs OVCAR-3/Taxol and MES-OV vs MES-OV/Taxol,-,-,ovarian carcinoma,in vitro,Low,Resistant,-,-,2015,The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.,"MiR-200c and miR-141 mimics conferred resistance to carboplatin in MES-OV/TP cells, similar to OVCAR-3/TP, but sensitized MES-OV to paclitaxel."
26026166,miR-107,hsa-mir-107,MI0000114,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Sensitive,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs,miR-648,miR-451,miR-16,miR-490-3p,miR-107,miR-223,miR-19b and miR-25 were up-regulated in non-responders, compared with responders"
26026166,miR-16,hsa-mir-16-1,MI0000070,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Sensitive,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs,miR-648,miR-451,miR-16,miR-490-3p,miR-107,miR-223,miR-19b and miR-25 were up-regulated in non-responders, compared with responders"
26026166,miR-19b,hsa-mir-19b-1,MI0000074,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Sensitive,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs,miR-648,miR-451,miR-16,miR-490-3p,miR-107,miR-223,miR-19b and miR-25 were up-regulated in non-responders, compared with responders"
26026166,miR-223,hsa-mir-223,MI0000300,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Sensitive,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs,miR-648,miR-451,miR-16,miR-490-3p,miR-107,miR-223,miR-19b and miR-25 were up-regulated in non-responders, compared with responders"
26026166,miR-25,hsa-mir-25,MI0000082,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Sensitive,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs,miR-648,miR-451,miR-16,miR-490-3p,miR-107,miR-223,miR-19b and miR-25 were up-regulated in non-responders, compared with responders"
26026166,miR-27a,hsa-mir-27a,MI0000085,Cisplatin,2767,TE8 and TE10,-,-,Patients,esophageal cancer,in vitro and in vivo,High,Resistant,-,TGF-Beta,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Our results indicated that miR-27a/b is involved in resistance to chemotherapy in esophageal cancer, through miR-27a/b-induced transformation of normal fibroblast into CAF."
26026166,miR-27b,hsa-mir-27b,MI0000440,Cisplatin,2767,TE8 and TE10,-,-,Patients,esophageal cancer,in vitro and in vivo,High,Resistant,-,TGF-Beta,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Our results indicated that miR-27a/b is involved in resistance to chemotherapy in esophageal cancer, through miR-27a/b-induced transformation of normal fibroblast into CAF."
26026166,miR-373,hsa-mir-373,MI0000781,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Resistant,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs, miR-411, miR-27b, miR-598, miR-520e, miR-875-3p, miR-519b-3p, miR-378b, miR-373, miR-449c and miR-27a were up-regulated in non-responders, compared with responders"
26026166,miR-378b,hsa-mir-378b,MI0014154,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Resistant,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs, miR-411, miR-27b, miR-598, miR-520e, miR-875-3p, miR-519b-3p, miR-378b, miR-373, miR-449c and miR-27a were up-regulated in non-responders, compared with responders"
26026166,miR-411,hsa-mir-411,MI0003675,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Resistant,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs, miR-411, miR-27b, miR-598, miR-520e, miR-875-3p, miR-519b-3p, miR-378b, miR-373, miR-449c and miR-27a were up-regulated in non-responders, compared with responders"
26026166,miR-449c,hsa-mir-449c,MI0003823,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Resistant,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs, miR-411, miR-27b, miR-598, miR-520e, miR-875-3p, miR-519b-3p, miR-378b, miR-373, miR-449c and miR-27a were up-regulated in non-responders, compared with responders"
26026166,miR-451,hsa-mir-451a,MI0001729,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Sensitive,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs,miR-648,miR-451,miR-16,miR-490-3p,miR-107,miR-223,miR-19b and miR-25 were up-regulated in non-responders, compared with responders"
26026166,miR-490,hsa-mir-490,MI0003125,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Sensitive,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs,miR-648,miR-451,miR-16,miR-490-3p,miR-107,miR-223,miR-19b and miR-25 were up-regulated in non-responders, compared with responders"
26026166,miR-519b,hsa-mir-519b,MI0003151,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Resistant,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs, miR-411, miR-27b, miR-598, miR-520e, miR-875-3p, miR-519b-3p, miR-378b, miR-373, miR-449c and miR-27a were up-regulated in non-responders, compared with responders"
26026166,miR-520e,hsa-mir-520e,MI0003143,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Resistant,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs, miR-411, miR-27b, miR-598, miR-520e, miR-875-3p, miR-519b-3p, miR-378b, miR-373, miR-449c and miR-27a were up-regulated in non-responders, compared with responders"
26026166,miR-598,hsa-mir-598,MI0003610,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Resistant,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs, miR-411, miR-27b, miR-598, miR-520e, miR-875-3p, miR-519b-3p, miR-378b, miR-373, miR-449c and miR-27a were up-regulated in non-responders, compared with responders"
26026166,miR-648,hsa-mir-648,MI0003663,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Sensitive,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs,miR-648,miR-451,miR-16,miR-490-3p,miR-107,miR-223,miR-19b and miR-25 were up-regulated in non-responders, compared with responders"
26026166,miR-875,hsa-mir-875,MI0005541,Cisplatin,2767,-,-,-,Patientss,esophageal cancer,in vivo,High,Resistant,-,-,2015,miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.,"Among these 18 miRNAs, miR-411, miR-27b, miR-598, miR-520e, miR-875-3p, miR-519b-3p, miR-378b, miR-373, miR-449c and miR-27a were up-regulated in non-responders, compared with responders"
26043084,let-7d,hsa-let-7d,MI0000065,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,let-7f,hsa-let-7f-1,MI0000067,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-1258,hsa-mir-1258,MI0006392,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-128,hsa-mir-128-1,MI0000447,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-1297,hsa-mir-1297,MI0006358,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-130a,hsa-mir-130a,MI0000448,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,Low,Resistant,-,MDR1 and PTEN,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.,"MiR-130a and miR-374a mimics decreased the sensitivity of A2780 cells to cisplatin, reversely, their inhibitors could resensitize A2780/DDP cells."
26043084,miR-1321,hsa-mir-1321,MI0006652,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-146a,hsa-mir-146a,MI0000477,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,Low,Sensitive,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-146b,hsa-mir-146b,MI0003129,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-155,hsa-mir-155,MI0000681,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-181a,hsa-mir-181a-2,MI0000269,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-182,hsa-mir-182,MI0000272,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,Low,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-183,hsa-mir-183,MI0000273,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-196a,hsa-mir-196a-1,MI0000238,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-200c,hsa-mir-200c,MI0000650,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-25,hsa-mir-25,MI0000082,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-27a,hsa-mir-27a,MI0000085,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-31,hsa-mir-31,MI0000089,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-3175,hsa-mir-3175,MI0014209,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-365,hsa-mir-365a,MI0000767,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-374a,hsa-mir-374a,MI0000782,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,Low,Resistant,-,MDR1 and PTEN,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.,"MiR-130a and miR-374a mimics decreased the sensitivity of A2780 cells to cisplatin, reversely, their inhibitors could resensitize A2780/DDP cells."
26043084,miR-374b,hsa-mir-374b,MI0005566,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-374c,hsa-mir-374c,MI0016684,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-378b,hsa-mir-378b,MI0014154,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-378c,hsa-mir-378c,MI0015825,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-4289,hsa-mir-4289,MI0015898,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-4297,hsa-mir-4297,MI0015824,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-590,hsa-mir-590,MI0003602,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-9,hsa-mir-9-1,MI0000466,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043084,miR-98,hsa-mir-98,MI0000100,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells,"As shown in Table 1, 32 miRNAs (24 up-regulated, 8 down-regulated) were found to be differentially expressed in A2780/DDP cells compared to its parental cells. The potential target gene of these miRNAs was predicted and listed in Table 1."
26043974,miR-522,hsa-mir-522,MI0003177,Doxorubicin (Adriamycin),31703,-,HT29 vs HT29/ADR,-,-,colon cancer,in vitro,Low,Sensitive,ABCB5,-,2015,MicroRNA-522 reverses drug resistance of doxorubicin-induced HT29 colon cancer cell by targeting ABCB5.,Overexpression of miR?522 in the HT29/DOX cells partially restored DOX sensitivity.
26045293,miR-146a,hsa-mir-146a,MI0000477,Cytarabine,6253,"U937, HL-60 and K562",-,-,-,leukemic monocytic cells,in vitro,Low,Associated,CXCR4,-,2015,Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: impact on response to chemotherapy.,"Altogether, our results demonstrate that hypoxia-mediated regulation of microRNA-146a, which controls CXCR4 expression in monocytic cells, is lost in acute monocytic leukemia, thus contributing to maintaining CXCR4 overexpression and protecting the cells from anti-leukemic drugs in the hypoxic bone marrow microenvironment."
26064968,miR-150,hsa-mir-150,MI0000479,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-155,hsa-mir-155,MI0000681,Sunitinib,5329102,-,-,-,Patients,renal cell carcinoma,in vivo,Low,Resistant,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Kaplan-Meier analysis revealed that lower level of miR-155 is associated with increased time to progression in Patient on sunitinibtreatment.
26064968,miR-196b,hsa-mir-196b,MI0001150,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-204,hsa-mir-204,MI0000284,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-21,hsa-mir-21,MI0000077,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-214,hsa-mir-214,MI0000290,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-29c,hsa-mir-29c,MI0000735,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-302c,hsa-mir-302c,MI0000773,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-30a,hsa-mir-30a,MI0000088,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-30a*,hsa-mir-30a,MI0000088,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-30d,hsa-mir-30d,MI0000255,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-30e,hsa-mir-30e,MI0000749,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-30e*,hsa-mir-30e,MI0000749,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-324,hsa-mir-324,MI0000813,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-454,hsa-mir-454,MI0003820,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-483,hsa-mir-483,MI0002467,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-484,hsa-mir-484,MI0002468,Sunitinib,5329102,-,-,-,Patients,renal cell carcinoma,in vivo,Low,Resistant,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Kaplan-Meier analysis revealed that lower level of miR-484 is associated with increased time to progression in Patient on sunitinibtreatment.
26064968,miR-636,hsa-mir-636,MI0003651,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26064968,miR-888,hsa-mir-888,MI0005537,Sunitinib,5329102,-,-,-,Patientss,renal cell carcinoma,in vivo,High,Associated,-,-,2015,miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.,Limma analysis of normalized expression data identiied 19 miRNAs diferentially expressed
26074357,miR-130a,hsa-mir-130a,MI0000448,Paclitaxel,36314,"PC-3, PR20, PR70, PR200",-,-,-,prostate cancer,in vitro,Low,Sensitive,SLAIN1,-,2015,miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells.,Transfection of a miR-130a precursor into a paclitaxel-resistant cell line suppressed cell growth and increased the sensitivity to paclitaxel.
26079799,miR-199a,hsa-mir-199a-1,MI0000242,Doxorubicin (Adriamycin),31703,U2OS,-,-,Patients,osteosarcoma,in vitro and in vivo,Low,Resistant,CD44,-,2015,CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma.,miR-199a-3p transfection increased drug sensitivity by knocking down CD44 in osteosarcoma.
26080425,miR-100,hsa-mir-100,MI0000102,TRAIL therapy,-,-,H292 vs H292/TRAIL and H460 vs H460/TRAIL,-,-,lung cancer,in vitro,Low,Resistant,TRAF-7,-,2015,A set of NF--kappaB-regulated microRNAs induces acquired TRAIL resistance in lung cancer.,"Enforced expression of each individual miRNA drastically reduced the sensitivity to TRAIL-induced apoptosis, as assessed by MTS and caspase-3/7 assays."
26080425,miR-21,hsa-mir-21,MI0000077,TRAIL therapy,-,-,H292 vs H292/TRAIL and H460 vs H460/TRAIL,-,-,lung cancer,in vitro,Low,Resistant,caspase-8 and caspase-3,-,2015,A set of NF-kappa-B-regulated microRNAs induces acquired TRAIL resistance in lung cancer.,"Enforced expression of each individual miRNA drastically reduced the sensitivity to TRAIL-induced apoptosis, as assessed by MTS and caspase-3/7 assays."
26080425,miR-30c,hsa-mir-30c-1,MI0000736,TRAIL therapy,-,-,H292 vs H292/TRAIL and H460 vs H460/TRAIL,-,-,lung cancer,in vitro,Low,Resistant,FoxO3a,-,2015,A set of NF--kappaB-regulated microRNAs induces acquired TRAIL resistance in lung cancer.,"Enforced expression of each individual miRNA drastically reduced the sensitivity to TRAIL-induced apoptosis, as assessed by MTS and caspase-3/7 assays."
26107137,let-7d*,hsa-let-7d,MI0000065,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,let-7f-1*,hsa-let-7f-1,MI0000067,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-125a,hsa-mir-125a,MI0000469,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-126*,hsa-mir-126,MI0000471,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-152,hsa-mir-152,MI0000462,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-17*,hsa-mir-17,MI0000071,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-182,hsa-mir-182,MI0000272,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-18a*,hsa-mir-18a,MI0000072,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-190b,hsa-mir-190b,MI0005545,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-199a,hsa-mir-199a-1,MI0000242,Cetuximab,91820602,-,CTX vs CTX/CET,-,-,colon cancer,in vitro,High,Resistant,PHLPP1,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1.,"We report that their enforced expression promotes CTX resistance, whereas their silencing sensitizes to the same drug."
26107137,miR-199b,hsa-mir-199b,MI0000282,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,PHLPP1,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-19b,hsa-mir-19b-1,MI0000074,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-203,hsa-mir-203a,MI0000283,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-21,hsa-mir-21,MI0000077,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-219-2,-,-,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-221,hsa-mir-221,MI0000298,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-26a,hsa-mir-26a-1,MI0000083,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-27b,hsa-mir-27b,MI0000440,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-296,hsa-mir-296,MI0000747,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-29c,hsa-mir-29c,MI0000735,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-337,hsa-mir-337,MI0000806,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-339,hsa-mir-339,MI0000815,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-375,hsa-mir-375,MI0000783,Cetuximab,91820602,-,CTX vs CTX/CET,-,-,colon cancer,in vitro,High,Resistant,PHLPP1,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1.,"We report that their enforced expression promotes CTX resistance, whereas their silencing sensitizes to the same drug."
26107137,miR-377,hsa-mir-377,MI0000785,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-383,hsa-mir-383,MI0000791,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-451,hsa-mir-451a,MI0001729,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-498,hsa-mir-498,MI0003142,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-516b,hsa-mir-516b-1,MI0003172,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-595,hsa-mir-595,MI0003607,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-609,hsa-mir-609,MI0003622,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-619,hsa-mir-619,MI0003633,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-640,hsa-mir-640,MI0003655,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-654,hsa-mir-654,MI0003676,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-768,hsa-mir-768,MI0005117,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-769,hsa-mir-769,MI0003834,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-801,hsa-mir-801,MI0005202,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26107137,miR-99b*,hsa-mir-99b,MI0000746,Cetuximab,91820602,-,GEO cells vs CEO cells/CTX,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1,"In summary, we found a list of 27 upregulated and 10 downregulated miRNAs with a fold change > 2 in GEO CR with respect to the GEO cells. "
26108539,miR-7,hsa-mir-7-1,MI0000263,Doxorubicin (Adriamycin),31703,-,H69 vs H69/ADR,-,-,small cell lung cancer,in vitro,Low,Associated,MRP1/ABCC1,-,2015,miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1.,miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1.
26109338,miR-217,hsa-mir-217,MI0000293,Etoposide,36462,MCF-7,-,-,-,breast cancer,in vitro,Low,Resistant,-,-,2015,MicroRNA-217 overexpression induces drug resistance and invasion of breast cancer cells by targeting PTEN signaling.,The survival rate of MCF7 cells was increased after overexpression of miR-217 when MCF7 cells were treated with tamoxifen and etoposide.
26109338,miR-217,hsa-mir-217,MI0000293,Lapatinib,25183872,SKBR3,-,-,-,breast cancer,in vitro,Low,Resistant,-,-,2015,MicroRNA-217 overexpression induces drug resistance and invasion of breast cancer cells by targeting PTEN signaling.,The survival rate of SKBR3 cells was significantly increased after overexpression of miR-217 when SKBR3 cells were treated with lapatinib.
26109338,miR-217,hsa-mir-217,MI0000293,Tamoxifen,2733526,MCF-7,-,-,-,breast cancer,in vitro,Low,Resistant,-,-,2015,MicroRNA-217 overexpression induces drug resistance and invasion of breast cancer cells by targeting PTEN signaling.,The survival rate of MCF7 cells was increased after overexpression of miR-217 when MCF7 cells were treated with tamoxifen and etoposide.
26115122,miR-124,-,-,Camptothecin,24360,MB-MDA-231,-,-,-,breast cancer,in vitro,Low,Sensitive,ATMIN and PARP1,-,2015,The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity.,A particularly important therapeutic implication of this finding is that overexpression of miR-124 enhanced cell sensitivity to multiple DNA-damaging agents via ATMIN- and PARP1-mediated mechanisms.
26115122,miR-124,-,-,Camptothecin,24360,U2OS,-,-,-,osteosarcoma,in vitro,Low,Sensitive,ATMIN and PARP1,-,2015,The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity.,A particularly important therapeutic implication of this finding is that overexpression of miR-124 enhanced cell sensitivity to multiple DNA-damaging agents via ATMIN- and PARP1-mediated mechanisms.
26115122,miR-124,-,-,Doxorubicin (Adriamycin),31703,MB-MDA-231,-,-,-,breast cancer,in vitro,Low,Sensitive,ATMIN and PARP1,-,2015,The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity.,A particularly important therapeutic implication of this finding is that overexpression of miR-124 enhanced cell sensitivity to multiple DNA-damaging agents via ATMIN- and PARP1-mediated mechanisms.
26115122,miR-124,-,-,Doxorubicin (Adriamycin),31703,U2OS,-,-,-,osteosarcoma,in vitro,Low,Sensitive,ATMIN and PARP1,-,2015,The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity.,A particularly important therapeutic implication of this finding is that overexpression of miR-124 enhanced cell sensitivity to multiple DNA-damaging agents via ATMIN- and PARP1-mediated mechanisms.
26115122,miR-124,-,-,Etoposide,36462,MB-MDA-231,-,-,-,breast cancer,in vitro,Low,Sensitive,ATMIN and PARP1,-,2015,The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity.,A particularly important therapeutic implication of this finding is that overexpression of miR-124 enhanced cell sensitivity to multiple DNA-damaging agents via ATMIN- and PARP1-mediated mechanisms.
26115122,miR-124,-,-,Etoposide,36462,U-2 OS,-,-,-,osteosarcoma,in vitro,Low,Sensitive,ATMIN and PARP1,-,2015,The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity.,A particularly important therapeutic implication of this finding is that overexpression of miR-124 enhanced cell sensitivity to multiple DNA-damaging agents via ATMIN- and PARP1-mediated mechanisms.
26115122,miR-124,-,-,IR,-,MB-MDA-231,-,-,-,breast cancer,in vitro,Low,Sensitive,ATMIN and PARP1,-,2015,The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity.,A particularly important therapeutic implication of this finding is that overexpression of miR-124 enhanced cell sensitivity to multiple DNA-damaging agents via ATMIN- and PARP1-mediated mechanisms.
26115122,miR-124,-,-,IR,-,U2OS,-,-,-,osteosarcoma,in vitro,Low,Sensitive,ATMIN and PARP1,-,2015,The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity.,A particularly important therapeutic implication of this finding is that overexpression of miR-124 enhanced cell sensitivity to multiple DNA-damaging agents via ATMIN- and PARP1-mediated mechanisms.
26143754,miR-363,hsa-mir-363,MI0000764,Cisplatin,2767,-,HepG2 vs HepG2/CDDP,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,MCL-1,-,2015,Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1.,MiR-363 decreasing cisplatin resistance by inhibiting Mcl-1 expression.
26145175,miR-101,hsa-mir-101-1,MI0000103,Bortezomib,387447,-,U2OS vs U2OS/BOR,-,-,cancer,in vitro,Low,Sensitive,POMP,-,2015,MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.,"Indeed, miR-101 overexpression as well as POMP knockdown by siRNA accumulated poly-ubiquitinated proteins in bortezomib-resistant cells."
26151540,miR-197,hsa-mir-197,MI0000239,5-Fluorouracil,3385,-,SGC7901 vs SGC7901/5?FU,-,-,gastric cancer,in vitro,Low,Sensitive,MAPK1,-,2015,MicroRNA?197 reverses the drug resistance of fluorouracil?induced SGC7901 cells by targeting mitogen?activated protein kinase 1.,Overexpression of miR?197 in SGC7901/5?FU cells was identified to partially restore 5?FU sensitivity.
26170223,miR-125b,hsa-mir-125b-1,MI0000446,Temozolomide,5394,Primary Glioblastoma Stem Cell,-,-,-,glioma stem cancer,in vitro,Low,Resistant,-,-,2015,PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/Beta-catenin signaling pathway.,"These results strongly indicate that the combined treatment of LY29400, miR-125b inhibitor, and 100 M TMZ has the most obvious inhibition on the invasion of GSCs."
26184032,miR-200a,hsa-mir-200a,MI0000737,Gefitinib,123631,"H3255, H1975 and HCC827",-,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,EGFR and c-Met ,-,2015,"MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.","Moreover, in NSCLC cell lines that are resistant to gefitinib, a drug often used in TKI therapies to treat NSCLC, miR-200a expression is able to render the cells much more sensitive to the drug treatment."
26206152,miR-10b,hsa-mir-10b,MI0000267,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM and T47D vs T47D/TAM,-,-,breast cancer,in vitro,Low,Resistant,HDAC4,-,2015,Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4.,Over-expression of miR-10b in ER-positive MCF-7 and T47D cells led to increased resistance to tamoxifen and an attenuation of tamoxifen-mediated inhibition of migration.
26218285,let-7a,hsa-let-7a-1,MI0000060,Epirubicin,41867,SK-3rd sphere,-,-,Patients,breast cancer,in vitro and in vivo,Low,Sensitive,-,-,2015,Reduced Let-7a Is Associated with Chemoresistance in Primary Breast Cancer.,"Collectively, these findings indicate that lower expression of let-7a miRNA can induce chemoresistance in breast cancer by enhancing cellular apoptosis and suggest that let-7a may be used as a therapeutic target to modulate epirubicin-based chemotherapy resistance."
26222667,miR-21,hsa-mir-21,MI0000077,Betulinic Acid,64971,HepG2,-,Mice,-,hepatocellular carcinoma,in vitro and in vivo,Low,Sensitive,SOD2,-,2015,p53-p66(shc)/miR-21-Sod2 signaling is critical for the inhibitory effect of betulinic acid on hepatocellular carcinoma.,"Furthermore, miR-21 was increased by BA in D/C-treated mice and HCC cells and inhibition of miR-21 significantly suppressed the pro-apoptotic effect of BA."
26223974,miR-149,hsa-mir-149,MI0000478,Paclitaxel,36314,A2780,-,-,-,ovarian cancer,in vitro,Low,Sensitive,MyD88,-,2015,MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88.,Down-regulation of miRNA-149 in A2780 cells increased MyD88 expression and decreased their sensitivity to paclitaxel treatment.
26238082,miR-219,hsa-mir-219a-1,MI0000296,5-Fluorouracil,3385,"HT-29, Caco-2, DLD-1, SW480 and SW620",-,-,-,colon cancer,in vitro,Low,Sensitive,Sall4,-,2015,miR-219-5p plays a tumor suppressive role in colon cancer by targeting oncogene Sall4.,miR-219-5p reduces colon cancer drug resistance by targeting Sall4.
26238082,miR-219,hsa-mir-219a-1,MI0000296,Oxaliplatin,5310940,"HT-29, Caco-2, DLD-1, SW480 and SW620",-,-,-,colon cancer,in vitro,Low,Sensitive,Sall4,-,2015,miR-219-5p plays a tumor suppressive role in colon cancer by targeting oncogene Sall4.,miR-219-5p reduces colon cancer drug resistance by targeting Sall4.
26239225,miR-133a,-,-,5-Fluorouracil,3385,HepG2,-,-,-,hepatocellular carcinoma ,in vitro,Low,Sensitive,Bcl?xl,-,2015,MicroRNA-133a and microRNA-326 co-contribute to hepatocellular carcinoma 5-fluorouracil and cisplatin sensitivity by directly targeting B-cell lymphoma-extra large.,Combining miR-133a or miR-326 with 5-fluorouracil (5-FU) or cisplatin (DDP) resulted in increased cell death.
26239225,miR-133a,-,-,Cisplatin,2767,HepG2,-,-,-,hepatocellular carcinoma ,in vitro,Low,Sensitive,Bcl?xl,-,2015,MicroRNA-133a and microRNA-326 co-contribute to hepatocellular carcinoma 5-fluorouracil and cisplatin sensitivity by directly targeting B-cell lymphoma-extra large.,Combining miR-133a or miR-326 with 5-fluorouracil (5-FU) or cisplatin (DDP) resulted in increased cell death.
26239225,miR-326,hsa-mir-326,MI0000808,5-Fluorouracil,3385,HepG2,-,-,-,hepatocellular carcinoma ,in vitro,Low,Sensitive,Bcl?xl,-,2015,MicroRNA-133a and microRNA-326 co-contribute to hepatocellular carcinoma 5-fluorouracil and cisplatin sensitivity by directly targeting B-cell lymphoma-extra large.,Combining miR-133a or miR-326 with 5-fluorouracil (5-FU) or cisplatin (DDP) resulted in increased cell death.
26239225,miR-326,hsa-mir-326,MI0000808,Cisplatin,2767,HepG2,-,-,-,hepatocellular carcinoma ,in vitro,Low,Sensitive,Bcl?xl,-,2015,MicroRNA?133a and microRNA?326 co?contribute to hepatocellular carcinoma 5?fluorouracil and cisplatin sensitivity by directly targeting B?cell lymphoma?extra large.,Combining miR?133a or miR?326 with 5?fluorouracil (5?FU) or cisplatin (DDP) resulted in increased cell death.
26247730,miR-587,hsa-mir-587,MI0003595,5-Fluorouracil,3385,"RKO, HCT-116, FET and GEO",-,Mice,Patients,colorectal cancer,in vitro and in vivo,Low,Resistant,PPP2R1B,AKT,2015,MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer.,"In this study, we show that microRNA (miR)-587 confers resistance to 5-fluorouracil (5-FU)-induced apoptosis in vitro and reduces the potency of 5-FU in the inhibition of tumor growth in a mouse xenograft model in vivo."
26251897,miR-199a,hsa-mir-199a-1,MI0000242,Doxorubicin (Adriamycin),31703,"RI-1, U2932, Karpas-422 and SUDHL4",-,-,-,diffuse large B-cell lymphoma,in vitro,Low,Sensitive,-,-,2015,miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patient.,"In summary, these data suggest that overexpression of either miR-199a or miR-497 increases the chemosensitivity of aggressive lymphoma cells towards doxorubicin, rituximab and vincristine."
26251897,miR-199a,hsa-mir-199a-1,MI0000242,Rituximab,24801580,"RI-1, U2932, Karpas-422 and SUDHL4",-,-,-,diffuse large B-cell lymphoma,in vitro,Low,Sensitive,-,-,2015,miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patient.,"In summary, these data suggest that overexpression of either miR-199a or miR-497 increases the chemosensitivity of aggressive lymphoma cells towards doxorubicin, rituximab and vincristine."
26251897,miR-199a,hsa-mir-199a-1,MI0000242,Vincristine,5978,"RI-1, U2932, Karpas-422 and SUDHL4",-,-,-,diffuse large B-cell lymphoma,in vitro,Low,Sensitive,-,-,2015,miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patient.,"In summary, these data suggest that overexpression of either miR-199a or miR-497 increases the chemosensitivity of aggressive lymphoma cells towards doxorubicin, rituximab and vincristine."
26251897,miR-497,hsa-mir-497,MI0003138,Doxorubicin (Adriamycin),31703,"RI-1, U2932, Karpas-422 and SUDHL4",-,-,-,diffuse large B-cell lymphoma,in vitro,Low,Sensitive,-,-,2015,miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patient.,"In summary, these data suggest that overexpression of either miR-199a or miR-497 increases the chemosensitivity of aggressive lymphoma cells towards doxorubicin, rituximab and vincristine"
26251897,miR-497,hsa-mir-497,MI0003138,Rituximab,24801581,"RI-1, U2932, Karpas-422 and SUDHL4",-,-,-,diffuse large B-cell lymphoma,in vitro,Low,Sensitive,-,-,2015,miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patient.,"In summary, these data suggest that overexpression of either miR-199a or miR-497 increases the chemosensitivity of aggressive lymphoma cells towards doxorubicin, rituximab and vincristine."
26251897,miR-497,hsa-mir-497,MI0003138,Vincristine,5978,"RI-1, U2932, Karpas-422 and SUDHL4",-,-,-,diffuse large B-cell lymphoma,in vitro,Low,Sensitive,-,-,2015,miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patient.,"In summary, these data suggest that overexpression of either miR-199a or miR-497 increases the chemosensitivity of aggressive lymphoma cells towards doxorubicin, rituximab and vincristine."
26258416,miR-150,hsa-mir-150,MI0000479,Crizotinib,11626560,crizotinib-resistant NPM-ALK(+) ALCL cells,-,-,-,anaplastic large-cell lymphoma,in vitro,Low,Associated,-,-,2015,Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.,Demethylating treatment or ectopic miR-150 expression correlates with growth inhibition of crizotinib-resistant NPM-ALK(+) ALCL cells.
26261488,miR-127,hsa-mir-127,MI0000472,Doxorubicin (Adriamycin),31703,-,U251 vs U251/ADR and U87-MG vs U87-MG/ADR,-,-,glioma,in vitro,Low,Resistant,-,"AKT, MDR1, MRP1, Runx2, Bcl-2, Survivin and ErbB4 ",2015,Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells.,"Silencing of microRNA-127 significantly increased the sensitivity of U251/ADR and U87-MG/adr cells to adriamycin, compared to cells transfected with negative control siRNA. "
26261515,miR-218,hsa-mir-218-1,MI0000294,5-Fluorouracil,3385,-,SGC7901 vs SGC7901/ADR and SGC7901 vs SGC7901/L-OHP,-,-,gastric cancer,in vitro,Low,Sensitive,SMO,-,2015,MiR-218 inhibits multidrug resistance (MDR) of gastric cancer cells by targeting Hedgehog/smoothened.,"Overexpressing miR-218 chemosensitizes gastric cancer cells, slowed efflux of adriamycin, and accelerated drug-induced apoptosis."
26261515,miR-218,hsa-mir-218-1,MI0000294,Doxorubicin (Adriamycin),31703,-,SGC7901 vs SGC7901/ADR and SGC7901 vs SGC7901/L-OHP,-,-,gastric cancer,in vitro,Low,Sensitive,SMO,-,2015,MiR-218 inhibits multidrug resistance (MDR) of gastric cancer cells by targeting Hedgehog/smoothened.,"Overexpressing miR-218 chemosensitizes gastric cancer cells, slowed efflux of adriamycin, and accelerated drug-induced apoptosis."
26261515,miR-218,hsa-mir-218-1,MI0000294,Oxaliplatin,5310940,-,SGC7901 vs SGC7901/ADM and SGC7901 vs SGC7901/L-OHP,-,-,gastric cancer,in vitro,Low,Sensitive,SMO,-,2015,MiR-218 inhibits multidrug resistance (MDR) of gastric cancer cells by targeting Hedgehog/smoothened.,"Overexpressing miR-218 chemosensitizes gastric cancer cells, slowed efflux of adriamycin, and accelerated drug-induced apoptosis."
26261572,miR-141,hsa-mir-141,MI0000457,Cisplatin,2767,-,"SKOV3 vs SKOV3/CDDP, and A2780 vs A2780/CDDP ",-,-,ovarian cancer,in vitro,High,Sensitive,-,-,2015,Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cance,"As shown in Table 2, after rigorous screening using adj. P < 0.05 and fold > 2 as thresholds, a total of nine differentially expressed microRNAs were identified from the GSE54665 microarray dataset. "
26261572,miR-18b,hsa-mir-18b,MI0001518,Cisplatin,2767,-,"SKOV3 vs SKOV3/CDDP, and A2780 vs A2780/CDDP ",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cance,"As shown in Table 2, after rigorous screening using adj. P < 0.05 and fold > 2 as thresholds, a total of nine differentially expressed microRNAs were identified from the GSE54665 microarray dataset. "
26261572,miR-199a,hsa-mir-199a-1,MI0000242,Cisplatin,2767,-,"SKOV3 vs SKOV3/CDDP, and A2780 vs A2780/CDDP",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cance,"As shown in Table 2, after rigorous screening using adj. P < 0.05 and fold > 2 as thresholds, a total of nine differentially expressed microRNAs were identified from the GSE54665 microarray dataset. "
26261572,miR-199b,hsa-mir-199b,MI0000282,Cisplatin,2767,-,"SKOV3 vs SKOV3/CDDP, and A2780 vs A2780/CDDP",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cance,"As shown in Table 2, after rigorous screening using adj. P < 0.05 and fold > 2 as thresholds, a total of nine differentially expressed microRNAs were identified from the GSE54665 microarray dataset. "
26261572,miR-215,hsa-mir-215,MI0000291,Cisplatin,2767,-,"SKOV3 vs SKOV3/CDDP, and A2780 vs A2780/CDDP",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cance,"As shown in Table 2, after rigorous screening using adj. P < 0.05 and fold > 2 as thresholds, a total of nine differentially expressed microRNAs were identified from the GSE54665 microarray dataset. "
26261572,miR-335,hsa-mir-335,MI0000816,Cisplatin,2767,-,"SKOV3 vs SKOV3/CDDP, and A2780 vs A2780/CDDP",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cance,"As shown in Table 2, after rigorous screening using adj. P < 0.05 and fold > 2 as thresholds, a total of nine differentially expressed microRNAs were identified from the GSE54665 microarray dataset. "
26261572,miR-363,hsa-mir-363,MI0000764,Cisplatin,2767,-,"SKOV3 vs SKOV3/CDDP, and A2780 vs A2780/CDDP",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cance,"As shown in Table 2, after rigorous screening using adj. P < 0.05 and fold > 2 as thresholds, a total of nine differentially expressed microRNAs were identified from the GSE54665 microarray dataset. "
26261572,miR-645,hsa-mir-645,MI0003660,Cisplatin,2767,-,"SKOV3 vs SKOV3/CDDP, and A2780 vs A2780/CDDP",-,-,ovarian cancer,in vitro,High,Resistant,-,-,2015,Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cance,"As shown in Table 2, after rigorous screening using adj. P < 0.05 and fold > 2 as thresholds, a total of nine differentially expressed microRNAs were identified from the GSE54665 microarray dataset. "
26276504,miR-202,hsa-mir-202,MI0003130,Doxorubicin (Adriamycin),31703,U2OS and G293,-,-,-,osteosarcoma,in vitro,Low,Resistant,PDCD4,-,2016,TGF-Beta1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma.,"Transfection of miR-202 mimics into osteosarcoma cell lines significantly promotes chemotherapy resistance by targeting PDCD4,"
26287405,miR-335,hsa-mir-335,MI0000816,chemotherapy,-,-,-,-,Patients,acute myeloid leukemia,in vivo,Low,Resistant,-,-,2015,Bone Marrow MicroRNA-335 Level Predicts the Chemotherapy Response and Prognosis of Adult Acute Myeloid Leukemia.,"In contrast, high bone marrow miR-335 level was significantly associated with a poor treatment response and also predicted a worse prognosis indicated by the relapse-free survival and overall survival periods in adult AML Patient receiving Ara-C-based chemotherapy."
26299922,miR-139,hsa-mir-139,MI0000261,Docetaxel,148124,-,MCF7 vs MCF-7/DOC,-,-,breast cancer,in vitro,Low,Sensitive,Notch1,-,2015,MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel.,"MiR-139-5p induces apoptosis, causes cell cycle arrest in S phase, inhibits migration and invasion in breast cancer cells, however, MiR-139-5p play the opposite role in docetaxel-induced breast cancer cells."
26318721,miR-134,hsa-mir-134,MI0000474,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Sensitive,-,ABCC1,2015,MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1.,MicroRNA-134 modulates resistance to doxorubicin in breast cancer cells by downregulating the expression of ABCC1 which is known to encode the multidrug resistance-associated protein 1.
26323558,miR-10b,hsa-mir-10b,MI0000267,Cisplatin,2767,-,U251 vs U251/CDDP,-,-,glioma,in vitro,High,Resistant,-,-,2015,miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2,"Then, we found that several miRNAs that had been identified in the previous cluster analysis were dysregulated in the U87/DDP or U251/DDP cells (Fig. 1C and E). "
26323558,miR-10b,hsa-mir-10b,MI0000267,Cisplatin,2767,-,U87 vs U87/CDDP,-,-,glioma,in vitro,High,Resistant,-,-,2015,miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2,"Then, we found that several miRNAs that had been identified in the previous cluster analysis were dysregulated in the U87/DDP or U251/DDP cells (Fig. 1C and E). "
26323558,miR-128,hsa-mir-128-1,MI0000447,Cisplatin,2767,-,U251 vs U251/CDDP,-,-,glioma,in vitro,High,Sensitive,-,-,2015,miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2,"Then, we found that several miRNAs that had been identified in the previous cluster analysis were dysregulated in the U87/DDP or U251/DDP cells (Fig. 1C and E). "
26323558,miR-128,hsa-mir-128-1,MI0000447,Cisplatin,2767,-,U87 vs U87/CDDP,-,-,glioma,in vitro,High,Sensitive,-,-,2015,miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2,"Then, we found that several miRNAs that had been identified in the previous cluster analysis were dysregulated in the U87/DDP or U251/DDP cells (Fig. 1C and E). "
26323558,miR-129,hsa-mir-129-1,MI0000252,Cisplatin,2767,-,U251 vs U251/CDDP,-,-,glioma,in vitro,High,Sensitive,-,-,2015,miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2,"Then, we found that several miRNAs that had been identified in the previous cluster analysis were dysregulated in the U87/DDP or U251/DDP cells (Fig. 1C and E). "
26323558,miR-129,hsa-mir-129-1,MI0000252,Cisplatin,2767,-,U87 vs U87/CDDP,-,-,glioma,in vitro,High,Sensitive,-,-,2015,miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2,"Then, we found that several miRNAs that had been identified in the previous cluster analysis were dysregulated in the U87/DDP or U251/DDP cells (Fig. 1C and E). "
26323558,miR-139,hsa-mir-139,MI0000261,Cisplatin,2767,-,U251 vs U251/CDDP,-,-,glioma,in vitro,High,Sensitive,-,-,2015,miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2,"Then, we found that several miRNAs that had been identified in the previous cluster analysis were dysregulated in the U87/DDP or U251/DDP cells (Fig. 1C and E). "
26323558,miR-139,hsa-mir-139,MI0000261,Cisplatin,2767,-,U87 vs U87/CDDP,-,-,glioma,in vitro,High,Sensitive,-,-,2015,miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2,"Then, we found that several miRNAs that had been identified in the previous cluster analysis were dysregulated in the U87/DDP or U251/DDP cells (Fig. 1C and E). "
26323558,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,-,U251 vs U251/CDDP,-,-,glioma,in vitro,High,Resistant,-,-,2015,miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2,"Then, we found that several miRNAs that had been identified in the previous cluster analysis were dysregulated in the U87/DDP or U251/DDP cells (Fig. 1C and E). "
26323558,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,-,U87 vs U87/CDDP,-,-,glioma,in vitro,High,Resistant,-,-,2015,miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2,"Then, we found that several miRNAs that had been identified in the previous cluster analysis were dysregulated in the U87/DDP or U251/DDP cells (Fig. 1C and E). "
26323558,miR-873,-,-,Cisplatin,2767,-,U87 vs U87/CDDP and U251 vs U251/CDDP,-,-,glioma,in vitro,Low,Sensitive,Bcl-2,-,2015,MiR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2.,"Overexpression of miR?873 decreased the cell proliferation, migration and invasion while increased apoptosis of cisplatin-resistant glioma cells and sensitized the cells to cisplatin-induced cell growth arrest and apoptosis."
26323677,let-7g,hsa-let-7g,MI0000433,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,Ten miRNAs were significantly upregulated and 5 were significantly downregulated in A549/PTX cells relative to A549 cells (absolute log fold-change >4; Table V). 
26323677,miR-128,hsa-mir-128-1,MI0000447,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,Ten miRNAs were significantly upregulated and 5 were significantly downregulated in A549/PTX cells relative to A549 cells (absolute log fold-change >4; Table V). 
26323677,miR-135b,hsa-mir-135b,MI0000810,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,Ten miRNAs were significantly upregulated and 5 were significantly downregulated in A549/PTX cells relative to A549 cells (absolute log fold-change >4; Table V). 
26323677,miR-155,hsa-mir-155,MI0000681,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,Ten miRNAs were significantly upregulated and 5 were significantly downregulated in A549/PTX cells relative to A549 cells (absolute log fold-change >4; Table V). 
26323677,miR-181a,hsa-mir-181a-2,MI0000269,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,lung adenocarcinoma,in vitro,Low,Associated,PTEN,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,"miR-181a is differentially expressed in A549/PTX, A549/DDP, and A549 parental A549 cells."
26323677,miR-181a,hsa-mir-181a-2,MI0000269,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,Low,Associated,PTEN,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,"miR-181a is differentially expressed in A549/PTX, A549/DDP, and A549 parental A549 cells."
26323677,miR-181b,hsa-mir-181b-1,MI0000270,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,Ten miRNAs were significantly upregulated and 5 were significantly downregulated in A549/PTX cells relative to A549 cells (absolute log fold-change >4; Table V). 
26323677,miR-181c,hsa-mir-181c,MI0000271,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,Ten miRNAs were significantly upregulated and 5 were significantly downregulated in A549/PTX cells relative to A549 cells (absolute log fold-change >4; Table V). 
26323677,miR-191,hsa-mir-191,MI0000465,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,Ten miRNAs were significantly upregulated and 5 were significantly downregulated in A549/PTX cells relative to A549 cells (absolute log fold-change >4; Table V). 
26323677,miR-19a,hsa-mir-19a,MI0000073,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,Ten miRNAs were significantly upregulated and 5 were significantly downregulated in A549/PTX cells relative to A549 cells (absolute log fold-change >4; Table V). 
26323677,miR-200c,hsa-mir-200c,MI0000650,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,Ten miRNAs were significantly upregulated and 5 were significantly downregulated in A549/PTX cells relative to A549 cells (absolute log fold-change >4; Table V). 
26323677,miR-205,hsa-mir-205,MI0000285,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,Ten miRNAs were significantly upregulated and 5 were significantly downregulated in A549/PTX cells relative to A549 cells (absolute log fold-change >4; Table V). 
26323677,miR-23b,hsa-mir-23b,MI0000439,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,Ten miRNAs were significantly upregulated and 5 were significantly downregulated in A549/PTX cells relative to A549 cells (absolute log fold-change >4; Table V). 
26323677,miR-25,hsa-mir-25,MI0000082,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Sensitive,-,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,Ten miRNAs were significantly upregulated and 5 were significantly downregulated in A549/PTX cells relative to A549 cells (absolute log fold-change >4; Table V). 
26323677,miR-301a,hsa-mir-301a,MI0000745,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,Ten miRNAs were significantly upregulated and 5 were significantly downregulated in A549/PTX cells relative to A549 cells (absolute log fold-change >4; Table V). 
26323677,miR-96,hsa-mir-96,MI0000098,Paclitaxel,36314,-,A549 vs A549/Taxol,-,-,lung adenocarcinoma,in vitro,High,Resistant,-,-,2015,MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.,Ten miRNAs were significantly upregulated and 5 were significantly downregulated in A549/PTX cells relative to A549 cells (absolute log fold-change >4; Table V). 
26351908,miR-125b,hsa-mir-125b-1,MI0000446,Paclitaxel,36314,-,A549 vs A549/Taxol and H460 vs H460/Taxol,-,-,lung cancer,in vitro,Low,Sensitive,Sema4C,-,2015,Up-regulation of miR-125b reverses epithelial-mesenchymal transition in paclitaxel-resistant lung cancer cells.,"More importantly, overexpression of miR-125b or depletion of Sema4C sensitized PR cells to paclitaxel. "
26376998,miR-196a,hsa-mir-196a-1,MI0000238,Cisplatin,2767,-,A549 vs A549/CDDP,-,-,non-small-cell lung cancer,in vitro,Low,Resistant,-,"MDR1, MRP1, ERCC1, survivin, Bcl-2, and RhoE",2016,Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.,"Inhibition of miR-196a could reverse cisplatin resistance of A549/DDP cell lines, which might relate with inhibition of drug efflux, down-regulation of drug-resistant protein expression, cell apoptosis, and cell proliferation suppression."
26390698,miR-224,hsa-mir-224,MI0000301,Paclitaxel,36314,SiHa,-,-,-,cervical cancer,in vitro,Low,Sensitive,-,-,2015,Upregulation of microRNA-224 sensitizes human cervical cells SiHa to paclitaxel.,Exogenous miR-224 facilitates paclitaxel sensitivity in cervical cancer cells. The IC50 value was decreased in SiHa with overexpression of miR-224 compared with miRNA-negative control (p < 0.0001).
26396496,miR-133b,hsa-mir-133b,MI0000822,Cisplatin,2767,-,A2780 vs A2780/CDDP,-,-,ovarian carcinoma,in vitro,Low,Sensitive,GST-pie,MDR1,2015,MicroRNA-133b targets glutathione S-transferase pie expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.,"Following miR-133b transfection, four cell lines showed increased sensitivity to paclitaxel and cisplatin, while anti-miR-133b transfection reduced cell sensitivity to paclitaxel and cisplatin."
26396496,miR-133b,hsa-mir-133b,MI0000822,Paclitaxel,36314,-,A2780 vs A2780/Taxol,-,-,ovarian carcinoma,in vitro,Low,Sensitive,GST-pie,MDR1,2015,MicroRNA-133b targets glutathione S-transferase pie expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.,"Following miR-133b transfection, four cell lines showed increased sensitivity to paclitaxel and cisplatin, while anti-miR-133b transfection reduced cell sensitivity to paclitaxel and cisplatin."
26416415,miR-134,hsa-mir-134,MI0000474,Cisplatin,2767,Hs578Ts(i)8,-,-,-,breast cancer,in vitro,Low,Sensitive,-,-,2015,miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.,"Delivery via miR-134-enriched EVs also reduced STAT5B and Hsp90, reduced cellular migration and invasion, and enhanced sensitivity to anti-Hsp90 drugs."
26416415,miR-134,hsa-mir-134,MI0000474,PU-H71,104758,Hs578Ts(i)8,-,-,-,breast cancer,in vitro,Low,Sensitive,-,-,2015,miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.,"Here, miR-134-enriched EVs increased the sensitivity of Hs578Ts(i) 8 cells to their approximate IC 50 concentration of 17-AAG and PU-H71"
26416415,miR-134,hsa-mir-134,MI0000474,Tanespimycin,6505803,Hs578Ts(i)8,-,-,-,breast cancer,in vitro,Low,Sensitive,-,-,2015,miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.,"Here, miR-134-enriched EVs increased the sensitivity of Hs578Ts(i) 8 cells to their approximate IC 50 concentration of 17-AAG and PU-H71"
26418978,miR-21,hsa-mir-21,MI0000077,5-Fluorouracil,3385,RKO-WT,-,-,-,colon cancer,in vitro,Low,Resistant,PDCD4,ABCC5 and CD44,2015,Drug resistance of colon cancer cells to 5-fluorouracil mediated by microRNA-21,"MTT assay reveals that the IC50 of 5-FU in RKO-WT cells was about 67% higher than in miR-21 knockout cells (P < 0.05), and the apoptosis ratio elevated after knockout of miR-21. "
26452030,miR-21,hsa-mir-21,MI0000077,Trastuzumab,9903,SKBr-3,-,-,Patients,breast cancer,in vitro and in vivo,Low,Resistant,PTEN and PDCD4,-,2015,MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer Patient.,Overexpression of miR-21 is associated with resistance to neoadjuvant trastuzumab-chemotherapy in HER2-positive breast cancer Patient;
26456124,let-7a,hsa-let-7a-1,MI0000060,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,let-7b,hsa-let-7b,MI0000063,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,let-7c,hsa-let-7c,MI0000064,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,let-7e,hsa-let-7e,MI0000066,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-100,hsa-mir-100,MI0000102,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-128,hsa-mir-128-1,MI0000447,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-1287,hsa-mir-1287,MI0006349,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-1291,hsa-mir-1291,MI0006353,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,Low,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-1293,hsa-mir-1293,MI0006355,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-1301,hsa-mir-1301,MI0003815,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-132,hsa-mir-132,MI0000449,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-146a,hsa-mir-146a,MI0000477,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-155,hsa-mir-155,MI0000681,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-184,hsa-mir-184,MI0000481,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,Low,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-185,hsa-mir-185,MI0000482,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-192,hsa-mir-192,MI0000234,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-21,hsa-mir-21,MI0000077,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,Low,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-2277,hsa-mir-2277,MI0011284,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-23a,hsa-mir-23a,MI0000079,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-23b,hsa-mir-23b,MI0000439,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-24-2,hsa-mir-24-2,MI0000081,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-27a,hsa-mir-27a,MI0000085,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-27b,hsa-mir-27b,MI0000440,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-30b,hsa-mir-30b,MI0000441,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-30d,hsa-mir-30d,MI0000255,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-3187,hsa-mir-3187,MI0014231,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-3200,hsa-mir-3200,MI0014249,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-320a,hsa-mir-320a,MI0000542,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-328,hsa-mir-328,MI0000804,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-331,hsa-mir-331,MI0000812,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-335,hsa-mir-335,MI0000816,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-340,hsa-mir-340,MI0000802,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-3607,hsa-mir-3607,MI0015997,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-361,hsa-mir-361,MI0000760,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-363,hsa-mir-363,MI0000764,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,Low,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-3651,hsa-mir-3651,MI0016051,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-3653,hsa-mir-3653,MI0016053,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-3917,hsa-mir-3917,MI0016423,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-409,hsa-mir-409,MI0001735,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-424,hsa-mir-424,MI0001446,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-425,hsa-mir-425,MI0001448,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-4467,hsa-mir-4467,MI0016818,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-4473,hsa-mir-4473,MI0016825,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-449c,hsa-mir-449c,MI0003823,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-4664,hsa-mir-4664,MI0017294,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-4745,hsa-mir-4745,MI0017384,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-490,hsa-mir-490,MI0003125,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-503,hsa-mir-503,MI0003188,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-504,hsa-mir-504,MI0003189,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-543,hsa-mir-543,MI0005565,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-584,hsa-mir-584,MI0003591,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-660,hsa-mir-660,MI0003684,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-664a,hsa-mir-664a,MI0006442,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-7,hsa-mir-7-1,MI0000263,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-760,hsa-mir-760,MI0005567,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-769,hsa-mir-769,MI0003834,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Sensitive,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-92a-1,hsa-mir-92a-1,MI0000093,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-96,hsa-mir-96,MI0000098,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,Low,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26456124,miR-99a,hsa-mir-99a,MI0000101,PLX4720,24180719,"8505c(v600E/ ), and BCPAP(v600E/wt)",,-,-,thyroid cancer,in vitro,High,Resistant,-,-,2015,Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines,"According to criteria see Methods), we detected differential expression between 8505c-R and parental 8505c cells in 61 known and 2 novel (predicted) miRNAs (Table I and Supplementary Table II). "
26458859,miR-26a,hsa-mir-26a-1,MI0000083,Cisplatin,2767,-,SGC-7901 vs SGC-7901/CDDP,-,-,gastric cancer,in vitro,Low,Sensitive,NRAS and E2F2,-,2015,MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2.,"Using both gain- and loss-of-function analyses, we further revealed that miR-26a could improve the sensitivity of GC cells to cisplatin."
26492332,miR-26a,hsa-mir-26a-1,MI0000083,Cisplatin,2767,A549,-,-,-,non-small cell lung cancer,in vitro,Low,Sensitive,HMGA2,E2F1-Akt pathway,2015,Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer.,MiR-26a is responsible for A549 cell sensitivity in the treatment of CDDP through regulating HMGA2-mediated E2F1-Akt pathway.
26494558,miR-130a,hsa-mir-130a,MI0000448,Imatinib,5291,-,-,-,Patients,chronic myeloid leukemia,in vivo,Low,Sensitive,"BCL-2, MCL-1 and XIAP",-,2015,Functional studies of miR-130a on the inhibitory pathways of apoptosis in Patient with chronic myeloid leukemia.,Transfected miR-130a significantly increased the CML sensitivity to Gleevec.
26500892,miR-17,hsa-mir-17,MI0000071,Paclitaxel,36314,OVCAR-3 and SKOV-3,-,-,-,ovarian carcinoma,in vitro,Low,Resistant,PTEN,-,2015,MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling.,Overexpression of miR-17-5p induces drug resistance of ovarian cancer cells
26526790,miR-193b,hsa-mir-193b,MI0003137,Doxorubicin (Adriamycin),31703,-,MCF-7 vs MCF-7/ADR,-,-,breast cancer,in vitro,Low,Sensitive,MCL-1,-,2015,miR-193b Modulates Resistance to Doxorubicin in Human Breast Cancer Cells by Downregulating MCL-1.,Further studies indicated that miR-193b sensitized MCF-7/DOXR cells to doxorubicin through a mechanism involving the downregulation of MCL-1. 
26527748,miR-221,hsa-mir-221,MI0000298,Melphalan,460612,RPMI-8226 and AMO1 Abzb,U266 vs U266/MEL,Mice,-,multiple myeloma,in vitro and in vivo,Low,Resistant,PUMA and BBC3,-,2016,A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.,Inhibition of miR-221/222 overcame melphalan resistance and triggered apoptosis of multiple myeloma cells in vitro.
26527748,miR-222,-,-,Melphalan,460612,RPMI-8226 and AMO1 Abzb,U266 vs U266/MEL,Mice,-,multiple myeloma,in vitro and in vivo,Low,Resistant,PUMA and BBC3,-,2016,A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.,Inhibition of miR-221/222 overcame melphalan resistance and triggered apoptosis of multiple myeloma cells in vitro.
26542803,miR-7,hsa-mir-7-1,MI0000263,Cisplatin,2767,A549,-,-,-,lung cancer,in vitro,Low,Resistant,SMARCD1,BAX and p21,2016,MicroRNA-7 Compromises p53 Protein-dependent Apoptosis by Controlling the Expression of the Chromatin Remodeling Factor SMARCD1.,"We found that although SMARCD1 sensitized lung cancer cells to chemotherapy drug-induced apoptosis, miR-7 enhanced the drug resistance potential of lung cancer cells against chemotherapy drugs."
26550261,miR-23a,hsa-mir-23a,MI0000079,Cisplatin,2767,A2780,-,-,-,ovarian cancer,in vitro,Low,Sensitive,-,-,2015,Molecular mechanism of increased sensitivity of cisplatin to ovarian cancer by inhibition of microRNA-23a expression.,The inhibition of miR-23a expression could significantly increase the sensitivity of cisplatin towards tumor cells.
26555418,miR-21,hsa-mir-21,MI0000077,Paclitaxel,36314,-,MCF-7 vs MCF-7/Taxol and SKBR-3 vs SKBR-3/Taxol,-,-,-,in vitro,Low,Resistant,-,-,2015,Effects of miRNA-21 on paclitaxel-resistance in human breast cancer cells,"MiR-21 inhibitors significantly suppressed G0/G1 transition of the cell cycle, and induced cell apoptosis in MCF-7/PR and SKBR-3/PR cells."
26560033,miR-200,-,-,Cyclophosphamide,2907,Tri-PyMT cells,-,-,Patients,breast cancer,in vitro and in vivo,Low,Sensitive,-,-,2015,Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.,"With increasing concentrations of CTX, the miR-200 cells were significantly more susceptible to therapy."
26566625,miR-144,hsa-mir-144,MI0000460,Cisplatin,2767,PC3 and LNCap,-,-,Patients,prostate cancer,in vitro and in vivo,Low,Sensitive,Beclin-1,-,2015,VEGF-activated miR-144 regulates autophagic survival of prostate cancer cells against Cisplatin.,"Together, these data suggest that cisplatin may induce VEGF to suppress miR-144 levels in PC cells, which subsequently upregulates Beclin-1 to increase autophagic cell survival against cisplatin-induced cell death."
26573417,miR-101,hsa-mir-101-1,MI0000103,Cisplatin,2767,-,SGC7901 vs SGC7901/CDDP,-,-,gastric cancer,in vitro,Low,Sensitive,VEGF-C,-,2016,MicroRNA-101 induces apoptosis in cisplatin-resistant gastric cancer cells by targeting VEGF-C.,"In addition, forced overexpression of miR?101 significantly inhibited cell proliferation, while enhancing cisplatin?induced apoptosis of SGC7901/DDP cells."
26573761,miR-106b-25,-,-,Colchicine,6167,MTMECs,-,-,-,breast cancer,in vitro,Low,Resistant,-,-,2016,MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300.,"We find that overexpression of miR-106b-25 cluster led to the generation of MDR MTMECs (resistant to etoposide, colchicine and paclitaxel)."
26573761,miR-106b-25,-,-,Cyclosporin A,5284373,MTMECs,-,-,-,breast cancer,in vitro,Low,Resistant,-,-,2016,MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300.,"We find that overexpression of miR-106b-25 cluster led to the generation of MDR MTMECs (resistant to etoposide, colchicine and paclitaxel)."
26573761,miR-106b-25,-,-,Etoposide,36462,MTMECs,-,-,-,breast cancer,in vitro,Low,Resistant,-,-,2016,MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300.,"We find that overexpression of miR-106b-25 cluster led to the generation of MDR MTMECs (resistant to etoposide, colchicine and paclitaxel)."
26573761,miR-106b-25,-,-,Paclitaxel,36314,MTMECs,-,-,-,breast cancer,in vitro,Low,Resistant,-,-,2016,MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300.,"We find that overexpression of miR-106b-25 cluster led to the generation of MDR MTMECs (resistant to etoposide, colchicine and paclitaxel)."
26576679,miR-634,hsa-mir-634,MI0003649,Carboplatin,38904,-,-,-,Patients,ovarian cancer,in vivo,Low,Sensitive,"CCND1, GRB2, ERK2, RSK2",Ras-MAPK pathway,2015,miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.,"miR-634 resensitized resistant ovarian cancer cell lines and patient derived drug resistant tumor cells to cisplatin. Similarly, miR-634 enhanced the response to carboplatin and doxorubicin, but not to paclitaxel."
26576679,miR-634,hsa-mir-634,MI0003649,Cisplatin,2767,"OV56, OAW42, TOV112D and TOV21G","A2780 vs A2780/CDDP, T24 vs T24/CDDP and HCT-8 vs HCT-8/CDDP",-,Patients,bladder cancer,in vitro and in vivo,Low,Sensitive,"CCND1, GRB2, ERK2, RSK2",Ras-MAPK pathway,2015,miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.,"miR-634 resensitized resistant ovarian cancer cell lines and patient derived drug resistant tumor cells to cisplatin. Similarly, miR-634 enhanced the response to carboplatin and doxorubicin, but not to paclitaxel."
26576679,miR-634,hsa-mir-634,MI0003649,Cisplatin,2767,"OV56, OAW42, TOV112D and TOV21G","A2780 vs A2780/CDDP, T24 vs T24/CDDP and HCT-8 vs HCT-8/CDDP",-,Patients,ovarian cancer,in vitro and in vivo,Low,Sensitive,"CCND1, GRB2, ERK2, RSK2",Ras-MAPK pathway,2015,miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.,"miR-634 resensitized resistant ovarian cancer cell lines and patient derived drug resistant tumor cells to cisplatin. Similarly, miR-634 enhanced the response to carboplatin and doxorubicin, but not to paclitaxel."
26576679,miR-634,hsa-mir-634,MI0003649,Doxorubicin (Adriamycin),31703,-,-,-,Patients,ovarian cancer,in vivo,Low,Sensitive,"CCND1, GRB2, ERK2, RSK2",Ras-MAPK pathway,2015,miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.,"miR-634 resensitized resistant ovarian cancer cell lines and patient derived drug resistant tumor cells to cisplatin. Similarly, miR-634 enhanced the response to carboplatin and doxorubicin, but not to paclitaxel."
26581910,miR-143,hsa-mir-143,MI0000459,Paclitaxel,36314,SW48 and LoVo,-,-,-,colorectal cancer,in vitro,Low,Sensitive,-,-,2015,"MicroRNA-143 replenishment re-sensitizes colorectal cancer cells harboring mutant, but not wild-type, KRAS to paclitaxel treatment.","Our results showed that miR-143, but not let-7b, increased sensitization of KRAS mutant tumor cells to paclitaxel."
26589846,miR-181a,hsa-mir-181a-2,MI0000269,Cisplatin,2767,-,SGC7901 vs SGC7901/CDDP,-,-,gastric cancer,in vitro,Low,Sensitive,ATG5,-,2016,MiR-181a suppresses autophagy and sensitizes gastric cancer cells to cisplatin.,"Furthermore, overexpression of miR-181a significantly enhanced the sensitivity of SGC7901/CDDP cells to cisplatin in vitro and reduced the volumes of gastric tumor xenografts in nude mice."
26607088,miR-100,hsa-mir-100,MI0000102,Cisplatin,2767,-,SKOV3 vs SKOV3/CDDP,-,-,ovarian cancer,in vitro,Low,Sensitive,-,-,2015,Expression of microRNA-100 and its correlation with drug resistance in human ovarian cancer SKOV3/DDP cells,Overexpressing miR-100 may effectively increase the sensitivity to cisplatin of human ovarian epithelial cancer SKOV3/DDP cells and may reverse cisplatin-resistance of EOC (epithelial ovarian cancer).
26617885,chr15-10055,-,-,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,chr16-11501,-,-,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,chr19-16126,-,-,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-100,hsa-mir-100,MI0000102,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-101,hsa-mir-101-1,MI0000103,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-1247,hsa-mir-1247,MI0006382,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-125b,hsa-mir-125b-1,MI0000446,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-125b-1,hsa-mir-125b-1,MI0000446,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-126,hsa-mir-126,MI0000471,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-145,hsa-mir-145,MI0000461,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-146a,hsa-mir-146a,MI0000477,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-181a,hsa-mir-181a-2,MI0000269,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-215,hsa-mir-215,MI0000291,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-218,hsa-mir-218-1,MI0000294,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-3141,hsa-mir-3141,MI0014165,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-3687,hsa-mir-3687-1,MI0016088,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-582,hsa-mir-582,MI0003589,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-6087,hsa-mir-6087,MI0020364,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-675,hsa-mir-675,MI0005416,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Sensitive,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26617885,miR-92b,hsa-mir-92b,MI0003560,Vincristine,5978,-,HCT-8 vs HCT-8/VCR,-,-,colon cancer,in vitro,High,Resistant,-,-,2015,Deep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cells,"As shown in Table 5, 1651 miRNAs were sequenced, revealing 48 miRNAs differing in their expression."
26644266,miR-302a,hsa-mir-302a,MI0000738,Mitoxantrone,4212,-,MCF-7 vs MCF-7/MIX,-,-,breast cancer,in vitro,Low,Sensitive,BCRP,-,2015,miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells.,Overexpression of miR-302 increased intracellular accumulation of MX and sensitized breast cancer cells to MX.
26644266,miR-302b,hsa-mir-302b,MI0000772,Mitoxantrone,4212,-,MCF-7 vs MCF-7/MIX,-,-,breast cancer,in vitro,Low,Sensitive,BCRP,-,2015,miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells.,Overexpression of miR-302 increased intracellular accumulation of MX and sensitized breast cancer cells to MX.
26644266,miR-302c,hsa-mir-302c,MI0000773,Mitoxantrone,4212,-,MCF-7 vs MCF-7/MIX,-,-,breast cancer,in vitro,Low,Sensitive,BCRP,-,2015,miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells.,Overexpression of miR-302 increased intracellular accumulation of MX and sensitized breast cancer cells to MX.
26644266,miR-302d,hsa-mir-302d,MI0000774,Mitoxantrone,4212,-,MCF-7 vs MCF-7/MIX,-,-,breast cancer,in vitro,Low,Sensitive,BCRP,-,2015,miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells.,Overexpression of miR-302 increased intracellular accumulation of MX and sensitized breast cancer cells to MX.
26647742,miR-425,hsa-mir-425,MI0001448,5-Fluorouracil,3385,-,HCT-116 vs HCT-116/5-FU,Mice,-,colorectal cancer,in vitro and in vivo,Low,Resistant,PDCD10,-,2016,MicroRNA-425-5p regulates chemoresistance in colorectal cancer cells via regulation of Programmed Cell Death 10.,Inhibition of miR-425-5p reversed chemoresistance in HCT116-R cells.
26647742,miR-425,hsa-mir-425,MI0001448,Oxaliplatin,5310940,-,HCT116 vs HCT116/OXP,Mice,-,colorectal cancer,in vitro and in vivo,Low,Resistant,PDCD10,-,2016,MicroRNA-425-5p regulates chemoresistance in colorectal cancer cells via regulation of Programmed Cell Death 10.,Inhibition of miR-425-5p reversed chemoresistance in HCT116-R cells.
26655271,let-7g,hsa-let-7g,MI0000433,Cisplatin,2767,EC109 and TE10,-,-,-,esophageal carcinoma,in vitro,Low,Sensitive,ABCC10,-,2016,BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10.,Overexpression of miR-let-7g/i significantly inhibited the cell proliferation and promoted DDP-induced apoptosis of EC109 and TE10 cells
26655271,let-7i,hsa-let-7i,MI0000434,Cisplatin,2767,EC109 and TE10,-,-,-,esophageal carcinoma,in vitro,Low,Sensitive,ABCC10,-,2016,BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10.,Overexpression of miR-let-7g/i significantly inhibited the cell proliferation and promoted DDP-induced apoptosis of EC109 and TE10 cells
26655273,miR-122,hsa-mir-122,MI0000442,Sorafenib,216239,-,PLC vs PLC/SOR and Huh7 vs Huh7/SOR,-,-,hepatocellular carcinoma,in vitro,Low,Resistant,IGF-1R,RAS/RAF/ERK signaling pathways,2016,MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.,"These results indicated that activation of IGF-1R by ectopic down-regulation of miR-122 counteracted the effects of sorafenib-induced apoptosis, thus conferring sorafenib resistance."
26675258,miR-30a,hsa-mir-30a,MI0000088,Cisplatin,2767,-,A2780 vs A2780/CDDP and 2008 vs 2008/CDDP,Mice,-,ovarian carcinoma,in vitro and in vivo,Low,Sensitive,ETAR,-,2016,miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.,Overexpression of miR-30a sensitizes EOC cells to cisplatinum-induced apoptosis
26676926,miR-100,hsa-mir-100,MI0000102,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-10a,hsa-mir-10a,MI0000266,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Resistant,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-125b,hsa-mir-125b-1,MI0000446,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-1307,hsa-mir-1307,MI0006444,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Resistant,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-181a-2,hsa-mir-181a-2,MI0000269,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-204,hsa-mir-204,MI0000284,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Resistant,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-21,hsa-mir-21,MI0000077,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-222,hsa-mir-222,MI0000299,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-224,hsa-mir-224,MI0000301,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-23a,hsa-mir-23a,MI0000079,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-27b,hsa-mir-27b,MI0000440,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-29a,hsa-mir-29a,MI0000087,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-320a,hsa-mir-320a,MI0000542,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Resistant,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-320b,hsa-mir-320b-1,MI0003776,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Resistant,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-423,hsa-mir-423,MI0001445,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Resistant,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-452,hsa-mir-4521,MI0001733,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Sensitive,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-7,hsa-mir-7-1,MI0000263,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Resistant,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-92a-1,hsa-mir-92a-1,MI0000093,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Resistant,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26676926,miR-92b,hsa-mir-92b,MI0003560,Cisplatin,2767,-,H446 vs H446/CCDDP,-,-,small cell lung cancer,in vitro,High,Resistant,-,-,2015,Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines,"More importantly, there were 72 de-regulated and 55 upregulated miRNAs in the H446/CDDP cells; the difference was statistically significant (P<0.01) compared with that of the H446 cells. We also identified the most markedly changed 10 miRNAs from the H446 and H446/CDDP cells (Tables III and IV)."
26684239,miR-100,hsa-mir-100,MI0000102,Vemurafenib,42611257,-,PLX4032 vs PLX4032/VEM and LM16 vs LM16/VEM,-,Patients,melanoma,in vitro and in vivo,Low,Resistant,-,-,2016,"Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.","Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b."
26684239,miR-125b,hsa-mir-125b-1,MI0000446,Vemurafenib,42611257,-,PLX4032 vs PLX4032/VEM and LM16 vs LM16/VEM,-,Patients,melanoma,in vitro and in vivo,Low,Resistant,-,-,2016,"Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.","Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b."
26684239,miR-34a,hsa-mir-34a,MI0000268,Vemurafenib,42611257,-,PLX4032 vs PLX4032/VEM and LM16 vs LM16/VEM,-,Patients,melanoma,in vitro and in vivo,Low,Resistant,-,-,2016,"Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.","Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b."
26689580,miR-202,hsa-mir-202,MI0003130,Bortezomib,387447,Multiple Myeloma Cells,-,-,-,multiple myeloma,in vitro,Low,Sensitive,BAFF,JNK/SAPK signaling pathway,2015,Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells.,miR-202 over-expression sensitized MM cells to bortezomib (Bort) but less to Thalidomide (Thal) and dexamethasone (Dex).
26692956,miR-155,hsa-mir-155,MI0000681,Tamoxifen,2733526,-,MCF-7 vs MCF-7/TAM and SKBR3 vs SKBR3/TAM,-,-,breast cancer,in vitro,Low,Resistant,SOCS6,STAT3,2015,MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer.,"Ectopic expression of miR-155 induces cell survival and resistance to TAM, whereas inhibition of miR-155 causes cells to apoptosis and enhances TAM sensitivity."
26701615,miR-224,hsa-mir-224,MI0000301,Doxorubicin (Adriamycin),31703,-,T47D vs T47D/ADR,-,-,breast cancer,in vitro,Low,Sensitive,FUT4,-,2016,Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4.,"In addition, miR-224-3p overexpression sensitized T47D/ADR cells to chemotherapeutics and reduced the growth rate of breast cancer xenografts in vivo."
26711968,miR-542,hsa-mir-542,MI0003686,Doxorubicin (Adriamycin),31703,MCF-7 and MDA-MB-231,-,-,-,triple negative breast cancer,in vitro,Low,Sensitive,P53 and Survivin,-,2016,Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy.,"In this article, the authors developed a hyaluronic acid (HA)-decorated polyethylenimine-poly(D,L-lactide-co-glycolide) (PEI-PLGA) nanoparticle system for the delivery of both doxorubicin (DOX) and miR-542-3p against this tumor sub-type."
26718267,miR-101,hsa-mir-101-1,MI0000103,Doxorubicin (Adriamycin),31703,HepG2,-,-,-,hepatocellular carcinoma,in vitro,Low,Sensitive,Mcl-1,-,2016,MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1.,"Furthermore, transfection of miR-101 significantly enhanced the cytotoxicity of doxorubicin to HepG2 cells."
26722459,miR-16,hsa-mir-16-1,MI0000070,Temozolomide,5394,-,U251MG vs U251MG/TEM,-,-,glioma,in vitro,Low,Resistant,Bcl-2,-,2015,MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.,"We found that treatment with the mimics of miR-16 greatly decreased the sensitivity of U251MG/TR cells to temozolomide, while sensitivity to these drugs was increased by treatment with the miR-16 inhibitor."
